activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	1173948	CHEMBL648220	Inhibition of Brutons tyrosine kinase	B	CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C		CHEMBL281957	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	uM	0.0004
	1173948	CHEMBL648220	Inhibition of Brutons tyrosine kinase	B	CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C		CHEMBL281957	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	uM	0.0004
Not Active	1650954	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554		Kd			CHEMBL5251	Homo sapiens	Kd		
	1650955	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	1500.0	CHEMBL5251	Homo sapiens	Kd	uM	1.5
Not Active	1650956	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1650957	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1650958	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1650959	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1650960	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1650961	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1650962	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Kd			CHEMBL5251	Homo sapiens	Kd		
	1651335	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	710.0	CHEMBL5251	Homo sapiens	Kd	uM	0.71
Not Active	1651336	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651337	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651338	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651339	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651340	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651341	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651342	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651343	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553		Kd			CHEMBL5251	Homo sapiens	Kd		
Not Active	1651344	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828		Kd			CHEMBL5251	Homo sapiens	Kd		
	1651345	CHEMBL860638	Average Binding Constant for BTK; NA=Not Active at 10 uM	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	=	Kd	nM	750.0	CHEMBL5251	Homo sapiens	Kd	uM	0.75
	1712362	CHEMBL861964	Inhibition of BTK	B	NC(=O)c1sc(-c2ccccc2)cc1N		CHEMBL207028	=	IC50	nM	15100.0	CHEMBL5251	Homo sapiens	IC50	uM	15.1
	1713430	CHEMBL861964	Inhibition of BTK	B	Cc1cc(C)c2c(N)c(C(N)=O)sc2n1		CHEMBL377085	=	IC50	nM	4100.0	CHEMBL5251	Homo sapiens	IC50	uM	4.1
	1727538	CHEMBL859736	Inhibition of human BTK kinase at 3 uM in presence of 10 uM ATP	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Inhibition	%	14.0	CHEMBL5251	Homo sapiens	Inhibition	%	14.0
	1734751	CHEMBL865400	Inhibition of Btk	B	COc1cc(C)c(Sc2cnc(NC(=O)c3ccc(CNC(C)C(C)(C)C)cc3)s2)cc1C(=O)N1CCN(C(C)=O)CC1		CHEMBL209148	=	IC50	nM	4100.0	CHEMBL5251	Homo sapiens	IC50	uM	4.1
	1748681	CHEMBL870355	Inhibition of Btk	B	COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3cc(OC)c(OCCCN4CCN(C)CC4)c(OC)c3)n2)c(OC)c1		CHEMBL386760	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	uM	0.1
	1765468	CHEMBL853494	Inhibition of Btk by HTRF kinase assay	B	CNc1ncc2cc(-c3cc(C(=O)Nc4cc(C(F)(F)F)ccc4OC4CCN(C)CC4)ccc3C)ccc2n1		CHEMBL386661	=	IC50	nM	3330.0	CHEMBL5251	Homo sapiens	IC50	uM	3.33
	1765497	CHEMBL853494	Inhibition of Btk by HTRF kinase assay	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2nc(NCCN3CCOCC3)ncc2c1		CHEMBL215943	=	IC50	nM	545.0	CHEMBL5251	Homo sapiens	IC50	uM	0.545
	1815214	CHEMBL908525	Inhibition of BTK	B	CNc1ncnc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)ccc3N(C)CCCN(C)C)c2)n1		CHEMBL373882	=	IC50	nM	25000.0	CHEMBL5251	Homo sapiens	IC50	nM	25000.0
	1914047	CHEMBL894873	Effect on thrombin-induced Btk activation at 10 uM after 30 mins	B	Oc1cc(O)c2c(c1)O[C@@]1(c3ccc(O)c(O)c3)Oc3cc(O)c4c(c3[C@@H]2[C@H]1O)O[C@H](c1ccc(O)c(O)c1)[C@H](O)[C@H]4c1c(O)cc(O)c2c1O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2		CHEMBL540956	=	Activity	%	50.0	CHEMBL5251	Homo sapiens	Activity	%	50.0
	1914051	CHEMBL894874	Effect on thrombin-induced Btk activation in presence of catalase	B	Oc1cc(O)c2c(c1)O[C@@]1(c3ccc(O)c(O)c3)Oc3cc(O)c4c(c3[C@@H]2[C@H]1O)O[C@H](c1ccc(O)c(O)c1)[C@H](O)[C@H]4c1c(O)cc(O)c2c1O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2		CHEMBL540956	=	Activity	%	90.0	CHEMBL5251	Homo sapiens	Activity	%	90.0
	1923433	CHEMBL896207	Inhibition of BTK	B	Cn1cnc(CNc2cc(Br)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)c1		CHEMBL230761	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	1968054	CHEMBL896380	Inhibition of BTK	B	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1cccs1)n2CCCN		CHEMBL233338	>	IC50	nM	22000.0	CHEMBL5251	Homo sapiens	IC50	uM	22.0
	2025118	CHEMBL886945	Inhibition of human BTK at 1 uM relative to control	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	Inhibition	%	106.0	CHEMBL5251	Homo sapiens	Inhibition	%	106.0
	2025246	CHEMBL886945	Inhibition of human BTK at 1 uM relative to control	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	Inhibition	%	105.0	CHEMBL5251	Homo sapiens	Inhibition	%	105.0
	2025247	CHEMBL886945	Inhibition of human BTK at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	Inhibition	%	104.0	CHEMBL5251	Homo sapiens	Inhibition	%	104.0
	2025248	CHEMBL886945	Inhibition of human BTK at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	Inhibition	%	106.0	CHEMBL5251	Homo sapiens	Inhibition	%	106.0
	2025988	CHEMBL887093	Inhibition of BTK by radioactive filtration assay	B	CNc1ncnc(-c2cccnc2Oc2cc(NC(=O)c3cccc(OC(F)(F)C(F)F)c3)ccc2C)n1		CHEMBL246356	=	IC50	nM	25000.0	CHEMBL5251	Homo sapiens	IC50	nM	25000.0
	2038502	CHEMBL923138	Inhibition of Btk	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	2038506	CHEMBL923138	Inhibition of Btk	B	Cc1ccc2[nH]ncc2c1Nc1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL248676	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	nM	69.0
	2038507	CHEMBL923138	Inhibition of Btk	B	Cc1ccc2[nH]ncc2c1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL398422	=	IC50	nM	97.0	CHEMBL5251	Homo sapiens	IC50	nM	97.0
Not Determined	2038508	CHEMBL923138	Inhibition of Btk	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL249317		IC50			CHEMBL5251	Homo sapiens	IC50		
	2050263	CHEMBL925560	Inhibition of BTK at 1 uM	B	CC1CCN(c2ccc(CO)cc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL400754	=	Inhibition	%	9.0	CHEMBL5251	Homo sapiens	Inhibition	%	9.0
	2081778	CHEMBL928800	Inhibition of Btk at 10 uM	B	CC[C@@H](C)Nc1nc2ccc(-c3c(-c4ccccc4F)n[nH]c3N)cc2s1		CHEMBL404115	<=	Inhibition	%	20.0	CHEMBL5251	Homo sapiens	Inhibition	%	20.0
	2110269	CHEMBL950971	Inhibition of BTK	B	COC[C@H]1OC(=O)/C(=C/N(CCO)C(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C		CHEMBL271190	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	2110280	CHEMBL950971	Inhibition of BTK	B	COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C		CHEMBL410643	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	2112051	CHEMBL934202	Inhibition of Btk by HTRF assay	B	Cc1cccc(C)c1-n1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n2c3ccccc3nc12		CHEMBL410295	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	uM	0.41
	2137125	CHEMBL921719	Inhibition of human BTK	B	C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br		CHEMBL228043	=	IC50	nM	17200.0	CHEMBL5251	Homo sapiens	IC50	nM	17200.0
	2137126	CHEMBL921720	Inhibition of recombinant BTK	B	C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br		CHEMBL228043	=	IC50	nM	2500.0	CHEMBL5251	Homo sapiens	IC50	nM	2500.0
	2137286	CHEMBL937067	Inhibition of Btk	B	Cl.Cl.NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL3216211	=	IC50	nM	15500.0	CHEMBL5251	Homo sapiens	IC50	nM	15500.0
	2147201	CHEMBL927945	Activity of human BTK kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	90.0	CHEMBL5251	Homo sapiens	Activity	%	90.0
Active	2150084	CHEMBL923533	Binding affinity to Btk from human K562 cells extract by LC-MSMS	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Activity			CHEMBL5251	Homo sapiens	Activity		
	2150087	CHEMBL923536	Inhibition of recombinant Btk	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
Active	2150091	CHEMBL924607	Reduction of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at 30 nM after 1 hr	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Activity			CHEMBL5251	Homo sapiens	Activity		
	2150092	CHEMBL924608	Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at >= 100 nM after 1 hr	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	2150093	CHEMBL924609	Inhibition of TAP-tagged wild-type Btk	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
Not Active	2150094	CHEMBL924610	Inhibition of TAP-tagged Btk T474I mutant	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	2150095	CHEMBL924611	Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells after 1 hr	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	2150096	CHEMBL924611	Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells after 1 hr	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	2150097	CHEMBL924611	Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells after 1 hr	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	2150098	CHEMBL924612	Inhibition of LPS-induced Btk T474I autophosphorylation on Tyr223 in human U937 cells after 1 hr	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	2150099	CHEMBL924613	Inhibition of LPS-induced Btk autophosphorylation of tyrosine in human Namalwa cells	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	2170352	CHEMBL927911	Activity at Btk at 10 uM	B	COc1c(NC(=O)c2ccc(C)c(N3C=C(C(=O)NCC(C)(C)CN(C)C)NN3)c2)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL254992		Activity			CHEMBL5251	Homo sapiens	Activity		
	2182408	CHEMBL941307	Inhibition of BTK at 1 uM	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	2182803	CHEMBL941430	Inhibition of BTK at 5 uM	B	O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12		CHEMBL179242	=	Inhibition	%	9.0	CHEMBL5251	Homo sapiens	INH	%	9.0
	2206993	CHEMBL966759	Inhibition of BTK	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
Not Active	2240594	CHEMBL971753	Inhibition of BTK at 30 uM	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(C(F)(F)F)cc3)c2)n1		CHEMBL523411		Activity			CHEMBL5251	Homo sapiens	Activity		
	2248189	CHEMBL1012672	Inhibition of BTK at 5 uM	B	O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1		CHEMBL183906	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	2248219	CHEMBL1012672	Inhibition of BTK at 5 uM	B	CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1		CHEMBL84558	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	2264753	CHEMBL963874	Binding affinity to BTK	B	CS(=O)(=O)c1ccc(CNCc2cc(C(=O)O)c(Nc3ccc(I)cc3F)c(F)c2F)cc1		CHEMBL465465	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	2264754	CHEMBL963874	Binding affinity to BTK	B	NC(=O)C[C@H](N)C(=O)NCc1cc(C(=O)O)c(Nc2ccc(I)cc2F)c(F)c1F		CHEMBL517647	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	2264755	CHEMBL963874	Binding affinity to BTK	B	O=C(N/N=C/c1cc(C(=O)O)c(Nc2ccc(I)cc2F)c(F)c1F)c1ccc(CO)o1		CHEMBL481968	=	IC50	nM	7000.0	CHEMBL5251	Homo sapiens	IC50	uM	7.0
	2264756	CHEMBL963874	Binding affinity to BTK	B	O=C(CS(=O)(=O)c1ccc(Cl)cc1)N/N=C/c1cc(C(=O)O)c(Nc2ccc(I)cc2F)c(F)c1F		CHEMBL481969	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	2280921	CHEMBL960929	Inhibition of Btk	B	CNc1nc2oc(-c3ccccc3)nc2c2c1ncn2C		CHEMBL493940	=	IC50	nM	23000.0	CHEMBL5251	Homo sapiens	IC50	uM	23.0
	2280922	CHEMBL960929	Inhibition of Btk	B	CNc1nc2c(nc(-c3ccccc3)n2C)c2c1ncn2C		CHEMBL522011	=	IC50	nM	14000.0	CHEMBL5251	Homo sapiens	IC50	uM	14.0
	2280923	CHEMBL960929	Inhibition of Btk	B	CNc1nc2sc(-c3cccc(CNC(C)=O)c3)nc2c2c1ncn2C		CHEMBL454973	=	IC50	nM	17000.0	CHEMBL5251	Homo sapiens	IC50	uM	17.0
	2353887	CHEMBL953221	Inhibition of Btk	B	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1		CHEMBL494979	>	Activity	uM	10.0	CHEMBL5251	Homo sapiens	Activity	uM	10.0
	2356990	CHEMBL958286	Inhibition of BTK at 1 uM relative to control	B	Cc1ccn(-c2ccc(-c3ncco3)cc2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL525893	>	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	2361174	CHEMBL971826	Inhibition of BTK	B	COc1cc2c(Oc3ccc(-c4cnc(Cc5ccccc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL505896	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	2361196	CHEMBL971826	Inhibition of BTK	B	COc1cc2c(Oc3ccc(-c4cnc(Nc5ccc(F)cc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL453737	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
	2361218	CHEMBL971826	Inhibition of BTK	B	COc1cc2c(Oc3ccc(-c4cnc(Nc5ccc(F)cc5)n(C)c4=O)nc3)ccnc2cc1OCCCN1CCOCC1		CHEMBL447602	=	IC50	nM	126.0	CHEMBL5251	Homo sapiens	IC50	nM	126.0
	2362692	CHEMBL1034896	Inhibition of BTK	B	COc1ccc(-c2cncc(C#N)c2Nc2ccc3[nH]ccc3c2)cc1OC		CHEMBL492251	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	2380459	CHEMBL942223	Inhibition of BTK	B	CN(C(=O)c1ccccc1)c1ccc2c(c1)[nH]/c(=N\C(=O)c1ccc(/C=C/c3ncc(N)cn3)s1)n2CCC(N)=O		CHEMBL500517	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	2395406	CHEMBL957092	Inhibition of BTK	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	IC50	nM	2000.0	CHEMBL5251	Homo sapiens	IC50	nM	2000.0
	2418051	CHEMBL1018813	Inhibition of BTK at 1 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	INH	%	1.0
Not Active	2468245	CHEMBL992564	Inhibition of Btk	B	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1cccs1)n2CCC(N)=O		CHEMBL485564		Activity			CHEMBL5251	Homo sapiens	Activity		
	2470125	CHEMBL1032268	Inhibition of BTK at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	2476603	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Activity	%	10.1	CHEMBL5251	Homo sapiens	Activity	%	10.1
Not Evaluated	2476806	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2478645	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2478848	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2479703	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	2480702	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL5251	Homo sapiens	Activity		
	2503647	CHEMBL960391	Inhibition of BTK	B	C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br		CHEMBL228043	=	IC50	nM	2500.0	CHEMBL5251	Homo sapiens	IC50	uM	2.5
	2511565	CHEMBL972524	Inhibition of BTK	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	uM	0.036
	2512026	CHEMBL970569	Inhibition of BTK at 1 uM	B	CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1		CHEMBL508307	=	Inhibition	%	46.0	CHEMBL5251	Homo sapiens	INH	%	46.0
Not Active	2527115	CHEMBL984140	Inhibition of BTK at => 3 ug/mL	B	COc1c(NC(=O)Nc2ccc(-c3ccc(CN4CCOCC4)nc3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL451523		Activity			CHEMBL5251	Homo sapiens	Activity		
	2567226	CHEMBL973709	Inhibition of human BTK kinase assessed as residual enzyme activity at 0.1 uM	B	CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4		CHEMBL223147	=	Activity	%	86.0	CHEMBL5251	Homo sapiens	Activity	%	86.0
Not Evaluated	2577324	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2577527	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL5251	Homo sapiens	Activity		
	2584869	CHEMBL955779	Inhibition of Btk	B	O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12		CHEMBL461139	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	2584897	CHEMBL955779	Inhibition of Btk	B	CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1		CHEMBL461140	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	2585354	CHEMBL1018102	Inhibition of BTK	B	CCOc1ccccc1Oc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(=O)Nc1c(C)cccc1C		CHEMBL459044	=	Ki	nM	78.0	CHEMBL5251	Homo sapiens	Ki	uM	0.078
	2585355	CHEMBL1018102	Inhibition of BTK	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)cc3)nc21		CHEMBL458333	=	Ki	nM	0.25	CHEMBL5251	Homo sapiens	Ki	uM	0.00025
	2585356	CHEMBL1018102	Inhibition of BTK	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)c(F)c3)nc21		CHEMBL502156	=	Ki	nM	125.0	CHEMBL5251	Homo sapiens	Ki	uM	0.125
Not Evaluated	2593529	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL5251	Homo sapiens	Activity		
	2593732	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097	=	Activity	%	4.0	CHEMBL5251	Homo sapiens	Activity	%	4.0
	2593998	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519	=	Activity	%	2.2	CHEMBL5251	Homo sapiens	Activity	%	2.2
Not Evaluated	2594941	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2595144	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2595210	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2596341	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2597610	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Evaluated	2597813	CHEMBL1035867	Binding affinity to human BTK at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL5251	Homo sapiens	Activity		
	2615707	CHEMBL1026513	Inhibition of Btk	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	=	IC50	nM	185.0	CHEMBL5251	Homo sapiens	IC50	uM	0.185
	2615725	CHEMBL1026513	Inhibition of Btk	B	C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL285063	=	IC50	nM	5830.0	CHEMBL5251	Homo sapiens	IC50	uM	5.83
	2676430	CHEMBL1036425	Inhibition of BTK	B	CCOC(=O)c1cnn2c(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)ccnc12		CHEMBL565061	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	2721560	CHEMBL1060968	Inhibition of BTK at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	2903619	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903620	CHEMBL1060238	Binding constant for full-length BTK	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903621	CHEMBL1060238	Binding constant for full-length BTK	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903622	CHEMBL1060238	Binding constant for full-length BTK	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903623	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903624	CHEMBL1060238	Binding constant for full-length BTK	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903625	CHEMBL1060238	Binding constant for full-length BTK	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903626	CHEMBL1060238	Binding constant for full-length BTK	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903627	CHEMBL1060238	Binding constant for full-length BTK	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	=	Kd	nM	1600.0	CHEMBL5251	Homo sapiens	Kd	nM	1600.0
	2903628	CHEMBL1060238	Binding constant for full-length BTK	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903629	CHEMBL1060238	Binding constant for full-length BTK	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903630	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	1.4	CHEMBL5251	Homo sapiens	Kd	nM	1.4
	2903631	CHEMBL1060238	Binding constant for full-length BTK	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	4900.0	CHEMBL5251	Homo sapiens	Kd	nM	4900.0
	2903632	CHEMBL1060238	Binding constant for full-length BTK	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903633	CHEMBL1060238	Binding constant for full-length BTK	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903634	CHEMBL1060238	Binding constant for full-length BTK	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903635	CHEMBL1060238	Binding constant for full-length BTK	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903636	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903637	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903638	CHEMBL1060238	Binding constant for full-length BTK	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903639	CHEMBL1060238	Binding constant for full-length BTK	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903640	CHEMBL1060238	Binding constant for full-length BTK	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903641	CHEMBL1060238	Binding constant for full-length BTK	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903642	CHEMBL1060238	Binding constant for full-length BTK	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Kd	nM	4200.0	CHEMBL5251	Homo sapiens	Kd	nM	4200.0
	2903643	CHEMBL1060238	Binding constant for full-length BTK	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903644	CHEMBL1060238	Binding constant for full-length BTK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903645	CHEMBL1060238	Binding constant for full-length BTK	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903646	CHEMBL1060238	Binding constant for full-length BTK	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903647	CHEMBL1060238	Binding constant for full-length BTK	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903648	CHEMBL1060238	Binding constant for full-length BTK	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903649	CHEMBL1060238	Binding constant for full-length BTK	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903650	CHEMBL1060238	Binding constant for full-length BTK	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903651	CHEMBL1060238	Binding constant for full-length BTK	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	210.0	CHEMBL5251	Homo sapiens	Kd	nM	210.0
	2903652	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903653	CHEMBL1060238	Binding constant for full-length BTK	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903654	CHEMBL1060238	Binding constant for full-length BTK	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	4400.0	CHEMBL5251	Homo sapiens	Kd	nM	4400.0
	2903655	CHEMBL1060238	Binding constant for full-length BTK	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2903656	CHEMBL1060238	Binding constant for full-length BTK	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	2921422	CHEMBL1052870	Inhibition of BTK assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	91.0	CHEMBL5251	Homo sapiens	Activity	%	91.0
	2926258	CHEMBL1056931	Inhibition of BTK assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	52.0	CHEMBL5251	Homo sapiens	Activity	%	52.0
	2928444	CHEMBL1055355	Inhibition of BTK assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	33.0	CHEMBL5251	Homo sapiens	Activity	%	33.0
	2938526	CHEMBL1041339	Inhibition of BTK at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
Not Active	2938603	CHEMBL1040616	Inhibition of BTK at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	2942576	CHEMBL1060307	Inhibition of BTK by HTRF assay	B	O=c1[nH]c(CN2CC[C@H](O)C2)nc2c1sc1ccc(-c3ccc(O)cc3)cc12		CHEMBL583187	>	Ki	nM	1000.0	CHEMBL5251	Homo sapiens	Ki	microM	1.0
	2942577	CHEMBL1060307	Inhibition of BTK by HTRF assay	B	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	=	Ki	nM	636.5	CHEMBL5251	Homo sapiens	Ki	microM	0.6365
	2992199	CHEMBL1044502	Inhibition of human BTK at 20 uM by FRET assay	B	C#Cn1c(C#CCCO)nc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL576620	=	Inhibition	%	9.0	CHEMBL5251	Homo sapiens	INH	%	9.0
	2993557	CHEMBL1040932	Inhibition of human recombinant Btk	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	2999917	CHEMBL1041098	Inhibition of BTK assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	92.0	CHEMBL5251	Homo sapiens	Activity	%	92.0
	2999993	CHEMBL1041098	Inhibition of BTK assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	105.0	CHEMBL5251	Homo sapiens	Activity	%	105.0
	3005036	CHEMBL1049080	Inhibition of Btk	B	CCCc1cc(N2CCC(N)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL578601	>	IC50	nM	7000.0	CHEMBL5251	Homo sapiens	IC50	uM	7.0
	3005037	CHEMBL1049080	Inhibition of Btk	B	CCCc1cc(N2CCNCC2)nc2sc(C(N)=O)c(N)c12		CHEMBL568922	>	IC50	nM	7000.0	CHEMBL5251	Homo sapiens	IC50	uM	7.0
	3005038	CHEMBL1049080	Inhibition of Btk	B	CCCc1cc(N2CCC(O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL576887	>	IC50	nM	7000.0	CHEMBL5251	Homo sapiens	IC50	uM	7.0
	3005039	CHEMBL1049080	Inhibition of Btk	B	CCCc1cc(N2CCCC(O)C2)nc2sc(C(N)=O)c(N)c12		CHEMBL576989	>	IC50	nM	7000.0	CHEMBL5251	Homo sapiens	IC50	uM	7.0
	3052539	CHEMBL1050404	Residual activity of BTK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	114.0	CHEMBL5251	Homo sapiens	Residual activity	%	114.0
	3052791	CHEMBL1047817	Residual activity of BTK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	6.0	CHEMBL5251	Homo sapiens	Residual activity	%	6.0
	3054100	CHEMBL1066618	Residual activity of BTK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	100.0	CHEMBL5251	Homo sapiens	Residual activity	%	100.0
	3055387	CHEMBL1050404	Residual activity of BTK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	124.0	CHEMBL5251	Homo sapiens	Residual activity	%	124.0
	3055639	CHEMBL1047817	Residual activity of BTK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	40.0	CHEMBL5251	Homo sapiens	Residual activity	%	40.0
	3056944	CHEMBL1066618	Residual activity of BTK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	106.0	CHEMBL5251	Homo sapiens	Residual activity	%	106.0
	3058264	CHEMBL1050404	Residual activity of BTK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	163.0	CHEMBL5251	Homo sapiens	Residual activity	%	163.0
	3058516	CHEMBL1047817	Residual activity of BTK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	53.0	CHEMBL5251	Homo sapiens	Residual activity	%	53.0
	3062447	CHEMBL1048640	Binding affinity to human BTK at 200 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595545	=	Activity	%	62.0	CHEMBL5251	Homo sapiens	Activity	%	62.0
	3063582	CHEMBL1045168	Binding affinity to human BTK at 500 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595546	=	Activity	%	31.0	CHEMBL5251	Homo sapiens	Activity	%	31.0
	3063672	CHEMBL1038883	Binding affinity to human BTK at 50 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL609010	=	Activity	%	98.0	CHEMBL5251	Homo sapiens	Activity	%	98.0
	3065852	CHEMBL1069282	Inhibition of BTK at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	3066918	CHEMBL1069282	Inhibition of BTK at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	13.0	CHEMBL5251	Homo sapiens	INH	%	13.0
	3072862	CHEMBL1066618	Residual activity of BTK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	101.0	CHEMBL5251	Homo sapiens	Residual activity	%	101.0
	3210402	CHEMBL1109423	Inhibition of Btk after 1 hr	B	O=C(Nc1cccc(-c2cn3ccnc3c(NCc3ccncc3)n2)c1)Nc1cccc(C(F)(F)F)c1		CHEMBL1081198	=	IC50	nM	7800.0	CHEMBL5251	Homo sapiens	IC50	uM	7.8
	3213786	CHEMBL1107590	Inhibition of BTK at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	101.0	CHEMBL5251	Homo sapiens	INH	%	101.0
	3224734	CHEMBL1102609	Inhibition of BTK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3225017	CHEMBL1102609	Inhibition of BTK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3246482	CHEMBL1117093	Inhibition of BTK	B	O=C(Nc1cccc(-c2ncnc3sc(-c4ccncc4)cc23)c1)c1cccc(C(F)(F)F)c1		CHEMBL1090143	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	3260091	CHEMBL1115998	Inhibition of BTK at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	36.0	CHEMBL5251	Homo sapiens	Activity	%	36.0
	3261382	CHEMBL1115998	Inhibition of BTK at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	79.0	CHEMBL5251	Homo sapiens	Activity	%	79.0
Not Active	3271760	CHEMBL1112900	Inhibition of BTK	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271761	CHEMBL1112900	Inhibition of BTK	B	COc1ccccc1/C=C1/C(=O)Nc2ccccc21		CHEMBL444673		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271762	CHEMBL1112900	Inhibition of BTK	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F		CHEMBL1088391		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271763	CHEMBL1112900	Inhibition of BTK	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-]		CHEMBL1088392		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271764	CHEMBL1112900	Inhibition of BTK	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O		CHEMBL1088529		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271765	CHEMBL1112900	Inhibition of BTK	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2		CHEMBL1086669		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271766	CHEMBL1112900	Inhibition of BTK	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1		CHEMBL1086670		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271767	CHEMBL1112900	Inhibition of BTK	B	NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL1086795		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271768	CHEMBL1112900	Inhibition of BTK	B	COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC		CHEMBL1086796		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	3271769	CHEMBL1112900	Inhibition of BTK	B	COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC		CHEMBL383871		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	3271770	CHEMBL1112900	Inhibition of BTK	B	COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1		CHEMBL1086939	<	Inhibition	%	20.0	CHEMBL5251	Homo sapiens	INH	%	20.0
Not Active	3271771	CHEMBL1112900	Inhibition of BTK	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	3307891	CHEMBL1119350	Inhibition of human BTK	B	Cc1cn(-c2cc(NC(=O)Nc3ccc(-c4nc5[nH]ncc5[nH]4)c(C)c3)cc(C(F)(F)F)c2)cn1		CHEMBL1084036	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	3316769	CHEMBL1120194	Inhibition of BTK at 1 uM	B	O=C(Nc1cccc(-n2ccc3c(NC(=O)c4ccccc4)nccc32)c1)c1ccc(N2CCOCC2)c(C(F)(F)F)c1		CHEMBL1084450	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	3331847	CHEMBL1168806	Inhibition of BTK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3333262	CHEMBL1168806	Inhibition of BTK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3334667	CHEMBL1168806	Inhibition of BTK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3336087	CHEMBL1168806	Inhibition of BTK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3337468	CHEMBL1168806	Inhibition of BTK at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3337716	CHEMBL1168806	Inhibition of BTK at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3339048	CHEMBL1168806	Inhibition of BTK at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3340350	CHEMBL1168806	Inhibition of BTK at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3340615	CHEMBL1168806	Inhibition of BTK at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3342031	CHEMBL1168806	Inhibition of BTK at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	3358474	CHEMBL1174088	Inhibition of BTK at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	2.0	CHEMBL5251	Homo sapiens	INH	%	2.0
	3358916	CHEMBL1174088	Inhibition of BTK at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	1.2	CHEMBL5251	Homo sapiens	INH	%	1.2
	3439123	CHEMBL1247970	Inhibition of BTK by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3cccc(C(F)(F)F)c3)cc2C)n1		CHEMBL1242977	>	IC50	nM	8000.0	CHEMBL5251	Homo sapiens	IC50	nM	8000.0
	3439190	CHEMBL1247970	Inhibition of BTK by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3ccccc3Nc3ccccc3)cc2)n1		CHEMBL1243200	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	3439203	CHEMBL1247970	Inhibition of BTK by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(Nc3nnc(-c4ccc(F)cc4)c4ccccc34)cc2)n1		CHEMBL1243326	>	IC50	nM	25000.0	CHEMBL5251	Homo sapiens	IC50	nM	25000.0
	3443348	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	95.0	CHEMBL5251	Homo sapiens	INH	%	95.0
	3443565	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	84.0	CHEMBL5251	Homo sapiens	INH	%	84.0
	3444720	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	57.0	CHEMBL5251	Homo sapiens	INH	%	57.0
	3445046	CHEMBL1244744	Binding affinity to BTK	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	66.0	CHEMBL5251	Homo sapiens	Kd	nM	66.0
	3445344	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	66.0	CHEMBL5251	Homo sapiens	INH	%	66.0
	3445561	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	30.0	CHEMBL5251	Homo sapiens	INH	%	30.0
	3445776	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	88.0	CHEMBL5251	Homo sapiens	INH	%	88.0
	3445966	CHEMBL1244381	Inhibition of BTK at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	48.0	CHEMBL5251	Homo sapiens	INH	%	48.0
	3446190	CHEMBL1244330	Inhibition of BTK	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	3447997	CHEMBL1249775	Inhibition of human BTK activity at 10 uM by radiometric assay	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	3448073	CHEMBL1249775	Inhibition of human BTK activity at 10 uM by radiometric assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	19.0	CHEMBL5251	Homo sapiens	INH	%	19.0
	3448703	CHEMBL1244744	Binding affinity to BTK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	3449580	CHEMBL1244744	Binding affinity to BTK	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	3450004	CHEMBL1244744	Binding affinity to BTK	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	3450298	CHEMBL1244744	Binding affinity to BTK	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	3450928	CHEMBL1244744	Binding affinity to BTK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	3451219	CHEMBL1244744	Binding affinity to BTK	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	uM	10.0
	3463181	CHEMBL1251641	Inhibition of BTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	4.0	CHEMBL5251	Homo sapiens	INH	%	4.0
	3463400	CHEMBL1251641	Inhibition of BTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	3463944	CHEMBL1251641	Inhibition of BTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	23.0	CHEMBL5251	Homo sapiens	INH	%	23.0
	3556504	CHEMBL1285573	Inhibition of BTK at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	48.0	CHEMBL5251	Homo sapiens	INH	%	48.0
	3590864	CHEMBL1292162	Inhibition of Btk	B	Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N		CHEMBL1290746	>	IC50	nM	15000.0	CHEMBL5251	Homo sapiens	IC50	uM	15.0
	5121129	CHEMBL1648185	Inhibition of human BTK R28H mutant at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	113.0	CHEMBL5251	Homo sapiens	INH	%	113.0
	5121159	CHEMBL1648184	Inhibition of human BTK at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	118.0	CHEMBL5251	Homo sapiens	INH	%	118.0
	5133710	CHEMBL1648532	Inhibition of BTK assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	52.0	CHEMBL5251	Homo sapiens	Activity	%	52.0
	5133805	CHEMBL1648532	Inhibition of BTK assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	72.0	CHEMBL5251	Homo sapiens	Activity	%	72.0
	5133866	CHEMBL1648532	Inhibition of BTK assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	76.0	CHEMBL5251	Homo sapiens	Activity	%	76.0
	5140485	CHEMBL1646802	Inhibition of BTK at 10 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	5140528	CHEMBL1646066	Inhibition of BTK at 1 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	5152474	CHEMBL1656385	Inhibition of BTK by TR-FRET based LanthaScreen assay	B	COc1cc(O)c2c(c1)CCC[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL2012519	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	5152499	CHEMBL1656385	Inhibition of BTK by TR-FRET based LanthaScreen assay	B	COc1cc(O)c2c(c1)CCC[C@H](O)CC(=O)/C=C\C[C@H](C)OC2=O		CHEMBL1651521	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	5191469	CHEMBL1664091	Inhibition of BTK at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	15.0	CHEMBL5251	Homo sapiens	INH	%	15.0
	5191470	CHEMBL1664091	Inhibition of BTK at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	75.0	CHEMBL5251	Homo sapiens	INH	%	75.0
	5242946	CHEMBL1685640	Inhibition of BTK at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	38.0	CHEMBL5251	Homo sapiens	INH	%	38.0
	5243785	CHEMBL1685889	Inhibition of BTK at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	-4.0	CHEMBL5251	Homo sapiens	INH	%	-4.0
	5243898	CHEMBL1685640	Inhibition of BTK at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	69.0	CHEMBL5251	Homo sapiens	INH	%	69.0
	5244006	CHEMBL1685889	Inhibition of BTK at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	5244879	CHEMBL1685640	Inhibition of BTK at 0.1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	104.0	CHEMBL5251	Homo sapiens	INH	%	104.0
	5244987	CHEMBL1685889	Inhibition of BTK at 1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	78.0	CHEMBL5251	Homo sapiens	INH	%	78.0
	5245138	CHEMBL1685640	Inhibition of BTK at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	73.0	CHEMBL5251	Homo sapiens	INH	%	73.0
	5245968	CHEMBL1685889	Inhibition of BTK at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	39.0	CHEMBL5251	Homo sapiens	INH	%	39.0
	6161904	CHEMBL1764212	Inhibition of BTK	B	NC(=O)c1cc(-c2ccccc2)cc2c(C3CCCNC3)c[nH]c12		CHEMBL1761510	=	IC50	nM	1258.93	CHEMBL5251	Homo sapiens	pIC50		5.9
	6161905	CHEMBL1764212	Inhibition of BTK	B	CCCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1		CHEMBL1761512	=	IC50	nM	1584.89	CHEMBL5251	Homo sapiens	pIC50		5.8
	6167004	CHEMBL1768890	Inhibition of BTK	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL5251	Homo sapiens	Ki	uM	1.0
	6262757	CHEMBL1798629	Inhibition of BTK	B	Cc1ccc(C(=O)NCCO)cc1-n1cnc(OCc2ccc(F)cc2F)c(Cl)c1=O		CHEMBL1738710	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	6264915	CHEMBL1799798	Inhibition of BTK at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4NS(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796254	<	Inhibition	%	65.0	CHEMBL5251	Homo sapiens	INH	%	65.0
	6265639	CHEMBL1799798	Inhibition of BTK at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4N(C)S(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796257	<	Inhibition	%	65.0	CHEMBL5251	Homo sapiens	INH	%	65.0
	6267491	CHEMBL1798817	Inhibition of BTK at 10 uM	B	O=c1c(Cl)c(OCc2ccc(F)cc2F)cc(CO)n1-c1c(F)cccc1F		CHEMBL1797211	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	6267492	CHEMBL1798817	Inhibition of BTK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cccc(C(N)=O)c1		CHEMBL1797224	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	6273855	CHEMBL1806275	Inhibition of BTK assessed as residual enzyme activity at 10 uM	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833	=	Activity	%	91.0	CHEMBL5251	Homo sapiens	Activity	%	91.0
	6294800	CHEMBL1811527	Inhibition of Btk	B	CC(C)c1nc(-c2ccc(F)c(NS(=O)(=O)c3c(F)cccc3F)c2)c(-c2ccnc(Nc3ccc(N4CCOCC4)nc3)n2)s1		CHEMBL1808264	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	6318061	CHEMBL1816261	Inhibition of BTK kinase at 1 uM	B	CC(=O)Nc1cccc(Nc2ncnc(N3CCC(OCc4ccccc4)CC3)n2)c1C		CHEMBL1813033	>	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	6318062	CHEMBL1816261	Inhibition of BTK kinase at 1 uM	B	CC(=O)Nc1cccc(Nc2ncnc(N3CCC(OCc4ccccc4)CC3)n2)c1		CHEMBL1813032	=	Inhibition	%	54.0	CHEMBL5251	Homo sapiens	INH	%	54.0
	6340918	CHEMBL1826942	Activity of BTK kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	91.0	CHEMBL5251	Homo sapiens	Activity	%	91.0
	6352193	CHEMBL1825648	Inhibition of BTK assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	41.0	CHEMBL5251	Homo sapiens	Activity	%	41.0
	6386354	CHEMBL1839861	Inhibition of recombinant BTK	B	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O		CHEMBL1834657	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	7567173	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	=	Kd	nM	4300.0	CHEMBL5251	Homo sapiens	Kd	nM	4300.0
	7567632	CHEMBL1908476	Binding constant for BTK kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7568103	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7568571	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7569003	CHEMBL1908476	Binding constant for BTK kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2100.0	CHEMBL5251	Homo sapiens	Kd	nM	2100.0
	7569146	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7569606	CHEMBL1908476	Binding constant for BTK kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	7800.0	CHEMBL5251	Homo sapiens	Kd	nM	7800.0
	7570078	CHEMBL1908476	Binding constant for BTK kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7571122	CHEMBL1908476	Binding constant for BTK kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7571579	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	1.4	CHEMBL5251	Homo sapiens	Kd	nM	1.4
	7572055	CHEMBL1908476	Binding constant for BTK kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	77.0	CHEMBL5251	Homo sapiens	Kd	nM	77.0
	7572076	CHEMBL1908476	Binding constant for BTK kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7572492	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	23.0	CHEMBL5251	Homo sapiens	Kd	nM	23.0
	7573103	CHEMBL1908476	Binding constant for BTK kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	310.0	CHEMBL5251	Homo sapiens	Kd	nM	310.0
	7573560	CHEMBL1908476	Binding constant for BTK kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7574063	CHEMBL1908476	Binding constant for BTK kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7574471	CHEMBL1908476	Binding constant for BTK kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7575081	CHEMBL1908476	Binding constant for BTK kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7575571	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	=	Kd	nM	7400.0	CHEMBL5251	Homo sapiens	Kd	nM	7400.0
	7576036	CHEMBL1908476	Binding constant for BTK kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7576444	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	850.0	CHEMBL5251	Homo sapiens	Kd	nM	850.0
	7577055	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7577072	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	76.0	CHEMBL5251	Homo sapiens	Kd	nM	76.0
	7577550	CHEMBL1908476	Binding constant for BTK kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	1000.0	CHEMBL5251	Homo sapiens	Kd	nM	1000.0
	7578020	CHEMBL1908476	Binding constant for BTK kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	3200.0	CHEMBL5251	Homo sapiens	Kd	nM	3200.0
	7578425	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Kd	nM	1700.0	CHEMBL5251	Homo sapiens	Kd	nM	1700.0
	7578621	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7579445	CHEMBL1908476	Binding constant for BTK kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7579919	CHEMBL1908476	Binding constant for BTK kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7580388	CHEMBL1908476	Binding constant for BTK kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7580791	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	4400.0	CHEMBL5251	Homo sapiens	Kd	nM	4400.0
	7580979	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7581364	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7581809	CHEMBL1908476	Binding constant for BTK kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7582280	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7582744	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	190.0	CHEMBL5251	Homo sapiens	Kd	nM	190.0
	7583144	CHEMBL1908476	Binding constant for BTK kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7583325	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7583722	CHEMBL1908476	Binding constant for BTK kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7584167	CHEMBL1908476	Binding constant for BTK kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7584638	CHEMBL1908476	Binding constant for BTK kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7585100	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7585655	CHEMBL1908476	Binding constant for BTK kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7586063	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7586509	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7586980	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7587616	CHEMBL1908476	Binding constant for BTK kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7588035	CHEMBL1908476	Binding constant for BTK kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	66.0	CHEMBL5251	Homo sapiens	Kd	nM	66.0
	7588488	CHEMBL1908476	Binding constant for BTK kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7588968	CHEMBL1908476	Binding constant for BTK kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7589581	CHEMBL1908476	Binding constant for BTK kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7590005	CHEMBL1908476	Binding constant for BTK kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7590472	CHEMBL1908476	Binding constant for BTK kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7590504	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7590955	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7591554	CHEMBL1908476	Binding constant for BTK kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7591976	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7592479	CHEMBL1908476	Binding constant for BTK kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Kd	nM	4200.0	CHEMBL5251	Homo sapiens	Kd	nM	4200.0
	7592932	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	4.8	CHEMBL5251	Homo sapiens	Kd	nM	4.8
	7593521	CHEMBL1908476	Binding constant for BTK kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7593986	CHEMBL1908476	Binding constant for BTK kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7594459	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7594911	CHEMBL1908476	Binding constant for BTK kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7595491	CHEMBL1908476	Binding constant for BTK kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	=	Kd	nM	1600.0	CHEMBL5251	Homo sapiens	Kd	nM	1600.0
	7595965	CHEMBL1908476	Binding constant for BTK kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7596436	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7596883	CHEMBL1908476	Binding constant for BTK kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	210.0	CHEMBL5251	Homo sapiens	Kd	nM	210.0
	7597019	CHEMBL1908476	Binding constant for BTK kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	=	Kd	nM	1200.0	CHEMBL5251	Homo sapiens	Kd	nM	1200.0
	7597472	CHEMBL1908476	Binding constant for BTK kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL5251	Homo sapiens	Kd	nM	10000.0
	7597945	CHEMBL1908476	Binding constant for BTK kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	160.0	CHEMBL5251	Homo sapiens	Kd	nM	160.0
	7598415	CHEMBL1908476	Binding constant for BTK kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	=	Kd	nM	220.0	CHEMBL5251	Homo sapiens	Kd	nM	220.0
	7598857	CHEMBL1908476	Binding constant for BTK kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	4000.0	CHEMBL5251	Homo sapiens	Kd	nM	4000.0
	7930322	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	7930323	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	COc1cc2nc(Nc3ccccc3C)c3cncn3c2cc1NC(=O)C#CCN1CCOCC1		CHEMBL1916712	=	IC50	nM	0.847	CHEMBL5251	Homo sapiens	IC50	nM	0.847
	7930324	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	COc1cc2nc(Nc3ccccc3C)c3cncn3c2cc1NC(=O)C#CCN1CCCCC1		CHEMBL1916713	=	IC50	nM	0.847	CHEMBL5251	Homo sapiens	IC50	nM	0.847
	7930325	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	C=C(CN1CCOCC1)C(=O)Nc1cc2c(cc1OC)nc(Nc1ccccc1C)c1cncn12		CHEMBL1916714	=	IC50	nM	2.52	CHEMBL5251	Homo sapiens	IC50	nM	2.52
	7930326	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	COc1cc2nc(Nc3ccccc3C)c3cncn3c2cc1NC(=O)/C=C/CN(C)C		CHEMBL1916715	=	IC50	nM	0.884	CHEMBL5251	Homo sapiens	IC50	nM	0.884
	7930327	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	COc1cc2nc(Nc3ccccc3C)c3cncn3c2cc1N(CC1CC1)C(=O)/C=C/CN(C)C		CHEMBL1916716	=	IC50	nM	45.3	CHEMBL5251	Homo sapiens	IC50	nM	45.3
	7930328	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CCN(C(=O)/C=C/CN(C)C)c1cc2c(cc1OC)nc(Nc1ccccc1C)c1cncn12		CHEMBL1916717	=	IC50	nM	19.1	CHEMBL5251	Homo sapiens	IC50	nM	19.1
	7930329	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916718	=	IC50	nM	3.99	CHEMBL5251	Homo sapiens	IC50	nM	3.99
	7930330	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CN(C)C/C=C/C(=O)N(C)c1ccc2nc(Cl)c3cncn3c2c1		CHEMBL1916719	=	IC50	nM	4290.0	CHEMBL5251	Homo sapiens	IC50	nM	4290.0
	7930331	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916879	=	IC50	nM	16.8	CHEMBL5251	Homo sapiens	IC50	nM	16.8
	7930332	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(F)cc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916880	=	IC50	nM	3.33	CHEMBL5251	Homo sapiens	IC50	nM	3.33
	7930333	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(F)ccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916881	=	IC50	nM	2.96	CHEMBL5251	Homo sapiens	IC50	nM	2.96
	7930334	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1c(F)cccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916882	=	IC50	nM	1.89	CHEMBL5251	Homo sapiens	IC50	nM	1.89
	7930335	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cccc(Cl)c1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916883	=	IC50	nM	10.3	CHEMBL5251	Homo sapiens	IC50	nM	10.3
	7930336	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(Cl)cc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916884	=	IC50	nM	13.2	CHEMBL5251	Homo sapiens	IC50	nM	13.2
	7930337	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(Cl)ccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916885	=	IC50	nM	7.56	CHEMBL5251	Homo sapiens	IC50	nM	7.56
	7930338	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1c(Cl)cccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916886	=	IC50	nM	60.6	CHEMBL5251	Homo sapiens	IC50	nM	60.6
	7930339	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cccc(O)c1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916887	=	IC50	nM	10.4	CHEMBL5251	Homo sapiens	IC50	nM	10.4
	7930340	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(O)cc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916888	=	IC50	nM	1.55	CHEMBL5251	Homo sapiens	IC50	nM	1.55
	7930341	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(O)ccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916889	=	IC50	nM	12.2	CHEMBL5251	Homo sapiens	IC50	nM	12.2
	7930342	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1c(O)cccc1Nc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916890	=	IC50	nM	76.5	CHEMBL5251	Homo sapiens	IC50	nM	76.5
	7930343	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	IC50	nM	1.93	CHEMBL5251	Homo sapiens	IC50	nM	1.93
	7930344	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CN(C)C/C=C/C(=O)N(C)c1cc2c(cc1F)nc(Nc1ccccc1Cl)c1cncn12		CHEMBL1916892	=	IC50	nM	1.82	CHEMBL5251	Homo sapiens	IC50	nM	1.82
	7930345	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(F)cc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916893	=	IC50	nM	6.76	CHEMBL5251	Homo sapiens	IC50	nM	6.76
	7930346	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(F)ccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916894	=	IC50	nM	5.35	CHEMBL5251	Homo sapiens	IC50	nM	5.35
	7930347	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccccc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916895	=	IC50	nM	4.83	CHEMBL5251	Homo sapiens	IC50	nM	4.83
	7930348	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CN(C)C/C=C/C(=O)N(C)c1cc2c(cc1Cl)nc(Nc1ccccc1Cl)c1cncn12		CHEMBL1916896	=	IC50	nM	5.03	CHEMBL5251	Homo sapiens	IC50	nM	5.03
	7930349	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(F)cc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916897	=	IC50	nM	3.98	CHEMBL5251	Homo sapiens	IC50	nM	3.98
	7930350	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(F)ccc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916898	=	IC50	nM	9.53	CHEMBL5251	Homo sapiens	IC50	nM	9.53
	7930351	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccccc1Oc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916899	=	IC50	nM	5.51	CHEMBL5251	Homo sapiens	IC50	nM	5.51
	7930352	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccc(F)cc1Oc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916900	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	7930353	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(F)ccc1Oc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916901	=	IC50	nM	9.53	CHEMBL5251	Homo sapiens	IC50	nM	9.53
	7930354	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1cc(F)ccc1Oc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916902	=	IC50	nM	6.58	CHEMBL5251	Homo sapiens	IC50	nM	6.58
	7930355	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	Cc1ccccc1Sc1nc2ccc(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916903	=	IC50	nM	283.0	CHEMBL5251	Homo sapiens	IC50	nM	283.0
	7930356	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CNc1ccc2nc(Nc3cc(F)ccc3C)c3cncn3c2c1		CHEMBL1916904	=	IC50	nM	72.0	CHEMBL5251	Homo sapiens	IC50	nM	72.0
	7930357	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CNc1ccc2nc(Oc3ccc(F)cc3C)c3cncn3c2c1		CHEMBL1916905	=	IC50	nM	1220.0	CHEMBL5251	Homo sapiens	IC50	nM	1220.0
	7930358	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CNc1cc2c(cc1F)nc(Nc1ccccc1C)c1cncn12		CHEMBL1916906	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	7930359	CHEMBL1918488	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	B	CNc1cc2c(cc1F)nc(Oc1ccccc1C)c1cncn12		CHEMBL1916907	=	IC50	nM	670.0	CHEMBL5251	Homo sapiens	IC50	nM	670.0
	7930431	CHEMBL1919046	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate preincubated for 60 mins measured after 60 mins by TR-FRET Assay	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	7930432	CHEMBL1919046	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate preincubated for 60 mins measured after 60 mins by TR-FRET Assay	B	Cc1ccc(F)cc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916897	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	7930445	CHEMBL1919053	Inhibition of BTK autophosphorylation at PY223 in human Ramos B cells after 20 mins by Western blot analysis	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
	7931072	CHEMBL1919252	Inhibition of BTK relative to control	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	Inhibition	%	99.0	CHEMBL5251	Homo sapiens	INH	%	99.0
	7931073	CHEMBL1919252	Inhibition of BTK relative to control	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	IC50	nM	3.31	CHEMBL5251	Homo sapiens	IC50	nM	3.31
	7931142	CHEMBL1917969	Ratio of Kinact to Ki for human full-length BTK expressed in Sf9 cells	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	Ratio	/M/s	53200.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	53200.0
	7931143	CHEMBL1917969	Ratio of Kinact to Ki for human full-length BTK expressed in Sf9 cells	B	Cc1ccc(F)cc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916897	=	Ratio	/M/s	11900.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	11900.0
Active	7931147	CHEMBL1917970	Binding affinity to human full-length BTK expressed in Sf9 cells assessed as stoichiometric complex formation at 35 uM after 20 mins by LC-Mass spectrometric analysis	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891		Activity			CHEMBL5251	Homo sapiens	Activity		
	7939625	CHEMBL1921403	Inhibition of human BTK	B	[O-][n+]1ccc2c(-c3ccc(F)cc3Cl)ccnc2c1-c1c(Cl)cccc1Cl		CHEMBL1916359	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	7959691	CHEMBL1932336	Inhibition of BTK	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	7959692	CHEMBL1932336	Inhibition of BTK	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	7969698	CHEMBL1930954	Inhibition of BTK assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	30.0	CHEMBL5251	Homo sapiens	Activity	%	30.0
	7970414	CHEMBL1930203	Inhibition of BTK at 10 uM	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247	=	Inhibition	%	12.0	CHEMBL5251	Homo sapiens	INH	%	12.0
	7982612	CHEMBL1936994	Inhibition of BTK at 10 uM after 1 hr by competitive binding assay	B	CCOC(=O)C[C@@H]1[C@@H](CNC(=O)NC)O[C@@H](n2cnc3c(NC(=O)Nc4ccccc4)ncnc32)[C@@H]1O[Si](C)(C)C(C)(C)C		CHEMBL1076310	=	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	7987182	CHEMBL1935937	Inhibition of BTK	B	C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccc(F)cc5[nH]4)c4ccccc43)C2)CN1		CHEMBL1933552	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	7992176	CHEMBL1935902	Inhibition of BTK at 1 uM	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	Inhibition	%	87.0	CHEMBL5251	Homo sapiens	INH	%	87.0
	8004376	CHEMBL1943336	Inhibition of human BTK in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	8004377	CHEMBL1943336	Inhibition of human BTK in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	8004378	CHEMBL1943336	Inhibition of human BTK in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	8004379	CHEMBL1943336	Inhibition of human BTK in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	8017842	CHEMBL1948814	Inhibition of BTK assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1		CHEMBL1945953	=	Activity	%	90.0	CHEMBL5251	Homo sapiens	Activity	%	90.0
	8017843	CHEMBL1948814	Inhibition of BTK assessed as activity remaining at 10 uM	B	CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1		CHEMBL1945950	=	Activity	%	84.0	CHEMBL5251	Homo sapiens	Activity	%	84.0
	8017844	CHEMBL1948814	Inhibition of BTK assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1		CHEMBL1946262	=	Activity	%	88.0	CHEMBL5251	Homo sapiens	Activity	%	88.0
	8047085	CHEMBL1958820	Inhibition of BTK at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	8061360	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.91	CHEMBL5251	Homo sapiens	Inhibition	%	1.91
	8061537	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-0.27	CHEMBL5251	Homo sapiens	Inhibition	%	-0.27
	8061868	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	1.25	CHEMBL5251	Homo sapiens	Inhibition	%	1.25
	8062059	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.87	CHEMBL5251	Homo sapiens	Inhibition	%	1.87
	8062399	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.86	CHEMBL5251	Homo sapiens	Inhibition	%	0.86
	8062561	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-2.64	CHEMBL5251	Homo sapiens	Inhibition	%	-2.64
	8062883	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.46	CHEMBL5251	Homo sapiens	Inhibition	%	1.46
	8063239	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	6.57	CHEMBL5251	Homo sapiens	Inhibition	%	6.57
	8063406	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.66	CHEMBL5251	Homo sapiens	Inhibition	%	0.66
	8063738	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	-0.29	CHEMBL5251	Homo sapiens	Inhibition	%	-0.29
	8063920	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	3.46	CHEMBL5251	Homo sapiens	Inhibition	%	3.46
	8064259	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.33	CHEMBL5251	Homo sapiens	Inhibition	%	0.33
	8064469	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.22	CHEMBL5251	Homo sapiens	Inhibition	%	-0.22
	8064831	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	0.8	CHEMBL5251	Homo sapiens	Inhibition	%	0.8
	8064997	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.36	CHEMBL5251	Homo sapiens	Inhibition	%	0.36
	8065337	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.83	CHEMBL5251	Homo sapiens	Inhibition	%	0.83
	8065512	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	-0.12	CHEMBL5251	Homo sapiens	Inhibition	%	-0.12
	8065736	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.88	CHEMBL5251	Homo sapiens	Inhibition	%	2.88
	8065851	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	-0.86	CHEMBL5251	Homo sapiens	Inhibition	%	-0.86
	8066061	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	1.84	CHEMBL5251	Homo sapiens	Inhibition	%	1.84
	8066285	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-0.56	CHEMBL5251	Homo sapiens	Inhibition	%	-0.56
	8066421	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	2.81	CHEMBL5251	Homo sapiens	Inhibition	%	2.81
	8066587	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.22	CHEMBL5251	Homo sapiens	Inhibition	%	0.22
	8066811	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-0.23	CHEMBL5251	Homo sapiens	Inhibition	%	-0.23
	8066935	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	1.15	CHEMBL5251	Homo sapiens	Inhibition	%	1.15
	8067334	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.86	CHEMBL5251	Homo sapiens	Inhibition	%	1.86
	8067455	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	-0.69	CHEMBL5251	Homo sapiens	Inhibition	%	-0.69
	8067679	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-2.02	CHEMBL5251	Homo sapiens	Inhibition	%	-2.02
	8067889	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.41	CHEMBL5251	Homo sapiens	Inhibition	%	0.41
	8068024	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	1.94	CHEMBL5251	Homo sapiens	Inhibition	%	1.94
	8068412	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.01	CHEMBL5251	Homo sapiens	Inhibition	%	1.01
	8068537	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.55	CHEMBL5251	Homo sapiens	Inhibition	%	0.55
	8068761	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-1.3	CHEMBL5251	Homo sapiens	Inhibition	%	-1.3
	8068935	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.94	CHEMBL5251	Homo sapiens	Inhibition	%	0.94
	8069284	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-1.29	CHEMBL5251	Homo sapiens	Inhibition	%	-1.29
	8069355	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	11.35	CHEMBL5251	Homo sapiens	Inhibition	%	11.35
	8069579	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	1.39	CHEMBL5251	Homo sapiens	Inhibition	%	1.39
	8069740	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	-0.7	CHEMBL5251	Homo sapiens	Inhibition	%	-0.7
	8070090	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-0.45	CHEMBL5251	Homo sapiens	Inhibition	%	-0.45
	8070262	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.83	CHEMBL5251	Homo sapiens	Inhibition	%	0.83
	8070611	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-1.28	CHEMBL5251	Homo sapiens	Inhibition	%	-1.28
	8070909	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	5.93	CHEMBL5251	Homo sapiens	Inhibition	%	5.93
	8071066	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	2.48	CHEMBL5251	Homo sapiens	Inhibition	%	2.48
	8071416	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.91	CHEMBL5251	Homo sapiens	Inhibition	%	-0.91
	8071589	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.4	CHEMBL5251	Homo sapiens	Inhibition	%	1.4
	8071813	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	-0.13	CHEMBL5251	Homo sapiens	Inhibition	%	-0.13
	8071938	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-1.36	CHEMBL5251	Homo sapiens	Inhibition	%	-1.36
	8072252	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.22	CHEMBL5251	Homo sapiens	Inhibition	%	-0.22
	8072409	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.33	CHEMBL5251	Homo sapiens	Inhibition	%	0.33
	8072633	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.55	CHEMBL5251	Homo sapiens	Inhibition	%	0.55
	8072758	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-1.51	CHEMBL5251	Homo sapiens	Inhibition	%	-1.51
	8073149	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	4.11	CHEMBL5251	Homo sapiens	Inhibition	%	4.11
	8073274	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.69	CHEMBL5251	Homo sapiens	Inhibition	%	-0.69
	8073617	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.42	CHEMBL5251	Homo sapiens	Inhibition	%	0.42
	8073850	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.18	CHEMBL5251	Homo sapiens	Inhibition	%	-0.18
	8074226	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.58	CHEMBL5251	Homo sapiens	Inhibition	%	0.58
	8074356	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-1.28	CHEMBL5251	Homo sapiens	Inhibition	%	-1.28
	8074737	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.29	CHEMBL5251	Homo sapiens	Inhibition	%	1.29
	8074864	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.85	CHEMBL5251	Homo sapiens	Inhibition	%	-0.85
	8075088	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.29	CHEMBL5251	Homo sapiens	Inhibition	%	-0.29
	8075199	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	3.78	CHEMBL5251	Homo sapiens	Inhibition	%	3.78
	8075436	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-1.44	CHEMBL5251	Homo sapiens	Inhibition	%	-1.44
	8075660	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-1.15	CHEMBL5251	Homo sapiens	Inhibition	%	-1.15
	8075801	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	-0.87	CHEMBL5251	Homo sapiens	Inhibition	%	-0.87
	8075943	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.85	CHEMBL5251	Homo sapiens	Inhibition	%	-0.85
	8076167	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.76	CHEMBL5251	Homo sapiens	Inhibition	%	-0.76
	8076315	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.76	CHEMBL5251	Homo sapiens	Inhibition	%	0.76
	8076673	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.05	CHEMBL5251	Homo sapiens	Inhibition	%	-0.05
	8076775	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.91	CHEMBL5251	Homo sapiens	Inhibition	%	-0.91
	8076999	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	2.71	CHEMBL5251	Homo sapiens	Inhibition	%	2.71
	8077246	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	-2.57	CHEMBL5251	Homo sapiens	Inhibition	%	-2.57
	8077374	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.33	CHEMBL5251	Homo sapiens	Inhibition	%	0.33
	8077749	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.74	CHEMBL5251	Homo sapiens	Inhibition	%	-0.74
	8077892	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.12	CHEMBL5251	Homo sapiens	Inhibition	%	1.12
	8078255	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.3	CHEMBL5251	Homo sapiens	Inhibition	%	-1.3
	8078581	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-1.11	CHEMBL5251	Homo sapiens	Inhibition	%	-1.11
	8078831	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	-0.15	CHEMBL5251	Homo sapiens	Inhibition	%	-0.15
	8078947	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.22	CHEMBL5251	Homo sapiens	Inhibition	%	-0.22
	8079171	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.88	CHEMBL5251	Homo sapiens	Inhibition	%	1.88
	8079329	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.29	CHEMBL5251	Homo sapiens	Inhibition	%	-0.29
	8079471	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.02	CHEMBL5251	Homo sapiens	Inhibition	%	0.02
	8079695	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.11	CHEMBL5251	Homo sapiens	Inhibition	%	1.11
	8079834	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-0.82	CHEMBL5251	Homo sapiens	Inhibition	%	-0.82
	8080163	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	3.08	CHEMBL5251	Homo sapiens	Inhibition	%	3.08
	8080415	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	-1.47	CHEMBL5251	Homo sapiens	Inhibition	%	-1.47
	8080754	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-0.01	CHEMBL5251	Homo sapiens	Inhibition	%	-0.01
	8080918	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.5	CHEMBL5251	Homo sapiens	Inhibition	%	-0.5
	8081277	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.74	CHEMBL5251	Homo sapiens	Inhibition	%	1.74
	8081421	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	-1.53	CHEMBL5251	Homo sapiens	Inhibition	%	-1.53
	8081748	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-0.33	CHEMBL5251	Homo sapiens	Inhibition	%	-0.33
	8082000	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	-1.1	CHEMBL5251	Homo sapiens	Inhibition	%	-1.1
	8082337	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.33	CHEMBL5251	Homo sapiens	Inhibition	%	1.33
	8082510	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.49	CHEMBL5251	Homo sapiens	Inhibition	%	-0.49
	8082857	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.87	CHEMBL5251	Homo sapiens	Inhibition	%	0.87
	8083013	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	-1.71	CHEMBL5251	Homo sapiens	Inhibition	%	-1.71
	8083237	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	-1.04	CHEMBL5251	Homo sapiens	Inhibition	%	-1.04
	8083336	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	1.57	CHEMBL5251	Homo sapiens	Inhibition	%	1.57
	8083590	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-0.64	CHEMBL5251	Homo sapiens	Inhibition	%	-0.64
	8083814	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-0.36	CHEMBL5251	Homo sapiens	Inhibition	%	-0.36
	8083924	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.47	CHEMBL5251	Homo sapiens	Inhibition	%	0.47
	8084109	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.59	CHEMBL5251	Homo sapiens	Inhibition	%	-0.59
	8084333	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	1.8	CHEMBL5251	Homo sapiens	Inhibition	%	1.8
	8084451	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.88	CHEMBL5251	Homo sapiens	Inhibition	%	0.88
	8084836	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	0.06	CHEMBL5251	Homo sapiens	Inhibition	%	0.06
	8084934	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.45	CHEMBL5251	Homo sapiens	Inhibition	%	0.45
	8085158	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	1.66	CHEMBL5251	Homo sapiens	Inhibition	%	1.66
	8085414	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.51	CHEMBL5251	Homo sapiens	Inhibition	%	-1.51
	8085522	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.93	CHEMBL5251	Homo sapiens	Inhibition	%	0.93
	8085746	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	-0.86	CHEMBL5251	Homo sapiens	Inhibition	%	-0.86
	8085935	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	12.97	CHEMBL5251	Homo sapiens	Inhibition	%	12.97
	8086050	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.09	CHEMBL5251	Homo sapiens	Inhibition	%	1.09
	8086274	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	9.11	CHEMBL5251	Homo sapiens	Inhibition	%	9.11
	8086436	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-3.39	CHEMBL5251	Homo sapiens	Inhibition	%	-3.39
	8086759	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-0.43	CHEMBL5251	Homo sapiens	Inhibition	%	-0.43
	8086970	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-3.87	CHEMBL5251	Homo sapiens	Inhibition	%	-3.87
	8087352	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	-0.35	CHEMBL5251	Homo sapiens	Inhibition	%	-0.35
	8087466	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	27.15	CHEMBL5251	Homo sapiens	Inhibition	%	27.15
	8087828	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.04	CHEMBL5251	Homo sapiens	Inhibition	%	2.04
	8087970	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	-1.34	CHEMBL5251	Homo sapiens	Inhibition	%	-1.34
	8088194	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	1.16	CHEMBL5251	Homo sapiens	Inhibition	%	1.16
	8088342	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-2.25	CHEMBL5251	Homo sapiens	Inhibition	%	-2.25
	8088694	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	-0.58	CHEMBL5251	Homo sapiens	Inhibition	%	-0.58
	8088787	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	1.6	CHEMBL5251	Homo sapiens	Inhibition	%	1.6
	8089011	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.63	CHEMBL5251	Homo sapiens	Inhibition	%	2.63
	8089139	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.06	CHEMBL5251	Homo sapiens	Inhibition	%	0.06
	8089511	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	1.86	CHEMBL5251	Homo sapiens	Inhibition	%	1.86
	8089631	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.19	CHEMBL5251	Homo sapiens	Inhibition	%	1.19
	8089855	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.72	CHEMBL5251	Homo sapiens	Inhibition	%	2.72
	8090035	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.4	CHEMBL5251	Homo sapiens	Inhibition	%	0.4
	8090200	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-0.03	CHEMBL5251	Homo sapiens	Inhibition	%	-0.03
	8090591	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.19	CHEMBL5251	Homo sapiens	Inhibition	%	0.19
	8090730	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.18	CHEMBL5251	Homo sapiens	Inhibition	%	1.18
	8090954	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.33	CHEMBL5251	Homo sapiens	Inhibition	%	0.33
	8091159	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.51	CHEMBL5251	Homo sapiens	Inhibition	%	0.51
	8091296	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.37	CHEMBL5251	Homo sapiens	Inhibition	%	0.37
	8091675	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.22	CHEMBL5251	Homo sapiens	Inhibition	%	0.22
	8091791	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	0.53	CHEMBL5251	Homo sapiens	Inhibition	%	0.53
	8092015	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.39	CHEMBL5251	Homo sapiens	Inhibition	%	3.39
	8092152	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-4.26	CHEMBL5251	Homo sapiens	Inhibition	%	-4.26
	8092527	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	-1.08	CHEMBL5251	Homo sapiens	Inhibition	%	-1.08
	8092675	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-2.03	CHEMBL5251	Homo sapiens	Inhibition	%	-2.03
	8093028	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.4	CHEMBL5251	Homo sapiens	Inhibition	%	1.4
	8093340	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.07	CHEMBL5251	Homo sapiens	Inhibition	%	0.07
	8093480	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.8	CHEMBL5251	Homo sapiens	Inhibition	%	0.8
	8093843	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	3.95	CHEMBL5251	Homo sapiens	Inhibition	%	3.95
	8094187	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.31	CHEMBL5251	Homo sapiens	Inhibition	%	2.31
	8094367	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.68	CHEMBL5251	Homo sapiens	Inhibition	%	0.68
	8094542	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-1.36	CHEMBL5251	Homo sapiens	Inhibition	%	-1.36
	8094766	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	-0.63	CHEMBL5251	Homo sapiens	Inhibition	%	-0.63
	8094922	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.66	CHEMBL5251	Homo sapiens	Inhibition	%	0.66
	8095286	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	5.19	CHEMBL5251	Homo sapiens	Inhibition	%	5.19
	8095489	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	6.4	CHEMBL5251	Homo sapiens	Inhibition	%	6.4
	8095630	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	-2.03	CHEMBL5251	Homo sapiens	Inhibition	%	-2.03
	8095854	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	-0.62	CHEMBL5251	Homo sapiens	Inhibition	%	-0.62
	8096002	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	4.09	CHEMBL5251	Homo sapiens	Inhibition	%	4.09
	8096343	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	-0.1	CHEMBL5251	Homo sapiens	Inhibition	%	-0.1
	8096482	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-4.63	CHEMBL5251	Homo sapiens	Inhibition	%	-4.63
	8096706	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-1.44	CHEMBL5251	Homo sapiens	Inhibition	%	-1.44
	8096862	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.76	CHEMBL5251	Homo sapiens	Inhibition	%	0.76
	8097009	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.95	CHEMBL5251	Homo sapiens	Inhibition	%	-0.95
	8097233	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.95	CHEMBL5251	Homo sapiens	Inhibition	%	-0.95
	8097320	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-3.34	CHEMBL5251	Homo sapiens	Inhibition	%	-3.34
	8097540	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.45	CHEMBL5251	Homo sapiens	Inhibition	%	0.45
	8097690	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	-0.1	CHEMBL5251	Homo sapiens	Inhibition	%	-0.1
	8097914	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	1.72	CHEMBL5251	Homo sapiens	Inhibition	%	1.72
	8098047	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-1.95	CHEMBL5251	Homo sapiens	Inhibition	%	-1.95
	8098391	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.36	CHEMBL5251	Homo sapiens	Inhibition	%	0.36
	8098571	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.5	CHEMBL5251	Homo sapiens	Inhibition	%	1.5
	8098980	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	-0.07	CHEMBL5251	Homo sapiens	Inhibition	%	-0.07
	8099124	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	-0.04	CHEMBL5251	Homo sapiens	Inhibition	%	-0.04
	8099490	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.17	CHEMBL5251	Homo sapiens	Inhibition	%	1.17
	8099684	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-0.25	CHEMBL5251	Homo sapiens	Inhibition	%	-0.25
	8100055	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	-0.28	CHEMBL5251	Homo sapiens	Inhibition	%	-0.28
	8100201	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	29.1	CHEMBL5251	Homo sapiens	Inhibition	%	29.1
	8100541	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.74	CHEMBL5251	Homo sapiens	Inhibition	%	2.74
	8100905	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-0.83	CHEMBL5251	Homo sapiens	Inhibition	%	-0.83
	8101065	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	-1.01	CHEMBL5251	Homo sapiens	Inhibition	%	-1.01
	8101431	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-0.88	CHEMBL5251	Homo sapiens	Inhibition	%	-0.88
	8101616	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-4.3	CHEMBL5251	Homo sapiens	Inhibition	%	-4.3
	8101869	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	0.88	CHEMBL5251	Homo sapiens	Inhibition	%	0.88
	8102248	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	3.23	CHEMBL5251	Homo sapiens	Inhibition	%	3.23
	8102379	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-2.57	CHEMBL5251	Homo sapiens	Inhibition	%	-2.57
	8102603	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.59	CHEMBL5251	Homo sapiens	Inhibition	%	2.59
	8102723	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.76	CHEMBL5251	Homo sapiens	Inhibition	%	-0.76
	8102901	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.63	CHEMBL5251	Homo sapiens	Inhibition	%	0.63
	8103125	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.73	CHEMBL5251	Homo sapiens	Inhibition	%	1.73
	8103321	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	0.09	CHEMBL5251	Homo sapiens	Inhibition	%	0.09
	8103459	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	2.66	CHEMBL5251	Homo sapiens	Inhibition	%	2.66
	8103683	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.63	CHEMBL5251	Homo sapiens	Inhibition	%	0.63
	8103833	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.75	CHEMBL5251	Homo sapiens	Inhibition	%	1.75
	8104018	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-2.34	CHEMBL5251	Homo sapiens	Inhibition	%	-2.34
	8104242	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.06	CHEMBL5251	Homo sapiens	Inhibition	%	0.06
	8104390	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	0.44	CHEMBL5251	Homo sapiens	Inhibition	%	0.44
	8104536	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-4.28	CHEMBL5251	Homo sapiens	Inhibition	%	-4.28
	8104760	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-2.57	CHEMBL5251	Homo sapiens	Inhibition	%	-2.57
	8104874	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	-1.09	CHEMBL5251	Homo sapiens	Inhibition	%	-1.09
	8105238	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.07	CHEMBL5251	Homo sapiens	Inhibition	%	0.07
	8105404	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	-0.13	CHEMBL5251	Homo sapiens	Inhibition	%	-0.13
	8105766	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.25	CHEMBL5251	Homo sapiens	Inhibition	%	0.25
	8106046	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	2.74	CHEMBL5251	Homo sapiens	Inhibition	%	2.74
	8106211	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	2.48	CHEMBL5251	Homo sapiens	Inhibition	%	2.48
	8106435	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-3.09	CHEMBL5251	Homo sapiens	Inhibition	%	-3.09
	8106591	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	19.94	CHEMBL5251	Homo sapiens	Inhibition	%	19.94
	8106944	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	3.38	CHEMBL5251	Homo sapiens	Inhibition	%	3.38
	8107065	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.34	CHEMBL5251	Homo sapiens	Inhibition	%	0.34
	8107461	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.15	CHEMBL5251	Homo sapiens	Inhibition	%	0.15
	8107662	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	0.56	CHEMBL5251	Homo sapiens	Inhibition	%	0.56
	8108021	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	7.3	CHEMBL5251	Homo sapiens	Inhibition	%	7.3
	8108179	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.62	CHEMBL5251	Homo sapiens	Inhibition	%	0.62
	8108578	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.37	CHEMBL5251	Homo sapiens	Inhibition	%	-0.37
	8108725	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	Inhibition	%	0.0
	8109091	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-1.67	CHEMBL5251	Homo sapiens	Inhibition	%	-1.67
	8109205	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.54	CHEMBL5251	Homo sapiens	Inhibition	%	0.54
	8109429	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	-0.86	CHEMBL5251	Homo sapiens	Inhibition	%	-0.86
	8109559	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.2	CHEMBL5251	Homo sapiens	Inhibition	%	1.2
	8109730	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-4.65	CHEMBL5251	Homo sapiens	Inhibition	%	-4.65
	8109954	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-3.35	CHEMBL5251	Homo sapiens	Inhibition	%	-3.35
	8110086	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	-1.03	CHEMBL5251	Homo sapiens	Inhibition	%	-1.03
	8110365	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	5.12	CHEMBL5251	Homo sapiens	Inhibition	%	5.12
	8110755	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-2.3	CHEMBL5251	Homo sapiens	Inhibition	%	-2.3
	8110913	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	2.31	CHEMBL5251	Homo sapiens	Inhibition	%	2.31
	8111260	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.67	CHEMBL5251	Homo sapiens	Inhibition	%	1.67
	8111387	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	3.3	CHEMBL5251	Homo sapiens	Inhibition	%	3.3
	8111611	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	0.66	CHEMBL5251	Homo sapiens	Inhibition	%	0.66
	8111777	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	-0.21	CHEMBL5251	Homo sapiens	Inhibition	%	-0.21
	8111982	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	0.69	CHEMBL5251	Homo sapiens	Inhibition	%	0.69
	8112343	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.11	CHEMBL5251	Homo sapiens	Inhibition	%	0.11
	8112511	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	3.2	CHEMBL5251	Homo sapiens	Inhibition	%	3.2
	8112735	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.15	CHEMBL5251	Homo sapiens	Inhibition	%	3.15
	8112907	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.01	CHEMBL5251	Homo sapiens	Inhibition	%	0.01
	8113059	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	0.95	CHEMBL5251	Homo sapiens	Inhibition	%	0.95
	8113283	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	-1.33	CHEMBL5251	Homo sapiens	Inhibition	%	-1.33
	8113419	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-1.3	CHEMBL5251	Homo sapiens	Inhibition	%	-1.3
	8113767	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	-0.39	CHEMBL5251	Homo sapiens	Inhibition	%	-0.39
	8113883	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.99	CHEMBL5251	Homo sapiens	Inhibition	%	-0.99
	8114283	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	-2.4	CHEMBL5251	Homo sapiens	Inhibition	%	-2.4
	8114415	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	0.87	CHEMBL5251	Homo sapiens	Inhibition	%	0.87
	8114639	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	-1.13	CHEMBL5251	Homo sapiens	Inhibition	%	-1.13
	8114691	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.78	CHEMBL5251	Homo sapiens	Inhibition	%	1.78
	8114915	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	3.37	CHEMBL5251	Homo sapiens	Inhibition	%	3.37
	8115081	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.97	CHEMBL5251	Homo sapiens	Inhibition	%	0.97
	8115246	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	2.06	CHEMBL5251	Homo sapiens	Inhibition	%	2.06
	8115470	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.29	CHEMBL5251	Homo sapiens	Inhibition	%	0.29
	8115590	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.57	CHEMBL5251	Homo sapiens	Inhibition	%	1.57
	8115947	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	1.17	CHEMBL5251	Homo sapiens	Inhibition	%	1.17
	8116106	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.27	CHEMBL5251	Homo sapiens	Inhibition	%	0.27
	8116309	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	1.31	CHEMBL5251	Homo sapiens	Inhibition	%	1.31
	8116533	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	0.17	CHEMBL5251	Homo sapiens	Inhibition	%	0.17
	8116667	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.4	CHEMBL5251	Homo sapiens	Inhibition	%	-0.4
	8117063	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	25.1	CHEMBL5251	Homo sapiens	Inhibition	%	25.1
	8117234	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.8	CHEMBL5251	Homo sapiens	Inhibition	%	0.8
	8117616	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	-0.61	CHEMBL5251	Homo sapiens	Inhibition	%	-0.61
	8117746	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-0.28	CHEMBL5251	Homo sapiens	Inhibition	%	-0.28
	8118108	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-4.19	CHEMBL5251	Homo sapiens	Inhibition	%	-4.19
	8118224	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.94	CHEMBL5251	Homo sapiens	Inhibition	%	-0.94
	8118448	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	-1.27	CHEMBL5251	Homo sapiens	Inhibition	%	-1.27
	8118620	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.46	CHEMBL5251	Homo sapiens	Inhibition	%	0.46
	8118980	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.35	CHEMBL5251	Homo sapiens	Inhibition	%	1.35
	8119251	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.31	CHEMBL5251	Homo sapiens	Inhibition	%	0.31
	8119410	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	5.11	CHEMBL5251	Homo sapiens	Inhibition	%	5.11
	8119801	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.86	CHEMBL5251	Homo sapiens	Inhibition	%	0.86
	8119920	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	0.64	CHEMBL5251	Homo sapiens	Inhibition	%	0.64
	8120283	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.75	CHEMBL5251	Homo sapiens	Inhibition	%	0.75
	8120443	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-2.23	CHEMBL5251	Homo sapiens	Inhibition	%	-2.23
	8120667	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	2.14	CHEMBL5251	Homo sapiens	Inhibition	%	2.14
	8120868	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	0.56	CHEMBL5251	Homo sapiens	Inhibition	%	0.56
	8120996	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.25	CHEMBL5251	Homo sapiens	Inhibition	%	-0.25
	8121220	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.07	CHEMBL5251	Homo sapiens	Inhibition	%	0.07
	8121392	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-0.44	CHEMBL5251	Homo sapiens	Inhibition	%	-0.44
	8121559	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.17	CHEMBL5251	Homo sapiens	Inhibition	%	0.17
	8121946	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	-0.65	CHEMBL5251	Homo sapiens	Inhibition	%	-0.65
	8122067	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.13	CHEMBL5251	Homo sapiens	Inhibition	%	0.13
	8122291	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.09	CHEMBL5251	Homo sapiens	Inhibition	%	0.09
	8122429	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-4.23	CHEMBL5251	Homo sapiens	Inhibition	%	-4.23
	8122773	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	-0.85	CHEMBL5251	Homo sapiens	Inhibition	%	-0.85
	8122940	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	-0.06	CHEMBL5251	Homo sapiens	Inhibition	%	-0.06
	8123306	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-3.7	CHEMBL5251	Homo sapiens	Inhibition	%	-3.7
	8123584	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.16	CHEMBL5251	Homo sapiens	Inhibition	%	0.16
	8123734	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	1.25	CHEMBL5251	Homo sapiens	Inhibition	%	1.25
	8124125	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-2.61	CHEMBL5251	Homo sapiens	Inhibition	%	-2.61
	8124244	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	4.51	CHEMBL5251	Homo sapiens	Inhibition	%	4.51
	8124468	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	0.35	CHEMBL5251	Homo sapiens	Inhibition	%	0.35
	8124607	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.71	CHEMBL5251	Homo sapiens	Inhibition	%	1.71
	8124996	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	1.05	CHEMBL5251	Homo sapiens	Inhibition	%	1.05
	8125197	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	-0.17	CHEMBL5251	Homo sapiens	Inhibition	%	-0.17
	8125551	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.26	CHEMBL5251	Homo sapiens	Inhibition	%	0.26
	8125719	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.44	CHEMBL5251	Homo sapiens	Inhibition	%	1.44
	8125883	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.16	CHEMBL5251	Homo sapiens	Inhibition	%	0.16
	8126107	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	Inhibition	%	0.0
	8126271	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	-0.19	CHEMBL5251	Homo sapiens	Inhibition	%	-0.19
	8126610	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	1.18	CHEMBL5251	Homo sapiens	Inhibition	%	1.18
	8126746	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	-2.5	CHEMBL5251	Homo sapiens	Inhibition	%	-2.5
	8127092	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	-2.01	CHEMBL5251	Homo sapiens	Inhibition	%	-2.01
	8127259	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	3.39	CHEMBL5251	Homo sapiens	Inhibition	%	3.39
	8127483	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	3.65	CHEMBL5251	Homo sapiens	Inhibition	%	3.65
	8127625	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-1.82	CHEMBL5251	Homo sapiens	Inhibition	%	-1.82
	8127913	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.08	CHEMBL5251	Homo sapiens	Inhibition	%	1.08
	8128065	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	2.34	CHEMBL5251	Homo sapiens	Inhibition	%	2.34
	8128289	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.28	CHEMBL5251	Homo sapiens	Inhibition	%	1.28
	8128456	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-2.79	CHEMBL5251	Homo sapiens	Inhibition	%	-2.79
	8128799	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	4.57	CHEMBL5251	Homo sapiens	Inhibition	%	4.57
	8128936	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.4	CHEMBL5251	Homo sapiens	Inhibition	%	1.4
	8129160	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.62	CHEMBL5251	Homo sapiens	Inhibition	%	1.62
	8129331	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.42	CHEMBL5251	Homo sapiens	Inhibition	%	0.42
	8129520	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	0.53	CHEMBL5251	Homo sapiens	Inhibition	%	0.53
	8129883	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.1	CHEMBL5251	Homo sapiens	Inhibition	%	-0.1
	8130044	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.18	CHEMBL5251	Homo sapiens	Inhibition	%	0.18
	8130440	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.5	CHEMBL5251	Homo sapiens	Inhibition	%	-0.5
	8130600	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-3.74	CHEMBL5251	Homo sapiens	Inhibition	%	-3.74
	8130940	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	-0.44	CHEMBL5251	Homo sapiens	Inhibition	%	-0.44
	8131079	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	0.29	CHEMBL5251	Homo sapiens	Inhibition	%	0.29
	8131303	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	-0.07	CHEMBL5251	Homo sapiens	Inhibition	%	-0.07
	8131423	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	0.33	CHEMBL5251	Homo sapiens	Inhibition	%	0.33
	8131814	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	28.55	CHEMBL5251	Homo sapiens	Inhibition	%	28.55
	8131955	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	0.15	CHEMBL5251	Homo sapiens	Inhibition	%	0.15
	8132241	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.57	CHEMBL5251	Homo sapiens	Inhibition	%	1.57
	8132612	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.08	CHEMBL5251	Homo sapiens	Inhibition	%	1.08
	8132780	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	1.39	CHEMBL5251	Homo sapiens	Inhibition	%	1.39
	8133125	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.65	CHEMBL5251	Homo sapiens	Inhibition	%	0.65
	8133487	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.54	CHEMBL5251	Homo sapiens	Inhibition	%	0.54
	8133659	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	2.57	CHEMBL5251	Homo sapiens	Inhibition	%	2.57
	8133839	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	1.59	CHEMBL5251	Homo sapiens	Inhibition	%	1.59
	8134063	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	16.04	CHEMBL5251	Homo sapiens	Inhibition	%	16.04
	8134211	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.13	CHEMBL5251	Homo sapiens	Inhibition	%	-0.13
	8134371	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.42	CHEMBL5251	Homo sapiens	Inhibition	%	0.42
	8134595	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.36	CHEMBL5251	Homo sapiens	Inhibition	%	0.36
	8134779	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-1.06	CHEMBL5251	Homo sapiens	Inhibition	%	-1.06
	8134939	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-0.83	CHEMBL5251	Homo sapiens	Inhibition	%	-0.83
	8135163	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.43	CHEMBL5251	Homo sapiens	Inhibition	%	2.43
	8135278	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	-0.02	CHEMBL5251	Homo sapiens	Inhibition	%	-0.02
	8135643	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	0.6	CHEMBL5251	Homo sapiens	Inhibition	%	0.6
	8135764	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-4.19	CHEMBL5251	Homo sapiens	Inhibition	%	-4.19
	8135988	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-3.63	CHEMBL5251	Homo sapiens	Inhibition	%	-3.63
	8136156	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	-0.27	CHEMBL5251	Homo sapiens	Inhibition	%	-0.27
	8136300	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	6.68	CHEMBL5251	Homo sapiens	Inhibition	%	6.68
	8136524	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	-0.46	CHEMBL5251	Homo sapiens	Inhibition	%	-0.46
	8136590	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-1.73	CHEMBL5251	Homo sapiens	Inhibition	%	-1.73
	8136814	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-2.02	CHEMBL5251	Homo sapiens	Inhibition	%	-2.02
	8136949	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.53	CHEMBL5251	Homo sapiens	Inhibition	%	0.53
	8137112	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.01	CHEMBL5251	Homo sapiens	Inhibition	%	2.01
	8137336	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	1.43	CHEMBL5251	Homo sapiens	Inhibition	%	1.43
	8137456	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	1.7	CHEMBL5251	Homo sapiens	Inhibition	%	1.7
	8137828	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.15	CHEMBL5251	Homo sapiens	Inhibition	%	1.15
	8137994	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.32	CHEMBL5251	Homo sapiens	Inhibition	%	0.32
	8138397	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.43	CHEMBL5251	Homo sapiens	Inhibition	%	0.43
	8138545	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.38	CHEMBL5251	Homo sapiens	Inhibition	%	-0.38
	8138927	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.35	CHEMBL5251	Homo sapiens	Inhibition	%	0.35
	8139112	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.9	CHEMBL5251	Homo sapiens	Inhibition	%	-0.9
	8139495	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.75	CHEMBL5251	Homo sapiens	Inhibition	%	0.75
	8139609	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.47	CHEMBL5251	Homo sapiens	Inhibition	%	1.47
	8139833	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.16	CHEMBL5251	Homo sapiens	Inhibition	%	1.16
	8139974	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	-0.42	CHEMBL5251	Homo sapiens	Inhibition	%	-0.42
	8140321	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	-1.81	CHEMBL5251	Homo sapiens	Inhibition	%	-1.81
	8140480	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	-1.35	CHEMBL5251	Homo sapiens	Inhibition	%	-1.35
	8140847	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	0.77	CHEMBL5251	Homo sapiens	Inhibition	%	0.77
	8141149	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.01	CHEMBL5251	Homo sapiens	Inhibition	%	1.01
	8141279	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	3.13	CHEMBL5251	Homo sapiens	Inhibition	%	3.13
	8141663	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	4.2	CHEMBL5251	Homo sapiens	Inhibition	%	4.2
	8141782	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-1.07	CHEMBL5251	Homo sapiens	Inhibition	%	-1.07
	8142006	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	7.27	CHEMBL5251	Homo sapiens	Inhibition	%	7.27
	8142167	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.65	CHEMBL5251	Homo sapiens	Inhibition	%	0.65
	8142335	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.23	CHEMBL5251	Homo sapiens	Inhibition	%	-0.23
	8142559	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	0.52	CHEMBL5251	Homo sapiens	Inhibition	%	0.52
	8142735	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.66	CHEMBL5251	Homo sapiens	Inhibition	%	1.66
	8142884	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.46	CHEMBL5251	Homo sapiens	Inhibition	%	-0.46
	8143108	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.32	CHEMBL5251	Homo sapiens	Inhibition	%	-1.32
	8143263	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	-0.24	CHEMBL5251	Homo sapiens	Inhibition	%	-0.24
	8143450	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	-1.22	CHEMBL5251	Homo sapiens	Inhibition	%	-1.22
	8143674	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	-0.86	CHEMBL5251	Homo sapiens	Inhibition	%	-0.86
	8143833	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	0.51	CHEMBL5251	Homo sapiens	Inhibition	%	0.51
	8144171	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-3.57	CHEMBL5251	Homo sapiens	Inhibition	%	-3.57
	8144310	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	0.99	CHEMBL5251	Homo sapiens	Inhibition	%	0.99
	8144664	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	-0.67	CHEMBL5251	Homo sapiens	Inhibition	%	-0.67
	8144817	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	-1.58	CHEMBL5251	Homo sapiens	Inhibition	%	-1.58
	8145041	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	-0.59	CHEMBL5251	Homo sapiens	Inhibition	%	-0.59
	8145178	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	-0.83	CHEMBL5251	Homo sapiens	Inhibition	%	-0.83
	8145491	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	2.65	CHEMBL5251	Homo sapiens	Inhibition	%	2.65
	8145615	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.36	CHEMBL5251	Homo sapiens	Inhibition	%	0.36
	8145839	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.7	CHEMBL5251	Homo sapiens	Inhibition	%	0.7
	8146000	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	18.76	CHEMBL5251	Homo sapiens	Inhibition	%	18.76
	8146344	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	2.12	CHEMBL5251	Homo sapiens	Inhibition	%	2.12
	8146504	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	3.53	CHEMBL5251	Homo sapiens	Inhibition	%	3.53
	8146895	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-1.06	CHEMBL5251	Homo sapiens	Inhibition	%	-1.06
	8147064	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.29	CHEMBL5251	Homo sapiens	Inhibition	%	0.29
	8147430	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.03	CHEMBL5251	Homo sapiens	Inhibition	%	0.03
	8147583	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.11	CHEMBL5251	Homo sapiens	Inhibition	%	1.11
	8147994	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	-1.29	CHEMBL5251	Homo sapiens	Inhibition	%	-1.29
	8148152	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	5.18	CHEMBL5251	Homo sapiens	Inhibition	%	5.18
	8148490	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-0.34	CHEMBL5251	Homo sapiens	Inhibition	%	-0.34
	8148629	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	-0.77	CHEMBL5251	Homo sapiens	Inhibition	%	-0.77
	8148853	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	-0.84	CHEMBL5251	Homo sapiens	Inhibition	%	-0.84
	8148991	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	-0.49	CHEMBL5251	Homo sapiens	Inhibition	%	-0.49
	8149374	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-4.96	CHEMBL5251	Homo sapiens	Inhibition	%	-4.96
	8149508	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	1.59	CHEMBL5251	Homo sapiens	Inhibition	%	1.59
	8149830	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	3.71	CHEMBL5251	Homo sapiens	Inhibition	%	3.71
	8150179	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-3.7	CHEMBL5251	Homo sapiens	Inhibition	%	-3.7
	8150339	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	26.49	CHEMBL5251	Homo sapiens	Inhibition	%	26.49
	8150683	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	2.1	CHEMBL5251	Homo sapiens	Inhibition	%	2.1
	8150848	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.44	CHEMBL5251	Homo sapiens	Inhibition	%	0.44
	8151072	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	Inhibition	%	1.0
	8151235	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	0.06	CHEMBL5251	Homo sapiens	Inhibition	%	0.06
	8151412	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.46	CHEMBL5251	Homo sapiens	Inhibition	%	0.46
	8151774	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	-0.49	CHEMBL5251	Homo sapiens	Inhibition	%	-0.49
	8151928	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.09	CHEMBL5251	Homo sapiens	Inhibition	%	0.09
	8152152	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.7	CHEMBL5251	Homo sapiens	Inhibition	%	1.7
	8152340	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	0.81	CHEMBL5251	Homo sapiens	Inhibition	%	0.81
	8152498	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	-0.11	CHEMBL5251	Homo sapiens	Inhibition	%	-0.11
	8152722	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	0.49	CHEMBL5251	Homo sapiens	Inhibition	%	0.49
	8152836	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.21	CHEMBL5251	Homo sapiens	Inhibition	%	2.21
	8153199	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	-0.21	CHEMBL5251	Homo sapiens	Inhibition	%	-0.21
	8153336	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	0.73	CHEMBL5251	Homo sapiens	Inhibition	%	0.73
	8153717	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-5.01	CHEMBL5251	Homo sapiens	Inhibition	%	-5.01
	8153850	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	-1.55	CHEMBL5251	Homo sapiens	Inhibition	%	-1.55
	8154074	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	0.11	CHEMBL5251	Homo sapiens	Inhibition	%	0.11
	8154171	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	7.17	CHEMBL5251	Homo sapiens	Inhibition	%	7.17
	8154521	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-3.03	CHEMBL5251	Homo sapiens	Inhibition	%	-3.03
	8154680	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	2.52	CHEMBL5251	Homo sapiens	Inhibition	%	2.52
	8154904	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.29	CHEMBL5251	Homo sapiens	Inhibition	%	-0.29
	8155024	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.59	CHEMBL5251	Homo sapiens	Inhibition	%	0.59
	8155424	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.89	CHEMBL5251	Homo sapiens	Inhibition	%	0.89
	8155585	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-1.33	CHEMBL5251	Homo sapiens	Inhibition	%	-1.33
	8155763	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.24	CHEMBL5251	Homo sapiens	Inhibition	%	0.24
	8155987	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.76	CHEMBL5251	Homo sapiens	Inhibition	%	0.76
	8156125	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.07	CHEMBL5251	Homo sapiens	Inhibition	%	0.07
	8156337	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	7.04	CHEMBL5251	Homo sapiens	Inhibition	%	7.04
	8156561	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	0.73	CHEMBL5251	Homo sapiens	Inhibition	%	0.73
	8156711	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	8.89	CHEMBL5251	Homo sapiens	Inhibition	%	8.89
	8156854	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	Inhibition	%	0.0
	8157078	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	1.06	CHEMBL5251	Homo sapiens	Inhibition	%	1.06
	8157198	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.29	CHEMBL5251	Homo sapiens	Inhibition	%	1.29
	8157563	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	2.11	CHEMBL5251	Homo sapiens	Inhibition	%	2.11
	8157693	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.03	CHEMBL5251	Homo sapiens	Inhibition	%	3.03
	8157917	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	1.08	CHEMBL5251	Homo sapiens	Inhibition	%	1.08
	8158078	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	3.61	CHEMBL5251	Homo sapiens	Inhibition	%	3.61
	8158328	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	0.28	CHEMBL5251	Homo sapiens	Inhibition	%	0.28
	8158710	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-2.42	CHEMBL5251	Homo sapiens	Inhibition	%	-2.42
	8158879	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-1.19	CHEMBL5251	Homo sapiens	Inhibition	%	-1.19
	8159238	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	0.42	CHEMBL5251	Homo sapiens	Inhibition	%	0.42
	8159358	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	0.33	CHEMBL5251	Homo sapiens	Inhibition	%	0.33
	8159582	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-5.15	CHEMBL5251	Homo sapiens	Inhibition	%	-5.15
	8159713	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	0.41	CHEMBL5251	Homo sapiens	Inhibition	%	0.41
	8160078	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	-1.35	CHEMBL5251	Homo sapiens	Inhibition	%	-1.35
	8160215	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	0.98	CHEMBL5251	Homo sapiens	Inhibition	%	0.98
	8160589	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-0.78	CHEMBL5251	Homo sapiens	Inhibition	%	-0.78
	8160883	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.92	CHEMBL5251	Homo sapiens	Inhibition	%	1.92
	8161033	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.05	CHEMBL5251	Homo sapiens	Inhibition	%	1.05
	8161400	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	1.69	CHEMBL5251	Homo sapiens	Inhibition	%	1.69
	8161525	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	2.32	CHEMBL5251	Homo sapiens	Inhibition	%	2.32
	8161749	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	0.01	CHEMBL5251	Homo sapiens	Inhibition	%	0.01
	8161887	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	4.31	CHEMBL5251	Homo sapiens	Inhibition	%	4.31
	8162241	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	1.15	CHEMBL5251	Homo sapiens	Inhibition	%	1.15
	8162401	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-3.09	CHEMBL5251	Homo sapiens	Inhibition	%	-3.09
	8162654	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	-0.23	CHEMBL5251	Homo sapiens	Inhibition	%	-0.23
	8163026	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	0.4	CHEMBL5251	Homo sapiens	Inhibition	%	0.4
	8163195	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-2.01	CHEMBL5251	Homo sapiens	Inhibition	%	-2.01
	8163419	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-1.4	CHEMBL5251	Homo sapiens	Inhibition	%	-1.4
	8163553	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	-0.33	CHEMBL5251	Homo sapiens	Inhibition	%	-0.33
	8163900	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-4.99	CHEMBL5251	Homo sapiens	Inhibition	%	-4.99
	8164034	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	0.49	CHEMBL5251	Homo sapiens	Inhibition	%	0.49
	8164398	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-1.42	CHEMBL5251	Homo sapiens	Inhibition	%	-1.42
	8164553	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	3.11	CHEMBL5251	Homo sapiens	Inhibition	%	3.11
	8164777	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	2.23	CHEMBL5251	Homo sapiens	Inhibition	%	2.23
	8164921	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.08	CHEMBL5251	Homo sapiens	Inhibition	%	1.08
	8165215	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	0.46	CHEMBL5251	Homo sapiens	Inhibition	%	0.46
	8165356	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.3	CHEMBL5251	Homo sapiens	Inhibition	%	2.3
	8165580	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.41	CHEMBL5251	Homo sapiens	Inhibition	%	0.41
	8165723	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	3.99	CHEMBL5251	Homo sapiens	Inhibition	%	3.99
	8166073	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.37	CHEMBL5251	Homo sapiens	Inhibition	%	1.37
	8166211	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	0.73	CHEMBL5251	Homo sapiens	Inhibition	%	0.73
	8166565	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.03	CHEMBL5251	Homo sapiens	Inhibition	%	2.03
	8166890	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	34.93	CHEMBL5251	Homo sapiens	Inhibition	%	34.93
	8166978	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	-1.15	CHEMBL5251	Homo sapiens	Inhibition	%	-1.15
	8167202	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	-1.45	CHEMBL5251	Homo sapiens	Inhibition	%	-1.45
	8167343	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	3.74	CHEMBL5251	Homo sapiens	Inhibition	%	3.74
	8167731	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.24	CHEMBL5251	Homo sapiens	Inhibition	%	0.24
	8167864	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	0.19	CHEMBL5251	Homo sapiens	Inhibition	%	0.19
	8168212	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	-0.15	CHEMBL5251	Homo sapiens	Inhibition	%	-0.15
	8168353	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	-1.31	CHEMBL5251	Homo sapiens	Inhibition	%	-1.31
	8168577	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	0.41	CHEMBL5251	Homo sapiens	Inhibition	%	0.41
	8168713	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-1.35	CHEMBL5251	Homo sapiens	Inhibition	%	-1.35
	8169101	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	5.13	CHEMBL5251	Homo sapiens	Inhibition	%	5.13
	8169243	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	Inhibition	%	1.0
	8169547	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.22	CHEMBL5251	Homo sapiens	Inhibition	%	1.22
	8169905	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	-0.19	CHEMBL5251	Homo sapiens	Inhibition	%	-0.19
	8170050	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	2.44	CHEMBL5251	Homo sapiens	Inhibition	%	2.44
	8170399	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.48	CHEMBL5251	Homo sapiens	Inhibition	%	1.48
	8170539	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	0.11	CHEMBL5251	Homo sapiens	Inhibition	%	0.11
	8170763	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	-3.09	CHEMBL5251	Homo sapiens	Inhibition	%	-3.09
	8170898	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.36	CHEMBL5251	Homo sapiens	Inhibition	%	2.36
	8171095	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	1.43	CHEMBL5251	Homo sapiens	Inhibition	%	1.43
	8171319	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	7.82	CHEMBL5251	Homo sapiens	Inhibition	%	7.82
	8171536	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	-2.04	CHEMBL5251	Homo sapiens	Inhibition	%	-2.04
	8171677	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	0.08	CHEMBL5251	Homo sapiens	Inhibition	%	0.08
	8172054	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-5.62	CHEMBL5251	Homo sapiens	Inhibition	%	-5.62
	8172186	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	-0.49	CHEMBL5251	Homo sapiens	Inhibition	%	-0.49
	8172410	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	0.87	CHEMBL5251	Homo sapiens	Inhibition	%	0.87
	8172538	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	-1.83	CHEMBL5251	Homo sapiens	Inhibition	%	-1.83
	8172904	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	0.35	CHEMBL5251	Homo sapiens	Inhibition	%	0.35
	8173040	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.13	CHEMBL5251	Homo sapiens	Inhibition	%	-0.13
	8173429	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	-0.08	CHEMBL5251	Homo sapiens	Inhibition	%	-0.08
	8173570	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.7	CHEMBL5251	Homo sapiens	Inhibition	%	1.7
	8173794	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	0.22	CHEMBL5251	Homo sapiens	Inhibition	%	0.22
	8173881	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.88	CHEMBL5251	Homo sapiens	Inhibition	%	1.88
	8174237	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.9	CHEMBL5251	Homo sapiens	Inhibition	%	1.9
	8174385	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	9.01	CHEMBL5251	Homo sapiens	Inhibition	%	9.01
	8174609	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.12	CHEMBL5251	Homo sapiens	Inhibition	%	1.12
	8174731	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.48	CHEMBL5251	Homo sapiens	Inhibition	%	1.48
	8175098	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	-3.54	CHEMBL5251	Homo sapiens	Inhibition	%	-3.54
	8175234	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	-1.04	CHEMBL5251	Homo sapiens	Inhibition	%	-1.04
	8175458	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	-0.53	CHEMBL5251	Homo sapiens	Inhibition	%	-0.53
	8175490	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	0.25	CHEMBL5251	Homo sapiens	Inhibition	%	0.25
	8175714	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	-0.4	CHEMBL5251	Homo sapiens	Inhibition	%	-0.4
	8175877	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	-0.96	CHEMBL5251	Homo sapiens	Inhibition	%	-0.96
	8176030	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	1.1	CHEMBL5251	Homo sapiens	Inhibition	%	1.1
	8176254	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	-0.77	CHEMBL5251	Homo sapiens	Inhibition	%	-0.77
	8176403	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-4.52	CHEMBL5251	Homo sapiens	Inhibition	%	-4.52
	8176759	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.29	CHEMBL5251	Homo sapiens	Inhibition	%	4.29
	8176889	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.31	CHEMBL5251	Homo sapiens	Inhibition	%	0.31
	8177255	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-0.39	CHEMBL5251	Homo sapiens	Inhibition	%	-0.39
	8177393	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-1.52	CHEMBL5251	Homo sapiens	Inhibition	%	-1.52
	8177617	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	0.07	CHEMBL5251	Homo sapiens	Inhibition	%	0.07
	8177781	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.16	CHEMBL5251	Homo sapiens	Inhibition	%	2.16
	8178145	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.61	CHEMBL5251	Homo sapiens	Inhibition	%	1.61
	8178233	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.29	CHEMBL5251	Homo sapiens	Inhibition	%	1.29
	8178457	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	-1.08	CHEMBL5251	Homo sapiens	Inhibition	%	-1.08
	8178584	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.92	CHEMBL5251	Homo sapiens	Inhibition	%	2.92
	8178957	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.69	CHEMBL5251	Homo sapiens	Inhibition	%	1.69
	8179080	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.15	CHEMBL5251	Homo sapiens	Inhibition	%	1.15
	8179304	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.29	CHEMBL5251	Homo sapiens	Inhibition	%	1.29
	8179448	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	0.85	CHEMBL5251	Homo sapiens	Inhibition	%	0.85
	8179809	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	-0.01	CHEMBL5251	Homo sapiens	Inhibition	%	-0.01
	8180066	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	-0.63	CHEMBL5251	Homo sapiens	Inhibition	%	-0.63
	8180220	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	6.74	CHEMBL5251	Homo sapiens	Inhibition	%	6.74
	8180600	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	0.66	CHEMBL5251	Homo sapiens	Inhibition	%	0.66
	8180748	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	-1.88	CHEMBL5251	Homo sapiens	Inhibition	%	-1.88
	8181105	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	63.84	CHEMBL5251	Homo sapiens	Inhibition	%	63.84
	8181236	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-1.64	CHEMBL5251	Homo sapiens	Inhibition	%	-1.64
	8181460	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-2.32	CHEMBL5251	Homo sapiens	Inhibition	%	-2.32
	8181600	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	7.14	CHEMBL5251	Homo sapiens	Inhibition	%	7.14
	8181963	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	8.32	CHEMBL5251	Homo sapiens	Inhibition	%	8.32
	8182126	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	0.27	CHEMBL5251	Homo sapiens	Inhibition	%	0.27
	8182490	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.62	CHEMBL5251	Homo sapiens	Inhibition	%	1.62
	8182806	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.74	CHEMBL5251	Homo sapiens	Inhibition	%	0.74
	8182928	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.48	CHEMBL5251	Homo sapiens	Inhibition	%	1.48
	8183152	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.13	CHEMBL5251	Homo sapiens	Inhibition	%	1.13
	8183301	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	3.67	CHEMBL5251	Homo sapiens	Inhibition	%	3.67
	8183654	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.26	CHEMBL5251	Homo sapiens	Inhibition	%	0.26
	8183796	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	0.4	CHEMBL5251	Homo sapiens	Inhibition	%	0.4
	8184156	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.03	CHEMBL5251	Homo sapiens	Inhibition	%	0.03
	8184422	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	-0.24	CHEMBL5251	Homo sapiens	Inhibition	%	-0.24
	8184569	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-5.43	CHEMBL5251	Homo sapiens	Inhibition	%	-5.43
	8184793	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-4.27	CHEMBL5251	Homo sapiens	Inhibition	%	-4.27
	8184950	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	-1.09	CHEMBL5251	Homo sapiens	Inhibition	%	-1.09
	8185099	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	-0.24	CHEMBL5251	Homo sapiens	Inhibition	%	-0.24
	8185323	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-1.42	CHEMBL5251	Homo sapiens	Inhibition	%	-1.42
	8185454	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	77.27	CHEMBL5251	Homo sapiens	Inhibition	%	77.27
	8185809	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-1.09	CHEMBL5251	Homo sapiens	Inhibition	%	-1.09
	8185948	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.13	CHEMBL5251	Homo sapiens	Inhibition	%	1.13
	8186172	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	2.12	CHEMBL5251	Homo sapiens	Inhibition	%	2.12
	8186313	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	0.77	CHEMBL5251	Homo sapiens	Inhibition	%	0.77
	8186477	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	0.99	CHEMBL5251	Homo sapiens	Inhibition	%	0.99
	8186701	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.91	CHEMBL5251	Homo sapiens	Inhibition	%	1.91
	8186840	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.94	CHEMBL5251	Homo sapiens	Inhibition	%	0.94
	8187162	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	-0.17	CHEMBL5251	Homo sapiens	Inhibition	%	-0.17
	8187510	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.66	CHEMBL5251	Homo sapiens	Inhibition	%	1.66
	8187658	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	21.64	CHEMBL5251	Homo sapiens	Inhibition	%	21.64
	8188011	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	7.22	CHEMBL5251	Homo sapiens	Inhibition	%	7.22
	8188154	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	0.31	CHEMBL5251	Homo sapiens	Inhibition	%	0.31
	8188378	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	0.56	CHEMBL5251	Homo sapiens	Inhibition	%	0.56
	8188513	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	-4.35	CHEMBL5251	Homo sapiens	Inhibition	%	-4.35
	8188787	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	-0.71	CHEMBL5251	Homo sapiens	Inhibition	%	-0.71
	8189159	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	-0.92	CHEMBL5251	Homo sapiens	Inhibition	%	-0.92
	8189315	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	5.26	CHEMBL5251	Homo sapiens	Inhibition	%	5.26
	8189688	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.78	CHEMBL5251	Homo sapiens	Inhibition	%	-0.78
	8189820	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-3.76	CHEMBL5251	Homo sapiens	Inhibition	%	-3.76
	8190044	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	1.2	CHEMBL5251	Homo sapiens	Inhibition	%	1.2
	8190176	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	1.5	CHEMBL5251	Homo sapiens	Inhibition	%	1.5
	8190540	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.6	CHEMBL5251	Homo sapiens	Inhibition	%	1.6
	8190677	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	0.68	CHEMBL5251	Homo sapiens	Inhibition	%	0.68
	8191065	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.84	CHEMBL5251	Homo sapiens	Inhibition	%	0.84
	8191203	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.45	CHEMBL5251	Homo sapiens	Inhibition	%	2.45
	8191427	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	3.65	CHEMBL5251	Homo sapiens	Inhibition	%	3.65
	8191523	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.64	CHEMBL5251	Homo sapiens	Inhibition	%	2.64
	8191869	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	2.02	CHEMBL5251	Homo sapiens	Inhibition	%	2.02
	8192018	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	2.48	CHEMBL5251	Homo sapiens	Inhibition	%	2.48
	8192242	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	2.98	CHEMBL5251	Homo sapiens	Inhibition	%	2.98
	8192371	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.04	CHEMBL5251	Homo sapiens	Inhibition	%	0.04
	8192739	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	0.03	CHEMBL5251	Homo sapiens	Inhibition	%	0.03
	8192875	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	-3.39	CHEMBL5251	Homo sapiens	Inhibition	%	-3.39
	8193147	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.62	CHEMBL5251	Homo sapiens	Inhibition	%	2.62
	8193516	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.84	CHEMBL5251	Homo sapiens	Inhibition	%	0.84
	8193673	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	0.73	CHEMBL5251	Homo sapiens	Inhibition	%	0.73
	8193897	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	-0.4	CHEMBL5251	Homo sapiens	Inhibition	%	-0.4
	8194046	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.03	CHEMBL5251	Homo sapiens	Inhibition	%	0.03
	8194401	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	0.81	CHEMBL5251	Homo sapiens	Inhibition	%	0.81
	8194532	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.07	CHEMBL5251	Homo sapiens	Inhibition	%	2.07
	8194899	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	11.79	CHEMBL5251	Homo sapiens	Inhibition	%	11.79
	8195032	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.96	CHEMBL5251	Homo sapiens	Inhibition	%	0.96
	8195256	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.09	CHEMBL5251	Homo sapiens	Inhibition	%	0.09
	8195420	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.4	CHEMBL5251	Homo sapiens	Inhibition	%	1.4
	8195783	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	3.02	CHEMBL5251	Homo sapiens	Inhibition	%	3.02
	8195881	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.06	CHEMBL5251	Homo sapiens	Inhibition	%	0.06
	8196105	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.16	CHEMBL5251	Homo sapiens	Inhibition	%	0.16
	8196222	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.25	CHEMBL5251	Homo sapiens	Inhibition	%	0.25
	8196596	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.84	CHEMBL5251	Homo sapiens	Inhibition	%	2.84
	8196724	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.36	CHEMBL5251	Homo sapiens	Inhibition	%	2.36
	8197089	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.29	CHEMBL5251	Homo sapiens	Inhibition	%	1.29
	8197226	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.58	CHEMBL5251	Homo sapiens	Inhibition	%	-0.58
	8197450	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.1	CHEMBL5251	Homo sapiens	Inhibition	%	-0.1
	8197501	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	0.21	CHEMBL5251	Homo sapiens	Inhibition	%	0.21
	8197725	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	-0.9	CHEMBL5251	Homo sapiens	Inhibition	%	-0.9
	8197865	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-0.87	CHEMBL5251	Homo sapiens	Inhibition	%	-0.87
	8198246	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-2.44	CHEMBL5251	Homo sapiens	Inhibition	%	-2.44
	8198384	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-1.53	CHEMBL5251	Homo sapiens	Inhibition	%	-1.53
	8198738	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	15.88	CHEMBL5251	Homo sapiens	Inhibition	%	15.88
	8198869	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	0.29	CHEMBL5251	Homo sapiens	Inhibition	%	0.29
	8199093	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	0.58	CHEMBL5251	Homo sapiens	Inhibition	%	0.58
	8199241	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	1.64	CHEMBL5251	Homo sapiens	Inhibition	%	1.64
	8199599	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.18	CHEMBL5251	Homo sapiens	Inhibition	%	1.18
	8199762	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.76	CHEMBL5251	Homo sapiens	Inhibition	%	1.76
	8200124	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	3.51	CHEMBL5251	Homo sapiens	Inhibition	%	3.51
	8200452	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.8	CHEMBL5251	Homo sapiens	Inhibition	%	0.8
	8200567	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.7	CHEMBL5251	Homo sapiens	Inhibition	%	1.7
	8200941	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	6.06	CHEMBL5251	Homo sapiens	Inhibition	%	6.06
	8201071	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-2.66	CHEMBL5251	Homo sapiens	Inhibition	%	-2.66
	8201295	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-0.98	CHEMBL5251	Homo sapiens	Inhibition	%	-0.98
	8201430	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.49	CHEMBL5251	Homo sapiens	Inhibition	%	0.49
	8201787	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.17	CHEMBL5251	Homo sapiens	Inhibition	%	-0.17
	8202066	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	0.73	CHEMBL5251	Homo sapiens	Inhibition	%	0.73
	8202206	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	1.14	CHEMBL5251	Homo sapiens	Inhibition	%	1.14
	8202597	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-3.5	CHEMBL5251	Homo sapiens	Inhibition	%	-3.5
	8202722	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.31	CHEMBL5251	Homo sapiens	Inhibition	%	0.31
	8202946	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	-1.93	CHEMBL5251	Homo sapiens	Inhibition	%	-1.93
	8203076	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	-1.36	CHEMBL5251	Homo sapiens	Inhibition	%	-1.36
	8203431	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-2.88	CHEMBL5251	Homo sapiens	Inhibition	%	-2.88
	8203577	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	4.82	CHEMBL5251	Homo sapiens	Inhibition	%	4.82
	8203935	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	0.79	CHEMBL5251	Homo sapiens	Inhibition	%	0.79
	8204101	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.92	CHEMBL5251	Homo sapiens	Inhibition	%	0.92
	8204325	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	12.76	CHEMBL5251	Homo sapiens	Inhibition	%	12.76
	8204462	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	4.79	CHEMBL5251	Homo sapiens	Inhibition	%	4.79
	8204791	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	2.63	CHEMBL5251	Homo sapiens	Inhibition	%	2.63
	8204906	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	1.57	CHEMBL5251	Homo sapiens	Inhibition	%	1.57
	8205130	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	7.64	CHEMBL5251	Homo sapiens	Inhibition	%	7.64
	8205279	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.63	CHEMBL5251	Homo sapiens	Inhibition	%	1.63
	8205639	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	1.49	CHEMBL5251	Homo sapiens	Inhibition	%	1.49
	8205778	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	-0.08	CHEMBL5251	Homo sapiens	Inhibition	%	-0.08
	8206134	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.66	CHEMBL5251	Homo sapiens	Inhibition	%	0.66
	8206410	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	-0.77	CHEMBL5251	Homo sapiens	Inhibition	%	-0.77
	8206553	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-1.45	CHEMBL5251	Homo sapiens	Inhibition	%	-1.45
	8206777	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.23	CHEMBL5251	Homo sapiens	Inhibition	%	-0.23
	8206957	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	0.72	CHEMBL5251	Homo sapiens	Inhibition	%	0.72
	8207307	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	0.83	CHEMBL5251	Homo sapiens	Inhibition	%	0.83
	8207437	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	1.02	CHEMBL5251	Homo sapiens	Inhibition	%	1.02
	8207793	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.31	CHEMBL5251	Homo sapiens	Inhibition	%	1.31
	8207938	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	-1.19	CHEMBL5251	Homo sapiens	Inhibition	%	-1.19
	8208162	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	-2.44	CHEMBL5251	Homo sapiens	Inhibition	%	-2.44
	8208294	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	2.09	CHEMBL5251	Homo sapiens	Inhibition	%	2.09
	8208684	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.23	CHEMBL5251	Homo sapiens	Inhibition	%	0.23
	8208817	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	34.46	CHEMBL5251	Homo sapiens	Inhibition	%	34.46
	8209146	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	-0.93	CHEMBL5251	Homo sapiens	Inhibition	%	-0.93
	8209486	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	1.06	CHEMBL5251	Homo sapiens	Inhibition	%	1.06
	8209636	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	2.33	CHEMBL5251	Homo sapiens	Inhibition	%	2.33
	8209996	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	2.44	CHEMBL5251	Homo sapiens	Inhibition	%	2.44
	8210137	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.4	CHEMBL5251	Homo sapiens	Inhibition	%	1.4
	8210361	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.39	CHEMBL5251	Homo sapiens	Inhibition	%	2.39
	8210497	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-1.38	CHEMBL5251	Homo sapiens	Inhibition	%	-1.38
	8210756	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-1.06	CHEMBL5251	Homo sapiens	Inhibition	%	-1.06
	8211124	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	-0.65	CHEMBL5251	Homo sapiens	Inhibition	%	-0.65
	8211294	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	0.12	CHEMBL5251	Homo sapiens	Inhibition	%	0.12
	8211641	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	-0.84	CHEMBL5251	Homo sapiens	Inhibition	%	-0.84
	8211770	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	-0.08	CHEMBL5251	Homo sapiens	Inhibition	%	-0.08
	8211994	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	0.5	CHEMBL5251	Homo sapiens	Inhibition	%	0.5
	8212126	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-0.27	CHEMBL5251	Homo sapiens	Inhibition	%	-0.27
	8212491	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	-1.4	CHEMBL5251	Homo sapiens	Inhibition	%	-1.4
	8212624	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.28	CHEMBL5251	Homo sapiens	Inhibition	%	1.28
	8212848	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	0.03	CHEMBL5251	Homo sapiens	Inhibition	%	0.03
	8213018	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	11.43	CHEMBL5251	Homo sapiens	Inhibition	%	11.43
	8213147	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.67	CHEMBL5251	Homo sapiens	Inhibition	%	1.67
	8213371	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.98	CHEMBL5251	Homo sapiens	Inhibition	%	1.98
	8213475	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	3.93	CHEMBL5251	Homo sapiens	Inhibition	%	3.93
	8213812	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.04	CHEMBL5251	Homo sapiens	Inhibition	%	0.04
	8213959	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.8	CHEMBL5251	Homo sapiens	Inhibition	%	1.8
	8214183	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.47	CHEMBL5251	Homo sapiens	Inhibition	%	1.47
	8214320	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	1.78	CHEMBL5251	Homo sapiens	Inhibition	%	1.78
	8214678	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	3.4	CHEMBL5251	Homo sapiens	Inhibition	%	3.4
	8214830	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.05	CHEMBL5251	Homo sapiens	Inhibition	%	0.05
	8215081	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-4.02	CHEMBL5251	Homo sapiens	Inhibition	%	-4.02
	8215305	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	-0.92	CHEMBL5251	Homo sapiens	Inhibition	%	-0.92
	8215458	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.6	CHEMBL5251	Homo sapiens	Inhibition	%	1.6
	8215622	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.02	CHEMBL5251	Homo sapiens	Inhibition	%	0.02
	8215846	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.23	CHEMBL5251	Homo sapiens	Inhibition	%	2.23
	8215965	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-2.66	CHEMBL5251	Homo sapiens	Inhibition	%	-2.66
	8216308	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	-0.59	CHEMBL5251	Homo sapiens	Inhibition	%	-0.59
	8216444	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	0.84	CHEMBL5251	Homo sapiens	Inhibition	%	0.84
	8216668	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	-0.87	CHEMBL5251	Homo sapiens	Inhibition	%	-0.87
	8216806	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	-0.88	CHEMBL5251	Homo sapiens	Inhibition	%	-0.88
	8217164	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.05	CHEMBL5251	Homo sapiens	Inhibition	%	1.05
	8217338	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	-0.86	CHEMBL5251	Homo sapiens	Inhibition	%	-0.86
	8217693	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.87	CHEMBL5251	Homo sapiens	Inhibition	%	1.87
	8217794	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.05	CHEMBL5251	Homo sapiens	Inhibition	%	-0.05
	8218018	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	0.05	CHEMBL5251	Homo sapiens	Inhibition	%	0.05
	8218133	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.76	CHEMBL5251	Homo sapiens	Inhibition	%	0.76
	8218484	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	1.25	CHEMBL5251	Homo sapiens	Inhibition	%	1.25
	8218627	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	6.48	CHEMBL5251	Homo sapiens	Inhibition	%	6.48
	8218851	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.43	CHEMBL5251	Homo sapiens	Inhibition	%	1.43
	8218982	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	29.06	CHEMBL5251	Homo sapiens	Inhibition	%	29.06
	8219142	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	0.21	CHEMBL5251	Homo sapiens	Inhibition	%	0.21
	8219366	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	6.66	CHEMBL5251	Homo sapiens	Inhibition	%	6.66
	8219616	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	-0.14	CHEMBL5251	Homo sapiens	Inhibition	%	-0.14
	8219777	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	0.04	CHEMBL5251	Homo sapiens	Inhibition	%	0.04
	8220170	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.52	CHEMBL5251	Homo sapiens	Inhibition	%	0.52
	8220299	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-4.6	CHEMBL5251	Homo sapiens	Inhibition	%	-4.6
	8220637	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	-2.44	CHEMBL5251	Homo sapiens	Inhibition	%	-2.44
	8220999	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	0.47	CHEMBL5251	Homo sapiens	Inhibition	%	0.47
	8221135	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	-4.68	CHEMBL5251	Homo sapiens	Inhibition	%	-4.68
	8221492	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	-0.37	CHEMBL5251	Homo sapiens	Inhibition	%	-0.37
	8221657	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.56	CHEMBL5251	Homo sapiens	Inhibition	%	0.56
	8222012	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	11.84	CHEMBL5251	Homo sapiens	Inhibition	%	11.84
	8222334	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	2.71	CHEMBL5251	Homo sapiens	Inhibition	%	2.71
	8222468	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.19	CHEMBL5251	Homo sapiens	Inhibition	%	1.19
	8222810	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	1.98	CHEMBL5251	Homo sapiens	Inhibition	%	1.98
	8223178	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	13.27	CHEMBL5251	Homo sapiens	Inhibition	%	13.27
	8223307	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.7	CHEMBL5251	Homo sapiens	Inhibition	%	0.7
	8223692	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	0.23	CHEMBL5251	Homo sapiens	Inhibition	%	0.23
	8223942	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	-2.49	CHEMBL5251	Homo sapiens	Inhibition	%	-2.49
	8224104	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.7	CHEMBL5251	Homo sapiens	Inhibition	%	2.7
	8224328	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-3.6	CHEMBL5251	Homo sapiens	Inhibition	%	-3.6
	8224498	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.39	CHEMBL5251	Homo sapiens	Inhibition	%	0.39
	8224633	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	1.29	CHEMBL5251	Homo sapiens	Inhibition	%	1.29
	8224857	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	-0.86	CHEMBL5251	Homo sapiens	Inhibition	%	-0.86
	8224971	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	-0.51	CHEMBL5251	Homo sapiens	Inhibition	%	-0.51
	8225329	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	-0.39	CHEMBL5251	Homo sapiens	Inhibition	%	-0.39
	8225467	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	-4.91	CHEMBL5251	Homo sapiens	Inhibition	%	-4.91
	8225691	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	-0.42	CHEMBL5251	Homo sapiens	Inhibition	%	-0.42
	8225826	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.06	CHEMBL5251	Homo sapiens	Inhibition	%	0.06
	8225984	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.93	CHEMBL5251	Homo sapiens	Inhibition	%	-0.93
	8226208	CHEMBL1962253	GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.22	CHEMBL5251	Homo sapiens	Inhibition	%	0.22
	8226333	CHEMBL1962252	GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	0.96	CHEMBL5251	Homo sapiens	Inhibition	%	0.96
inactive	9620436	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620437	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)CCOc1cc(-c2ccc(C(N)=O)cc2)cc2[nH]nc(N)c12		CHEMBL2001398	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620438	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9620439	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9620440	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620441	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9620442	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
active	9620443	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	=	Ki	nM	25.12	CHEMBL5251	Homo sapiens	pKi		7.6
inactive	9620444	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9620445	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	100.0	CHEMBL5251	Homo sapiens	pKi		7.0
inactive	9620446	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620447	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9620448	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9620449	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620450	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620451	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620452	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620453	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620454	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620455	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620456	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620457	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	50118.72	CHEMBL5251	Homo sapiens	pKi		4.3
inactive	9620458	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620459	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620460	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620461	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620462	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620463	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620464	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620465	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620466	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620467	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620468	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620469	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620470	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620471	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9620472	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	794.33	CHEMBL5251	Homo sapiens	pKi		6.1
inactive	9620473	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620474	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620475	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620476	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620477	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620478	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620479	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	<	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9620480	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9620481	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1C(=O)Nc1ccccc1N2		CHEMBL1980671	=	Ki	nM	50118.72	CHEMBL5251	Homo sapiens	pKi		4.3
inactive	9620482	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620483	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620484	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620485	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9620486	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9620487	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624034	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624035	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	10000.0	CHEMBL5251	Homo sapiens	pKi		5.0
active	9624036	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	=	Ki	nM	3.162	CHEMBL5251	Homo sapiens	pKi		8.5
active	9624037	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=CN(O)C(CS(=O)(=O)c1ccc(-c2ccc(C(F)(F)F)cc2)cc1)c1ccc(O)cc1		CHEMBL1971227	=	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624038	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
inactive	9624039	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624040	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624041	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	79432.82	CHEMBL5251	Homo sapiens	pKi		4.1
active	9624042	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9624043	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624044	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624045	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624046	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624047	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624048	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624049	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	=	Ki	nM	251.19	CHEMBL5251	Homo sapiens	pKi		6.6
active	9624050	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1966842	=	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9624051	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624052	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624053	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	19.95	CHEMBL5251	Homo sapiens	pKi		7.7
active	9624054	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624055	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624056	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624057	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624058	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624059	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624060	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624061	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624062	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1c2cc([N+](=O)[O-])ccc2-n2c1nc1cccc(Br)c1c2=O		CHEMBL1976158	<	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9624063	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624064	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624065	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
inactive	9624066	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9624067	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624068	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624069	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624070	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624071	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624072	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C1		CHEMBL1971132	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624073	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624074	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624075	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624076	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(=O)[nH]c2[nH]nc(-c3cccc(C(F)(F)F)c3)c12		CHEMBL1991377	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624077	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
inactive	9624078	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624079	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	12.59	CHEMBL5251	Homo sapiens	pKi		7.9
inactive	9624080	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624081	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1		CHEMBL1972462	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624082	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	31.62	CHEMBL5251	Homo sapiens	pKi		7.5
inactive	9624083	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624084	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624085	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9624086	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624087	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624088	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624089	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624090	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624091	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	31.62	CHEMBL5251	Homo sapiens	pKi		7.5
inactive	9624092	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9624093	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624094	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624095	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
inactive	9624096	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624097	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624098	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624099	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624100	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624101	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9624102	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624103	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624104	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624105	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
active	9624106	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)c1cc(=O)[nH]c2[nH][nH]c(=O)c12		CHEMBL1999120	=	Ki	nM	50118.72	CHEMBL5251	Homo sapiens	pKi		4.3
inactive	9624107	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624108	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624109	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624110	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624111	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9624112	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624113	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624114	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1Cl)c1ccccc1F		CHEMBL2001228	=	Ki	nM	1995.26	CHEMBL5251	Homo sapiens	pKi		5.7
inactive	9624115	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	39810.72	CHEMBL5251	Homo sapiens	pKi		4.4
inactive	9624116	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624117	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624118	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624119	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOC(=O)Cc1nc2c(N)cccc2[nH]1		CHEMBL1981671	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624120	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624121	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624122	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624123	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624124	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624125	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624126	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624127	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	=	Ki	nM	1995.26	CHEMBL5251	Homo sapiens	pKi		5.7
inactive	9624128	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624129	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624130	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9624131	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	=	Ki	nM	79.43	CHEMBL5251	Homo sapiens	pKi		7.1
active	9624132	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1ccc(CNc2nc(Nc3cc(C4CC4)[nH]n3)c3sccc3n2)cc1		CHEMBL1997924	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624133	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624134	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624135	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624136	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1c(NC(=O)Cc2ccccc2)cccc1-c1nc2sccn2c1-c1ccnc(Nc2cccc(N3CCOCC3)c2)n1		CHEMBL1971485	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624137	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)c1ccccc1		CHEMBL1978267	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624138	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624139	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624140	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624141	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624142	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)CC(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1992334	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624143	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624144	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624145	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624146	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	125.89	CHEMBL5251	Homo sapiens	pKi		6.9
inactive	9624147	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624148	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	63095.73	CHEMBL5251	Homo sapiens	pKi		4.2
inactive	9624149	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624150	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624151	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]n2ccccc2c1Br		CHEMBL2004033	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
active	9624152	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	=	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
active	9624153	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9624154	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624155	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624156	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9624157	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1ccccc1N1CCCC1)c1ccc2ccccc2n1		CHEMBL2002799	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624158	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	1000.0	CHEMBL5251	Homo sapiens	pKi		6.0
inactive	9624159	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624160	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624161	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624162	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624163	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624164	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624165	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	125.89	CHEMBL5251	Homo sapiens	pKi		6.9
inactive	9624166	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624167	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624168	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12		CHEMBL1990590	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624169	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624170	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624171	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	=	Ki	nM	100000.0	CHEMBL5251	Homo sapiens	pKi		4.0
inactive	9624172	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624173	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624174	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
active	9624175	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
inactive	9624176	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624177	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	=	Ki	nM	794.33	CHEMBL5251	Homo sapiens	pKi		6.1
inactive	9624178	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624179	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624180	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624181	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624182	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	79.43	CHEMBL5251	Homo sapiens	pKi		7.1
inactive	9624183	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624184	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624185	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624186	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624187	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624188	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624189	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624190	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624191	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624192	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	=	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9624193	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624194	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624195	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	=	Ki	nM	125.89	CHEMBL5251	Homo sapiens	pKi		6.9
inactive	9624196	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624197	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624198	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624199	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCNc1ccc(O)c2ccccc12		CHEMBL576113	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624200	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624201	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624202	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	=	Ki	nM	31.62	CHEMBL5251	Homo sapiens	pKi		7.5
inactive	9624203	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624204	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	25118.86	CHEMBL5251	Homo sapiens	pKi		4.6
inactive	9624205	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624206	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624207	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624208	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624209	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624210	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624211	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)NCCO)cc2)n1		CHEMBL2006149	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624212	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624213	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9624214	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624215	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624216	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624217	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Ki	nM	63.1	CHEMBL5251	Homo sapiens	pKi		7.2
inactive	9624218	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624219	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
inactive	9624220	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624221	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624222	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624223	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
active	9624224	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624225	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624226	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	125.89	CHEMBL5251	Homo sapiens	pKi		6.9
inactive	9624227	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624228	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9624229	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624230	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9624231	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624232	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Ki	nM	1995.26	CHEMBL5251	Homo sapiens	pKi		5.7
inactive	9624233	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624234	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624235	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624236	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1971223	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624237	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624238	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624239	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccccc3Cl)n2)c1		CHEMBL1995428	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624240	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624241	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624242	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624243	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	<	Ki	nM	1995.26	CHEMBL5251	Homo sapiens	pKi		5.7
inactive	9624244	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624245	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9624246	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	501.19	CHEMBL5251	Homo sapiens	pKi		6.3
inactive	9624247	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624248	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624249	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9624250	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624251	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624252	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624253	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624254	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624255	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624256	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624257	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624258	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624259	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624260	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9624261	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624262	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9624263	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624264	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	=	Ki	nM	10.0	CHEMBL5251	Homo sapiens	pKi		8.0
inactive	9624265	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9624266	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
inactive	9624267	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627822	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627823	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627824	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	=	Ki	nM	501.19	CHEMBL5251	Homo sapiens	pKi		6.3
active	9627825	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	1584.89	CHEMBL5251	Homo sapiens	pKi		5.8
inactive	9627826	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627827	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	=	Ki	nM	316.23	CHEMBL5251	Homo sapiens	pKi		6.5
inactive	9627828	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627829	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	=	Ki	nM	1000.0	CHEMBL5251	Homo sapiens	pKi		6.0
inactive	9627830	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9627831	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
inactive	9627832	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627833	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627834	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2scc(-c3ccccc3)c12		CHEMBL1975212	=	Ki	nM	31622.78	CHEMBL5251	Homo sapiens	pKi		4.5
active	9627835	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	31622.78	CHEMBL5251	Homo sapiens	pKi		4.5
inactive	9627836	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627837	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627838	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627839	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627840	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12		CHEMBL2000724	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627841	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627842	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
active	9627843	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	316.23	CHEMBL5251	Homo sapiens	pKi		6.5
inactive	9627844	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627845	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627846	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627847	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627848	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627849	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627850	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627851	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627852	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627853	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627854	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	=	Ki	nM	1000.0	CHEMBL5251	Homo sapiens	pKi		6.0
inactive	9627855	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627856	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	=	Ki	nM	19.95	CHEMBL5251	Homo sapiens	pKi		7.7
inactive	9627857	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9627858	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
inactive	9627859	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627860	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627861	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627862	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627863	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	=	Ki	nM	1584.89	CHEMBL5251	Homo sapiens	pKi		5.8
inactive	9627864	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627865	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627866	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627867	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627868	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627869	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627870	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627871	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627872	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627873	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627874	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627875	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOCC(C)Oc1cccc2[nH]nc(N)c12		CHEMBL2002736	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627876	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627877	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627878	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627879	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627880	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627881	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627882	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627883	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627884	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
active	9627885	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	39.81	CHEMBL5251	Homo sapiens	pKi		7.4
inactive	9627886	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4c(F)cccc4F)c3)nc3sccn23)n1		CHEMBL1997051	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627887	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	=	Ki	nM	251.19	CHEMBL5251	Homo sapiens	pKi		6.6
inactive	9627888	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627889	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627890	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627891	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627892	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627893	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627894	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	=	Ki	nM	316.23	CHEMBL5251	Homo sapiens	pKi		6.5
active	9627895	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9627896	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627897	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627898	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9627899	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	=	Ki	nM	501.19	CHEMBL5251	Homo sapiens	pKi		6.3
inactive	9627900	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627901	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9627902	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
inactive	9627903	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627904	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627905	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627906	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627907	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627908	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627909	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627910	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627911	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(NC(=O)CC2Nc3ccccc3NC2=O)cc1		CHEMBL1985469	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627912	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627913	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12		CHEMBL1994308	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627914	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	1995.26	CHEMBL5251	Homo sapiens	pKi		5.7
active	9627915	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9627916	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627917	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
active	9627918	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	50.12	CHEMBL5251	Homo sapiens	pKi		7.3
inactive	9627919	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627920	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627921	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627922	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627923	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627924	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627925	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627926	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627927	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627928	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627929	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	=	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627930	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627931	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627932	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627933	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
inactive	9627934	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9627935	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL1969483	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627936	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	=	Ki	nM	794.33	CHEMBL5251	Homo sapiens	pKi		6.1
inactive	9627937	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627938	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9627939	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627940	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627941	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627942	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	12.59	CHEMBL5251	Homo sapiens	pKi		7.9
inactive	9627943	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627944	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627945	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9627946	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ccc2c(C(=O)O)n(-c3ccccc3)nc2c1		CHEMBL1974574	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627947	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627948	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627949	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627950	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627951	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627952	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9627953	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627954	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	19.95	CHEMBL5251	Homo sapiens	pKi		7.7
inactive	9627955	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627956	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	1995.26	CHEMBL5251	Homo sapiens	pKi		5.7
inactive	9627957	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(N)c2ccccc12		CHEMBL1998253	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627958	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627959	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627960	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627961	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627962	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627963	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627964	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627965	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1		CHEMBL2001149	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627966	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627967	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL2000078	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627968	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627969	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	79.43	CHEMBL5251	Homo sapiens	pKi		7.1
inactive	9627970	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627971	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627972	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627973	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627974	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1ccccc1)Nc1cc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)ccc1Cl		CHEMBL2005482	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627975	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627976	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Ki	nM	1584.89	CHEMBL5251	Homo sapiens	pKi		5.8
inactive	9627977	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1997909	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627978	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627979	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627980	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627981	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9627982	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2002660	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627983	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9627984	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9627985	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627986	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
inactive	9627987	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9627988	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627989	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627990	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1cc(S(=O)(=O)NC(=O)c2ccc(-c3ccc(F)cc3)cc2)ccc1NC1CCCCC1		CHEMBL1996795	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627991	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627992	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627993	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	158.49	CHEMBL5251	Homo sapiens	pKi		6.8
active	9627994	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	=	Ki	nM	100.0	CHEMBL5251	Homo sapiens	pKi		7.0
inactive	9627995	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9627996	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627997	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9627998	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9627999	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1c2cc(N)ccc2-c2ccc(N)cc2C1(O)c1ccccc1		CHEMBL1991818	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9628000	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	1584.89	CHEMBL5251	Homo sapiens	pKi		5.8
active	9628001	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	=	Ki	nM	100.0	CHEMBL5251	Homo sapiens	pKi		7.0
inactive	9628002	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628003	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628004	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1ccc2c(c1)nnc1nnnn12		CHEMBL1986503	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9628005	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	=	Ki	nM	794.33	CHEMBL5251	Homo sapiens	pKi		6.1
inactive	9628006	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9628007	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628008	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628009	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628010	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628011	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628012	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628013	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628014	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628015	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9628016	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1cc2nnc(-c3ccccc3)n2cn1		CHEMBL1998228	=	Ki	nM	50118.72	CHEMBL5251	Homo sapiens	pKi		4.3
active	9628017	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	1584.89	CHEMBL5251	Homo sapiens	pKi		5.8
inactive	9628018	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628019	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628020	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628021	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628022	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628023	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628024	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628025	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628026	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628027	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628028	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628029	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628030	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628031	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628032	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628033	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628034	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628035	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628036	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628037	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628038	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1971223	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628039	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9628040	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	=	Ki	nM	63.1	CHEMBL5251	Homo sapiens	pKi		7.2
inactive	9628041	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628042	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9628043	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	63095.73	CHEMBL5251	Homo sapiens	pKi		4.2
inactive	9628044	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628045	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628046	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1		CHEMBL1983070	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628047	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628048	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628049	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628050	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628051	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628052	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9628053	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628054	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9628055	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631623	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631624	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631625	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631626	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C		CHEMBL1997611	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631627	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631628	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	=	Ki	nM	501.19	CHEMBL5251	Homo sapiens	pKi		6.3
inactive	9631629	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631630	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631631	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631632	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631633	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631634	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631635	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631636	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631637	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631638	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631639	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631640	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631641	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631642	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631643	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631644	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	25.12	CHEMBL5251	Homo sapiens	pKi		7.6
inactive	9631645	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631646	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9631647	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631648	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631649	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631650	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631651	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
active	9631652	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	251.19	CHEMBL5251	Homo sapiens	pKi		6.6
inactive	9631653	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631654	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631655	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9631656	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631657	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631658	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631659	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21		CHEMBL1984847	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631660	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631661	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631662	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631663	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4ccccc4)c3)nc3sccn23)n1		CHEMBL1988076	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631664	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
active	9631665	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	=	Ki	nM	794.33	CHEMBL5251	Homo sapiens	pKi		6.1
inactive	9631666	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631667	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631668	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9631669	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631670	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631671	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631672	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631673	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631674	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631675	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631676	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631677	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	501.19	CHEMBL5251	Homo sapiens	pKi		6.3
inactive	9631678	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631679	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
inactive	9631680	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631681	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631682	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631683	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631684	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9631685	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631686	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631687	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(OCc2cccc(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1966501	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631688	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631689	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631690	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631691	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631692	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631693	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631694	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631695	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631696	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1		CHEMBL1973016	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631697	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631698	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	50118.72	CHEMBL5251	Homo sapiens	pKi		4.3
inactive	9631699	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631700	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631701	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	31.62	CHEMBL5251	Homo sapiens	pKi		7.5
inactive	9631702	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9631703	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631704	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631705	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631706	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C		CHEMBL1233887	=	Ki	nM	5011.87	CHEMBL5251	Homo sapiens	pKi		5.3
inactive	9631707	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCCC(=O)O)cc2)n1		CHEMBL2003689	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631708	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631709	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9631710	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631711	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631712	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9631713	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631714	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631715	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9631716	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631717	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(CCC#N)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1974998	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631718	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631719	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631720	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631721	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631722	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	=	Ki	nM	630.96	CHEMBL5251	Homo sapiens	pKi		6.2
inactive	9631723	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631724	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631725	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
inactive	9631726	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631727	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631728	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	398.11	CHEMBL5251	Homo sapiens	pKi		6.4
inactive	9631729	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631730	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631731	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631732	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631733	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	=	Ki	nM	79.43	CHEMBL5251	Homo sapiens	pKi		7.1
active	9631734	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9631735	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631736	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	=	Ki	nM	794.33	CHEMBL5251	Homo sapiens	pKi		6.1
active	9631737	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	=	Ki	nM	199.53	CHEMBL5251	Homo sapiens	pKi		6.7
inactive	9631738	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631739	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631740	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Nc1nccc(Nc2ncc(-c3ccccc3)s2)n1		CHEMBL2002432	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631741	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631742	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631743	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631744	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631745	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631746	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631747	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631748	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631749	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631750	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	=	Ki	nM	10.0	CHEMBL5251	Homo sapiens	pKi		8.0
inactive	9631751	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631752	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	31622.78	CHEMBL5251	Homo sapiens	pKi		4.5
inactive	9631753	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631754	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631755	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9631756	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631757	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631758	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCO)c2)n1		CHEMBL2007073	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631759	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631760	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631761	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631762	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	=	Ki	nM	79432.82	CHEMBL5251	Homo sapiens	pKi		4.1
inactive	9631763	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631764	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	=	Ki	nM	1000.0	CHEMBL5251	Homo sapiens	pKi		6.0
inactive	9631765	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631766	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631767	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	=	Ki	nM	501.19	CHEMBL5251	Homo sapiens	pKi		6.3
inactive	9631768	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631769	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631770	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631771	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631772	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631773	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631774	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631775	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CS(=O)(=O)Nc1ccc(Nc2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1988872	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631776	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631777	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)N(CCN)CCO)c2)n1		CHEMBL1993634	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631778	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631779	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631780	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631781	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631782	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631783	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631784	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631785	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631786	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631787	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1c(NC(=O)c2c(F)cccc2F)cccc1-c1nc2sccn2c1-c1ccnc(Nc2cccc(N3CCOCC3)c2)n1		CHEMBL1992473	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631788	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	=	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631789	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631790	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1994318	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631791	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631792	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCC(=O)O)c2)n1		CHEMBL1999506	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631793	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	39.81	CHEMBL5251	Homo sapiens	pKi		7.4
inactive	9631794	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631795	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631796	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	=	Ki	nM	63.1	CHEMBL5251	Homo sapiens	pKi		7.2
inactive	9631797	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631798	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631799	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	=	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631800	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631801	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631802	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631803	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631804	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631805	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9631806	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631807	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	Ki	nM	3162.28	CHEMBL5251	Homo sapiens	pKi		5.5
inactive	9631808	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631809	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631810	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	=	Ki	nM	0.7943	CHEMBL5251	Homo sapiens	pKi		9.1
inactive	9631811	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631812	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631813	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631814	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631815	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631816	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631817	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
active	9631818	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	25.12	CHEMBL5251	Homo sapiens	pKi		7.6
active	9631819	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	2511.89	CHEMBL5251	Homo sapiens	pKi		5.6
inactive	9631820	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
inactive	9631821	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
inactive	9631822	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	1258.93	CHEMBL5251	Homo sapiens	pKi		5.9
active	9631823	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	=	Ki	nM	251.19	CHEMBL5251	Homo sapiens	pKi		6.6
inactive	9631824	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	3981.07	CHEMBL5251	Homo sapiens	pKi		5.4
inactive	9631825	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cccc(Cl)c2)cc1		CHEMBL1968606	<	Ki	nM	6309.57	CHEMBL5251	Homo sapiens	pKi		5.2
active	9631826	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	125.89	CHEMBL5251	Homo sapiens	pKi		6.9
active	9631827	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	=	Ki	nM	251.19	CHEMBL5251	Homo sapiens	pKi		6.6
active	9631828	CHEMBL1963733	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: BTK	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	199.53	CHEMBL5251	Homo sapiens	pKi		6.7
	10838556	CHEMBL2014129	Inhibition of BTK at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	10839621	CHEMBL2015928	Inhibition of BTK assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	38.0	CHEMBL5251	Homo sapiens	Activity	%	38.0
	10839659	CHEMBL2015836	Inhibition of BTK assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	53.0	CHEMBL5251	Homo sapiens	Activity	%	53.0
	10843862	CHEMBL2016106	Inhibition of human BTK using ATP as substrate	B	CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3		CHEMBL2010872	=	IC50	nM	93.0	CHEMBL5251	Homo sapiens	IC50	nM	93.0
	10850048	CHEMBL2019770	Inhibition of human BTK at 1 uM	B	Cn1cc(-c2cccc(-c3cnc(N)c(C(=O)N[C@H]4C5CC6CC4C[C@@](O)(C6)C5)n3)c2)cn1		CHEMBL2018022	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
Active	10884053	CHEMBL2033662	Binding affinity to BTK at 100 nM	B	C=CC(=O)Nc1cccc(N2C(=O)N(Cc3ccccc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL2029438		Activity			CHEMBL5251	Homo sapiens	Activity		
	10889050	CHEMBL2032465	Inhibition of BTK	B	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1		CHEMBL460472	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	uM	1.0
	10889077	CHEMBL2032465	Inhibition of BTK	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccccc5)c4=O)cc3F)c2cc1OC		CHEMBL2031893	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	uM	0.01
	10952709	CHEMBL2060513	Inhibition of human recombinant BTK expressed in baculovirus expression vector system	B	C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br		CHEMBL228043	=	IC50	nM	2500.0	CHEMBL5251	Homo sapiens	IC50	uM	2.5
	10952710	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	<=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	10952711	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCC1		CHEMBL2057912	=	IC50	nM	8.2	CHEMBL5251	Homo sapiens	IC50	nM	8.2
	10952712	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	C=CC(=O)N1CCCC(c2c(Cl)c(-c3ccc(Oc4ccc(Cl)c(Cl)c4)c(OC)c3)c3c(N)ncnn23)C1		CHEMBL2057913	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	10952713	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	IC50	nM	1.93	CHEMBL5251	Homo sapiens	IC50	nM	1.93
	10952714	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cn4ccnc4c(Nc4ccccc4)n3)c2)cc1		CHEMBL2057914	=	IC50	nM	400.0	CHEMBL5251	Homo sapiens	IC50	nM	400.0
	10952715	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@@H]3C(=O)N(C)CCN3C)cc2)n1		CHEMBL2057915	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	10952716	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	CCNC(=O)Nc1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2C)cn(C)c1=O		CHEMBL2057916	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	10952717	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(O)CO)ccc4c23)cccc1-n1cnc2ccc(F)cc2c1=O		CHEMBL2057919	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	10952718	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	CC(C)(C)c1ccc(C(=O)N[C@@H]2CCCN(c3nc(Nc4ccc(C(=O)N5CCNCC5)cc4)c4nccn4n3)C2)cc1		CHEMBL2057920	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	10952719	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Cc1c(NC(=O)c2ccc(N(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nccn2n1		CHEMBL2057921	=	IC50	nM	144.0	CHEMBL5251	Homo sapiens	IC50	nM	144.0
	10952720	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Cc1c(NC(=O)c2ccc(N(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2ncc(N)n2n1		CHEMBL2057922	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	10952721	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Nc1n[nH]c2cc(-c3ccc(C(=O)O)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL2057923	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	10952722	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	O=C(N[C@@H]1CCCN(c2ncnc3[nH]ccc23)C1)[C@H](Nc1ccccc1)C1CC1		CHEMBL2057924	<	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	10952723	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	O=C(CNc1ccccc1S(=O)(=O)N1CCCCC1)N[C@@H]1CCCN(c2ncnc3[nH]ccc23)C1		CHEMBL2057925	<	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	10952724	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	O=C1C(Nc2cc(F)cc(Cl)c2)CCCN1[C@@H]1CCCN(c2ncnc3[nH]ccc23)C1		CHEMBL2058193	<	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	10952725	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1c(Cl)cccc1Cl		CHEMBL2058194	<	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	10952726	CHEMBL2060514	Inhibition of human BTK by enzymatic assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	10952748	CHEMBL2060652	Competitive inhibition of BTK by TR-FRET based competitive assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	10952754	CHEMBL2060657	Inhibition of BTK in human Ramos cells by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(O)CO)ccc4c23)cccc1-n1cnc2ccc(F)cc2c1=O		CHEMBL2057919	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	10984763	CHEMBL2072059	Inhibition of human BTK at 1 uM	B	Nc1cc(Nc2cnccn2)nc(-c2ccnc(N3CCNCC3)c2)c1		CHEMBL2069349	>	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	12046250	CHEMBL2156487	Inhibition of BTK at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	-8.1	CHEMBL5251	Homo sapiens	INH	%	-8.1
	12051565	CHEMBL2154705	Inhibition of BTK	B	CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL2151321	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	12051587	CHEMBL2154966	Inhibition of BTK at 10 uM	B	CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL2151321	>	Inhibition	%	30.0	CHEMBL5251	Homo sapiens	INH	%	30.0
	12074620	CHEMBL2161017	Inhibition of BTK at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	12134256	CHEMBL2185026	Inhibition of BTK in presence of 50 uM ATP	B	C=CC(=O)N1CCCC(n2nc(-c3cccc(C(=O)Nc4cccc(C(C)(C)C)c4)c3)c3c(N)ncnc32)C1		CHEMBL2179790	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	uM	0.015
	12134257	CHEMBL2185026	Inhibition of BTK in presence of 50 uM ATP	B	CC(C)c1ccc(NC(=O)c2cccc(-c3nn([C@@H]4CCCN(C(=O)/C=C/CN5CCN(CCN)CC5)C4)c4ncnc(N)c34)c2)cc1		CHEMBL2179780	=	IC50	nM	1050.0	CHEMBL5251	Homo sapiens	IC50	uM	1.05
	12134258	CHEMBL2185026	Inhibition of BTK in presence of 50 uM ATP	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(=O)NCc4ccc(C(C)(C)C)cc4)c3)c3c(N)ncnc32)C1		CHEMBL2179806	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	uM	0.012
	12134259	CHEMBL2185026	Inhibition of BTK in presence of 50 uM ATP	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(=O)Nc4ccc(C(C)C)c(C)c4)c3)c3c(N)ncnc32)C1		CHEMBL2179805	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	uM	0.002
	12134260	CHEMBL2185026	Inhibition of BTK in presence of 50 uM ATP	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(=O)Nc4ccc(C(C)C)cc4)c3)c3c(N)ncnc32)C1		CHEMBL2179804	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	uM	0.005
	12166138	CHEMBL2211611	Binding affinity to BTK at 1 uM	B	Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1		CHEMBL2206921	<	Activity	%	50.0	CHEMBL5251	Homo sapiens	Activity	%	50.0
	12170837	CHEMBL2212704	Inhibition of BTK assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	87.0	CHEMBL5251	Homo sapiens	Activity	%	87.0
	12172138	CHEMBL2214393	Inhibition of BTK assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	86.0	CHEMBL5251	Homo sapiens	Activity	%	86.0
	12173718	CHEMBL2211632	Inhibition of BTK assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	64.0	CHEMBL5251	Homo sapiens	Activity	%	64.0
	12183921	CHEMBL2216381	Inhibition of BTK	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	pIC50		5.0
	12205221	CHEMBL2217247	Inhibition of Btk in human Ramos cells	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1		CHEMBL2216827	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	12205222	CHEMBL2217246	Inhibition of Btk	B	C=CC(=O)N1CCCC(c2c(Cl)c(-c3ccc(Oc4cccc(Cl)c4)c(OC)c3)c3c(N)ncnn23)C1		CHEMBL2216828	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	12205223	CHEMBL2217245	Inhibition of recombinant Btk after 60 mins	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	12205247	CHEMBL2217246	Inhibition of Btk	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1		CHEMBL2216827	<	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	12227148	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	92.0	CHEMBL5251	Homo sapiens	Residual Activity	%	92.0
	12227149	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12227150	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	99.0	CHEMBL5251	Homo sapiens	Residual Activity	%	99.0
	12227151	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	110.0	CHEMBL5251	Homo sapiens	Residual Activity	%	110.0
	12227152	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	98.0	CHEMBL5251	Homo sapiens	Residual Activity	%	98.0
	12227153	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227154	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	19.0	CHEMBL5251	Homo sapiens	Residual Activity	%	19.0
	12227155	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227156	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12227157	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	67.0	CHEMBL5251	Homo sapiens	Residual Activity	%	67.0
	12227158	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	47.0	CHEMBL5251	Homo sapiens	Residual Activity	%	47.0
	12227159	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12227160	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12227161	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	24.0	CHEMBL5251	Homo sapiens	Residual Activity	%	24.0
	12227162	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	84.0	CHEMBL5251	Homo sapiens	Residual Activity	%	84.0
	12227163	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227164	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12227165	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12227166	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	84.0	CHEMBL5251	Homo sapiens	Residual Activity	%	84.0
	12227167	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	71.0	CHEMBL5251	Homo sapiens	Residual Activity	%	71.0
	12227168	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227169	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12227170	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12227171	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	92.0	CHEMBL5251	Homo sapiens	Residual Activity	%	92.0
	12227172	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227173	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	72.0	CHEMBL5251	Homo sapiens	Residual Activity	%	72.0
	12227174	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	78.0	CHEMBL5251	Homo sapiens	Residual Activity	%	78.0
	12227175	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	80.0	CHEMBL5251	Homo sapiens	Residual Activity	%	80.0
	12227176	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	92.0	CHEMBL5251	Homo sapiens	Residual Activity	%	92.0
	12227177	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12227178	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	102.0	CHEMBL5251	Homo sapiens	Residual Activity	%	102.0
	12227179	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	50.0	CHEMBL5251	Homo sapiens	Residual Activity	%	50.0
	12227180	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227181	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227182	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	103.0	CHEMBL5251	Homo sapiens	Residual Activity	%	103.0
	12227183	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227184	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	22.0	CHEMBL5251	Homo sapiens	Residual Activity	%	22.0
	12227185	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227186	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12227187	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12227188	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	78.0	CHEMBL5251	Homo sapiens	Residual Activity	%	78.0
	12227189	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227190	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	10.0	CHEMBL5251	Homo sapiens	Residual Activity	%	10.0
	12227191	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227192	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	17.0	CHEMBL5251	Homo sapiens	Residual Activity	%	17.0
	12227193	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	99.0	CHEMBL5251	Homo sapiens	Residual Activity	%	99.0
	12227194	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	110.0	CHEMBL5251	Homo sapiens	Residual Activity	%	110.0
	12227195	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12227196	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12227197	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12227198	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12227199	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	1.0
	12227200	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12227201	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	104.0	CHEMBL5251	Homo sapiens	Residual Activity	%	104.0
	12227202	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	113.0	CHEMBL5251	Homo sapiens	Residual Activity	%	113.0
	12227203	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227204	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227205	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227206	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	85.0	CHEMBL5251	Homo sapiens	Residual Activity	%	85.0
	12227207	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	110.0	CHEMBL5251	Homo sapiens	Residual Activity	%	110.0
	12227208	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12227209	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	60.0	CHEMBL5251	Homo sapiens	Residual Activity	%	60.0
	12227210	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227211	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	104.0	CHEMBL5251	Homo sapiens	Residual Activity	%	104.0
	12227212	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12227213	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	113.0	CHEMBL5251	Homo sapiens	Residual Activity	%	113.0
	12227214	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	83.0	CHEMBL5251	Homo sapiens	Residual Activity	%	83.0
	12227215	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	114.0	CHEMBL5251	Homo sapiens	Residual Activity	%	114.0
	12227216	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	99.0	CHEMBL5251	Homo sapiens	Residual Activity	%	99.0
	12227217	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	15.0	CHEMBL5251	Homo sapiens	Residual Activity	%	15.0
	12227218	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227219	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	53.0	CHEMBL5251	Homo sapiens	Residual Activity	%	53.0
	12227220	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12227221	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	58.0	CHEMBL5251	Homo sapiens	Residual Activity	%	58.0
	12227222	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	104.0	CHEMBL5251	Homo sapiens	Residual Activity	%	104.0
	12227223	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12227224	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12227225	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	83.0	CHEMBL5251	Homo sapiens	Residual Activity	%	83.0
	12227226	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12227227	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL5251	Homo sapiens	Residual Activity	%	2.0
	12227228	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12227229	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12227230	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	79.0	CHEMBL5251	Homo sapiens	Residual Activity	%	79.0
	12227231	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12227232	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227233	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	106.0	CHEMBL5251	Homo sapiens	Residual Activity	%	106.0
	12227234	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227235	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227236	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12227237	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	31.0	CHEMBL5251	Homo sapiens	Residual Activity	%	31.0
	12227238	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12227239	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12227240	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	19.0	CHEMBL5251	Homo sapiens	Residual Activity	%	19.0
	12227241	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	81.0	CHEMBL5251	Homo sapiens	Residual Activity	%	81.0
	12227242	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	97.0	CHEMBL5251	Homo sapiens	Residual Activity	%	97.0
	12227243	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227244	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12227245	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	98.0	CHEMBL5251	Homo sapiens	Residual Activity	%	98.0
	12227246	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12227247	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	78.0	CHEMBL5251	Homo sapiens	Residual Activity	%	78.0
	12227248	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	70.0	CHEMBL5251	Homo sapiens	Residual Activity	%	70.0
	12227249	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	-1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	-1.0
	12227250	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227251	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	22.0	CHEMBL5251	Homo sapiens	Residual Activity	%	22.0
	12227252	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12227253	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12227254	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12227255	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227256	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12227257	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	85.0	CHEMBL5251	Homo sapiens	Residual Activity	%	85.0
	12227258	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227259	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227260	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	79.0	CHEMBL5251	Homo sapiens	Residual Activity	%	79.0
	12227261	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	98.0	CHEMBL5251	Homo sapiens	Residual Activity	%	98.0
	12227262	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12227263	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227264	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	38.0	CHEMBL5251	Homo sapiens	Residual Activity	%	38.0
	12227265	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12227266	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	97.0	CHEMBL5251	Homo sapiens	Residual Activity	%	97.0
	12227267	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12227268	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	33.0	CHEMBL5251	Homo sapiens	Residual Activity	%	33.0
	12227269	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	71.0	CHEMBL5251	Homo sapiens	Residual Activity	%	71.0
	12227270	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	72.0	CHEMBL5251	Homo sapiens	Residual Activity	%	72.0
	12227271	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	79.0	CHEMBL5251	Homo sapiens	Residual Activity	%	79.0
	12227272	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	12.0	CHEMBL5251	Homo sapiens	Residual Activity	%	12.0
	12227273	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	85.0	CHEMBL5251	Homo sapiens	Residual Activity	%	85.0
	12227274	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	56.0	CHEMBL5251	Homo sapiens	Residual Activity	%	56.0
	12227275	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12227276	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	35.0	CHEMBL5251	Homo sapiens	Residual Activity	%	35.0
	12227277	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	79.0	CHEMBL5251	Homo sapiens	Residual Activity	%	79.0
	12227278	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12227279	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	42.0	CHEMBL5251	Homo sapiens	Residual Activity	%	42.0
	12227280	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12227281	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12227282	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	21.0	CHEMBL5251	Homo sapiens	Residual Activity	%	21.0
	12227283	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	48.0	CHEMBL5251	Homo sapiens	Residual Activity	%	48.0
	12227284	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12227285	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	34.0	CHEMBL5251	Homo sapiens	Residual Activity	%	34.0
	12227286	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	1.0
	12227287	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12227288	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12229819	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229820	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12229821	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	69.0	CHEMBL5251	Homo sapiens	Residual Activity	%	69.0
	12229822	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	104.0	CHEMBL5251	Homo sapiens	Residual Activity	%	104.0
	12229823	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12229824	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	25.0	CHEMBL5251	Homo sapiens	Residual Activity	%	25.0
	12229825	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12229826	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	74.0	CHEMBL5251	Homo sapiens	Residual Activity	%	74.0
	12229827	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12229828	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12229829	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	102.0	CHEMBL5251	Homo sapiens	Residual Activity	%	102.0
	12229830	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12229831	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	106.0	CHEMBL5251	Homo sapiens	Residual Activity	%	106.0
	12229832	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	112.0	CHEMBL5251	Homo sapiens	Residual Activity	%	112.0
	12229833	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229834	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	108.0	CHEMBL5251	Homo sapiens	Residual Activity	%	108.0
	12229835	CHEMBL2218958	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	70.0	CHEMBL5251	Homo sapiens	Residual Activity	%	70.0
	12229836	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12229837	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	67.0	CHEMBL5251	Homo sapiens	Residual Activity	%	67.0
	12229838	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	71.0	CHEMBL5251	Homo sapiens	Residual Activity	%	71.0
	12229839	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229840	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	83.0	CHEMBL5251	Homo sapiens	Residual Activity	%	83.0
	12229841	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	99.0	CHEMBL5251	Homo sapiens	Residual Activity	%	99.0
	12229842	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	5.0	CHEMBL5251	Homo sapiens	Residual Activity	%	5.0
	12229843	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	41.0	CHEMBL5251	Homo sapiens	Residual Activity	%	41.0
	12229844	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	83.0	CHEMBL5251	Homo sapiens	Residual Activity	%	83.0
	12229845	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	44.0	CHEMBL5251	Homo sapiens	Residual Activity	%	44.0
	12229846	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	16.0	CHEMBL5251	Homo sapiens	Residual Activity	%	16.0
	12229847	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	109.0	CHEMBL5251	Homo sapiens	Residual Activity	%	109.0
	12229848	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	78.0	CHEMBL5251	Homo sapiens	Residual Activity	%	78.0
	12229849	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	3.0	CHEMBL5251	Homo sapiens	Residual Activity	%	3.0
	12229850	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	63.0	CHEMBL5251	Homo sapiens	Residual Activity	%	63.0
	12229851	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	115.0	CHEMBL5251	Homo sapiens	Residual Activity	%	115.0
	12229852	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	58.0	CHEMBL5251	Homo sapiens	Residual Activity	%	58.0
	12229853	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	102.0	CHEMBL5251	Homo sapiens	Residual Activity	%	102.0
	12229854	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	118.0	CHEMBL5251	Homo sapiens	Residual Activity	%	118.0
	12229855	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	59.0	CHEMBL5251	Homo sapiens	Residual Activity	%	59.0
	12229856	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	111.0	CHEMBL5251	Homo sapiens	Residual Activity	%	111.0
	12229857	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12229858	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	102.0	CHEMBL5251	Homo sapiens	Residual Activity	%	102.0
	12229859	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	108.0	CHEMBL5251	Homo sapiens	Residual Activity	%	108.0
	12229860	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12229861	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	28.0	CHEMBL5251	Homo sapiens	Residual Activity	%	28.0
	12229862	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	34.0	CHEMBL5251	Homo sapiens	Residual Activity	%	34.0
	12229863	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	33.0	CHEMBL5251	Homo sapiens	Residual Activity	%	33.0
	12229864	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	112.0	CHEMBL5251	Homo sapiens	Residual Activity	%	112.0
	12229865	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12229866	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12229867	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	10.0	CHEMBL5251	Homo sapiens	Residual Activity	%	10.0
	12229868	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	76.0	CHEMBL5251	Homo sapiens	Residual Activity	%	76.0
	12229869	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229870	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	108.0	CHEMBL5251	Homo sapiens	Residual Activity	%	108.0
	12229871	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	71.0	CHEMBL5251	Homo sapiens	Residual Activity	%	71.0
	12229872	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	4.0	CHEMBL5251	Homo sapiens	Residual Activity	%	4.0
	12229873	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	106.0	CHEMBL5251	Homo sapiens	Residual Activity	%	106.0
	12229874	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	116.0	CHEMBL5251	Homo sapiens	Residual Activity	%	116.0
	12229875	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	109.0	CHEMBL5251	Homo sapiens	Residual Activity	%	109.0
	12229876	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	109.0	CHEMBL5251	Homo sapiens	Residual Activity	%	109.0
	12229877	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	118.0	CHEMBL5251	Homo sapiens	Residual Activity	%	118.0
	12229878	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	9.0	CHEMBL5251	Homo sapiens	Residual Activity	%	9.0
	12229879	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	54.0	CHEMBL5251	Homo sapiens	Residual Activity	%	54.0
	12229880	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	2.0	CHEMBL5251	Homo sapiens	Residual Activity	%	2.0
	12229881	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	120.0	CHEMBL5251	Homo sapiens	Residual Activity	%	120.0
	12229882	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	122.0	CHEMBL5251	Homo sapiens	Residual Activity	%	122.0
	12229883	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	66.0	CHEMBL5251	Homo sapiens	Residual Activity	%	66.0
	12229884	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12229885	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	117.0	CHEMBL5251	Homo sapiens	Residual Activity	%	117.0
	12229886	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	85.0	CHEMBL5251	Homo sapiens	Residual Activity	%	85.0
	12229887	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	1.0
	12229888	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	47.0	CHEMBL5251	Homo sapiens	Residual Activity	%	47.0
	12229889	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	110.0	CHEMBL5251	Homo sapiens	Residual Activity	%	110.0
	12229890	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	117.0	CHEMBL5251	Homo sapiens	Residual Activity	%	117.0
	12229891	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	109.0	CHEMBL5251	Homo sapiens	Residual Activity	%	109.0
	12229892	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	68.0	CHEMBL5251	Homo sapiens	Residual Activity	%	68.0
	12229893	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	123.0	CHEMBL5251	Homo sapiens	Residual Activity	%	123.0
	12229894	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	109.0	CHEMBL5251	Homo sapiens	Residual Activity	%	109.0
	12229895	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	113.0	CHEMBL5251	Homo sapiens	Residual Activity	%	113.0
	12229896	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	70.0	CHEMBL5251	Homo sapiens	Residual Activity	%	70.0
	12229897	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	35.0	CHEMBL5251	Homo sapiens	Residual Activity	%	35.0
	12229898	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	118.0	CHEMBL5251	Homo sapiens	Residual Activity	%	118.0
	12229899	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	116.0	CHEMBL5251	Homo sapiens	Residual Activity	%	116.0
	12229900	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	92.0	CHEMBL5251	Homo sapiens	Residual Activity	%	92.0
	12229901	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229902	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12229903	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	106.0	CHEMBL5251	Homo sapiens	Residual Activity	%	106.0
	12229904	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12229905	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	2.0	CHEMBL5251	Homo sapiens	Residual Activity	%	2.0
	12229906	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	105.0	CHEMBL5251	Homo sapiens	Residual Activity	%	105.0
	12229907	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	6.0	CHEMBL5251	Homo sapiens	Residual Activity	%	6.0
	12229908	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	72.0	CHEMBL5251	Homo sapiens	Residual Activity	%	72.0
	12229909	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	43.0	CHEMBL5251	Homo sapiens	Residual Activity	%	43.0
	12229910	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	84.0	CHEMBL5251	Homo sapiens	Residual Activity	%	84.0
	12229911	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229912	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229913	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	17.0	CHEMBL5251	Homo sapiens	Residual Activity	%	17.0
	12229914	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12229915	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	0.0	CHEMBL5251	Homo sapiens	Residual Activity	%	0.0
	12229916	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229917	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	33.0	CHEMBL5251	Homo sapiens	Residual Activity	%	33.0
	12229918	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	68.0	CHEMBL5251	Homo sapiens	Residual Activity	%	68.0
	12229919	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	104.0	CHEMBL5251	Homo sapiens	Residual Activity	%	104.0
	12229920	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	50.0	CHEMBL5251	Homo sapiens	Residual Activity	%	50.0
	12229921	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229922	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12229923	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	73.0	CHEMBL5251	Homo sapiens	Residual Activity	%	73.0
	12229924	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	80.0	CHEMBL5251	Homo sapiens	Residual Activity	%	80.0
	12229925	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	4.0	CHEMBL5251	Homo sapiens	Residual Activity	%	4.0
	12229926	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	82.0	CHEMBL5251	Homo sapiens	Residual Activity	%	82.0
	12229927	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	47.0	CHEMBL5251	Homo sapiens	Residual Activity	%	47.0
	12229928	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	0.0	CHEMBL5251	Homo sapiens	Residual Activity	%	0.0
	12229929	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	78.0	CHEMBL5251	Homo sapiens	Residual Activity	%	78.0
	12229930	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	51.0	CHEMBL5251	Homo sapiens	Residual Activity	%	51.0
	12229931	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229932	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12229933	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12229934	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229935	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	33.0	CHEMBL5251	Homo sapiens	Residual Activity	%	33.0
	12229936	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	34.0	CHEMBL5251	Homo sapiens	Residual Activity	%	34.0
	12229937	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	-1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	-1.0
	12229938	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	100.0	CHEMBL5251	Homo sapiens	Residual Activity	%	100.0
	12229939	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	27.0	CHEMBL5251	Homo sapiens	Residual Activity	%	27.0
	12229940	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	90.0	CHEMBL5251	Homo sapiens	Residual Activity	%	90.0
	12229941	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12229942	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	89.0	CHEMBL5251	Homo sapiens	Residual Activity	%	89.0
	12229943	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	87.0	CHEMBL5251	Homo sapiens	Residual Activity	%	87.0
	12229944	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12229945	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	81.0	CHEMBL5251	Homo sapiens	Residual Activity	%	81.0
	12229946	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	56.0	CHEMBL5251	Homo sapiens	Residual Activity	%	56.0
	12229947	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	83.0	CHEMBL5251	Homo sapiens	Residual Activity	%	83.0
	12229948	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	66.0	CHEMBL5251	Homo sapiens	Residual Activity	%	66.0
	12229949	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	80.0	CHEMBL5251	Homo sapiens	Residual Activity	%	80.0
	12229950	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229951	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12229952	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	1.0
	12229953	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12229954	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229955	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	98.0	CHEMBL5251	Homo sapiens	Residual Activity	%	98.0
	12229956	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	10.0	CHEMBL5251	Homo sapiens	Residual Activity	%	10.0
	12229957	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	9.0	CHEMBL5251	Homo sapiens	Residual Activity	%	9.0
	12229958	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	32.0	CHEMBL5251	Homo sapiens	Residual Activity	%	32.0
	12229959	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229960	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	-2.0	CHEMBL5251	Homo sapiens	Residual Activity	%	-2.0
	12229961	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	71.0	CHEMBL5251	Homo sapiens	Residual Activity	%	71.0
	12229962	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	17.0	CHEMBL5251	Homo sapiens	Residual Activity	%	17.0
	12229963	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	84.0	CHEMBL5251	Homo sapiens	Residual Activity	%	84.0
	12229964	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	4.0	CHEMBL5251	Homo sapiens	Residual Activity	%	4.0
	12229965	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	27.0	CHEMBL5251	Homo sapiens	Residual Activity	%	27.0
	12229966	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	86.0	CHEMBL5251	Homo sapiens	Residual Activity	%	86.0
	12229967	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	35.0	CHEMBL5251	Homo sapiens	Residual Activity	%	35.0
	12229968	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	57.0	CHEMBL5251	Homo sapiens	Residual Activity	%	57.0
	12229969	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	95.0	CHEMBL5251	Homo sapiens	Residual Activity	%	95.0
	12229970	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	-1.0	CHEMBL5251	Homo sapiens	Residual Activity	%	-1.0
	12229971	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	5.0	CHEMBL5251	Homo sapiens	Residual Activity	%	5.0
	12229972	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	88.0	CHEMBL5251	Homo sapiens	Residual Activity	%	88.0
	12229973	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	-2.0	CHEMBL5251	Homo sapiens	Residual Activity	%	-2.0
	12229974	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	0.0	CHEMBL5251	Homo sapiens	Residual Activity	%	0.0
	12229975	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	76.0	CHEMBL5251	Homo sapiens	Residual Activity	%	76.0
	12229976	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	93.0	CHEMBL5251	Homo sapiens	Residual Activity	%	93.0
	12229977	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	96.0	CHEMBL5251	Homo sapiens	Residual Activity	%	96.0
	12229978	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	83.0	CHEMBL5251	Homo sapiens	Residual Activity	%	83.0
	12229979	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	23.0	CHEMBL5251	Homo sapiens	Residual Activity	%	23.0
	12229980	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	99.0	CHEMBL5251	Homo sapiens	Residual Activity	%	99.0
	12229981	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	97.0	CHEMBL5251	Homo sapiens	Residual Activity	%	97.0
	12229982	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	4.0	CHEMBL5251	Homo sapiens	Residual Activity	%	4.0
	12229983	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	43.0	CHEMBL5251	Homo sapiens	Residual Activity	%	43.0
	12229984	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	34.0	CHEMBL5251	Homo sapiens	Residual Activity	%	34.0
	12229985	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	105.0	CHEMBL5251	Homo sapiens	Residual Activity	%	105.0
	12229986	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	75.0	CHEMBL5251	Homo sapiens	Residual Activity	%	75.0
	12229987	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	91.0	CHEMBL5251	Homo sapiens	Residual Activity	%	91.0
	12229988	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12229989	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	102.0	CHEMBL5251	Homo sapiens	Residual Activity	%	102.0
	12229990	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	101.0	CHEMBL5251	Homo sapiens	Residual Activity	%	101.0
	12229991	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	94.0	CHEMBL5251	Homo sapiens	Residual Activity	%	94.0
	12229992	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	77.0	CHEMBL5251	Homo sapiens	Residual Activity	%	77.0
	12229993	CHEMBL2218959	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	58.0	CHEMBL5251	Homo sapiens	Residual Activity	%	58.0
	12628461	CHEMBL2321412	Inhibition of BTK (unknown origin) at 10 uM	B	N#Cc1c(N)nc2sc(C(=O)c3cccc(Cl)c3)c(N)c2c1-c1ccccc1Cl		CHEMBL2313853	>	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	12629557	CHEMBL2319137	Inhibition of BTK (unknown origin)	B	O=C(NCCCN1CCOC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312304	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	12629558	CHEMBL2319137	Inhibition of BTK (unknown origin)	B	O=C(NCCCN1CCCC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312303	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
Not Determined	12629559	CHEMBL2319137	Inhibition of BTK (unknown origin)	B	COc1ccccc1CNc1ncc(C(=O)NCCCN2CCCC2=O)c(NC2CCCC2)n1		CHEMBL2312301		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	12629560	CHEMBL2319137	Inhibition of BTK (unknown origin)	B	COc1ccc(CCNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)cc1OC		CHEMBL2312290		IC50			CHEMBL5251	Homo sapiens	IC50		
	12631747	CHEMBL2317786	Inhibition of BTK (unknown origin) in presence of ATP	B	Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)on1		CHEMBL2312654	=	IC50	nM	950.0	CHEMBL5251	Homo sapiens	IC50	uM	0.95
	12631748	CHEMBL2317786	Inhibition of BTK (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@@H]2COC[C@H]2O)CC1		CHEMBL2312652	=	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	12631749	CHEMBL2317786	Inhibition of BTK (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)CC1		CHEMBL2312649	=	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	12631750	CHEMBL2317786	Inhibition of BTK (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(NCc3cc(Cl)ccc3Cl)nc2NC2CCCC2)CC1		CHEMBL2312646	=	IC50	nM	25670.0	CHEMBL5251	Homo sapiens	IC50	uM	25.67
	12631751	CHEMBL2317786	Inhibition of BTK (unknown origin) in presence of ATP	B	COc1ccccc1CNc1ncc(C(=O)NC2CCN(C)CC2)c(NC2CCCC2)n1		CHEMBL2312645	=	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	uM	30.0
	12648015	CHEMBL2329395	Inhibition of BTK (unknown origin) at 1 uM	B	CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325895	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	12648016	CHEMBL2329395	Inhibition of BTK (unknown origin) at 1 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	INH	%	1.0
	12648017	CHEMBL2329395	Inhibition of BTK (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N		CHEMBL2325906	=	Inhibition	%	13.0	CHEMBL5251	Homo sapiens	INH	%	13.0
	12648018	CHEMBL2329395	Inhibition of BTK (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C		CHEMBL2325903	=	Inhibition	%	6.0	CHEMBL5251	Homo sapiens	INH	%	6.0
	12649672	CHEMBL2329563	Inhibition of BTK (unknown origin) at 10 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	18.0	CHEMBL5251	Homo sapiens	INH	%	18.0
	12649673	CHEMBL2329563	Inhibition of BTK (unknown origin) at 10 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O		CHEMBL2325904	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	12649674	CHEMBL2329563	Inhibition of BTK (unknown origin) at 10 uM	B	CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12		CHEMBL2325901	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	12657928	CHEMBL2330105	Inhibition of BTK (unknown origin)	B	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21		CHEMBL58	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	uM	1.0
	12657930	CHEMBL2330107	Inhibition of BTK (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	B	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21		CHEMBL58	=	Activity	%	45.9	CHEMBL5251	Homo sapiens	Activity	%	45.9
	12673087	CHEMBL2345629	Inhibition of recombinant BTK (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	48.0	CHEMBL5251	Homo sapiens	Activity	%	48.0
	12673088	CHEMBL2345629	Inhibition of recombinant BTK (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	53.0	CHEMBL5251	Homo sapiens	Activity	%	53.0
	12674223	CHEMBL2344197	Inhibition of human BTK using [gamma-33P]ATP assessed as residual activity at 3 uM after 30 mins by radiometric assay	B	CCCCn1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL2333603	=	Activity	%	58.0	CHEMBL5251	Homo sapiens	Activity	%	58.0
	12700139	CHEMBL2342677	Inhibition of recombinant BTK (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	44.0	CHEMBL5251	Homo sapiens	INH	%	44.0
	12728889	CHEMBL2349972	Inhibition of BTK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	96.0	CHEMBL5251	Homo sapiens	Activity	%	96.0
	12729788	CHEMBL2350033	Inhibition of BTK E41K mutant (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	12730031	CHEMBL2353906	Inhibition of BTK (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	102.0	CHEMBL5251	Homo sapiens	Activity	%	102.0
	12730922	CHEMBL2349849	Inhibition of BTK (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	95.0	CHEMBL5251	Homo sapiens	Activity	%	95.0
	12731168	CHEMBL2349972	Inhibition of BTK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	105.0	CHEMBL5251	Homo sapiens	Activity	%	105.0
	13282426	CHEMBL2378500	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376158	=	Inhibition	%	2.0	CHEMBL5251	Homo sapiens	INH	%	2.0
	13282427	CHEMBL2378500	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21		CHEMBL2376154	=	Inhibition	%	83.0	CHEMBL5251	Homo sapiens	INH	%	83.0
	13282428	CHEMBL2378500	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376153	=	Inhibition	%	14.0	CHEMBL5251	Homo sapiens	INH	%	14.0
	13282429	CHEMBL2378500	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376152	=	Inhibition	%	2.0	CHEMBL5251	Homo sapiens	INH	%	2.0
	13282430	CHEMBL2378500	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376144	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13282431	CHEMBL2378500	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376143	=	Inhibition	%	13.0	CHEMBL5251	Homo sapiens	INH	%	13.0
	13327698	CHEMBL2389847	Inhibition of BTK (unknown origin) at 1 uM	B	CC(C)(C)c1cc(NC(=O)NCc2ccc(-c3cc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)[nH]n3)cc2)no1		CHEMBL2386802	=	Inhibition	%	-6.0	CHEMBL5251	Homo sapiens	INH	%	-6.0
Not Determined	13327699	CHEMBL2389847	Inhibition of BTK (unknown origin) at 1 uM	B	Cc1cc(-c2cc(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)[nH]n2)ccc1NC(=O)Nc1cc(C(C)(C)C)on1		CHEMBL2386796		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	13328781	CHEMBL2388649	Inhibition of BTK (unknown origin)	B	Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12		CHEMBL2386917		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	13367192	CHEMBL2406346	Inhibition of BTK (unknown origin) after 60 mins	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	IC50	nM	3360.0	CHEMBL5251	Homo sapiens	IC50	uM	3.36
	13375934	CHEMBL2405944	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	-9.0	CHEMBL5251	Homo sapiens	INH	%	-9.0
	13419634	CHEMBL2422084	Inhibition of BTK (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13419635	CHEMBL2422084	Inhibition of BTK (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	13419636	CHEMBL2422084	Inhibition of BTK (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13442397	CHEMBL2428019	Competitive binding affinity to BTK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	13443075	CHEMBL2427503	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1		CHEMBL2426288	>	Inhibition	%	75.0	CHEMBL5251	Homo sapiens	INH	%	75.0
	13445532	CHEMBL2428019	Competitive binding affinity to BTK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	13448587	CHEMBL2428019	Competitive binding affinity to BTK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	13448723	CHEMBL2428019	Competitive binding affinity to BTK (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	13451518	CHEMBL2428019	Competitive binding affinity to BTK (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	13454703	CHEMBL2428019	Competitive binding affinity to BTK (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	13465481	CHEMBL2434231	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	85.0	CHEMBL5251	Homo sapiens	Activity	%	85.0
	13465507	CHEMBL2434780	Inhibition of human BTK assessed as residual activity at 10 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	69.0	CHEMBL5251	Homo sapiens	Activity	%	69.0
	13466482	CHEMBL2434231	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	103.13	CHEMBL5251	Homo sapiens	Activity	%	103.13
	13466509	CHEMBL2434780	Inhibition of human BTK assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	99.69	CHEMBL5251	Homo sapiens	Activity	%	99.69
	13466536	CHEMBL2434231	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	93.2	CHEMBL5251	Homo sapiens	Activity	%	93.2
	13466563	CHEMBL2434780	Inhibition of human BTK assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	16.5	CHEMBL5251	Homo sapiens	Activity	%	16.5
	13483409	CHEMBL2439333	Inhibition of BTK (unknown origin) at 1 uM after 1 hr relative to control	B	C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL2437469	<	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	INH	%	1.0
Active	13488401	CHEMBL2439417	Inhibition of human BTK at 1 uM	B	Clc1ccc2ncc(Br)n2n1		CHEMBL2436439		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	13488402	CHEMBL2439417	Inhibition of human BTK at 1 uM	B	CN1CCC(Nc2ccc3ncc(-c4cnn(-c5ccc(C#N)cc5)c4)n3n2)CC1		CHEMBL2436446		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	13490913	CHEMBL2446677	Inhibition of Btk (unknown origin)	B	CCc1ccc2nc(Nc3cc(Cc4ccccc4)nc(N[C@H]4CC[C@H](O)CC4)n3)sc2c1		CHEMBL2441273	=	IC50	nM	316.23	CHEMBL5251	Homo sapiens	pIC50		6.5
Active	13826426	CHEMBL3088495	Binding affinity to BTK (unknown origin)	B	C=CC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL3086102		Activity			CHEMBL5251	Homo sapiens	Activity		
	13872198	CHEMBL3102385	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	140.0	CHEMBL5251	Homo sapiens	Activity	%	140.0
Not Active	13907186	CHEMBL3118662	Inhibition of BTK (unknown origin) at 10 uM	B	CCCCCCCCCC(NC(=O)CNC(=O)OCc1ccccc1)C(=O)NCCc1ccccc1		CHEMBL3113587		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	13953220	CHEMBL3132657	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	112.0	CHEMBL5251	Homo sapiens	Activity	%	112.0
	13954665	CHEMBL3132657	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	13954694	CHEMBL3132657	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	93.0	CHEMBL5251	Homo sapiens	Activity	%	93.0
	13965719	CHEMBL3135931	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13966097	CHEMBL3134667	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	19.0	CHEMBL5251	Homo sapiens	INH	%	19.0
	13973999	CHEMBL3135899	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13974090	CHEMBL3135601	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13974181	CHEMBL3137121	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1		CHEMBL1928677	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	13974272	CHEMBL3136250	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]cnc23)CCO1		CHEMBL560373	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13975010	CHEMBL3135306	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1nc(N2CCOCC2)c2nc[nH]c2n1		CHEMBL271138	=	Inhibition	%	55.0	CHEMBL5251	Homo sapiens	INH	%	55.0
	13975101	CHEMBL3135555	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	INH	%	1.0
	13975192	CHEMBL3135646	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13975835	CHEMBL3134758	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	Inhibition	%	0.5	CHEMBL5251	Homo sapiens	INH	%	0.5
	13975926	CHEMBL3136400	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	Inhibition	%	4.5	CHEMBL5251	Homo sapiens	INH	%	4.5
	13976019	CHEMBL3135219	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	13976110	CHEMBL3136781	Inhibition of human full length BTK expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	Inhibition	%	17.0	CHEMBL5251	Homo sapiens	INH	%	17.0
	14582442	CHEMBL3240225	Inhibition of human BTK assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	102.5	CHEMBL5251	Homo sapiens	Activity	%	102.5
	14644608	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cn1cnc2c(Nc3ccc(C(=O)N4CCOCC4)cc3)nc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3)nc21		CHEMBL3263314	=	IC50	nM	67.0	CHEMBL5251	Homo sapiens	IC50	uM	0.067
	14644609	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cn1ncc2c(Nc3ccc(C(=O)N4CCOCC4)cc3)nc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3)nc21		CHEMBL3263315	=	IC50	nM	12700.0	CHEMBL5251	Homo sapiens	IC50	uM	12.7
	14644610	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cn1cnc2c(Nc3ccc(C(=O)N4CCOCC4)cc3)nc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3)cc21		CHEMBL3263313	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	uM	0.15
	14644611	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nccc(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL3263316	>	IC50	nM	50000.0	CHEMBL5251	Homo sapiens	IC50	uM	50.0
	14644612	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(C(=O)N5CCOCC5)cc4)c4cccn4n3)c2)cc1		CHEMBL3263317	>	IC50	nM	50000.0	CHEMBL5251	Homo sapiens	IC50	uM	50.0
	14644613	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2ncn(C)c2n1		CHEMBL3263628	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	uM	0.038
	14644614	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nccn2n1		CHEMBL3263629	=	IC50	nM	213.0	CHEMBL5251	Homo sapiens	IC50	uM	0.213
	14644615	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nccn2c1		CHEMBL3263630	=	IC50	nM	574.0	CHEMBL5251	Homo sapiens	IC50	uM	0.574
	14644616	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)O)cc2)c2ncn(C)c2n1		CHEMBL3263631	=	IC50	nM	64.0	CHEMBL5251	Homo sapiens	IC50	uM	0.064
	14644617	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCNCC3)cc2)c2ncn(C)c2n1		CHEMBL3263632	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	uM	0.025
	14644618	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCN(CCO)CC3)cc2)c2ncn(C)c2n1		CHEMBL3263633	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	uM	0.028
	14644619	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2)c2ncn(C)c2n1		CHEMBL3263634	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	uM	0.017
	14644620	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)OCCN(C)C)cc2)c2ncn(C)c2n1		CHEMBL3263635	=	IC50	nM	143.0	CHEMBL5251	Homo sapiens	IC50	uM	0.143
	14644621	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N(C)C)cc2)c2ncn(C)c2n1		CHEMBL3263636	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	uM	0.043
	14644622	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)NCCN(C)C)cc2)c2ncn(C)c2n1		CHEMBL3263637	=	IC50	nM	87.0	CHEMBL5251	Homo sapiens	IC50	uM	0.087
	14644623	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)NCCO)cc2)c2ncn(C)c2n1		CHEMBL3263638	=	IC50	nM	126.0	CHEMBL5251	Homo sapiens	IC50	uM	0.126
	14644624	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(N3CCNCC3)cc2)c2ncn(C)c2n1		CHEMBL3263639	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	uM	0.019
	14644625	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	14644626	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	CCCn1cnc2c(Nc3ccc(C(=O)N4CCOCC4)cc3)nc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)nc21		CHEMBL3263641	=	IC50	nM	170.0	CHEMBL5251	Homo sapiens	IC50	uM	0.17
	14644627	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2ncn(CCc3ccccc3)c2n1		CHEMBL3263642	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	uM	0.14
	14644628	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2ncn(CCCc3ccccc3)c2n1		CHEMBL3263643	>	IC50	nM	50000.0	CHEMBL5251	Homo sapiens	IC50	uM	50.0
	14644629	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2ncn(CC(=O)OC(C)(C)C)c2n1		CHEMBL3263644	=	IC50	nM	29000.0	CHEMBL5251	Homo sapiens	IC50	uM	29.0
	14644630	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2ncn(CC(=O)O)c2n1		CHEMBL3263645	=	IC50	nM	970.0	CHEMBL5251	Homo sapiens	IC50	uM	0.97
	14644631	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(C(=O)N5CCOCC5)cc4)c4nc[nH]c4n3)c2)cc1		CHEMBL3263646	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	uM	0.033
	14644632	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1ccc(NC(=O)c2ccc(C(C)(C)C)cc2)cc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263647	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	uM	0.065
	14644633	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1ccc(-c2nc(Nc3ccc(C(=O)N4CCOCC4)cc3)c3nc[nH]c3n2)cc1NC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL3263648	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	uM	0.026
	14644634	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)C2CCC(C(C)(C)C)CC2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263649	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	uM	0.032
	14644635	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(F)(F)F)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263650	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	uM	0.048
	14644636	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)c2ccccc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263651	=	IC50	nM	83.0	CHEMBL5251	Homo sapiens	IC50	uM	0.083
	14644637	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)C2CCCCC2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263652	=	IC50	nM	169.0	CHEMBL5251	Homo sapiens	IC50	uM	0.169
	14644638	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)C(C)(C)C)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263653	=	IC50	nM	109.0	CHEMBL5251	Homo sapiens	IC50	uM	0.109
	14644639	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(N)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263654	=	IC50	nM	77.0	CHEMBL5251	Homo sapiens	IC50	uM	0.077
	14644640	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1cccc(-c2nc(Nc3ccc(C(=O)N4CCOCC4)cc3)c3nc[nH]c3n2)c1C		CHEMBL3263655	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	uM	0.035
	14644641	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)Nc2ccccc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263656	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	uM	0.018
	14644642	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NC(=O)NC2CCCCC2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263657	=	IC50	nM	49.0	CHEMBL5251	Homo sapiens	IC50	uM	0.049
	14644643	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263658	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	uM	0.027
	14644644	CHEMBL3270595	Inhibition of full length human wild type his-tagged BTK expressed in Sf9 cells using biotinylated peptide as substrate after 1 hr by Fluorescence assay	B	Cc1c(NS(C)(=O)=O)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263659	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	uM	0.041
	14645936	CHEMBL3270977	Inhibition of BTK-induced calcium flux in human Ramos cells	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	uM	0.009
	14645937	CHEMBL3270978	Inhibition of BTK phosphorylation in human Ramos cells by Western blotting	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	uM	0.05
	14645938	CHEMBL3270979	Inhibition of BTK in human tonsilar B cells assessed as inhibition of IL6 expression after 1 hr by EIA	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	uM	0.03
	14645939	CHEMBL3270980	Inhibition of BTK-mediated proliferation in human tonsilar B cells assessed as [3H]thymidine incorporation after 1 hr by liquid scintillation counting	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	14645940	CHEMBL3270981	Inhibition of BTK-mediated CD86 surface expression in human peripheral blood mononuclear cells after 18 hrs by antibody-based FACS analysis	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	142.0	CHEMBL5251	Homo sapiens	IC50	uM	0.142
	14648164	CHEMBL3267039	Inhibition of human BTK at 1 uM relative to control	B	CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1		CHEMBL2380687	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	14648165	CHEMBL3267039	Inhibition of human BTK at 1 uM relative to control	B	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1		CHEMBL3264059	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	14654612	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	O=C1[C@@H]2C[C@H]3CC[C@@]2(O3)[C@@H](P(=O)(O)O)N1Cc1ccccc1		CHEMBL3263336	=	Inhibition	%	38.0	CHEMBL5251	Homo sapiens	INH	%	38.0
	14654613	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	O=C1[C@@H]2C[C@@H]3O[C@]2(C(O)C3O)[C@@H](P(=O)(O)O)N1Cc1ccccc1		CHEMBL3263337	=	Inhibition	%	13.0	CHEMBL5251	Homo sapiens	INH	%	13.0
	14654614	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	O=C1[C@@H]2C[C@@H]3O[C@]2(C(O)C3OP(=O)(O)O)[C@@H](P(=O)(O)O)N1Cc1ccccc1		CHEMBL3263338	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	14654615	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	CC1(C(=O)O)CC([PH](=O)O)=NN1		CHEMBL3263339	=	Inhibition	%	71.0	CHEMBL5251	Homo sapiens	INH	%	71.0
	14654616	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	COP(=O)(O)C1=NNC(C)(C(=O)O)C1		CHEMBL3263340	=	Inhibition	%	52.0	CHEMBL5251	Homo sapiens	INH	%	52.0
	14654617	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	CCOP(=O)(O)C1=NNC(C)(C(=O)O)C1		CHEMBL3263341	=	Inhibition	%	41.0	CHEMBL5251	Homo sapiens	INH	%	41.0
	14654618	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	CC1(C(=O)O)NN=C(P(=O)(O)O)C1C(=O)O		CHEMBL3263342	=	Inhibition	%	64.0	CHEMBL5251	Homo sapiens	INH	%	64.0
	14654619	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	O=C(O)c1cc(P(=O)(O)O)n[nH]1		CHEMBL3263343	=	Inhibition	%	95.0	CHEMBL5251	Homo sapiens	INH	%	95.0
	14654620	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	COP(=O)(O)c1cc(C(=O)O)[nH]n1		CHEMBL3263344	=	Inhibition	%	48.0	CHEMBL5251	Homo sapiens	INH	%	48.0
	14654621	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	CCOP(=O)(O)c1cc(C(=O)O)[nH]n1		CHEMBL3263345	=	Inhibition	%	37.0	CHEMBL5251	Homo sapiens	INH	%	37.0
	14654622	CHEMBL3267159	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells at 100 uM by surface plasmon resonance assay relative to untreated control	B	CCOP(=O)(O)c1n[nH]c(C(=O)O)c1C(=O)O		CHEMBL3263346	=	Inhibition	%	34.0	CHEMBL5251	Homo sapiens	INH	%	34.0
	14654623	CHEMBL3267160	Inhibition of PtdIns(3,4,5)P3 binding to Btk PH domain (unknown origin) expressed in Escherichia coli BL21(DE3) RIL cells by surface plasmon resonance assay relative to untreated control	B	O=C(O)c1cc(P(=O)(O)O)n[nH]1		CHEMBL3263343	=	IC50	nM	17000.0	CHEMBL5251	Homo sapiens	IC50	uM	17.0
	14659155	CHEMBL3269730	Inhibition of BTK (unknown origin) at 25 uM	B	CC(=O)c1cccc(NC(=O)c2sc3nc4cc5c(cc4cc3c2N)OCCO5)c1		CHEMBL3261343	=	Inhibition	%	42.0	CHEMBL5251	Homo sapiens	INH	%	42.0
	14663220	CHEMBL3268849	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	92.0	CHEMBL5251	Homo sapiens	INH	%	92.0
	14663221	CHEMBL3268849	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	75.0	CHEMBL5251	Homo sapiens	INH	%	75.0
	14663222	CHEMBL3268849	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	76.0	CHEMBL5251	Homo sapiens	INH	%	76.0
	14728253	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(N)nc1		CHEMBL411632	=	IC50	nM	3423.0	CHEMBL5251	Homo sapiens	IC50	nM	3423.0
	14728254	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	CCNc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2C)cn1		CHEMBL3290116	=	IC50	nM	1106.0	CHEMBL5251	Homo sapiens	IC50	nM	1106.0
	14728255	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(NC2CC2)nc1		CHEMBL3290117	=	IC50	nM	2153.0	CHEMBL5251	Homo sapiens	IC50	nM	2153.0
	14728256	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2ccccc2)nc1		CHEMBL3290118	=	IC50	nM	133.0	CHEMBL5251	Homo sapiens	IC50	nM	133.0
	14728257	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(C(F)(F)F)c2)nc1		CHEMBL3290119	=	IC50	nM	304.0	CHEMBL5251	Homo sapiens	IC50	nM	304.0
	14728258	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	COc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290120	=	IC50	nM	53.0	CHEMBL5251	Homo sapiens	IC50	nM	53.0
	14728259	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(F)c2)nc1		CHEMBL3290121	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
	14728260	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2ccc(N)cc2)nc1		CHEMBL3290122	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	14728261	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290123	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	14728262	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	CCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290124	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	14728263	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(NC(=O)CCN(C)C)c2)nc1		CHEMBL3290125	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	14728264	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	CCC(=O)N(C(=O)CC)c1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290126	=	IC50	nM	1410.0	CHEMBL5251	Homo sapiens	IC50	nM	1410.0
	14728265	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3Cl)cn2)c1		CHEMBL3290127	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	14728266	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3F)cn2)c1		CHEMBL3290128	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
	14728267	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Nc1cccc(Nc2ncc(NC(=O)c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)cn2)c1		CHEMBL3290129	=	IC50	nM	233.0	CHEMBL5251	Homo sapiens	IC50	nM	233.0
	14728268	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Nc1cccc(Nc2ncc(NC(=O)c3cccc(C(=O)Nc4cccc(C(F)(F)F)c4)c3)cn2)c1		CHEMBL3290130	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
	14728269	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290131	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	14728270	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	CCC(=O)Nc1ccc(C)c(C(=O)Nc2cnc(Nc3cccc(N)c3)nc2)c1		CHEMBL3290132	=	IC50	nM	8563.0	CHEMBL5251	Homo sapiens	IC50	nM	8563.0
	14728271	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)C2CC2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290133	=	IC50	nM	4946.0	CHEMBL5251	Homo sapiens	IC50	nM	4946.0
	14728272	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(Cl)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290134	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	14728273	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290135	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
	14728274	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(F)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290136	=	IC50	nM	166.0	CHEMBL5251	Homo sapiens	IC50	nM	166.0
	14728275	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cc(Cl)cc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290137	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	14728276	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2ccc(Cl)c(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290138	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	14728277	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)cc2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290139	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	14728278	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)/C=C/c2ccccc2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290140	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	14728279	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2ccc3ccccc3c2)cc1C(=O)Nc1cnc(Nc2cccc(N)c2)nc1		CHEMBL3290141	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	14728280	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	14728281	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C/C=C/C(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290143	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	14728282	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(NC(=O)/C=C/CN(C)C)c2)nc1		CHEMBL3290144	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	14728283	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CS(=O)(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290145	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	14728284	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(NC(=O)CCl)c2)nc1		CHEMBL3286434	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	14728285	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2cccc(NC(=O)Cn3sc4ccccc4c3=O)c2)nc1		CHEMBL3290146	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	14728286	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CC(=O)N(C(=O)C=C)c1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290147	=	IC50	nM	208.0	CHEMBL5251	Homo sapiens	IC50	nM	208.0
	14728287	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CC(=O)NCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290148	<	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
	14728288	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(F)c4)ccc3C)cn2)c1		CHEMBL3290149	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
	14728289	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4ccc(Cl)c(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290150	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	14728290	CHEMBL3296229	Inhibition of Btk (unknown origin) after 1 hr by HTRF assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4ccc5ccccc5c4)ccc3C)cn2)c1		CHEMBL3290151	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
Active	14730383	CHEMBL3292446	Binding affinity to Btk kinase domain (387 to 659) (unknown origin) assessed as compound-protein covalent adduct formation at 1:3 protein to compound molar ratio at 4 degC after 1 hr by LC-MS analysis	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	14730384	CHEMBL3292446	Binding affinity to Btk kinase domain (387 to 659) (unknown origin) assessed as compound-protein covalent adduct formation at 1:3 protein to compound molar ratio at 4 degC after 1 hr by LC-MS analysis	B	C=CC(=O)NCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290148		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	14730385	CHEMBL3292447	Binding affinity to Btk kinase domain (387 to 659) (unknown origin) assessed as compound-protein covalent adduct formation at Cys481 residue at 1:3 protein to compound molar ratio incubated for 3 hrs at 0 degC followed by overnight incubation with trypsin at 37 degC by LC-MS analysis	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142		Activity			CHEMBL5251	Homo sapiens	Activity		
	14730386	CHEMBL3292448	Inhibition of Btk phosphorylation at Tyr551 in human Ramos cells after 1 hr by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	14730387	CHEMBL3292448	Inhibition of Btk phosphorylation at Tyr551 in human Ramos cells after 1 hr by Western blot analysis	B	C=CC(=O)NCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290148	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	14730388	CHEMBL3292448	Inhibition of Btk phosphorylation at Tyr551 in human Ramos cells after 1 hr by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	IC50	nM	7.5	CHEMBL5251	Homo sapiens	IC50	nM	7.5
	14730389	CHEMBL3292449	Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	IC50	nM	8.5	CHEMBL5251	Homo sapiens	IC50	nM	8.5
	14730390	CHEMBL3292449	Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis	B	C=CC(=O)NCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290148	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	14730391	CHEMBL3292449	Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
Not Active	14730392	CHEMBL3292450	Irreversible inhibition of Btk phosphorylation at Tyr551 in human Ramos cells at 1 uM incubated for 1 hr followed by compound washout with fresh media measured after 2 hrs by Western blot analysis	B	CCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290124		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	14730393	CHEMBL3292450	Irreversible inhibition of Btk phosphorylation at Tyr551 in human Ramos cells at 1 uM incubated for 1 hr followed by compound washout with fresh media measured after 2 hrs by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	14730394	CHEMBL3292450	Irreversible inhibition of Btk phosphorylation at Tyr551 in human Ramos cells at 1 uM incubated for 1 hr followed by compound washout with fresh media measured after 2 hrs by Western blot analysis	B	C=CC(=O)NCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290148		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	14746148	CHEMBL3292181	Inhibition of human BTK assessed as residual activity at 10 uM relative to control	B	CC1=CC(=O)N(Nc2nc(-c3cccs3)nc3scc(-c4ccccc4)c23)C1=O		CHEMBL3290628	=	Activity	%	76.0	CHEMBL5251	Homo sapiens	Activity	%	76.0
	14746149	CHEMBL3292181	Inhibition of human BTK assessed as residual activity at 10 uM relative to control	B	CC1=CC(=O)N(Nc2nc(-c3cccs3)nc3scc(-c4cccc(OCCN5CCCCC5)c4)c23)C1=O.Cl		CHEMBL3290631	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	14979187	CHEMBL3379054	Inhibition of BTK (unknown origin) by Omnia continuous read kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCO)cc3)ncc2F)c1		CHEMBL3355047	<	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	14979188	CHEMBL3379054	Inhibition of BTK (unknown origin) by Omnia continuous read kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)c1		CHEMBL3355048	<	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	14979189	CHEMBL3379054	Inhibition of BTK (unknown origin) by Omnia continuous read kinase assay	B	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C(O)CO)c3)n2)cc1		CHEMBL3355049	=	IC50	nM	101.0	CHEMBL5251	Homo sapiens	IC50	nM	101.0
	14979190	CHEMBL3379054	Inhibition of BTK (unknown origin) by Omnia continuous read kinase assay	B	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C4CO4)c3)n2)cc1		CHEMBL3355050	<	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	14979191	CHEMBL3379054	Inhibition of BTK (unknown origin) by Omnia continuous read kinase assay	B	C=CC(=O)Nc1cccc(N(C)c2nc(Nc3ccc(OCCO)cc3)ncc2F)c1		CHEMBL3355051	<	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	14979192	CHEMBL3379054	Inhibition of BTK (unknown origin) by Omnia continuous read kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(N(C)c3ccc(OCCO)cc3)ncc2F)c1		CHEMBL3355052	=	IC50	nM	101.0	CHEMBL5251	Homo sapiens	IC50	nM	101.0
Not Determined	14984234	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cc1c(Nc2ncnc3ccccc23)cccc1-c1c[nH]c(=O)c(Nc2ccc(N3CCN(C)CC3)cn2)c1C		CHEMBL3358410		IC50			CHEMBL5251	Homo sapiens	IC50		
	14984235	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(N3CCN(C)CC3)cn2)c(=O)n(C)c1		CHEMBL3358409	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	14984236	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C5COC5)CC4)cn3)c(=O)n(C)c2)cccc1-n1ccc2cc(C3CC3)cc(F)c2c1=O		CHEMBL3358408	=	IC50	nM	171.0	CHEMBL5251	Homo sapiens	IC50	nM	171.0
	14984237	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)c(=O)n(C)c2)cccc1-n1ccc2cc(C3CC3)cc(F)c2c1=O		CHEMBL3358407	=	IC50	nM	254.0	CHEMBL5251	Homo sapiens	IC50	nM	254.0
	14984238	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4)cn(C)c3=O)nc2)CC1		CHEMBL3358406	=	IC50	nM	472.0	CHEMBL5251	Homo sapiens	IC50	nM	472.0
	14984239	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(C(=O)Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3358405	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
Not Determined	14984240	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(CNc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3358404		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	14984241	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6ccccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358403		IC50			CHEMBL5251	Homo sapiens	IC50		
	14984242	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(N(C)C)ncc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358402	=	IC50	nM	1030.0	CHEMBL5251	Homo sapiens	IC50	nM	1030.0
	14984243	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)ncc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358401	=	IC50	nM	124.0	CHEMBL5251	Homo sapiens	IC50	nM	124.0
	14984244	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6nc(C7CC7)ccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358400	=	IC50	nM	3250.0	CHEMBL5251	Homo sapiens	IC50	nM	3250.0
	14984245	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)ccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358399	=	IC50	nM	115.0	CHEMBL5251	Homo sapiens	IC50	nM	115.0
	14984246	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc(Nc2ccc(N3CCN(C(=O)C4CC4)CC3)cn2)c1=O		CHEMBL3358398	=	IC50	nM	4360.0	CHEMBL5251	Homo sapiens	IC50	nM	4360.0
	14984247	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CC(N2CCN(c3ccc(Nc4cc(-c5cccc(-n6ccc7cc(C8CC8)cc(F)c7c6=O)c5CO)cn(C)c4=O)nc3)CC2)C1		CHEMBL3358397	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
	14984248	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3358396	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	14984249	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc(Nc2ccc(C3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3358395	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	14984250	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
	14984251	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)c(=O)n(C)c2)cccc1N1C(=O)c2ccc(C(C)(C)C)cc2C1=O		CHEMBL3358412	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	14984252	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)c(=O)n(C)c2)cccc1-c1nc2cc(C(C)(C)C)ccc2[nH]1		CHEMBL3358411	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	14984253	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cc1c(Nc2ncnc3ccccc23)cccc1-c1c[nH]c(=O)c(Nc2ccc(N3CCN(C)CC3)cn2)c1C		CHEMBL3358410	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	14984254	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(N3CCN(C)CC3)cn2)c(=O)n(C)c1		CHEMBL3358409	=	IC50	nM	875.0	CHEMBL5251	Homo sapiens	IC50	nM	875.0
	14984255	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C5COC5)CC4)cn3)c(=O)n(C)c2)cccc1-n1ccc2cc(C3CC3)cc(F)c2c1=O		CHEMBL3358408	=	IC50	nM	203.0	CHEMBL5251	Homo sapiens	IC50	nM	203.0
	14984256	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)c(=O)n(C)c2)cccc1-n1ccc2cc(C3CC3)cc(F)c2c1=O		CHEMBL3358407	=	IC50	nM	365.0	CHEMBL5251	Homo sapiens	IC50	nM	365.0
	14984257	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4)cn(C)c3=O)nc2)CC1		CHEMBL3358406	=	IC50	nM	503.0	CHEMBL5251	Homo sapiens	IC50	nM	503.0
	14984258	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(C(=O)Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3358405	=	IC50	nM	818.0	CHEMBL5251	Homo sapiens	IC50	nM	818.0
	14984259	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(CNc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3358404	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	14984260	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6ccccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358403	=	IC50	nM	1030.0	CHEMBL5251	Homo sapiens	IC50	nM	1030.0
	14984261	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(N(C)C)ncc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358402	=	IC50	nM	431.0	CHEMBL5251	Homo sapiens	IC50	nM	431.0
	14984262	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)ncc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358401	=	IC50	nM	255.0	CHEMBL5251	Homo sapiens	IC50	nM	255.0
	14984263	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6nc(C7CC7)ccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358400	=	IC50	nM	564.0	CHEMBL5251	Homo sapiens	IC50	nM	564.0
	14984264	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)ccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358399	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
	14984265	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc(Nc2ccc(N3CCN(C(=O)C4CC4)CC3)cn2)c1=O		CHEMBL3358398	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	14984266	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CC(N2CCN(c3ccc(Nc4cc(-c5cccc(-n6ccc7cc(C8CC8)cc(F)c7c6=O)c5CO)cn(C)c4=O)nc3)CC2)C1		CHEMBL3358397	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	14984267	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3358396	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	14984268	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc(Nc2ccc(C3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3358395	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	14984269	CHEMBL3375466	Inhibition of BTK (unknown origin) using biotin-labeled peptide substrate incubated for 1 hr by TR-FRET based HTRF kinase assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
Not Determined	14984270	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)c(=O)n(C)c2)cccc1-c1nc2cc(C(C)(C)C)ccc2[nH]1		CHEMBL3358411		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	14984271	CHEMBL3375467	Inhibition of BTK in human Ramos cells assessed as reduction in IgM-induced calcium influx incubated for 20 mins by Fluo-4 dye based fluorescence assay	B	Cc1c(-c2cc(Nc3ccc(N4CCN(C)CC4)cn3)c(=O)n(C)c2)cccc1N1C(=O)c2ccc(C(C)(C)C)cc2C1=O		CHEMBL3358412		IC50			CHEMBL5251	Homo sapiens	IC50		
	14984395	CHEMBL3384396	Inhibition of BTK (unknown origin) at 1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	28.0	CHEMBL5251	Homo sapiens	INH	%	28.0
	14984461	CHEMBL3381886	Inhibition of BTK (unknown origin) at 0.1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	14993272	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CCNC(=O)Nc1cc(-c2cccc(N3CCc4cc(N(C)C)ccc4C3=O)c2CO)cn(C)c1=O		CHEMBL3358334	=	IC50	nM	1600.0	CHEMBL5251	Homo sapiens	IC50	nM	1600.0
	14993273	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CNC(=O)Nc1cc(-c2ccc(F)c(N3CCc4cc(N(C)C)ccc4C3=O)c2CO)cn(C)c1=O		CHEMBL3358335	=	IC50	nM	3700.0	CHEMBL5251	Homo sapiens	IC50	nM	3700.0
	14993274	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN(C)c1ccc2c(c1)CCN(c1cccc(-c3cc(Nc4ccc(N5CCOCC5)cn4)c(=O)n(C)c3)c1CO)C2=O		CHEMBL3358336	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	nM	190.0
	14993275	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN(C)c1ccc2c(c1)CCN(c1cc(F)cc(-c3cc(Nc4ccc(N5CCOCC5)cn4)c(=O)n(C)c3)c1CO)C2=O		CHEMBL3358337	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	nM	200.0
	14993276	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN(C)c1ccc2c(=O)n(-c3cccc(-c4cc(Nc5ccc(C(=O)N6CCOCC6)cn5)c(=O)n(C)c4)c3CO)ccc2c1		CHEMBL3358338	=	IC50	nM	280.0	CHEMBL5251	Homo sapiens	IC50	nM	280.0
	14993277	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN(C)c1cc(F)c2c(=O)n(-c3cccc(-c4cc(Nc5ccc(C(=O)N6CCOCC6)cn5)c(=O)n(C)c4)c3CO)ccc2c1		CHEMBL3358339	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	14993278	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCc6cc(C(C)(C)C#N)ccc6C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358340	=	IC50	nM	60.0	CHEMBL5251	Homo sapiens	IC50	nM	60.0
	14993279	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCc6cc(C(C)(C)C#N)cc(F)c6C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358341	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	nM	50.0
	14993280	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CCN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)ccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358342	=	IC50	nM	1600.0	CHEMBL5251	Homo sapiens	IC50	nM	1600.0
	14993281	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CCN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3352876	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	14993282	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(Cl)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358343	=	IC50	nM	400.0	CHEMBL5251	Homo sapiens	IC50	nM	400.0
	14993283	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CCN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ncc6cc(C(C)(C)C)ccc6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358344	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	14993284	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CCN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ncc6cc(C(C)(C)C)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358345	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	14993285	CHEMBL3371883	Inhibition of BTK in human whole blood assessed as decrease in CD69 positive cells	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ncc6cc(C(C)(C)C)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3358346	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	15009761	CHEMBL3363733	Inhibition of BTK (unknown origin) at 10 uM	B	C[C@H](O)CNc1nccc(-n2ccnc2Cc2cccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)n1		CHEMBL3309549	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	15014111	CHEMBL3361866	Inhibition of BTK (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	-0.2	CHEMBL5251	Homo sapiens	INH	%	-0.2
	15072594	CHEMBL3382654	Inhibition of BTK (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	92.0	CHEMBL5251	Homo sapiens	Activity	%	92.0
Active	15119515	CHEMBL3388037	Inhibition of BTK phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	15119516	CHEMBL3388037	Inhibition of BTK phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	15119517	CHEMBL3388037	Inhibition of BTK phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method	B	CN1CCN(c2ccc(Nc3nc(N)c4cc(-c5c(Cl)cccc5Cl)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3331534		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	15119523	CHEMBL3388034	Inhibition of BTK phosphorylation in human Rec1 cells at 5 uM incubated for 6 hrs by Western blotting method	B	CN1CCN(c2ccc(Nc3nc(N)c4cc(-c5c(Cl)cccc5Cl)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3331534	=	Inhibition	%	40.0	CHEMBL5251	Homo sapiens	INH	%	40.0
	15119524	CHEMBL3388033	Inhibition of BTK phosphorylation in human Rec1 cells at 1 uM incubated for 6 hrs by Western blotting method	B	CN1CCN(c2ccc(Nc3nc(N)c4cc(-c5c(Cl)cccc5Cl)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3331534	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	15119533	CHEMBL3386182	Inhibition of BTK (unknown origin) assessed as enzyme residual activity at 10 uM by radiometric protein kinase assay	B	Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2c(N)nc(Nc3ccc(OCCN4CCOCC4)cc3)nc21		CHEMBL3331536	=	Activity	%	16.0	CHEMBL5251	Homo sapiens	Activity	%	16.0
	15119534	CHEMBL3386182	Inhibition of BTK (unknown origin) assessed as enzyme residual activity at 10 uM by radiometric protein kinase assay	B	Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2c(N)nc(Nc3ccc(NCCN4CCOCC4)cc3)nc21		CHEMBL3331535	=	Activity	%	10.0	CHEMBL5251	Homo sapiens	Activity	%	10.0
	15119535	CHEMBL3386182	Inhibition of BTK (unknown origin) assessed as enzyme residual activity at 10 uM by radiometric protein kinase assay	B	CN1CCN(c2ccc(Nc3nc(N)c4cc(-c5c(Cl)cccc5Cl)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3331534	=	Activity	%	3.0	CHEMBL5251	Homo sapiens	Activity	%	3.0
	15149908	CHEMBL3395790	Inhibition of BTK (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CCCCC2)ccn1		CHEMBL3394105	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	15149919	CHEMBL3395790	Inhibition of BTK (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CC2)ccn1		CHEMBL3394102	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	15149934	CHEMBL3395790	Inhibition of BTK (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(Sc3cccc(I)n3)n2C2CCCCC2)ccn1		CHEMBL3394118	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	15149935	CHEMBL3395790	Inhibition of BTK (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	COC(Cn1c(SC2CCC(C(=O)O)CC2O)nc(-c2ccc(F)cc2)c1-c1ccnc(NC(C)=O)c1)OC		CHEMBL3394112	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	15149936	CHEMBL3395790	Inhibition of BTK (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2CC2CCCO2)ccn1		CHEMBL3394108	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	15154249	CHEMBL3399473	Inhibition of BTK (unknown origin) using ATP and Y5 Sox15 substrate mix incubated for 30 mins by fluorescence based assay	B	C=CC(=O)Nc1cccc(N(C)c2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3397910	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50(app)	nM	0.5
	15154250	CHEMBL3399473	Inhibition of BTK (unknown origin) using ATP and Y5 Sox15 substrate mix incubated for 30 mins by fluorescence based assay	B	C=CC(=O)Nc1cccc(N(C)c2nc(Nc3cccc(OCCCN(C)C(=O)CCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCC[C@H]4SC[C@H]5NC(=O)N[C@H]54)c3)ncc2C)c1		CHEMBL3397911	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50(app)	nM	0.5
	15154251	CHEMBL3399474	Inhibition of BTK (unknown origin) assessed as ratio of Kinact to Ki using ATP and Y5 Sox15 substrate mix incubated for 30 mins by fluorescence based assay	B	C=CC(=O)Nc1cccc(N(C)c2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3397910	=	Ratio	/M/s	7690.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	7690.0
	15163635	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]ccc23)c1CO		CHEMBL3400973	=	IC50	nM	1568.0	CHEMBL5251	Homo sapiens	IC50	nM	1568.0
	15163636	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4ccccc4)cc23)c1CO		CHEMBL3400974	=	IC50	nM	90.3	CHEMBL5251	Homo sapiens	IC50	nM	90.3
	15163637	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4ccc(O)cc4)cc23)c1CO		CHEMBL3400975	=	IC50	nM	73.9	CHEMBL5251	Homo sapiens	IC50	nM	73.9
	15163638	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3400976	=	IC50	nM	58.3	CHEMBL5251	Homo sapiens	IC50	nM	58.3
	15163639	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	Nc1cccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)c1		CHEMBL3400977	=	IC50	nM	135.5	CHEMBL5251	Homo sapiens	IC50	nM	135.5
	15163640	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CC(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3400978	=	IC50	nM	41.7	CHEMBL5251	Homo sapiens	IC50	nM	41.7
	15163641	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)C(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3400979	=	IC50	nM	17.8	CHEMBL5251	Homo sapiens	IC50	nM	17.8
	15163642	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=C(c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1)N1CCOCC1		CHEMBL3402569	=	IC50	nM	18.2	CHEMBL5251	Homo sapiens	IC50	nM	18.2
	15163643	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=C(c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1)N1CCCCC1		CHEMBL3402570	=	IC50	nM	50.8	CHEMBL5251	Homo sapiens	IC50	nM	50.8
	15163644	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)Cc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3402571	=	IC50	nM	31.6	CHEMBL5251	Homo sapiens	IC50	nM	31.6
	15163645	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)c1CO		CHEMBL3402572	=	IC50	nM	63.6	CHEMBL5251	Homo sapiens	IC50	nM	63.6
	15163646	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)C(=O)c1cccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)c1		CHEMBL3402573	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	nM	69.0
	15163647	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CC(=O)c1cc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cs1		CHEMBL3402574	=	IC50	nM	118.8	CHEMBL5251	Homo sapiens	IC50	nM	118.8
	15163648	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4cc[nH]n4)cc23)c1CO		CHEMBL3402575	=	IC50	nM	38.8	CHEMBL5251	Homo sapiens	IC50	nM	38.8
	15163649	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	Cn1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)n1		CHEMBL3402576	=	IC50	nM	21.3	CHEMBL5251	Homo sapiens	IC50	nM	21.3
	15163650	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cn1		CHEMBL3402577	=	IC50	nM	197.4	CHEMBL5251	Homo sapiens	IC50	nM	197.4
	15163651	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)C(=O)c1cc2c(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)ncnc2[nH]1		CHEMBL3402578	=	IC50	nM	1357.0	CHEMBL5251	Homo sapiens	IC50	nM	1357.0
	15163652	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCCCC4)cc23)c1CO		CHEMBL3402579	=	IC50	nM	77.8	CHEMBL5251	Homo sapiens	IC50	nM	77.8
	15163653	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCSCC4)cc23)c1CO		CHEMBL3402580	=	IC50	nM	67.1	CHEMBL5251	Homo sapiens	IC50	nM	67.1
	15163654	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCNCC4)cc23)c1CO		CHEMBL3402581	=	IC50	nM	32.5	CHEMBL5251	Homo sapiens	IC50	nM	32.5
	15163655	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402582	=	IC50	nM	57.1	CHEMBL5251	Homo sapiens	IC50	nM	57.1
	15163656	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CC(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402583	=	IC50	nM	15.3	CHEMBL5251	Homo sapiens	IC50	nM	15.3
	15163657	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402584	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	15163658	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=C(N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1)N1CCOCC1		CHEMBL3402585	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
	15163659	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CNC(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402586	=	IC50	nM	25.2	CHEMBL5251	Homo sapiens	IC50	nM	25.2
	15163660	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)S(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402587	=	IC50	nM	16.5	CHEMBL5251	Homo sapiens	IC50	nM	16.5
	15163661	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3400174	=	IC50	nM	15.8	CHEMBL5251	Homo sapiens	IC50	nM	15.8
	15163662	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3402588	=	IC50	nM	24.8	CHEMBL5251	Homo sapiens	IC50	nM	24.8
	15163663	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCN(c5ncccn5)CC4)cc23)c1CO		CHEMBL3402589	=	IC50	nM	45.3	CHEMBL5251	Homo sapiens	IC50	nM	45.3
	15163664	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)C(=O)N1CCC(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402590	=	IC50	nM	574.0	CHEMBL5251	Homo sapiens	IC50	nM	574.0
	15163665	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3n2C)CC1		CHEMBL3402591	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	15163666	CHEMBL3407032	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET analysis	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	13.2	CHEMBL5251	Homo sapiens	IC50	nM	13.2
	15163667	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]ccc23)c1CO		CHEMBL3400973	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	15163668	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4ccccc4)cc23)c1CO		CHEMBL3400974	=	IC50	nM	79.0	CHEMBL5251	Homo sapiens	IC50	nM	79.0
	15163669	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4ccc(O)cc4)cc23)c1CO		CHEMBL3400975	=	IC50	nM	211.0	CHEMBL5251	Homo sapiens	IC50	nM	211.0
	15163670	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3400976	=	IC50	nM	38.8	CHEMBL5251	Homo sapiens	IC50	nM	38.8
	15163671	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	Nc1cccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)c1		CHEMBL3400977	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
	15163672	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CC(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3400978	=	IC50	nM	49.0	CHEMBL5251	Homo sapiens	IC50	nM	49.0
	15163673	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)C(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3400979	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	15163674	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=C(c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1)N1CCOCC1		CHEMBL3402569	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	15163675	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=C(c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1)N1CCCCC1		CHEMBL3402570	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
	15163676	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)Cc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cc1		CHEMBL3402571	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
	15163677	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)c1CO		CHEMBL3402572	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	15163678	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)C(=O)c1cccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)c1		CHEMBL3402573	=	IC50	nM	87.3	CHEMBL5251	Homo sapiens	IC50	nM	87.3
	15163679	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CC(=O)c1cc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cs1		CHEMBL3402574	=	IC50	nM	58.0	CHEMBL5251	Homo sapiens	IC50	nM	58.0
	15163680	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(-c4cc[nH]n4)cc23)c1CO		CHEMBL3402575	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
	15163681	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	Cn1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)n1		CHEMBL3402576	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	15163682	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)cn1		CHEMBL3402577	=	IC50	nM	74.0	CHEMBL5251	Homo sapiens	IC50	nM	74.0
	15163683	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)C(=O)c1cc2c(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)ncnc2[nH]1		CHEMBL3402578	=	IC50	nM	1560.0	CHEMBL5251	Homo sapiens	IC50	nM	1560.0
	15163684	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCCCC4)cc23)c1CO		CHEMBL3402579	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	nM	350.0
	15163685	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCSCC4)cc23)c1CO		CHEMBL3402580	=	IC50	nM	46.0	CHEMBL5251	Homo sapiens	IC50	nM	46.0
	15163686	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCNCC4)cc23)c1CO		CHEMBL3402581	=	IC50	nM	96.5	CHEMBL5251	Homo sapiens	IC50	nM	96.5
	15163687	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402582	=	IC50	nM	125.0	CHEMBL5251	Homo sapiens	IC50	nM	125.0
	15163688	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CC(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402583	=	IC50	nM	21.4	CHEMBL5251	Homo sapiens	IC50	nM	21.4
	15163689	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402584	=	IC50	nM	21.6	CHEMBL5251	Homo sapiens	IC50	nM	21.6
	15163690	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=C(N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1)N1CCOCC1		CHEMBL3402585	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	15163691	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CNC(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402586	=	IC50	nM	51.3	CHEMBL5251	Homo sapiens	IC50	nM	51.3
	15163692	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)S(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402587	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	15163693	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3400174	=	IC50	nM	7.9	CHEMBL5251	Homo sapiens	IC50	nM	7.9
	15163694	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3402588	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	15163695	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ncnc3[nH]c(C4=CCN(c5ncccn5)CC4)cc23)c1CO		CHEMBL3402589	=	IC50	nM	69.7	CHEMBL5251	Homo sapiens	IC50	nM	69.7
	15163696	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)C(=O)N1CCC(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402590	=	IC50	nM	1648.0	CHEMBL5251	Homo sapiens	IC50	nM	1648.0
	15163697	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3n2C)CC1		CHEMBL3402591	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	15163698	CHEMBL3407033	Inhibition of BTK in human Ramos cells after 20 mins by fluorescence assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	27.3	CHEMBL5251	Homo sapiens	IC50	nM	27.3
	15166694	CHEMBL3406079	Inhibition of BTK in human whole blood B-cells assessed as inhibition of both anti-IgD-stimulated CD69 expression	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@@H]3C(=O)N(C)CCN3C)cc2)n1		CHEMBL2057915	=	EC50	nM	380.0	CHEMBL5251	Homo sapiens	EC50	uM	0.38
	15166695	CHEMBL3406078	Inhibition of BTK in human whole blood basophils assessed as inhibition of both anti-IgE-stimulated CD63 expression	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@@H]3C(=O)N(C)CCN3C)cc2)n1		CHEMBL2057915	=	EC50	nM	350.0	CHEMBL5251	Homo sapiens	EC50	uM	0.35
	15166727	CHEMBL3406074	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL1230541	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	15166728	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@@H]3C(=O)N(C)CCN3C)cc2)n1		CHEMBL2057915	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	uM	0.006
	15166729	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@H]3C(=O)N(C)CCN3C)cc2)n1		CHEMBL3401292	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	uM	0.02
	15166730	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(-c3ncc[nH]3)cc2)n1		CHEMBL3401291	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	uM	0.05
	15166731	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(N3CC[C@@H](N(C)C)C3)cc2)n1		CHEMBL3401290	=	IC50	nM	60.0	CHEMBL5251	Homo sapiens	IC50	uM	0.06
	15166732	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(C3CCN(C)CC3)cc2)n1		CHEMBL3401289	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	uM	0.01
	15166733	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccn3ccnc3c2)n1		CHEMBL3401288	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	uM	0.054
	15166734	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc3ocnc3c2)n1		CHEMBL3401287	=	IC50	nM	210.0	CHEMBL5251	Homo sapiens	IC50	uM	0.21
	15166735	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc3[nH]ccc3c2)n1		CHEMBL3401286	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	uM	0.043
	15166736	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccncn2)n1		CHEMBL3401285	=	IC50	nM	650.0	CHEMBL5251	Homo sapiens	IC50	uM	0.65
	15166737	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccnnc2)n1		CHEMBL3401284	=	IC50	nM	490.0	CHEMBL5251	Homo sapiens	IC50	uM	0.49
	15166738	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2cccnc2)n1		CHEMBL3401283	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	uM	0.05
	15166739	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccccc2)n1		CHEMBL3401282	=	IC50	nM	230.0	CHEMBL5251	Homo sapiens	IC50	uM	0.23
	15166740	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3ccccc3s2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401281	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	uM	0.03
	15166741	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3n(c2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401280	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	uM	0.19
	15166742	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2nc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401279	=	IC50	nM	340.0	CHEMBL5251	Homo sapiens	IC50	uM	0.34
	15166743	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCOC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401278	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	uM	0.15
	15166744	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401277	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	15166745	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cnc(C(C)(C)C)cn2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401276	=	IC50	nM	70.0	CHEMBL5251	Homo sapiens	IC50	uM	0.07
	15166746	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)nc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401275	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	uM	0.13
	15166747	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ncc(C(C)(C)C)cn2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401274	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	uM	0.05
	15166748	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2cnc(C(C)(C)C)nc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401273	=	IC50	nM	270.0	CHEMBL5251	Homo sapiens	IC50	uM	0.27
	15166749	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)s2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401272	=	IC50	nM	60.0	CHEMBL5251	Homo sapiens	IC50	uM	0.06
	15166750	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc([Si](C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401271	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	uM	0.09
	15166751	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc(C(C)(C)O)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401270	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	uM	0.15
	15166752	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc(C3(C)CC3)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401269	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	uM	0.03
	15166753	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401268	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	uM	0.11
	15166754	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	CCC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cn(C)c(=O)c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2C)cc1		CHEMBL3401267	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	uM	0.04
	15166755	CHEMBL3406073	Inhibition of BTK (unknown origin) by Lanthascreen method	B	Cc1c(NC(=O)c2ccc(N(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401266	=	IC50	nM	230.0	CHEMBL5251	Homo sapiens	IC50	uM	0.23
	15166756	CHEMBL3406072	Inhibition of BTK (unknown origin) after 1 hr by FRET assay	B	CCc1ccc(C(=O)Nc2cccc(-c3cn(C)c(=O)c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2C)cc1		CHEMBL3401265	=	IC50	nM	225.0	CHEMBL5251	Homo sapiens	IC50	uM	0.225
	15166757	CHEMBL3406072	Inhibition of BTK (unknown origin) after 1 hr by FRET assay	B	Cc1ccc(C(=O)Nc2cccc(-c3cn(C)c(=O)c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2C)cc1		CHEMBL3401264	=	IC50	nM	860.0	CHEMBL5251	Homo sapiens	IC50	uM	0.86
	15166758	CHEMBL3406072	Inhibition of BTK (unknown origin) after 1 hr by FRET assay	B	Cc1c(NC(=O)c2ccccc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL3401263	=	IC50	nM	4600.0	CHEMBL5251	Homo sapiens	IC50	uM	4.6
	15172831	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400825	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	uM	0.29
	15172832	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400826	=	IC50	nM	208.0	CHEMBL5251	Homo sapiens	IC50	uM	0.208
	15172833	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402353	=	IC50	nM	189.0	CHEMBL5251	Homo sapiens	IC50	uM	0.189
	15172834	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCOCCOCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402354	=	IC50	nM	305.0	CHEMBL5251	Homo sapiens	IC50	uM	0.305
	15172835	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCN(C(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)CC3)cc2)n1		CHEMBL3402355	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	uM	0.069
	15172836	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOC(CNC(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)C3)cc2)n1		CHEMBL3402356	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	uM	0.35
	15172837	CHEMBL3407011	Inhibition of biotinylated and activated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL1230541	=	IC50	nM	81.0	CHEMBL5251	Homo sapiens	IC50	uM	0.081
	15172838	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400825	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	uM	0.0056
	15172839	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400826	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	uM	0.0032
	15172840	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402353	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	uM	0.0043
	15172841	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCOCCOCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402354	=	IC50	nM	7.8	CHEMBL5251	Homo sapiens	IC50	uM	0.0078
	15172842	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCN(C(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)CC3)cc2)n1		CHEMBL3402355	=	IC50	nM	0.61	CHEMBL5251	Homo sapiens	IC50	uM	0.00061
	15172843	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOC(CNC(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)C3)cc2)n1		CHEMBL3402356	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	uM	0.0048
	15172844	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL1230541	=	IC50	nM	0.61	CHEMBL5251	Homo sapiens	IC50	uM	0.00061
	15172845	CHEMBL3407012	Inhibition of biotinylated and unactivated BTK (unknown origin) using FITC-labeled Srctide peptide substrate and ATP	B	CC(=O)Nc1cccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c1		CHEMBL3402357	=	IC50	nM	4700.0	CHEMBL5251	Homo sapiens	IC50	uM	4.7
	15172846	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400825	=	Kd	nM	6.1	CHEMBL5251	Homo sapiens	Kd	uM	0.0061
	15172847	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400826	=	Kd	nM	6.2	CHEMBL5251	Homo sapiens	Kd	uM	0.0062
	15172848	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402353	=	Kd	nM	5.5	CHEMBL5251	Homo sapiens	Kd	uM	0.0055
	15172849	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCOCCOCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402354	=	Kd	nM	8.8	CHEMBL5251	Homo sapiens	Kd	uM	0.0088
	15172850	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCN(C(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)CC3)cc2)n1		CHEMBL3402355	=	Kd	nM	2.5	CHEMBL5251	Homo sapiens	Kd	uM	0.0025
	15172851	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOC(CNC(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)C3)cc2)n1		CHEMBL3402356	=	Kd	nM	3.8	CHEMBL5251	Homo sapiens	Kd	uM	0.0038
Not Determined	15172852	CHEMBL3407013	Binding affinity to biotinylated and unactivated BTK (unknown origin) incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL1230541		Kd			CHEMBL5251	Homo sapiens	Kd		
Active	15172853	CHEMBL3407014	Binding affinity to biotinylated and unactivated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400825		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	15172854	CHEMBL3407014	Binding affinity to biotinylated and unactivated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400826		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	15172855	CHEMBL3407014	Binding affinity to biotinylated and unactivated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402353		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	15172856	CHEMBL3407014	Binding affinity to biotinylated and unactivated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCOCCOCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402354		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	15172857	CHEMBL3407014	Binding affinity to biotinylated and unactivated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCN(C(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)CC3)cc2)n1		CHEMBL3402355		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	15172858	CHEMBL3407014	Binding affinity to biotinylated and unactivated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOC(CNC(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)C3)cc2)n1		CHEMBL3402356		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	15172859	CHEMBL3407015	Binding affinity to biotinylated and activated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400825		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	15172860	CHEMBL3407015	Binding affinity to biotinylated and activated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3400826		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	15172861	CHEMBL3407015	Binding affinity to biotinylated and activated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402353		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	15172862	CHEMBL3407015	Binding affinity to biotinylated and activated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)NCCOCCOCCNC(=S)Nc3ccc(-c4c5ccc(=O)cc-5oc5cc(O)ccc45)c(C(=O)O)c3)cc2)n1		CHEMBL3402354		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	15172863	CHEMBL3407015	Binding affinity to biotinylated and activated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCN(C(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)CC3)cc2)n1		CHEMBL3402355		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	15172864	CHEMBL3407015	Binding affinity to biotinylated and activated BTK (unknown origin) at 0.001 to 0.1 uM incubated for 1 hr by TR-FRET assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOC(CNC(=S)Nc4ccc(-c5c6ccc(=O)cc-6oc6cc(O)ccc56)c(C(=O)O)c4)C3)cc2)n1		CHEMBL3402356		Activity			CHEMBL5251	Homo sapiens	Activity		
	15172868	CHEMBL3407017	Inhibition of unactivated BTK (unknown origin) using 30 uM probe 5-(4-(4-(6-(3-(4-tert-butylbenzamido)-2-methylphenyl)-4-methyl-3-oxo-3,4-dihydropyrazin-2-ylamino)benzoyl)piperazine-1-carbothioamido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid	B	CC(=O)Nc1cccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c1		CHEMBL3402357	>	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
Not Active	15172869	CHEMBL3407018	Inhibition of biotinylated and activated BTK (unknown origin) up to 100 uM using FITC-labeled Srctide peptide substrate and ATP	B	CC(=O)Nc1cccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c1		CHEMBL3402357		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	15249272	CHEMBL3428302	Inhibition of human BTK using KVEKIGEGTYGVVYK peptide substrate at 1 uM by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426891	=	Inhibition	%	45.1	CHEMBL5251	Homo sapiens	INH	%	45.1
	15251789	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	88.0	CHEMBL5251	Homo sapiens	Activity	%	88.0
	15251891	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	36.0	CHEMBL5251	Homo sapiens	Activity	%	36.0
	15252008	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	113.0	CHEMBL5251	Homo sapiens	Activity	%	113.0
	15252653	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	54.0	CHEMBL5251	Homo sapiens	Activity	%	54.0
	15252755	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	52.0	CHEMBL5251	Homo sapiens	Activity	%	52.0
	15252857	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	52.0	CHEMBL5251	Homo sapiens	Activity	%	52.0
	15253531	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	73.0	CHEMBL5251	Homo sapiens	Activity	%	73.0
	15253633	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	60.0	CHEMBL5251	Homo sapiens	Activity	%	60.0
	15253735	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	73.0	CHEMBL5251	Homo sapiens	Activity	%	73.0
	15253813	CHEMBL3429881	Inhibition of human Btk	B	CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21		CHEMBL3426225	=	IC50	nM	67.0	CHEMBL5251	Homo sapiens	IC50	uM	0.067
	15254401	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	15.0	CHEMBL5251	Homo sapiens	Activity	%	15.0
	15254503	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	21.0	CHEMBL5251	Homo sapiens	Activity	%	21.0
	15254605	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	51.0	CHEMBL5251	Homo sapiens	Activity	%	51.0
	15255296	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	20.0	CHEMBL5251	Homo sapiens	Activity	%	20.0
	15255398	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	29.0	CHEMBL5251	Homo sapiens	Activity	%	29.0
	15255501	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	28.0	CHEMBL5251	Homo sapiens	Activity	%	28.0
	15256232	CHEMBL3427811	Inhibition of BTK (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	31.0	CHEMBL5251	Homo sapiens	Activity	%	31.0
	15622499	CHEMBL3588264	Inhibition of human recombinant Btk at 1 uM	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	Inhibition	%	101.0	CHEMBL5251	Homo sapiens	INH	%	101.0
	15622510	CHEMBL3588253	Inhibition of BTK in human Raji cells after 30 mins by HTRF assay	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	IC50	nM	4000.0	CHEMBL5251	Homo sapiens	IC50	uM	4.0
	15622511	CHEMBL3588253	Inhibition of BTK in human Raji cells after 30 mins by HTRF assay	B	NC(=O)c1nnc2c(-c3ccc4cn[nH]c4c3)cccc2c1N		CHEMBL3586446	=	IC50	nM	12000.0	CHEMBL5251	Homo sapiens	IC50	uM	12.0
	15622512	CHEMBL3588253	Inhibition of BTK in human Raji cells after 30 mins by HTRF assay	B	NC(=O)c1nnc2c(-c3ccc4cc[nH]c4c3)cccc2c1N		CHEMBL3586445	=	IC50	nM	850000.0	CHEMBL5251	Homo sapiens	IC50	uM	850.0
	15622513	CHEMBL3588253	Inhibition of BTK in human Raji cells after 30 mins by HTRF assay	B	Cc1ccncc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586444	=	IC50	nM	100000.0	CHEMBL5251	Homo sapiens	IC50	uM	100.0
	15622514	CHEMBL3588253	Inhibition of BTK in human Raji cells after 30 mins by HTRF assay	B	Cn1cc(-c2cccc3c(N)c(C(N)=O)nnc23)cn1		CHEMBL3586443	=	IC50	nM	240000.0	CHEMBL5251	Homo sapiens	IC50	uM	240.0
	15622515	CHEMBL3588253	Inhibition of BTK in human Raji cells after 30 mins by HTRF assay	B	NC(=O)c1nnc2ccccc2c1N		CHEMBL449216	=	IC50	nM	3500.0	CHEMBL5251	Homo sapiens	IC50	uM	3.5
	15622544	CHEMBL3588237	Inhibition of BTK autophosphorylation in human Raji cells after 30 mins by Phos-Y223 Btk HTRF assay	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	EC50	nM	28.0	CHEMBL5251	Homo sapiens	EC50	uM	0.028
	15622545	CHEMBL3588237	Inhibition of BTK autophosphorylation in human Raji cells after 30 mins by Phos-Y223 Btk HTRF assay	B	NC(=O)c1nnc2c(-c3ccc4cn[nH]c4c3)cccc2c1N		CHEMBL3586446	=	EC50	nM	92.0	CHEMBL5251	Homo sapiens	EC50	uM	0.092
Not Determined	15622546	CHEMBL3588237	Inhibition of BTK autophosphorylation in human Raji cells after 30 mins by Phos-Y223 Btk HTRF assay	B	NC(=O)c1nnc2c(-c3ccc4cc[nH]c4c3)cccc2c1N		CHEMBL3586445		EC50			CHEMBL5251	Homo sapiens	EC50		
	15622547	CHEMBL3588237	Inhibition of BTK autophosphorylation in human Raji cells after 30 mins by Phos-Y223 Btk HTRF assay	B	Cc1ccncc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586444	=	EC50	nM	28600.0	CHEMBL5251	Homo sapiens	EC50	uM	28.6
	15622548	CHEMBL3588237	Inhibition of BTK autophosphorylation in human Raji cells after 30 mins by Phos-Y223 Btk HTRF assay	B	Cn1cc(-c2cccc3c(N)c(C(N)=O)nnc23)cn1		CHEMBL3586443	>	EC50	nM	50000.0	CHEMBL5251	Homo sapiens	EC50	uM	50.0
	15622552	CHEMBL3588277	Inhibition of human recombinant Btk	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	15649095	CHEMBL3594875	Inhibition of BTK (unknown origin)	B	N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1		CHEMBL3593777	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	15650143	CHEMBL3595409	Inhibition of human BTK at 0.1 uM relative to control	B	CCc1cc(NC(=O)Nc2ccc(-c3cnc(Nc4cc(N5CCN(CC)CC5)nc(C)n4)s3)cc2)no1		CHEMBL3593290	=	Inhibition	%	46.0	CHEMBL5251	Homo sapiens	INH	%	46.0
	15666986	CHEMBL3603324	Inhibition of BTK (unknown origin) by Z'-Lyte assay	B	C=CC(=O)Nc1cccc(CNc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1		CHEMBL3601223	=	IC50	nM	794.0	CHEMBL5251	Homo sapiens	IC50	nM	794.0
	15686148	CHEMBL3606968	Inhibition of BTK (unknown origin) at 250 nM by radioactive filter-binding assay	B	c1ccc2c(Nc3cc(C4CCC4)[nH]n3)nc(Nc3ccc4[nH]cnc4c3)nc2c1		CHEMBL3605055	>=	Inhibition	%	80.0	CHEMBL5251	Homo sapiens	INH	%	80.0
	15686977	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Cn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605102	=	IC50	nM	107.4	CHEMBL5251	Homo sapiens	IC50	nM	107.4
	15686978	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2cn[nH]c2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605101	=	IC50	nM	1052.0	CHEMBL5251	Homo sapiens	IC50	nM	1052.0
	15686979	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CCCCc1cnc(N)c2c(-c3ccc(Oc4ccccc4)cc3)csc12		CHEMBL3605100	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15686980	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(C2CC2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605095	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15686981	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2ccco2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605094	=	IC50	nM	767.5	CHEMBL5251	Homo sapiens	IC50	nM	767.5
	15686982	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	COc1ccc2cc(-c3cnc(N)c4c(-c5ccc(Oc6ccccc6)cc5)csc34)ccc2c1		CHEMBL3605093	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15686983	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2ccc(Oc3ccccc3)cc2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605099	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15686984	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2ccc(N3CCOCC3)cc2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605098	=	IC50	nM	2295.0	CHEMBL5251	Homo sapiens	IC50	nM	2295.0
	15686985	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605097	=	IC50	nM	1954.0	CHEMBL5251	Homo sapiens	IC50	nM	1954.0
	15686986	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2ccccc2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605096	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15686987	CHEMBL3607386	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	15687012	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	15687013	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CNC(=O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)c5cccc(Cl)c5)cc4)csc23)cn1		CHEMBL3605113	=	IC50	nM	408.7	CHEMBL5251	Homo sapiens	IC50	nM	408.7
	15687014	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)c5cccc(Cl)c5)cc4)csc23)cn1		CHEMBL3605112	=	IC50	nM	420.9	CHEMBL5251	Homo sapiens	IC50	nM	420.9
	15687015	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CNC(=O)Cn1cc(-c2cnc(N)c3c(-c4ccc(C(=O)Nc5ccccc5)cc4)csc23)cn1		CHEMBL3605111	=	IC50	nM	137.0	CHEMBL5251	Homo sapiens	IC50	nM	137.0
	15687016	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CNC(=O)Cn1cc(-c2cnc(N)c3c(-c4cccc(C(=O)Nc5ccccc5)c4)csc23)cn1		CHEMBL3605110	=	IC50	nM	291.5	CHEMBL5251	Homo sapiens	IC50	nM	291.5
	15687017	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CC(=O)n1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605109	=	IC50	nM	454.2	CHEMBL5251	Homo sapiens	IC50	nM	454.2
	15687018	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CN(C)S(=O)(=O)n1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605108	=	IC50	nM	527.6	CHEMBL5251	Homo sapiens	IC50	nM	527.6
	15687019	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CNC(=O)Cn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605107	=	IC50	nM	12.8	CHEMBL5251	Homo sapiens	IC50	nM	12.8
	15687020	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	COCCCn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605106	=	IC50	nM	279.7	CHEMBL5251	Homo sapiens	IC50	nM	279.7
	15687021	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	Nc1ncc(-c2cnn(Cc3ccccc3)c2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3605105	=	IC50	nM	699.2	CHEMBL5251	Homo sapiens	IC50	nM	699.2
	15687022	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CCCCn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605104	=	IC50	nM	387.1	CHEMBL5251	Homo sapiens	IC50	nM	387.1
	15687023	CHEMBL3607488	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	B	CCn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605103	=	IC50	nM	176.2	CHEMBL5251	Homo sapiens	IC50	nM	176.2
	15709951	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	15709952	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(C2CCNCC2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612995	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15709953	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C=CC(=O)N1CC=C(c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)CC1		CHEMBL3612994	=	IC50	nM	183.3	CHEMBL5251	Homo sapiens	IC50	nM	183.3
	15709954	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(C2=CCNCC2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612993	=	IC50	nM	853.9	CHEMBL5251	Homo sapiens	IC50	nM	853.9
	15709955	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CC(C)(C)OC(=O)N1CC=C(c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)CC1		CHEMBL3612077	=	IC50	nM	1659.0	CHEMBL5251	Homo sapiens	IC50	nM	1659.0
	15709956	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCCC(c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)C1		CHEMBL3612992	=	IC50	nM	2295.0	CHEMBL5251	Homo sapiens	IC50	nM	2295.0
	15709957	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(C2CCCNC2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612991	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	15709958	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C=CC(=O)N1C=C(c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)CCC1		CHEMBL3612990	=	IC50	nM	342.6	CHEMBL5251	Homo sapiens	IC50	nM	342.6
	15709959	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CNC(=O)CN1C=C(c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)CCC1		CHEMBL3612989	=	IC50	nM	455.7	CHEMBL5251	Homo sapiens	IC50	nM	455.7
	15709960	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(C2=CNCCC2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612850	=	IC50	nM	3601.0	CHEMBL5251	Homo sapiens	IC50	nM	3601.0
	15709961	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CC(C)(C)OC(=O)N1C=C(c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)CCC1		CHEMBL3612849	=	IC50	nM	2867.0	CHEMBL5251	Homo sapiens	IC50	nM	2867.0
	15709962	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C=CC(=O)n1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3612848	=	IC50	nM	1687.0	CHEMBL5251	Homo sapiens	IC50	nM	1687.0
	15709963	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C=CC(=O)NCCn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3612847	=	IC50	nM	9.9	CHEMBL5251	Homo sapiens	IC50	nM	9.9
	15709964	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(-c2cnn(CCC(=O)O)c2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612846	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	15709965	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CS(=O)(=O)OC1CCCN(C(=O)CCn2cc(-c3cnc(N)c4c(-c5ccc(Oc6ccccc6)cc5)csc34)cn2)C1		CHEMBL3612845	=	IC50	nM	54.9	CHEMBL5251	Homo sapiens	IC50	nM	54.9
	15709966	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CNC(=O)CCn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3612844	=	IC50	nM	25.5	CHEMBL5251	Homo sapiens	IC50	nM	25.5
	15709967	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	C#CCn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3612843	=	IC50	nM	7.4	CHEMBL5251	Homo sapiens	IC50	nM	7.4
	15709968	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CC(=O)Cn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3612842	=	IC50	nM	7.8	CHEMBL5251	Homo sapiens	IC50	nM	7.8
	15709969	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(-c2cnn(C3CCCNC3=O)c2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612841	=	IC50	nM	9.5	CHEMBL5251	Homo sapiens	IC50	nM	9.5
	15709970	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(-c2cnn(CC(=O)N3CCOCC3)c2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612840	=	IC50	nM	11.8	CHEMBL5251	Homo sapiens	IC50	nM	11.8
	15709971	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	Nc1ncc(-c2cnn(CC(=O)N3CCCCC3)c2)c2scc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3612839	=	IC50	nM	12.2	CHEMBL5251	Homo sapiens	IC50	nM	12.2
	15709972	CHEMBL3614375	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	B	CNC(=O)Cn1cc(-c2cnc(N)c3c(-c4ccc(Oc5ccccc5)cc4)csc23)cn1		CHEMBL3605107	=	IC50	nM	12.8	CHEMBL5251	Homo sapiens	IC50	nM	12.8
	15728215	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3[nH]c4c(C(N)=O)ccc(-c5ccccc5F)c4c3c2)CC1		CHEMBL3621457	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	15728216	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1cccc(-c2ccc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCN(C)CC5)cc4c23)c1		CHEMBL3621458	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	15728217	CHEMBL3627421	Inhibition of human recombinant BTK	B	CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCN(C)CC5)cc4c23)c1		CHEMBL3621459	=	IC50	nM	88.0	CHEMBL5251	Homo sapiens	IC50	nM	88.0
	15728218	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1ccc(-c2ccc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCN(C)CC5)cc4c23)cc1		CHEMBL3621460	=	IC50	nM	29.0	CHEMBL5251	Homo sapiens	IC50	nM	29.0
	15728219	CHEMBL3627421	Inhibition of human recombinant BTK	B	CC(=O)Nc1ccc(-c2ccc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCN(C)CC5)cc4c23)cc1		CHEMBL3621495	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	15728220	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccccc4F)c23)CC1		CHEMBL3621496	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	15728221	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)c1		CHEMBL3621497	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	15728222	CHEMBL3627421	Inhibition of human recombinant BTK	B	CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)c1		CHEMBL3621498	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	15728223	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1ccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)cc1		CHEMBL3621499	=	IC50	nM	55.0	CHEMBL5251	Homo sapiens	IC50	nM	55.0
	15728224	CHEMBL3627421	Inhibition of human recombinant BTK	B	CC(=O)Nc1ccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)cc1		CHEMBL3621500	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	15728225	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1ccccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3621501	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	15728226	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1ccccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3621502	=	IC50	nM	144.0	CHEMBL5251	Homo sapiens	IC50	nM	144.0
	15728227	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccccc4Cl)c23)CC1		CHEMBL3621503	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	15728228	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(Cl)c4)c23)CC1		CHEMBL3621504	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	15728229	CHEMBL3627421	Inhibition of human recombinant BTK	B	CNC(=O)c1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)c1		CHEMBL3621505	=	IC50	nM	71.0	CHEMBL5251	Homo sapiens	IC50	nM	71.0
	15728230	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccc(Cl)cc4)c23)CC1		CHEMBL3621506	=	IC50	nM	59.0	CHEMBL5251	Homo sapiens	IC50	nM	59.0
	15728231	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccc(C(C)(C)C)cc4)c23)CC1		CHEMBL3621507	=	IC50	nM	103.0	CHEMBL5251	Homo sapiens	IC50	nM	103.0
	15728232	CHEMBL3627421	Inhibition of human recombinant BTK	B	CNC(=O)c1ccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)cc1		CHEMBL3621508	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	15728233	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccc(Oc5ccccc5)cc4)c23)CC1		CHEMBL3621509	=	IC50	nM	127.0	CHEMBL5251	Homo sapiens	IC50	nM	127.0
	15728234	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccc(Cl)c(Cl)c4)c23)CC1		CHEMBL3621510	=	IC50	nM	101.0	CHEMBL5251	Homo sapiens	IC50	nM	101.0
	15728235	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(Cl)c4Cl)c23)CC1		CHEMBL3621511	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	15728236	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(F)c4F)c23)CC1		CHEMBL3621512	=	IC50	nM	6.9	CHEMBL5251	Homo sapiens	IC50	nM	6.9
	15728237	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1c(Cl)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3621513	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	15728238	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1c(N)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3621514	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	15728239	CHEMBL3627421	Inhibition of human recombinant BTK	B	CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)c1C		CHEMBL3621515	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	15728240	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4ccc(F)cc4F)c23)CC1		CHEMBL3621516	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
	15728241	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cc(F)ccc4F)c23)CC1		CHEMBL3621517	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	15728242	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4c(F)cccc4F)c23)CC1		CHEMBL3621518	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	15728243	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1c(NC(=O)c2ccccc2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3621519	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	15728244	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1c(NC(=O)c2ccc(F)cc2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3622189	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
	15728245	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1c(NC(=O)c2ccc(N(C)C)cc2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3622190	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	15728246	CHEMBL3627421	Inhibition of human recombinant BTK	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3622191	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	15728247	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(NC(=O)c5ccc(F)cc5)c4F)c23)CC1		CHEMBL3622192	=	IC50	nM	9.4	CHEMBL5251	Homo sapiens	IC50	nM	9.4
	15728248	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(NC(=O)c5ccc(N(C)C)cc5)c4F)c23)CC1		CHEMBL3622193	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	15728249	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)ccc(-c4cccc(NC(=O)c5ccc(F)cc5)c4)c23)CC1		CHEMBL3622194	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	15728250	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1cccc(-c2cc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCOCC5)cc4c3c2)c1		CHEMBL3589166	=	IC50	nM	360.0	CHEMBL5251	Homo sapiens	IC50	nM	360.0
	15728251	CHEMBL3627421	Inhibition of human recombinant BTK	B	NC(=O)c1cc(-c2cccc(Cl)c2)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12		CHEMBL3622195	=	IC50	nM	189.0	CHEMBL5251	Homo sapiens	IC50	nM	189.0
	15728252	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1ccc(-c2cc(C(N)=O)c3[nH]c4ccc(C(=O)N5CCOCC5)cc4c3c2)cc1		CHEMBL3622196	=	IC50	nM	327.0	CHEMBL5251	Homo sapiens	IC50	nM	327.0
	15728253	CHEMBL3627421	Inhibition of human recombinant BTK	B	NC(=O)c1cc(-c2ccc(Cl)cc2)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12		CHEMBL3622197	=	IC50	nM	308.0	CHEMBL5251	Homo sapiens	IC50	nM	308.0
	15728254	CHEMBL3627421	Inhibition of human recombinant BTK	B	NC(=O)c1cc(-c2ccc(Cl)c(Cl)c2)cc2c1[nH]c1ccc(C(=O)N3CCOCC3)cc12		CHEMBL3589164	=	IC50	nM	461.0	CHEMBL5251	Homo sapiens	IC50	nM	461.0
	15728255	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3[nH]c4c(C(N)=O)cc(-c5ccc(Cl)cc5)cc4c3c2)CC1		CHEMBL3589169	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
	15728256	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1cccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c3c2)c1		CHEMBL3622198	=	IC50	nM	404.0	CHEMBL5251	Homo sapiens	IC50	nM	404.0
	15728257	CHEMBL3627421	Inhibition of human recombinant BTK	B	COc1ccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c3c2)cc1		CHEMBL3622199	=	IC50	nM	436.0	CHEMBL5251	Homo sapiens	IC50	nM	436.0
	15728258	CHEMBL3627421	Inhibition of human recombinant BTK	B	CN1CCN(C(=O)c2ccc3c(c2)[nH]c2c(C(N)=O)cc(-c4ccc(Cl)c(Cl)c4)cc23)CC1		CHEMBL3622200	=	IC50	nM	812.0	CHEMBL5251	Homo sapiens	IC50	nM	812.0
	15728259	CHEMBL3627421	Inhibition of human recombinant BTK	B	CC(=O)Nc1cccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c3c2)c1		CHEMBL3622201	=	IC50	nM	379.0	CHEMBL5251	Homo sapiens	IC50	nM	379.0
	15736623	CHEMBL3625828	Inhibition of human recombinant BTK	B	CN(C)CCCNC(=O)c1csc2nc(-c3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)cn12		CHEMBL3623375	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	15754278	CHEMBL3631704	Inhibition of BTK (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	32.4	CHEMBL5251	Homo sapiens	INH	%	32.4
	15755838	CHEMBL3630638	Inhibition of BTK (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control	B	O=C1c2ccccc2-c2c1oc1ccccc1c2=O		CHEMBL3629616	=	Activity	%	76.0	CHEMBL5251	Homo sapiens	Activity	%	76.0
	15756095	CHEMBL3632171	Inhibition of BTK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	96.05	CHEMBL5251	Homo sapiens	INH	%	96.05
	15757075	CHEMBL3632171	Inhibition of BTK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	20.32	CHEMBL5251	Homo sapiens	INH	%	20.32
	15758627	CHEMBL3632171	Inhibition of BTK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	19.35	CHEMBL5251	Homo sapiens	INH	%	19.35
	15771596	CHEMBL3635820	Competitive binding affinity to human BTK at 1 uM in presence of immobilized ligand relative to control	B	C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1		CHEMBL3633152	=	Activity	%	17.0	CHEMBL5251	Homo sapiens	Activity	%	17.0
	15771599	CHEMBL3635824	Competitive binding affinity to human BTK in presence of immobilized ligand	B	C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1		CHEMBL3633152	=	Kd	nM	290.0	CHEMBL5251	Homo sapiens	Kd	nM	290.0
213460	16261471	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647967	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
213462	16274151	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647965	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
213463	16281063	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
213465	16284889	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647970	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
213454	16286650	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3182647	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
213457	16289756	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)CCl)C1		CHEMBL3647972	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
213458	16292867	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C#CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647969	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
213461	16295317	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647966	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
213456	16312904	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CS(=O)(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647968	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
213464	16320295	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
213459	16330276	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647973	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
306889	16337073	CHEMBL3707518	Inhibition Assay: The inhibitory activity measurement against the kinases mentioned above was measured in the kinase inhibition reaction mixture containing 2 ul purified kinase protein (10-50 ng), 20 mM Tris-HCl, pH 8.0, 5 mM MgCl2, 0.5 mM dithiothreitol, 0.01 mM ATP, 4 ug of poly(D4Y)n peptide substrate (Promega), 0.2 uCi of 32P-ATP and the each compound shown in tablel. The mixture was incubated for 15 min at 30° C. and the reaction was then ended by adding a half volume of 30% phosphoric acid solution. Subsequently, the reaction mixture solution was spotted in avidin coated membrane (Promega). This membrane was washed using 50 mM phosphate, 0.1N NaCl buffer (pH 6.0) solution for 10 min 5 times and then the radioactivity of each spot was quantified by using a BAS image analyzer (Fuji).	B	Oc1cccc(Nc2ccnc3cc(-c4cccc(CN5CCOCC5)c4)sc23)c1		CHEMBL2336005	=	IC50	nM	17.7	CHEMBL5251	Homo sapiens	IC50	nM	17.7
213455	16350871	CHEMBL3705255	In Vitro Inhibition Assay: Measurements were performed in a reaction volume of 50 μL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 μM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25 μL of 1× Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1× Lance buffer were added in a 25 μL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour. The TR-FRET signal was measured on a multimode plate reader with an excitation wavelength (πEx) of 330 nm and detection wavelengths (πEm) of 615 and 665 nm. Activity was determined by the ratio of the fluorescence at 665 nm to that at 615 nm. For each compound, enzyme activity was measured at various concentrations of compound. Negative control reactions were performed in the absence of inhibitor in replicates of six, and two no-enzyme controls were used to determine baseline fluorescence levels.	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647971	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	16369085	CHEMBL3734112	Inhibition of Btk (unknown origin) by FRET assay	B	O=C(c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2ncncc12		CHEMBL3733302	<=	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16370662	CHEMBL3734197	Inhibition of Btk (unknown origin)	B	CCCS(=O)(=O)Nc1ccc(Cl)c(C(=O)Nc2ccc(Nc3ncc(C)s3)nc2)c1F		CHEMBL3730067	<=	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16376437	CHEMBL3734461	Inhibition of recombinant human BTK using fluorescein-labeled peptide as substrate by fluorescence-electrophoretic mobility shift assay	B	Cl.NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL3732044	=	Inhibition	%	12.0	CHEMBL5251	Homo sapiens	INH	%	12.0
	16388286	CHEMBL3738899	Inhibition of BTK (unknown origin) at 1 uM by selectscreen kinase profiling assay in presence of ATP	B	COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2		CHEMBL3091673	=	Inhibition	%	12.0	CHEMBL5251	Homo sapiens	INH	%	12.0
	16413411	CHEMBL3743733	Inhibition of BTK (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16421898	CHEMBL3750235	Inhibition of BTK (unknown origin)	B	C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1		CHEMBL3651966	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16425434	CHEMBL3749825	Inhibition of BTK (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	91.7	CHEMBL5251	Homo sapiens	INH	%	91.7
	16425963	CHEMBL3749079	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	CN(C)CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3745919	=	IC50	nM	421.0	CHEMBL5251	Homo sapiens	IC50	nM	421.0
	16425973	CHEMBL3749069	Inhibition of BTK (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CN(C)CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3745919	=	Activity	%	0.2	CHEMBL5251	Homo sapiens	Activity	%	0.2
	16426078	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cnc(C(C)(C)C)cn1		CHEMBL3746333	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	16426079	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL3747417	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	16426080	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2cccnc2s1		CHEMBL3747130	=	IC50	nM	103.0	CHEMBL5251	Homo sapiens	IC50	nM	103.0
	16426081	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ncccc2s1		CHEMBL3746854	=	IC50	nM	132.0	CHEMBL5251	Homo sapiens	IC50	nM	132.0
	16426082	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCn2nc(Nc3cc(-c4ccc(F)c(NC(=O)c5cc6ccccc6s5)c4)n[nH]c3=O)cc2C1		CHEMBL3746036	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	16426083	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)c(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3747019	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	16426084	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)c(C)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746971	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	16426085	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCn2nc(Nc3cc(-c4ccc(F)c(NC(=O)c5cc6ccccc6s5)c4F)n[nH]c3=O)cc2C1		CHEMBL3745935	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	16426086	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	16426087	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(NC(=O)c2cc3ccccc3s2)cccc1-c1cc(Nc2cc3n(n2)CCN(C)C3)c(=O)[nH]n1		CHEMBL3746115	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	16426088	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)c(C)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3746820	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	16426089	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)c(Cl)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3747742	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	16426090	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)c(Cl)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3747742	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	16426091	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(Cl)c(NC(=O)c5cc6c(s5)CCCC6)c4F)cn(C)c3=O)cc2)C1=O		CHEMBL3747268	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	16426092	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(Cl)c(NC(=O)c5cc6c(s5)CCCC6)c4F)cn(C)c3=O)cc2)C1=O		CHEMBL3747268	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	16426093	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cn(C)c(=O)c(Nc3ccc([C@@H]4C(=O)N(C)CCN4C)cc3)n2)c(F)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3747315	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	16426094	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1ccc(-c2cn(C)c(=O)c(Nc3ccc([C@H]4C(=O)N(C)CCN4C)cc3)n2)c(F)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3747161	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	16426095	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)ccc(F)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3747322	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	16426096	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)ccc(F)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3747322	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	16426097	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(Cl)c(NC(=O)c5cc6c(s5)CCCC6)c4Cl)cn(C)c3=O)cc2)C1=O		CHEMBL3747672	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	16426098	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(F)c(NC(=O)c5cc6c(s5)CCCC6)c4F)cn(C)c3=O)cc2)C1=O		CHEMBL3745934	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	16426099	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(F)c(NC(=O)c5cc6c(s5)CCCC6)c4F)cn(C)c3=O)cc2)C1=O		CHEMBL3745934	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	16426100	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)ccc(Cl)c1NC(=O)c1cc2c(s1)CCCC2		CHEMBL3746575	=	IC50	nM	88.0	CHEMBL5251	Homo sapiens	IC50	nM	88.0
	16426101	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(F)c(NC(=O)c5cc6c(s5)CCCC6)c4)cn(C)c3=O)cc2)C1=O		CHEMBL3747551	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	16426102	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(F)c(NC(=O)c5cc6c(s5)CCCC6)c4)cn(C)c3=O)cc2)C1=O		CHEMBL3747551	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	16426103	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(Cl)c(NC(=O)c5cc6c(s5)CCCC6)c4)cn(C)c3=O)cc2)C1=O		CHEMBL3746205	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	nM	61.0
	16426104	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4ccc(C#N)c(NC(=O)c5cc6c(s5)CCCC6)c4)cn(C)c3=O)cc2)C1=O		CHEMBL3746848	=	IC50	nM	1400.0	CHEMBL5251	Homo sapiens	IC50	nM	1400.0
	16426105	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cc6c(s5)CCCC6)c4Cl)cn(C)c3=O)cc2)C1=O		CHEMBL3747554	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	16426106	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cc6c(s5)CCCC6)c4F)cn(C)c3=O)cc2)C1=O		CHEMBL3746128	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	16426107	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	CN1CCN(C)C(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cc6c(s5)CCCC6)c4)cn(C)c3=O)cc2)C1=O		CHEMBL3745795	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	16426108	CHEMBL3748501	Inhibition of BTK (unknown origin) by Lanthascreen assay	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@@H]3C(=O)N(C)CCN3C)cc2)n1		CHEMBL2057915	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	16431744	CHEMBL3748636	Inhibition of human BTK using [KVEKIGEGTYGVVYK] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16433831	CHEMBL3756752	Inhibition of human BTK using srctide as substrate at 10 uM after 1 hr in presence of 30 uM ATP	B	CN1CCN(c2ccc(NC(=O)c3ccc(-c4cc(Cl)ccc4Cl)o3)cc2)CC1		CHEMBL3754324	=	Inhibition	%	4.3	CHEMBL5251	Homo sapiens	INH	%	4.3
	16433832	CHEMBL3756752	Inhibition of human BTK using srctide as substrate at 10 uM after 1 hr in presence of 30 uM ATP	B	Cc1c(Cl)cccc1-c1ccc(C(=O)Nc2ccc(S(N)(=O)=O)cc2)o1		CHEMBL3752265	=	Inhibition	%	-2.3	CHEMBL5251	Homo sapiens	INH	%	-2.3
	16450770	CHEMBL3762156	Inhibition of BTK (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	19.8	CHEMBL5251	Homo sapiens	INH	%	19.8
	16451700	CHEMBL3762156	Inhibition of BTK (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	17.0	CHEMBL5251	Homo sapiens	INH	%	17.0
	16467124	CHEMBL3767269	Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684	=	IC50	nM	46510.0	CHEMBL5251	Homo sapiens	IC50	uM	46.51
	16467125	CHEMBL3767269	Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1N		CHEMBL3763907	=	IC50	nM	3180.0	CHEMBL5251	Homo sapiens	IC50	uM	3.18
	16467126	CHEMBL3767269	Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction after 30 mins by competitive SPR analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886	=	IC50	nM	10910.0	CHEMBL5251	Homo sapiens	IC50	uM	10.91
	16467136	CHEMBL3767266	Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	16467137	CHEMBL3767266	Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1N		CHEMBL3763907	=	Inhibition	%	79.0	CHEMBL5251	Homo sapiens	INH	%	79.0
	16467138	CHEMBL3767266	Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886	=	Inhibition	%	40.0	CHEMBL5251	Homo sapiens	INH	%	40.0
	16485706	CHEMBL3773960	Inhibition of human recombinant BTK assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	16495345	CHEMBL3776892	Inhibition of N-terminal His6-tagged recombinant human BTK R28H mutant expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-12.0	CHEMBL5251	Homo sapiens	Activity	%	-12.0
Not Active	16497495	CHEMBL3777938	Inhibition of human BTK (2 to 659 residues) at 1 uM by radioactive [33P]-ATP filter binding assay	B	O=c1[nH]cnc2c(-n3cc(CCN4CCC(c5cccc(Cl)c5)CC4)cn3)nccc12		CHEMBL3774537		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16507182	CHEMBL3778994	Inhibition of recombinant BTK (unknown origin) assessed as residual activity at 1 uM relative to control	B	CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1		CHEMBL3774632	>=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	16508114	CHEMBL3776892	Inhibition of N-terminal His6-tagged recombinant human BTK R28H mutant expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	1.0	CHEMBL5251	Homo sapiens	Activity	%	1.0
	16509091	CHEMBL3776892	Inhibition of N-terminal His6-tagged recombinant human BTK R28H mutant expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	24.0	CHEMBL5251	Homo sapiens	Activity	%	24.0
Not Active	16514105	CHEMBL3782153	Inhibition of partial length human BTK expressed in mammalian system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16533867	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	4.61	CHEMBL5251	Homo sapiens	IC50	nM	4.61
	16533868	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2SC)c1		CHEMBL3787531	=	IC50	nM	6.6	CHEMBL5251	Homo sapiens	IC50	nM	6.6
	16533869	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2[S+](C)[O-])c1		CHEMBL3786656	=	IC50	nM	3.76	CHEMBL5251	Homo sapiens	IC50	nM	3.76
	16533870	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2S(C)(=O)=O)c1		CHEMBL3786922	=	IC50	nM	31.2	CHEMBL5251	Homo sapiens	IC50	nM	31.2
	16533871	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2SC)c1		CHEMBL3787615	=	IC50	nM	1.08	CHEMBL5251	Homo sapiens	IC50	nM	1.08
	16533872	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2[S+](C)[O-])c1		CHEMBL3785165	=	IC50	nM	0.903	CHEMBL5251	Homo sapiens	IC50	nM	0.903
	16533873	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N(C)C)nc3)ncc2[S+](C)[O-])c1		CHEMBL3786931	=	IC50	nM	1.48	CHEMBL5251	Homo sapiens	IC50	nM	1.48
	16533874	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2[S+](C)[O-])c1		CHEMBL3787055	=	IC50	nM	5.65	CHEMBL5251	Homo sapiens	IC50	nM	5.65
	16533875	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c3cnc(Nc4ccc(Oc5ccnc(C(=O)NC)c5)cc4)nc32)c1		CHEMBL3785329	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	16533876	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c3cnc(Nc4ccc(OCCOC)cc4)nc32)c1		CHEMBL3787191	=	IC50	nM	4.11	CHEMBL5251	Homo sapiens	IC50	nM	4.11
	16533877	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CC3CC3)c3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)c1		CHEMBL3787217	=	IC50	nM	31.0	CHEMBL5251	Homo sapiens	IC50	nM	31.0
	16533878	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CC3CC3)c3cnc(Nc4ccc(N(C)C)nc4)nc32)c1		CHEMBL3787671	=	IC50	nM	30.6	CHEMBL5251	Homo sapiens	IC50	nM	30.6
	16533879	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CC3CC3)c3cnc(Nc4ccc(OC)nc4)nc32)c1		CHEMBL3787652	=	IC50	nM	222.0	CHEMBL5251	Homo sapiens	IC50	nM	222.0
	16534464	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CCOC)c3cnc(Nc4ccc(OC)nc4)nc32)c1		CHEMBL3787293	=	IC50	nM	265.0	CHEMBL5251	Homo sapiens	IC50	nM	265.0
	16534465	CHEMBL3789511	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C3CCOCC3)c3cnc(Nc4ccc(OC)nc4)nc32)c1		CHEMBL3785991	=	IC50	nM	318.0	CHEMBL5251	Homo sapiens	IC50	nM	318.0
	16540743	CHEMBL3789976	Inhibition of BTK (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL1614712	=	IC50	nM	7600.0	CHEMBL5251	Homo sapiens	IC50	uM	7.6
	16540744	CHEMBL3789976	Inhibition of BTK (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(OC[C@@H]3CCCO3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL3787614	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16540745	CHEMBL3789976	Inhibition of BTK (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL3787112	=	IC50	nM	580.0	CHEMBL5251	Homo sapiens	IC50	uM	0.58
	16540746	CHEMBL3789976	Inhibition of BTK (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(OCC34CCC(CC3)O4)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL3785500	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16540747	CHEMBL3789976	Inhibition of BTK (unknown origin) in presence of [gamma33P]ATP	B	CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cccc(OC[C@@H]5CCCO5)c4F)c4c(N)ncnc43)C2)CC1		CHEMBL3786167	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16540748	CHEMBL3789976	Inhibition of BTK (unknown origin) in presence of [gamma33P]ATP	B	CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3785951	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16578363	CHEMBL3804622	Inhibition of full length wild type human BTK expressed in mammalian system assessed as enzyme activity at 1 uM relative to control	B	CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F		CHEMBL3798256	=	Activity	%	95.0	CHEMBL5251	Homo sapiens	Activity	%	95.0
	16593538	CHEMBL3811541	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using Fluorescein-Poly GT as substrate at 100 nM	B	COC(=O)c1cc2cc(NCc3cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc3C)cnc2[nH]1		CHEMBL3808884	<	Inhibition	%	40.0	CHEMBL5251	Homo sapiens	INH	%	40.0
	16594909	CHEMBL3812230	Inhibition of full length human BTK assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
Not Determined	16606399	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(NC(C)C)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3810413		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606400	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(NCC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808468		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606401	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(NC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808544		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606402	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(NC(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808839		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606403	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(NCC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808439		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606404	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(NC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808560		IC50			CHEMBL5251	Homo sapiens	IC50		
	16606405	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808573	=	IC50	nM	1070.0	CHEMBL5251	Homo sapiens	IC50	uM	1.07
Not Determined	16606406	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NCC)c2C(=O)c2ccc(OCC)cc2)C1		CHEMBL3810165		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606407	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NC)c2C(=O)c2ccc(OCC)cc2)C1		CHEMBL3810013		IC50			CHEMBL5251	Homo sapiens	IC50		
	16606408	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2C(=O)c2ccc(OCC)cc2)C1		CHEMBL3810080	=	IC50	nM	1800.0	CHEMBL5251	Homo sapiens	IC50	uM	1.8
Not Determined	16606409	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N3CCCCC3)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809336		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606410	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809448		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606411	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NC(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3808550		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606412	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NCC)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809499		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606413	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NC)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809569		IC50			CHEMBL5251	Homo sapiens	IC50		
	16606414	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3810269	=	IC50	nM	70.0	CHEMBL5251	Homo sapiens	IC50	uM	0.07
	16606415	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
	16606416	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(NC(C)C)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808909	=	Inhibition	%	24.04	CHEMBL5251	Homo sapiens	INH	%	24.04
	16606417	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(NCC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808470	=	Inhibition	%	6.43	CHEMBL5251	Homo sapiens	INH	%	6.43
	16606418	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(NC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808814	=	Inhibition	%	11.87	CHEMBL5251	Homo sapiens	INH	%	11.87
	16606419	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(N)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3809893	=	Inhibition	%	87.67	CHEMBL5251	Homo sapiens	INH	%	87.67
	16606420	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(NC(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3810017	=	Inhibition	%	48.54	CHEMBL5251	Homo sapiens	INH	%	48.54
	16606421	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(NCC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808566	=	Inhibition	%	17.53	CHEMBL5251	Homo sapiens	INH	%	17.53
	16606422	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(NC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3810037	=	Inhibition	%	8.14	CHEMBL5251	Homo sapiens	INH	%	8.14
	16606423	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCN(c2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808547	=	Inhibition	%	93.21	CHEMBL5251	Homo sapiens	INH	%	93.21
	16606424	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(N(C)C)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3810313	=	Inhibition	%	9.8	CHEMBL5251	Homo sapiens	INH	%	9.8
	16606425	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(NC(C)C)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3810413	=	Inhibition	%	8.69	CHEMBL5251	Homo sapiens	INH	%	8.69
	16606426	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(NCC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808468	=	Inhibition	%	6.81	CHEMBL5251	Homo sapiens	INH	%	6.81
	16606427	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(NC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808544	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	16606428	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(NC(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808839	=	Inhibition	%	1.2	CHEMBL5251	Homo sapiens	INH	%	1.2
	16606429	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(NCC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808439	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	16606430	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(NC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808560	=	Inhibition	%	10.61	CHEMBL5251	Homo sapiens	INH	%	10.61
	16606431	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC(Nc2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808573	=	Inhibition	%	78.14	CHEMBL5251	Homo sapiens	INH	%	78.14
	16606432	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NCC)c2C(=O)c2ccc(OCC)cc2)C1		CHEMBL3810165	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	16606433	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NC)c2C(=O)c2ccc(OCC)cc2)C1		CHEMBL3810013	=	Inhibition	%	10.27	CHEMBL5251	Homo sapiens	INH	%	10.27
	16606434	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2C(=O)c2ccc(OCC)cc2)C1		CHEMBL3810080	=	Inhibition	%	52.88	CHEMBL5251	Homo sapiens	INH	%	52.88
	16606435	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N3CCCCC3)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809336	=	Inhibition	%	15.67	CHEMBL5251	Homo sapiens	INH	%	15.67
	16606436	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809448	=	Inhibition	%	11.42	CHEMBL5251	Homo sapiens	INH	%	11.42
	16606437	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NC(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3808550	=	Inhibition	%	14.56	CHEMBL5251	Homo sapiens	INH	%	14.56
	16606438	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NCC)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809499	=	Inhibition	%	18.24	CHEMBL5251	Homo sapiens	INH	%	18.24
	16606439	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(NC)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3809569	=	Inhibition	%	6.66	CHEMBL5251	Homo sapiens	INH	%	6.66
	16606440	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3810269	=	Inhibition	%	100.51	CHEMBL5251	Homo sapiens	INH	%	100.51
	16606441	CHEMBL3813050	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	100.13	CHEMBL5251	Homo sapiens	INH	%	100.13
Not Determined	16606442	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCC(Nc2ncnc(N(C)C)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3810313		IC50			CHEMBL5251	Homo sapiens	IC50		
	16606443	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808547	=	IC50	nM	880.0	CHEMBL5251	Homo sapiens	IC50	uM	0.88
Not Determined	16606444	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(NC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3810037		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606445	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(NCC)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3808566		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606446	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(NC(C)C)c2C(=O)c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL3810017		IC50			CHEMBL5251	Homo sapiens	IC50		
	16606447	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(N)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3809893	=	IC50	nM	1320.0	CHEMBL5251	Homo sapiens	IC50	uM	1.32
Not Determined	16606448	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(NC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808814		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606449	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(NCC)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808470		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16606450	CHEMBL3813051	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	B	C=CC(=O)N1CCN(c2ncnc(NC(C)C)c2C(=O)c2ccc(OCC)cc2)CC1		CHEMBL3808909		IC50			CHEMBL5251	Homo sapiens	IC50		
	16606451	CHEMBL3813052	Irreversible inhibition of recombinant BTK (unknown origin) incubated for 1 hr by FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	16606452	CHEMBL3813053	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3809874	=	IC50	nM	23.9	CHEMBL5251	Homo sapiens	IC50	nM	23.9
	16606453	CHEMBL3813053	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1		CHEMBL3786343	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
Active	16606454	CHEMBL3813054	Covalent inhibition of BTK catalytic domain (393 to 657 residues) (unknown origin) assessed as covalent adduct formation at protein/ligand 1:3 molar ratio by LC-MS method	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3810269		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16606455	CHEMBL3813055	Inhibition of recombinant BTK (unknown origin) preincubated for 1 hr followed by ATP addition by IMAP assay	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
	16611828	CHEMBL3816644	Inhibition of human BTK (2 to 659 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3815046	=	Activity	%	-28.0	CHEMBL5251	Homo sapiens	Activity	%	-28.0
	16611829	CHEMBL3816644	Inhibition of human BTK (2 to 659 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3814140	=	Activity	%	-31.0	CHEMBL5251	Homo sapiens	Activity	%	-31.0
	16611830	CHEMBL3816644	Inhibition of human BTK (2 to 659 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-13.0	CHEMBL5251	Homo sapiens	Activity	%	-13.0
	16613782	CHEMBL3817218	Inhibition of human BTK at 1 uM using [KVEKIGEGTYGVVYK] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-1.0	CHEMBL5251	Homo sapiens	INH	%	-1.0
	16621481	CHEMBL3820474	Inhibition of BTK (unknown origin) incubated for 1 hr by spectrophotometric analysis	B	CN1C(=O)COc2c1cnc1ccc(Sc3nnc4c(F)cc(-c5cnn(C)c5)cn34)cc21		CHEMBL3818247	>	IC50	nM	30000.0	CHEMBL5251	Homo sapiens	IC50	nM	30000.0
	16622196	CHEMBL3820474	Inhibition of BTK (unknown origin) incubated for 1 hr by spectrophotometric analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
Not Active	16625065	CHEMBL3821462	Inhibition of N-terminal his-tagged full length human recombinant BTK PH domain expressed in baculovirus infected Sf9 insect cells at 100 uM by ADP-glo luminescence assay	B	O.O=C(O)C(F)(F)F.O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5nc[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL3819449		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	16625066	CHEMBL3821462	Inhibition of N-terminal his-tagged full length human recombinant BTK PH domain expressed in baculovirus infected Sf9 insect cells at 100 uM by ADP-glo luminescence assay	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	16625067	CHEMBL3821462	Inhibition of N-terminal his-tagged full length human recombinant BTK PH domain expressed in baculovirus infected Sf9 insect cells at 100 uM by ADP-glo luminescence assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16628477	CHEMBL3820180	Inhibition of BTK (unknown origin) at 1 uM	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	<	Inhibition	%	80.0	CHEMBL5251	Homo sapiens	INH	%	80.0
	16641959	CHEMBL3826041	Inhibition of His-tagged full-length human BTK expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	-3.0	CHEMBL5251	Homo sapiens	INH	%	-3.0
	16654242	CHEMBL3829776	Inhibition of human BTK (2 to 659 residues) assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	58.0	CHEMBL5251	Homo sapiens	Activity	%	58.0
	16673531	CHEMBL3855900	Inhibition of full length human BTK expressed in mammalian expression system at 1 uM	B	C=CC(=O)N1CCN(S(=O)(=O)c2cccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)c2)CC1		CHEMBL3979343		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16737931	CHEMBL3856648	Inhibition of recombinant human BTK expressed in insect Sf21 cells assessed as remaining activity at 10 uM preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay	B	CNCCOc1ccc(-c2sc3nc(-c4cccs4)nc(NN4C(=O)C=C(C)C4=O)c3c2C)cc1.Cl		CHEMBL3966536	=	Activity	%	83.0	CHEMBL5251	Homo sapiens	Activity	%	83.0
	16746156	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	990.0	CHEMBL5251	Homo sapiens	IC50	nM	990.0
	16746157	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
	16746158	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	630.0	CHEMBL5251	Homo sapiens	IC50	nM	630.0
	16746159	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	16746160	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	16746161	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	16746162	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	nM	550.0
	16746166	CHEMBL3858930	Inhibition of BTK in human peripheral B cells assessed as suppression of BCR/anti-IgM/IgG-stimulated cell proliferation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	16746167	CHEMBL3858931	Inhibition of BTK in human peripheral B cells assessed as suppression of BCR/anti-IgM/IgG-stimulated CD86 surface expression	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	uM	0.04
	16746168	CHEMBL3858932	Inhibition of BTK in human peripheral B cells assessed as suppression of CD40/CD40L-stimulated CD69 surface expression	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16746169	CHEMBL3858933	Inhibition of BTK in human PBM cells assessed as suppression of FCRgammaR/immune complex-stimulated TNFalpha production	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	uM	0.014
Not Determined	16746171	CHEMBL3858937	Inhibition of BTK in human whole blood basophils assessed as suppression of FceRI/anti-IgE-stimulated CD63 surface expression	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580		IC50			CHEMBL5251	Homo sapiens	IC50		
	16746172	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3)c12		CHEMBL3939772	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	16746173	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3)c12		CHEMBL3939772	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	nM	410.0
Not Determined	16746174	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3)c12		CHEMBL3939772		IC50			CHEMBL5251	Homo sapiens	IC50		
	16746175	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3F)c12		CHEMBL3977725	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	16746176	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3F)c12		CHEMBL3977725	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
Not Determined	16746177	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3F)c12		CHEMBL3977725		IC50			CHEMBL5251	Homo sapiens	IC50		
	16746178	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	16746179	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	16746180	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3908310	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	nM	190.0
	16746192	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	16746193	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	16746194	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	nM	90.0
	16746201	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1cc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2c(=O)c3cccc(F)c3n(C)c2=O)c1C		CHEMBL3931086	=	IC50	nM	0.65	CHEMBL5251	Homo sapiens	IC50	nM	0.65
	16746202	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1cc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2c(=O)c3cccc(F)c3n(C)c2=O)c1C		CHEMBL3931086	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	16746203	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1cc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2c(=O)c3cccc(F)c3n(C)c2=O)c1C		CHEMBL3931086	=	IC50	nM	240.0	CHEMBL5251	Homo sapiens	IC50	nM	240.0
	16746210	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(C#N)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3899411	=	IC50	nM	0.27	CHEMBL5251	Homo sapiens	IC50	nM	0.27
	16746211	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(C#N)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3899411	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	16746212	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(C#N)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3899411	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	16746217	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
	16746218	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	16746219	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	nM	90.0
	16746225	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3891391	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	16746226	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3891391	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	nM	190.0
Not Determined	16746227	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3891391		IC50			CHEMBL5251	Homo sapiens	IC50		
	16746229	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3976719	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	16746230	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3976719	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	16746231	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3976719	=	IC50	nM	380.0	CHEMBL5251	Homo sapiens	IC50	nM	380.0
	16746236	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3944049	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	16746237	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3944049	=	IC50	nM	84.0	CHEMBL5251	Homo sapiens	IC50	nM	84.0
	16746238	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3944049	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	nM	350.0
	16746240	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3897349	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	16746241	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3897349	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	16746242	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3897349	=	IC50	nM	160.0	CHEMBL5251	Homo sapiens	IC50	nM	160.0
	16746248	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	16746249	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	16746250	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	nM	150.0
	16746252	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	16746253	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	16746254	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	nM	90.0
	16746261	CHEMBL3858930	Inhibition of BTK in human peripheral B cells assessed as suppression of BCR/anti-IgM/IgG-stimulated cell proliferation	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	uM	0.003
	16746262	CHEMBL3858931	Inhibition of BTK in human peripheral B cells assessed as suppression of BCR/anti-IgM/IgG-stimulated CD86 surface expression	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	uM	0.004
	16746263	CHEMBL3858932	Inhibition of BTK in human peripheral B cells assessed as suppression of CD40/CD40L-stimulated CD69 surface expression	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	16746264	CHEMBL3858933	Inhibition of BTK in human PBM cells assessed as suppression of FCRgammaR/immune complex-stimulated TNFalpha production	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	uM	0.003
	16746268	CHEMBL3858937	Inhibition of BTK in human whole blood basophils assessed as suppression of FceRI/anti-IgE-stimulated CD63 surface expression	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	89.0	CHEMBL5251	Homo sapiens	IC50	uM	0.089
	16746354	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	16746355	CHEMBL3858906	Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	750.0	CHEMBL5251	Homo sapiens	IC50	nM	750.0
Not Determined	16746356	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554		IC50			CHEMBL5251	Homo sapiens	IC50		
	16746363	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	nM	130.0
	16746366	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	16746367	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	320.0	CHEMBL5251	Homo sapiens	IC50	nM	320.0
	16746370	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3936156	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	16746371	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3936156	=	IC50	nM	260.0	CHEMBL5251	Homo sapiens	IC50	nM	260.0
	16746378	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3936156	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	16746379	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3936156	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	16746381	CHEMBL3858905	Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescent assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2ccccc2n(C)c1=O		CHEMBL3941224	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	16746382	CHEMBL3858907	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by FITC-staining based FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2ccccc2n(C)c1=O		CHEMBL3941224	=	IC50	nM	460.0	CHEMBL5251	Homo sapiens	IC50	nM	460.0
	16756523	CHEMBL3861210	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCn4ccnc4)cc3)ncc2Cl)c1		CHEMBL3947759		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16756524	CHEMBL3861210	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCn4ccnc4)cc3)ncc2[N+](=O)[O-])c1		CHEMBL3953593		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	16772254	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	16772255	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	16772256	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2c(=O)[nH]c3cnc(Nc4ccc(N5CCOCC5)cc4OC)nc32)c1		CHEMBL3973451	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	16772257	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2c(=O)[nH]c3cnc(Nc4ccc(N5CCN(CC)CC5)cc4)nc32)c1		CHEMBL3963986	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	16772258	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(OC)cc4)nc32)c1		CHEMBL3962478	=	IC50	nM	97.1	CHEMBL5251	Homo sapiens	IC50	nM	97.1
	16772259	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(OCCCN5CCOCC5)cc4)nc32)c1		CHEMBL3893465	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	16772260	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(C(C)=O)C(C)C5)cc4)nc32)c1		CHEMBL3953720	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	16772261	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(S(C)(=O)=O)C(C)C5)cc4)nc32)c1		CHEMBL3982421	=	IC50	nM	13.2	CHEMBL5251	Homo sapiens	IC50	nM	13.2
	16772262	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(S(C)(=O)=O)CC5)cc4OC)nc32)c1		CHEMBL3946985	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	16772263	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(S(C)(=O)=O)CC5)cc4)nc32)c1		CHEMBL3919900	=	IC50	nM	17.1	CHEMBL5251	Homo sapiens	IC50	nM	17.1
	16772264	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(CC)CC5)cc4OC)nc32)c1		CHEMBL3895185	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	16772265	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(CC)CC5)cc4)nc32)c1		CHEMBL3966494	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	16772266	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL3904111	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	16772267	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)c1		CHEMBL3975003	=	IC50	nM	10.2	CHEMBL5251	Homo sapiens	IC50	nM	10.2
	16772268	CHEMBL3864052	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(-n2cnc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)c1		CHEMBL3975962	=	IC50	nM	15.1	CHEMBL5251	Homo sapiens	IC50	nM	15.1
	16781910	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Cc1ccccc1-n1c(Cn2nc(-c3cc(O)cc(F)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O		CHEMBL1213084	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	16781911	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	COc1cc(F)cc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)c1		CHEMBL3977335	=	IC50	nM	1970.0	CHEMBL5251	Homo sapiens	IC50	nM	1970.0
	16781912	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	COc1cc(F)cc(-c2nn(C3CCc4ccccc43)c3ncnc(N)c23)c1		CHEMBL3920744	=	IC50	nM	584.0	CHEMBL5251	Homo sapiens	IC50	nM	584.0
	16781913	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	COc1cc(F)cc(-c2nn(C3CCc4ccccc4C3)c3ncnc(N)c23)c1		CHEMBL3892739	=	IC50	nM	891.0	CHEMBL5251	Homo sapiens	IC50	nM	891.0
	16781914	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1Cc2ccccc2C1		CHEMBL3896635	=	IC50	nM	67.0	CHEMBL5251	Homo sapiens	IC50	nM	67.0
	16781915	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCc2ccccc21		CHEMBL3924678	=	IC50	nM	217.0	CHEMBL5251	Homo sapiens	IC50	nM	217.0
	16781916	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCc2ccccc2C1		CHEMBL3905578	=	IC50	nM	86.0	CHEMBL5251	Homo sapiens	IC50	nM	86.0
Not Determined	16781917	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cccc(O)c1)nn2C1Cc2ccccc2C1		CHEMBL3933590		IC50			CHEMBL5251	Homo sapiens	IC50		
	16781918	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(O)cc(Cl)c1)nn2C1Cc2ccccc2C1		CHEMBL3914552	=	IC50	nM	142.0	CHEMBL5251	Homo sapiens	IC50	nM	142.0
	16781919	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1Cc2ccccc2C1		CHEMBL3942550	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	16781920	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1Cc2ccccc2C1		CHEMBL3923573	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	16781921	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1Cc2ccccc2C1		CHEMBL3964073	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	16781922	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Cc1ccc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)cc1O		CHEMBL3957821	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
	16781923	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	COc1ccc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)cc1O		CHEMBL3983045	=	IC50	nM	84.0	CHEMBL5251	Homo sapiens	IC50	nM	84.0
	16781924	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(O)c(F)c(F)c1)nn2C1Cc2ccccc2C1		CHEMBL3907591	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
	16781925	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c3c(c1)NCCO3)nn2C1Cc2ccccc2C1		CHEMBL3948373	=	IC50	nM	104.0	CHEMBL5251	Homo sapiens	IC50	nM	104.0
Not Determined	16781926	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c3c(c1)NCCO3)nn2C1CCc2ccccc2C1		CHEMBL3893661		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	16781927	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c3c(c1)NCCO3)nn2C1Cc2cc(F)ccc2C1=O		CHEMBL3906843		IC50			CHEMBL5251	Homo sapiens	IC50		
	16781928	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ccc2c(c1)CC(n1nc(-c3cc(F)c4c(c3)NCCO4)c3c(N)ncnc31)C2		CHEMBL3897842	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	16781929	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ccc2c(c1)CC(n1nc(-c3cc(F)c4c(c3)NCCO4)c3c(N)ncnc31)C2		CHEMBL3897842	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	16781930	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ccc2c(c1)CC(n1nc(-c3cc(F)c4c(c3)NCCO4)c3c(N)ncnc31)CC2		CHEMBL3925929	=	IC50	nM	176.0	CHEMBL5251	Homo sapiens	IC50	nM	176.0
	16781931	CHEMBL3865685	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate after 20 mins by [gamma-33P]ATP based assay	B	Nc1ccc2c(c1)CC(n1nc(-c3cc(F)c4c(c3)NCCO4)c3c(N)ncnc31)CC2		CHEMBL3925929	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	16781954	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cccc(O)c1)nn2C1Cc2ccccc2C1		CHEMBL3933590	=	Inhibition	%	66.0	CHEMBL5251	Homo sapiens	INH	%	66.0
	16781955	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(O)c(F)c(F)c1)nn2C1Cc2ccccc2C1		CHEMBL3907591	=	Inhibition	%	74.0	CHEMBL5251	Homo sapiens	INH	%	74.0
	16781956	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c(F)c(F)c1)nn2C1Cc2ccccc2C1		CHEMBL3921872	=	Inhibition	%	21.0	CHEMBL5251	Homo sapiens	INH	%	21.0
	16781957	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1cc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)ccc1F		CHEMBL3944020	=	Inhibition	%	79.0	CHEMBL5251	Homo sapiens	INH	%	79.0
	16781958	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1cc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)cc(F)c1F		CHEMBL3938517	=	Inhibition	%	63.0	CHEMBL5251	Homo sapiens	INH	%	63.0
	16781959	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	COc1ccc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)cc1N		CHEMBL3939609	=	Inhibition	%	72.0	CHEMBL5251	Homo sapiens	INH	%	72.0
	16781960	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)NCCO3)nn2C1Cc2ccccc2C1		CHEMBL3911636	=	Inhibition	%	57.0	CHEMBL5251	Homo sapiens	INH	%	57.0
	16781961	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c3c(c1)NCCO3)nn2C1Cc2ccccc2C1		CHEMBL3948373	=	Inhibition	%	52.0	CHEMBL5251	Homo sapiens	INH	%	52.0
	16781962	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1ccc3cc[nH]c3c1)nn2C1Cc2ccccc2C1		CHEMBL3920574	=	Inhibition	%	46.0	CHEMBL5251	Homo sapiens	INH	%	46.0
	16781963	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1ccc3nc[nH]c3c1)nn2C1Cc2ccccc2C1		CHEMBL3921674	=	Inhibition	%	9.6	CHEMBL5251	Homo sapiens	INH	%	9.6
	16781964	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c3c(c1)NCCO3)nn2C1CCc2ccccc2C1		CHEMBL3893661	=	Inhibition	%	34.0	CHEMBL5251	Homo sapiens	INH	%	34.0
	16781965	CHEMBL3865687	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate at 100 nM after 20 mins by [gamma-33P]ATP based assay	B	Nc1ncnc2c1c(-c1cc(F)c3c(c1)NCCO3)nn2C1Cc2cc(F)ccc2C1=O		CHEMBL3906843	=	Inhibition	%	6.6	CHEMBL5251	Homo sapiens	INH	%	6.6
	16782070	CHEMBL3865719	Inhibition of BTK (unknown origin) by FRET assay	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCC1		CHEMBL2057912	=	IC50	nM	8.2	CHEMBL5251	Homo sapiens	IC50	nM	8.2
	16828847	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CP(=O)(OCC)N4CCOCC4)cc3)ncc2Cl)c1		CHEMBL3905062	=	IC50	nM	112.0	CHEMBL5251	Homo sapiens	IC50	nM	112.0
	16828848	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCP(=O)(OCC)N4CCOCC4)cc3)ncc2Cl)c1		CHEMBL3904000	=	IC50	nM	0.82	CHEMBL5251	Homo sapiens	IC50	nM	0.82
	16828849	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CP(=O)(OCC)OCC)cc3)ncc2Cl)c1		CHEMBL3932000	=	IC50	nM	1.23	CHEMBL5251	Homo sapiens	IC50	nM	1.23
	16828850	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCP(=O)(OCC)OCC)cc3)ncc2Cl)c1		CHEMBL3895072	=	IC50	nM	10.6	CHEMBL5251	Homo sapiens	IC50	nM	10.6
	16828851	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CP(=O)(OCC)OCC)cc3)ncc2F)c1		CHEMBL3895794	=	IC50	nM	32.1	CHEMBL5251	Homo sapiens	IC50	nM	32.1
	16828852	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCP(=O)(OCC)OCC)cc3)ncc2F)c1		CHEMBL3972321	=	IC50	nM	21.6	CHEMBL5251	Homo sapiens	IC50	nM	21.6
	16828853	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
	16828854	CHEMBL3874808	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
	16837409	CHEMBL3876081	Inhibition of human recombinant full length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	1879.0	CHEMBL5251	Homo sapiens	IC50	nM	1879.0
	16844189	CHEMBL3877212	Inhibition of PF-06658607 binding to BTK in human Ramos cells after 1 hr by gel-based ABPP assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
214868	17604006	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3182647	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
214869	17604007	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647971	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
214870	17604008	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CS(=O)(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647968	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
214871	17604009	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)CCl)C1		CHEMBL3647972	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
214872	17604010	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C#CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647969	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
214873	17604011	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647973	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
214874	17604012	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647973	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
214875	17604013	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3669312	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
214876	17604014	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3669312	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
214877	17604015	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3182647	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
214878	17604016	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
214879	17604017	CHEMBL3705285	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology.	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647970	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
219972	17608670	CHEMBL3705343	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.	B	Cn1cc(Nc2nc(-c3cccc(N4CCc5cc(C6CC6)ccc5C4=O)c3CO)cn(C)c2=O)cn1		CHEMBL3674679	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
219973	17608671	CHEMBL3705343	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.	B	CN(C)C(=O)c1ccc(Nc2nc(-c3cccc(N4CCc5cc(C6CC6)ccc5C4=O)c3CO)cn(C)c2=O)cc1		CHEMBL3674680	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
219974	17608672	CHEMBL3705343	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.	B	Cn1cc(-c2cccc(N3CCc4cc(C5(F)CC5)ccc4C3=O)c2CO)nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c1=O		CHEMBL3674681	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
219975	17608673	CHEMBL3705343	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.	B	Cn1cc(-c2cccc(N3CCc4cc(C5CC5)ccc4C3=O)c2CO)nc(Nc2ccc(C(=O)N3CCC(O)CC3)cc2)c1=O		CHEMBL3674682	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
232402	17620371	CHEMBL3705846	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter. Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore).	B	CNC(=O)Nc1cc(-c2cccc(-n3cnc4cc(C(C)(C)C)ccc4c3=O)c2C)cn(C)c1=O		CHEMBL3665115	=	IC50	nM	112.0	CHEMBL5251	Homo sapiens	IC50	nM	112.0
232403	17620372	CHEMBL3705846	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter. Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore).	B	Cc1c(-c2cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c(=O)n(C)c2)cccc1N1CNc2cc(N(C)C)ccc2C1=O		CHEMBL3665116	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
232404	17620373	CHEMBL3705846	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter. Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore).	B	Cc1c(-c2cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c(=O)n(C)c2)cccc1N1CNc2cc(C(C)(C)O)ccc2C1=O		CHEMBL3665117	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
232405	17620374	CHEMBL3705846	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter. Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore).	B	Cc1c(-c2cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c(=O)n(C)c2)cccc1-n1ncc2cc(N(C)C)ccc2c1=O		CHEMBL3665118	=	IC50	nM	124.0	CHEMBL5251	Homo sapiens	IC50	nM	124.0
232990	17620888	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)cccc1N1CCn2c(cc3c2CCCC3)C1=O		CHEMBL3670078	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
232991	17620889	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)cccc1N1CCn2c(cc3ccccc32)C1=O		CHEMBL3670079	=	IC50	nM	22.9	CHEMBL5251	Homo sapiens	IC50	nM	22.9
232992	17620890	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)n(C)n2)cccc1N1Cc2c(sc3ccccc23)C1=O		CHEMBL3670080	=	IC50	nM	3200.0	CHEMBL5251	Homo sapiens	IC50	nM	3200.0
232993	17620891	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670081	=	IC50	nM	0.87	CHEMBL5251	Homo sapiens	IC50	nM	0.87
232994	17620892	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670082	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
232995	17620893	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2cc(C3CC3)n[nH]2)c1=O		CHEMBL3670083	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
232996	17620894	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCOCC3)cn2)c1=O		CHEMBL3670084	=	IC50	nM	10.1	CHEMBL5251	Homo sapiens	IC50	nM	10.1
232997	17620895	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CC(=O)N1CCn2nc(Nc3cc(-c4cccc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)cc2C1		CHEMBL3670085	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
232998	17620896	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670086	=	IC50	nM	6.2	CHEMBL5251	Homo sapiens	IC50	nM	6.2
232999	17620897	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2cc3n(n2)CCOC3)c1=O		CHEMBL3670087	=	IC50	nM	7.7	CHEMBL5251	Homo sapiens	IC50	nM	7.7
233000	17620898	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670088	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
233001	17620899	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)nc(Nc2cnn(CCO)c2)c1=O		CHEMBL3670089	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
233002	17620900	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1nc(Nc2cc(-c3cccc(N4CCc5c(sc6c5CCCC6)C4=O)c3CO)nn(C)c2=O)cc1C(C)(C)O		CHEMBL3670090	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
233003	17620901	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)cc(Nc2cc(C3CC3)n[nH]2)c1=O		CHEMBL3670091	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
233004	17620902	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCn1cc(Nc2nc(-c3cccc(N4CCc5c(sc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)cn1		CHEMBL3670092	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
233005	17620903	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2cc3n(n2)CCOC3)c1=O		CHEMBL3670093	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
233006	17620904	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670094	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
233007	17620905	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670095	=	IC50	nM	3.9	CHEMBL5251	Homo sapiens	IC50	nM	3.9
233008	17620906	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3903500	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
233009	17620907	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(C3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670096	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
233010	17620908	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670097	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
233011	17620909	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN(C)CCOc1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670098	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
233012	17620910	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670099	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
233013	17620911	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN(C)CCN(C)c1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670100	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
233014	17620912	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CC(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)C1		CHEMBL3670101	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
233015	17620913	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670102	=	IC50	nM	6.4	CHEMBL5251	Homo sapiens	IC50	nM	6.4
233016	17620914	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(CCF)CC3)cn2)c1=O		CHEMBL3639689	=	IC50	nM	6.35	CHEMBL5251	Homo sapiens	IC50	nM	6.35
233017	17620915	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(CN3CCOCC3)cn2)c1=O		CHEMBL3670103	=	IC50	nM	2.34	CHEMBL5251	Homo sapiens	IC50	nM	2.34
233018	17620916	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCc6c(cc7n6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670104	=	IC50	nM	16.3	CHEMBL5251	Homo sapiens	IC50	nM	16.3
233019	17620917	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cc1cc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)[nH]n1		CHEMBL3670105	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
233020	17620918	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CC(C)N(C)Cc1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670106	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
233021	17620919	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3nc(-c4cc(F)cc(N5CCc6c(sc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3670107	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
233022	17620920	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCn2nc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)cc2C1		CHEMBL3670108	=	IC50	nM	4.9	CHEMBL5251	Homo sapiens	IC50	nM	4.9
233023	17620921	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc3c(n2)CCN(C2COC2)C3)c1=O		CHEMBL3670109	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
233024	17620922	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3nc(-c4cc(F)cc(N5CCc6c(sc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3670110	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
233025	17620923	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3nc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3670111	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
233026	17620924	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCc2cc(Nc3nc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)ccc2C1		CHEMBL3670112	=	IC50	nM	8.1	CHEMBL5251	Homo sapiens	IC50	nM	8.1
233027	17620925	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCN1CCc2nc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)ccc2C1		CHEMBL3670113	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
233028	17620926	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCN1CCn2nc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)cc2C1		CHEMBL3670114	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
233029	17620927	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN(C)CCN(C)c1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670115	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
233030	17620928	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCCC1c1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670116	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
233031	17620929	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCCC1c1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670117	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
233032	17620930	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCOCC3)cn2)c1=O		CHEMBL3670118	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
233033	17620931	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC[C@@H]1c1ccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670119	=	IC50	nM	1.74	CHEMBL5251	Homo sapiens	IC50	nM	1.74
233034	17620932	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc3c(n2)CCN(C2COC2)C3)c1=O		CHEMBL3670120	=	IC50	nM	11.6	CHEMBL5251	Homo sapiens	IC50	nM	11.6
233035	17620933	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CC(Oc2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)C1		CHEMBL3670121	=	IC50	nM	9.8	CHEMBL5251	Homo sapiens	IC50	nM	9.8
233036	17620934	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3nc(-c4cc(F)cc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)cc2)CC1		CHEMBL3670122	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
233037	17620935	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670123	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
233038	17620936	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN(C)CCOc1ccc(Nc2cc(-c3cc(F)cc(N4CCc5c(sc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670124	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
233039	17620937	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN(C)CCOc1ccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL3670125	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
233040	17620938	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CC(c2ccc(Nc3nc(-c4cc(F)cc(N5CCc6c(sc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)cc2)C1		CHEMBL3670126	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
233041	17620939	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(C3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670127	=	IC50	nM	8.7	CHEMBL5251	Homo sapiens	IC50	nM	8.7
233042	17620940	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	COc1nccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3670128	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
233043	17620941	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCNCC3)cn2)c1=O		CHEMBL3670129	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
233044	17620942	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCn1nc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)cc1C		CHEMBL3670130	=	IC50	nM	9.9	CHEMBL5251	Homo sapiens	IC50	nM	9.9
233045	17620943	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(C3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670131	=	IC50	nM	4.9	CHEMBL5251	Homo sapiens	IC50	nM	4.9
233046	17620944	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670132	=	IC50	nM	7.8	CHEMBL5251	Homo sapiens	IC50	nM	7.8
233047	17620945	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)nc(Nc2ccc(C3CCN(C4COC4)CC3)cc2)c1=O		CHEMBL3670133	=	IC50	nM	17.1	CHEMBL5251	Homo sapiens	IC50	nM	17.1
233048	17620946	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)nn(C)c3=O)nc2)CC1		CHEMBL3670134	=	IC50	nM	7.1	CHEMBL5251	Homo sapiens	IC50	nM	7.1
233049	17620947	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CN1CCC(c2ccc(Nc3cc(-c4cc(F)cc(N5CCc6c(sc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)C1		CHEMBL3670135	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
233050	17620948	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(cc5n4CCCC5)C3=O)c2CO)cc(Nc2cc3n(n2)CCOC3)c1=O		CHEMBL3670136	=	IC50	nM	16.5	CHEMBL5251	Homo sapiens	IC50	nM	16.5
233051	17620949	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	CCN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCc6c(cc7n6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670137	=	IC50	nM	16.6	CHEMBL5251	Homo sapiens	IC50	nM	16.6
233052	17620950	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670138	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
233053	17620951	CHEMBL3705848	Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds. Alternatively, the Lanthascreen assay can be used to evaluate Btk activity through quantification of its phosphorylated peptide product. The FRET (Fluorescence Resonance Energy Transfer) that occurs between the fluorescein on the peptide product and the terbium on the detection antibody decreases with the addition of inhibitors of Btk that reduce the phosphorylation of the peptide.	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670139	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
248798	17632099	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)nc3n[nH]cc23)c1		CHEMBL3685418	=	IC50	nM	79.0	CHEMBL5251	Homo sapiens	IC50	nM	79.0
248799	17632100	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3n[nH]cc23)c1		CHEMBL3685419	=	IC50	nM	187.0	CHEMBL5251	Homo sapiens	IC50	nM	187.0
248800	17632101	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)c(F)c3)nc3n[nH]cc23)c1		CHEMBL3685420	=	IC50	nM	230.0	CHEMBL5251	Homo sapiens	IC50	nM	230.0
248801	17632102	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Cl)nc3n[nH]cc23)c1		CHEMBL3685421	=	IC50	nM	263.0	CHEMBL5251	Homo sapiens	IC50	nM	263.0
248802	17632103	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Cl)ncc2Nc2ccccc2)c1		CHEMBL3685422	=	IC50	nM	1810.0	CHEMBL5251	Homo sapiens	IC50	nM	1810.0
248803	17632104	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2Nc2ccccc2)c1		CHEMBL3685423	>	IC50	nM	100000.0	CHEMBL5251	Homo sapiens	IC50	nM	100000.0
248804	17632105	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)c(F)c3)ncc2Cl)c1		CHEMBL3685424	=	IC50	nM	518.0	CHEMBL5251	Homo sapiens	IC50	nM	518.0
248805	17632106	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2Cl)c1		CHEMBL3685425	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
248806	17632107	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)c1		CHEMBL3685426	=	IC50	nM	1270.0	CHEMBL5251	Homo sapiens	IC50	nM	1270.0
248807	17632108	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Cl)ncc2Br)c1		CHEMBL3685427	=	IC50	nM	4700.0	CHEMBL5251	Homo sapiens	IC50	nM	4700.0
248808	17632109	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Cl)ncc2Cl)c1		CHEMBL3685428	=	IC50	nM	14400.0	CHEMBL5251	Homo sapiens	IC50	nM	14400.0
248809	17632110	CHEMBL3705215	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 μM ATP, and 20 μM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes.	B	C=CC(=O)Nc1cccc(-c2nc(Cl)ncc2Nc2cccc(F)c2)c1		CHEMBL3685429	=	IC50	nM	829.0	CHEMBL5251	Homo sapiens	IC50	nM	829.0
248810	17632111	CHEMBL3705216	Time Resolved-FRET Assay: Activity of compounds was routinely confirmed using a secondary assay as described herein. The secondary assay was a time resolved-FRET kinase assay. Test compound are diluted to desired concentrations in kinase reaction buffer and briefly incubated with BTK kinase (as described above; Invitrogen). The reaction is initiated by the addition of ATP and enzyme substrate, HTRF® KinEASE-TK Substrate-biotin (Cisbio US, Bedford, Mass.). The composition of the reaction (10 μl) was: 1% v/v DMSO, 10 nM BTK, 60 μM ATP, and 1 μM substrate. After incubation at room temperature for 60 min, the enzyme reaction is stopped by EDTA-containing buffer, which also contains europium-labeled (Eu3+-Cryptate) anti-phosphotyrosine antibody (Cisbio) and Streptavidin-XL665 (Cisbio). The europium-labeled antibody generates a time-resolved FRET signal with the Stepavidin-XL665, which binds to the biotinylated TK substrate through the streptavidin conjugate when the substrate is phosphorylated.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)nc3n[nH]cc23)c1		CHEMBL3685418	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
248811	17632112	CHEMBL3705216	Time Resolved-FRET Assay: Activity of compounds was routinely confirmed using a secondary assay as described herein. The secondary assay was a time resolved-FRET kinase assay. Test compound are diluted to desired concentrations in kinase reaction buffer and briefly incubated with BTK kinase (as described above; Invitrogen). The reaction is initiated by the addition of ATP and enzyme substrate, HTRF® KinEASE-TK Substrate-biotin (Cisbio US, Bedford, Mass.). The composition of the reaction (10 μl) was: 1% v/v DMSO, 10 nM BTK, 60 μM ATP, and 1 μM substrate. After incubation at room temperature for 60 min, the enzyme reaction is stopped by EDTA-containing buffer, which also contains europium-labeled (Eu3+-Cryptate) anti-phosphotyrosine antibody (Cisbio) and Streptavidin-XL665 (Cisbio). The europium-labeled antibody generates a time-resolved FRET signal with the Stepavidin-XL665, which binds to the biotinylated TK substrate through the streptavidin conjugate when the substrate is phosphorylated.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3n[nH]cc23)c1		CHEMBL3685419	=	IC50	nM	562.0	CHEMBL5251	Homo sapiens	IC50	nM	562.0
248812	17632113	CHEMBL3705216	Time Resolved-FRET Assay: Activity of compounds was routinely confirmed using a secondary assay as described herein. The secondary assay was a time resolved-FRET kinase assay. Test compound are diluted to desired concentrations in kinase reaction buffer and briefly incubated with BTK kinase (as described above; Invitrogen). The reaction is initiated by the addition of ATP and enzyme substrate, HTRF® KinEASE-TK Substrate-biotin (Cisbio US, Bedford, Mass.). The composition of the reaction (10 μl) was: 1% v/v DMSO, 10 nM BTK, 60 μM ATP, and 1 μM substrate. After incubation at room temperature for 60 min, the enzyme reaction is stopped by EDTA-containing buffer, which also contains europium-labeled (Eu3+-Cryptate) anti-phosphotyrosine antibody (Cisbio) and Streptavidin-XL665 (Cisbio). The europium-labeled antibody generates a time-resolved FRET signal with the Stepavidin-XL665, which binds to the biotinylated TK substrate through the streptavidin conjugate when the substrate is phosphorylated.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)c(F)c3)nc3n[nH]cc23)c1		CHEMBL3685420	=	IC50	nM	126.0	CHEMBL5251	Homo sapiens	IC50	nM	126.0
248813	17632114	CHEMBL3705216	Time Resolved-FRET Assay: Activity of compounds was routinely confirmed using a secondary assay as described herein. The secondary assay was a time resolved-FRET kinase assay. Test compound are diluted to desired concentrations in kinase reaction buffer and briefly incubated with BTK kinase (as described above; Invitrogen). The reaction is initiated by the addition of ATP and enzyme substrate, HTRF® KinEASE-TK Substrate-biotin (Cisbio US, Bedford, Mass.). The composition of the reaction (10 μl) was: 1% v/v DMSO, 10 nM BTK, 60 μM ATP, and 1 μM substrate. After incubation at room temperature for 60 min, the enzyme reaction is stopped by EDTA-containing buffer, which also contains europium-labeled (Eu3+-Cryptate) anti-phosphotyrosine antibody (Cisbio) and Streptavidin-XL665 (Cisbio). The europium-labeled antibody generates a time-resolved FRET signal with the Stepavidin-XL665, which binds to the biotinylated TK substrate through the streptavidin conjugate when the substrate is phosphorylated.	B	C=CC(=O)Nc1cccc(-c2nc(Cl)nc3n[nH]cc23)c1		CHEMBL3685421	=	IC50	nM	3770.0	CHEMBL5251	Homo sapiens	IC50	nM	3770.0
248814	17632115	CHEMBL3705216	Time Resolved-FRET Assay: Activity of compounds was routinely confirmed using a secondary assay as described herein. The secondary assay was a time resolved-FRET kinase assay. Test compound are diluted to desired concentrations in kinase reaction buffer and briefly incubated with BTK kinase (as described above; Invitrogen). The reaction is initiated by the addition of ATP and enzyme substrate, HTRF® KinEASE-TK Substrate-biotin (Cisbio US, Bedford, Mass.). The composition of the reaction (10 μl) was: 1% v/v DMSO, 10 nM BTK, 60 μM ATP, and 1 μM substrate. After incubation at room temperature for 60 min, the enzyme reaction is stopped by EDTA-containing buffer, which also contains europium-labeled (Eu3+-Cryptate) anti-phosphotyrosine antibody (Cisbio) and Streptavidin-XL665 (Cisbio). The europium-labeled antibody generates a time-resolved FRET signal with the Stepavidin-XL665, which binds to the biotinylated TK substrate through the streptavidin conjugate when the substrate is phosphorylated.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)c(F)c3)ncc2Cl)c1		CHEMBL3685424	=	IC50	nM	287.0	CHEMBL5251	Homo sapiens	IC50	nM	287.0
248815	17632116	CHEMBL3705216	Time Resolved-FRET Assay: Activity of compounds was routinely confirmed using a secondary assay as described herein. The secondary assay was a time resolved-FRET kinase assay. Test compound are diluted to desired concentrations in kinase reaction buffer and briefly incubated with BTK kinase (as described above; Invitrogen). The reaction is initiated by the addition of ATP and enzyme substrate, HTRF® KinEASE-TK Substrate-biotin (Cisbio US, Bedford, Mass.). The composition of the reaction (10 μl) was: 1% v/v DMSO, 10 nM BTK, 60 μM ATP, and 1 μM substrate. After incubation at room temperature for 60 min, the enzyme reaction is stopped by EDTA-containing buffer, which also contains europium-labeled (Eu3+-Cryptate) anti-phosphotyrosine antibody (Cisbio) and Streptavidin-XL665 (Cisbio). The europium-labeled antibody generates a time-resolved FRET signal with the Stepavidin-XL665, which binds to the biotinylated TK substrate through the streptavidin conjugate when the substrate is phosphorylated.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2Cl)c1		CHEMBL3685425	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
250976	17634192	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2cccc(-n3ncc4cc(C(C)(C)C)ccc4c3=O)c2CO)nc1C(N)=O		CHEMBL3649448	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	nM	50.0
250977	17634193	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1ccc2c(=O)n(-c3cccc(-c4nc(C(N)=O)cs4)c3CO)ncc2c1		CHEMBL3649449	=	IC50	nM	280.83	CHEMBL5251	Homo sapiens	IC50	nM	280.83
250978	17634194	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1ccc2c(=O)n(-c3cccc(-c4c[nH]c(C(N)=O)c4)c3CO)ncc2c1		CHEMBL3649450	=	IC50	nM	27.02	CHEMBL5251	Homo sapiens	IC50	nM	27.02
250979	17634195	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2cccc(-n3ncc4cc(C(C)(C)C)ccc4c3=O)c2CO)cc1C(N)=O		CHEMBL3649451	=	IC50	nM	11.57	CHEMBL5251	Homo sapiens	IC50	nM	11.57
250980	17634196	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cc1nc(-c2cccc(-n3ncc4cc(C(C)(C)C)ccc4c3=O)c2CO)oc1C(N)=O		CHEMBL3649452	=	IC50	nM	1255.0	CHEMBL5251	Homo sapiens	IC50	nM	1255.0
250981	17634197	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-c4nc(C(N)=O)cs4)c3CO)ncc2c1		CHEMBL3649453	=	IC50	nM	129.9	CHEMBL5251	Homo sapiens	IC50	nM	129.9
250982	17634198	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)nc1C(N)=O		CHEMBL3649454	=	IC50	nM	18.23	CHEMBL5251	Homo sapiens	IC50	nM	18.23
250983	17634199	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc1C(N)=O		CHEMBL3649455	=	IC50	nM	2.51	CHEMBL5251	Homo sapiens	IC50	nM	2.51
250984	17634200	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-c4ccc(C(N)=O)o4)c3CO)ncc2c1		CHEMBL3649456	=	IC50	nM	832.5	CHEMBL5251	Homo sapiens	IC50	nM	832.5
250985	17634201	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-c4coc(C(N)=O)c4)c3CO)ncc2c1		CHEMBL3649457	=	IC50	nM	51.35	CHEMBL5251	Homo sapiens	IC50	nM	51.35
250986	17634202	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2cccc(-n3ncc4cc(C(C)(C)C)cc(CO)c4c3=O)c2CO)cc1C(N)=O		CHEMBL3649458	=	IC50	nM	695.5	CHEMBL5251	Homo sapiens	IC50	nM	695.5
250987	17634203	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)cc1C(N)=O		CHEMBL3649459	=	IC50	nM	39.35	CHEMBL5251	Homo sapiens	IC50	nM	39.35
250988	17634204	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CN1Cc2cc(C(C)(C)C)ccc2C(=O)N1c1cccc(-c2cc(C(N)=O)n(C)c2)c1CO		CHEMBL3649460	=	IC50	nM	26.73	CHEMBL5251	Homo sapiens	IC50	nM	26.73
250989	17634205	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5cccnc54)c3CO)ncc2c1		CHEMBL3649461	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
250990	17634206	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc1C(N)=O		CHEMBL3652649	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
250991	17634207	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccccc54)c3CO)ncc2c1		CHEMBL3652650	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
250992	17634208	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(C(C)(C)O)cc5)n4)c3CO)ncc2c1		CHEMBL3652651	=	IC50	nM	91.54	CHEMBL5251	Homo sapiens	IC50	nM	91.54
250993	17634209	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(Cl)cn5)n4)c3CO)ncc2c1		CHEMBL3652652	=	IC50	nM	0.29	CHEMBL5251	Homo sapiens	IC50	nM	0.29
250994	17634210	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(CN1CCC1)Oc1ccc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c3CO)cc2C(N)=O)nc1		CHEMBL3652653	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
250995	17634211	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CN1CCn2nc(Nc3nn(-c4cccc(-n5ncc6cc(C(C)(C)C)cc(F)c6c5=O)c4CO)cc3C(N)=O)cc2C1		CHEMBL3652654	=	IC50	nM	0.09	CHEMBL5251	Homo sapiens	IC50	nM	0.09
250996	17634212	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccccn5)n4)c3CO)ncc2c1		CHEMBL3652655	=	IC50	nM	0.36	CHEMBL5251	Homo sapiens	IC50	nM	0.36
250997	17634213	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(S(C)(=O)=O)cc5)n4)c3CO)ncc2c1		CHEMBL3652656	=	IC50	nM	0.09	CHEMBL5251	Homo sapiens	IC50	nM	0.09
250998	17634214	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cn1ccc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c3CO)cc2C(N)=O)n1		CHEMBL3652657	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
250999	17634215	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5cnccn5)n4)c3CO)ncc2c1		CHEMBL3652658	=	IC50	nM	0.43	CHEMBL5251	Homo sapiens	IC50	nM	0.43
251000	17634216	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(F)cn5)n4)c3CO)ncc2c1		CHEMBL3652659	=	IC50	nM	0.24	CHEMBL5251	Homo sapiens	IC50	nM	0.24
251001	17634217	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cc1cc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c3CO)cc2C(N)=O)nn1C		CHEMBL3652660	=	IC50	nM	0.29	CHEMBL5251	Homo sapiens	IC50	nM	0.29
251002	17634218	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(C(F)(F)F)cn5)n4)c3CO)ncc2c1		CHEMBL3652661	=	IC50	nM	0.57	CHEMBL5251	Homo sapiens	IC50	nM	0.57
251003	17634219	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cc1ccc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c3CO)cc2C(N)=O)nc1		CHEMBL3652662	=	IC50	nM	0.24	CHEMBL5251	Homo sapiens	IC50	nM	0.24
251004	17634220	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cc1cc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)ccc5c4=O)c3CO)cc2C(N)=O)nn1C		CHEMBL3652663	=	IC50	nM	0.51	CHEMBL5251	Homo sapiens	IC50	nM	0.51
251005	17634221	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1ccc2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(F)cn5)n4)c3CO)ncc2c1		CHEMBL3652664	=	IC50	nM	0.56	CHEMBL5251	Homo sapiens	IC50	nM	0.56
251006	17634222	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1ccc2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5cnccn5)n4)c3CO)ncc2c1		CHEMBL3652665	=	IC50	nM	0.83	CHEMBL5251	Homo sapiens	IC50	nM	0.83
251007	17634223	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	Cc1ccc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)ccc5c4=O)c3CO)cc2C(N)=O)nc1		CHEMBL3652666	=	IC50	nM	1.13	CHEMBL5251	Homo sapiens	IC50	nM	1.13
251008	17634224	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(S(C)(=O)=O)cn5)n4)c3CO)ncc2c1		CHEMBL3652667	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
251009	17634225	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccc(C#N)cn5)n4)c3CO)ncc2c1		CHEMBL3652668	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
251010	17634226	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4ccc(C(N)=O)n4)c3CO)ncc2c1		CHEMBL3652669	=	IC50	nM	333.06	CHEMBL5251	Homo sapiens	IC50	nM	333.06
251011	17634227	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)cn4)c3CO)ncc2c1		CHEMBL3652670	=	IC50	nM	267.74	CHEMBL5251	Homo sapiens	IC50	nM	267.74
251012	17634228	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5cncnc54)c3CO)ncc2c1		CHEMBL3652671	=	IC50	nM	7.32	CHEMBL5251	Homo sapiens	IC50	nM	7.32
251013	17634229	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CN1CCN(c2ccc3c(C(N)=O)cn(-c4cccc(-n5ncc6cc(C(C)(C)C)cc(F)c6c5=O)c4CO)c3n2)CC1		CHEMBL3652672	=	IC50	nM	2.83	CHEMBL5251	Homo sapiens	IC50	nM	2.83
251014	17634230	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccc(N6CCOCC6)nc54)c3CO)ncc2c1		CHEMBL3652673	=	IC50	nM	10.28	CHEMBL5251	Homo sapiens	IC50	nM	10.28
251015	17634231	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CCOc1ccc(-c2ccc3c(C(N)=O)cn(-c4cccc(-n5ncc6cc(C(C)(C)C)cc(F)c6c5=O)c4CO)c3n2)cn1		CHEMBL3652674	=	IC50	nM	11.04	CHEMBL5251	Homo sapiens	IC50	nM	11.04
251016	17634232	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccc(-c6ccccc6F)nc54)c3CO)ncc2c1		CHEMBL3652675	=	IC50	nM	14.28	CHEMBL5251	Homo sapiens	IC50	nM	14.28
251017	17634233	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccc(-c6ccccc6Cl)nc54)c3CO)ncc2c1		CHEMBL3652676	=	IC50	nM	28.35	CHEMBL5251	Homo sapiens	IC50	nM	28.35
251018	17634234	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccc(Br)nc54)c3CO)ncc2c1		CHEMBL3652677	=	IC50	nM	7.74	CHEMBL5251	Homo sapiens	IC50	nM	7.74
251019	17634235	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccc(C(O)CO)nc54)c3CO)ncc2c1		CHEMBL3652678	=	IC50	nM	13.91	CHEMBL5251	Homo sapiens	IC50	nM	13.91
251020	17634236	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)c5ccc(N6CCS(=O)(=O)CC6)nc54)c3CO)ncc2c1		CHEMBL3639515	=	IC50	nM	12.74	CHEMBL5251	Homo sapiens	IC50	nM	12.74
251021	17634237	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CN(C)CCNc1ccc2c(C(N)=O)cn(-c3cccc(-n4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c3CO)c2n1		CHEMBL3652679	=	IC50	nM	3562.18	CHEMBL5251	Homo sapiens	IC50	nM	3562.18
251022	17634238	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(=O)c1ccc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)ccc5c4=O)c3CO)cc2C(N)=O)cc1		CHEMBL3652680	=	IC50	nM	0.12	CHEMBL5251	Homo sapiens	IC50	nM	0.12
251023	17634239	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1ccc2c(=O)n(-c3cccc(-n4cc(C(N)=O)c(Nc5ccccn5)n4)c3CO)ncc2c1		CHEMBL3652681	=	IC50	nM	0.95	CHEMBL5251	Homo sapiens	IC50	nM	0.95
251024	17634240	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CN(C)Cc1ccc(Nc2nn(-c3cccc(-n4ncc5cc(C(C)(C)C)ccc5c4=O)c3CO)cc2C(N)=O)nc1		CHEMBL3652682	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
251025	17634241	CHEMBL3705288	Inhibition Assay: Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 μm hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 μM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 μM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 μM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 μM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 μCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-n4cc(C(N)=O)cn4)c3)ncc2c1		CHEMBL3652683	=	IC50	nM	3700.0	CHEMBL5251	Homo sapiens	IC50	nM	3700.0
262411	17644903	CHEMBL3705524	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 uM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 uM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 uM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 uM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 uCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco).	B	CNC(=O)Nc1cc(-c2cccc(-n3cnc4cc(C(C)(C)C)ccc4c3=O)c2C)cn(C)c1=O		CHEMBL3665115	=	IC50	nM	112.0	CHEMBL5251	Homo sapiens	IC50	nM	112.0
262412	17644904	CHEMBL3705524	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 uM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 uM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 uM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 uM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 uCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco).	B	Cc1c(-c2cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c(=O)n(C)c2)cccc1N1CNc2cc(N(C)C)ccc2C1=O		CHEMBL3665116	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
262413	17644905	CHEMBL3705524	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 uM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 uM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 uM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 uM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 uCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco).	B	Cc1c(-c2cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c(=O)n(C)c2)cccc1N1CNc2cc(C(C)(C)O)ccc2C1=O		CHEMBL3665117	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
262414	17644906	CHEMBL3705524	Inhibition Assay: The assay is a capture of radioactive 33P phosphorylated product through filtration. The interactions of Btk, biotinylated SH2 peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 um hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 uM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 uM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH2), 100 uM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 uM EGTA (Roche Diagnostics), 1 mM MnCl2 (Sigma), 20 mM MgCl2 (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 uCi 33P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco).	B	Cc1c(-c2cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c(=O)n(C)c2)cccc1-n1ncc2cc(N(C)C)ccc2c1=O		CHEMBL3665118	=	IC50	nM	124.0	CHEMBL5251	Homo sapiens	IC50	nM	124.0
267603	17649922	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Cc1cccc(Oc2ccc(-c3cc(C4CCCC4)nc(N)c3C(=N)N)cc2)c1		CHEMBL3657209	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
267604	17649923	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CC(C)(C)OC(=O)NC1CCN(c2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c3n2)C1		CHEMBL3657210	=	IC50	nM	8640.0	CHEMBL5251	Homo sapiens	IC50	nM	8640.0
267605	17649924	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	COc1ccc(Oc2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c3n2)cc1		CHEMBL3657211	=	IC50	nM	27910.0	CHEMBL5251	Homo sapiens	IC50	nM	27910.0
267606	17649925	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Cc1csc(NC(=O)NC2CCN(c3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)n[nH]c4n3)C2)n1		CHEMBL3657212	=	IC50	nM	9410.0	CHEMBL5251	Homo sapiens	IC50	nM	9410.0
267607	17649926	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CC(C)Oc1ccc(-c2cncc3[nH]nc(N)c23)cc1		CHEMBL3657213	=	IC50	nM	9310.0	CHEMBL5251	Homo sapiens	IC50	nM	9310.0
267608	17649927	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cncc(-c3ccc(OC4CCCC4)cc3)c12		CHEMBL3657214	=	IC50	nM	9490.0	CHEMBL5251	Homo sapiens	IC50	nM	9490.0
267609	17649928	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cncc(-c3ccc(C(=O)N4CCCC4)cc3)c12		CHEMBL3657215	=	IC50	nM	40570.0	CHEMBL5251	Homo sapiens	IC50	nM	40570.0
267610	17649929	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3ccc(NC(=O)c4ccccc4)cc3)ncc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657216	=	IC50	nM	14860.0	CHEMBL5251	Homo sapiens	IC50	nM	14860.0
267611	17649930	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CS(=O)(=O)Nc1cccc(-c2ncc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c23)c1		CHEMBL3657217	=	IC50	nM	270.0	CHEMBL5251	Homo sapiens	IC50	nM	270.0
267612	17649931	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3ccc(Cl)c(Cl)c3)ncc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657218	=	IC50	nM	9180.0	CHEMBL5251	Homo sapiens	IC50	nM	9180.0
267613	17649932	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3ccc(O)cc3)ncc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657219	=	IC50	nM	280.0	CHEMBL5251	Homo sapiens	IC50	nM	280.0
267614	17649933	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3ccc4[nH]ccc4c3)ncc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657220	=	IC50	nM	250.0	CHEMBL5251	Homo sapiens	IC50	nM	250.0
267615	17649934	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CS(=O)(=O)Nc1ccc(-c2ncc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c23)cc1		CHEMBL3657221	=	IC50	nM	280.0	CHEMBL5251	Homo sapiens	IC50	nM	280.0
267616	17649935	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CC(C)COc1cccc(-c2ncc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c23)c1		CHEMBL3657222	=	IC50	nM	14000.0	CHEMBL5251	Homo sapiens	IC50	nM	14000.0
267617	17649936	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Cc1ccccc1-c1ncc(-c2ccc(Oc3ccccc3)cc2)c2c(N)n[nH]c12		CHEMBL3657223	=	IC50	nM	12680.0	CHEMBL5251	Homo sapiens	IC50	nM	12680.0
267618	17649937	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3cccc(C(F)(F)F)c3)ncc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657224	=	IC50	nM	16090.0	CHEMBL5251	Homo sapiens	IC50	nM	16090.0
267619	17649938	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3cccc(OC(F)(F)F)c3)ncc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657225	=	IC50	nM	13840.0	CHEMBL5251	Homo sapiens	IC50	nM	13840.0
267620	17649939	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2nc(-c3cccs3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657226	=	IC50	nM	240.0	CHEMBL5251	Homo sapiens	IC50	nM	240.0
267621	17649940	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	COc1cccc(-c2cnc(Nc3ccccc3)c3[nH]nc(N)c23)c1		CHEMBL3657227	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
267622	17649941	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	COc1cccc(-c2cnc(Nc3ccccc3Cl)c(Cl)c2C#N)c1		CHEMBL3657228	=	IC50	nM	230.0	CHEMBL5251	Homo sapiens	IC50	nM	230.0
267623	17649942	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	COc1ccc(-c2cnc(Nc3ccccc3C)c3[nH]nc(N)c23)cc1		CHEMBL3657229	=	IC50	nM	260.0	CHEMBL5251	Homo sapiens	IC50	nM	260.0
267624	17649943	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Cc1ccccc1Nc1ncc(-c2cccc(OC(C)C)c2)c2c(N)n[nH]c12		CHEMBL3657230	=	IC50	nM	240.0	CHEMBL5251	Homo sapiens	IC50	nM	240.0
267625	17649944	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc4ccccc4c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657231	=	IC50	nM	260.0	CHEMBL5251	Homo sapiens	IC50	nM	260.0
267626	17649945	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc(C(=O)O)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL2057923	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
267627	17649946	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CNC(=O)c1ccc(-c2cc3[nH]nc(N)c3c(-c3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL3657232	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
267628	17649947	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc(C(=O)Nc4nnn[nH]4)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3639560	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
267629	17649948	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc(C(=O)NCC(=O)O)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657233	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
267630	17649949	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc(-c4nnn[nH]4)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657234	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
267631	17649950	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2c(-c3ccccn3)cnc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657235	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
267632	17649951	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(C3CCCN(C(=O)Nc4ccccc4)C3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657236	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
267633	17649952	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	C=CC(=O)N1CCCC(c2cc3[nH]nc(N)c3c(-c3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL3657237	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
267634	17649953	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	COC(=O)C(=O)N1CCCC(c2cc3[nH]nc(N)c3c(-c3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL3657238	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
267635	17649954	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(C3CCN(C(=O)Nc4ccccc4)CC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657239	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
267636	17649955	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc(C(=O)O)c(F)c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3657240	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
267637	17649956	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CN(C)C(=O)Cn1ccc(Nc2cc3[nH]nc(N)c3c(-c3ccc(Oc4ccccc4)cc3)n2)n1		CHEMBL3657241	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
267638	17649957	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	COc1ccc2cc(-c3nc(-c4ccc(C(=O)O)cc4)cc4[nH]nc(N)c34)ccc2c1		CHEMBL3657242	=	IC50	nM	280.0	CHEMBL5251	Homo sapiens	IC50	nM	280.0
267639	17649958	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	CC(C)Oc1ccc(-c2nc(-c3ccc(C(=O)O)cc3)cc3[nH]nc(N)c23)cc1		CHEMBL3657243	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
267640	17649959	CHEMBL3705416	Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 uM), ATP (20 uM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT in 1.6% DMSO), with a final volume of 30 uL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 ul of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and no inhibitor controls for 0% inhibition. Dose response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC50). Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at eleven concentrations.	B	Nc1n[nH]c2cc(-c3ccc(C(=O)O)cc3)nc(-c3ccc(Oc4cccc(F)c4)cc3)c12		CHEMBL3657244	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
279398	17661743	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC1(/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)COC1		CHEMBL3982962	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
279399	17661744	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCC1		CHEMBL3950862	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
279400	17661745	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)CO		CHEMBL3954211	=	IC50	nM	8.1	CHEMBL5251	Homo sapiens	IC50	nM	8.1
279401	17661746	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	[C-]#[N+]/C(=C/C(C)(C)N1CCN(C)CC1)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3952977	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
279402	17661747	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCCC1		CHEMBL3702831	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
279403	17661748	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	[C-]#[N+]/C(=C/C(C)(C)N1CCNCC1)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3985927	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
279404	17661749	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CC(O)C1		CHEMBL3942079	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
279405	17661750	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H]2Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)CC1		CHEMBL3702834	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
279406	17661751	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H]2Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)CC1		CHEMBL3702859	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
279407	17661752	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCNCC1		CHEMBL3702835	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
279408	17661753	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3702836	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
279409	17661754	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC1COC1		CHEMBL3702837	=	IC50	nM	16.1	CHEMBL5251	Homo sapiens	IC50	nM	16.1
279410	17661755	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)/C=C(\C#N)C(=O)N1CCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3702838	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
279411	17661756	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3941568	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
279412	17661757	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3965958	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
279413	17661758	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N(C1CC1)C1COC1		CHEMBL3702841	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
279414	17661759	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)/C=C(/C#N)C(=O)N1CC(Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3889963	=	IC50	nM	20.4	CHEMBL5251	Homo sapiens	IC50	nM	20.4
279415	17661760	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCOCC1		CHEMBL3702843	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
279416	17661761	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCC(O)CC1		CHEMBL3967056	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
279417	17661762	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CC2(COC2)C1		CHEMBL3933784	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
279418	17661763	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CC2(COC2)C1		CHEMBL3702846	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	nM	5.6
279419	17661764	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3903174	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
279420	17661765	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3918726	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
279421	17661766	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(C)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3890663	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
279422	17661767	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	COCCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3913230	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
279423	17661768	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1=O		CHEMBL3979968	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
279424	17661769	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(S(C)(=O)=O)CC1		CHEMBL3904226	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
279425	17661770	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)CN1CCOCC1		CHEMBL3702853	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
279426	17661771	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1		CHEMBL3979355	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
279427	17661772	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(=O)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3912580	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
279428	17661773	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	COC(=O)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3890002	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
279429	17661774	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1=O		CHEMBL3918024	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
279430	17661775	CHEMBL3706082	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN=C(O)C1		CHEMBL3902505	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
279476	17661821	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C=CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)C2)C1		CHEMBL3647514	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
279477	17661822	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CN(C)C/C=C/C(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)C2)C1		CHEMBL3647515	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
279478	17661823	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CC#CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)C2)C1		CHEMBL3647516	=	IC50	nM	0.83	CHEMBL5251	Homo sapiens	IC50	nM	0.83
279479	17661824	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CC2(C1)CN(C(=O)C1CO1)C2		CHEMBL3647517	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
279480	17661825	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C=CC(=O)N1CCC2(CC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)C2)C1		CHEMBL3647518	=	IC50	nM	0.87	CHEMBL5251	Homo sapiens	IC50	nM	0.87
279481	17661826	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C=CC(=O)N1CC2(CC(n3nc(-c4ccc(-c5cnc(Cc6ccccc6)n(C)c5=O)cc4F)c4c(N)ncnc43)C2)C1		CHEMBL3647519	=	IC50	nM	0.85	CHEMBL5251	Homo sapiens	IC50	nM	0.85
279482	17661827	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CC#CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)nc4)c4c(N)ncnc43)C2)C1		CHEMBL3647520	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
279483	17661828	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C=CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)nc4)c4c(N)ncnc43)C2)C1		CHEMBL3647521	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
279484	17661829	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C/C=C/C(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)nc4)c4c(N)ncnc43)C2)C1		CHEMBL3647522	=	IC50	nM	83.0	CHEMBL5251	Homo sapiens	IC50	nM	83.0
279485	17661830	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C/C=C/C(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cn4)c4c(N)ncnc43)C2)C1		CHEMBL3647523	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
279486	17661831	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	C=CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cn4)c4c(N)ncnc43)C2)C1		CHEMBL3647524	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
279487	17661832	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CC#CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cn4)c4c(N)ncnc43)C2)C1		CHEMBL3647525	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
279488	17661833	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CC#CC(=O)N1CC[C@]2(C1)C[C@@H](n1nc(-c3ccc(Oc4ccccc4)cn3)c3c(N)ncnc31)C2		CHEMBL3647526	=	IC50	nM	0.74	CHEMBL5251	Homo sapiens	IC50	nM	0.74
279489	17661834	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CC#CC(=O)N1CC[C@]2(C1)C[C@H](n1nc(-c3ccc(Oc4ccccc4)cn3)c3c(N)ncnc31)C2		CHEMBL3647527	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
279490	17661835	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CN(C)C/C=C/C(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cn4)c4c(N)ncnc43)C2)C1		CHEMBL3647528	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
279491	17661836	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CN(C)C/C=C/C(=O)N1CC[C@]2(C1)C[C@@H](n1nc(-c3ccc(Oc4ccccc4)cn3)c3c(N)ncnc31)C2		CHEMBL3647529	=	IC50	nM	8.1	CHEMBL5251	Homo sapiens	IC50	nM	8.1
279492	17661837	CHEMBL3706140	HTRF Assay: An HTRF assay (Cisbio KinEASE-TK cat #62TKOPEC) was performed to quantitate the ability of test compounds to inhibit BTK mediated phosphorylation of substrate. Assays were assembled in 384 well plates where 6 nM of full-length human His-tagged BTK (Life Technologies cat #PV3587) and test compound at varying concentrations were preincubated for 15 minutes at 28Â° C. Then, 1 uM of TK substrate-biotin and 30 uM ATP were added and incubated for an additional 30 minutes at 28Â° C. Phospohrylation was detected by adding 62.5 nM Streptavidin-XL665 and TK-Antibody Cryptate diluted 1:100 in HTRF detection buffer (Cisbio cat #62SDBRDF) and incubated for 60 minutes at RT. The plate was read on an Envision plate reader and the fluoresence is measured at 620 nm (cryptate) and 665 nm (XL665). A ratio is calculated (665/620) and converted to POC relative to control and blank wells.Assay Buffer:50 mM HEPES (Invitrogen #15630), 0.01% Brij-35 (sigma #B4184), 10 mM MgC12 (Sigma M1028), 1 mM EGTA.	B	CN(C)C/C=C/C(=O)N1CC[C@]2(C1)C[C@H](n1nc(-c3ccc(Oc4ccccc4)cn3)c3c(N)ncnc31)C2		CHEMBL3647530	=	IC50	nM	7.1	CHEMBL5251	Homo sapiens	IC50	nM	7.1
287909	17670273	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3699638	=	IC50	nM	4000.0	CHEMBL5251	Homo sapiens	IC50	nM	4000.0
287910	17670274	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)cccc1N1Cc2ccc(C(C)(C)C)cc2C1=O		CHEMBL3699639	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
287911	17670275	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1c(-c2cc(Nc3cc(C)n(C)n3)c(=O)[nH]n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3699640	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
287912	17670276	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1c(-c2cc(Nc3cc(C4CC4)[nH]n3)c(=O)[nH]n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3699641	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
287913	17670277	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1cc(Nc2cc(-c3ccc(F)c(N4Cc5cc(C(C)(C)C)sc5C4=O)c3)n[nH]c2=O)nn1C		CHEMBL3699642	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
287914	17670278	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1cc(Nc2cc(-c3cccc(N4Cc5cc(C(C)(C)C)sc5C4=O)c3C)n[nH]c2=O)no1		CHEMBL3699643	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
287915	17670279	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	CC(C)(C)c1cc2c(s1)C(=O)N(c1nc(-c3cc(Nc4cc(C5CC5)[nH]n4)c(=O)[nH]n3)ccc1F)C2		CHEMBL3699644	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	nM	35.0
287916	17670280	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1cc(Nc2cc(-c3ccc(F)c(N4Cc5cc(C(C)(C)C)sc5C4=O)n3)n[nH]c2=O)nn1C		CHEMBL3699645	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
287917	17670281	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1c(-c2cc(Nc3nc4c(s3)CNCC4)c(=O)[nH]n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3699646	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
287918	17670282	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	Cc1c(-c2cc(Nc3cc(CN4CC(F)(F)C4)n(C)n3)c(=O)[nH]n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3699647	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
287919	17670283	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	CN1CCn2nc(Nc3cc(-c4cccc(N5Cc6cc(C(C)(C)C)sc6C5=O)c4CO)nn(C)c3=O)cc2C1		CHEMBL3699648	=	IC50	nM	55.0	CHEMBL5251	Homo sapiens	IC50	nM	55.0
287920	17670284	CHEMBL3705508	"Biochemical Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing IX Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta- glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3V04, 10 mM MgCl2), 0.5 ul Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing IX Cell Signaling kinase buffer, 0.5 ul PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6x His tag was subcloned into pFastBac vector for making baculo virus carrying this epitope-tagged Btk. Generation of baculovirus is done based on Invitrogen's instructions detailed in its published protocol ""Bac-to-Bac Baculovirus Expression Systems""."	B	CN1CCn2nc(Nc3cc(-c4cccc(N5Cc6cc(C(C)(C)C)sc6C5=O)c4CO)n[nH]c3=O)cc2C1		CHEMBL3699649	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
312169	17692422	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CNC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114685	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
312171	17692424	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc(F)cc(F)c4)cc3)c3c(N)ncnc32)C1		CHEMBL4114740	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
312172	17692425	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4cc(F)cc(F)c4)cc3)c3c(N)ncnc32)C1		CHEMBL4114800	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
326614	17705341	CHEMBL3887254	Enzymatic Kinase Assay: Kinase activity is measured in vitro using electrophoretic mobility shift assay. The kinase reactions are assembled in a total volume of 25 uL in 384 well plates. The reactions comprise: BTK enzyme (1 nM, N-terminal His6-tagged, recombinant, full-length, human BTK purified from baculovirus Sf21 insect cell system), inhibitor, ATP (16 uM, the apparent Km for the kinase), fluorescently labeled peptide substrate (1 uM, FAM-GEEPLYWSFPAKKK-NH2) in a reaction buffer composed of 100 mM HEPES, pH7.5, 5 mM MgCl2 1 mM DTT, 0.1% bovine serum albumin, 0.01% Triton X-100, and 1% DMSO. The reaction is incubated for one hour and is quenched by the addition of 45 uL of termination buffer (100 mM HEPES, pH7.5, 0.01% Triton X-100, 30 mM EDTA). The terminated reactions are analyzed using 12 channel LabChip 3000 microfluidic detection instrument (Caliper Life Sciences). The enzymatic phosphorylation of the peptide results in a change in net charge, enabling electrophoretic separation.	B	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C(O)CO)c3)n2)cc1		CHEMBL3355049	<	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
327853	17706552	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3182647	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
327854	17706553	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647971	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
327855	17706554	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CS(=O)(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4107734	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
327856	17706555	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)CCl)C1		CHEMBL3647972	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
327857	17706556	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C#CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647969	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
327858	17706557	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647973	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
327859	17706558	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647967	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
327860	17706559	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647966	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
327861	17706560	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647965	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
327862	17706561	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3182647	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
327863	17706562	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3182647	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
327864	17706563	CHEMBL3887275	Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: Btk kinase activity was determined using a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. Measurements were performed in a reaction volume of 50 uL using 96-well assay plates. Kinase enzyme, inhibitor, ATP (at the Km for the kinase), and 1 uM peptide substrate (Biotin-AVLESEEELYSSARQ-NH2) were incubated in a reaction buffer composed of 20 mM Tris, 50 mM NaCl, MgCl2 (5-25 mM depending on the kinase), MnCl2 (0-10 mM), 1 mM DTT, 0.1 mM EDTA, 0.01% bovine serum albumin, 0.005% Tween-20, and 10% DMSO at pH 7.4 for one hour. The reaction was quenched by the addition of 1.2 equivalents of EDTA (relative to divalent cation) in 25uL of 1x Lance buffer (Perkin-Elmer). Streptavidin-APC (Perkin-Elmer) and Eu-labeled p-Tyr100 antibody (Perkin-Elmer) in 1x Lance buffer were added in a 25 uL volume to give final concentrations of 100 nM and 2.5 nM, respectively, and the mixture was allowed to incubate for one hour.	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647970	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
342601	17719992	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
342622	17720013	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647967	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
342643	17720034	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
342644	17720035	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647970	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
342645	17720036	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1)CCO		CHEMBL3931858	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
342646	17720037	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/c2c[nH]cn2)C1		CHEMBL3926657	=	IC50	nM	22.2	CHEMBL5251	Homo sapiens	IC50	nM	22.2
342647	17720038	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL3902180	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	nM	5.6
342648	17720039	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647973	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
342649	17720040	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3917698	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
342650	17720041	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3889694	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
342651	17720042	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647967	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
342652	17720043	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N[C@H]1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3912266	=	IC50	nM	1.31	CHEMBL5251	Homo sapiens	IC50	nM	1.31
342653	17720044	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3903870	=	IC50	nM	0.92	CHEMBL5251	Homo sapiens	IC50	nM	0.92
342654	17720045	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3903249	=	IC50	nM	1.33	CHEMBL5251	Homo sapiens	IC50	nM	1.33
342655	17720046	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4109796	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
342656	17720047	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3910496	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
342657	17720048	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4107879	=	IC50	nM	4.16	CHEMBL5251	Homo sapiens	IC50	nM	4.16
342658	17720049	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3905432	=	IC50	nM	3.14	CHEMBL5251	Homo sapiens	IC50	nM	3.14
342659	17720050	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4106607	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
342660	17720051	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N[C@H]1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3893004	=	IC50	nM	1.38	CHEMBL5251	Homo sapiens	IC50	nM	1.38
342661	17720052	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3921017	=	IC50	nM	1.58	CHEMBL5251	Homo sapiens	IC50	nM	1.58
342662	17720053	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCN(C(=O)/C=C/CN2CCOCC2)CC1		CHEMBL3982014	=	IC50	nM	4.07	CHEMBL5251	Homo sapiens	IC50	nM	4.07
342663	17720054	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C[C@@H]1CCCN1C(=O)/C=C/CN1CCOCC1		CHEMBL3915538	=	IC50	nM	4.15	CHEMBL5251	Homo sapiens	IC50	nM	4.15
342664	17720055	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3921655	=	IC50	nM	1.57	CHEMBL5251	Homo sapiens	IC50	nM	1.57
342665	17720056	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)NCCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3894938	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
342666	17720057	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL4110614	=	IC50	nM	0.89	CHEMBL5251	Homo sapiens	IC50	nM	0.89
342667	17720058	CHEMBL3887529	HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H]1CC[C@@H](NC(=O)/C=C/CN2CCOCC2)CC1		CHEMBL3894102	=	IC50	nM	3.48	CHEMBL5251	Homo sapiens	IC50	nM	3.48
346408	17722945	CHEMBL3887629	Z'-LYTE Kinase Assay: The measurement of Btk enzyme inhibitory activity was performed using the following reagents: Z'-LYTE Kinase Assay Kit-Tyr 1 (containing Tyr 1 peptide, Thy 1 phospho-peptide, 5x kinase buffer, ATP, development reagent B, development buffer, and stop reagent), Tyr 1 peptide (Invitrogen), and Btk (Invitrogen) according to the instructions accompanying the kit.First 5 uL/well of either a solution prepared by diluting the test compound in dimethyl sulfoxide (DMSO) or DMSO alone was added to the wells of a 96-well assay plate together with 10 uL/well of substrate/enzyme mixture and allowed to react for 20 minutes at 30° C. The substrate/enzyme mixture solutions were prepared by dilution in kinase buffer (DL-dithiothreitol (DTT; 2.7 mM) and 1.33x kinase buffer) so that the final concentration of Tyr-1 peptide would be 4 uM, and the final concentration of Btk would be 5 nM. Next 5 uL/well of adenosine triphosphate was added (ATP; final concentration 36 uM).	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	1057.0	CHEMBL5251	Homo sapiens	IC50	nM	1057.0
346409	17722946	CHEMBL3887630	Z'-LYTE Kinase Assay: The measurement of Btk enzyme inhibitory activity was performed using the following reagents: Z'-LYTE Kinase Assay Kit-Tyr 1 (containing Tyr 1 peptide, Thy 1 phospho-peptide, 5x kinase buffer, ATP, development reagent B, development buffer, and stop reagent), Tyr 1 peptide (Invitrogen), and Btk (Invitrogen) according to the instructions accompanying the kit.First 5 uL/well of either a solution prepared by diluting the test compound in dimethyl sulfoxide (DMSO) or DMSO alone was added to the wells of a 96-well assay plate together with 10 uL/well of substrate/enzyme mixture and allowed to react for 20 minutes at 30° C. The substrate/enzyme mixture solutions were prepared by dilution in kinase buffer (DL-dithiothreitol (DTT; 2.7 mM) and 1.33x kinase buffer) so that the final concentration of Tyr-1 peptide would be 4 uM, and the final concentration of Btk would be 5 nM. Next 5 uL/well of adenosine triphosphate was added (ATP; final concentration 36 uM).	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	1662.0	CHEMBL5251	Homo sapiens	IC50	nM	1662.0
348501	17724878	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cc5ccccc5[nH]4)c3n2)c1		CHEMBL3984768	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348502	17724879	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)c1		CHEMBL3963521	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348503	17724880	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(C)c3c2)c1		CHEMBL3902509	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348504	17724881	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC1(C(=O)Nc2cccc(-c3cnc4[nH]cc(Cl)c4c3)c2)CC1		CHEMBL3901385	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348505	17724882	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)c1		CHEMBL3919260	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348506	17724883	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)c1		CHEMBL3915825	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348507	17724884	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)c1		CHEMBL3926317	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348508	17724885	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	O=C(CF)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)c1		CHEMBL3953949	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348509	17724886	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(C)c3c2)c1		CHEMBL3938761	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348510	17724887	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(C)c3c2)c1		CHEMBL3962690	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348511	17724888	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	Cc1c[nH]c2ncc(-c3cccc(NC(=O)CF)c3)cc12		CHEMBL3911910	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348512	17724889	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(F)c4OC)c3c2)c1		CHEMBL3939895	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348513	17724890	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(S(=O)(=O)N(C)C(C)(C)C)c4)c3c2)c1		CHEMBL3917327	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348514	17724891	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(S(=O)(=O)N(CC)CC)c4)c3c2)c1		CHEMBL3948653	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348515	17724892	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(C(=O)OCC)c4)c3c2)c1		CHEMBL3918545	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348516	17724893	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cc(F)cc(F)c4OC)c3c2)c1		CHEMBL3946420	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348517	17724894	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cc(-c2cnc3[nH]cc(C)c3c2)ccc1F		CHEMBL3909234	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348518	17724895	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(S(=O)(=O)N(C)C(C)(C)C)c4)c3c2)c1		CHEMBL3979472	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348519	17724896	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(S(=O)(=O)N(C)C(C)(C)C)c4)c3n2)c1		CHEMBL3918168	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348520	17724897	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	Cc1n[nH]c2ncc(-c3cccc(NC(=O)/C=C/N(C)C)c3)cc12		CHEMBL3979809	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348521	17724898	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	Cc1n[nH]c2ncc(-c3ccc(Cl)c(NC(=O)/C=C/N(C)C)c3)cc12		CHEMBL3942125	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348522	17724899	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cc(-c2cnc3[nH]nc(C)c3c2)ccc1Cl		CHEMBL3968188	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348523	17724900	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC/C=C/C(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL3967741	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348524	17724901	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]ccc3c2)n1		CHEMBL3976245	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348525	17724902	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)n1		CHEMBL3964955	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348526	17724903	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cc(-c2cnc3[nH]ccc3c2)ccc1F		CHEMBL3904442	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348527	17724904	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cc(-c2cnc3[nH]cc(Cl)c3c2)ccc1F		CHEMBL3907847	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348528	17724905	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cc5ccccc5[nH]4)c3c2)c1		CHEMBL3958574	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348529	17724906	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cc5ccc(C)cc5[nH]4)c3c2)c1		CHEMBL3914851	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348530	17724907	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cccc(-c2cnc3[nH]ccc3c2)n1		CHEMBL3920364	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348531	17724908	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cccc(-c2cnc3[nH]ccc3c2)n1		CHEMBL3951591	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348532	17724909	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)n1		CHEMBL3937076	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348533	17724910	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)n1		CHEMBL3966831	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348534	17724911	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cccc(-c2cnc3[nH]ccc3c2)n1		CHEMBL3968455	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348535	17724912	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)n1		CHEMBL3962931	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348536	17724913	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cc(-c2cnc3[nH]ccc3c2)ccc1F		CHEMBL3986267	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348537	17724914	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cc(-c2cnc3[nH]cc(Cl)c3c2)ccc1F		CHEMBL3957567	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348538	17724915	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cc(-c2cnc3[nH]ccc3c2)ccc1F		CHEMBL3981782	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348539	17724916	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cc(-c2cnc3[nH]cc(Cl)c3c2)ccc1F		CHEMBL3956377	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348540	17724917	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cc(-c2cnc3[nH]ccc3c2)ccc1F		CHEMBL3973770	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348541	17724918	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cc(-c2cnc3[nH]cc(Cl)c3c2)ccc1F		CHEMBL3944305	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348542	17724919	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cccc(-c2cnc3[nH]cc(C)c3c2)n1		CHEMBL3958612	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348543	17724920	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CCC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(C)c3c2)n1		CHEMBL3927614	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348544	17724921	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CC#CC(=O)Nc1cccc(-c2cnc3[nH]cc(C)c3c2)n1		CHEMBL3967872	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348545	17724922	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C#CC(=O)Nc1cc(-c2cnc3[nH]cc(C)c3c2)ccc1F		CHEMBL3893228	=	IC50	nM	739.0	CHEMBL5251	Homo sapiens	IC50	nM	739.0
348546	17724923	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	COc1c(F)cc(F)cc1-c1c[nH]c2ncc(-c3cc(NC(=O)/C=C/CN(C)C)ccc3F)cc12		CHEMBL3925725	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348547	17724924	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	COc1cc(F)c(C)cc1-c1c[nH]c2ncc(-c3cccc(NC(=O)/C=C/CN(C)C)c3)cc12		CHEMBL3948029	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348548	17724925	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cc(C)c(F)cc4OC)c3c2)c1		CHEMBL3920230	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348549	17724926	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	Cc1cccc(-c2c[nH]c3ncc(-c4cccc(NC(=O)/C=C/CN(C)C)c4)cc23)c1F		CHEMBL3943435	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348550	17724927	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3[nH]cc(-c4cccc(C)c4F)c3c2)c1		CHEMBL3919033	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348551	17724928	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	C=CC(=O)Nc1cccc(-c2cnc3c(c2)CC(=O)N3)c1		CHEMBL3934456	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348552	17724929	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	Cc1c[nH]c2ncc(-c3cccc(NC(=O)/C=C/CN(C)C)c3)cc12		CHEMBL3906494	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348553	17724930	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CN(C)C/C=C/C(=O)Nc1cccc(-c2cnc3[nH]cc(Cl)c3c2)c1		CHEMBL3921295	=	IC50	nM	7558.0	CHEMBL5251	Homo sapiens	IC50	nM	7558.0
348669	17725046	CHEMBL3887688	Biochemical Inhibition Assay: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine series of compounds exhibited over >100 fold selective against Janus and TEC family of kinases except for the BMX and TXK it had activity of 30 and 45 nM respectively.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	22.07	CHEMBL5251	Homo sapiens	IC50	nM	22.07
350366	17726562	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3972359	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
350367	17726563	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1cc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3957855	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
350368	17726564	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3894476	=	IC50	nM	175.0	CHEMBL5251	Homo sapiens	IC50	nM	175.0
350369	17726565	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	COc1cc(-c2nn(CC3CCCN(C(=O)/C(C#N)=C/C4CC4)C3)c3ncnc(N)c23)ccc1Oc1ccc(Cl)c(Cl)c1		CHEMBL4114659	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	nM	61.0
350370	17726566	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	COc1cc(-c2nn(C3CCCN(C(=O)/C(C#N)=C/C4CC4)C3)c3ncnc(N)c23)ccc1Oc1ccc(Cl)c(Cl)c1		CHEMBL4114799	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
350371	17726567	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	[C-]#[N+]/C(=C\C1CC1)C(=O)N1CCC(n2nc(-c3ccc(Oc4ccc(Cl)c(Cl)c4)c(OC)c3)c3c(N)ncnc32)CC1		CHEMBL3924792	=	IC50	nM	365.0	CHEMBL5251	Homo sapiens	IC50	nM	365.0
350372	17726568	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4114764	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
350373	17726569	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC(Cc2[nH]c(C3CCC(Oc4ccccc4)CC3)c3c(N)ncnc23)C1		CHEMBL4114674	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
350374	17726570	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2)c2c(N)ncnc21		CHEMBL4114753	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
350375	17726571	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3c(F)cccc3F)cc2)c2c(N)ncnc21		CHEMBL4114709	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
350376	17726572	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)NCCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3981330	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
350377	17726573	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(F)c4F)cc3)c3c(N)ncnc32)C1		CHEMBL4114699	=	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
350378	17726574	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccc(F)c(F)c3)cc2)c2c(N)ncnc21		CHEMBL4115692	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
350379	17726575	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114690	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
350380	17726576	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3cc(F)ccc3F)cc2)c2c(N)ncnc21		CHEMBL3940151	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
350381	17726577	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3cc(F)cc(F)c3)cc2F)c2c(N)ncnc21		CHEMBL3984974	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
350382	17726578	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL3975610	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
350383	17726579	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	Cc1c(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc2n1C[C@H]1CCCN1C(=O)/C(C#N)=C/C1CC1		CHEMBL4114730	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
350384	17726580	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	Cc1c(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc2n1C[C@H]1CCCN1C(=O)/C(C#N)=C/C1CC1		CHEMBL4114784	=	IC50	nM	56.0	CHEMBL5251	Homo sapiens	IC50	nM	56.0
350385	17726581	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(CNC(=O)/C(C#N)=C/C1CC1)Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3949721	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
350386	17726582	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)c(F)c2)c2c(N)ncnc21		CHEMBL3901377	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
350387	17726583	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3cccc(F)c3)cc2F)c2c(N)ncnc21		CHEMBL4114710	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
350388	17726584	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	Cc1c(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc2n1C[C@H]1CCCN1C(=O)/C(C#N)=C\C(C)(C)N(C)C		CHEMBL4109085	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
350389	17726585	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cc(F)ccc3F)cc2)c2c(N)ncnc21		CHEMBL4110649	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
350390	17726586	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114661	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
350391	17726587	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3c(F)cccc3F)cc2)c2c(N)ncnc21		CHEMBL4114651	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
350392	17726588	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(/C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2)c2c(N)ncnc21		CHEMBL4108729	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
350393	17726589	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3c(F)cccc3F)cc2F)c2c(N)ncnc21		CHEMBL4108779	=	IC50	nM	7.5	CHEMBL5251	Homo sapiens	IC50	nM	7.5
350394	17726590	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC1CC1		CHEMBL3959434	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
350395	17726591	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CN(C)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114808	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
350396	17726592	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CN(C)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3902317	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
350397	17726593	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCNC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3927641	=	IC50	nM	17.2	CHEMBL5251	Homo sapiens	IC50	nM	17.2
350398	17726594	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	COCCNC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3900330	=	IC50	nM	29.0	CHEMBL5251	Homo sapiens	IC50	nM	29.0
350399	17726595	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCOCC1		CHEMBL4114701	=	IC50	nM	26.5	CHEMBL5251	Homo sapiens	IC50	nM	26.5
350400	17726596	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL4109651	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
350401	17726597	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H](n2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3921806	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
350402	17726598	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CNC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL4114795	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
350403	17726599	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CN(C)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL4115686	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
350404	17726600	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CN(C)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL3894014	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
350405	17726601	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCOC(C)(C)/C=C(\C#N)C(=O)C1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL4114660	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
350406	17726602	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCOC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(F)c4F)cc3F)c3c(N)ncnc32)C1		CHEMBL4114793	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
350407	17726603	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1cc(-c2ccc(Oc3cccc(F)c3F)cc2)c2c(N)ncnc21		CHEMBL4114814	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
350408	17726604	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1cc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4114748	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
350409	17726605	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N[C@H](C)Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114703	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
350410	17726606	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	C[C@H](Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC(=O)/C(C#N)=C/C(C)(C)N(C)C		CHEMBL4114755	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
350411	17726607	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	C[C@H](Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC(=O)/C(C#N)=C/C(C)(C)N		CHEMBL4114762	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
350412	17726608	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCN(CC)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1cc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3893632	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
350413	17726609	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(F)c4F)cc3F)c3c(N)ncnc32)C1)N1CCOCC1		CHEMBL4114774	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
350414	17726610	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4114765	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
350415	17726611	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4114765	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
350416	17726612	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3894476	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	nM	130.0
350417	17726613	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3891008	=	IC50	nM	980.0	CHEMBL5251	Homo sapiens	IC50	nM	980.0
350418	17726614	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1n1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4114719	=	IC50	nM	5.4	CHEMBL5251	Homo sapiens	IC50	nM	5.4
350419	17726615	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)NC1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4114712	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
350420	17726616	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(F)c4)cc3)c3c(N)ncnc32)C1		CHEMBL4114702	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
350421	17726617	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3)cc2)c2c(N)ncnc21		CHEMBL4114716	=	IC50	nM	6.2	CHEMBL5251	Homo sapiens	IC50	nM	6.2
350422	17726618	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccc(F)c(F)c3)cc2)c2c(N)ncnc21		CHEMBL4115692	=	IC50	nM	9.6	CHEMBL5251	Homo sapiens	IC50	nM	9.6
350423	17726619	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114689	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
350424	17726620	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3972359	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
350425	17726621	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)ncnc32)C1		CHEMBL4114770	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
350426	17726622	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc(F)ccc4F)cc3)c3c(N)ncnc32)C1		CHEMBL4114704	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
350427	17726623	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cc(F)ccc3F)cc2)c2c(N)ncnc21		CHEMBL4114688	=	IC50	nM	7.1	CHEMBL5251	Homo sapiens	IC50	nM	7.1
350428	17726624	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4114773	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
350429	17726625	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3c(F)cccc3F)cc2F)c2c(N)ncnc21		CHEMBL3922858	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
350430	17726626	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3c(F)cccc3F)cc2F)c2c(N)ncnc21		CHEMBL4114665	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
350431	17726627	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4114679	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
350432	17726628	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2cc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL4109432	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
350433	17726629	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1F)nn2C[C@H]1CCCN1C(=O)C1CC1		CHEMBL4107999	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
350434	17726630	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	Cc1cc(Oc2ccccc2)ccc1-c1nn(C[C@@H]2CCCN2C(=O)/C(C#N)=C/C2CC2)c2ncnc(N)c12		CHEMBL4115679	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
350435	17726631	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2Cl)c2c(N)ncnc21		CHEMBL4114741	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
350436	17726632	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	[C-]#[N+]/C(=C\C(C)(C)N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3)cc2F)c2c(N)ncnc21		CHEMBL4114718	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
350437	17726633	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(N)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3)cc2F)c2c(N)ncnc21		CHEMBL4114706	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
350438	17726634	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CC(F)(F)C[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3922830	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
350439	17726635	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1cc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3898929	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
350440	17726636	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CC(F)(F)C[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4115689	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
350441	17726637	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114732	=	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
350442	17726638	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3912377	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
350443	17726639	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(N)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114723	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
350444	17726640	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(N)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114727	=	IC50	nM	113.0	CHEMBL5251	Homo sapiens	IC50	nM	113.0
350445	17726641	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CNC(C)(C)/C=C(\C#N)C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114695	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
350446	17726642	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3c(F)cccc3F)cc2F)c2c(N)ncnc21		CHEMBL3922858	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
350447	17726643	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCNC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114726	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
350448	17726644	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCOC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114656	=	IC50	nM	3100.0	CHEMBL5251	Homo sapiens	IC50	nM	3100.0
350449	17726645	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCOC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3933092	=	IC50	nM	6600.0	CHEMBL5251	Homo sapiens	IC50	nM	6600.0
350450	17726646	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1(N)CC1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3973427	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
350451	17726647	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCOCC1		CHEMBL3892680	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
350452	17726648	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL3974518	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
350453	17726649	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(N)/C=C(\C#N)C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL4114819	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
350454	17726650	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CNC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3cccc(F)c3F)cc2F)c2c(N)ncnc21		CHEMBL3942076	=	IC50	nM	25.5	CHEMBL5251	Homo sapiens	IC50	nM	25.5
350455	17726651	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)/C=C(\C#N)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL4114802	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
350456	17726652	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(N)/C=C(\C#N)C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL4114772	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
350457	17726653	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCOCC1		CHEMBL3892680	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
350458	17726654	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H]1Cn1cc(-c2ccc(Oc3cccc(F)c3F)cc2)c2c(N)ncnc21		CHEMBL4115694	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
350459	17726655	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1cc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3918201	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
350460	17726656	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	C[C@H](Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC(=O)/C(C#N)=C/C(C)(C)C		CHEMBL4114691	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
350461	17726657	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCOC(C)(C)/C=C(\C#N)C(=O)N[C@H](C)Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL4114722	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
350462	17726658	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	N#C/C(=C\C1CCCN1)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3980841	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
350463	17726659	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC(=O)/C(C#N)=C/C(C)(C)N		CHEMBL3949568	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
350464	17726660	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CCN(CC)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1cc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL4114678	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
350465	17726661	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC1(/C=C(\C#N)C(=O)N2CCC[C@H]2Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)COC1		CHEMBL3968888	=	IC50	nM	32.5	CHEMBL5251	Homo sapiens	IC50	nM	32.5
350466	17726662	CHEMBL3887135	Enzymatic Activity Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of Formula (IA), (I′) or (I). Serial dilutions of test compounds were incubated with human recombinant Btk (2 nM), ATP (40 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000). Percent inhibition was calculated for each compound dilution and the concentration that produced 50% inhibition was calculated.	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL4114766	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356839	17732502	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C3(F)CC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3946923	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
356840	17732503	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc3c(c2)OCC3(C)C)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3934649	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
356841	17732504	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2cc3c(s2)CCC(C)C3)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3908775	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
356842	17732505	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(N(C)C(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3984000	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356843	17732506	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc3c(C)c[nH]c3c2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3914504	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
356844	17732507	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)CO)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3902940	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356845	17732508	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(N3CCCCC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3930926	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
356846	17732509	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	C=C(C)c1ccc(C(=O)Nc2cc(F)cc(-c3ncnc4[nH]c(C5=CCN(C(=O)N(C)C)CC5)cc34)c2C)cc1		CHEMBL3919531	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
356847	17732510	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C3(C(F)(F)F)CC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3900123	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
356848	17732511	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(OC(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3948911	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
356849	17732512	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B			CHEMBL4115903	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
356850	17732513	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	COCC(C)(C)c1ccc(C(=O)Nc2cc(F)cc(-c3ncnc4[nH]c(C5=CCN(C(=O)N(C)C)CC5)cc34)c2C)cc1		CHEMBL3909128	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
356851	17732514	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	COC(C)(C)c1ccc(C(=O)Nc2cc(F)cc(-c3ncnc4[nH]c(C5=CCN(C(=O)N(C)C)CC5)cc34)c2C)cc1		CHEMBL3982520	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
356852	17732515	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc3ccn(C)c3n2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3900253	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
356853	17732516	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(N(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3971224	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
356854	17732517	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(NC(=O)c5ccc(C(C)(C)O)cc5F)c4CO)ncnc3[nH]2)CC1		CHEMBL3968447	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356855	17732518	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(NC(=O)c5ccc(C6CC6)cc5)c4CO)ncnc3[nH]2)CC1		CHEMBL3919346	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
356856	17732519	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(O)C(F)(F)F)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3972813	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
356857	17732520	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(=O)c1ccc(C(=O)Nc2cc(F)cc(-c3ncnc4[nH]c(C5=CCN(C(=O)N(C)C)CC5)cc34)c2C)cc1		CHEMBL3905197	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
356858	17732521	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4ccc(F)c(NC(=O)c5ccc(C6CC6)cc5)c4)ncnc3[nH]2)CC1		CHEMBL3967476	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
356859	17732522	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4ccc(F)c(NC(=O)c5ccc(C(C)(C)CO)cc5)c4)ncnc3[nH]2)CC1		CHEMBL3935663	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
356860	17732523	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)O)cc2F)cc(F)cc1-c1ncnc2[nH]c(C3=CCOCC3)cc12		CHEMBL3917989	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
356861	17732524	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(C)(O)c1ccc(C(=O)Nc2cccc(-c3ncnc4[nH]c(C5=CCOCC5)cc34)c2CO)c(F)c1		CHEMBL3903518	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
356862	17732525	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCSCC3)cc12		CHEMBL3982378	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
356863	17732526	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CC[S+]([O-])CC3)cc12		CHEMBL3967153	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356864	17732527	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCS(=O)(=O)CC3)cc12		CHEMBL3933887	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	nM	35.0
356865	17732528	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCC4(CC3)OCCO4)cc12		CHEMBL3972467	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
356866	17732529	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCC(O)CC3)cc12		CHEMBL3948532	=	IC50	nM	46.0	CHEMBL5251	Homo sapiens	IC50	nM	46.0
356867	17732530	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3959777	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
356868	17732531	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N4CCCC4)CC3)cc12		CHEMBL3911315	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
356869	17732532	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(=O)OCC(=O)N1CC=C(c2cc3c(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)ncnc3[nH]2)CC1		CHEMBL3939270	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
356870	17732533	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)CO)CC3)cc12		CHEMBL3894539	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
356871	17732534	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)CC#N)CC3)cc12		CHEMBL3926072	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
356872	17732535	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B			CHEMBL4115904	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
356873	17732536	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B			CHEMBL4115905	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
356874	17732537	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B			CHEMBL4115906	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
356875	17732538	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(NC(=O)c5ccc(C(C)(C)C)cc5)c4CO)ncnc3[nH]2)CC1		CHEMBL3942924	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
356876	17732539	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ncnc4[nH]c(C5=CCN(C(=O)CF)CC5)cc34)c2CO)cc1		CHEMBL3941531	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
356877	17732540	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)O)cc2F)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3920235	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
356878	17732541	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCNCC3)cc12		CHEMBL3980902	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
356879	17732542	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3904945	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
356880	17732543	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)cc12		CHEMBL3975732	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
356881	17732544	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(S(=O)(=O)N(C)C)CC3)cc12		CHEMBL3971384	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
356882	17732545	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCN(S(C)(=O)=O)CC3)cc12		CHEMBL3896703	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
356883	17732546	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCc6cc(C(C)(C)C)ccc6C5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3948173	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
356884	17732547	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCc6cc(C7CC7)ccc6C5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3890115	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
356885	17732548	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCc6cc(C(C)(C)O)ccc6C5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3984599	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356886	17732549	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ncnc4[nH]c(C5=CCOCC5)cc34)c2CO)cc1		CHEMBL3891532	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
356887	17732550	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCOCC3)cc12		CHEMBL3960567	=	IC50	nM	99.0	CHEMBL5251	Homo sapiens	IC50	nM	99.0
356888	17732551	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(N(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCOCC3)cc12		CHEMBL3977671	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
356889	17732552	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCSCC3)cc12		CHEMBL3903393	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
356890	17732553	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CC[S+]([O-])CC3)cc12		CHEMBL3912276	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
356891	17732554	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCS(=O)(=O)CC3)cc12		CHEMBL3896706	=	IC50	nM	64.0	CHEMBL5251	Homo sapiens	IC50	nM	64.0
356892	17732555	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ncnc4[nH]c(C5=CCC6(CC5)OCCO6)cc34)c2CO)cc1		CHEMBL3921217	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
356893	17732556	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ncnc4[nH]c(C5=CCC(O)CC5)cc34)c2CO)cc1		CHEMBL3920088	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
356894	17732557	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C1CC=C(c2cc3c(-c4cccc(NC(=O)c5ccc(C(C)(C)C)cc5)c4CO)ncnc3[nH]2)CC1		CHEMBL3940129	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356895	17732558	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)N2CC(OC(C)(C)C)C2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3939935	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
356896	17732559	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)N2CC(OC(C)C)C2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3908428	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
356897	17732560	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)N2Cc3ccc(F)cc3C2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3932096	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
356898	17732561	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)N2CC(OC(C(F)(F)F)C(F)(F)F)C2)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3958729	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
356899	17732562	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)N2CC(OC(C)(C)C)C2)cc(F)cc1-c1ncnc2[nH]c(C3=CCOCC3)cc12		CHEMBL3954000	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
356900	17732563	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4ccc(F)c(NC(=O)N5CC(OC(C)(C)C)C5)c4)ncnc3[nH]2)CC1		CHEMBL3929806	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356901	17732564	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(-c2ncnc3[nH]c(C4=CCN(C(=O)N(C)C)CC4)cc23)ccc(F)c1NC(=O)N1CC(OC(C)(C)C)C1		CHEMBL3968367	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
356902	17732565	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCOCC3)cc12		CHEMBL3969286	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
356903	17732566	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCC4(CC3)OCCO4)cc12		CHEMBL3963489	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
356904	17732567	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCC(O)CC3)cc12		CHEMBL3973521	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
356905	17732568	CHEMBL3887838	Biochemical Enzyme Assay: The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO. The kinase reactions were started by stepwise addition of 4.5 ul per well of peptide/ATP-solution (4 uM FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2, 164 uM ATP) in kinase buffer (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 uM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 ul per well of enzyme solution (6.4 nM full-length human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 30° C. for 60 minutes and subsequently terminated by addition of 16 ul per well of stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10 mM EDTA, and 0.015% Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100% inhibition) and without inhibitors (0% inhibition).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(C3=CCC(N(C)C)CC3)cc12		CHEMBL3926464	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
356906	17732569	CHEMBL3887839	Cellular Assay: Alternatively, the present compounds might also be assessed for their capacity to inhibit Btk-dependent FcG receptor-induced IL-8 secretion in human cells. The human myeloid leukemia THP1 cell line (ATCC TIB202) was grown in RPMI 1640 medium supplemented with 10% FCS and 15 nM 1, 25-dihydroxy Vitamin D3 during 4 days before use to induced myeloid differentiation. A sufficient number of tissue-culture grade 384-well plates was coated with human IgG of unknown specificity by incubating overnight at 4° C. with 40 ul/well of a 50 ug/ml IgG solution in PBS. On the day of the experiment, plates were washed 5 times with 80 ul water on a Molecular Devices Aquamax DW4 plate washer. Solutions of the test compounds in 90% DMSO were added to each well on a Hamilton Microlab Star liquid handling station to 40 ul/well tissue culture medium and the total DMSO concentration was adjusted to 0.1%. Differentiated THP1 cells were then added in 40 ul/well to reach a final density of 5'000 cells/well in 80 ul culture medium. After 24 hours, IL-8 secretion was measured in the supernatant by the IL-8 HTRF assay following the protocol of the vendor (CisBio international).	B	Cc1c(NC(=O)c2cc3c(s2)CCC(C)C3)cc(F)cc1-c1ncnc2[nH]c(C3=CCN(C(=O)N(C)C)CC3)cc12		CHEMBL3908775	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
356907	17732570	CHEMBL3887839	Cellular Assay: Alternatively, the present compounds might also be assessed for their capacity to inhibit Btk-dependent FcG receptor-induced IL-8 secretion in human cells. The human myeloid leukemia THP1 cell line (ATCC TIB202) was grown in RPMI 1640 medium supplemented with 10% FCS and 15 nM 1, 25-dihydroxy Vitamin D3 during 4 days before use to induced myeloid differentiation. A sufficient number of tissue-culture grade 384-well plates was coated with human IgG of unknown specificity by incubating overnight at 4° C. with 40 ul/well of a 50 ug/ml IgG solution in PBS. On the day of the experiment, plates were washed 5 times with 80 ul water on a Molecular Devices Aquamax DW4 plate washer. Solutions of the test compounds in 90% DMSO were added to each well on a Hamilton Microlab Star liquid handling station to 40 ul/well tissue culture medium and the total DMSO concentration was adjusted to 0.1%. Differentiated THP1 cells were then added in 40 ul/well to reach a final density of 5'000 cells/well in 80 ul culture medium. After 24 hours, IL-8 secretion was measured in the supernatant by the IL-8 HTRF assay following the protocol of the vendor (CisBio international).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(NC(=O)c5ccc(C(C)(C)O)cc5F)c4CO)ncnc3[nH]2)CC1		CHEMBL3968447	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	nM	69.0
356908	17732571	CHEMBL3887839	Cellular Assay: Alternatively, the present compounds might also be assessed for their capacity to inhibit Btk-dependent FcG receptor-induced IL-8 secretion in human cells. The human myeloid leukemia THP1 cell line (ATCC TIB202) was grown in RPMI 1640 medium supplemented with 10% FCS and 15 nM 1, 25-dihydroxy Vitamin D3 during 4 days before use to induced myeloid differentiation. A sufficient number of tissue-culture grade 384-well plates was coated with human IgG of unknown specificity by incubating overnight at 4° C. with 40 ul/well of a 50 ug/ml IgG solution in PBS. On the day of the experiment, plates were washed 5 times with 80 ul water on a Molecular Devices Aquamax DW4 plate washer. Solutions of the test compounds in 90% DMSO were added to each well on a Hamilton Microlab Star liquid handling station to 40 ul/well tissue culture medium and the total DMSO concentration was adjusted to 0.1%. Differentiated THP1 cells were then added in 40 ul/well to reach a final density of 5'000 cells/well in 80 ul culture medium. After 24 hours, IL-8 secretion was measured in the supernatant by the IL-8 HTRF assay following the protocol of the vendor (CisBio international).	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cc(F)cc1-c1ncnc2[nH]c(C3=CCSCC3)cc12		CHEMBL3982378	=	IC50	nM	94.0	CHEMBL5251	Homo sapiens	IC50	nM	94.0
356909	17732572	CHEMBL3887839	Cellular Assay: Alternatively, the present compounds might also be assessed for their capacity to inhibit Btk-dependent FcG receptor-induced IL-8 secretion in human cells. The human myeloid leukemia THP1 cell line (ATCC TIB202) was grown in RPMI 1640 medium supplemented with 10% FCS and 15 nM 1, 25-dihydroxy Vitamin D3 during 4 days before use to induced myeloid differentiation. A sufficient number of tissue-culture grade 384-well plates was coated with human IgG of unknown specificity by incubating overnight at 4° C. with 40 ul/well of a 50 ug/ml IgG solution in PBS. On the day of the experiment, plates were washed 5 times with 80 ul water on a Molecular Devices Aquamax DW4 plate washer. Solutions of the test compounds in 90% DMSO were added to each well on a Hamilton Microlab Star liquid handling station to 40 ul/well tissue culture medium and the total DMSO concentration was adjusted to 0.1%. Differentiated THP1 cells were then added in 40 ul/well to reach a final density of 5'000 cells/well in 80 ul culture medium. After 24 hours, IL-8 secretion was measured in the supernatant by the IL-8 HTRF assay following the protocol of the vendor (CisBio international).	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ncnc4[nH]c(C5=CCN(C(=O)CF)CC5)cc34)c2CO)cc1		CHEMBL3941531	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
356910	17732573	CHEMBL3887839	Cellular Assay: Alternatively, the present compounds might also be assessed for their capacity to inhibit Btk-dependent FcG receptor-induced IL-8 secretion in human cells. The human myeloid leukemia THP1 cell line (ATCC TIB202) was grown in RPMI 1640 medium supplemented with 10% FCS and 15 nM 1, 25-dihydroxy Vitamin D3 during 4 days before use to induced myeloid differentiation. A sufficient number of tissue-culture grade 384-well plates was coated with human IgG of unknown specificity by incubating overnight at 4° C. with 40 ul/well of a 50 ug/ml IgG solution in PBS. On the day of the experiment, plates were washed 5 times with 80 ul water on a Molecular Devices Aquamax DW4 plate washer. Solutions of the test compounds in 90% DMSO were added to each well on a Hamilton Microlab Star liquid handling station to 40 ul/well tissue culture medium and the total DMSO concentration was adjusted to 0.1%. Differentiated THP1 cells were then added in 40 ul/well to reach a final density of 5'000 cells/well in 80 ul culture medium. After 24 hours, IL-8 secretion was measured in the supernatant by the IL-8 HTRF assay following the protocol of the vendor (CisBio international).	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4ccc(F)c(NC(=O)N5CC(OC(C)(C)C)C5)c4)ncnc3[nH]2)CC1		CHEMBL3929806	=	IC50	nM	71.0	CHEMBL5251	Homo sapiens	IC50	nM	71.0
358152	17733815	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3968928	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358153	17733816	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCNCC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3979851	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358154	17733817	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4cccc(CN5CCNCC5)c4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3913119	=	IC50	nM	515.0	CHEMBL5251	Homo sapiens	IC50	nM	515.0
358155	17733818	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4cccc(CN5CCNCC5)c4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3975009	=	IC50	nM	396.0	CHEMBL5251	Homo sapiens	IC50	nM	396.0
358156	17733819	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3964529	=	IC50	nM	92.0	CHEMBL5251	Homo sapiens	IC50	nM	92.0
358157	17733820	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3966506	=	IC50	nM	143.0	CHEMBL5251	Homo sapiens	IC50	nM	143.0
358158	17733821	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4cccc(CN5CCOCC5)c4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3891638	=	IC50	nM	415.0	CHEMBL5251	Homo sapiens	IC50	nM	415.0
358159	17733822	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4cccc(CN5CCOCC5)c4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3930318	=	IC50	nM	825.0	CHEMBL5251	Homo sapiens	IC50	nM	825.0
358160	17733823	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3921350	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
358161	17733824	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3968928	=	IC50	nM	31.0	CHEMBL5251	Homo sapiens	IC50	nM	31.0
358162	17733825	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3974246	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
358163	17733826	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCc7cc(C8CC8)ccc7C6=O)c5C)ncnc4[nH]3)cc2)CC1		CHEMBL3948209	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
358164	17733827	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)c1CO		CHEMBL3935716	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
358165	17733828	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3907763	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358166	17733829	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3901371	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
358167	17733830	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(-n6ccc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3962290	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358168	17733831	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1-n1ccc2cc(C3CC3)ccc2c1=O		CHEMBL3952062	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
358169	17733832	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(-n6ncc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3980912	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358170	17733833	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCNC(=O)C5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3966597	=	IC50	nM	254.0	CHEMBL5251	Homo sapiens	IC50	nM	254.0
358171	17733834	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCC(C)(O)CC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3903267	=	IC50	nM	115.0	CHEMBL5251	Homo sapiens	IC50	nM	115.0
358172	17733835	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)CC1		CHEMBL3967663	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358173	17733836	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	N#CC1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)CC1		CHEMBL3931607	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358174	17733837	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ccnc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3973003	=	IC50	nM	103.0	CHEMBL5251	Homo sapiens	IC50	nM	103.0
358175	17733838	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)CC1		CHEMBL3976070	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
358176	17733839	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)C1		CHEMBL3927548	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
358177	17733840	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)c(F)c2)CC1		CHEMBL3900430	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
358178	17733841	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ccnc3[nH]c(-c4ccc(CN5CCN(C)CC5)c(F)c4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3949342	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	nM	190.0
358179	17733842	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)CC1		CHEMBL3950770	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358180	17733843	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)CC1		CHEMBL3924327	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
358181	17733844	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCC(O)CC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3973506	=	IC50	nM	32.5	CHEMBL5251	Homo sapiens	IC50	nM	32.5
358182	17733845	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(c2ccc(-c3cc4c(-c5cccc(-n6ccc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3942801	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
358183	17733846	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3968892	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
358184	17733847	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(N5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3958000	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
358185	17733848	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CC=C(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)CC1		CHEMBL3986676	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
358186	17733849	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCOC(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)C1		CHEMBL3956789	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358187	17733850	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cn2)CC1		CHEMBL3891185	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
358188	17733851	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4cnn(C5CCN(C)CC5)c4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3981948	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
358189	17733852	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(n2cc(-c3cc4c(-c5cccc(-n6ccc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cn2)CC1		CHEMBL3953196	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
358190	17733853	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(c2ccc(-c3cc4c(-c5cccc(-n6ccc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3892930	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358191	17733854	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)CC1		CHEMBL3958477	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
358192	17733855	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCCC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cn2)C1		CHEMBL3898339	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
358193	17733856	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)C1		CHEMBL3969541	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
358194	17733857	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(C)N1CC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)C1		CHEMBL3977803	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
358195	17733858	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(n2cc(-c3cc4c(-c5cccc(-n6ncc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cn2)CC1		CHEMBL3952007	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358196	17733859	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)C1		CHEMBL3891695	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358197	17733860	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)CC1		CHEMBL3930057	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
358198	17733861	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(C)N1CC(Oc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)C1		CHEMBL3976332	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
358199	17733862	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCC(n2cc(-c3cc4c(-c5cccc(-n6ncc7cc(C8CC8)ccc7c6=O)c5CO)ncnc4[nH]3)cn2)CC1		CHEMBL3905596	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358200	17733863	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4cnn(C5CCN(C6COC6)CC5)c4)cc23)c1CO		CHEMBL3959033	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
358201	17733864	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1nn(C2CN(C)C2)cc1-c1cc2c(-c3cccc(N4CCOc5cc(C6CC6)ccc5C4=O)c3CO)ccnc2[nH]1		CHEMBL3921994	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
358202	17733865	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4cnn(C5COC5)c4)cc23)c1CO		CHEMBL3960244	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358203	17733866	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4cnn(C5CCOCC5)c4)cc23)c1CO		CHEMBL3891177	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
358204	17733867	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CCC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)CC1		CHEMBL3967820	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
358205	17733868	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(Oc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3900184	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358206	17733869	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CC(Oc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)C1		CHEMBL3962146	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
358207	17733870	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C5CCN(CCO)CC5)cc4)cc23)cccc1-n1ccc2cc(C3CC3)ccc2c1=O		CHEMBL3904110	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
358208	17733871	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3922230	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
358209	17733872	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3928203	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
358210	17733873	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cnc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3983770	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	nM	35.0
358211	17733874	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3906723	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358212	17733875	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(C6CC6)CC5)cn4)cc23)c1CO		CHEMBL3957625	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358213	17733876	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CS(=O)(=O)N1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3958922	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
358214	17733877	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(C)N1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3963720	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358215	17733878	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCS(=O)(=O)CC5)cn4)cc23)c1CO		CHEMBL3971512	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
358216	17733879	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(CC(F)(F)F)CC5)cn4)cc23)c1CO		CHEMBL3984930	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
358217	17733880	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(S(=O)(=O)C6CC6)CC5)cn4)cc23)c1CO		CHEMBL3904399	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358218	17733881	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN(C)C(=O)N1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3940945	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358219	17733882	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3967108	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358220	17733883	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(C6COC6)CC5)cn4)cc23)c1CO		CHEMBL3928390	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358221	17733884	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1CN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC(C)N1C		CHEMBL3955997	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
358222	17733885	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1=O		CHEMBL3919488	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
358223	17733886	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(CC(F)(F)F)CC5)cn4)cc23)c1CO		CHEMBL3950703	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
358224	17733887	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(CN4CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3941978	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
358225	17733888	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(CC(F)(F)F)CC5)cn4)cc23)c1CO		CHEMBL3904999	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
358226	17733889	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(-c4ccc(CN5CCN(CC(F)F)CC5)cn4)cc23)c1CO		CHEMBL3929445	=	IC50	nM	0.65	CHEMBL5251	Homo sapiens	IC50	nM	0.65
358227	17733890	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(-c4ccc(CN5CCOCC5)cn4)cc23)c1CO		CHEMBL3967515	=	IC50	nM	0.55	CHEMBL5251	Homo sapiens	IC50	nM	0.55
358228	17733891	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCC(F)(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3937906	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
358229	17733892	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCCC(F)(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)C1		CHEMBL3965546	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
358230	17733893	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3950134	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
358231	17733894	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCC(O)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3951173	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
358232	17733895	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCCC(O)C5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3923452	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	nM	42.0
358233	17733896	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCC(C)(O)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3959907	=	IC50	nM	51.0	CHEMBL5251	Homo sapiens	IC50	nM	51.0
358234	17733897	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCCCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3928872	=	IC50	nM	171.0	CHEMBL5251	Homo sapiens	IC50	nM	171.0
358235	17733898	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCNCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3957615	=	IC50	nM	9.7	CHEMBL5251	Homo sapiens	IC50	nM	9.7
358236	17733899	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)NCC(F)(F)F)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3930105	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358237	17733900	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CC(O)C5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3983885	=	IC50	nM	360.0	CHEMBL5251	Homo sapiens	IC50	nM	360.0
358238	17733901	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3914067	=	IC50	nM	137.0	CHEMBL5251	Homo sapiens	IC50	nM	137.0
358239	17733902	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	COC1CCN(C(=O)c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5C)ncnc4[nH]3)cc2)CC1		CHEMBL3958033	=	IC50	nM	233.0	CHEMBL5251	Homo sapiens	IC50	nM	233.0
358240	17733903	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	COC1CN(C(=O)c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5C)ncnc4[nH]3)cc2)C1		CHEMBL3895833	=	IC50	nM	162.0	CHEMBL5251	Homo sapiens	IC50	nM	162.0
358241	17733904	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCCC5C(=O)O)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3900513	=	IC50	nM	114.0	CHEMBL5251	Homo sapiens	IC50	nM	114.0
358242	17733905	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCCCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3928872	=	IC50	nM	133.0	CHEMBL5251	Homo sapiens	IC50	nM	133.0
358243	17733906	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCCCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3928872	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358244	17733907	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCOCC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3937490	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	nM	130.0
358245	17733908	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCC(O)CC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3987117	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
358246	17733909	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CC(O)C5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3926871	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
358247	17733910	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCN(C)CC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3949596	=	IC50	nM	208.0	CHEMBL5251	Homo sapiens	IC50	nM	208.0
358248	17733911	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCNCC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3940111	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
358249	17733912	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCC(O)CC5)cc4)cc23)cccc1-n1ncc2cc(C3CC3)ccc2c1=O		CHEMBL3895937	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
358250	17733913	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(C(=O)N5CCN(C)CC5)cc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3949596	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358251	17733914	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	NC(=O)c1ccc(-c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)ccc6C5=O)c4CO)ccnc3[nH]2)nc1		CHEMBL3949916	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358252	17733915	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CCN(C(=O)c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3918651	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
358253	17733916	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CCN(C(=O)c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cc2)CC1		CHEMBL3929529	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
358254	17733917	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CCN(C(=O)c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3913167	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
358255	17733918	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CN(C(=O)c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)C1		CHEMBL3898737	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
358256	17733919	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccccc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3946872	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358257	17733920	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccccc4)cc23)cccc1N1CCc2cc(C3CC3)ccc2C1=O		CHEMBL3958502	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358258	17733921	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(N5CCOCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3968916	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358259	17733922	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2nc(N)nc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3958017	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
358260	17733923	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2nc(N)nc3[nH]c(-c4ccc(N5CCOCC5)nc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3984106	=	IC50	nM	181.0	CHEMBL5251	Homo sapiens	IC50	nM	181.0
358261	17733924	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2nc(N)nc3[nH]c(-c4ccc(C(=O)N5CCOCC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3906165	=	IC50	nM	55.0	CHEMBL5251	Homo sapiens	IC50	nM	55.0
358262	17733925	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(C4=CCN(CCO)CC4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3982192	=	IC50	nM	272.0	CHEMBL5251	Homo sapiens	IC50	nM	272.0
358263	17733926	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(C4=CCN(CCO)CC4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3982192	=	IC50	nM	611.0	CHEMBL5251	Homo sapiens	IC50	nM	611.0
358264	17733927	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(C4CCN(CCCO)CC4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3901691	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358265	17733928	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	Cc1c(-c2ncnc3[nH]c(C4=CCCNC4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3928043	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
358266	17733929	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)ccc6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3959052	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
358267	17733930	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5)c(C#N)cnc4[nH]3)cc2)CC1		CHEMBL3896189	=	IC50	nM	82.0	CHEMBL5251	Homo sapiens	IC50	nM	82.0
358268	17733931	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C(O)c1ccc(-c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)ccc6C5=O)c4CO)ccnc3[nH]2)nc1		CHEMBL3967425	=	IC50	nM	46.0	CHEMBL5251	Homo sapiens	IC50	nM	46.0
358269	17733932	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(C(O)CO)cc4)cc23)c1CO		CHEMBL3894094	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
358270	17733933	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(C)N1CC(n2cnc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)c2)C1		CHEMBL3957182	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
358271	17733934	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C(C)(C)O)ccc6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3980662	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
358272	17733935	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3891434	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
358273	17733936	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3966346	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
358274	17733937	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C(N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1)N1CCC1		CHEMBL3957396	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
358275	17733938	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3936823	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
358276	17733939	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC1(O)CN(C(=O)N2CC=C(c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)CC2)C1		CHEMBL3982806	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
358277	17733940	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3954122	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
358278	17733941	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3962739	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
358279	17733942	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C(N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1)N1CCOCC1		CHEMBL3921953	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
358280	17733943	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN(CC)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3970328	=	IC50	nM	14.6	CHEMBL5251	Homo sapiens	IC50	nM	14.6
358281	17733944	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(C)(O)CN1CC=C(c2cc3c(-c4cc(F)cc(N5CCOc6cc(C7CC7)ccc6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3940779	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
358282	17733945	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5CCOC5)CC4)cc23)c1CO		CHEMBL3978618	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
358283	17733946	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C(CN1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1)N1CCC1		CHEMBL3952971	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
358284	17733947	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(C)(O)CN1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3946460	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
358285	17733948	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3968064	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
358286	17733949	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1nccc(-c2ccnc3[nH]c(C4=CCNCC4)cc23)c1CO		CHEMBL3948372	=	IC50	nM	618.0	CHEMBL5251	Homo sapiens	IC50	nM	618.0
358287	17733950	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5CCOCC5)CC4)cc23)c1CO		CHEMBL3951652	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
358288	17733951	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	N#CCC(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)ccc6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3943034	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
358289	17733952	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C(CN1CCC1)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3972631	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
358290	17733953	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(O)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3911350	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
358291	17733954	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C(CO)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3967939	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
358292	17733955	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	NC(=O)CC1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3929335	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
358293	17733956	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(OCCN5CCOCC5)cn4)cc23)c1CO		CHEMBL3912688	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
358294	17733957	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4ccc(OCCN5CCC5)cn4)cc23)c1CO		CHEMBL3944128	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
358295	17733958	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cc(F)cc(-c2ccnc3[nH]c(-c4ccc(OC5CCN(C6COC6)CC5)cn4)cc23)c1CO		CHEMBL3918358	=	IC50	nM	1.15	CHEMBL5251	Homo sapiens	IC50	nM	1.15
358296	17733959	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CC(=O)N1CC(N2CC=C(c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)CC2)C1		CHEMBL3909430	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
358297	17733960	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CC(N2CC=C(c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)CC2)C1		CHEMBL3979659	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
358298	17733961	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3960361	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
358299	17733962	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CC(N2CC=C(c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)CC2)C1		CHEMBL3936413	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
358300	17733963	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CCN1CC(C(=O)N2CC=C(c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)CC2)C1		CHEMBL3923814	=	IC50	nM	0.75	CHEMBL5251	Homo sapiens	IC50	nM	0.75
358301	17733964	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	C=CC(=O)N1CCCC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ncnc4[nH]3)cn2)C1		CHEMBL3895812	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
358302	17733965	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	N#CCN1CC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)cn2)C1		CHEMBL3982709	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
358303	17733966	CHEMBL3887851	Recombinant Human BTK Inhibition Assay: The inhibition assays were performed using the generic tyrosine kinase assay kit from C is Bio (HTRF KinEASE-TK #62TK0PEB). The assay is based on the principle of fluorescence resonance energy transfer (FRET) between the Europium Cryptate labeled anti-phosphotyrosine antibody and streptavidin labeled fluorophore, XL-665. In an uninhibited kinase reaction the biotinylated peptide substrate (Tk-Biotin) gets phosphorylated at an intermediate tyrosine site which is captured by anti-phosphotyrosine antibody which eventually acts as a FRET donor. The streptavidin labeled XL-665 binds strongly to the Tk-Biotin substrate and act as a FRET acceptor. The resultant FRET signal is measured at 665 nm. A ratio of this specific fluorescence (665 nm) to the background fluorescence (620 nm), conferred by the free antibody, is directly proportional to the kinase activity. Inhibition of the kinase activity by a pharmacological intervention such as a Btk inhibitor of the present disclosure will result into decreased FRET signal.	B	CN1CCN(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3963872	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
363325	17738700	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)cccc1N1Cc2cc(C(C)(C)C)ccc2C1=O		CHEMBL3972734	=	IC50	nM	36.4	CHEMBL5251	Homo sapiens	IC50	nM	36.4
363326	17738701	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4NCCN(C)C4=O)cc3)n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3901657	=	IC50	nM	11.5	CHEMBL5251	Homo sapiens	IC50	nM	11.5
363327	17738702	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)NCCN4C)cc3)n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3924953	=	IC50	nM	95.0	CHEMBL5251	Homo sapiens	IC50	nM	95.0
363328	17738703	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)cccc1N1Cc2cc(C(C)(C)C)ccc2C1=O		CHEMBL3910685	=	IC50	nM	29.4	CHEMBL5251	Homo sapiens	IC50	nM	29.4
363329	17738704	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	CN1CCN(C)[C@@H](c2ccc(Nc3nc(-c4ccc(F)c(N5Cc6cc(C(C)(C)C)sc6C5=O)c4F)cn(C)c3=O)cc2)C1=O		CHEMBL3928675	=	IC50	nM	33.7	CHEMBL5251	Homo sapiens	IC50	nM	33.7
363330	17738705	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	CN1CCN(C)[C@@H](c2ccc(Nc3nc(-c4ccc(F)c(N5Cc6cc(C(C)(C)C)sc6C5=O)c4)cn(C)c3=O)cc2)C1=O		CHEMBL3891597	=	IC50	nM	47.4	CHEMBL5251	Homo sapiens	IC50	nM	47.4
363331	17738706	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)NCCN4C)cc3)n2)cccc1N1Cc2cc(C(C)(C)C)sc2C1=O		CHEMBL3924953	=	IC50	nM	24.7	CHEMBL5251	Homo sapiens	IC50	nM	24.7
363332	17738707	CHEMBL3887917	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 μM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 μM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector for making baculovirus carrying this epitope-tagged Btk.	B	Cc1c(-c2cn(C)c(=O)c(Nc3ccc(C4C(=O)N(C)CCN4C)cc3)n2)cccc1N1Cc2cc(N3CCCCC3)ccc2C1=O		CHEMBL3967362	=	IC50	nM	245.0	CHEMBL5251	Homo sapiens	IC50	nM	245.0
365176	17740221	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)NCCOc1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3913800	=	Ki	nM	0.792	CHEMBL5251	Homo sapiens	Ki	nM	0.792
365177	17740222	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccnc(N3CCC(C(=O)NCC#N)C3)n2)c1=O		CHEMBL3986379	=	Ki	nM	0.864	CHEMBL5251	Homo sapiens	Ki	nM	0.864
365178	17740223	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)NCCOc1cccc(Nc2cc(-c3ccnc(-n4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c3CO)cn(C)c2=O)n1		CHEMBL3954850	=	Ki	nM	0.915	CHEMBL5251	Homo sapiens	Ki	nM	0.915
365179	17740224	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)NCCNc1cccc(Nc2cc(-c3cc(F)cc(-n4ncc5c6c(sc5c4=O)CCCC6)c3CO)cn(C)c2=O)n1		CHEMBL3899326	=	Ki	nM	0.248	CHEMBL5251	Homo sapiens	Ki	nM	0.248
365180	17740225	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	CC#CC(=O)NCCOc1cccc(Nc2cc(-c3cc(F)cc(-n4ncc5c6c(sc5c4=O)CCCC6)c3CO)cn(C)c2=O)n1		CHEMBL3967132	=	Ki	nM	0.306	CHEMBL5251	Homo sapiens	Ki	nM	0.306
365181	17740226	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)N[C@@H](C)COc1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3890374	=	Ki	nM	0.612	CHEMBL5251	Homo sapiens	Ki	nM	0.612
365182	17740227	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)N[C@@H](C)COc1cccc(Nc2cc(-c3cc(F)cc(-n4ncc5c6c(sc5c4=O)CCCC6)c3CO)cn(C)c2=O)n1		CHEMBL3959446	=	Ki	nM	2.57	CHEMBL5251	Homo sapiens	Ki	nM	2.57
365183	17740228	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)NCCNc1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3917719	=	Ki	nM	4.33	CHEMBL5251	Homo sapiens	Ki	nM	4.33
365184	17740229	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)NCCN(C)c1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3950730	=	Ki	nM	0.683	CHEMBL5251	Homo sapiens	Ki	nM	0.683
365185	17740230	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)NCCN(C)c1cccc(Nc2cc(-c3cc(F)cc(-n4ncc5c6c(sc5c4=O)CCCC6)c3CO)cn(C)c2=O)n1		CHEMBL3966856	=	Ki	nM	0.494	CHEMBL5251	Homo sapiens	Ki	nM	0.494
365186	17740231	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)N(C)CCOc1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3904869	=	Ki	nM	1.75	CHEMBL5251	Homo sapiens	Ki	nM	1.75
365187	17740232	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)N(C)CCOc1cccc(Nc2cc(-c3cc(F)cc(-n4ncc5c6c(sc5c4=O)CCCC6)c3CO)cn(C)c2=O)n1		CHEMBL3981261	=	Ki	nM	0.146	CHEMBL5251	Homo sapiens	Ki	nM	0.146
365188	17740233	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)N[C@H]1CCCN(c2cccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)n2)C1		CHEMBL3911251	=	Ki	nM	0.888	CHEMBL5251	Homo sapiens	Ki	nM	0.888
365189	17740234	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=CC(=O)N[C@H]1CCCN(c2cccc(Nc3cc(-c4cc(F)cc(-n5ncc6c7c(sc6c5=O)CCCC7)c4CO)cn(C)c3=O)n2)C1		CHEMBL3973265	=	Ki	nM	2.16	CHEMBL5251	Homo sapiens	Ki	nM	2.16
365190	17740235	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	CC#CC(=O)NCCOc1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3905684	=	Ki	nM	2.37	CHEMBL5251	Homo sapiens	Ki	nM	2.37
365191	17740236	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=C(C#N)C(=O)NCCOc1cccc(Nc2cc(-c3cc(F)cc(-n4ncc5c6c(sc5c4=O)CCCC6)c3CO)cn(C)c2=O)n1		CHEMBL3967905	=	Ki	nM	0.576	CHEMBL5251	Homo sapiens	Ki	nM	0.576
365192	17740237	CHEMBL3887975	Biochemical Btk Assay: A generalized procedure for a standard biochemical Btk, Kinase Assay that can be used to test Formula I compounds is as follows. A master mix minus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2), 0.5 uM Promega PTK Biotinylated peptide substrate 2, and 0.01% BSA. A master mix plus Btk enzyme is prepared containing 1x Cell Signaling kinase buffer, 0.5 uM PTK Biotinylated peptide substrate 2, 0.01% BSA, and 100 ng/well (0.06 mU/well) Btk enzyme. Btk enzyme is prepared as follows: full length human wildtype Btk (accession number NM-000061) with a C-terminal V5 and 6xHis tag was subcloned into pFastBac vector (Invitrogen/Life Technologies) for making baculovirus carrying this epitope-tagged Btk.	B	C=C(C#N)C(=O)NCCOc1cccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)n1		CHEMBL3896744	=	Ki	nM	1.7	CHEMBL5251	Homo sapiens	Ki	nM	1.7
369500	17744366	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC1(/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)COC1		CHEMBL3702827	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
369501	17744367	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCC1		CHEMBL3702828	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
369502	17744368	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)CO		CHEMBL3702829	=	IC50	nM	8.1	CHEMBL5251	Homo sapiens	IC50	nM	8.1
369503	17744369	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	[C-]#[N+]/C(=C\C(C)(C)N1CCN(C)CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3702830	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
369504	17744370	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCCC1		CHEMBL3702831	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
369505	17744371	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	[C-]#[N+]/C(=C\C(C)(C)N1CCNCC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3702832	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
369506	17744372	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CC(O)C1		CHEMBL3702833	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
369507	17744373	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H]2Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)CC1		CHEMBL3702834	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
369508	17744374	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@H]2Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)CC1		CHEMBL3702859	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
369509	17744375	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCNCC1		CHEMBL3702835	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
369510	17744376	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3702836	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
369511	17744377	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC1COC1		CHEMBL3702837	=	IC50	nM	16.1	CHEMBL5251	Homo sapiens	IC50	nM	16.1
369512	17744378	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)/C=C(\C#N)C(=O)N1CCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3702838	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
369513	17744379	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3702839	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
369514	17744380	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3702840	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
369515	17744381	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N(C1CC1)C1COC1		CHEMBL3702841	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
369516	17744382	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)/C=C(\C#N)C(=O)N1CC(Cn2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1		CHEMBL3702842	=	IC50	nM	20.4	CHEMBL5251	Homo sapiens	IC50	nM	20.4
369517	17744383	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCOCC1		CHEMBL3702843	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
369518	17744384	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCC(O)CC1		CHEMBL3702844	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
369519	17744385	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CC2(COC2)C1		CHEMBL3702845	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
369520	17744386	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CC2(COC2)C1		CHEMBL3702846	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	nM	5.6
369521	17744387	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3702847	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
369522	17744388	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3702848	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
369523	17744389	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(C)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3702849	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
369524	17744390	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	COCCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3702850	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
369525	17744391	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1=O		CHEMBL3702851	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
369526	17744392	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(S(C)(=O)=O)CC1		CHEMBL3702852	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
369527	17744393	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)CN1CCOCC1		CHEMBL3702853	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
369528	17744394	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1		CHEMBL3702854	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
369529	17744395	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(=O)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3702855	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
369530	17744396	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	COC(=O)N1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3702856	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
369531	17744397	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CCN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1=O		CHEMBL3702857	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
369532	17744398	CHEMBL3888040	Caliper-Based Kinase Assay: A Caliper-based kinase assay (Caliper Life Sciences, Hopkinton, Mass.) was used to measure inhibition of Btk kinase activity of a compound of the present disclosure. Serial dilutions of test compounds were incubated with human recombinant Btk (0.5 nM), ATP (16 μM) and a phosphoacceptor peptide substrate FAM-GEEPLYWSFPAKKK-NH2 (1 μM) at room temperature for 3 h. The reaction was then terminated with EDTA, final concentration 20 mM and the phosphorylated reaction product was quantified on a Caliper Desktop Profiler (Caliper LabChip 3000).	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCNC(=O)C1		CHEMBL3702858	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
377108	17751169	CHEMBL3888171	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 uM ATP, and 20 uM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes. The reagent stopped the kinase reaction and depleted the unconsumed ATP. Kinase Detection reagent (10 mL; Promega Corporation) was then added to each well. The Kinase Detection reagent comprises reagents to convert ADP to ATP and provide luciferase and luciferin to detect ATP. Luminescence was measured on an EnVision microplate reader (PerkinElmer). The amount of luminescence from each reaction is directly correlated with BTK kinase activity. Percent inhibition and IC50 values were calculated by comparing enzyme activity in drug-treated wells to the appropriate controls.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)c(O)c3)ncc2Cl)c1		CHEMBL3940287	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
377109	17751170	CHEMBL3888171	ADP Generation Assay: The primary assay for compound inhibitory activity was the ADP generation assay described herein. Test compounds were diluted to desired concentrations in kinase reaction buffer and briefly incubated with recombinant full-length human BTK kinase with a (His)6 tag (81.3 kDa; Invitrogen Corporation, Carlsbad, Calif.). The assay as described is based on volumes used in a standard 384 well format using solid, white-wall plates. The reaction was subsequently initiated by the addition of ATP and myelin basic protein (MBP) substrate (Millipore Corporation, Waltham, Mass.). Composition of the assay reaction mixture (5 mL volume) was: 5% v/v DMSO, 60 nM BTK, 1.6 uM ATP, and 20 uM MBP substrate. After incubation at room temperature for 60 min, 5 mL of the ADP-Glo reagent (Promega Corporation, Madison, Wis.) was added to each well and incubated for an additional 40 minutes. The reagent stopped the kinase reaction and depleted the unconsumed ATP. Kinase Detection reagent (10 mL; Promega Corporation) was then added to each well. The Kinase Detection reagent comprises reagents to convert ADP to ATP and provide luciferase and luciferin to detect ATP. Luminescence was measured on an EnVision microplate reader (PerkinElmer). The amount of luminescence from each reaction is directly correlated with BTK kinase activity. Percent inhibition and IC50 values were calculated by comparing enzyme activity in drug-treated wells to the appropriate controls.	B	C=CC(=O)Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)c(OP(=O)(OC(C)C)OC(C)C)c3)ncc2Cl)c1		CHEMBL3907789	=	IC50	nM	3580.0	CHEMBL5251	Homo sapiens	IC50	nM	3580.0
384993	17758415	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
385014	17758436	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647967	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
385035	17758457	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
385036	17758458	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647970	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
385037	17758459	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1)CCO		CHEMBL3931858	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
385038	17758460	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/c2c[nH]cn2)C1		CHEMBL3926657	=	IC50	nM	22.2	CHEMBL5251	Homo sapiens	IC50	nM	22.2
385039	17758461	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL3902180	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	nM	5.6
385040	17758462	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647973	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
385041	17758463	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3917698	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
385042	17758464	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3889694	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
385043	17758465	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3647967	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
385044	17758466	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N[C@H]1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3912266	=	IC50	nM	1.31	CHEMBL5251	Homo sapiens	IC50	nM	1.31
385045	17758467	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Cc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C[C@H]1CCCN1C(=O)/C=C/CN(C)C		CHEMBL4107818	=	IC50	nM	0.92	CHEMBL5251	Homo sapiens	IC50	nM	0.92
385046	17758468	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3903249	=	IC50	nM	1.33	CHEMBL5251	Homo sapiens	IC50	nM	1.33
385047	17758469	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3910496	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
385048	17758470	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3910496	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
385049	17758471	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3905432	=	IC50	nM	4.16	CHEMBL5251	Homo sapiens	IC50	nM	4.16
385050	17758472	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3905432	=	IC50	nM	3.14	CHEMBL5251	Homo sapiens	IC50	nM	3.14
385051	17758473	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3929922	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
385052	17758474	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CN(C)C/C=C/C(=O)NC1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3980550	=	IC50	nM	1.38	CHEMBL5251	Homo sapiens	IC50	nM	1.38
385053	17758475	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3921017	=	IC50	nM	1.58	CHEMBL5251	Homo sapiens	IC50	nM	1.58
385054	17758476	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCN(C(=O)/C=C/CN2CCOCC2)CC1		CHEMBL3982014	=	IC50	nM	4.07	CHEMBL5251	Homo sapiens	IC50	nM	4.07
385055	17758477	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C[C@@H]1CCCN1C(=O)/C=C/CN1CCOCC1		CHEMBL3915538	=	IC50	nM	4.15	CHEMBL5251	Homo sapiens	IC50	nM	4.15
385056	17758478	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	CC#CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL3921655	=	IC50	nM	1.57	CHEMBL5251	Homo sapiens	IC50	nM	1.57
385057	17758479	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	C=CC(=O)NCCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21		CHEMBL3894938	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
385058	17758480	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL3968716	=	IC50	nM	0.89	CHEMBL5251	Homo sapiens	IC50	nM	0.89
385059	17758481	CHEMBL3888236	In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H]1CC[C@@H](NC(=O)/C=C/CN2CCOCC2)CC1		CHEMBL3894102	=	IC50	nM	3.48	CHEMBL5251	Homo sapiens	IC50	nM	3.48
401936	17768460	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
401937	17768461	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
401938	17768462	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2ccccc2n(C)c1=O		CHEMBL3974859	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
401939	17768463	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(C)c2n(C)c1=O		CHEMBL3903970	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
401940	17768464	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	COc1ccc2c(=O)n(-c3cccc(-c4c(Cl)cc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)n(C)c2c1		CHEMBL3939795	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
401941	17768465	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	COc1ccc2c(=O)n(-c3cccc(-c4c(Cl)cc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)n(C)c2c1		CHEMBL3939795	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
401942	17768466	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	COc1cccc2c(=O)n(-c3cccc(-c4c(Cl)cc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)n(C)c12		CHEMBL3895530	=	IC50	nM	0.81	CHEMBL5251	Homo sapiens	IC50	nM	0.81
401943	17768467	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cc(F)ccc2n(C)c1=O		CHEMBL3918568	=	IC50	nM	0.65	CHEMBL5251	Homo sapiens	IC50	nM	0.65
401944	17768468	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2ccc(F)cc2n(C)c1=O		CHEMBL3946439	=	IC50	nM	0.62	CHEMBL5251	Homo sapiens	IC50	nM	0.62
401945	17768469	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O		CHEMBL3943055	=	IC50	nM	0.83	CHEMBL5251	Homo sapiens	IC50	nM	0.83
401946	17768470	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
401947	17768471	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3936249	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
401948	17768472	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3936156	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
401949	17768473	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3936156	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
401950	17768474	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(C#N)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3899411	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
401951	17768475	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(C#N)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3899411	=	IC50	nM	0.27	CHEMBL5251	Homo sapiens	IC50	nM	0.27
401952	17768476	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	0.59	CHEMBL5251	Homo sapiens	IC50	nM	0.59
401953	17768477	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	0.65	CHEMBL5251	Homo sapiens	IC50	nM	0.65
401954	17768478	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
401955	17768479	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3907348	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
401956	17768480	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3907348	=	IC50	nM	0.48	CHEMBL5251	Homo sapiens	IC50	nM	0.48
401957	17768481	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3907348	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
401958	17768482	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O		CHEMBL3913962	=	IC50	nM	0.44	CHEMBL5251	Homo sapiens	IC50	nM	0.44
401959	17768483	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)ccn(-c2ccc(F)cc2)c1=O		CHEMBL3913962	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
401960	17768484	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3897349	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
401961	17768485	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3897349	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
401962	17768486	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
401963	17768487	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3900554	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
401964	17768488	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1cc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2c(=O)c3cccc(F)c3n(C)c2=O)c1C		CHEMBL3931086	=	IC50	nM	0.66	CHEMBL5251	Homo sapiens	IC50	nM	0.66
401965	17768489	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
401966	17768490	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
401967	17768491	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	0.55	CHEMBL5251	Homo sapiens	IC50	nM	0.55
401968	17768492	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
401969	17768493	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3944101	=	IC50	nM	0.85	CHEMBL5251	Homo sapiens	IC50	nM	0.85
401970	17768494	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3944101	=	IC50	nM	0.25	CHEMBL5251	Homo sapiens	IC50	nM	0.25
401971	17768495	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3944101	=	IC50	nM	0.28	CHEMBL5251	Homo sapiens	IC50	nM	0.28
401972	17768496	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	COc1cccn2c(=O)n(-c3cccc(-c4c(Cl)cc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc12		CHEMBL3891767	=	IC50	nM	0.91	CHEMBL5251	Homo sapiens	IC50	nM	0.91
401973	17768497	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2sccn2c1=O		CHEMBL3917869	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
401974	17768498	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2sccn2c1=O		CHEMBL3917869	=	IC50	nM	0.31	CHEMBL5251	Homo sapiens	IC50	nM	0.31
401975	17768499	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3923822	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
401976	17768500	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3923822	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
401977	17768501	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(Cl)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2ccccc21		CHEMBL3954590	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
401978	17768502	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(Cl)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2ccccc21		CHEMBL3954590	=	IC50	nM	0.47	CHEMBL5251	Homo sapiens	IC50	nM	0.47
401979	17768503	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(Cl)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2cccc(F)c21		CHEMBL3903416	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
401980	17768504	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(Cl)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2cccc(F)c21		CHEMBL3903416	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
401981	17768505	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(F)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2cccc(F)c21		CHEMBL3912426	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
401982	17768506	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)cc(Cl)c(-c3cccc(-n4c(=O)[nH]c5c(F)cccc5c4=O)c3Cl)c12		CHEMBL3960384	=	IC50	nM	0.35	CHEMBL5251	Homo sapiens	IC50	nM	0.35
401983	17768507	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O		CHEMBL3943055	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
401984	17768508	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O		CHEMBL3894000	=	IC50	nM	0.77	CHEMBL5251	Homo sapiens	IC50	nM	0.77
401985	17768509	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O		CHEMBL3894000	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
401986	17768510	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2cc(F)ccc2c1=O		CHEMBL3945518	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
401987	17768511	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	0.48	CHEMBL5251	Homo sapiens	IC50	nM	0.48
401988	17768512	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(Cl)cccc2c1=O		CHEMBL3908440	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
401989	17768513	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(Cl)cccc2c1=O		CHEMBL3908440	=	IC50	nM	0.35	CHEMBL5251	Homo sapiens	IC50	nM	0.35
401990	17768514	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3945408	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
401991	17768515	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3945408	=	IC50	nM	0.62	CHEMBL5251	Homo sapiens	IC50	nM	0.62
401992	17768516	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O		CHEMBL3910427	=	IC50	nM	0.25	CHEMBL5251	Homo sapiens	IC50	nM	0.25
401993	17768517	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cc(F)cc(F)c2n(C)c1=O		CHEMBL3951540	=	IC50	nM	0.84	CHEMBL5251	Homo sapiens	IC50	nM	0.84
401994	17768518	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL3929953	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
401995	17768519	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(F)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2cccc(F)c21		CHEMBL3912426	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
401996	17768520	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(F)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2cccc(F)c21		CHEMBL3912426	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
401997	17768521	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cn1c(=O)n(-c2cccc(-c3c(F)cc(C(N)=O)c4[nH]c5cc(C(C)(C)O)ccc5c34)c2Cl)c(=O)c2cccc(F)c21		CHEMBL3912426	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
401998	17768522	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)[nH]c2c(Cl)cccc2c1=O		CHEMBL3955854	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
401999	17768523	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3984475	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
402000	17768524	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3984475	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
402001	17768525	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1cc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2c(=O)[nH]c3c(F)cccc3c2=O)c1Cl		CHEMBL3987197	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
402002	17768526	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O		CHEMBL4114536	=	IC50	nM	0.49	CHEMBL5251	Homo sapiens	IC50	nM	0.49
402003	17768527	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3901137	=	IC50	nM	0.56	CHEMBL5251	Homo sapiens	IC50	nM	0.56
402004	17768528	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3901137	=	IC50	nM	0.84	CHEMBL5251	Homo sapiens	IC50	nM	0.84
402005	17768529	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(CCO)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL3959154	=	IC50	nM	0.59	CHEMBL5251	Homo sapiens	IC50	nM	0.59
402006	17768530	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1cc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2c(=O)cc3c(Cl)cccn3c2=O)c1C		CHEMBL3932965	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
402007	17768531	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(C#N)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3965224	=	IC50	nM	0.49	CHEMBL5251	Homo sapiens	IC50	nM	0.49
402008	17768532	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O		CHEMBL3894000	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
402009	17768533	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3896019	=	IC50	nM	0.79	CHEMBL5251	Homo sapiens	IC50	nM	0.79
402010	17768534	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
402011	17768535	CHEMBL3888436	Btk Enzyme Assay: To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 0.015% Brij 35 surfactant and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LABCHIP® 3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of the fluorescent substrate and phosphorylated product.	B	Cc1nc(C(N)=O)c2[nH]c3cc(C(C)(C)O)ccc3c2c1-c1cccc(-n2cnc3ccccc3c2=O)c1C		CHEMBL3973901	=	IC50	nM	6.9	CHEMBL5251	Homo sapiens	IC50	nM	6.9
402966	17769537	CHEMBL3888459	Kinase-Glo Plus Luminescence Kinase Assay: Method B conducts the kinase assay with the following condition and procedure: The assay was performed using Kinase-Glo Plus luminescence kinase assay kit (Promega). It measures kinase activity by quantitating the amount of ATP remaining in solution following a kinase reaction. The luminescent signal from the assay is correlated with the amount of ATP present and is inversely correlated with the amount of kinase activity. The compounds were diluted in 10% DMSO and 5 μl of the dilution was added to a 50 μl reaction so that the final concentration of DMSO is 1% in all of reactions. All of the enzymatic reactions were conducted at 30° C. for 40 minutes. The 50 μl reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/ml BSA, 1 mM DTT, 0.2 mg/ml substrate peptide, 10 μM ATP and BTK. After the enzymatic reaction, 50 μl of Kinase-Glo Plus Luminescence kinase assay solution (Promega) was added to each reaction and incubate the plate for 5 minutes at room temperature. Luminescence signal was measured using a BioTek Synergy 2 microplate reader. Btk activity assays were performed in duplicate at each concentration.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(Oc4ccccc4)cc3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL3925401	<	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
402967	17769538	CHEMBL3888459	Kinase-Glo Plus Luminescence Kinase Assay: Method B conducts the kinase assay with the following condition and procedure: The assay was performed using Kinase-Glo Plus luminescence kinase assay kit (Promega). It measures kinase activity by quantitating the amount of ATP remaining in solution following a kinase reaction. The luminescent signal from the assay is correlated with the amount of ATP present and is inversely correlated with the amount of kinase activity. The compounds were diluted in 10% DMSO and 5 μl of the dilution was added to a 50 μl reaction so that the final concentration of DMSO is 1% in all of reactions. All of the enzymatic reactions were conducted at 30° C. for 40 minutes. The 50 μl reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/ml BSA, 1 mM DTT, 0.2 mg/ml substrate peptide, 10 μM ATP and BTK. After the enzymatic reaction, 50 μl of Kinase-Glo Plus Luminescence kinase assay solution (Promega) was added to each reaction and incubate the plate for 5 minutes at room temperature. Luminescence signal was measured using a BioTek Synergy 2 microplate reader. Btk activity assays were performed in duplicate at each concentration.	B	CN(C)C/C=C/C(=O)Nc1ccc2ncc(C#N)c(Nc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL3956409	<	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
409807	17774800	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	NC(=O)c1nc(N2CCC[C@@H](NC(=O)N3Cc4ccccc4C3)C2)sc1Nc1ccccn1		CHEMBL4111419	=	IC50	nM	254.3	CHEMBL5251	Homo sapiens	IC50	nM	254.3
409808	17774801	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	NC(=O)c1nc(N2CCC[C@@H](NC(=O)N3Cc4ccc(Cl)cc4C3)C2)sc1Nc1ccccn1		CHEMBL4108697	=	IC50	nM	7735.2	CHEMBL5251	Homo sapiens	IC50	nM	7735.2
409809	17774802	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	CC(C)(C)OC(=O)N[C@@H]1CCCN(c2nc(C(N)=O)c(Nc3ccccn3)s2)C1		CHEMBL4113085	=	IC50	nM	1214.6	CHEMBL5251	Homo sapiens	IC50	nM	1214.6
409810	17774803	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	CC(C)(C)c1ccc(C(=O)N[C@@H]2CCCN(c3nc(C(N)=O)c(Nc4ccccn4)s3)C2)cn1		CHEMBL4110962	=	IC50	nM	1728.8	CHEMBL5251	Homo sapiens	IC50	nM	1728.8
409811	17774804	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	NC(=O)c1nc(N2CCC[C@@H](NC(=O)Cc3ccccc3)C2)sc1Nc1ccccn1		CHEMBL4114563	=	IC50	nM	6236.0	CHEMBL5251	Homo sapiens	IC50	nM	6236.0
409812	17774805	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	Cc1cccc(CC(=O)N[C@@H]2CCCN(c3nc(C(N)=O)c(Nc4ccccn4)s3)C2)c1		CHEMBL4112641	=	IC50	nM	7506.4	CHEMBL5251	Homo sapiens	IC50	nM	7506.4
409813	17774806	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	CC(C)(C)c1ccc(C(=O)N[C@@H]2CCCN(c3nc(C(N)=O)c(Nc4ccccn4)s3)C2)cc1		CHEMBL4113883	=	IC50	nM	469.9	CHEMBL5251	Homo sapiens	IC50	nM	469.9
409814	17774807	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	CS(=O)(=O)N[C@@H]1CCCN(c2nc(C(N)=O)c(Nc3ccccn3)s2)C1		CHEMBL4108989	=	IC50	nM	5065.1	CHEMBL5251	Homo sapiens	IC50	nM	5065.1
409815	17774808	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	NC(=O)c1nc(N2CCC[C@@H](NS(=O)(=O)c3ccccc3)C2)sc1Nc1ccccn1		CHEMBL4111119	=	IC50	nM	1614.8	CHEMBL5251	Homo sapiens	IC50	nM	1614.8
409816	17774809	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	CC(C)S(=O)(=O)N[C@@H]1CCCN(c2nc(C(N)=O)c(Nc3ccccn3)s2)C1		CHEMBL4113694	=	IC50	nM	5803.8	CHEMBL5251	Homo sapiens	IC50	nM	5803.8
409817	17774810	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	NC(=O)c1nc(N2CCC[C@@H](NC(=O)CNc3cccc(Cl)c3)C2)sc1Nc1ccccn1		CHEMBL4114462	=	IC50	nM	5368.6	CHEMBL5251	Homo sapiens	IC50	nM	5368.6
409818	17774811	CHEMBL3888580	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10× concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10× stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission).	B	CC(=O)N[C@@H]1CCCN(c2nc(C(N)=O)c(Nc3ccccn3)s2)C1		CHEMBL4111841	=	IC50	nM	6027.1	CHEMBL5251	Homo sapiens	IC50	nM	6027.1
429692	17791358	CHEMBL3889024	IMAP-FP Assay: Assay Method A: BTK enzymatic activity was determined in an IMAP-FP assay (Immobilized Metal ion Affinity-based fluorescence Polarization; Molecular Devices). Using this assay format, the potency (IC50) of each compound was determined from a 10 point (1:3 serial dilution, final compound concentration range in assay from 10 μM to 0.508 nM) titration curve using the following outlined procedure. To each well of a black Corning 384-well microplate (Corning Catalog #3575), 200 nL of compound (100 fold dilution in final assay volume of 20 μL) was dispensed, followed by the addition of 10 μL of 1× kinase buffer (10 mM Tris pH 7.2, 10 mM MgCl2, 0.01% Tween 20, 2 mM MnCl2, and 1 mM DTT) containing 0.16 ng/μL (2.1 nM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 10 μL kinase buffer containing 100 nM â¿¿Blk/Lyntideâ¿ IMAP substrate peptide (5-carboxyfluorescein-EFPIYDFLPAKKK-NH2; Molecular Devices Catalog #R7188), and 10 μM ATP. The final reaction in each well of 20 μL consists of 1.05 nM hBTK, 50 nM Blk/Lyntide IMAP substrate, and 5 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes and were immediately quenched by the addition of 40 μL IMAP detection beads resuspended in IMAP progressive binding buffer (beads were diluted 1:600 in 75% and 25% progressive binding buffer A and B, respectively; Molecular Devices). Plates were read on Packard microplate reader after 60 minutes binding equilibration using Fluorescence Polarization protocol. Specifically, fluorescence at 535 nm is measured using emission filters oriented both parallel and perpendicular to the polarized excitation filter.	B	Cn1ncc2c1CCCC2(O)c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)nccn12		CHEMBL3903659	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
429693	17791359	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1ncc2c1CCC[C@@]2(O)c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)nccn12		CHEMBL3916236	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
429694	17791360	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1ncc2c1CCC[C@]2(O)c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)nccn12		CHEMBL4109483	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
429695	17791361	CHEMBL3889024	IMAP-FP Assay: Assay Method A: BTK enzymatic activity was determined in an IMAP-FP assay (Immobilized Metal ion Affinity-based fluorescence Polarization; Molecular Devices). Using this assay format, the potency (IC50) of each compound was determined from a 10 point (1:3 serial dilution, final compound concentration range in assay from 10 μM to 0.508 nM) titration curve using the following outlined procedure. To each well of a black Corning 384-well microplate (Corning Catalog #3575), 200 nL of compound (100 fold dilution in final assay volume of 20 μL) was dispensed, followed by the addition of 10 μL of 1× kinase buffer (10 mM Tris pH 7.2, 10 mM MgCl2, 0.01% Tween 20, 2 mM MnCl2, and 1 mM DTT) containing 0.16 ng/μL (2.1 nM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 10 μL kinase buffer containing 100 nM â¿¿Blk/Lyntideâ¿ IMAP substrate peptide (5-carboxyfluorescein-EFPIYDFLPAKKK-NH2; Molecular Devices Catalog #R7188), and 10 μM ATP. The final reaction in each well of 20 μL consists of 1.05 nM hBTK, 50 nM Blk/Lyntide IMAP substrate, and 5 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes and were immediately quenched by the addition of 40 μL IMAP detection beads resuspended in IMAP progressive binding buffer (beads were diluted 1:600 in 75% and 25% progressive binding buffer A and B, respectively; Molecular Devices). Plates were read on Packard microplate reader after 60 minutes binding equilibration using Fluorescence Polarization protocol. Specifically, fluorescence at 535 nm is measured using emission filters oriented both parallel and perpendicular to the polarized excitation filter.	B	CCn1ncc2c1CCCC2(O)c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)nccn12		CHEMBL3926242	=	IC50	nM	12.04	CHEMBL5251	Homo sapiens	IC50	nM	12.04
429696	17791362	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nn2[C@@H]1CCCc2[nH]ncc21		CHEMBL4113933	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
429697	17791363	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nn2[C@H]1CCCc2[nH]ncc21		CHEMBL3894721	=	IC50	nM	60.0	CHEMBL5251	Homo sapiens	IC50	nM	60.0
429698	17791364	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1ncc2c1CCC[C@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL4107331	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
429699	17791365	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1cc2c(n1)CCC[C@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL4114231	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
429700	17791366	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1ncc2c1CCC[C@@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL3948238	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
429701	17791367	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1cc2c(n1)CCC[C@@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL3928649	=	IC50	nM	83.0	CHEMBL5251	Homo sapiens	IC50	nM	83.0
429702	17791368	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	CCn1ncc2c1CCC[C@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL4114902	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
429703	17791369	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	CCn1cc2c(n1)CCC[C@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL4113578	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
429704	17791370	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	CCn1ncc2c1CCC[C@@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL3901103	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
429705	17791371	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	CCn1cc2c(n1)CCC[C@@H]2n1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)ncnc21		CHEMBL3902516	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
429706	17791372	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nn2[C@@H]1CCCc2c1cnn2CCO		CHEMBL4113220	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
429707	17791373	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nn2[C@@H]1CCCc2nn(CCO)cc21		CHEMBL4112398	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
429708	17791374	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nn2[C@H]1CCCc2c1cnn2CCO		CHEMBL3913277	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
429709	17791375	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nn2[C@H]1CCCc2nn(CCO)cc21		CHEMBL3943053	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
429710	17791376	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1nccn2c([C@@H]3CCCn4c(C5CC5)nnc43)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3902397	=	IC50	nM	67.0	CHEMBL5251	Homo sapiens	IC50	nM	67.0
429711	17791377	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1nccn2c([C@H]3CCCn4c(C5CC5)nnc43)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4115608	=	IC50	nM	56.0	CHEMBL5251	Homo sapiens	IC50	nM	56.0
429712	17791378	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1nccn2c([C@H]3CCn4c(nnc4C(F)(F)F)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3941392	=	IC50	nM	0.81	CHEMBL5251	Homo sapiens	IC50	nM	0.81
429713	17791379	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Nc1nccn2c([C@@H]3CCn4c(nnc4C(F)(F)F)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4108415	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
429714	17791380	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1ncc2c1CCC[C@H]2c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)nccn12		CHEMBL4111146	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
429715	17791381	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	Cn1ncc2c1CCC[C@@H]2c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c2c(N)nccn12		CHEMBL3912750	=	IC50	nM	740.0	CHEMBL5251	Homo sapiens	IC50	nM	740.0
429716	17791382	CHEMBL3889025	"LANCE-TR-FRET Assay: Assay Method B: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 μM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 μL) was dispensed, followed by the addition of 7.5 μL of 1× kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/μL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 μL 1× kinase buffer containing 8 μM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2), and 100 μM ATP. The final reaction in each well of 10 μL consists of 50 pM hBTK, 2 μM biotin-A5-peptide, and 25 μM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 μL of 1× quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity)."	B	CC(C)Oc1ccnc(NC(=O)c2ccc(-c3nc(N4CCn5c(nnc5C(F)(F)F)C4)n4ccnc(N)c34)cc2)c1		CHEMBL3984936	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
434801	17794762	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(Cc3ccc(-c4cc[nH]c(=O)c4)cc3)ncc2c1		CHEMBL3936224	=	IC50	nM	3319.09	CHEMBL5251	Homo sapiens	IC50	nM	3319.09
434802	17794763	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(Cc3ccc(-c4cc[nH]c(=O)c4)cc3F)ncc2c1		CHEMBL3953957	=	IC50	nM	982.77	CHEMBL5251	Homo sapiens	IC50	nM	982.77
434803	17794764	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(-c3cccc(-c4cc[nH]c(=O)c4)c3CO)ncc2c1		CHEMBL3958072	=	IC50	nM	365.77	CHEMBL5251	Homo sapiens	IC50	nM	365.77
434804	17794765	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(Cc3c(F)cc(-c4cc[nH]c(=O)c4)cc3F)ncc2c1		CHEMBL3959202	=	IC50	nM	13314.57	CHEMBL5251	Homo sapiens	IC50	nM	13314.57
434805	17794766	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(Cc3ccc(-c4cc[nH]c(=O)c4)cc3CO)ncc2c1		CHEMBL3893726	=	IC50	nM	3144.94	CHEMBL5251	Homo sapiens	IC50	nM	3144.94
434806	17794767	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	Cn1cc(-c2cc(-c3ccc(Cn4ncc5cc(C(C)(C)C)cc(F)c5c4=O)c(F)c3)cc(=O)[nH]2)cn1		CHEMBL3935131	=	IC50	nM	14.19	CHEMBL5251	Homo sapiens	IC50	nM	14.19
434807	17794768	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc[nH]c(=O)c1		CHEMBL3962622	=	IC50	nM	6911.39	CHEMBL5251	Homo sapiens	IC50	nM	6911.39
434808	17794769	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(Cc3ccc(-c4cc[nH]c(=O)c4)c(CO)c3)ncc2c1		CHEMBL3961094	>	IC50	nM	100000.0	CHEMBL5251	Homo sapiens	IC50	nM	100000.0
434809	17794770	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	CC(C)(C)c1cc(F)c2c(=O)n(Cc3cc(CO)c(-c4cc[nH]c(=O)c4)cc3F)ncc2c1		CHEMBL3902517	=	IC50	nM	52269.88	CHEMBL5251	Homo sapiens	IC50	nM	52269.88
434810	17794771	CHEMBL3889112	TR-FRET (Time Resolved FRET) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog #AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 μl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C.	B	Cn1cc(-c2cc(-c3ccc(CN4Cc5cc(C(C)(C)C)sc5C4=O)c(F)c3)cc(=O)[nH]2)cn1		CHEMBL3975094	=	IC50	nM	7.11	CHEMBL5251	Homo sapiens	IC50	nM	7.11
435786	17795747	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#Cc1c(-c2ccc(Oc3ccccc3)cc2)nn2c(-c3cccc(N)c3)ccnc12		CHEMBL3908127	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435787	17795748	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1cccc(N)c1		CHEMBL3930113	=	IC50	nM	360.0	CHEMBL5251	Homo sapiens	IC50	nM	360.0
435788	17795749	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC[C@@H]2c1cccc(N)c1		CHEMBL4109460	=	IC50	nM	270.0	CHEMBL5251	Homo sapiens	IC50	nM	270.0
435789	17795750	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC[C@H]2c1cccc(N)c1		CHEMBL3905597	=	IC50	nM	210.0	CHEMBL5251	Homo sapiens	IC50	nM	210.0
435790	17795751	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
435791	17795752	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cccc([C@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL4108484	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
435792	17795753	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cccc([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3964332	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
435793	17795754	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CCC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3893163	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
435794	17795755	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3949083	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	nM	200.0
435795	17795756	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732	=	IC50	nM	0.71	CHEMBL5251	Homo sapiens	IC50	nM	0.71
435796	17795757	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@H]1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL4112596	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
435797	17795758	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@@H]1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3925479	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
435798	17795759	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c(-c3cccc(N)c3)ccnc12		CHEMBL3896850	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435799	17795760	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cccc(-c2ccnc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3921373	=	IC50	nM	860.0	CHEMBL5251	Homo sapiens	IC50	nM	860.0
435800	17795761	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(OCc3ccccc3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3982342	=	IC50	nM	3700.0	CHEMBL5251	Homo sapiens	IC50	nM	3700.0
435801	17795762	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccc4)cc3)nn21		CHEMBL3912412	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
435802	17795763	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@H]1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccc4)cc3)nn21		CHEMBL4109100	=	IC50	nM	0.51	CHEMBL5251	Homo sapiens	IC50	nM	0.51
435803	17795764	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@@H]1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccc4)cc3)nn21		CHEMBL3930909	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	nM	42.0
435804	17795765	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3974343	=	IC50	nM	4500.0	CHEMBL5251	Homo sapiens	IC50	nM	4500.0
435805	17795766	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccc(F)cc4)cc3)nn21		CHEMBL3906926	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
435806	17795767	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CNc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3969103	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
435807	17795768	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N(C)c1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3897911	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
435808	17795769	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CNc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccc(F)cc4)cc3)nn21		CHEMBL3904623	=	IC50	nM	2700.0	CHEMBL5251	Homo sapiens	IC50	nM	2700.0
435809	17795770	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N(C)c1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccc(F)cc4)cc3)nn21		CHEMBL3929088	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
435810	17795771	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(OC3CCCC3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3932485	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435811	17795772	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC4CCCC4)cc3)nn21		CHEMBL3904488	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
435812	17795773	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(OCC3CC3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3941460	=	IC50	nM	5300.0	CHEMBL5251	Homo sapiens	IC50	nM	5300.0
435813	17795774	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
435814	17795775	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@H]1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL4110931	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
435815	17795776	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@@H]1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3924266	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
435816	17795777	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	COCCOc1ccc(-c2nn3c(c2C(N)=O)NCCC3c2ccccc2N)cc1		CHEMBL3918101	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435817	17795778	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCCOC)cc3)nn21		CHEMBL3890068	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
435818	17795779	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(OC3CCOCC3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3927047	=	IC50	nM	3200.0	CHEMBL5251	Homo sapiens	IC50	nM	3200.0
435819	17795780	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC4CCOCC4)cc3)nn21		CHEMBL3895544	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
435820	17795781	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC(C)(C)OC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3940305	=	IC50	nM	3100.0	CHEMBL5251	Homo sapiens	IC50	nM	3100.0
435821	17795782	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2C1CCNCC1		CHEMBL3912307	=	IC50	nM	1700.0	CHEMBL5251	Homo sapiens	IC50	nM	1700.0
435822	17795783	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3973435	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
435823	17795784	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC([C@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL4107402	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
435824	17795785	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
435825	17795786	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2C1CNC1		CHEMBL3947318	=	IC50	nM	3400.0	CHEMBL5251	Homo sapiens	IC50	nM	3400.0
435826	17795787	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	0.48	CHEMBL5251	Homo sapiens	IC50	nM	0.48
435827	17795788	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC([C@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL4114482	=	IC50	nM	0.43	CHEMBL5251	Homo sapiens	IC50	nM	0.43
435828	17795789	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3937995	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
435829	17795790	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC2C(CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3962583	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
435830	17795791	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC[C@@H]2[C@H](CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL4111503	=	IC50	nM	0.66	CHEMBL5251	Homo sapiens	IC50	nM	0.66
435831	17795792	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC[C@H]2[C@@H](CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3943386	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
435832	17795793	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC[C@H]2Nc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3C[C@H]2C1		CHEMBL4112842	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
435833	17795794	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3929771	=	IC50	nM	1700.0	CHEMBL5251	Homo sapiens	IC50	nM	1700.0
435834	17795795	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
435835	17795796	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NC[C@H]1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL4109830	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
435836	17795797	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NC[C@@H]1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3916524	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
435837	17795798	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CNCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3943321	=	IC50	nM	1900.0	CHEMBL5251	Homo sapiens	IC50	nM	1900.0
435838	17795799	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N(C)CC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3916950	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435839	17795800	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NCC1CCNc2c(C(N)=O)c(-c3cnn(Cc4ccccc4)c3)nn21		CHEMBL3983632	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435840	17795801	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3cnn(Cc4ccccc4)c3)nn21		CHEMBL3940428	=	IC50	nM	640.0	CHEMBL5251	Homo sapiens	IC50	nM	640.0
435841	17795802	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC21CCN(Cc2ccccc2)CC1		CHEMBL3969979	=	IC50	nM	490.0	CHEMBL5251	Homo sapiens	IC50	nM	490.0
435842	17795803	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC21CCNCC1		CHEMBL3945749	=	IC50	nM	1400.0	CHEMBL5251	Homo sapiens	IC50	nM	1400.0
435843	17795804	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC2(CC1)CNc1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn12		CHEMBL3978314	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
435844	17795805	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC21CCN(Cc2ccccc2)CC1		CHEMBL3954461	=	IC50	nM	180.0	CHEMBL5251	Homo sapiens	IC50	nM	180.0
435845	17795806	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC21CCNCC1		CHEMBL3983095	=	IC50	nM	330.0	CHEMBL5251	Homo sapiens	IC50	nM	330.0
435846	17795807	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC2(CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3939197	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
435847	17795808	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC21CN(Cc2ccccc2)C1		CHEMBL3963054	=	IC50	nM	220.0	CHEMBL5251	Homo sapiens	IC50	nM	220.0
435848	17795809	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC21CNC1		CHEMBL3947976	=	IC50	nM	510.0	CHEMBL5251	Homo sapiens	IC50	nM	510.0
435849	17795810	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC2(CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3977236	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
435850	17795811	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2cc(-c3cccc(N)c3)[nH]c12		CHEMBL3939699	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
435851	17795812	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cccc(-c2cn3nc(-c4ccc(Oc5ccccc5)cc4)c(C(N)=O)c3[nH]2)c1		CHEMBL3906908	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	nM	150.0
435852	17795813	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c(-c3cccc(N)c3)c[nH]c12		CHEMBL3961487	=	IC50	nM	29.0	CHEMBL5251	Homo sapiens	IC50	nM	29.0
435853	17795814	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cccc(-c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3924160	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
435854	17795815	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c3c([nH]c12)CCNC3		CHEMBL3897084	=	IC50	nM	310.0	CHEMBL5251	Homo sapiens	IC50	nM	310.0
435855	17795816	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3968222	=	IC50	nM	0.14	CHEMBL5251	Homo sapiens	IC50	nM	0.14
435856	17795817	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c3c([nH]c12)CCN(C(=O)CCCl)C3		CHEMBL3934154	=	IC50	nM	7.7	CHEMBL5251	Homo sapiens	IC50	nM	7.7
435857	17795818	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)C/C=C/C(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3973566	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
435858	17795819	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3944462	=	IC50	nM	82.0	CHEMBL5251	Homo sapiens	IC50	nM	82.0
435859	17795820	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#CCC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3974534	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
435860	17795821	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)CCC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3945118	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
435861	17795822	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C/C=C/C(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3914651	=	IC50	nM	0.43	CHEMBL5251	Homo sapiens	IC50	nM	0.43
435862	17795823	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#C/C=C\CN1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3895077	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
435863	17795824	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#C/C=C/CN1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3927476	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
435864	17795825	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1cnccc12		CHEMBL3896294	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
435865	17795826	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c3c([nH]c12)CNCC3		CHEMBL3963114	=	IC50	nM	240.0	CHEMBL5251	Homo sapiens	IC50	nM	240.0
435866	17795827	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCc2c([nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)C1		CHEMBL3962133	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
435867	17795828	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)C/C=C/C(=O)N1CCc2c([nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)C1		CHEMBL3905984	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
435868	17795829	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1ccc([N+](=O)[O-])cc12		CHEMBL3939090	=	IC50	nM	320.0	CHEMBL5251	Homo sapiens	IC50	nM	320.0
435869	17795830	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1ccc(N)cc12		CHEMBL3977187	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
435870	17795831	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2c1		CHEMBL3948065	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
435871	17795832	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCc1ccc(N)cc1-2		CHEMBL3963772	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	nM	190.0
435872	17795833	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc2c(c1)-n1nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c1NC2		CHEMBL3917502	=	IC50	nM	7.8	CHEMBL5251	Homo sapiens	IC50	nM	7.8
435873	17795834	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCc1cc([N+](=O)[O-])ccc1-2		CHEMBL3955025	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
435874	17795835	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCc1cc(N)ccc1-2		CHEMBL3978821	=	IC50	nM	55.0	CHEMBL5251	Homo sapiens	IC50	nM	55.0
435875	17795836	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc2c(c1)CCCc1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn1-2		CHEMBL3949761	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
435876	17795837	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NC(=O)Cc1cc([N+](=O)[O-])ccc1-2		CHEMBL3948856	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435877	17795838	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NC(=O)Cc1cc(N)ccc1-2		CHEMBL3907456	=	IC50	nM	240.0	CHEMBL5251	Homo sapiens	IC50	nM	240.0
435878	17795839	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc2c(c1)CC(=O)Nc1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn1-2		CHEMBL3895210	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
435879	17795840	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c(=O)c1cc([N+](=O)[O-])ccc12		CHEMBL3894975	=	IC50	nM	5500.0	CHEMBL5251	Homo sapiens	IC50	nM	5500.0
435880	17795841	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c(=O)c1cc(N)ccc12		CHEMBL3926833	=	IC50	nM	480.0	CHEMBL5251	Homo sapiens	IC50	nM	480.0
435881	17795842	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc2c(c1)c(=O)[nH]c1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn12		CHEMBL3919539	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
435882	17795843	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c(=O)c1ccc(N)cc12		CHEMBL3953696	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	nM	50.0
435883	17795844	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c(C3CCNCC3)cc(=O)[nH]c12		CHEMBL3939737	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435884	17795845	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(c2cc(=O)[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)CC1		CHEMBL3931363	=	IC50	nM	5900.0	CHEMBL5251	Homo sapiens	IC50	nM	5900.0
435885	17795846	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NC(=O)C21CCNCC1		CHEMBL3890197	=	IC50	nM	3100.0	CHEMBL5251	Homo sapiens	IC50	nM	3100.0
435886	17795847	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC2(CC1)C(=O)Nc1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn12		CHEMBL3941442	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	nM	130.0
435887	17795848	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC(N)C2		CHEMBL3924383	=	IC50	nM	2900.0	CHEMBL5251	Homo sapiens	IC50	nM	2900.0
435888	17795849	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NC1CNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn2C1		CHEMBL3896817	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
435889	17795850	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1CNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn2C1		CHEMBL3894155	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
435890	17795851	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC1(CNC1)C2		CHEMBL3947816	=	IC50	nM	2000.0	CHEMBL5251	Homo sapiens	IC50	nM	2000.0
435891	17795852	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC2(CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3C2)C1		CHEMBL3977070	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
435892	17795853	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC(c1ccccc1N)C2		CHEMBL3963131	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435893	17795854	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC(c1cccc(N)c1)C2		CHEMBL3959301	=	IC50	nM	1900.0	CHEMBL5251	Homo sapiens	IC50	nM	1900.0
435894	17795855	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)CCOc1cccc(C2CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3C2)c1		CHEMBL3942135	=	IC50	nM	1900.0	CHEMBL5251	Homo sapiens	IC50	nM	1900.0
435895	17795856	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)C/C=C/C(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3913669	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435896	17795857	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	COc1ccc(-c2nn3c(c2C(N)=O)NCCC3c2ccccc2N)cc1		CHEMBL3984995	=	IC50	nM	1500.0	CHEMBL5251	Homo sapiens	IC50	nM	1500.0
435897	17795858	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
435898	17795859	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1cc(N)ccc1Cl		CHEMBL3898115	=	IC50	nM	470.0	CHEMBL5251	Homo sapiens	IC50	nM	470.0
435899	17795860	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc(Cl)c(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3955425	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
435900	17795861	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)ccc1Cl		CHEMBL3889791	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435901	17795862	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1ccc(N)cc1		CHEMBL3950138	=	IC50	nM	77.0	CHEMBL5251	Homo sapiens	IC50	nM	77.0
435902	17795863	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)cc1		CHEMBL3979176	=	IC50	nM	9.5	CHEMBL5251	Homo sapiens	IC50	nM	9.5
435903	17795864	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1ccncc1		CHEMBL3928597	=	IC50	nM	260.0	CHEMBL5251	Homo sapiens	IC50	nM	260.0
435904	17795865	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1cccnc1		CHEMBL3904180	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	nM	550.0
435905	17795866	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1ccccn1		CHEMBL3966567	=	IC50	nM	830.0	CHEMBL5251	Homo sapiens	IC50	nM	830.0
435906	17795867	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCCC1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3895268	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435907	17795868	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(OCc5ccccc5)cc4)nn32)C1		CHEMBL3894176	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
435908	17795869	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(OCc5ccccn5)cc4)nn32)C1		CHEMBL3953494	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
435909	17795870	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(Cl)cc5)cc4)nn32)C1		CHEMBL3953428	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
435910	17795871	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5cccc(Cl)c5)cc4)nn32)C1		CHEMBL3929217	=	IC50	nM	0.48	CHEMBL5251	Homo sapiens	IC50	nM	0.48
435911	17795872	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NC1(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3944698	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
435912	17795873	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NC(C)(C)C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3916800	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
435913	17795874	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NCC1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccc4)cc3)nn21		CHEMBL3939337	=	IC50	nM	3000.0	CHEMBL5251	Homo sapiens	IC50	nM	3000.0
435914	17795875	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccc4)cc3)nn21		CHEMBL3940302	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
435915	17795876	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NCC1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3957987	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
435916	17795877	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3930480	=	IC50	nM	94.0	CHEMBL5251	Homo sapiens	IC50	nM	94.0
435917	17795878	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC(C)(C)OC(=O)N1C[C@@H]2CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3[C@H]2C1		CHEMBL3945892	=	IC50	nM	6000.0	CHEMBL5251	Homo sapiens	IC50	nM	6000.0
435918	17795879	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NC[C@@H]1CNC[C@@H]12		CHEMBL3921532	=	IC50	nM	8200.0	CHEMBL5251	Homo sapiens	IC50	nM	8200.0
435919	17795880	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1C[C@H]2CNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3[C@H]2C1		CHEMBL4115303	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
435920	17795881	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(c2cn3nc(-c4ccc(Oc5ccccc5)cc4)c(C(N)=O)c3[nH]2)C1		CHEMBL3926815	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
435921	17795882	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC21CNC1		CHEMBL3904241	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	nM	410.0
435922	17795883	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
435923	17795884	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c3c([nH]c12)CCNCC3		CHEMBL3960383	=	IC50	nM	180.0	CHEMBL5251	Homo sapiens	IC50	nM	180.0
435924	17795885	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2CC1		CHEMBL3913116	=	IC50	nM	0.36	CHEMBL5251	Homo sapiens	IC50	nM	0.36
435925	17795886	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)C/C=C/C(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2CC1		CHEMBL3897574	=	IC50	nM	0.78	CHEMBL5251	Homo sapiens	IC50	nM	0.78
435926	17795887	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3922120	=	IC50	nM	0.15	CHEMBL5251	Homo sapiens	IC50	nM	0.15
435927	17795888	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)C/C=C/C(=O)N1CCCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3959966	=	IC50	nM	0.62	CHEMBL5251	Homo sapiens	IC50	nM	0.62
435928	17795889	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(OCc3ccccc3)cc2)nn2c3c([nH]c12)CCNC3		CHEMBL3890883	=	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
435929	17795890	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(OCc5ccccc5)cc4)nn3c2C1		CHEMBL3895297	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
435930	17795891	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(OCC5CC5)cc4)nn3c2C1		CHEMBL3897152	=	IC50	nM	300.0	CHEMBL5251	Homo sapiens	IC50	nM	300.0
435931	17795892	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1cc([N+](=O)[O-])ccc12		CHEMBL3978173	=	IC50	nM	930.0	CHEMBL5251	Homo sapiens	IC50	nM	930.0
435932	17795893	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1cc(N)ccc12		CHEMBL3964516	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
435933	17795894	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccc2c(c1)[nH]c1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn12		CHEMBL3935234	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
435934	17795895	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1cccc(N)c12		CHEMBL3908157	=	IC50	nM	170.0	CHEMBL5251	Homo sapiens	IC50	nM	170.0
435935	17795896	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(Cl)c(Cl)c5)cc4)nn32)C1		CHEMBL3984082	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
435936	17795897	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C)c(OC)c3)nn21		CHEMBL3917828	=	IC50	nM	0.53	CHEMBL5251	Homo sapiens	IC50	nM	0.53
435937	17795898	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@H]1CCNc2c(C(N)=O)c(-c3ccc(C)c(OC)c3)nn21		CHEMBL4111890	=	IC50	nM	0.23	CHEMBL5251	Homo sapiens	IC50	nM	0.23
435938	17795899	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@@H]1CCNc2c(C(N)=O)c(-c3ccc(C)c(OC)c3)nn21		CHEMBL3903037	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
435939	17795900	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697	=	IC50	nM	0.78	CHEMBL5251	Homo sapiens	IC50	nM	0.78
435940	17795901	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@H]1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL4112625	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
435941	17795902	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1[C@@H]1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3962144	=	IC50	nM	1500.0	CHEMBL5251	Homo sapiens	IC50	nM	1500.0
435942	17795903	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5C#N)cc4)nn32)C1		CHEMBL3972744	=	IC50	nM	0.38	CHEMBL5251	Homo sapiens	IC50	nM	0.38
435943	17795904	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)CC1		CHEMBL3925102	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
435944	17795905	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)c(F)c3)nn21		CHEMBL3900591	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
435945	17795906	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2(C)CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3916090	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
435946	17795907	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(Cl)c4)nn32)C1		CHEMBL3985855	=	IC50	nM	0.44	CHEMBL5251	Homo sapiens	IC50	nM	0.44
435947	17795908	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(OC)c4)nn32)C1		CHEMBL3902892	=	IC50	nM	3000.0	CHEMBL5251	Homo sapiens	IC50	nM	3000.0
435948	17795909	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(OCCc5ccccc5)cc4)nn32)C1		CHEMBL3890581	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
435949	17795910	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccc4)c(OC)c3)nn21		CHEMBL3968704	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
435950	17795911	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)NCC1(C)CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3901100	=	IC50	nM	0.89	CHEMBL5251	Homo sapiens	IC50	nM	0.89
435951	17795912	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccccc4)nn32)CC1		CHEMBL3961123	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
435952	17795913	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Cl)cc4)nn32)C1		CHEMBL3892137	=	IC50	nM	72.0	CHEMBL5251	Homo sapiens	IC50	nM	72.0
435953	17795914	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCc4ccccn4)c(Cl)c3)nn21		CHEMBL3959953	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
435954	17795915	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cc(Cl)ccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3985149	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
435955	17795916	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1cc(C)ccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3977203	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	nM	5.6
435956	17795917	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC(F)(F)F)cc3)nn21		CHEMBL3906546	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
435957	17795918	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccccc3)nn21		CHEMBL3976076	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
435958	17795919	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)cc3)nn21		CHEMBL3908905	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
435959	17795920	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)c(Br)c3)nn21		CHEMBL3975936	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
435960	17795921	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(F)c(Cl)c2)nn2c1NCCC2c1ccccc1NC(=O)/C=C/CN1CCCCC1		CHEMBL3946624	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
435961	17795922	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)c(F)c3)nn21		CHEMBL3983966	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
435962	17795923	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cccc(Cl)c3)nn21		CHEMBL3951926	=	IC50	nM	0.96	CHEMBL5251	Homo sapiens	IC50	nM	0.96
435963	17795924	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)c(Cl)c3)nn21		CHEMBL3891595	=	IC50	nM	0.55	CHEMBL5251	Homo sapiens	IC50	nM	0.55
435964	17795925	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)c(C)c3)nn21		CHEMBL3960617	=	IC50	nM	0.38	CHEMBL5251	Homo sapiens	IC50	nM	0.38
435965	17795926	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cc(F)c(F)c(Cl)c3)nn21		CHEMBL3982878	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
435966	17795927	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)c(OC)c3)nn21		CHEMBL3945450	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
435967	17795928	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)c(OC)c3)nn21		CHEMBL3959393	=	IC50	nM	0.49	CHEMBL5251	Homo sapiens	IC50	nM	0.49
435968	17795929	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C(F)(F)F)cc3)nn21		CHEMBL3954175	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
435969	17795930	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C(F)(F)F)c(Cl)c3)nn21		CHEMBL3903690	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
435970	17795931	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)c(C(F)(F)F)c3)nn21		CHEMBL3931690	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
435971	17795932	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C)cc3)nn21		CHEMBL3965262	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
435972	17795933	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	COc1cc(-c2nn3c(c2C(N)=O)NCCC3c2ccccc2NC(=O)/C=C/CN(C)C)ccc1C		CHEMBL3940696	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
435973	17795934	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cccc(OC)c3)nn21		CHEMBL3918154	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
435974	17795935	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cc(OC)c(OC)c(OC)c3)nn21		CHEMBL3946044	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
435975	17795936	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)c(OC)c3)nn21		CHEMBL3930626	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
435976	17795937	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cc(Cl)c(OC)c(Cl)c3)nn21		CHEMBL3954730	=	IC50	nM	0.15	CHEMBL5251	Homo sapiens	IC50	nM	0.15
435977	17795938	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2C1CCN(C(=O)/C=C/CN2CCCCC2)CC1		CHEMBL3939637	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
435978	17795939	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)C/C=C/C(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3969173	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
435979	17795940	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(OC)c4)nn32)CC1		CHEMBL3927293	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435980	17795941	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(Cl)c4)nn32)CC1		CHEMBL3902845	=	IC50	nM	0.81	CHEMBL5251	Homo sapiens	IC50	nM	0.81
435981	17795942	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(C)c(OC)c4)nn32)CC1		CHEMBL3918344	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
435982	17795943	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CC(C2(C)CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3894703	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
435983	17795944	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3932338	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
435984	17795945	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC[C@H]2C1CCN(C(=O)CCCl)CC1		CHEMBL3979645	=	IC50	nM	5.7	CHEMBL5251	Homo sapiens	IC50	nM	5.7
435985	17795946	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC[C@H]2C1CCN(C(=O)/C=C/CN2CCN(CCNC(=O)CCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCC[C@@H]3C[C@@H]4NC(=O)N[C@@H]4S3)CC2)CC1		CHEMBL4107336	=	IC50	nM	46.0	CHEMBL5251	Homo sapiens	IC50	nM	46.0
435986	17795947	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)nn32)CC1		CHEMBL3903899	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
435987	17795948	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#CCC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3974783	=	IC50	nM	87.0	CHEMBL5251	Homo sapiens	IC50	nM	87.0
435988	17795949	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#C/C(=C\C1CC1)C(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL4114721	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
435989	17795950	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	N#CN1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3910506	=	IC50	nM	124.0	CHEMBL5251	Homo sapiens	IC50	nM	124.0
435990	17795951	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)nn32)CC1		CHEMBL3935034	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
435991	17795952	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3910644	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
435992	17795953	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3968870	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
435993	17795954	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CCC#CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3894235	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435994	17795955	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC[C@H]2C1CCN(C(=O)C#CCN2CCCC2)CC1		CHEMBL3891285	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
435995	17795956	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CN(C)CC#CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3983090	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
435996	17795957	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)nn32)C1		CHEMBL3945746	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	nM	42.0
435997	17795958	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccc(F)cc4F)cc3)nn21		CHEMBL3978311	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
435998	17795959	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCC[C@H]2C1CCN(C(=O)C#CCO)CC1		CHEMBL3940423	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
435999	17795960	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	COCC#CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3969976	=	IC50	nM	0.91	CHEMBL5251	Homo sapiens	IC50	nM	0.91
436000	17795961	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CCCC#CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3958870	=	IC50	nM	3.9	CHEMBL5251	Homo sapiens	IC50	nM	3.9
436001	17795962	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)nn32)CC1		CHEMBL3897758	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
436002	17795963	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	CC#CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5cccc(Cl)c5)cc4)nn32)CC1		CHEMBL3969461	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
436003	17795964	CHEMBL3889138	Time-Resolved Fluorescence Resonance Energy Transfer Assay: Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfer methodology. Recombinant Btk was pre-incubated with the compounds disclosed herein at room temperature for 1 hour in an assay buffer containing 50 mM Tris pH7.4, 10 mM MgCl2, 2 mM MnCl2, 0.1 mM EDTA, 1 mM DT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH2). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 hour, and then the TR-FRET signals (ex337 nm, em 620 nm/665 nm) were read on BMG PHERAstar FS instrument. The residual enzyme activity in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 615 nm to that at 665 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)c(Cl)c3)nn21		CHEMBL3912667	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
436763	17796728	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	CC(C)(C)c1ccc(C(=O)NC2CCCC(Nc3ncnc4[nH]cnc34)C2)cc1		CHEMBL3967766	=	IC50	nM	9572.72	CHEMBL5251	Homo sapiens	IC50	nM	9572.72
436764	17796729	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	O=C(NCc1cccc(Cl)c1)C1CCCC(Nc2ncnc3[nH]cnc23)C1		CHEMBL3929151	=	IC50	nM	100000.0	CHEMBL5251	Homo sapiens	IC50	nM	100000.0
436765	17796730	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	Cn1cc(Nc2nc(NC3CCCCC3)c3nc[nH]c3n2)cn1		CHEMBL3956698	=	IC50	nM	2821.72	CHEMBL5251	Homo sapiens	IC50	nM	2821.72
436766	17796731	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	CC1CCCC(Nc2nc(Nc3cnn(C)c3)nc3[nH]cnc23)C1		CHEMBL3912497	=	IC50	nM	40626.4	CHEMBL5251	Homo sapiens	IC50	nM	40626.4
436767	17796732	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	Cn1cc(Nc2nc(NC3CCCC(NC(=O)c4ccc(C(C)(C)C)cc4)C3)c3nc[nH]c3n2)cn1		CHEMBL3923793	=	IC50	nM	56.94	CHEMBL5251	Homo sapiens	IC50	nM	56.94
436768	17796733	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	O=C(NC1CCCC(Nc2ncnc3[nH]cnc23)C1)c1ccccc1		CHEMBL3967742	=	IC50	nM	45.32	CHEMBL5251	Homo sapiens	IC50	nM	45.32
436769	17796734	CHEMBL3889150	"FRET (Forster/Flouresence Resonance Energy Transfer) Assay: This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (FOrster/Flouresence Resonance Energy Transfer) technology. The BTK-Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease: 10 nM Eu-streptavidin (Perkin-Elmer Catalog# AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl2, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog #STB-K02). After 1 h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: 1 nM Eu-Streptavidin complex (donor fluorophore). 18 ul of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog #PV5593,) with BTK-Eu alone as no negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24 h at 14° C. After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive ""no inhibitor"" control wells were averaged to obtain the mean maximum."	B	CC(C)(C)OC(=O)NC1CCCC(C(=O)O)C1		CHEMBL3934587	=	IC50	nM	109.0	CHEMBL5251	Homo sapiens	IC50	nM	109.0
445157	17804865	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3953056	=	IC50	nM	5.5	CHEMBL5251	Homo sapiens	IC50	nM	5.5
445158	17804866	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4113872	=	IC50	nM	15.6	CHEMBL5251	Homo sapiens	IC50	nM	15.6
445159	17804867	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CN1C[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4110412	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
445160	17804868	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106978	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
445161	17804869	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(OC5CC5)ccn4)cc3)c12		CHEMBL4112085	=	IC50	nM	0.24	CHEMBL5251	Homo sapiens	IC50	nM	0.24
445162	17804870	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4ccccn4)cc3)c12		CHEMBL4112851	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
445163	17804871	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CCC5)ccn4)cc3)c12		CHEMBL4115449	=	IC50	nM	60.6	CHEMBL5251	Homo sapiens	IC50	nM	60.6
445164	17804872	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)s1		CHEMBL4112500	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
445165	17804873	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4ccccn4)cc3)c12		CHEMBL3899641	=	IC50	nM	194.0	CHEMBL5251	Homo sapiens	IC50	nM	194.0
445166	17804874	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4112448	=	IC50	nM	14.7	CHEMBL5251	Homo sapiens	IC50	nM	14.7
445167	17804875	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3922212	=	IC50	nM	15.3	CHEMBL5251	Homo sapiens	IC50	nM	15.3
445168	17804876	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4109282	=	IC50	nM	0.083	CHEMBL5251	Homo sapiens	IC50	nM	0.083
445169	17804877	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL3899763	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
445170	17804878	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)F)ccn4)cc3F)c12		CHEMBL4112025	=	IC50	nM	0.12	CHEMBL5251	Homo sapiens	IC50	nM	0.12
445171	17804879	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	N#Cc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL4109557	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
445172	17804880	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3F)c12		CHEMBL4112223	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
445173	17804881	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)F)ccn4)cc3)c12		CHEMBL4112027	=	IC50	nM	0.31	CHEMBL5251	Homo sapiens	IC50	nM	0.31
445174	17804882	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)c1		CHEMBL4111650	=	IC50	nM	0.16	CHEMBL5251	Homo sapiens	IC50	nM	0.16
445175	17804883	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3)c12		CHEMBL4113354	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
445176	17804884	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4nccc(C(F)(F)F)n4)cc3)c12		CHEMBL4109782	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
445177	17804885	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(F)(F)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL4112201	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
445178	17804886	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(-c2nc([C@@H]3CC[C@H]4CCC(=O)N4C3)n3ccnc(N)c23)ccc1C(=O)Nc1cc(C(F)(F)F)ccn1		CHEMBL4106497	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
445179	17804887	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108563	=	IC50	nM	0.11	CHEMBL5251	Homo sapiens	IC50	nM	0.11
445180	17804888	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)c(F)c3)c12		CHEMBL4110290	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
445181	17804889	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(F)(F)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2F)c1		CHEMBL4115042	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
445182	17804890	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)F)ccn4)c(F)c3)c12		CHEMBL4114570	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
445183	17804891	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)c(F)c3)c12		CHEMBL4108885	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
445184	17804892	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(-c2nc([C@@H]3CC[C@H]4CCC(=O)N4C3)n3ccnc(N)c23)ccc1C(=O)Nc1cc(C2CC2)ccn1		CHEMBL4112420	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
445185	17804893	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5(F)COC5)ccn4)cc3)c12		CHEMBL4112747	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
445186	17804894	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)(F)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)c1		CHEMBL4112427	=	IC50	nM	0.85	CHEMBL5251	Homo sapiens	IC50	nM	0.85
445187	17804895	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@@H]12		CHEMBL4108545	=	IC50	nM	0.096	CHEMBL5251	Homo sapiens	IC50	nM	0.096
445188	17804896	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C6CC6)ccn5)cc4F)c4c(N)nccn34)CC[C@@H]12		CHEMBL4111521	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
445189	17804897	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@@H]12		CHEMBL3922148	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
445190	17804898	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	N#Cc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2F)c1		CHEMBL4111685	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
445191	17804899	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C#N)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110803	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
445192	17804900	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(-c2nc([C@@H]3CC[C@H]4CCC(=O)N4C3)n3ccnc(N)c23)ccc1C(=O)Nc1cc(C#N)ccn1		CHEMBL4111181	=	IC50	nM	0.98	CHEMBL5251	Homo sapiens	IC50	nM	0.98
445193	17804901	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C6CC6)ccn5)cc4F)c4c(N)nccn34)CC[C@@H]12		CHEMBL3903010	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
445194	17804902	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C3CC3)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4109186	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
445195	17804903	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4COCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108825	=	IC50	nM	0.12	CHEMBL5251	Homo sapiens	IC50	nM	0.12
445196	17804904	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CNCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4111645	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
445197	17804905	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4CNCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3939414	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
445198	17804906	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)c(Cl)c3)c12		CHEMBL4107273	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
445199	17804907	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(OC5CC5)ccn4)cc3F)c12		CHEMBL4109294	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
445200	17804908	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4CCCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL3924979	=	IC50	nM	0.095	CHEMBL5251	Homo sapiens	IC50	nM	0.095
445201	17804909	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4111979	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
445202	17804910	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C6CC6)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3952685	=	IC50	nM	0.53	CHEMBL5251	Homo sapiens	IC50	nM	0.53
445203	17804911	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C6CC6)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4110653	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
445204	17804912	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3942777	=	IC50	nM	0.14	CHEMBL5251	Homo sapiens	IC50	nM	0.14
445205	17804913	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4110644	=	IC50	nM	0.11	CHEMBL5251	Homo sapiens	IC50	nM	0.11
445206	17804914	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CN1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4113994	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
445207	17804915	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CN1CC(=O)N2C[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]2C1		CHEMBL3905726	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
445208	17804916	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC1(C)OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]21		CHEMBL4108687	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
445209	17804917	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C3CC3)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3[C@@H](C)OC(=O)N3C2)n2ccnc(N)c12		CHEMBL4106896	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
445210	17804918	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@@H]4CNCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4112108	=	IC50	nM	9.6	CHEMBL5251	Homo sapiens	IC50	nM	9.6
445211	17804919	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4COCCN4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4110169	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
445212	17804920	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4COCCN4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3906813	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
445213	17804921	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@H]4CNCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3901061	=	IC50	nM	0.28	CHEMBL5251	Homo sapiens	IC50	nM	0.28
445214	17804922	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4C[C@H](O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3929022	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
445215	17804923	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4C[C@@H](O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4108593	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
445216	17804924	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CNc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4111689	=	IC50	nM	12.7	CHEMBL5251	Homo sapiens	IC50	nM	12.7
445217	17804925	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCNC(=O)Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4107727	=	IC50	nM	17.7	CHEMBL5251	Homo sapiens	IC50	nM	17.7
445218	17804926	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4114924	=	IC50	nM	6.7	CHEMBL5251	Homo sapiens	IC50	nM	6.7
445219	17804927	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]12		CHEMBL4113670	=	IC50	nM	0.058	CHEMBL5251	Homo sapiens	IC50	nM	0.058
445220	17804928	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]12		CHEMBL3923011	=	IC50	nM	0.77	CHEMBL5251	Homo sapiens	IC50	nM	0.77
445221	17804929	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3938520	=	IC50	nM	0.085	CHEMBL5251	Homo sapiens	IC50	nM	0.085
445222	17804930	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CN(CCO)CC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4108579	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
445223	17804931	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4C[C@@H](O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3893811	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
445224	17804932	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4C[C@H](O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4109744	=	IC50	nM	0.081	CHEMBL5251	Homo sapiens	IC50	nM	0.081
445225	17804933	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110388	=	IC50	nM	0.16	CHEMBL5251	Homo sapiens	IC50	nM	0.16
445226	17804934	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OCc3ccccc3)c12		CHEMBL4114502	=	IC50	nM	10.7	CHEMBL5251	Homo sapiens	IC50	nM	10.7
445227	17804935	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)F)c12		CHEMBL4111338	=	IC50	nM	0.48	CHEMBL5251	Homo sapiens	IC50	nM	0.48
445228	17804936	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@@H]4CC(O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4108773	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
445229	17804937	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@H]4C[C@@H](O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3939080	=	IC50	nM	0.93	CHEMBL5251	Homo sapiens	IC50	nM	0.93
445230	17804938	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@H]4CC(O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3964420	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
445231	17804939	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@@H]4C[C@H](O)C(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4108688	=	IC50	nM	7.6	CHEMBL5251	Homo sapiens	IC50	nM	7.6
445232	17804940	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CN4C(=O)OC[C@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4113153	=	IC50	nM	24.9	CHEMBL5251	Homo sapiens	IC50	nM	24.9
445233	17804941	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@H]1OC[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4108295	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
445234	17804942	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	N#C/N=C1\CC[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN12		CHEMBL4111520	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
445235	17804943	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COC(=O)Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4111790	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
445236	17804944	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCN1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4111825	=	IC50	nM	0.27	CHEMBL5251	Homo sapiens	IC50	nM	0.27
445237	17804945	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)N1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4112832	=	IC50	nM	0.29	CHEMBL5251	Homo sapiens	IC50	nM	0.29
445238	17804946	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COC(=O)CN1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4109144	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
445239	17804947	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CN1CC[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4109792	=	IC50	nM	0.092	CHEMBL5251	Homo sapiens	IC50	nM	0.092
445240	17804948	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CN1CC[C@H]2CC[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL3908219	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
445241	17804949	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CN(C(=O)c4ccncc4)CC(=O)N3C2)n2ccnc(N)c12		CHEMBL4111143	=	IC50	nM	0.89	CHEMBL5251	Homo sapiens	IC50	nM	0.89
445242	17804950	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)(C(=O)O)N1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4113154	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
445243	17804951	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCN4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106651	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
445244	17804952	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114929	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
445245	17804953	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3[C@@H](C)OC(=O)N3C2)n2ccnc(N)c12		CHEMBL4107482	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
445246	17804954	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@@H]3N(C2)C(=O)OC3(C)C)n2ccnc(N)c12		CHEMBL4113263	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
445247	17804955	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@H]2CN3C(=O)CC[C@@H]3CO2)n2ccnc(N)c12		CHEMBL4114251	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
445248	17804956	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCOC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4113445	=	IC50	nM	0.075	CHEMBL5251	Homo sapiens	IC50	nM	0.075
445249	17804957	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CC[C@@H]4CCOC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL3917607	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
445250	17804958	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC1(C)C[C@H]2CC[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL3916919	=	IC50	nM	0.14	CHEMBL5251	Homo sapiens	IC50	nM	0.14
445251	17804959	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC1(C)C[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4113946	=	IC50	nM	11.4	CHEMBL5251	Homo sapiens	IC50	nM	11.4
445252	17804960	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C[C@@H]1OC(=N)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3968737	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
445253	17804961	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(O)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)c1		CHEMBL4111750	=	IC50	nM	9.7	CHEMBL5251	Homo sapiens	IC50	nM	9.7
445254	17804962	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)(O)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)c1		CHEMBL4107333	=	IC50	nM	49.3	CHEMBL5251	Homo sapiens	IC50	nM	49.3
445255	17804963	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COC(C)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)c1		CHEMBL4110507	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
445256	17804964	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CC(C)(C)C(=O)N3C2)n2ccnc(N)c12		CHEMBL4112030	=	IC50	nM	0.51	CHEMBL5251	Homo sapiens	IC50	nM	0.51
445257	17804965	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@H]2CC[C@@H]3CC(C)(C)C(=O)N3C2)n2ccnc(N)c12		CHEMBL3903534	=	IC50	nM	45.4	CHEMBL5251	Homo sapiens	IC50	nM	45.4
445258	17804966	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CN(C(=O)c5ccncc5)CC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4112274	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
445259	17804967	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COC(=O)c1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)c1		CHEMBL4111935	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
445260	17804968	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)cnn4)cc3)c12		CHEMBL4113482	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
445261	17804969	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CN(C(=O)c5ccccc5)CC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4109377	=	IC50	nM	0.23	CHEMBL5251	Homo sapiens	IC50	nM	0.23
445262	17804970	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc5ccccc5cn4)cc3)c12		CHEMBL4107467	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
445263	17804971	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@H]3CN4C(=O)CC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4114094	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
445264	17804972	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CN(CC(=O)O)CC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4111121	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
445265	17804973	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C=C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4109690	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
445266	17804974	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C=C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4113649	=	IC50	nM	16.8	CHEMBL5251	Homo sapiens	IC50	nM	16.8
445267	17804975	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CN1CC[C@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4107322	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
445268	17804976	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Cl)c12		CHEMBL4108437	=	IC50	nM	0.57	CHEMBL5251	Homo sapiens	IC50	nM	0.57
445269	17804977	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CC(C)(C)C(=O)N3C2)n2ccnc(N)c12		CHEMBL4110940	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
445270	17804978	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(F)(F)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110264	=	IC50	nM	830.9	CHEMBL5251	Homo sapiens	IC50	nM	830.9
445271	17804979	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4112880	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
445272	17804980	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114929	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
445273	17804981	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	N#Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)cc1C(F)(F)F		CHEMBL4114368	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
445274	17804982	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3O)c12		CHEMBL4110993	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
445275	17804983	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)nc3)c12		CHEMBL4110723	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
445276	17804984	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(C(F)(F)F)cc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)n1		CHEMBL4108285	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
445277	17804985	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CC3)c12		CHEMBL4107779	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
445278	17804986	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1c(C(F)(F)F)ccnc1NC(=O)c1ccc(-c2nc([C@@H]3CC[C@H]4CCC(=O)N4C3)n3ccnc(N)c23)cc1		CHEMBL4107764	=	IC50	nM	12.4	CHEMBL5251	Homo sapiens	IC50	nM	12.4
445279	17804987	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	N#Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4107939	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
445280	17804988	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	NC(=O)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110727	=	IC50	nM	347.5	CHEMBL5251	Homo sapiens	IC50	nM	347.5
445281	17804989	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)c1cc(C(F)(F)F)cc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)n1		CHEMBL4115483	=	IC50	nM	278.3	CHEMBL5251	Homo sapiens	IC50	nM	278.3
445282	17804990	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)cc(C5CCC5)n4)cc3)c12		CHEMBL4109802	=	IC50	nM	765.9	CHEMBL5251	Homo sapiens	IC50	nM	765.9
445283	17804991	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(=O)O)c12		CHEMBL4111886	=	IC50	nM	83.5	CHEMBL5251	Homo sapiens	IC50	nM	83.5
445284	17804992	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4109533	=	IC50	nM	0.27	CHEMBL5251	Homo sapiens	IC50	nM	0.27
445285	17804993	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cccc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)n1		CHEMBL4110379	=	IC50	nM	81.2	CHEMBL5251	Homo sapiens	IC50	nM	81.2
445286	17804994	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4111374	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
445287	17804995	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4111802	=	IC50	nM	0.74	CHEMBL5251	Homo sapiens	IC50	nM	0.74
445288	17804996	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4111899	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
445289	17804997	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4108221	=	IC50	nM	0.55	CHEMBL5251	Homo sapiens	IC50	nM	0.55
445290	17804998	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)cc(F)c1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114985	=	IC50	nM	0.28	CHEMBL5251	Homo sapiens	IC50	nM	0.28
445291	17804999	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4110406	=	IC50	nM	0.23	CHEMBL5251	Homo sapiens	IC50	nM	0.23
445292	17805000	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C3CC3)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4113827	=	IC50	nM	0.78	CHEMBL5251	Homo sapiens	IC50	nM	0.78
445293	17805001	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C3CC3)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4112206	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
445294	17805002	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CCCCC3)c12		CHEMBL4112704	=	IC50	nM	135.3	CHEMBL5251	Homo sapiens	IC50	nM	135.3
445295	17805003	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)Oc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4113636	=	IC50	nM	5.7	CHEMBL5251	Homo sapiens	IC50	nM	5.7
445296	17805004	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CCC3)c12		CHEMBL4108745	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
445297	17805005	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CCCC3)c12		CHEMBL4111257	=	IC50	nM	23.7	CHEMBL5251	Homo sapiens	IC50	nM	23.7
445298	17805006	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)(C)COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4113108	=	IC50	nM	17.5	CHEMBL5251	Homo sapiens	IC50	nM	17.5
445299	17805007	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4107715	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
445300	17805008	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(Cl)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CC3)c12		CHEMBL4110893	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
445301	17805009	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)c(OC3CC3)c2)cc1C(F)(F)F		CHEMBL4109975	=	IC50	nM	0.44	CHEMBL5251	Homo sapiens	IC50	nM	0.44
445302	17805010	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)c(OC3CC3)c2)cc1C(F)(F)F		CHEMBL4110307	=	IC50	nM	0.59	CHEMBL5251	Homo sapiens	IC50	nM	0.59
445303	17805011	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(Cl)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3OC3CC3)c12		CHEMBL4115167	=	IC50	nM	0.75	CHEMBL5251	Homo sapiens	IC50	nM	0.75
445304	17805012	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3OC3CC3)c12		CHEMBL4109428	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
445305	17805013	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)c(OC3CNC3)c2)cc1C(F)(F)F		CHEMBL4107684	=	IC50	nM	96.7	CHEMBL5251	Homo sapiens	IC50	nM	96.7
445306	17805014	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2cc(OC3CC3)c(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)cc2F)cc1C(F)(F)F		CHEMBL4107623	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
445307	17805015	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114626	=	IC50	nM	0.75	CHEMBL5251	Homo sapiens	IC50	nM	0.75
445308	17805016	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4106682	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
445309	17805017	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(Cl)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106573	=	IC50	nM	0.16	CHEMBL5251	Homo sapiens	IC50	nM	0.16
445310	17805018	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)cc2)s1		CHEMBL4110295	=	IC50	nM	0.81	CHEMBL5251	Homo sapiens	IC50	nM	0.81
445311	17805019	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(=O)Oc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4106583	=	IC50	nM	3.9	CHEMBL5251	Homo sapiens	IC50	nM	3.9
445312	17805020	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(=O)Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3O)c12		CHEMBL4106570	=	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
445313	17805021	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COCCN(C(=O)c1ccc(-c2nc([C@@H]3CC[C@H]4CCC(=O)N4C3)n3ccnc(N)c23)c(O)c1)c1cc(C(F)(F)F)ccn1		CHEMBL4113960	=	IC50	nM	291.6	CHEMBL5251	Homo sapiens	IC50	nM	291.6
445314	17805022	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2ncc(C)s2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4111910	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
445315	17805023	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2ncc(C)s2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4109249	=	IC50	nM	0.63	CHEMBL5251	Homo sapiens	IC50	nM	0.63
445316	17805024	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4112426	=	IC50	nM	0.28	CHEMBL5251	Homo sapiens	IC50	nM	0.28
445317	17805025	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(F)cnc(N)c12		CHEMBL4113487	=	IC50	nM	0.99	CHEMBL5251	Homo sapiens	IC50	nM	0.99
445318	17805026	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(F)cnc(N)c12		CHEMBL4115294	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
445319	17805027	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(F)cnc(N)c12		CHEMBL4115382	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
445320	17805028	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2ncc(C)s2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(F)cnc(N)c12		CHEMBL4114840	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
445321	17805029	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3O)c12		CHEMBL4108849	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
445322	17805030	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4106893	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
445323	17805031	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3F)c12		CHEMBL4114433	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
445324	17805032	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3)c12		CHEMBL4113785	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
445325	17805033	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(F)cnc(N)c12		CHEMBL4110276	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
445326	17805034	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)[nH]n4)cc3)c12		CHEMBL4110111	=	IC50	nM	36.9	CHEMBL5251	Homo sapiens	IC50	nM	36.9
445327	17805035	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)cc1C(F)(F)F		CHEMBL4115636	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
445328	17805036	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4ncc[nH]4)cc3)c12		CHEMBL4107491	=	IC50	nM	50.7	CHEMBL5251	Homo sapiens	IC50	nM	50.7
445329	17805037	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)on4)cc3)c12		CHEMBL4112520	=	IC50	nM	245.4	CHEMBL5251	Homo sapiens	IC50	nM	245.4
445330	17805038	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)no4)cc3)c12		CHEMBL4107443	=	IC50	nM	240.6	CHEMBL5251	Homo sapiens	IC50	nM	240.6
445331	17805039	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)nn1C		CHEMBL4111981	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
445332	17805040	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1nsc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)n1		CHEMBL4107735	=	IC50	nM	14.9	CHEMBL5251	Homo sapiens	IC50	nM	14.9
445333	17805041	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4nc(C(F)(F)F)c[nH]4)cc3)c12		CHEMBL4114105	=	IC50	nM	144.2	CHEMBL5251	Homo sapiens	IC50	nM	144.2
445334	17805042	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCc1nsc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)n1		CHEMBL4113559	=	IC50	nM	27.6	CHEMBL5251	Homo sapiens	IC50	nM	27.6
445335	17805043	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(C)c1nsc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)n1		CHEMBL4111797	=	IC50	nM	68.9	CHEMBL5251	Homo sapiens	IC50	nM	68.9
445336	17805044	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)n(C5CCCC5)n4)cc3)c12		CHEMBL4112914	=	IC50	nM	284.9	CHEMBL5251	Homo sapiens	IC50	nM	284.9
445337	17805045	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)cc1C1CC1		CHEMBL4113593	=	IC50	nM	0.93	CHEMBL5251	Homo sapiens	IC50	nM	0.93
445338	17805046	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1nnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)s1		CHEMBL4109500	=	IC50	nM	272.1	CHEMBL5251	Homo sapiens	IC50	nM	272.1
445339	17805047	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)cc2)cc1C(F)(F)F		CHEMBL4110832	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
445340	17805048	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOC(=O)c1oc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)nc1C(F)(F)F		CHEMBL4108219	=	IC50	nM	155.3	CHEMBL5251	Homo sapiens	IC50	nM	155.3
445341	17805049	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)cc2)cc1C(F)(F)F		CHEMBL4107900	=	IC50	nM	237.4	CHEMBL5251	Homo sapiens	IC50	nM	237.4
445342	17805050	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4115206	=	IC50	nM	6.9	CHEMBL5251	Homo sapiens	IC50	nM	6.9
445343	17805051	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114033	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
445344	17805052	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4107901	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
445345	17805053	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4111479	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
445346	17805054	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)c(Cl)c2)cc1C(F)(F)F		CHEMBL4112629	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
445347	17805055	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)c(Cl)c2)cc1C(F)(F)F		CHEMBL4109244	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
445348	17805056	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cn1nc(NC(=O)c2cc(Cl)c(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)cc2F)cc1C(F)(F)F		CHEMBL4112798	=	IC50	nM	24.6	CHEMBL5251	Homo sapiens	IC50	nM	24.6
445349	17805057	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3cc(F)c(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Cl)c12		CHEMBL4110336	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
445350	17805058	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(Cl)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Cl)c12		CHEMBL4114207	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
445351	17805059	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4ccnc(N)c34)c(Cl)c2)s1		CHEMBL4108011	=	IC50	nM	0.63	CHEMBL5251	Homo sapiens	IC50	nM	0.63
445352	17805060	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)c(Cl)c2)s1		CHEMBL4115467	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
445353	17805061	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4110933	=	IC50	nM	7.8	CHEMBL5251	Homo sapiens	IC50	nM	7.8
445354	17805062	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(F)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4106878	=	IC50	nM	8.2	CHEMBL5251	Homo sapiens	IC50	nM	8.2
445355	17805063	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COCCOc1cc(C(=O)Nc2cccc(C(F)(F)F)c2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114242	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
445356	17805064	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OCCO)c12		CHEMBL4115000	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
445357	17805065	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOCCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110969	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
445358	17805066	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2ncc(C)s2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4113598	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
445359	17805067	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2ncc(C)s2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4110442	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
445360	17805068	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	C#CCCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4115363	=	IC50	nM	0.75	CHEMBL5251	Homo sapiens	IC50	nM	0.75
445361	17805069	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(C)cnc(N)c12		CHEMBL4114832	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
445362	17805070	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(C(F)(F)F)cnc(N)c12		CHEMBL4107513	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
445363	17805071	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)c(OC)c2)c1		CHEMBL4106492	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
445364	17805072	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CC[C@H]5CCC(=O)N5C4)n4c(Cl)cnc(N)c34)c(OC)c2)c1		CHEMBL4106703	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
445365	17805073	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C3CCC3)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4110184	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
445366	17805074	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2ccc(C)cn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4115078	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
445367	17805075	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(C(F)(F)F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Cl)c12		CHEMBL4107483	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
445368	17805076	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Nc1ncc(C(F)(F)F)n2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C5CC5)ccn4)cc3F)c12		CHEMBL4111707	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
445369	17805077	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(C(F)(F)F)cnc(N)c12		CHEMBL4114465	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
445370	17805078	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)cc(F)c1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4111005	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
445371	17805079	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)n(C)n2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(C(F)(F)F)cnc(N)c12		CHEMBL4111703	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
445372	17805080	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CC(F)(F)Oc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4108663	=	IC50	nM	6.6	CHEMBL5251	Homo sapiens	IC50	nM	6.6
445373	17805081	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)cc(F)c1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4111363	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
445374	17805082	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)c(Cl)cc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(Cl)cnc(N)c12		CHEMBL4113370	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
445375	17805083	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)cc(F)c1-c1nc([C@@H]2CC[C@H]3CC(C)(C)C(=O)N3C2)n2ccnc(N)c12		CHEMBL4111662	=	IC50	nM	0.28	CHEMBL5251	Homo sapiens	IC50	nM	0.28
445376	17805084	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)cc(F)c1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2c(F)cnc(N)c12		CHEMBL4110390	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
445377	17805085	CHEMBL3889266	"LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) Assay: BTK enzymatic activity was determined with the LANCE (Lanthanide Chelate Excite) TR-FRET (Time-resolved fluorescence resonance energy transfer) assay. In this assay, the potency (IC50) of each compound was determined from an eleven point (1:3 serial dilution; final compound concentration range in assay from 1 uM to 0.017 nM) titration curve using the following outlined procedure. To each well of a black non-binding surface Corning 384-well microplate (Corning Catalog #3820), 5 nL of compound (2000 fold dilution in final assay volume of 10 uL) was dispensed, followed by the addition of 7.5 uL of 1x kinase buffer (50 mM Hepes 7.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 0.05% BSA & 1 mM DTT) containing 5.09 pg/uL (66.67 pM) of BTK enzyme (recombinant protein from baculovirus-transfected Sf9 cells: full-length BTK, 6HIS-tag cleaved). Following a 60 minute compound & enzyme incubation, each reaction was initiated by the addition of 2.5 uL 1x kinase buffer containing 8 uM biotinylated ""A5"" peptide (Biotin-EQEDEPEGDYFEWLE-NH2) (SEQ ID NO: 1), and 100 uM ATP. The final reaction in each well of 10 uL consists of 100 pM hBTK, 2 uM biotin-A5-peptide, and 25 uM ATP. Phosphorylation reactions were allowed to proceed for 120 minutes. Reactions were immediately quenched by the addition of 20 uL of 1x quench buffer (15 mM EDTA, 25 mM Hepes 7.3, and 0.1% Triton X-100) containing detection reagents (0.626 nM of LANCE-Eu-W1024-anti-phosphoTyrosine antibody, PerkinElmer and 86.8 nM of Streptavidin-conjugated Dylight 650, Dyomics/ThermoFisher Scientific). After 60 minutes incubation with detection reagents, reaction plates were read on a PerkinElmer EnVision plate reader using standard TR-FRET protocol. Briefly, excitation of donor molecules (Eu-chelate:anti-phospho-antibody) with a laser light source at 337 nm produces energy that can be transferred to Dylight-650 acceptor molecules if this donor:acceptor pair is within close proximity. Fluorescence intensity at both 665 nm (acceptor) and 615 nm (donor) are measured and a TR-FRET ratio calculated for each well (acceptor intensity/donor intensity). IC50 values were determined by 4 parameter robust fit of TR-FRET ratio values vs. (Log10) compound concentrations."	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@@H]3N(C2)C(=O)CC3(C)C)n2ccnc(N)c12		CHEMBL4114097	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
Inactive	17885960	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885961	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885962	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885963	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	=	Kd	nM	494.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	494.0
Inactive	17885964	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885965	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885966	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885967	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885968	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885969	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885970	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885971	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885972	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885973	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	=	Kd	nM	4.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	4.0
Inactive	17885974	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885975	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885976	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	=	Kd	nM	2839.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	2839.0
Inactive	17885977	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885978	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885979	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17885980	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	15816.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	15816.0
Inactive	17885981	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885982	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885983	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885984	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885985	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	=	Kd	nM	504.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	504.0
Inactive	17885986	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885987	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885988	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	=	Kd	nM	10153.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	10153.0
Inactive	17885989	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885990	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885991	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885992	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885993	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885994	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885995	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	=	Kd	nM	588.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	588.0
Inactive	17885996	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885997	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17885998	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17885999	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	=	Kd	nM	3.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	3.0
Inactive	17886000	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886001	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	3066.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	3066.0
Active	17886002	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	1567.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1567.0
Inactive	17886003	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886004	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886005	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886006	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886007	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886008	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886009	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886010	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886011	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886012	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886013	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	328.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	328.0
Inactive	17886014	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886015	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886016	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	=	Kd	nM	525.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	525.0
Inactive	17886017	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886018	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	=	Kd	nM	1555.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1555.0
Inactive	17886019	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886020	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886021	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886022	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886023	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	=	Kd	nM	1623.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1623.0
Inactive	17886024	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886025	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886026	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886027	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886028	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886029	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886030	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886031	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886032	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886033	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886034	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886035	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886036	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886037	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886038	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886039	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886040	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886041	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886042	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886043	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886044	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886045	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886046	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886047	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886048	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886049	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886050	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886051	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886052	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	25.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	25.0
Inactive	17886053	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886054	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886055	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886056	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886057	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886058	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886059	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886060	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886061	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886062	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886063	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886064	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886065	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886066	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886067	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886068	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886069	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886070	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	1179.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1179.0
Inactive	17886071	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886072	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886073	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886074	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886075	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	=	Kd	nM	345.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	345.0
Inactive	17886076	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886077	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886078	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886079	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886080	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886081	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886082	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886083	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886084	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886085	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886086	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886087	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886088	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886089	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886090	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886091	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886092	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886093	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886094	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886095	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886096	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	=	Kd	nM	1219.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1219.0
Inactive	17886097	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886098	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886099	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17886100	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	=	Kd	nM	1841.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1841.0
Inactive	17886101	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886102	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886103	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886104	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886105	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	=	Kd	nM	547.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	547.0
Inactive	17886106	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886107	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886108	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886109	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886110	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886111	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886112	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886113	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886114	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886115	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	537.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	537.0
Inactive	17886116	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886117	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886118	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886119	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886120	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886121	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886122	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886123	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	5.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	5.0
Inactive	17886124	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886125	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	423.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	423.0
Inactive	17886126	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886127	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886128	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886129	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	1208.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1208.0
Inactive	17886130	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886131	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886132	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886133	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17886134	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	1230.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1230.0
Inactive	17886135	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886136	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886137	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Kd	nM	10.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	10.0
Inactive	17886138	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886139	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886140	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886141	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886142	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886143	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886144	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886145	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886146	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886147	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886148	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17886149	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	386.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	386.0
Inactive	17886150	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886151	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886152	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886153	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886154	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886155	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886156	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886157	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886158	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886159	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886160	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	3430.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	3430.0
Inactive	17886161	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886162	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886163	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886164	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886165	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886166	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886167	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886168	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886169	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886170	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	514.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	514.0
Inactive	17886171	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886172	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886173	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886174	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886175	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	=	Kd	nM	1461.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	1461.0
Inactive	17886176	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886177	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886178	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886179	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886180	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886181	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Active	17886182	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	361.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	361.0
Inactive	17886183	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886184	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886185	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886186	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886187	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886188	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886189	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886190	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886191	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886192	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886193	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886194	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886195	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886196	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886197	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886198	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886199	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886200	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886201	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17886202	CHEMBL3991638	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL5251	Homo sapiens	Kd apparent	nM	30000.0
	17952349	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N(CCOC)CCOC)cc3)ncc2Cl)c1		CHEMBL4100369	=	IC50	nM	4.94	CHEMBL5251	Homo sapiens	IC50	nM	4.94
	17952350	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N(CCOC)CCOC)cc3)ncc2F)c1		CHEMBL4082353	=	IC50	nM	7.12	CHEMBL5251	Homo sapiens	IC50	nM	7.12
	17952351	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N(CCOC)CCOC)cc3)ncc2Cl)c1		CHEMBL4074951	=	IC50	nM	2.83	CHEMBL5251	Homo sapiens	IC50	nM	2.83
	17952352	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N(CCOC)CCOC)cc3)ncc2F)c1		CHEMBL4095386	=	IC50	nM	27.2	CHEMBL5251	Homo sapiens	IC50	nM	27.2
	17952353	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N(CCOC)CCOC)c(Cl)c3)ncc2Cl)c1		CHEMBL4066344	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	17952354	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CN(CCOC)CCOC)cc3)ncc2Cl)c1		CHEMBL4087694	=	IC50	nM	22.6	CHEMBL5251	Homo sapiens	IC50	nM	22.6
	17952355	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CN(CCOC)CCOC)cc3)ncc2F)c1		CHEMBL4092943	=	IC50	nM	91.3	CHEMBL5251	Homo sapiens	IC50	nM	91.3
	17952356	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CN(CCOC)CCOC)c(OC)c3)ncc2Cl)c1		CHEMBL4065282	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	17952357	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CN(CCOC)CCOC)c(C)c3)ncc2Cl)c1		CHEMBL4085200	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	17952358	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC4CCCO4)cc3)ncc2Cl)c1		CHEMBL4103138	=	IC50	nM	12.1	CHEMBL5251	Homo sapiens	IC50	nM	12.1
	17952359	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC4CCCO4)cc3)ncc2F)c1		CHEMBL4087240	=	IC50	nM	22.4	CHEMBL5251	Homo sapiens	IC50	nM	22.4
	17952360	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)OCC4CCCO4)cc3)ncc2Cl)c1		CHEMBL4060363	=	IC50	nM	0.23	CHEMBL5251	Homo sapiens	IC50	nM	0.23
	17952361	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
	17952362	CHEMBL3992978	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
	17952363	CHEMBL3992979	Irreversible inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate assessed as luminescence of compound linked enzyme at 5000 nmol/L incubated for 60 mins by ADP-Glo kinase assay (Rvb = 9976 No_unit)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC4CCCO4)cc3)ncc2Cl)c1		CHEMBL4103138	=	Activity	RLU	383.0	CHEMBL5251	Homo sapiens	Activity	RLU	383.0
	17964880	CHEMBL3994989	Inhibition of full length human BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	17979239	CHEMBL3998044	Inhibition of recombinant human His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 10 uM by Z'-LYTE assay relative to control	B	CC1=Nc2c(Sc3ccccc3)ncnc2Sc2ccccc21		CHEMBL4061152	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	17989712	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CCC[C@H](C(=O)O)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4087679	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	17989713	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CS(=O)(=O)NC(=O)[C@H]1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4105560	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	17989714	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CCC[C@H](c4nn[nH]n4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4062247	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	17989715	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CCC[C@H](c4noc(=O)[nH]4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4090257	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	17989716	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CCC[C@H](c4nnc[nH]4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4100424	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	17989717	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Cn1nnc([C@H]2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)n1		CHEMBL4082411	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	17989718	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Cn1nnnc1[C@H]1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4081452	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	17989719	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CCC[C@H](c4n[nH]c(=O)o4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4059483	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	17989720	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	NC(=O)[C@H]1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4070865	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	17989721	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@H]1CC[C@H](C(=O)O)CC1		CHEMBL4097968	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	17989722	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@H]1CC[C@@H](C(=O)O)CC1		CHEMBL4074674	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	17989723	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H](C(=O)O)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4101367	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	17989724	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3C[C@H]4[C@@H](C3)[C@@H]4C(=O)O)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4097957	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	17989725	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(C)[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C[C@H]1C(=O)O		CHEMBL4070853	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	17989726	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c(C34CCC(C(=O)O)(CC3)CC4)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4059473	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	17989727	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@]12CCC[C@](C(=O)O)(CC1)CC2		CHEMBL4081444	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	17989728	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@]12CC[C@](C(=O)O)(CC1)C2		CHEMBL4068131	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	17989729	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c(C34CC(C(=O)O)(C3)C4)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4089318	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	17989730	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c(C34C5C6C3C3C4C5C63C(=O)O)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4079005	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	17989731	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc(C23CCC(C(=O)O)(CC2)CC3)n2ccnc(N)c12		CHEMBL4097019	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	17989732	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@]1(C(=O)O)CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4063275	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	17989733	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(C)[C@]1(C(=O)O)CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4084927	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	17989734	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@]1(C(=O)O)CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4087578	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	17989735	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(C)[C@]1(C(=O)O)CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4066216	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	17989736	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)O)CCC(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)CC1		CHEMBL4095276	=	IC50	nM	4.5	CHEMBL5251	Homo sapiens	IC50	nM	4.5
	17989737	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@]1(C(=O)O)CCC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4074833	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	17989738	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4068919	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	17989739	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(C)[C@@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4096195	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	17989740	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn32)CC1		CHEMBL4079697	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	17989741	CHEMBL3999900	Inhibition of 6-His-tagged recombinant full length BTK (unknown origin) expressed in baculovirus-transfected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	17989742	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3CCC[C@H](C(=O)O)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4087679	=	IC50	nM	98.0	CHEMBL5251	Homo sapiens	IC50	nM	98.0
	17989743	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CS(=O)(=O)NC(=O)[C@H]1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4105560	=	IC50	nM	648.0	CHEMBL5251	Homo sapiens	IC50	nM	648.0
	17989744	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3CCC[C@H](c4nn[nH]n4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4062247	=	IC50	nM	1587.0	CHEMBL5251	Homo sapiens	IC50	nM	1587.0
	17989745	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3CCC[C@H](c4noc(=O)[nH]4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4090257	=	IC50	nM	979.0	CHEMBL5251	Homo sapiens	IC50	nM	979.0
	17989746	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3CCC[C@H](c4nnc[nH]4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4100424	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	17989747	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Cn1nnc([C@H]2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)n1		CHEMBL4082411	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	17989748	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Cn1nnnc1[C@H]1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4081452	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	17989749	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3CCC[C@H](c4n[nH]c(=O)o4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4059483	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
	17989750	CHEMBL3999901	Inhibition of BTK in human PBMC	B	NC(=O)[C@H]1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4070865	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	17989751	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@H]1CC[C@H](C(=O)O)CC1		CHEMBL4097968	=	IC50	nM	77.0	CHEMBL5251	Homo sapiens	IC50	nM	77.0
	17989752	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@H]1CC[C@@H](C(=O)O)CC1		CHEMBL4074674	=	IC50	nM	1237.0	CHEMBL5251	Homo sapiens	IC50	nM	1237.0
	17989753	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3CC[C@H](C(=O)O)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4101367	=	IC50	nM	132.0	CHEMBL5251	Homo sapiens	IC50	nM	132.0
	17989754	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c([C@@H]3C[C@H]4[C@@H](C3)[C@@H]4C(=O)O)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4097957	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	17989755	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CC(C)[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C[C@H]1C(=O)O		CHEMBL4070853	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
	17989756	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c(C34CCC(C(=O)O)(CC3)CC4)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4059473	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	17989757	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@]12CCC[C@](C(=O)O)(CC1)CC2		CHEMBL4081444	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	17989758	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@]12CC[C@](C(=O)O)(CC1)C2		CHEMBL4068131	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	17989759	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c(C34CC(C(=O)O)(C3)C4)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4089318	=	IC50	nM	67.0	CHEMBL5251	Homo sapiens	IC50	nM	67.0
	17989760	CHEMBL3999901	Inhibition of BTK in human PBMC	B	Nc1nccn2c(C34C5C6C3C3C4C5C63C(=O)O)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4079005	=	IC50	nM	49.0	CHEMBL5251	Homo sapiens	IC50	nM	49.0
	17989761	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc(C23CCC(C(=O)O)(CC2)CC3)n2ccnc(N)c12		CHEMBL4097019	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	17989762	CHEMBL3999901	Inhibition of BTK in human PBMC	B	C[C@]1(C(=O)O)CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4063275	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	17989763	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CC(C)[C@]1(C(=O)O)CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4084927	=	IC50	nM	128.0	CHEMBL5251	Homo sapiens	IC50	nM	128.0
	17989764	CHEMBL3999901	Inhibition of BTK in human PBMC	B	C[C@]1(C(=O)O)CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4087578	=	IC50	nM	62.0	CHEMBL5251	Homo sapiens	IC50	nM	62.0
	17989765	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CC(C)[C@]1(C(=O)O)CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4066216	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
	17989766	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CC1(C(=O)O)CCC(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)CC1		CHEMBL4095276	=	IC50	nM	546.0	CHEMBL5251	Homo sapiens	IC50	nM	546.0
	17989767	CHEMBL3999901	Inhibition of BTK in human PBMC	B	C[C@]1(C(=O)O)CCC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4074833	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	17989768	CHEMBL3999901	Inhibition of BTK in human PBMC	B	C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4068919	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	17989769	CHEMBL3999901	Inhibition of BTK in human PBMC	B	CC(C)[C@@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4096195	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	17989770	CHEMBL3999901	Inhibition of BTK in human PBMC	B	C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn32)CC1		CHEMBL4079697	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	17989771	CHEMBL3999901	Inhibition of BTK in human PBMC	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	17989772	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c([C@@H]3CCC[C@H](C(=O)O)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12	Non standard unit for type	CHEMBL4087679	=	INH	nM	2788.0	CHEMBL5251	Homo sapiens	INH	nM	2788.0
	17989773	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@H]1CC[C@H](C(=O)O)CC1	Non standard unit for type	CHEMBL4097968	=	INH	nM	2307.0	CHEMBL5251	Homo sapiens	INH	nM	2307.0
Not Determined	17989774	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@H]1CC[C@@H](C(=O)O)CC1		CHEMBL4074674		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Determined	17989775	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c([C@@H]3CC[C@H](C(=O)O)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4101367		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	17989776	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c([C@@H]3C[C@H]4[C@@H](C3)[C@@H]4C(=O)O)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12	Non standard unit for type	CHEMBL4097957	=	INH	nM	232.0	CHEMBL5251	Homo sapiens	INH	nM	232.0
	17989777	CHEMBL3999902	Inhibition of BTK in human whole blood	B	CC(C)[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C[C@H]1C(=O)O	Non standard unit for type	CHEMBL4070853	=	INH	nM	246.0	CHEMBL5251	Homo sapiens	INH	nM	246.0
	17989778	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c(C34CCC(C(=O)O)(CC3)CC4)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12	Non standard unit for type	CHEMBL4059473	=	INH	nM	99.0	CHEMBL5251	Homo sapiens	INH	nM	99.0
	17989779	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@]12CCC[C@](C(=O)O)(CC1)CC2	Non standard unit for type	CHEMBL4081444	=	INH	nM	161.0	CHEMBL5251	Homo sapiens	INH	nM	161.0
	17989780	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c1c(-c1ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc1)nc2[C@]12CC[C@](C(=O)O)(CC1)C2	Non standard unit for type	CHEMBL4068131	=	INH	nM	264.0	CHEMBL5251	Homo sapiens	INH	nM	264.0
	17989781	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c(C34CC(C(=O)O)(C3)C4)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12	Non standard unit for type	CHEMBL4089318	=	INH	nM	1909.0	CHEMBL5251	Homo sapiens	INH	nM	1909.0
	17989782	CHEMBL3999902	Inhibition of BTK in human whole blood	B	Nc1nccn2c(C34C5C6C3C3C4C5C63C(=O)O)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12	Non standard unit for type	CHEMBL4079005	=	INH	nM	1267.0	CHEMBL5251	Homo sapiens	INH	nM	1267.0
	17989783	CHEMBL3999902	Inhibition of BTK in human whole blood	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc(C23CCC(C(=O)O)(CC2)CC3)n2ccnc(N)c12	Non standard unit for type	CHEMBL4097019	=	INH	nM	67.0	CHEMBL5251	Homo sapiens	INH	nM	67.0
	17989784	CHEMBL3999902	Inhibition of BTK in human whole blood	B	C[C@]1(C(=O)O)CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1	Non standard unit for type	CHEMBL4063275	=	INH	nM	1071.0	CHEMBL5251	Homo sapiens	INH	nM	1071.0
Not Determined	17989785	CHEMBL3999902	Inhibition of BTK in human whole blood	B	CC(C)[C@]1(C(=O)O)CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4084927		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	17989786	CHEMBL3999902	Inhibition of BTK in human whole blood	B	C[C@]1(C(=O)O)CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1	Non standard unit for type	CHEMBL4087578	=	INH	nM	909.0	CHEMBL5251	Homo sapiens	INH	nM	909.0
	17989787	CHEMBL3999902	Inhibition of BTK in human whole blood	B	CC(C)[C@]1(C(=O)O)CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1	Non standard unit for type	CHEMBL4066216	=	INH	nM	604.0	CHEMBL5251	Homo sapiens	INH	nM	604.0
Not Determined	17989788	CHEMBL3999902	Inhibition of BTK in human whole blood	B	CC1(C(=O)O)CCC(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)CC1		CHEMBL4095276		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	17989789	CHEMBL3999902	Inhibition of BTK in human whole blood	B	C[C@]1(C(=O)O)CCC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1	Non standard unit for type	CHEMBL4074833	=	INH	nM	210.0	CHEMBL5251	Homo sapiens	INH	nM	210.0
	17989790	CHEMBL3999902	Inhibition of BTK in human whole blood	B	C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1	Non standard unit for type	CHEMBL4068919	=	INH	nM	145.0	CHEMBL5251	Homo sapiens	INH	nM	145.0
	17989791	CHEMBL3999902	Inhibition of BTK in human whole blood	B	CC(C)[C@@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1	Non standard unit for type	CHEMBL4096195	=	INH	nM	289.0	CHEMBL5251	Homo sapiens	INH	nM	289.0
	17989792	CHEMBL3999902	Inhibition of BTK in human whole blood	B	C[C@]1(C(=O)O)CC[C@@](C)(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn32)CC1	Non standard unit for type	CHEMBL4079697	=	INH	nM	272.0	CHEMBL5251	Homo sapiens	INH	nM	272.0
	17989793	CHEMBL3999902	Inhibition of BTK in human whole blood	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1	Non standard unit for type	CHEMBL4103954	=	INH	nM	94.0	CHEMBL5251	Homo sapiens	INH	nM	94.0
	17992312	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CC(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4073491	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	17992313	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	Nc1cccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)c1		CHEMBL4065778	=	IC50	nM	2410.0	CHEMBL5251	Homo sapiens	IC50	nM	2410.0
	17992314	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4093393	=	IC50	nM	56.3	CHEMBL5251	Homo sapiens	IC50	nM	56.3
	17992315	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(-c4ccc(O)cc4)cc23)c1CO		CHEMBL4081221	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
	17992316	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	Cc1cc2c(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)ccnc2[nH]1		CHEMBL4105470	=	IC50	nM	213.0	CHEMBL5251	Homo sapiens	IC50	nM	213.0
	17992317	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]ccc23)c1CO		CHEMBL4070603	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	nM	350.0
	17992318	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	13.2	CHEMBL5251	Homo sapiens	IC50	nM	13.2
	17992319	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402584	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	17992320	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cccc3[nH]2)CC1		CHEMBL4087870	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	17992321	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN(C)C(=O)c1ccc(-c2nc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4097010	=	IC50	nM	33.3	CHEMBL5251	Homo sapiens	IC50	nM	33.3
	17992322	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL4079989	=	IC50	nM	31.4	CHEMBL5251	Homo sapiens	IC50	nM	31.4
	17992323	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN(C)S(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4085393	=	IC50	nM	9.7	CHEMBL5251	Homo sapiens	IC50	nM	9.7
	17992324	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4103325	=	IC50	nM	7.1	CHEMBL5251	Homo sapiens	IC50	nM	7.1
	17992325	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=C(N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1)N1CCOCC1		CHEMBL4075160	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
	17992326	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4095573	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	17992327	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=C(C1CC1)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4105206	=	IC50	nM	10.4	CHEMBL5251	Homo sapiens	IC50	nM	10.4
	17992328	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CC(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4087347	=	IC50	nM	6.7	CHEMBL5251	Homo sapiens	IC50	nM	6.7
	17992329	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(C4=CCNCC4)cc23)c1CO		CHEMBL4101864	=	IC50	nM	28.3	CHEMBL5251	Homo sapiens	IC50	nM	28.3
	17992330	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	Cn1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)n1		CHEMBL4083867	=	IC50	nM	20.6	CHEMBL5251	Homo sapiens	IC50	nM	20.6
	17992331	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cn1		CHEMBL4063859	=	IC50	nM	68.3	CHEMBL5251	Homo sapiens	IC50	nM	68.3
	17992332	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CC(=O)c1cc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cs1		CHEMBL4091642	=	IC50	nM	78.1	CHEMBL5251	Homo sapiens	IC50	nM	78.1
	17992333	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)c1CO		CHEMBL4086354	=	IC50	nM	18.1	CHEMBL5251	Homo sapiens	IC50	nM	18.1
	17992334	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=C(c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1)N1CCCCC1		CHEMBL4064893	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	17992335	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CN(C)C(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4094133	=	IC50	nM	12.1	CHEMBL5251	Homo sapiens	IC50	nM	12.1
	17992336	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	CC(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4073491	=	IC50	nM	21.3	CHEMBL5251	Homo sapiens	IC50	nM	21.3
	17992337	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	Nc1cccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)c1		CHEMBL4065778	=	IC50	nM	110.3	CHEMBL5251	Homo sapiens	IC50	nM	110.3
	17992338	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4093393	=	IC50	nM	27.3	CHEMBL5251	Homo sapiens	IC50	nM	27.3
	17992339	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(-c4ccc(O)cc4)cc23)c1CO		CHEMBL4081221	=	IC50	nM	39.8	CHEMBL5251	Homo sapiens	IC50	nM	39.8
	17992340	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	Cc1cc2c(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)ccnc2[nH]1		CHEMBL4105470	=	IC50	nM	395.0	CHEMBL5251	Homo sapiens	IC50	nM	395.0
	17992341	CHEMBL4000359	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus using biotin labeled peptide substrate after 1 hr by HRTF kinase/TR-FRET assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]ccc23)c1CO		CHEMBL4070603	=	IC50	nM	562.2	CHEMBL5251	Homo sapiens	IC50	nM	562.2
	17992342	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN(C)C(=O)c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4094133	=	IC50	nM	94.2	CHEMBL5251	Homo sapiens	IC50	nM	94.2
	17992343	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=C(c1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1)N1CCCCC1		CHEMBL4064893	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
	17992344	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)c1CO		CHEMBL4086354	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	nM	69.0
	17992345	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CC(=O)c1cc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cs1		CHEMBL4091642	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	nM	69.0
	17992346	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	COc1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cn1		CHEMBL4063859	=	IC50	nM	196.0	CHEMBL5251	Homo sapiens	IC50	nM	196.0
	17992347	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	Cn1ccc(-c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)n1		CHEMBL4083867	=	IC50	nM	9.5	CHEMBL5251	Homo sapiens	IC50	nM	9.5
	17992348	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(C4=CCNCC4)cc23)c1CO		CHEMBL4101864	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	17992349	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CC(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4087347	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	17992350	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=C(C1CC1)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4105206	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	17992351	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4095573	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	17992352	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=C(N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1)N1CCOCC1		CHEMBL4075160	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	nM	42.0
	17992353	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4103325	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	nM	410.0
	17992354	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN(C)S(=O)(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4085393	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
	17992355	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	O=c1c2c(F)cc(C3CC3)cc2ccn1-c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL4079989	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	17992356	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN(C)C(=O)c1ccc(-c2nc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ccnc3[nH]2)cc1		CHEMBL4097010	=	IC50	nM	92.7	CHEMBL5251	Homo sapiens	IC50	nM	92.7
	17992357	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cccc3[nH]2)CC1		CHEMBL4087870	>	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	nM	5000.0
	17992358	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)ncnc3[nH]2)CC1		CHEMBL3402584	=	IC50	nM	21.6	CHEMBL5251	Homo sapiens	IC50	nM	21.6
	17992359	CHEMBL4000360	Inhibition of BTK in human Ramos cells assessed as inhibition of anti human IgM-induced calcium influx preincubated for 20 mins in dark followed by anti human IgM induction for 8 mins by FLIPR assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	27.3	CHEMBL5251	Homo sapiens	IC50	nM	27.3
	17996248	CHEMBL4001396	Inhibition of human wild type full length BTK (M1 to S659 residues) expressed in mammalian expression system at 10 uM by KinomeScan method relative to control	B	Cc1nc2nc(Sc3ccccc3)cnc2cc1NC(=O)Nc1ccccc1		CHEMBL4083528	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	18020380	CHEMBL4005758	Inhibition of full length recombinant human His-tagged cytoplasmic BTK expressed in baculovirus expression system assessed as inactivation rate by KT236 probe based TR-FRET assay	B	C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C		CHEMBL4085457	=	Kinact	/s	0.124	CHEMBL5251	Homo sapiens	Kinact	/s	0.124
	18020387	CHEMBL4005765	Inhibition of full length recombinant human His-tagged cytoplasmic BTK expressed in baculovirus expression system by KT236 probe based TR-FRET assay	B	C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C		CHEMBL4085457	=	Ki	nM	62300.0	CHEMBL5251	Homo sapiens	Ki	uM	62.3
	18020394	CHEMBL4005772	Ratio of Kinact to Ki for full length recombinant human His-tagged cytoplasmic BTK	B	C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C		CHEMBL4085457	=	Ratio	10'3/M/s	1.99	CHEMBL5251	Homo sapiens	Ratio	10'3/M/s	1.99
	18020401	CHEMBL4005779	Inhibition of full length recombinant human His-tagged cytoplasmic BTK expressed in baculovirus expression system in presence of 1 mM ATP by KT236 probe based TR-FRET assay	B	C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C		CHEMBL4085457	=	IC50	nM	607.0	CHEMBL5251	Homo sapiens	IC50	nM	607.0
	18031622	CHEMBL4007688	Inhibition of BTK (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	4950.0	CHEMBL5251	Homo sapiens	IC50	uM	4.95
	18031623	CHEMBL4007688	Inhibition of BTK (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18031624	CHEMBL4007688	Inhibition of BTK (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18031625	CHEMBL4007688	Inhibition of BTK (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	5020.0	CHEMBL5251	Homo sapiens	IC50	uM	5.02
	18031626	CHEMBL4007688	Inhibition of BTK (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18034735	CHEMBL4008337	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system using Poly(4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo kinase assay	B	C=CC(=O)Nc1cc(Nc2ncc(C(=O)Nc3cc(NC(=O)c4cc(OC)c(OC)c(OC)c4)ccc3C)c(NC)n2)ccc1C		CHEMBL4066104	=	IC50	nM	437.0	CHEMBL5251	Homo sapiens	IC50	nM	437.0
	18034736	CHEMBL4008337	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system using Poly(4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo kinase assay	B	CCC(=O)Nc1cc(Nc2ncc(C(=O)Nc3cc(NC(=O)c4cc(OC)c(OC)c(OC)c4)ccc3C)c(NC)n2)ccc1C		CHEMBL4087478	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18034772	CHEMBL4008371	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system by Z'-LYTE assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NS(C)(=O)=O)cc5)cc4c32)ccc1C		CHEMBL4091991	=	IC50	nM	10.4	CHEMBL5251	Homo sapiens	IC50	nM	10.4
	18040170	CHEMBL4009517	Inhibition of full-length recombinant human His-tagged cytoplasmic BTK expressed in baculovirus expression system at 1 uM by Z'-LYTE assay	B	C=CC(=O)Nc1cc(Nc2n[nH]c3cc(Nc4cccc(F)c4)ccc23)c(OC)cc1N(C)CCN(C)C		CHEMBL4068763	>	Inhibition	%	85.0	CHEMBL5251	Homo sapiens	INH	%	85.0
Not Determined	18066707	CHEMBL4014528	Inhibition of human BTK	B	COc1ccc(-c2cnc3scc(NC(=O)C4CCCCC4)c3c2)cc1OC		CHEMBL3334979		IC50			CHEMBL5251	Homo sapiens	IC50		
	18066708	CHEMBL4014528	Inhibition of human BTK	B	CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O		CHEMBL4105195	=	IC50	nM	5000.0	CHEMBL5251	Homo sapiens	IC50	uM	5.0
	18066709	CHEMBL4014528	Inhibition of human BTK	B	COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2		CHEMBL4087337	=	IC50	nM	5030.0	CHEMBL5251	Homo sapiens	IC50	uM	5.03
	18066710	CHEMBL4014528	Inhibition of human BTK	B	O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21		CHEMBL490355	=	IC50	nM	6020.0	CHEMBL5251	Homo sapiens	IC50	uM	6.02
	18084574	CHEMBL4018335	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4089245	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18084606	CHEMBL4018328	Inhibition of human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1		CHEMBL4068896	=	Inhibition	%	-7.0	CHEMBL5251	Homo sapiens	INH	%	-7.0
	18084613	CHEMBL4018335	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1		CHEMBL4068896	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18084622	CHEMBL4018328	Inhibition of human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4089245	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	18084666	CHEMBL4018328	Inhibition of human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control	B	C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4077859	=	Inhibition	%	14.0	CHEMBL5251	Homo sapiens	INH	%	14.0
	18084673	CHEMBL4018335	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4077859	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18084682	CHEMBL4018335	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	15000.0	CHEMBL5251	Homo sapiens	IC50	uM	15.0
	18092320	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	Fc1cccc(Cl)c1CNc1nc(-c2ccco2)n[nH]1		CHEMBL1354522	=	IC50	nM	1091.0	CHEMBL5251	Homo sapiens	IC50	uM	1.091
	18092321	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	Fc1cccc(Cl)c1CNc1nc(-c2ccccc2)n[nH]1		CHEMBL4103618	=	IC50	nM	1380.0	CHEMBL5251	Homo sapiens	IC50	uM	1.38
	18092322	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	Oc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4079354	=	IC50	nM	1213.0	CHEMBL5251	Homo sapiens	IC50	uM	1.213
	18092323	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	Nc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4100228	=	IC50	nM	526.0	CHEMBL5251	Homo sapiens	IC50	uM	0.526
	18092324	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	CNc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4073371	=	IC50	nM	271.0	CHEMBL5251	Homo sapiens	IC50	uM	0.271
	18092325	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	COc1ccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)cc1N		CHEMBL4064000	=	IC50	nM	334.0	CHEMBL5251	Homo sapiens	IC50	uM	0.334
	18092326	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	COc1ccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)cc1OC		CHEMBL4091764	=	IC50	nM	153.0	CHEMBL5251	Homo sapiens	IC50	uM	0.153
	18092327	CHEMBL4020190	Inhibition of human N-terminal His-tagged BTK expressed in bacmid transfected Sf21 insect cells using TK-substrate-biotin after 40 mins by HTRF assay	B	C=CC(=O)Nc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4101977	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	18092351	CHEMBL4020207	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition by filter binding method	B	C=CC(=O)Nc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4101977	=	IC50	nM	1.91	CHEMBL5251	Homo sapiens	IC50	nM	1.91
	18092352	CHEMBL4020207	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition by filter binding method	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.11	CHEMBL5251	Homo sapiens	IC50	nM	0.11
	18092357	CHEMBL4020210	Inhibition of BTK (unknown origin) preincubated for 1 hr followed by ATP addition measured after 1 hr by immobilized metal ion affinity-based fluorescence polarization assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
Dose-dependent effect	18092360	CHEMBL4020213	Inhibition of BTK autophosphorylation at Y223 in human Ramos cells after 1.5 hrs by immunoblot method	B	Fc1cccc(Cl)c1CNc1nc(-c2ccco2)n[nH]1		CHEMBL1354522		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18092361	CHEMBL4020213	Inhibition of BTK autophosphorylation at Y223 in human Ramos cells after 1.5 hrs by immunoblot method	B	COc1ccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)cc1OC		CHEMBL4091764		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18092362	CHEMBL4020213	Inhibition of BTK autophosphorylation at Y223 in human Ramos cells after 1.5 hrs by immunoblot method	B	C=CC(=O)Nc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4101977		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18092363	CHEMBL4020214	Inhibition of BTK in human Ramos cells assessed as decrease in PLCgamma2 phosphorylation at Y1217 after 1.5 hrs by immunoblot method	B	Fc1cccc(Cl)c1CNc1nc(-c2ccco2)n[nH]1		CHEMBL1354522		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18092364	CHEMBL4020214	Inhibition of BTK in human Ramos cells assessed as decrease in PLCgamma2 phosphorylation at Y1217 after 1.5 hrs by immunoblot method	B	COc1ccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)cc1OC		CHEMBL4091764		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18092365	CHEMBL4020214	Inhibition of BTK in human Ramos cells assessed as decrease in PLCgamma2 phosphorylation at Y1217 after 1.5 hrs by immunoblot method	B	C=CC(=O)Nc1cccc(-c2n[nH]c(NCc3c(F)cccc3Cl)n2)c1		CHEMBL4101977		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18109155	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670095	=	Ki	nM	0.69	CHEMBL5251	Homo sapiens	Ki	nM	0.69
	18109156	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4085477	=	Ki	nM	1.8	CHEMBL5251	Homo sapiens	Ki	nM	1.8
	18109157	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2cncc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4101904	=	Ki	nM	6.3	CHEMBL5251	Homo sapiens	Ki	nM	6.3
	18109158	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2nccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4075253	=	Ki	nM	6.9	CHEMBL5251	Homo sapiens	Ki	nM	6.9
	18109159	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC1C=C(c2ccnc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4075845	=	Ki	nM	5.97	CHEMBL5251	Homo sapiens	Ki	nM	5.97
	18109160	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC1C=C(c2ccnc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4063638	=	Ki	nM	0.58	CHEMBL5251	Homo sapiens	Ki	nM	0.58
	18109161	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC1C=C(c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4086408	=	Ki	nM	1.8	CHEMBL5251	Homo sapiens	Ki	nM	1.8
	18109162	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC1C=C(c2ccnc(-n3ccn4c5c(cc4c3=O)CCCC5)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4104307	=	Ki	nM	4.2	CHEMBL5251	Homo sapiens	Ki	nM	4.2
	18109163	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC1C=C(c2ccnc(N3CCn4c5c(c(F)c4C3=O)CCCC5)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4090946	=	Ki	nM	2.5	CHEMBL5251	Homo sapiens	Ki	nM	2.5
	18109164	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC1C=C(c2ccnc(N3Cc4cc(C(C)(C)C)sc4C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4093188	=	Ki	nM	1.0	CHEMBL5251	Homo sapiens	Ki	nM	1.0
	18109165	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2cccc(N3CCN(C4COC4)CC3)n2)c1=O		CHEMBL4082268	=	Ki	nM	1.8	CHEMBL5251	Homo sapiens	Ki	nM	1.8
	18109166	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC(=O)N1CCN(c2ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4060356	=	Ki	nM	1.8	CHEMBL5251	Homo sapiens	Ki	nM	1.8
	18109167	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC(=O)N1CC2(C1)CN(c1ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc1)C2		CHEMBL4071754	=	Ki	nM	3.3	CHEMBL5251	Homo sapiens	Ki	nM	3.3
	18109168	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	COCCN1CCN(c2ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4062634	=	Ki	nM	1.2	CHEMBL5251	Homo sapiens	Ki	nM	1.2
	18109169	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	COCCCN1CCN(c2ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4097832	=	Ki	nM	1.0	CHEMBL5251	Homo sapiens	Ki	nM	1.0
	18109170	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(CCC(F)(F)F)CC3)cn2)c1=O		CHEMBL4079803	=	Ki	nM	4.0	CHEMBL5251	Homo sapiens	Ki	nM	4.0
	18109171	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4CCOCC4)CC3)cn2)c1=O		CHEMBL4090117	=	Ki	nM	0.45	CHEMBL5251	Homo sapiens	Ki	nM	0.45
	18109172	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(C3CN(C4COC4)C3)cn2)c1=O		CHEMBL4069790	=	Ki	nM	0.43	CHEMBL5251	Homo sapiens	Ki	nM	0.43
	18109173	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670094	=	Ki	nM	0.35	CHEMBL5251	Homo sapiens	Ki	nM	0.35
	18109174	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@@H]1CN(C)CCN1c1ccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4095379	=	Ki	nM	0.37	CHEMBL5251	Homo sapiens	Ki	nM	0.37
	18109175	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@H]1CN(C)CCN1c1ccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4085043	=	Ki	nM	0.65	CHEMBL5251	Homo sapiens	Ki	nM	0.65
	18109176	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@H]1CN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CCN1C		CHEMBL4102992	=	Ki	nM	0.32	CHEMBL5251	Homo sapiens	Ki	nM	0.32
	18109177	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@@H]1CN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CCN1C		CHEMBL4092794	=	Ki	nM	0.43	CHEMBL5251	Homo sapiens	Ki	nM	0.43
	18109178	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Ki	nM	0.91	CHEMBL5251	Homo sapiens	Ki	nM	0.91
	18109179	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4066176	=	Ki	nM	1.8	CHEMBL5251	Homo sapiens	Ki	nM	1.8
	18109180	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	CC[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4087543	=	Ki	nM	0.96	CHEMBL5251	Homo sapiens	Ki	nM	0.96
	18109181	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@H]1CN(C2COC2)[C@H](C)CN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4074792	=	Ki	nM	1.3	CHEMBL5251	Homo sapiens	Ki	nM	1.3
	18109182	CHEMBL4023697	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues)-mediated synthetic peptide substrate phosphorylation expressed in baculovirus-infected insect cells	B	C[C@H]1CN(C2COC2)CCN1c1cnc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)cn1		CHEMBL4070991	=	Ki	nM	0.8	CHEMBL5251	Homo sapiens	Ki	nM	0.8
	18109183	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18109184	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	103.0	CHEMBL5251	Homo sapiens	IC50	nM	103.0
	18109185	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	198.0	CHEMBL5251	Homo sapiens	IC50	nM	198.0
	18109186	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670095	=	IC50	nM	36.5	CHEMBL5251	Homo sapiens	IC50	nM	36.5
	18109187	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4085477	=	IC50	nM	54.9	CHEMBL5251	Homo sapiens	IC50	nM	54.9
	18109188	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2cncc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4101904	=	IC50	nM	64.4	CHEMBL5251	Homo sapiens	IC50	nM	64.4
	18109189	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2nccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4075253	=	IC50	nM	387.0	CHEMBL5251	Homo sapiens	IC50	nM	387.0
	18109190	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC1C=C(c2ccnc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4075845	=	IC50	nM	121.1	CHEMBL5251	Homo sapiens	IC50	nM	121.1
	18109191	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC1C=C(c2ccnc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4063638	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	18109192	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC1C=C(c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4086408	=	IC50	nM	15.4	CHEMBL5251	Homo sapiens	IC50	nM	15.4
	18109193	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC1C=C(c2ccnc(-n3ccn4c5c(cc4c3=O)CCCC5)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4104307	=	IC50	nM	77.8	CHEMBL5251	Homo sapiens	IC50	nM	77.8
	18109194	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC1C=C(c2ccnc(N3CCn4c5c(c(F)c4C3=O)CCCC5)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4090946	=	IC50	nM	42.4	CHEMBL5251	Homo sapiens	IC50	nM	42.4
	18109195	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC1C=C(c2ccnc(N3Cc4cc(C(C)(C)C)sc4C3=O)c2CO)C=C(Nc2ccc(N3CCN(C4COC4)CC3)cc2)C1=O		CHEMBL4093188	=	IC50	nM	61.9	CHEMBL5251	Homo sapiens	IC50	nM	61.9
	18109196	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2cccc(N3CCN(C4COC4)CC3)n2)c1=O		CHEMBL4082268	=	IC50	nM	240.9	CHEMBL5251	Homo sapiens	IC50	nM	240.9
	18109197	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC(=O)N1CCN(c2ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4060356	=	IC50	nM	66.5	CHEMBL5251	Homo sapiens	IC50	nM	66.5
	18109198	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC(=O)N1CC2(C1)CN(c1ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc1)C2		CHEMBL4071754	=	IC50	nM	33.4	CHEMBL5251	Homo sapiens	IC50	nM	33.4
	18109199	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	COCCN1CCN(c2ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4062634	=	IC50	nM	36.6	CHEMBL5251	Homo sapiens	IC50	nM	36.6
	18109200	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	COCCCN1CCN(c2ccc(Nc3cc(-c4ccnc(N5CCn6c(cc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4097832	=	IC50	nM	32.2	CHEMBL5251	Homo sapiens	IC50	nM	32.2
	18109201	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(CCC(F)(F)F)CC3)cn2)c1=O		CHEMBL4079803	=	IC50	nM	116.1	CHEMBL5251	Homo sapiens	IC50	nM	116.1
	18109202	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4CCOCC4)CC3)cn2)c1=O		CHEMBL4090117	=	IC50	nM	31.6	CHEMBL5251	Homo sapiens	IC50	nM	31.6
	18109203	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(C3CN(C4COC4)C3)cn2)c1=O		CHEMBL4069790	=	IC50	nM	23.5	CHEMBL5251	Homo sapiens	IC50	nM	23.5
	18109204	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670094	=	IC50	nM	27.6	CHEMBL5251	Homo sapiens	IC50	nM	27.6
	18109205	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@@H]1CN(C)CCN1c1ccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4095379	=	IC50	nM	16.9	CHEMBL5251	Homo sapiens	IC50	nM	16.9
	18109206	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C)CCN1c1ccc(Nc2cc(-c3cc(F)cc(N4CCn5c(cc6c5CCCC6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4085043	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
	18109207	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CCN1C		CHEMBL4102992	=	IC50	nM	27.5	CHEMBL5251	Homo sapiens	IC50	nM	27.5
	18109208	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@@H]1CN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CCN1C		CHEMBL4092794	=	IC50	nM	12.7	CHEMBL5251	Homo sapiens	IC50	nM	12.7
	18109209	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	18109210	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC70	nM	27.0	CHEMBL5251	Homo sapiens	IC70	nM	27.0
	18109211	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC90	nM	135.0	CHEMBL5251	Homo sapiens	IC90	nM	135.0
	18109212	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4066176	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	18109213	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	CC[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4087543	=	IC50	nM	15.9	CHEMBL5251	Homo sapiens	IC50	nM	15.9
	18109214	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)[C@H](C)CN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4074792	=	IC50	nM	10.2	CHEMBL5251	Homo sapiens	IC50	nM	10.2
	18109215	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)nn(C)c2=O)nc1		CHEMBL4095248	=	IC50	nM	16.1	CHEMBL5251	Homo sapiens	IC50	nM	16.1
	18109216	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)CCN1c1cnc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)cn1		CHEMBL4070991	=	IC50	nM	51.5	CHEMBL5251	Homo sapiens	IC50	nM	51.5
	18109217	CHEMBL4023698	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	IC50	nM	88.3	CHEMBL5251	Homo sapiens	IC50	nM	88.3
	18109292	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	101.0	CHEMBL5251	Homo sapiens	INH	%	101.0
	18109293	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	Inhibition	%	100.0	CHEMBL5251	Homo sapiens	INH	%	100.0
	18109294	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	Inhibition	%	98.0	CHEMBL5251	Homo sapiens	INH	%	98.0
	18109295	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	Inhibition	%	100.0	CHEMBL5251	Homo sapiens	INH	%	100.0
	18109296	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Inhibition	%	99.0	CHEMBL5251	Homo sapiens	INH	%	99.0
	18109297	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	Inhibition	%	90.0	CHEMBL5251	Homo sapiens	INH	%	90.0
	18109298	CHEMBL4023728	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	Inhibition	%	91.0	CHEMBL5251	Homo sapiens	INH	%	91.0
	18109378	CHEMBL4023692	Inhibition of anti-IgM-induced BTK phosphorylation at Y233 in human whole blood after 6 hrs	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	18109379	CHEMBL4023691	Inhibition of BTK in human isolated primary B cells assessed as inhibition of anti-IgM-induced cell proliferation by [3H]thymidine incorporation assay	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	18109380	CHEMBL4023749	Inhibition of BTK in human isolated primary B cells assessed as inhibition of CD40L-induced cell proliferation by [3H]thymidine incorporation assay	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	18109381	CHEMBL4023750	Inhibition of anti-IgM-induced BTK phosphorylation at Y233 in human primary B cells	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
	18109382	CHEMBL4023751	Inhibition of BTK in human mononuclear cell-derived monocytes assessed as inhibition of FCgammaR3 activation-induced TNFalpha production by ELISA	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	18109383	CHEMBL4023752	Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	171.0	CHEMBL5251	Homo sapiens	IC50	nM	171.0
	18109384	CHEMBL4023752	Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	312.3	CHEMBL5251	Homo sapiens	IC50	nM	312.3
	18109385	CHEMBL4023752	Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	296.9	CHEMBL5251	Homo sapiens	IC50	nM	296.9
	18109386	CHEMBL4023752	Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	30.7	CHEMBL5251	Homo sapiens	IC50	nM	30.7
	18109387	CHEMBL4023752	Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O		CHEMBL3952795	=	IC50	nM	374.3	CHEMBL5251	Homo sapiens	IC50	nM	374.3
	18109405	CHEMBL4023770	Inhibition of BTK C481S mutant (unknown origin) expressed in HEK293 cells	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Ki	nM	1.6	CHEMBL5251	Homo sapiens	Ki	nM	1.6
	18109406	CHEMBL4023771	Inhibition of BTK C481R mutant (unknown origin) expressed in HEK293 cells	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Ki	nM	1.3	CHEMBL5251	Homo sapiens	Ki	nM	1.3
	18109407	CHEMBL4023772	Inhibition of BTK T474I mutant (unknown origin) expressed in HEK293 cells	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Ki	nM	12.6	CHEMBL5251	Homo sapiens	Ki	nM	12.6
	18109408	CHEMBL4023773	Inhibition of BTK T474M mutant (unknown origin) expressed in HEK293 cells	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Ki	nM	3.4	CHEMBL5251	Homo sapiens	Ki	nM	3.4
Active	18109409	CHEMBL4023774	Inhibition of BTK (unknown origin) autophosphorylation at Y223 expressed in HEK293 cells at 1 uM by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18109410	CHEMBL4023774	Inhibition of BTK (unknown origin) autophosphorylation at Y223 expressed in HEK293 cells at 1 uM by Western blot analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18109411	CHEMBL4023775	Inhibition of BTK C481S mutant (unknown origin) autophosphorylation at Y223 expressed in HEK293 cells at 1 uM by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18109412	CHEMBL4023775	Inhibition of BTK C481S mutant (unknown origin) autophosphorylation at Y223 expressed in HEK293 cells at 1 uM by Western blot analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18109434	CHEMBL4023783	Ratio of inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues) preincubated for 2 hrs to inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues) without preincubation	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	Ratio		8.0	CHEMBL5251	Homo sapiens	Ratio		8.0
	18109435	CHEMBL4023784	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues) expressed in baculovirus-infected insect cells assessed as residence time at 11 nM preincubated for 2 hrs followed by 200 fold dilution into assay mixture containing ATP and peptide substrate measured every 2.5 mins for 8.5 hrs	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	TIME	hr	18.3	CHEMBL5251	Homo sapiens	Time	hr	18.3
	18109436	CHEMBL4023785	Inhibition of human recombinant C-terminal polyhistidine tagged BTK (1 to 659 residues) expressed in baculovirus-infected insect cells assessed as dissociation rate constant at 11 nM preincubated for 2 hrs followed by 200 fold dilution into assay mixture containing ATP and peptide substrate measured every 2.5 mins for 8.5 hrs	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1	Non standard unit for type	CHEMBL4065122	=	K	10'-5/s	1.52	CHEMBL5251	Homo sapiens	K	10'-5/s	1.52
	18114461	CHEMBL4025033	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	0.9	CHEMBL5251	Homo sapiens	Activity	%	0.9
Active	18114575	CHEMBL4024960	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18114576	CHEMBL4024960	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18114577	CHEMBL4024960	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18114578	CHEMBL4024959	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114579	CHEMBL4024959	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114580	CHEMBL4024959	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114581	CHEMBL4024958	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114582	CHEMBL4024958	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114583	CHEMBL4024958	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114584	CHEMBL4024957	Effect on BTK transphosphorylation at Y551 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Activity			CHEMBL5251	Homo sapiens	Activity		
	18114585	CHEMBL4024956	Inhibition of BTK auto-phosphorylation at Y223 in human Pfeiffer cells measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	<	EC50	nM	30.0	CHEMBL5251	Homo sapiens	EC50	nM	30.0
Active	18114586	CHEMBL4024955	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18114587	CHEMBL4024955	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18114588	CHEMBL4024955	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18114589	CHEMBL4024954	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114590	CHEMBL4024954	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114591	CHEMBL4024954	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114592	CHEMBL4024953	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114593	CHEMBL4024953	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114594	CHEMBL4024953	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	18114595	CHEMBL4024952	Effect on BTK transphosphorylation at Y551 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123		Activity			CHEMBL5251	Homo sapiens	Activity		
	18114596	CHEMBL4024951	Inhibition of BTK auto-phosphorylation at Y223 in human U2932 cells measured after 4 hrs by chemiluminescent assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	<	EC50	nM	30.0	CHEMBL5251	Homo sapiens	EC50	nM	30.0
	18114662	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	Ratio	/uM/s	0.01	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.01
	18114663	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1		CHEMBL2216827	=	Ratio	/uM/s	0.01	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.01
	18114664	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	Ratio	/uM/s	0.12	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.12
	18114665	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Ratio	/uM/s	0.15	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.15
	18114666	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Ratio	/uM/s	0.38	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.38
	18114667	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cc5c(s4)CCCC5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4096207	=	Ratio	/uM/s	0.42	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.42
	18114668	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4085868	=	Ratio	/uM/s	0.05	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.05
	18114669	CHEMBL4024939	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Ratio	/uM/s	0.11	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.11
	18114670	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	Ki	nM	27.2	CHEMBL5251	Homo sapiens	Ki	nM	27.2
	18114671	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1		CHEMBL2216827	=	Ki	nM	209.2	CHEMBL5251	Homo sapiens	Ki	nM	209.2
	18114672	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	Ki	nM	20.7	CHEMBL5251	Homo sapiens	Ki	nM	20.7
	18114673	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Ki	nM	14.2	CHEMBL5251	Homo sapiens	Ki	nM	14.2
	18114674	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Ki	nM	4.8	CHEMBL5251	Homo sapiens	Ki	nM	4.8
	18114675	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cc5c(s4)CCCC5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4096207	=	Ki	nM	6.0	CHEMBL5251	Homo sapiens	Ki	nM	6.0
	18114676	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4085868	=	Ki	nM	113.0	CHEMBL5251	Homo sapiens	Ki	nM	113.0
	18114677	CHEMBL4024938	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Ki	nM	8.9	CHEMBL5251	Homo sapiens	Ki	nM	8.9
	18114678	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	Kinact	/min	0.01	CHEMBL5251	Homo sapiens	Kinact	/min	0.01
	18114679	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1		CHEMBL2216827	=	Kinact	/min	0.15	CHEMBL5251	Homo sapiens	Kinact	/min	0.15
	18114680	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	Kinact	/min	0.15	CHEMBL5251	Homo sapiens	Kinact	/min	0.15
	18114681	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Kinact	/min	0.13	CHEMBL5251	Homo sapiens	Kinact	/min	0.13
	18114682	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Kinact	/min	0.11	CHEMBL5251	Homo sapiens	Kinact	/min	0.11
	18114683	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cc5c(s4)CCCC5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4096207	=	Kinact	/min	0.05	CHEMBL5251	Homo sapiens	Kinact	/min	0.05
	18114684	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4085868	=	Kinact	/min	0.33	CHEMBL5251	Homo sapiens	Kinact	/min	0.33
	18114685	CHEMBL4024937	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Kinact	/min	0.06	CHEMBL5251	Homo sapiens	Kinact	/min	0.06
	18114686	CHEMBL4024936	Irreversible inhibition of recombinant full length 3'-FLAG-tagged BTK C481S mutant (unknown origin) expressed in HEK293T cells assessed as reduction in Y223 phosphorylation measured after 4 hrs by Western blot method	B	CCC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4081428	>	EC50	nM	100.0	CHEMBL5251	Homo sapiens	EC50	nM	100.0
	18114687	CHEMBL4024936	Irreversible inhibition of recombinant full length 3'-FLAG-tagged BTK C481S mutant (unknown origin) expressed in HEK293T cells assessed as reduction in Y223 phosphorylation measured after 4 hrs by Western blot method	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	>	EC50	nM	100.0	CHEMBL5251	Homo sapiens	EC50	nM	100.0
	18114688	CHEMBL4024935	Irreversible inhibition of recombinant full length wild-type 3'-FLAG-tagged BTK (unknown origin) expressed in HEK293T cells assessed as reduction in Y223 phosphorylation measured after 4 hrs by Western blot method	B	CCC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4081428	>	EC50	nM	100.0	CHEMBL5251	Homo sapiens	EC50	nM	100.0
	18114689	CHEMBL4024935	Irreversible inhibition of recombinant full length wild-type 3'-FLAG-tagged BTK (unknown origin) expressed in HEK293T cells assessed as reduction in Y223 phosphorylation measured after 4 hrs by Western blot method	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	EC50	nM	4.7	CHEMBL5251	Homo sapiens	EC50	nM	4.7
	18114714	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1		CHEMBL3290142	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	18114715	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1		CHEMBL2216827	=	IC50	nM	9.5	CHEMBL5251	Homo sapiens	IC50	nM	9.5
	18114716	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	18114717	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18114718	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18114719	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)NC1CCCC(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)C1		CHEMBL4093722	=	IC50	nM	2946.0	CHEMBL5251	Homo sapiens	IC50	nM	2946.0
	18114720	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCC(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)CC1		CHEMBL4066147	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18114721	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)N1CCCC(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)C1		CHEMBL4101439	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18114722	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)NC1CCCN(c2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)C1		CHEMBL4074757	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18114723	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)NC1CCN(c2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)CC1		CHEMBL4097628	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18114724	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCC(OC)CC1		CHEMBL4079595	=	IC50	nM	596.0	CHEMBL5251	Homo sapiens	IC50	nM	596.0
	18114725	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCCC(O)C1		CHEMBL4103674	=	IC50	nM	244.0	CHEMBL5251	Homo sapiens	IC50	nM	244.0
	18114726	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCC(O)CC1		CHEMBL4105457	=	IC50	nM	187.0	CHEMBL5251	Homo sapiens	IC50	nM	187.0
	18114727	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N(CCOCC)CCOCC		CHEMBL4062079	=	IC50	nM	3187.0	CHEMBL5251	Homo sapiens	IC50	nM	3187.0
	18114728	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)NCCOC		CHEMBL4069186	=	IC50	nM	667.0	CHEMBL5251	Homo sapiens	IC50	nM	667.0
	18114729	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCC(OC)CC1		CHEMBL4066966	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
	18114730	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCCC(O)C1		CHEMBL4088999	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	18114731	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1		CHEMBL4071818	=	IC50	nM	68.0	CHEMBL5251	Homo sapiens	IC50	nM	68.0
	18114732	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCN(C)CC1		CHEMBL4076040	=	IC50	nM	127.0	CHEMBL5251	Homo sapiens	IC50	nM	127.0
	18114733	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)NC1CC1		CHEMBL4101519	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
	18114734	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCCC1		CHEMBL4074840	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	18114735	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)OC		CHEMBL4093800	=	IC50	nM	197.0	CHEMBL5251	Homo sapiens	IC50	nM	197.0
	18114736	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N(C)C		CHEMBL4066223	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
	18114737	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C		CHEMBL4068683	=	IC50	nM	365.0	CHEMBL5251	Homo sapiens	IC50	nM	365.0
	18114738	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)c1		CHEMBL4103968	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18114739	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cc(OC)c(OC)c(OC)c4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4078155	=	IC50	nM	1426.0	CHEMBL5251	Homo sapiens	IC50	nM	1426.0
	18114740	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cc5c(s4)CCCC5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4096207	=	IC50	nM	16.5	CHEMBL5251	Homo sapiens	IC50	nM	16.5
	18114741	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc5c(c4)CCCC5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4067226	=	IC50	nM	57.0	CHEMBL5251	Homo sapiens	IC50	nM	57.0
	18114742	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc5c(c4)OCCO5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4088485	=	IC50	nM	89.0	CHEMBL5251	Homo sapiens	IC50	nM	89.0
	18114743	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc5c(c4)OCO5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4071893	=	IC50	nM	282.0	CHEMBL5251	Homo sapiens	IC50	nM	282.0
	18114744	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(OC)c(OC)c4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4098885	=	IC50	nM	4996.0	CHEMBL5251	Homo sapiens	IC50	nM	4996.0
	18114745	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C)c(C(F)(F)F)c4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077998	=	IC50	nM	1261.0	CHEMBL5251	Homo sapiens	IC50	nM	1261.0
	18114746	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cccc(OC)c4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4102259	=	IC50	nM	1191.0	CHEMBL5251	Homo sapiens	IC50	nM	1191.0
	18114747	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4067041	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18114748	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N5CCOCC5)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4094515	=	IC50	nM	273.0	CHEMBL5251	Homo sapiens	IC50	nM	273.0
	18114749	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N5CCCC5)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4093610	=	IC50	nM	86.0	CHEMBL5251	Homo sapiens	IC50	nM	86.0
	18114750	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(OC)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4072911	=	IC50	nM	2610.0	CHEMBL5251	Homo sapiens	IC50	nM	2610.0
	18114751	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4085868	=	IC50	nM	5.8	CHEMBL5251	Homo sapiens	IC50	nM	5.8
	18114752	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(F)(F)F)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4064326	=	IC50	nM	76.0	CHEMBL5251	Homo sapiens	IC50	nM	76.0
	18114753	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4059850	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	18114754	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(CC)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4081768	=	IC50	nM	210.0	CHEMBL5251	Homo sapiens	IC50	nM	210.0
	18114755	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4074645	=	IC50	nM	114.0	CHEMBL5251	Homo sapiens	IC50	nM	114.0
	18114756	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccccc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4069348	=	IC50	nM	3736.0	CHEMBL5251	Homo sapiens	IC50	nM	3736.0
	18114757	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	CCC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4081428	=	IC50	nM	163.0	CHEMBL5251	Homo sapiens	IC50	nM	163.0
	18114758	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)c(NC(=O)CCl)c2)c(=O)n(C)c1		CHEMBL4077618	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	18114759	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1ccc(NC(=O)c2ccc(C(C)(C)C)cc2)c(C)c1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4075774	=	IC50	nM	1697.0	CHEMBL5251	Homo sapiens	IC50	nM	1697.0
	18114760	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(C(=O)N2CCOCC2)ccc1Nc1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2C)cn(C)c1=O		CHEMBL4063526	=	IC50	nM	231.0	CHEMBL5251	Homo sapiens	IC50	nM	231.0
	18114761	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	18114762	CHEMBL4024931	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1		CHEMBL4076543	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	18135433	CHEMBL4029686	Inhibition of full length wild type human BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	O=C1NC(=S)S/C1=C\c1cscn1		CHEMBL4061891	=	Activity	%	48.0	CHEMBL5251	Homo sapiens	Activity	%	48.0
	18135450	CHEMBL4029686	Inhibition of full length wild type human BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	O=C1NC(=S)S/C1=C\c1csc(-c2ccc(C(F)(F)F)cc2)n1		CHEMBL4075290	=	Activity	%	90.0	CHEMBL5251	Homo sapiens	Activity	%	90.0
	18135467	CHEMBL4029686	Inhibition of full length wild type human BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	O=C1NC(=S)N2C(=O)C3Nc4cc(Cl)cc(Cl)c4C3C=C12		CHEMBL4096175	=	Activity	%	94.0	CHEMBL5251	Homo sapiens	Activity	%	94.0
	18135484	CHEMBL4029686	Inhibition of full length wild type human BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	N=C1NC(=O)/C(=C/c2csc(-c3ccc(C(F)(F)F)cc3)n2)S1		CHEMBL4064860	=	Activity	%	88.0	CHEMBL5251	Homo sapiens	Activity	%	88.0
	18136523	CHEMBL4029947	Ratio of Kinact to ki for recombinant full length BTK (unknown origin)	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC1COC1		CHEMBL4093436	=	Ratio		0.4	CHEMBL5251	Homo sapiens	Ratio		0.4
	18136524	CHEMBL4029958	Inhibition of recombinant full length BTK (unknown origin) using peptide substrate by capillary elctrophoresis	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC1COC1		CHEMBL4093436	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	18136525	CHEMBL4029957	Binding affinity to recombinant full length BTK (unknown origin) assessed as residence time by fluorescent tracer based TR-FRET assay	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)NC1COC1		CHEMBL4093436	=	TIME	hr	167.0	CHEMBL5251	Homo sapiens	Time	hr	167.0
	18141796	CHEMBL4031407	Inhibition of BTK (unknown origin) using poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo kinase assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-n3nc(-c4ccc(OCCN5CCOCC5)cc4)c4c(N)ncnc43)cc2)no1		CHEMBL4101411	=	IC50	nM	95.0	CHEMBL5251	Homo sapiens	IC50	nM	95.0
	18156559	CHEMBL4035086	Inhibition of BTK (unknown origin)	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364	=	IC50	nM	6700.0	CHEMBL5251	Homo sapiens	IC50	uM	6.7
	18167283	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670081	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	uM	0.001
	18167284	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670086	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	uM	0.006
	18167285	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCc4c(cc5n4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4071845	=	IC50	nM	81.0	CHEMBL5251	Homo sapiens	IC50	uM	0.081
	18167286	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCn4c(nc5c4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4100365	=	IC50	nM	2600.0	CHEMBL5251	Homo sapiens	IC50	uM	2.6
	18167287	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCc4c(nc5n4CCCC5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4082346	=	IC50	nM	16700.0	CHEMBL5251	Homo sapiens	IC50	uM	16.7
	18167288	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670082	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	uM	0.002
	18167289	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670082	=	Ki	nM	1.28	CHEMBL5251	Homo sapiens	Ki(app)	nM	1.28
	18167290	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4090189	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	uM	0.002
	18167291	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3Cc4cc(C(C)(C)C)sc4C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4067714	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	uM	0.003
	18167292	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3Cc4nc(C(C)(C)C)sc4C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4095477	=	IC50	nM	139.0	CHEMBL5251	Homo sapiens	IC50	uM	0.139
	18167293	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3Cc4cc(C(C)(C)C)ccc4C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4077625	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	uM	0.003
	18167294	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCNc4cc(C(C)(C)C)ccc4C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4069030	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	uM	0.004
	18167295	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCOc4cc(C(C)(C)C)ccc4C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL4096404	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	uM	0.005
	18167296	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCc6c(sc7c6CC(C)(C)C7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL4080943	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	uM	0.003
	18167297	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670139	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	uM	0.004
	18167298	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670088	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	uM	0.004
	18167299	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4060453	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	18167300	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	CN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670094	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	uM	0.002
	18167301	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670095	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	uM	0.004
	18167302	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cc(Nc2ccncn2)c(=O)n(C)c1		CHEMBL4084331	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	uM	0.042
	18167303	CHEMBL4036699	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system by Z-LYTE assay	B	Cc1c(-c2cc(Nc3ccncn3)c(=O)n(C)c2)cccc1N1CCc2c(sc3c2CCCC3)C1=O		CHEMBL4102294	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	uM	0.011
	18167323	CHEMBL4036701	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells preincubated for 1 hr followed by blood stimulation measured after 18 hrs by FACS analysis	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670082	=	IC50	nM	87.0	CHEMBL5251	Homo sapiens	IC50	uM	0.087
	18167324	CHEMBL4036701	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells preincubated for 1 hr followed by blood stimulation measured after 18 hrs by FACS analysis	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670139	=	IC50	nM	89.0	CHEMBL5251	Homo sapiens	IC50	uM	0.089
	18167325	CHEMBL4036701	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells preincubated for 1 hr followed by blood stimulation measured after 18 hrs by FACS analysis	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670088	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	uM	0.045
	18167326	CHEMBL4036701	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells preincubated for 1 hr followed by blood stimulation measured after 18 hrs by FACS analysis	B	Cn1cc(-c2cccc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL4060453	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	uM	0.069
	18167327	CHEMBL4036701	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells preincubated for 1 hr followed by blood stimulation measured after 18 hrs by FACS analysis	B	CN1CCN(c2ccc(Nc3cc(-c4cc(F)cc(N5CCn6c(cc7c6CCCC7)C5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL3670094	=	IC50	nM	29.0	CHEMBL5251	Homo sapiens	IC50	uM	0.029
	18167328	CHEMBL4036701	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells preincubated for 1 hr followed by blood stimulation measured after 18 hrs by FACS analysis	B	Cn1cc(-c2cc(F)cc(N3CCn4c(cc5c4CCCC5)C3=O)c2CO)cc(Nc2ccc(N3CCN(C4COC4)CC3)cn2)c1=O		CHEMBL3670095	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	uM	0.035
	18167405	CHEMBL4036725	Inhibition of BTK in human B-cells assessed as decrease in BCR-stimulated B-cell proliferation after 8 hrs by [3H]-thymidine incorporation assay	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670082	=	EC50	nM	22.0	CHEMBL5251	Homo sapiens	EC50	nM	22.0
	18167406	CHEMBL4036726	Inhibition of BTK in human monocytes assessed as inhibition of FCgammaR activation-induced TNFalpha production by ELISA	B	Cn1cc(-c2cccc(N3CCc4c(sc5c4CC(C)(C)C5)C3=O)c2CO)cc(Nc2ccncn2)c1=O		CHEMBL3670082	=	EC50	nM	33.0	CHEMBL5251	Homo sapiens	EC50	nM	33.0
Active	18188452	CHEMBL4041142	Inhibition of human full length BTK expressed in mammalian expression system at 10 uM by kinomescan assay	B	CNc1nc(-c2cc(C(=O)N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cn2)cs1		CHEMBL4088706		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18200528	CHEMBL4043034	Inhibition of recombinant full length His-tagged human BTK cytoplasmic domain expressed in baculovirus expression system by Z'-Lyte assay	B	Cc1ccc(-n2c(=O)ccc3ccc4ccc(-c5cnn(C)c5)cc4c32)cc1NC(=O)/C=C/CN(C)C		CHEMBL4064534	=	IC50	nM	911.0	CHEMBL5251	Homo sapiens	IC50	nM	911.0
	18203557	CHEMBL4043844	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	99.0	CHEMBL5251	Homo sapiens	Activity	%	99.0
	18211642	CHEMBL4045641	Inhibition of BTK labeling at activation Loop (YVLDDEYTSSVGSKFPVR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	17.4	CHEMBL5251	Homo sapiens	INH	%	17.4
	18211788	CHEMBL4045884	Inhibition of BTK labeling at activation Loop (YVLDDEYTSSVGSKFPVR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	14.2	CHEMBL5251	Homo sapiens	INH	%	14.2
	18218997	CHEMBL4047252	Inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate measured after 10 mins in presence of ATP by topcount scintillation counting analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	>	IC50	nM	2500.0	CHEMBL5251	Homo sapiens	IC50	uM	2.5
	18218999	CHEMBL4047254	Inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate measured immediately in presence of ATP by topcount scintillation counting analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	=	EC50	nM	19800.0	CHEMBL5251	Homo sapiens	EC50	uM	19.8
	18219000	CHEMBL4047255	Inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate pretreated for 15 mins followed by ATP addition measured after 10 mins by topcount scintillation counting analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	=	EC50	nM	6557.0	CHEMBL5251	Homo sapiens	EC50	uM	6.557
	18219001	CHEMBL4047256	Inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate pretreated for 45 mins followed by ATP addition measured after 10 mins by topcount scintillation counting analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	=	EC50	nM	2890.0	CHEMBL5251	Homo sapiens	EC50	uM	2.89
	18219002	CHEMBL4047257	Inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate pretreated for 120 mins followed by ATP addition measured after 10 mins by topcount scintillation counting analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	=	EC50	nM	1576.0	CHEMBL5251	Homo sapiens	EC50	uM	1.576
Active	18219003	CHEMBL4047258	Time-dependent inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate by topcount scintillation counting analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693		TDI			CHEMBL5251	Homo sapiens	TDI		
	18219005	CHEMBL4047260	Ratio of Kinact to Ki for His-tagged BTK (unknown origin) by HTRF assay	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	=	Ratio	/uM/s	0.00005	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.00005
	18219006	CHEMBL4047261	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of BCR-induced CD69 expression on B cells after 18 hrs by FACS analysis	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18231694	CHEMBL4050186	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate in presence of [gamma-32P]ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	18.1	CHEMBL5251	Homo sapiens	IC50	10'-8M	1.81
Not Determined	18231724	CHEMBL4050186	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate in presence of [gamma-32P]ATP	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339		IC50			CHEMBL5251	Homo sapiens	IC50		
	18232190	CHEMBL4050316	Inhibition of human BTK assessed as residual activity at 1 uM in presence of 33P-ATP by filter-binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	62.0	CHEMBL5251	Homo sapiens	Activity	%	62.0
	18232351	CHEMBL4050449	Binding affinity to full-length wild-type human BTK expressed in mammalian system assessed as control score at 1 uM by KINOMEScan assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(OCc4ccccn4)c(Cl)c3)c3c(N)ncnc32)C1		CHEMBL4068839	=	Activity	%	0.05	CHEMBL5251	Homo sapiens	Activity	%	0.05
	18232361	CHEMBL4050459	Inhibition of full-length recombinant human His-tagged BTK cytoplasmic domain expressed in baculovirus by Z'-LYTE assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(OCc4ccccn4)c(Cl)c3)c3c(N)ncnc32)C1		CHEMBL4068839	=	IC50	nM	24.5	CHEMBL5251	Homo sapiens	IC50	nM	24.5
	18243288	CHEMBL4052510	Inhibition of recombinant full-length human N-terminally GST-HIS6 tagged BTK (M1 to S659 residues) harboring 3C-cleavage site expressed in Baculovirus infected Sf9 cells assessed as residual activity at 1 uM in presence of [33-gamma]-ATP after 60 mins by scintillation counting method relative to control	B	C=CC(=O)Nc1cccc(-c2c[nH]c3nccc(-c4[nH]c(CCCO)nc4-c4ccc(F)cc4)c23)c1		CHEMBL4071827	=	Activity	%	17.0	CHEMBL5251	Homo sapiens	Activity	%	17.0
	18248578	CHEMBL4053861	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4104658	=	Inhibition	%	48.0	CHEMBL5251	Homo sapiens	INH	%	48.0
	18248762	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.34	CHEMBL5251	Homo sapiens	IC50	nM	0.34
	18248763	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
	18248764	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(NS(=O)(=O)c4ccc(C)cc4)c(C)c3)ncc2Cl)c1		CHEMBL4092347	=	IC50	nM	1.05	CHEMBL5251	Homo sapiens	IC50	nM	1.05
	18248765	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(NS(=O)(=O)c4ccc(OC)cc4)cc3)ncc2Cl)c1		CHEMBL4071567	=	IC50	nM	0.42	CHEMBL5251	Homo sapiens	IC50	nM	0.42
	18248766	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(OC)cc4)cc3)ncc2F)c1		CHEMBL4070521	=	IC50	nM	0.92	CHEMBL5251	Homo sapiens	IC50	nM	0.92
	18248767	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(OC)cc4)cc3)ncc2[N+](=O)[O-])c1		CHEMBL4097689	=	IC50	nM	23.8	CHEMBL5251	Homo sapiens	IC50	nM	23.8
	18248768	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(OC)cc4)cc3)ncc2Cl)c1		CHEMBL4061898	=	IC50	nM	9.14	CHEMBL5251	Homo sapiens	IC50	nM	9.14
	18248769	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(F)cc4)c(C)c3)ncc2[N+](=O)[O-])c1		CHEMBL4089960	=	IC50	nM	85.4	CHEMBL5251	Homo sapiens	IC50	nM	85.4
	18248770	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(C)cc4)c(OC)c3)ncc2[N+](=O)[O-])c1		CHEMBL4074077	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	18248771	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(C)cc4)c(C)c3)ncc2[N+](=O)[O-])c1		CHEMBL4094611	=	IC50	nM	48.6	CHEMBL5251	Homo sapiens	IC50	nM	48.6
	18248772	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(F)cc4)c(OC)c3)ncc2Cl)c1		CHEMBL4065460	=	IC50	nM	1.18	CHEMBL5251	Homo sapiens	IC50	nM	1.18
	18248773	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(F)cc4)c(C)c3)ncc2Cl)c1		CHEMBL4086899	=	IC50	nM	78.6	CHEMBL5251	Homo sapiens	IC50	nM	78.6
	18248774	CHEMBL4053931	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NS(=O)(=O)c4ccc(C)cc4)cc3)ncc2Cl)c1		CHEMBL4103300	=	IC50	nM	58.5	CHEMBL5251	Homo sapiens	IC50	nM	58.5
	18253703	CHEMBL4055136	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	99.0	CHEMBL5251	Homo sapiens	Activity	%	99.0
	18253704	CHEMBL4055136	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18265928	CHEMBL4057378	Inhibition of BTK (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	18266133	CHEMBL4057583	Inhibition of BTK (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	0.3	CHEMBL5251	Homo sapiens	INH	%	0.3
	18266202	CHEMBL4057652	Inhibition of BTK (unknown origin) at 0.078 uM relative to control	B	COC(=O)Nc1noc2cc(-c3c(-c4ccccn4)n[nH]c3C)ccc12		CHEMBL4066592	=	Inhibition	%	7.7	CHEMBL5251	Homo sapiens	INH	%	7.7
	18267952	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	C[C@H]1CO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4096669	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
	18267953	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	Nc1nccn2c([C@H]3CN(C4CCOCC4)CCO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4060757	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	18267954	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	Nc1nccn2c([C@@H]3CCCN(C4CCOCC4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4077588	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
	18267955	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	COCC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4062498	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18267956	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	COCC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4076024	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	18267957	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC(C)C(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4075954	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	18267958	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC(C)C(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4069387	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	18267959	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4065907	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	18267960	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4079820	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	18267961	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CCO[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)CCC1		CHEMBL4059723	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	nM	35.0
	18267962	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)CCC1		CHEMBL4081661	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
Not Determined	18267963	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	COCCC(=O)N1CCN[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4087095		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	18267964	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	COCCC(=O)N1CCS(=O)(=O)C(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4104951		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	18267965	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	COCCC(=O)N1CCSC(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4079225		IC50			CHEMBL5251	Homo sapiens	IC50		
	18267966	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	COCCC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4097247	=	IC50	nM	58.0	CHEMBL5251	Homo sapiens	IC50	nM	58.0
	18267967	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CCO[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4075605	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
Not Determined	18267968	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CCCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4099975		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	18267969	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N[C@@H]2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4096526		IC50			CHEMBL5251	Homo sapiens	IC50		
	18267970	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CCC(c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC2)COC1		CHEMBL4078497	=	IC50	nM	80.0	CHEMBL5251	Homo sapiens	IC50	nM	80.0
	18267971	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4104254	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
	18267972	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CC(c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4086348	=	IC50	nM	167.0	CHEMBL5251	Homo sapiens	IC50	nM	167.0
	18267973	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	Nc1nccn2c(CN3CCOCC3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4066585	=	IC50	nM	1225.0	CHEMBL5251	Homo sapiens	IC50	nM	1225.0
	18267974	CHEMBL4057948	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced MIP1beta	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4094125	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	18267975	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	C[C@H]1CO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4096669	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18267976	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@H]3CN(C4CCOCC4)CCO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4060757	=	IC50	nM	0.59	CHEMBL5251	Homo sapiens	IC50	nM	0.59
	18267977	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c([C@@H]3CCCN(C4CCOCC4)C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4077588	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	18267978	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	COCC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4062498	=	IC50	nM	0.37	CHEMBL5251	Homo sapiens	IC50	nM	0.37
	18267979	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	COCC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4076024	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	18267980	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(C)C(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4075954	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18267981	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(C)C(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4069387	=	IC50	nM	0.25	CHEMBL5251	Homo sapiens	IC50	nM	0.25
	18267982	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4065907	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18267983	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)C1		CHEMBL4079820	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	18267984	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CCO[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)CCC1		CHEMBL4059723	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	18267985	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)CCC1		CHEMBL4081661	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	18267986	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	COCCC(=O)N1CCN[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4087095	=	IC50	nM	377.0	CHEMBL5251	Homo sapiens	IC50	nM	377.0
	18267987	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	COCCC(=O)N1CCS(=O)(=O)C(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4104951	=	IC50	nM	294.0	CHEMBL5251	Homo sapiens	IC50	nM	294.0
	18267988	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	COCCC(=O)N1CCSC(c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4079225	=	IC50	nM	6.6	CHEMBL5251	Homo sapiens	IC50	nM	6.6
	18267989	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	COCCC(=O)N1CCO[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)C1		CHEMBL4097247	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
	18267990	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CCO[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4075605	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	18267991	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CCCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4099975	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
	18267992	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N[C@@H]2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4096526	=	IC50	nM	10.7	CHEMBL5251	Homo sapiens	IC50	nM	10.7
	18267993	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CCC(c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC2)COC1		CHEMBL4078497	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
	18267994	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4104254	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	18267995	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CC(c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4086348	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
	18267996	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	Nc1nccn2c(CN3CCOCC3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4066585	=	IC50	nM	132.0	CHEMBL5251	Homo sapiens	IC50	nM	132.0
	18267997	CHEMBL4057947	Inhibition of recombinant full-length His6-tagged BTK (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated A5 peptide as substrate preincubated for 60 mins followed by substrate addition measured after 120 mins by LANCE TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4094125	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	18268989	CHEMBL4058120	Inhibition of recombinant human full length N-terminal His6-tagged BTK expressed in baculovirus Sf21 insect cells preincubated for 5 mins followed by LSNLYHQGKFLQT substrate addition after 30 to 60 mins in presence of ATP by fluorescence assay	B	C=CS(=O)(=O)N1CCC[C@@H]1Cn1cc(-c2ccc3c(c2)OCO3)c2c(N)ncnc21		CHEMBL4095253	=	IC50	nM	88.6	CHEMBL5251	Homo sapiens	IC50	nM	88.6
	18282039	CHEMBL4119994	Inhibition of recombinant full length His-tagged human BTK cytoplasmic domain expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	9.9	CHEMBL5251	Homo sapiens	INH	%	9.9
	18282358	CHEMBL4119994	Inhibition of recombinant full length His-tagged human BTK cytoplasmic domain expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	19.9	CHEMBL5251	Homo sapiens	INH	%	19.9
	18282728	CHEMBL4120313	Inhibition of BTK (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	18282955	CHEMBL4120540	Inhibition of BTK (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	-1.7	CHEMBL5251	Homo sapiens	INH	%	-1.7
	18283179	CHEMBL4120764	Inhibition of BTK (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12	Outside typical range	CHEMBL4129737	=	Inhibition	%	-29.3	CHEMBL5251	Homo sapiens	INH	%	-29.3
	18298465	CHEMBL4124196	Inhibition of kinase tracer-05 binding to C-terminal NanoLuc tagged full length BTK (unknown origin) expressed in HEK cells by NanoBRET assay	B	N#C/C=C/c1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1		CHEMBL4128266	=	EC50	nM	13300.0	CHEMBL5251	Homo sapiens	EC50	nM	13300.0
	18298466	CHEMBL4124196	Inhibition of kinase tracer-05 binding to C-terminal NanoLuc tagged full length BTK (unknown origin) expressed in HEK cells by NanoBRET assay	B	CN(C)C(=O)C(C#N)=Cc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1		CHEMBL4128181	>	EC50	nM	10000.0	CHEMBL5251	Homo sapiens	EC50	nM	10000.0
	18298467	CHEMBL4124196	Inhibition of kinase tracer-05 binding to C-terminal NanoLuc tagged full length BTK (unknown origin) expressed in HEK cells by NanoBRET assay	B	N#CC(C#N)=Cc1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1		CHEMBL4125719	=	EC50	nM	5790.0	CHEMBL5251	Homo sapiens	EC50	nM	5790.0
	18298468	CHEMBL4124196	Inhibition of kinase tracer-05 binding to C-terminal NanoLuc tagged full length BTK (unknown origin) expressed in HEK cells by NanoBRET assay	B	CN1CCN(C(=O)C(C#N)=Cc2ccc(-c3nc4cnc5[nH]ccc5c4n3C3CCCCC3)o2)CC1		CHEMBL4125861	>	EC50	nM	10000.0	CHEMBL5251	Homo sapiens	EC50	nM	10000.0
	18307151	CHEMBL4130974	Inhibition of BTK autophosphorylation at Y223 in anti-IgM stimulated human Ramos cells after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	<	EC50	nM	100.0	CHEMBL5251	Homo sapiens	EC50	nM	100.0
	18307152	CHEMBL4130973	Inhibition of BTK autophosphorylation at Y223 in anti-IgM stimulated human MOLM13 cells after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	<	EC50	nM	100.0	CHEMBL5251	Homo sapiens	EC50	nM	100.0
	18307199	CHEMBL4130926	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate assessed as ratio of Kinact to Ki preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	=	Ratio	/uM/s	0.01	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.01
	18307200	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	=	Ki	nM	97.0	CHEMBL5251	Homo sapiens	Ki	nM	97.0
Active	18307201	CHEMBL4130924	Irreversible binding affinity to recombinant full length His-tagged human BTK expressed in baculovirus expression system assessed as modification of Cys481 residue containing fragment at 100 uM after 1 hr by LC/MS-MS method	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664		Activity			CHEMBL5251	Homo sapiens	Activity		
	18307205	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	=	IC50	nM	75.6	CHEMBL5251	Homo sapiens	IC50	nM	75.6
	18307209	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cnn(C)c5)cc4c32)ccc1C		CHEMBL4098453	=	IC50	nM	13.5	CHEMBL5251	Homo sapiens	IC50	nM	13.5
	18307213	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3cnc4ccc(-c5cn[nH]c5)cc4c32)c1		CHEMBL4161110	=	IC50	nM	17.7	CHEMBL5251	Homo sapiens	IC50	nM	17.7
	18307214	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cn[nH]c5)cc4c32)ccc1C		CHEMBL4075449	=	Kinact	/min	0.14	CHEMBL5251	Homo sapiens	Kinact	/min	0.14
	18307215	CHEMBL4130926	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate assessed as ratio of Kinact to Ki preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cn[nH]c5)cc4c32)ccc1C		CHEMBL4075449	=	Ratio	/uM/s	1.17	CHEMBL5251	Homo sapiens	Ratio	/uM/s	1.17
	18307216	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cn[nH]c5)cc4c32)ccc1C		CHEMBL4075449	=	Ki	nM	2.0	CHEMBL5251	Homo sapiens	Ki	nM	2.0
	18307220	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cn[nH]c5)cc4c32)ccc1C		CHEMBL4075449	=	IC50	nM	5.34	CHEMBL5251	Homo sapiens	IC50	nM	5.34
	18307224	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccoc5)cc4c32)ccc1C		CHEMBL4159628	=	IC50	nM	17.4	CHEMBL5251	Homo sapiens	IC50	nM	17.4
	18307228	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccsc5)cc4c32)ccc1C		CHEMBL4173695	=	IC50	nM	38.6	CHEMBL5251	Homo sapiens	IC50	nM	38.6
	18307232	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccccc5)cc4c32)ccc1C		CHEMBL4162994	=	IC50	nM	25.3	CHEMBL5251	Homo sapiens	IC50	nM	25.3
	18307236	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cccnc5)cc4c32)ccc1C		CHEMBL4163399	=	IC50	nM	115.0	CHEMBL5251	Homo sapiens	IC50	nM	115.0
	18307240	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(N)nc5)cc4c32)ccc1C		CHEMBL4077107	=	IC50	nM	16.4	CHEMBL5251	Homo sapiens	IC50	nM	16.4
	18307244	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3cnc4ccc(-c5ccc(N)nc5)cc4c32)c1		CHEMBL4166849	=	IC50	nM	19.1	CHEMBL5251	Homo sapiens	IC50	nM	19.1
	18307245	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	CCC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4174577	=	IC50	nM	6873.0	CHEMBL5251	Homo sapiens	IC50	nM	6873.0
	18307246	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	=	Kinact	/min	0.07	CHEMBL5251	Homo sapiens	Kinact	/min	0.07
Not Active	18307256	CHEMBL4130981	Inhibition of BTK in anti-IgM stimulated human MOLM13 cells assessed as decrease in PLCgamma2 phosphorylation at Y1217 at 100 to 1000 nM after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18307257	CHEMBL4130980	Inhibition of BTK in anti-IgM stimulated human Pfeiffer cells assessed as decrease in PLCgamma2 phosphorylation at Y1217 at 100 to 1000 nM after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18307258	CHEMBL4130979	Inhibition of BTK in anti-IgM stimulated human Ramos cells assessed as decrease in PLCgamma2 phosphorylation at Y1217 after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	<	EC50	nM	1000.0	CHEMBL5251	Homo sapiens	EC50	nM	1000.0
Not Active	18307259	CHEMBL4130978	Inhibition of BTK transphosphorylation at Y551 in anti-IgM stimulated human Pfeiffer cells at 100 to 1000 nM after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18307260	CHEMBL4130977	Inhibition of BTK transphosphorylation at Y551 in anti-IgM stimulated human Ramos cells at 100 to 1000 nM after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18307261	CHEMBL4130976	Inhibition of BTK transphosphorylation at Y551 in anti-IgM stimulated human MOLM13 cells at 100 to 1000 nM after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18307262	CHEMBL4130975	Inhibition of BTK autophosphorylation at Y223 in anti-IgM stimulated human Pfeiffer cells after 4 hrs by chemiluminescence assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1C		CHEMBL4166664	<	EC50	nM	3000.0	CHEMBL5251	Homo sapiens	EC50	nM	3000.0
	18307312	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(/C=C/c5ccccc5)cc4c32)ccc1C		CHEMBL4170077	=	IC50	nM	105.0	CHEMBL5251	Homo sapiens	IC50	nM	105.0
	18307316	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NC(=O)NC)cc5)cc4c32)ccc1C		CHEMBL4159459	=	IC50	nM	79.1	CHEMBL5251	Homo sapiens	IC50	nM	79.1
	18307320	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(COc6cccc(C(F)(F)F)c6)cc5)cc4c32)ccc1C		CHEMBL4159852	=	IC50	nM	37.2	CHEMBL5251	Homo sapiens	IC50	nM	37.2
	18307324	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NS(C)(=O)=O)cc5)cc4c32)ccc1C		CHEMBL4091991	=	IC50	nM	10.4	CHEMBL5251	Homo sapiens	IC50	nM	10.4
	18307328	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NS(C)(=O)=O)cc5)cc4c32)ccc1C		CHEMBL4091991	=	Ki	nM	3.2	CHEMBL5251	Homo sapiens	Ki	nM	3.2
	18307329	CHEMBL4130926	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate assessed as ratio of Kinact to Ki preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NS(C)(=O)=O)cc5)cc4c32)ccc1C		CHEMBL4091991	=	Ratio	/uM/s	0.78	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.78
	18307330	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NS(C)(=O)=O)cc5)cc4c32)ccc1C		CHEMBL4091991	=	Kinact	/min	0.15	CHEMBL5251	Homo sapiens	Kinact	/min	0.15
	18307331	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc6c(c5)OCCO6)cc4c32)ccc1C		CHEMBL4163217	=	IC50	nM	16.3	CHEMBL5251	Homo sapiens	IC50	nM	16.3
	18307335	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)ccc1C		CHEMBL4071759	=	IC50	nM	24.5	CHEMBL5251	Homo sapiens	IC50	nM	24.5
	18307339	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	IC50	nM	6.59	CHEMBL5251	Homo sapiens	IC50	nM	6.59
	18307343	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Ki	nM	14.2	CHEMBL5251	Homo sapiens	Ki	nM	14.2
	18307344	CHEMBL4130926	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate assessed as ratio of Kinact to Ki preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Ratio	/uM/s	0.15	CHEMBL5251	Homo sapiens	Ratio	/uM/s	0.15
	18307345	CHEMBL4130925	Irreversible inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Kinact	/min	0.13	CHEMBL5251	Homo sapiens	Kinact	/min	0.13
	18307346	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cn[nH]c6)cc5c43)cc21		CHEMBL4160923	=	IC50	nM	12.3	CHEMBL5251	Homo sapiens	IC50	nM	12.3
	18307350	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6ccc(N)nc6)cc5c43)cc21		CHEMBL4161149	=	IC50	nM	6.01	CHEMBL5251	Homo sapiens	IC50	nM	6.01
	18307354	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc21		CHEMBL4171756	=	IC50	nM	7.15	CHEMBL5251	Homo sapiens	IC50	nM	7.15
	18307358	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6ccc(S(=O)(=O)NC(C)(C)C)cc6)cc5c43)cc21		CHEMBL4068097	=	IC50	nM	10.7	CHEMBL5251	Homo sapiens	IC50	nM	10.7
	18307362	CHEMBL4130920	Inhibition of recombinant full length His-tagged human BTK expressed in baculovirus expression system using poly (4:1 Glu, Tyr) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by ADP-glo assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6ccc(N7CCN(C)CC7)cc6)cc5c43)cc21		CHEMBL4175202	=	IC50	nM	155.0	CHEMBL5251	Homo sapiens	IC50	nM	155.0
	18330835	CHEMBL4136268	Inhibition of recombinant BTK (unknown origin) at 1 uM by off-chip mobility shift assay	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Inhibition	%	96.0	CHEMBL5251	Homo sapiens	INH	%	96.0
	18379900	CHEMBL4145802	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	COc1cc(NC(=O)Nc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C)cc2OC)cc(OC)c1		CHEMBL4159506	=	Inhibition	%	19.91	CHEMBL5251	Homo sapiens	INH	%	19.91
	18379953	CHEMBL4145854	Inhibition of BTK (unknown origin)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	13.38	CHEMBL5251	Homo sapiens	IC50	nM	13.38
	18415119	CHEMBL4152883	Inhibition of BTK (unknown origin) assessed as reduction in TNF production	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	18415120	CHEMBL4152884	Binding affinity to BTK (unknown origin) assessed as residence time	B	CN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3702836	=	TIME	hr	161.0	CHEMBL5251	Homo sapiens	Time	hr	161.0
	18415121	CHEMBL4152885	Binding affinity to BTK in human Ramos cells assessed as protein occupancy at 20 hrs post compound wash out	B	CC(C)(C)/C=C(/C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4167139	=	Occ	%	55.0	CHEMBL5251	Homo sapiens	Occ	%	55.0
	18415126	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1		CHEMBL3979355	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	18415127	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1		CHEMBL4163691	=	IC50	nM	651.95	CHEMBL5251	Homo sapiens	IC50	nM	651.95
	18415128	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	CN(C1COC1)C(C)(C)/C=C(\C#N)C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21		CHEMBL3702836	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	18415129	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	CC(C)(C)/C=C(/C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4167139	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	18415130	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	18415131	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	CC#CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4175428	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	18415132	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1		CHEMBL3263640	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	18415133	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	Cc1cc2[nH]ncc2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL4172284	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	18415134	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc(C3C(=O)N(C)CCN3C)cc2)n1		CHEMBL4162057	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
	18415135	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL1230541	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	18415136	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	18415137	CHEMBL4152874	Inhibition of BTK (unknown origin)	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	18415142	CHEMBL4152868	Inhibition of BTK (unknown origin) by FRET assay	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	18420968	CHEMBL4153937	Inhibition of DNA-tagged BTK (unknown origin) expressed in HEK293 cells at 10 uM after 1 hr by real-time fluorescent quantitative PCR analysis	B	Fc1ccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cc1		CHEMBL4175978	=	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	18434105	CHEMBL4156088	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	18434239	CHEMBL4156088	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	18434299	CHEMBL4156088	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	62.0	CHEMBL5251	Homo sapiens	INH	%	62.0
	18434371	CHEMBL4156088	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	9.0	CHEMBL5251	Homo sapiens	INH	%	9.0
	18440099	CHEMBL4156923	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18443252	CHEMBL4157930	Inhibition of human BTK assessed as enzyme residual activity at 100 nM by radiometric filter binding assay relative to control	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O		CHEMBL4177303	=	Activity	%	99.0	CHEMBL5251	Homo sapiens	Activity	%	99.0
	18449876	CHEMBL4178110	Inhibition of human BTK (2 to 659 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	105.0	CHEMBL5251	Homo sapiens	Activity	%	105.0
	18450141	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CC1(O)CN(C(=O)N2CC=C(c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)CC2)C1		CHEMBL3982806	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	18450142	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN(C)C(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3936823	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	18450143	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3966346	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
	18450144	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(-c4cnn(C5CCN(C6COC6)CC5)c4)cc23)c1CO		CHEMBL3959033	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	18450145	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3967108	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	18450146	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3928203	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	18450147	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3922230	=	IC50	nM	5.4	CHEMBL5251	Homo sapiens	IC50	nM	5.4
	18450148	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CCC(n2cc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cn2)CC1		CHEMBL3891185	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	18450149	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CC(Oc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)C1		CHEMBL3962146	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	18450150	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CCC(Oc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3900184	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	18450151	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	Cc1c(-c2ncnc3[nH]c(-c4ccc(CN5CCN(C)CC5)cc4)cc23)cccc1N1CCOc2cc(C3CC3)ccc2C1=O		CHEMBL3968928	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	18450152	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3921350	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	18450153	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CN1CCN(c2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3968892	=	IC50	nM	11.7	CHEMBL5251	Homo sapiens	IC50	nM	11.7
	18450154	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	O=C1c2ccc(C3CC3)cc2OCCN1c1cccc(-c2ncnc3[nH]c(-c4ccc(CN5CCOCC5)cc4)cc23)c1CO		CHEMBL3935716	=	IC50	nM	8.3	CHEMBL5251	Homo sapiens	IC50	nM	8.3
	18450155	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CC1(O)CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)ccc7C6=O)c5CO)ncnc4[nH]3)cc2)CC1		CHEMBL3907763	=	IC50	nM	6.8	CHEMBL5251	Homo sapiens	IC50	nM	6.8
	18450176	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	N#CCC(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL4216939	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	18450177	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CS(=O)(=O)N1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3891434	=	IC50	nM	5.5	CHEMBL5251	Homo sapiens	IC50	nM	5.5
	18450178	CHEMBL4178244	Inhibition of recombinant human full length BTK preincubated for 10 mins followed by Tk-biotin peptide substrate addition after 90 mins by TR-FRET assay	B	CC(C)(O)CN1CC=C(c2cc3c(-c4cccc(N5CCOc6cc(C7CC7)cc(F)c6C5=O)c4CO)ccnc3[nH]2)CC1		CHEMBL3946460	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	18450225	CHEMBL4178258	Inhibition of human BTK assessed as decrease in anti-mouse IgD antibody stimulated BCR mediated CD69 upregulation in whole blood preincubated for 1 hr followed by antibody challenge after 4 hrs by flow cytometry	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3967108	=	IC50	nM	83.5	CHEMBL5251	Homo sapiens	IC50	nM	83.5
	18450226	CHEMBL4178258	Inhibition of human BTK assessed as decrease in anti-mouse IgD antibody stimulated BCR mediated CD69 upregulation in whole blood preincubated for 1 hr followed by antibody challenge after 4 hrs by flow cytometry	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3966346	=	IC50	nM	261.0	CHEMBL5251	Homo sapiens	IC50	nM	261.0
	18450765	CHEMBL4178422	Inhibition of His-tagged full-length recombinant human BTK cytoplasmic domain expressed in Baculovirus expression system at 1 uM by FRET-based Z'-LYTE assay	B	C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F		CHEMBL3989970	>	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
Active	18450791	CHEMBL4178444	Inhibition of BTK (unknown origin) at 1 uM by cell based assay	B	C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F		CHEMBL3989970		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18462160	CHEMBL4180847	Inhibition of BTK (unknown origin) assessed as residual activity at 1 uM relative to control	B	CC(C)=CCC/C(C)=C/Cn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL4203120	=	Activity	%	58.0	CHEMBL5251	Homo sapiens	Activity	%	58.0
	18463722	CHEMBL4181138	Inhibition of recombinant human full length N-terminal His6-tagged BTK expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	18464422	CHEMBL4181429	Inhibition of recombinant full length His-tagged human BTK cytoplasmic domain expressed in baculovirus expression system at 100 nM relative to control	B	CCOP(=O)(CCCOc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)N1CCOCC1		CHEMBL4216755	=	Inhibition	%	33.0	CHEMBL5251	Homo sapiens	INH	%	33.0
	18470914	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(C3(CO)CC3)c2)n1		CHEMBL4210972	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18470915	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(C3CC3)c2)n1		CHEMBL4213985	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	18470916	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(C)(C)n1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4208439	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	18470917	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(C)n1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4212285	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	18470918	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CCn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4204719	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18470919	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(=O)c1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1C		CHEMBL4202615	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
	18470920	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4216909	=	IC50	nM	20.2	CHEMBL5251	Homo sapiens	IC50	nM	20.2
	18470921	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1ccc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)c1		CHEMBL4205446	=	IC50	nM	62.0	CHEMBL5251	Homo sapiens	IC50	nM	62.0
	18470922	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1ccc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)n1		CHEMBL4210336	=	IC50	nM	245.0	CHEMBL5251	Homo sapiens	IC50	nM	245.0
	18470923	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4216609	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
	18470924	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cn[nH]c2)n1		CHEMBL4214732	=	IC50	nM	8.1	CHEMBL5251	Homo sapiens	IC50	nM	8.1
	18470925	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	COc1ccc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1		CHEMBL4214229	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	18470926	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2ccc(CN3CCOCC3)cc2)n1		CHEMBL4202546	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18470927	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CN1CCN(c2ccc(Nc3nc(N)cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)n3)cc2)CC1		CHEMBL4218643	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
	18470928	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL4206900	=	IC50	nM	12.9	CHEMBL5251	Homo sapiens	IC50	nM	12.9
	18470939	CHEMBL4182608	Inhibition of BTK (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4203409	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	18470940	CHEMBL4182608	Inhibition of BTK (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	COc1cc(Nc2nccc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)n2)cc(OC)c1OC		CHEMBL4211270	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
	18470941	CHEMBL4182608	Inhibition of BTK (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ccnc(Nc4ccc5cc[nH]c5c4)n3)c2)cc1		CHEMBL4208579	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
	18470942	CHEMBL4182608	Inhibition of BTK (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL4212308	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	18470943	CHEMBL4182608	Inhibition of BTK (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL4205977	=	IC50	nM	440.0	CHEMBL5251	Homo sapiens	IC50	uM	0.44
	18470944	CHEMBL4182608	Inhibition of BTK (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3ccnc(Nc4ccc5cn[nH]c5c4)n3)c2)cc1		CHEMBL4217692	=	IC50	nM	7300.0	CHEMBL5251	Homo sapiens	IC50	uM	7.3
Active	18470991	CHEMBL4182614	Inhibition of anti-IgM antibody stimulated BTK Tyr223 autophosphorylation in human Ramos cells at 30 nM pre-incubated for 1 hr followed by anti-IgM stimulation for 10 mins by Western blotting	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(C3CC3)c2)n1		CHEMBL4213985		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18470992	CHEMBL4182614	Inhibition of anti-IgM antibody stimulated BTK Tyr223 autophosphorylation in human Ramos cells at 30 nM pre-incubated for 1 hr followed by anti-IgM stimulation for 10 mins by Western blotting	B	Cn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4216609		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18470993	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(CC(F)F)c2)n1		CHEMBL4211960	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	18470994	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(CC3CC3)c2)n1		CHEMBL4215160	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	18470995	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(C3(CO)CC3)c2)n1		CHEMBL4210972	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18470996	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(C3CC3)c2)n1		CHEMBL4213985	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	18470997	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(C)(C)n1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4208439	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18470998	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(C)n1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4212285	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	18470999	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CCn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4204719	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18471000	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CC(=O)c1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1C		CHEMBL4202615	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	18471001	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4216909	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	18471002	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1ccc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)c1		CHEMBL4205446	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	18471003	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1ccc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)n1		CHEMBL4210336	=	IC50	nM	13.9	CHEMBL5251	Homo sapiens	IC50	nM	13.9
	18471004	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Cn1cc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4216609	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18471005	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cn[nH]c2)n1		CHEMBL4214732	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18471006	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	COc1ccc(Nc2nc(N)cc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1		CHEMBL4214229	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	18471007	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2ccc(CN3CCOCC3)cc2)n1		CHEMBL4202546	=	IC50	nM	309.0	CHEMBL5251	Homo sapiens	IC50	nM	309.0
	18471008	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	CN1CCN(c2ccc(Nc3nc(N)cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)n3)cc2)CC1		CHEMBL4218643	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18471009	CHEMBL4182612	Inhibition of His-tagged lambda phosphatase pre-treated N-terminal DYKDDDDK tagged and biotinylated BTK unactivated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL4206900	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18471010	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(CC(F)F)c2)n1		CHEMBL4211960	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
	18471011	CHEMBL4182611	Inhibition of N-terminal DYKDDDDK tagged and biotinylated BTK activated form (unknown origin) using FITC-labeled Srctide substrate and ATP by microfluidic mobility shift assay	B	Nc1cc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)nc(Nc2cnn(CC3CC3)c2)n1		CHEMBL4215160	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
	18484539	CHEMBL4185702	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18485082	CHEMBL4185702	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	94.0	CHEMBL5251	Homo sapiens	Activity	%	94.0
	18489495	CHEMBL4187236	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18502819	CHEMBL4189647	Inhibition of recombinant full-length N-terminal His-tagged human BTK C481S mutant expressed in baculovirus infected Sf9 insect cells using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)NC1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4217006	=	IC50	nM	463.6	CHEMBL5251	Homo sapiens	IC50	nM	463.6
	18502820	CHEMBL4189647	Inhibition of recombinant full-length N-terminal His-tagged human BTK C481S mutant expressed in baculovirus infected Sf9 insect cells using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	14.4	CHEMBL5251	Homo sapiens	IC50	nM	14.4
	18502821	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(C(=O)N[C@@H](COC)c4ccccn4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4203739	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
	18502822	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(C(=O)NCc4ccccn4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4208616	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
	18502823	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(C(=O)N[C@@H](C)c4ccccn4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4207689	=	IC50	nM	50.4	CHEMBL5251	Homo sapiens	IC50	nM	50.4
	18502824	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4202814	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	18502825	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(C(=O)Nc4ccccn4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4206284	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	18502826	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccc(OC(F)(F)F)cc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4203064	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	18502827	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccc(C(F)(F)F)cc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4203756	=	IC50	nM	7.4	CHEMBL5251	Homo sapiens	IC50	nM	7.4
	18502828	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccc(F)cc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4217114	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	18502829	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccc(C(C)(C)C)cc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4217820	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
	18502830	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=C1c2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C[C@H]1NC(=O)C#CC		CHEMBL4214532	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18502831	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=C1c2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C[C@@H]1NC(=O)C#CC		CHEMBL4215249	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
	18502832	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4211949	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	18502833	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4214492	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
	18502834	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@H]1CCc2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C1		CHEMBL4214872	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	18502835	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1CCc2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C1		CHEMBL4211579	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	18502836	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=C1c2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2CC1NC(=O)CC		CHEMBL4217471	=	IC50	nM	62.6	CHEMBL5251	Homo sapiens	IC50	nM	62.6
	18502837	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=C1c2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2CC1N		CHEMBL4204932	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	18502838	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=C1c2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2CC1NC(=O)C#CC		CHEMBL4209773	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
	18502839	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=C1c2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2CC1NC(=O)/C=C/CN(C)C		CHEMBL4203826	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
	18502840	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)NCCC(=O)NC1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4218760	=	IC50	nM	725.2	CHEMBL5251	Homo sapiens	IC50	nM	725.2
	18502841	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)NC1(C(=O)NC2Cn3c(c(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)C2=C)CC1		CHEMBL4215470	=	IC50	nM	23.8	CHEMBL5251	Homo sapiens	IC50	nM	23.8
	18502842	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H](C)C(=O)NC1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4216788	=	IC50	nM	40.1	CHEMBL5251	Homo sapiens	IC50	nM	40.1
	18502843	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)NCC(=O)NC1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4204398	=	IC50	nM	23.6	CHEMBL5251	Homo sapiens	IC50	nM	23.6
	18502844	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)NC1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4217006	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	18502845	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	CCC(=O)NC1CCc2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C1		CHEMBL4209048	=	IC50	nM	417.4	CHEMBL5251	Homo sapiens	IC50	nM	417.4
	18502846	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)NC1CCc2c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc3n2C1		CHEMBL4209342	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
	18502847	CHEMBL4189646	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
Dose-dependent effect	18502867	CHEMBL4189703	Inhibition of BTK autophosphorylation at Y223 in human TMD8 cells after 4 hrs by Western blot method	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4211949		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18502868	CHEMBL4189705	Inhibition of BTK in human TMD8 cells assessed as decrease in PLCgamma2 phosphorylation at Y759 at 1 to 100 nM after 4 hrs by Western blot method	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4211949		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18502869	CHEMBL4189706	Irreversible inhibition of BTK autophosphorylation at Y223 in human TMD8 cells at 1 uM preincubated for 2 hrs followed by compound wash out measured after 2 to 24 hrs by Western blot method	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18502870	CHEMBL4189706	Irreversible inhibition of BTK autophosphorylation at Y223 in human TMD8 cells at 1 uM preincubated for 2 hrs followed by compound wash out measured after 2 to 24 hrs by Western blot method	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4211949		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18502896	CHEMBL4189703	Inhibition of BTK autophosphorylation at Y223 in human TMD8 cells after 4 hrs by Western blot method	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4211949	<	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
Active	18502897	CHEMBL4189704	Inhibition of BTK in human TMD8 cells assessed as decrease in PLCgamma2 phosphorylation at Y759 at 1 uM after 4 hrs by Western blot method	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18507879	CHEMBL4190888	Inhibition of recombinant full-length human BTK R28H mutant at 1 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	18507880	CHEMBL4190887	Inhibition of recombinant full-length human BTK at 1 uM using KVEKIGEGTYGVVYK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	25.0	CHEMBL5251	Homo sapiens	INH	%	25.0
	18507935	CHEMBL4190836	Inhibition of BTK (unknown origin)	B	Nc1nc2c(s1)CC(n1nc(-c3cc(F)c4[nH]ccc4c3)c3c(N)ncnc31)CC2		CHEMBL4216036	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	uM	0.022
	18507936	CHEMBL4190836	Inhibition of BTK (unknown origin)	B	Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1Cc2ccccc2C1		CHEMBL3964073	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	uM	0.012
	18507937	CHEMBL4190836	Inhibition of BTK (unknown origin)	B	Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCc2ccccc21		CHEMBL4211185	=	IC50	nM	123.0	CHEMBL5251	Homo sapiens	IC50	uM	0.123
Not Determined	18507938	CHEMBL4190836	Inhibition of BTK (unknown origin)	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCc2ccccc2C1		CHEMBL4207265		IC50			CHEMBL5251	Homo sapiens	IC50		
	18507957	CHEMBL4190833	Inhibition of BTK (unknown origin) at 100 nM	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCc2ccccc2C1		CHEMBL4207265	=	Inhibition	%	24.0	CHEMBL5251	Homo sapiens	INH	%	24.0
	18510265	CHEMBL4191745	Receptor occupancy at BTK in human Ramos B cells at 1 uM preincubated for 1 hr followed by compound washout measured after 20 hrs by PP-BODIPY probe based fluorescence assay	B	CC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4212697	=	Occ	%	50.0	CHEMBL5251	Homo sapiens	Occ	%	50.0
	18510266	CHEMBL4191745	Receptor occupancy at BTK in human Ramos B cells at 1 uM preincubated for 1 hr followed by compound washout measured after 20 hrs by PP-BODIPY probe based fluorescence assay	B	C/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4216469	=	Occ	%	5.0	CHEMBL5251	Homo sapiens	Occ	%	5.0
	18524335	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	COc1cccc(Oc2ccc(-c3nn([C@@H]4CCCN(C(=O)OC(C)(C)C)C4)c4c(OC)cncc34)cc2)c1F		CHEMBL4210846	<=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524336	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(Cl)c4)cc3)c3cnccc32)C1		CHEMBL4214322	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524337	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4cccc(OC)c4Cl)cc3)c3cnccc32)C1		CHEMBL4209426	<=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524338	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3cnccc32)C1		CHEMBL4218747	<=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524339	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CC[C@H](n2nc3ccncc3c2-c2ccc(Oc3cccc(Cl)c3Cl)cc2)C1		CHEMBL4213818	<=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524340	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CCC[C@H](n2nc3ccncc3c2-c2ccc(Oc3cccc(Cl)c3Cl)cc2)C1		CHEMBL4206488	<=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524341	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4cccc(OC)c4F)cc3)c3c2CCN(C(C)=O)C3)C1		CHEMBL4218219	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	18524342	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Sc4cccc(F)c4)cc3)c3cnccc32)C1		CHEMBL4210858	<=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524343	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4cccc(OC)c4C)cc3)c3cnccc32)C1		CHEMBL4205974	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18524344	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(OC)c4F)cc3)c3cncc(OC)c32)C1		CHEMBL4215275	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	18524345	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	CC#CC(=O)N1CCC[C@@H](n2nc(-c3ccc(C(=O)Nc4ccccn4)cc3)c3cnccc32)C1		CHEMBL4210340	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	18524346	CHEMBL4194325	Inhibition of BTK (unknown origin) using peptide substrate after 1 hr by HTRF assay	B	O=C(Nc1ccc(-c2nn(C3CCC(C(=O)O)CC3)c3ccncc23)cc1)c1ccccc1		CHEMBL4216160	>=	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18551456	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cnco4)s3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc31)C2		CHEMBL4203077	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
	18551457	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3cncs3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc31)C2		CHEMBL4202618	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
	18551458	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(C(F)F)s3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc31)C2		CHEMBL4206487	=	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
	18551459	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cnco4)s3)nc3ccccc31)C2		CHEMBL4211372	=	IC50	nM	0.94	CHEMBL5251	Homo sapiens	IC50	nM	0.94
	18551460	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(C#N)cc3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc31)C2		CHEMBL4210857	=	IC50	nM	1.34	CHEMBL5251	Homo sapiens	IC50	nM	1.34
	18551461	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccns3)nc3cc(CN[C@@H](C)C(C)(C)C)ccc31)C2		CHEMBL4215807	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	18551462	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(C(F)F)s3)nc3cc(CN4CCOCC4)ccc31)C2		CHEMBL4218914	=	IC50	nM	2.59	CHEMBL5251	Homo sapiens	IC50	nM	2.59
	18551463	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(C(C)(F)F)s3)nc3ccccc31)C2		CHEMBL4204572	=	IC50	nM	2.11	CHEMBL5251	Homo sapiens	IC50	nM	2.11
	18551464	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(C(F)F)s3)nc3cc(CNCC(C)(C)CO)ccc31)C2		CHEMBL4202941	=	IC50	nM	0.95	CHEMBL5251	Homo sapiens	IC50	nM	0.95
	18551465	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cnco4)s3)nc3cc(CN[C@H]4CC[C@H](O)CC4)ccc31)C2		CHEMBL4216529	=	IC50	nM	0.53	CHEMBL5251	Homo sapiens	IC50	nM	0.53
	18551466	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cnco4)s3)nc3cc(CNCC(C)(C)CO)ccc31)C2		CHEMBL4215147	=	IC50	nM	0.66	CHEMBL5251	Homo sapiens	IC50	nM	0.66
	18551467	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cnco4)s3)nc3cc(NC)ccc31)C2		CHEMBL4216187	=	IC50	nM	0.62	CHEMBL5251	Homo sapiens	IC50	nM	0.62
	18551468	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cnco4)s3)nc3cc(F)ccc31)C2		CHEMBL4208358	=	IC50	nM	1.09	CHEMBL5251	Homo sapiens	IC50	nM	1.09
	18551469	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4cc[nH]c(=O)c4)s3)nc3ccccc31)C2		CHEMBL4206765	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
	18551470	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4ccnc(N)c4)s3)nc3ccccc31)C2		CHEMBL4207292	=	IC50	nM	0.63	CHEMBL5251	Homo sapiens	IC50	nM	0.63
	18551471	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4ccnc(NC)c4)s3)nc3ccccc31)C2		CHEMBL4219011	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
	18551472	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4ccnc(N)n4)s3)nc3ccccc31)C2		CHEMBL4217959	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
	18551473	CHEMBL4199505	Inhibition of BTK (unknown origin) using fluorescently labeled peptide as substrate after 3 hrs by microfluidic mobility shift assay	B	C=CC(=O)N1CC[C@]2(C1)C[C@H](n1c(NC(=O)c3ccc(-c4ccnc(C)n4)s3)nc3ccccc31)C2		CHEMBL4214683	=	IC50	nM	0.68	CHEMBL5251	Homo sapiens	IC50	nM	0.68
	18562679	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
	18562680	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4203409	=	IC50	nM	1800.0	CHEMBL5251	Homo sapiens	IC50	nM	1800.0
	18562681	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cncc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4212668	=	IC50	nM	2500.0	CHEMBL5251	Homo sapiens	IC50	nM	2500.0
	18562682	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cnnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4207762	=	IC50	nM	5600.0	CHEMBL5251	Homo sapiens	IC50	nM	5600.0
	18562683	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4215184	=	IC50	nM	1800.0	CHEMBL5251	Homo sapiens	IC50	nM	1800.0
	18562684	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2C)n1		CHEMBL4210252	=	IC50	nM	7800.0	CHEMBL5251	Homo sapiens	IC50	nM	7800.0
	18562685	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(N)nc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4209148	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	nM	190.0
	18562686	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	COc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2C)n1		CHEMBL4214068	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18562687	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(O)nc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4213547	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18562688	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4218481	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
	18562689	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4217003	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
	18562690	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4205287	=	IC50	nM	82.0	CHEMBL5251	Homo sapiens	IC50	nM	82.0
	18562691	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3ccc(C4CC4)cc3)c2CO)n1		CHEMBL4204802	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
	18562692	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CN(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4209666	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	18562693	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)(C)c1cnc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)s1		CHEMBL4210081	=	IC50	nM	2500.0	CHEMBL5251	Homo sapiens	IC50	nM	2500.0
	18562694	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)s1		CHEMBL4215004	=	IC50	nM	820.0	CHEMBL5251	Homo sapiens	IC50	nM	820.0
	18562695	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3cc4c(s3)CCCC4)c2CO)n1		CHEMBL4213416	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	18562696	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)(C)c1ccc2c(c1)CN(c1cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c1CO)C2=O		CHEMBL4208482	=	IC50	nM	640.0	CHEMBL5251	Homo sapiens	IC50	nM	640.0
	18562697	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(-n3ncc4cc(C5CC5)ccc4c3=O)c2CO)n1		CHEMBL4209020	=	IC50	nM	280.0	CHEMBL5251	Homo sapiens	IC50	nM	280.0
	18562698	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(N3CCc4cc(C5CC5)ccc4C3=O)c2CO)n1		CHEMBL4204140	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	nM	350.0
	18562699	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)(C#N)c1cc(F)c2c(c1)CCN(c1cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c1CO)C2=O		CHEMBL4205586	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
	18562700	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(N3CCc4cc(C5CC5)cc(F)c4C3=O)c2CO)n1		CHEMBL4217295	=	IC50	nM	70.0	CHEMBL5251	Homo sapiens	IC50	nM	70.0
	18562701	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1		CHEMBL4217816	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	18562702	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC1(C)Cc2cc3n(c2C1)CCN(c1cccc(-c2nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n2)c1CO)C3=O		CHEMBL4212860	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	nM	42.0
	18562703	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2cn[nH]c2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1		CHEMBL4214343	=	IC50	nM	9.3	CHEMBL5251	Homo sapiens	IC50	nM	9.3
	18562704	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4209441	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
	18562705	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Nc1nc(Nc2cnn(C3CC3)c2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1		CHEMBL4216862	=	IC50	nM	8.3	CHEMBL5251	Homo sapiens	IC50	nM	8.3
	18562706	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C1CC1)n1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4211893	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	18562707	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4204675	=	IC50	nM	7.4	CHEMBL5251	Homo sapiens	IC50	nM	7.4
	18562708	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CCn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4216339	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
	18562709	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	CC(C)n1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4208062	=	IC50	nM	5.4	CHEMBL5251	Homo sapiens	IC50	nM	5.4
	18562710	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	N#Cc1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1C1CC1		CHEMBL4203192	=	IC50	nM	9.1	CHEMBL5251	Homo sapiens	IC50	nM	9.1
	18562711	CHEMBL4201924	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	B	COCCOCCn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4212436	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	18562712	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
	18562713	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4203409	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	18562714	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cncc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4212668	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	18562715	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cnnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4207762	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	18562716	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4215184	=	IC50	nM	6.4	CHEMBL5251	Homo sapiens	IC50	nM	6.4
	18562717	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2C)n1		CHEMBL4210252	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
	18562718	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(N)nc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4209148	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
	18562719	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	COc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2C)n1		CHEMBL4214068	=	IC50	nM	80.0	CHEMBL5251	Homo sapiens	IC50	nM	80.0
	18562720	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(O)nc(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4213547	=	IC50	nM	8800.0	CHEMBL5251	Homo sapiens	IC50	nM	8800.0
	18562721	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4218481	<	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	18562722	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4217003	=	IC50	nM	0.74	CHEMBL5251	Homo sapiens	IC50	nM	0.74
	18562723	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4205287	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	18562724	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3ccc(C4CC4)cc3)c2CO)n1		CHEMBL4204802	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
	18562725	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CN(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)cc1		CHEMBL4209666	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
	18562726	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)(C)c1cnc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)s1		CHEMBL4210081	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	18562727	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c2CO)s1		CHEMBL4215004	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	18562728	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(NC(=O)c3cc4c(s3)CCCC4)c2CO)n1		CHEMBL4213416	=	IC50	nM	0.81	CHEMBL5251	Homo sapiens	IC50	nM	0.81
	18562729	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)(C)c1ccc2c(c1)CN(c1cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c1CO)C2=O		CHEMBL4208482	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
	18562730	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(-n3ncc4cc(C5CC5)ccc4c3=O)c2CO)n1		CHEMBL4209020	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
	18562731	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(N3CCc4cc(C5CC5)ccc4C3=O)c2CO)n1		CHEMBL4204140	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
	18562732	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)(C#N)c1cc(F)c2c(c1)CCN(c1cccc(-c3nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n3)c1CO)C2=O		CHEMBL4205586	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	18562733	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(N3CCc4cc(C5CC5)cc(F)c4C3=O)c2CO)n1		CHEMBL4217295	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	18562734	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1		CHEMBL4217816	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
	18562735	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC1(C)Cc2cc3n(c2C1)CCN(c1cccc(-c2nc(N)nc(Nc4ccc(N5CCOCC5)cc4)n2)c1CO)C3=O		CHEMBL4212860	=	IC50	nM	0.62	CHEMBL5251	Homo sapiens	IC50	nM	0.62
	18562736	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2cn[nH]c2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1		CHEMBL4214343	=	IC50	nM	0.51	CHEMBL5251	Homo sapiens	IC50	nM	0.51
	18562737	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4209441	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
	18562738	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Nc1nc(Nc2cnn(C3CC3)c2)nc(-c2cccc(-n3ccc4cc(C5CC5)cc(F)c4c3=O)c2CO)n1		CHEMBL4216862	=	IC50	nM	0.57	CHEMBL5251	Homo sapiens	IC50	nM	0.57
	18562739	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C1CC1)n1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4211893	=	IC50	nM	0.49	CHEMBL5251	Homo sapiens	IC50	nM	0.49
	18562740	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4204675	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
	18562741	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CCn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4216339	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
	18562742	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	CC(C)n1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4208062	=	IC50	nM	0.53	CHEMBL5251	Homo sapiens	IC50	nM	0.53
	18562743	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	N#Cc1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1C1CC1		CHEMBL4203192	=	IC50	nM	0.86	CHEMBL5251	Homo sapiens	IC50	nM	0.86
	18562744	CHEMBL4201925	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	B	COCCOCCn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cc1C#N		CHEMBL4212436	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
	18562749	CHEMBL4201928	Inhibition of anti-IgM-stimulated BTK phosphorylation at Tyr551 in human Ramos cells pre-incubated for 1 hr followed by anti-IgM stimulation for 10 mins by Western blotting	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4209441	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	18562750	CHEMBL4201929	Inhibition of anti-IgM-stimulated BTK phosphorylation at Tyr223 in human Ramos cells pre-incubated for 1 hr followed by anti-IgM stimulation for 10 mins by Western blotting	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4209441	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18562751	CHEMBL4201930	Inhibition of anti-IgM-stimulated BTK-mediated PLCgamma2 phosphorylation at Tyr1217 in human Ramos cells pre-incubated for 1 hr followed by anti-IgM stimulation for 10 mins by Western blotting	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4209441	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	18562752	CHEMBL4201931	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-stimulated B-cell activation by measuring CD86 expression	B	Cn1cc(Nc2nc(N)nc(-c3cccc(-n4ccc5cc(C6CC6)cc(F)c5c4=O)c3CO)n2)cn1		CHEMBL4209441	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	18580343	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4226237	=	IC50	nM	7.95	CHEMBL5251	Homo sapiens	IC50	nM	7.95
	18580344	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(CCCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4224933	=	IC50	nM	22.18	CHEMBL5251	Homo sapiens	IC50	nM	22.18
	18580345	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(/C=C\COc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4229083	=	IC50	nM	23.2	CHEMBL5251	Homo sapiens	IC50	nM	23.2
	18580346	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(/C=C/COc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4225333	=	IC50	nM	11.3	CHEMBL5251	Homo sapiens	IC50	nM	11.3
	18580347	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4228867	=	IC50	nM	39.8	CHEMBL5251	Homo sapiens	IC50	nM	39.8
	18580348	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4226239	=	IC50	nM	102.4	CHEMBL5251	Homo sapiens	IC50	nM	102.4
	18580349	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCCc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4228608	=	IC50	nM	15.9	CHEMBL5251	Homo sapiens	IC50	nM	15.9
	18580350	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCNc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4227768	=	IC50	nM	18.1	CHEMBL5251	Homo sapiens	IC50	nM	18.1
	18580351	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCSc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4225882	=	IC50	nM	10.95	CHEMBL5251	Homo sapiens	IC50	nM	10.95
	18580352	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3C)c3c(N)ncnc32)C1		CHEMBL4225403	=	IC50	nM	49.23	CHEMBL5251	Homo sapiens	IC50	nM	49.23
	18580353	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3cccc(C)c3)c3c(N)ncnc32)C1		CHEMBL4228086	=	IC50	nM	20.85	CHEMBL5251	Homo sapiens	IC50	nM	20.85
	18580354	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccc(C)cc3)c3c(N)ncnc32)C1		CHEMBL4227235	=	IC50	nM	26.89	CHEMBL5251	Homo sapiens	IC50	nM	26.89
	18580355	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3OC)c3c(N)ncnc32)C1		CHEMBL4229038	=	IC50	nM	38.17	CHEMBL5251	Homo sapiens	IC50	nM	38.17
	18580356	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3cccc(OC)c3)c3c(N)ncnc32)C1		CHEMBL4227934	=	IC50	nM	9.84	CHEMBL5251	Homo sapiens	IC50	nM	9.84
	18580357	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccc(OC)cc3)c3c(N)ncnc32)C1		CHEMBL4224855	=	IC50	nM	89.62	CHEMBL5251	Homo sapiens	IC50	nM	89.62
	18580358	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3cccc(Cl)c3)c3c(N)ncnc32)C1		CHEMBL4225328	=	IC50	nM	18.11	CHEMBL5251	Homo sapiens	IC50	nM	18.11
	18580359	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3cccc(C(F)(F)F)c3)c3c(N)ncnc32)C1		CHEMBL4226585	=	IC50	nM	209.2	CHEMBL5251	Homo sapiens	IC50	nM	209.2
	18580360	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3cccc(C(C)C)c3)c3c(N)ncnc32)C1		CHEMBL4228138	=	IC50	nM	45.35	CHEMBL5251	Homo sapiens	IC50	nM	45.35
	18580361	CHEMBL4222711	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	5.49	CHEMBL5251	Homo sapiens	IC50	nM	5.49
	18653743	CHEMBL4230032	Inhibition of BTK (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	71.0	CHEMBL5251	Homo sapiens	INH	%	71.0
	18653744	CHEMBL4230032	Inhibition of BTK (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	18654947	CHEMBL4230602	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18663894	CHEMBL4232874	Inhibition of full length human BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	74.0	CHEMBL5251	Homo sapiens	Activity	%	74.0
	18663987	CHEMBL4232971	Binding affinity to full length human BTK (M1 to S659 residues) expressed in mammalian expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL5251	Homo sapiens	Kd	uM	5.0
	18665558	CHEMBL4233294	Inhibition of BTK (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	18666971	CHEMBL4233700	Inhibition of full length recombinant human N-terminal His-tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)NCC(=O)O)cc3)ncc2Cl)c1		CHEMBL4251213	=	IC50	nM	11.2	CHEMBL5251	Homo sapiens	IC50	nM	11.2
	18666972	CHEMBL4233700	Inhibition of full length recombinant human N-terminal His-tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCCC4C(=O)OC)cc3)ncc2Cl)c1		CHEMBL4243975	=	IC50	nM	8.7	CHEMBL5251	Homo sapiens	IC50	nM	8.7
	18666973	CHEMBL4233700	Inhibition of full length recombinant human N-terminal His-tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)NC(C)C(=O)OC)cc3)ncc2Cl)c1		CHEMBL4247474	=	IC50	nM	8.7	CHEMBL5251	Homo sapiens	IC50	nM	8.7
	18666974	CHEMBL4233700	Inhibition of full length recombinant human N-terminal His-tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)NCC(=O)OC)cc3)ncc2Cl)c1		CHEMBL4247870	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	18666975	CHEMBL4233700	Inhibition of full length recombinant human N-terminal His-tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
Dose-dependent effect	18667014	CHEMBL4233719	Inhibition of BTK phosphorylation in human NAMALWA cells after 48 hrs by Western blot method	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCCC4C(=O)OC)cc3)ncc2Cl)c1		CHEMBL4243975		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18667015	CHEMBL4233720	Inhibition of BTK phosphorylation in human NAMALWA cells at 10 uM after 48 hrs by Western blot method	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18673664	CHEMBL4235178	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	18673744	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(N)cc5)c4c3c2)cn1		CHEMBL4247073	=	Inhibition	%	32.2	CHEMBL5251	Homo sapiens	INH	%	32.2
	18673745	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)C(F)(F)F)cc5)c4c3c2)cn1		CHEMBL4250918	=	Inhibition	%	38.3	CHEMBL5251	Homo sapiens	INH	%	38.3
	18673746	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(OC)nc5)cc4c32)cc1		CHEMBL4246636	=	Inhibition	%	41.8	CHEMBL5251	Homo sapiens	INH	%	41.8
	18673747	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NS(C)(=O)=O)cc5)c4c3c2)cn1		CHEMBL4241165	=	Inhibition	%	12.7	CHEMBL5251	Homo sapiens	INH	%	12.7
	18673748	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	CCOC(=O)CNc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(OC)nc5)cc4c32)cc1		CHEMBL4251286	=	Inhibition	%	16.2	CHEMBL5251	Homo sapiens	INH	%	16.2
	18673749	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NCC(=O)O)cc5)c4c3c2)cn1		CHEMBL4244082	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	18673750	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN(C)C)cc5)c4c3c2)cn1		CHEMBL4248320	=	Inhibition	%	48.7	CHEMBL5251	Homo sapiens	INH	%	48.7
	18673751	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	100.0	CHEMBL5251	Homo sapiens	INH	%	100.0
	18673752	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	CCN(CC)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(OC)nc5)cc4c32)cc1		CHEMBL4237416	=	Inhibition	%	22.6	CHEMBL5251	Homo sapiens	INH	%	22.6
	18673753	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCOCC6)cc5)c4c3c2)cn1		CHEMBL4241577	=	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	18673754	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	CNCC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(OC)nc5)cc4c32)cc1		CHEMBL4241148	=	Inhibition	%	25.0	CHEMBL5251	Homo sapiens	INH	%	25.0
	18673755	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCCCC6)cc5)c4c3c2)cn1		CHEMBL4245357	=	Inhibition	%	52.3	CHEMBL5251	Homo sapiens	INH	%	52.3
	18673756	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCNCC6)cc5)c4c3c2)cn1		CHEMBL4243283	=	Inhibition	%	12.1	CHEMBL5251	Homo sapiens	INH	%	12.1
	18673757	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCN(C)CC6)cc5)c4c3c2)cn1		CHEMBL4247514	=	Inhibition	%	58.1	CHEMBL5251	Homo sapiens	INH	%	58.1
	18673758	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCCC6)cc5)c4c3c2)cn1		CHEMBL4250380	=	Inhibition	%	56.8	CHEMBL5251	Homo sapiens	INH	%	56.8
	18673759	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1		CHEMBL4246563	=	Inhibition	%	51.9	CHEMBL5251	Homo sapiens	INH	%	51.9
	18673760	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccc(N)c5)cc4c32)cc1		CHEMBL4242756	=	Inhibition	%	28.3	CHEMBL5251	Homo sapiens	INH	%	28.3
	18673761	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(O)cc5)cc4c32)cc1		CHEMBL4245446	=	Inhibition	%	23.2	CHEMBL5251	Homo sapiens	INH	%	23.2
	18673762	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(C(=O)O)cc5)cc4c32)cc1		CHEMBL4239011	=	Inhibition	%	22.1	CHEMBL5251	Homo sapiens	INH	%	22.1
	18673763	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccc6[nH]ccc56)cc4c32)cc1		CHEMBL4249078	=	Inhibition	%	38.3	CHEMBL5251	Homo sapiens	INH	%	38.3
	18673764	CHEMBL4235187	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cnn(C)c5)cc4c32)cc1		CHEMBL4251204	=	Inhibition	%	47.5	CHEMBL5251	Homo sapiens	INH	%	47.5
	18673765	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN(C)C)cc5)c4c3c2)cn1		CHEMBL4248320	=	IC50	nM	237.0	CHEMBL5251	Homo sapiens	IC50	uM	0.237
	18673766	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Potential transcription error	CHEMBL1873475	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	uM	0.001
	18673767	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCOCC6)cc5)c4c3c2)cn1		CHEMBL4241577	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	uM	0.2
	18673768	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCCCC6)cc5)c4c3c2)cn1		CHEMBL4245357	=	IC50	nM	106.0	CHEMBL5251	Homo sapiens	IC50	uM	0.106
	18673769	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCN(C)CC6)cc5)c4c3c2)cn1		CHEMBL4247514	=	IC50	nM	139.0	CHEMBL5251	Homo sapiens	IC50	uM	0.139
	18673770	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCCC6)cc5)c4c3c2)cn1		CHEMBL4250380	=	IC50	nM	183.0	CHEMBL5251	Homo sapiens	IC50	uM	0.183
	18673771	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1		CHEMBL4246563	=	IC50	nM	136.0	CHEMBL5251	Homo sapiens	IC50	uM	0.136
	18673772	CHEMBL4235188	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cnn(C)c5)cc4c32)cc1		CHEMBL4251204	=	IC50	nM	217.0	CHEMBL5251	Homo sapiens	IC50	uM	0.217
	18674562	CHEMBL4235321	Inhibition of Btk (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	10000.0	CHEMBL5251	Homo sapiens	Ki	nM	10000.0
	18674563	CHEMBL4235321	Inhibition of Btk (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL5251	Homo sapiens	Ki	nM	2000.0
Not Determined	18674564	CHEMBL4235321	Inhibition of Btk (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525		Ki			CHEMBL5251	Homo sapiens	Ki		
Active	18675663	CHEMBL4235718	Reversible inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 times IC50 using Src-tide as substrate pretreated for 1.5 hrs followed by 2 times dialysis for 6 hrs and subsequent substrate addition measured after 2 hrs	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)cccc1-n1cnc2ccccc2c1=O		CHEMBL4237800		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18675672	CHEMBL4235717	Irreversible inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 times IC50 using Src-tide as substrate pretreated for 1.5 hrs followed by 2 times dialysis for 6 hrs and subsequent substrate addition measured after 2 hrs	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4248386		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18675673	CHEMBL4235717	Irreversible inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 times IC50 using Src-tide as substrate pretreated for 1.5 hrs followed by 2 times dialysis for 6 hrs and subsequent substrate addition measured after 2 hrs	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4237557		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18675674	CHEMBL4235717	Irreversible inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 times IC50 using Src-tide as substrate pretreated for 1.5 hrs followed by 2 times dialysis for 6 hrs and subsequent substrate addition measured after 2 hrs	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4241958		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18675746	CHEMBL4235698	Irreversible inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system assessed as residual activity at 25 times IC50 using Src-tide as substrate pretreated for 1.5 hrs followed by 2 times dialysis for 6 hrs and subsequent substrate addition measured after 2 hrs relative to control	B	CCC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4238256	=	Activity	%	101.0	CHEMBL5251	Homo sapiens	Activity	%	101.0
	18675747	CHEMBL4235698	Irreversible inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system assessed as residual activity at 25 times IC50 using Src-tide as substrate pretreated for 1.5 hrs followed by 2 times dialysis for 6 hrs and subsequent substrate addition measured after 2 hrs relative to control	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1		CHEMBL4248271	=	Activity	%	3.5	CHEMBL5251	Homo sapiens	Activity	%	3.5
	18675748	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CS(=O)(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4237999	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	18675749	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4247992	=	IC50	nM	170.0	CHEMBL5251	Homo sapiens	IC50	nM	170.0
	18675750	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4242527	=	IC50	nM	6.4	CHEMBL5251	Homo sapiens	IC50	nM	6.4
	18675751	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4243995	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	18675752	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CS(=O)(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4246324	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	18675753	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4242058	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	nM	61.0
	18675754	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4248386	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	18675755	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]cc(C)c23)c1C		CHEMBL4245037	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	18675756	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)cc23)c1C		CHEMBL4238798	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
	18675757	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]ccc23)c1C		CHEMBL4248834	=	IC50	nM	57.0	CHEMBL5251	Homo sapiens	IC50	nM	57.0
	18675758	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4237557	=	IC50	nM	9.2	CHEMBL5251	Homo sapiens	IC50	nM	9.2
	18675759	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1[nH]c2c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3C)c2c1C		CHEMBL4241723	=	IC50	nM	890.0	CHEMBL5251	Homo sapiens	IC50	nM	890.0
	18675760	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]cc(C)c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4249677	>	IC50	nM	2000.0	CHEMBL5251	Homo sapiens	IC50	nM	2000.0
	18675761	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1cc2c(-c3cccc(-n4cnc5ccccc5c4=O)c3C)ccc(C(N)=O)c2[nH]1		CHEMBL4237436	>	IC50	nM	2000.0	CHEMBL5251	Homo sapiens	IC50	nM	2000.0
Not Determined	18675762	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]ccc23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4245876		IC50			CHEMBL5251	Homo sapiens	IC50		
	18675763	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4ccccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4243299	=	IC50	nM	1700.0	CHEMBL5251	Homo sapiens	IC50	nM	1700.0
	18675764	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)NC(C)(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4238212	=	IC50	nM	2000.0	CHEMBL5251	Homo sapiens	IC50	nM	2000.0
	18675765	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)NCc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4249247	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	nM	200.0
	18675766	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CS(=O)(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4248550	=	IC50	nM	8.8	CHEMBL5251	Homo sapiens	IC50	nM	8.8
Not Determined	18675767	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4240879		IC50			CHEMBL5251	Homo sapiens	IC50		
	18675768	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4239031	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	18675769	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4237249	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	18675770	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4248719	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	18675771	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1c(NC(=O)/C=C/CN(C)C)cccc1-c1ccc(C(N)=O)c2[nH]c3c(c12)CCC(C(C)(C)O)C3		CHEMBL4238297	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	18675772	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=C(C)C(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4244928	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
	18675773	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C/C=C/C(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4240731	=	IC50	nM	370.0	CHEMBL5251	Homo sapiens	IC50	nM	370.0
	18675774	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4241958	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
	18675775	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)cccc1-n1cnc2ccccc2c1=O		CHEMBL4237800	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	18675776	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	CCC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4238256	=	IC50	nM	59.0	CHEMBL5251	Homo sapiens	IC50	nM	59.0
	18675777	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1		CHEMBL4248271	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	18675778	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	CC(C)=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4251151	=	IC50	nM	75.0	CHEMBL5251	Homo sapiens	IC50	nM	75.0
	18675779	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C/C=C/C(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4246005	=	IC50	nM	68.0	CHEMBL5251	Homo sapiens	IC50	nM	68.0
	18675780	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4239747	=	IC50	nM	7.1	CHEMBL5251	Homo sapiens	IC50	nM	7.1
	18675781	CHEMBL4235697	Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	18675782	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CS(=O)(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4237999	=	IC50	nM	0.068	CHEMBL5251	Homo sapiens	IC50	nM	0.068
	18675783	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4247992	=	IC50	nM	0.23	CHEMBL5251	Homo sapiens	IC50	nM	0.23
	18675784	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4242527	=	IC50	nM	0.077	CHEMBL5251	Homo sapiens	IC50	nM	0.077
	18675785	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1		CHEMBL4243995	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
	18675786	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CS(=O)(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4246324	=	IC50	nM	0.11	CHEMBL5251	Homo sapiens	IC50	nM	0.11
	18675787	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4242058	=	IC50	nM	0.59	CHEMBL5251	Homo sapiens	IC50	nM	0.59
	18675788	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4248386	=	IC50	nM	0.14	CHEMBL5251	Homo sapiens	IC50	nM	0.14
	18675789	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]cc(C)c23)c1C		CHEMBL4245037	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	18675790	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)cc23)c1C		CHEMBL4238798	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
	18675791	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]ccc23)c1C		CHEMBL4248834	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	18675792	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)c1C		CHEMBL4237557	=	IC50	nM	0.38	CHEMBL5251	Homo sapiens	IC50	nM	0.38
	18675793	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1[nH]c2c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3C)c2c1C		CHEMBL4241723	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18675794	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]cc(C)c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4249677	=	IC50	nM	92.0	CHEMBL5251	Homo sapiens	IC50	nM	92.0
	18675795	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1cc2c(-c3cccc(-n4cnc5ccccc5c4=O)c3C)ccc(C(N)=O)c2[nH]1		CHEMBL4237436	=	IC50	nM	81.0	CHEMBL5251	Homo sapiens	IC50	nM	81.0
	18675796	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]ccc23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4245876	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	nM	550.0
	18675797	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4ccccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4243299	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	18675798	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)NC(C)(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4238212	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	18675799	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)NCc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4249247	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	18675800	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CS(=O)(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4248550	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
	18675801	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CS(=O)(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4240879	=	IC50	nM	0.079	CHEMBL5251	Homo sapiens	IC50	nM	0.079
	18675802	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4239031	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	18675803	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4237249	=	IC50	nM	0.24	CHEMBL5251	Homo sapiens	IC50	nM	0.24
	18675804	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1		CHEMBL4248719	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
	18675805	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1c(NC(=O)/C=C/CN(C)C)cccc1-c1ccc(C(N)=O)c2[nH]c3c(c12)CCC(C(C)(C)O)C3		CHEMBL4238297	=	IC50	nM	0.82	CHEMBL5251	Homo sapiens	IC50	nM	0.82
	18675806	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=C(C)C(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4244928	=	IC50	nM	9.1	CHEMBL5251	Homo sapiens	IC50	nM	9.1
	18675807	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C/C=C/C(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4240731	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18675808	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)c1C		CHEMBL4241958	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
	18675809	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4c(c23)CCC(C(C)(C)O)C4)cccc1-n1cnc2ccccc2c1=O		CHEMBL4237800	=	IC50	nM	9.3	CHEMBL5251	Homo sapiens	IC50	nM	9.3
	18675810	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	CCC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4238256	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
	18675811	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)N(C)c1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1		CHEMBL4248271	=	IC50	nM	0.16	CHEMBL5251	Homo sapiens	IC50	nM	0.16
	18675812	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	CC(C)=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4251151	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
	18675813	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C/C=C/C(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4246005	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	18675814	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	C=CC(=O)Nc1cccc(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)c1C		CHEMBL4239747	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
	18675815	CHEMBL4235696	Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled peptide as substrate measured after 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	18679225	CHEMBL4236259	Inhibition of BTK in whole blood (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18679226	CHEMBL4236258	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced CD69 expression incubated for 1 hr by flow cytometric analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
	18679229	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Potential transcription error	CHEMBL1873475	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	18679233	CHEMBL4236273	Inhibition of human full length BTK at 1 uM using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay relative to control	B	C=CC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc(C(N)=O)c(Oc2ccc(Oc3ccccc3)cc2)n1		CHEMBL4242598	=	Inhibition	%	98.0	CHEMBL5251	Homo sapiens	INH	%	98.0
	18679243	CHEMBL4236259	Inhibition of BTK in whole blood (unknown origin)	B	C=CC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc(C(N)=O)c(Oc2ccc(Oc3ccccc3)cc2)n1		CHEMBL4242598	=	IC50	nM	82.0	CHEMBL5251	Homo sapiens	IC50	nM	82.0
	18679244	CHEMBL4236258	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced CD69 expression incubated for 1 hr by flow cytometric analysis	B	C=CC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc(C(N)=O)c(Oc2ccc(Oc3ccccc3)cc2)n1		CHEMBL4242598	=	IC50	nM	9.7	CHEMBL5251	Homo sapiens	IC50	nM	9.7
	18679250	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1C[C@@H]2C[C@H]1CN2c1ccc(C(N)=O)c(Oc2ccc(Oc3ccccc3)cc2)n1		CHEMBL4242598	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	18679256	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1C[C@H]2C[C@@H]1CN2c1ccc(C(N)=O)c(Oc2ccc(Oc3ccccc3)cc2)n1		CHEMBL4246409	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	18679262	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1C2CCC1CN(c1ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n1)C2		CHEMBL4246399	=	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
	18679266	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1C2CC1CN(c1ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n1)C2		CHEMBL4240087	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	18679272	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1CCN(c2ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n2)CC1		CHEMBL4250200	=	IC50	nM	4.1	CHEMBL5251	Homo sapiens	IC50	nM	4.1
	18679276	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)NCC1CCCN(c2ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4243865	=	IC50	nM	5900.0	CHEMBL5251	Homo sapiens	IC50	nM	5900.0
	18679280	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N[C@@H]1CCCN(c2ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4239634	=	IC50	nM	430.0	CHEMBL5251	Homo sapiens	IC50	nM	430.0
	18679286	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1CC[C@H](Nc2ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4238999	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	18679292	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N1CC[C@@H](Nc2ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4243203	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	18679298	CHEMBL4236252	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Oc3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4241920	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	18679299	CHEMBL4236278	Inhibition of BTK (unknown origin)	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Oc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4246190	=	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	18679300	CHEMBL4236278	Inhibition of BTK (unknown origin)	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4245727	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	18680084	CHEMBL4236389	Inhibition of BTK (unknown origin) using TK-substrate-biotin measured after 30 mins by HTRF assay	B	C=CC(=O)N1CCCC(Cn2nc(-c3cnn(C)c3)c3c(N)ncnc32)C1		CHEMBL4241272	=	IC50	nM	481.2	CHEMBL5251	Homo sapiens	IC50	nM	481.2
	18680085	CHEMBL4236389	Inhibition of BTK (unknown origin) using TK-substrate-biotin measured after 30 mins by HTRF assay	B	C=CC(=O)N1CCCC(Cn2nc(-c3cnn(CCOC)c3)c3c(N)ncnc32)C1		CHEMBL4249872	=	IC50	nM	420.4	CHEMBL5251	Homo sapiens	IC50	nM	420.4
	18680086	CHEMBL4236389	Inhibition of BTK (unknown origin) using TK-substrate-biotin measured after 30 mins by HTRF assay	B	C=CC(=O)N1CCC(n2nc(-c3cnn(C)c3)c3c(N)ncnc32)C1		CHEMBL4249310	=	IC50	nM	203.1	CHEMBL5251	Homo sapiens	IC50	nM	203.1
	18680087	CHEMBL4236389	Inhibition of BTK (unknown origin) using TK-substrate-biotin measured after 30 mins by HTRF assay	B	C=CC(=O)N1CCC(n2nc(-c3cnn(CCOC)c3)c3c(N)ncnc32)C1		CHEMBL4245422	=	IC50	nM	126.4	CHEMBL5251	Homo sapiens	IC50	nM	126.4
	18680088	CHEMBL4236389	Inhibition of BTK (unknown origin) using TK-substrate-biotin measured after 30 mins by HTRF assay	B	C=CC(=O)N1CCCC(n2nc(-c3cnn(C)c3)c3c(N)ncnc32)C1		CHEMBL4244148	=	IC50	nM	180.3	CHEMBL5251	Homo sapiens	IC50	nM	180.3
	18680089	CHEMBL4236389	Inhibition of BTK (unknown origin) using TK-substrate-biotin measured after 30 mins by HTRF assay	B	C=CC(=O)N1CCCC(n2nc(-c3cnn(CCOC)c3)c3c(N)ncnc32)C1		CHEMBL4249492	=	IC50	nM	159.0	CHEMBL5251	Homo sapiens	IC50	nM	159.0
	18687137	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCOCC4)cc3)ncc2Cl)c1		CHEMBL4289688	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	18687138	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCOCC4)c(Cl)c3)ncc2Cl)c1		CHEMBL4286900	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	18687139	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCOCC4)c(OC)c3)ncc2Cl)c1		CHEMBL4278652	=	IC50	nM	10.5	CHEMBL5251	Homo sapiens	IC50	nM	10.5
	18687140	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCOCC4)c(OC)c3)ncc2F)c1		CHEMBL4280709	=	IC50	nM	17.1	CHEMBL5251	Homo sapiens	IC50	nM	17.1
	18687141	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCOCC4)cc3)ncc2Cl)c1		CHEMBL4290692	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18687142	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCOCC4)c(Cl)c3)ncc2Cl)c1		CHEMBL4284156	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	18687143	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCN(CC)CC4)c(Cl)c3)ncc2Cl)c1		CHEMBL4294772	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	18687144	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCOCC4)c(OC)c3)ncc2Cl)c1		CHEMBL4292468	=	IC50	nM	31.3	CHEMBL5251	Homo sapiens	IC50	nM	31.3
	18687145	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCN(CC)CC4)cc3C)ncc2Cl)c1		CHEMBL4284578	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	18687146	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCN(CC)CC4)cc3C)ncc2F)c1		CHEMBL4277319	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	nM	90.0
	18687147	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCN(C)CC4)cc3C)ncc2Cl)c1		CHEMBL4287960	=	IC50	nM	81.7	CHEMBL5251	Homo sapiens	IC50	nM	81.7
	18687148	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCOCC4)cc3C)ncc2Cl)c1		CHEMBL4279066	=	IC50	nM	89.32	CHEMBL5251	Homo sapiens	IC50	nM	89.32
	18687149	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)c(OCCCN4CCOCC4)c3)ncc2Cl)c1		CHEMBL4289281	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	18687150	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)c(OCCCN4CCOCC4)c3)ncc2F)c1		CHEMBL4290449	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	18687151	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18687152	CHEMBL4252316	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
Dose-dependent effect	18687278	CHEMBL4252342	Inhibition of BTK phosphorylation in human NAMALWA cells after 48 hrs by immunoblot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCC(=O)N4CCOCC4)c(Cl)c3)ncc2Cl)c1		CHEMBL4286900		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18687279	CHEMBL4252342	Inhibition of BTK phosphorylation in human NAMALWA cells after 48 hrs by immunoblot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCN4CCOCC4)cc3)ncc2Cl)c1		CHEMBL4290692		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18687290	CHEMBL4252348	Inhibition of BTK phosphorylation in human NAMALWA cells at 10 uM after 48 hrs by immunoblot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18693968	CHEMBL4253421	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 0.1 uM by TR-FRET assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	-9.0	CHEMBL5251	Homo sapiens	INH	%	-9.0
	18694050	CHEMBL4253503	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM by TR-FRET assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	18697616	CHEMBL4254289	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	83.0	CHEMBL5251	Homo sapiens	Activity	%	83.0
	18702505	CHEMBL4255102	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4278211	=	Inhibition	%	-3.0	CHEMBL5251	Homo sapiens	INH	%	-3.0
	18702534	CHEMBL4255102	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4282644	=	Inhibition	%	-5.0	CHEMBL5251	Homo sapiens	INH	%	-5.0
	18702578	CHEMBL4255102	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4287097	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	18702630	CHEMBL4255102	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4283739	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	18702674	CHEMBL4255102	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4294318	=	Inhibition	%	-4.0	CHEMBL5251	Homo sapiens	INH	%	-4.0
	18702717	CHEMBL4255102	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4289040	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
Active	18724495	CHEMBL4258935	Inhibition of anti-IgM-stimulated BTK activation in human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Y759 residue at 5 nM preincubated for 1.5 hrs followed by anti-IgM stimulation and measured after 15 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1		CHEMBL4277912		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18724496	CHEMBL4258935	Inhibition of anti-IgM-stimulated BTK activation in human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Y759 residue at 5 nM preincubated for 1.5 hrs followed by anti-IgM stimulation and measured after 15 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1		CHEMBL4288562		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18724497	CHEMBL4258935	Inhibition of anti-IgM-stimulated BTK activation in human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Y759 residue at 5 nM preincubated for 1.5 hrs followed by anti-IgM stimulation and measured after 15 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)[nH]c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4281367		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18724498	CHEMBL4258934	Inhibition of anti-IgM-induced BTK phosphorylation at Y233 residue in human Ramos cells at 5 nM preincubated for 1.5 hrs followed by anti-IgM stimulation and measured after 15 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1		CHEMBL4277912		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	18724499	CHEMBL4258934	Inhibition of anti-IgM-induced BTK phosphorylation at Y233 residue in human Ramos cells at 5 nM preincubated for 1.5 hrs followed by anti-IgM stimulation and measured after 15 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1		CHEMBL4288562		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	18724500	CHEMBL4258934	Inhibition of anti-IgM-induced BTK phosphorylation at Y233 residue in human Ramos cells at 5 nM preincubated for 1.5 hrs followed by anti-IgM stimulation and measured after 15 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)[nH]c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4281367		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18724505	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18724506	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCC(N6CCN(C)CC6)CC5)cc4OC)nc32)c1		CHEMBL4290785	=	IC50	nM	12.8	CHEMBL5251	Homo sapiens	IC50	nM	12.8
	18724507	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1		CHEMBL4286241	=	IC50	nM	31.9	CHEMBL5251	Homo sapiens	IC50	nM	31.9
	18724508	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N(C)CCN(C)C)cc4OC)nc32)c1		CHEMBL4278325	=	IC50	nM	20.8	CHEMBL5251	Homo sapiens	IC50	nM	20.8
	18724509	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1		CHEMBL4277912	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
	18724510	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1		CHEMBL4288562	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	18724511	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4293051	=	IC50	nM	47.4	CHEMBL5251	Homo sapiens	IC50	nM	47.4
	18724512	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(CCC)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4285217	=	IC50	nM	21.8	CHEMBL5251	Homo sapiens	IC50	nM	21.8
	18724513	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(CC)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4284780	=	IC50	nM	17.2	CHEMBL5251	Homo sapiens	IC50	nM	17.2
	18724514	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4276842	=	IC50	nM	236.6	CHEMBL5251	Homo sapiens	IC50	nM	236.6
	18724515	CHEMBL4258932	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)c(=O)[nH]c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4281367	=	IC50	nM	5.4	CHEMBL5251	Homo sapiens	IC50	nM	5.4
	18737836	CHEMBL4261403	Inhibition of recombinant full length human BTK using KVEKIGEGTYGVV as substrate after 40 mins in presence of [gamma-33P]-ATP by scintillation counting analysis	B	CCn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(OC(F)(F)F)c2)c2c(N)ncnc21		CHEMBL4281823	=	IC50	nM	862.0	CHEMBL5251	Homo sapiens	IC50	nM	862.0
	18751059	CHEMBL4263746	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	6.0	CHEMBL5251	Homo sapiens	INH	%	6.0
	18751469	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)NC(C)(C)C)cc3)n2)C1		CHEMBL4290066	=	IC50	nM	7.5	CHEMBL5251	Homo sapiens	IC50	nM	7.5
	18751470	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4245727	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	18751471	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCOCC4)nc3)n2)C1		CHEMBL4286628	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	18751472	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCCCC4)nc3)n2)C1		CHEMBL4278717	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	18751473	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCCCC4)cc3)n2)C1		CHEMBL4278321	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	18751474	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4CCC(F)(F)CC4)cc3)n2)C1		CHEMBL4288997	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	18751475	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)N4CC(C)OC(C)C4)cc3)n2)C1		CHEMBL4285083	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	18751476	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)nc3)n2)C1		CHEMBL4282893	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	18751477	CHEMBL4264020	Inhibition of full length human BTK (8 to 80 residues) using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)n2)C1		CHEMBL4281335	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	18751547	CHEMBL4264031	Inhibition of BTK in human PBMC	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)n2)C1		CHEMBL4281335	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18751548	CHEMBL4264031	Inhibition of BTK in human PBMC	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
	18751549	CHEMBL4264032	Inhibition of BTK in human WBC	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)n2)C1		CHEMBL4281335	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
	18751550	CHEMBL4264032	Inhibition of BTK in human WBC	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18751712	CHEMBL4264191	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18752958	CHEMBL4264695	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system at 100 uM using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay relative to control	B	NC(=O)c1ccc(NC2CCCCC2)nc1		CHEMBL4279288	=	Inhibition	%	71.0	CHEMBL5251	Homo sapiens	INH	%	71.0
	18752959	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	NC(=O)c1ccc(NC2CCCCC2)nc1		CHEMBL4279288	>	IC50	nM	6000.0	CHEMBL5251	Homo sapiens	IC50	nM	6000.0
	18752960	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ncc(C(N)=O)c(N)n2)C1		CHEMBL4287216	=	IC50	nM	180.0	CHEMBL5251	Homo sapiens	IC50	nM	180.0
	18752961	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@@H]1CCN(c2ncc(C(N)=O)c(N)n2)C1		CHEMBL4282745	=	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
	18752962	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(NC3CCCCC3)n2)C1		CHEMBL4290625	>	IC50	nM	6000.0	CHEMBL5251	Homo sapiens	IC50	nM	6000.0
	18752963	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ncc(C(N)=O)c(Nc3ccc(F)cc3)n2)C1		CHEMBL4291033	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	18752964	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4280401	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	18752965	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4245727	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	18752966	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4293010	=	IC50	nM	16.2	CHEMBL5251	Homo sapiens	IC50	nM	16.2
	18752967	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ncc(C(N)=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4290540	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	18752968	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	NC(=O)c1ccc(N2CC[C@H](N)C2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4289625	=	IC50	nM	1600.0	CHEMBL5251	Homo sapiens	IC50	nM	1600.0
	18752969	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ncc(C(N)=O)c(Nc3ccc(C(=O)N4CC(C)OC(C)C4)cc3)n2)C1		CHEMBL4277754	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	18752970	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)n2)C1		CHEMBL4281335	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	18752971	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)c(C(N)=O)cc2F)C1		CHEMBL4285813	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	18752972	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)C1		CHEMBL4277875	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	18752973	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N(C)[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)C1		CHEMBL4292583	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	18752974	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@@H]1CN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)CC12CC2		CHEMBL4279353	=	IC50	nM	0.09	CHEMBL5251	Homo sapiens	IC50	nM	0.09
	18752975	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)C1		CHEMBL4286664	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	18752976	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N1CCN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)CC1		CHEMBL4279430	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	18752977	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N1C[C@H]2C[C@@H]1CN2c1ccc(C(N)=O)c(Nc2ccc(C)nc2)n1		CHEMBL4276669	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	18752978	CHEMBL4264696	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Potential transcription error	CHEMBL1873475	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	18752979	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N[C@H]1CCN(c2ncc(C(N)=O)c(Nc3ccc(C(=O)N4CC(C)OC(C)C4)cc3)n2)C1		CHEMBL4277754	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	18752980	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)n2)C1		CHEMBL4281335	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
	18752981	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)c(C(N)=O)cc2F)C1		CHEMBL4285813	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18752982	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)C1		CHEMBL4277875	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	18752983	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N(C)[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)C1		CHEMBL4292583	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
	18752984	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N[C@@H]1CN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)CC12CC2		CHEMBL4279353	=	IC50	nM	4.9	CHEMBL5251	Homo sapiens	IC50	nM	4.9
	18752985	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CCN(c2ccc(C(N)=O)c(Nc3ccc(CCN4CCCC4)cc3)n2)CC1		CHEMBL4279430	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
	18752986	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N1C[C@H]2C[C@@H]1CN2c1ccc(C(N)=O)c(Nc2ccc(C)nc2)n1		CHEMBL4276669	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	18752996	CHEMBL4264700	Inhibition of BTK in human whole blood	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	18752997	CHEMBL4264700	Inhibition of BTK in human whole blood	B	C=CC(=O)N[C@H]1CCN(c2ccc(C(N)=O)c(Nc3ccc(N4C[C@H](C)O[C@H](C)C4)cc3)n2)C1		CHEMBL4281335	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
	18753026	CHEMBL4264697	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	4.6	CHEMBL5251	Homo sapiens	IC50	nM	4.6
	18757967	CHEMBL4265581	Inhibition of recombinant human full length BTK expressed in mammalian cells at 1 uM in presence of 1 mM ATP by kinomescan assay relative to control	B	COCCc1c[nH]c2ncnc(-c3ccc4c(c3)N(C#N)CC(F)(F)O4)c12		CHEMBL4284396	=	Inhibition	%	75.0	CHEMBL5251	Homo sapiens	INH	%	75.0
	18757976	CHEMBL4265586	Inhibition of BTK (unknown origin) in presence of 1 mM ATP concentration	B	N#CN[C@H]1CCc2ccc(-c3ncnc4[nH]ccc34)cc21		CHEMBL4281393	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18757977	CHEMBL4265586	Inhibition of BTK (unknown origin) in presence of 1 mM ATP concentration	B	N#CN[C@H]1C[C@@H](NS(=O)(=O)c2cccc(F)c2)c2ccc(-c3ncnc4[nH]ccc34)cc21		CHEMBL4277610	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18757978	CHEMBL4265586	Inhibition of BTK (unknown origin) in presence of 1 mM ATP concentration	B	N#CN[C@H]1CCc2ccc(-c3ncnc4[nH]cc(-c5cccc(CO)c5)c34)cc21		CHEMBL4292341	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18761492	CHEMBL4266532	Inhibition of recombinant human N-terminal His6-tagged full length BTK expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1	Outside typical range	CHEMBL4279192	=	Inhibition	%	-11.0	CHEMBL5251	Homo sapiens	INH	%	-11.0
	18761750	CHEMBL4266532	Inhibition of recombinant human N-terminal His6-tagged full length BTK expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	-6.0	CHEMBL5251	Homo sapiens	INH	%	-6.0
	18761913	CHEMBL4266532	Inhibition of recombinant human N-terminal His6-tagged full length BTK expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	-1.0	CHEMBL5251	Homo sapiens	INH	%	-1.0
	18764614	CHEMBL4267107	Inhibition of human BTK at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	<	Inhibition	%	70.0	CHEMBL5251	Homo sapiens	INH	%	70.0
	18764615	CHEMBL4267107	Inhibition of human BTK at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL5251	Homo sapiens	INH	%	70.0
	18764616	CHEMBL4267107	Inhibition of human BTK at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL5251	Homo sapiens	INH	%	70.0
	18782832	CHEMBL4270698	Inhibition of BTK (unknown origin) assessed as residual enzyme activity at 1 uM relative to untreated control	B	Cc1cccc(-c2nn3c(c2-c2ccc(O)cc2)C(C)C(C)(C)C3)n1		CHEMBL4277021	>	Activity	%	80.0	CHEMBL5251	Homo sapiens	Activity	%	80.0
	18785056	CHEMBL4271412	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Tyr759 residue by chemiluminescence based assay	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	EC50	nM	318.0	CHEMBL5251	Homo sapiens	EC50	nM	318.0
	18785057	CHEMBL4271411	Inhibition of 3x-FLAG-tagged BTK (unknown origin) expressed in HEK293T cells assessed as reduction in enzyme autophosphorylation at Y551 residue incubated for 1 hr by by Western blot analysis	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	EC50	nM	475.0	CHEMBL5251	Homo sapiens	EC50	nM	475.0
	18785058	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	18785059	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	C=CC(=C)Nc1cccc(Nc2nc(Nc3ccc(OCOC)cc3)ncc2F)c1		CHEMBL4288694	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	18785060	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/Cl)C1		CHEMBL4280795	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
	18785061	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647971	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	18785062	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	C#CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647969	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
	18785063	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	C=CS(=O)(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647968	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
	18785064	CHEMBL4271410	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
Not Active	18847337	CHEMBL4304883	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18857862	CHEMBL4307708	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18881247	CHEMBL4312057	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system by TR-FRET assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	10.0	CHEMBL5251	Homo sapiens	Ki	nM	10.0
	18886139	CHEMBL4313412	Inhibition of human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay relative to control	B	COc1ccc(-c2nn(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)cc2-c2ccncc2)cc1Cl		CHEMBL4553144	=	Inhibition	%	5.62	CHEMBL5251	Homo sapiens	INH	%	5.62
	18890190	CHEMBL4314035	Inhibition of recombinant full-legth His-tagged human BTK expressed in baculovirus expression system at 0.5 uM using tyr 01 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4448754	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	18892766	CHEMBL4314662	Inhibition of full-length recombinant human BTK assessed as residual activity at 10 uM using KVEKIGEGTYGVVYK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	85.0	CHEMBL5251	Homo sapiens	Activity	%	85.0
	18892767	CHEMBL4314663	Inhibition of full-length recombinant human BTK R28H mutant assessed as residual activity at 10 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	98.0	CHEMBL5251	Homo sapiens	Activity	%	98.0
	18913086	CHEMBL4321362	Inhibition of BTK in goat F(ab')2 anti-human IgM-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 30 mins followed by goat F(ab')2 anti-human IgM-stimulation and measured after 20 hrs by flow cytometry	B	Cn1c2c(cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c1=O)-c1cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c1C[C@@H](O)C2		CHEMBL4466633	=	IC50	nM	148.0	CHEMBL5251	Homo sapiens	IC50	nM	148.0
	18913087	CHEMBL4321362	Inhibition of BTK in goat F(ab')2 anti-human IgM-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 30 mins followed by goat F(ab')2 anti-human IgM-stimulation and measured after 20 hrs by flow cytometry	B	Cn1c2c(cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c1=O)-c1cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c1C[C@H](O)C2		CHEMBL4468226	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	18913088	CHEMBL4321362	Inhibition of BTK in goat F(ab')2 anti-human IgM-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 30 mins followed by goat F(ab')2 anti-human IgM-stimulation and measured after 20 hrs by flow cytometry	B	Cn1c2c(cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c1=O)-c1cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c1CC(O)C2		CHEMBL4469132	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	18913089	CHEMBL4321362	Inhibition of BTK in goat F(ab')2 anti-human IgM-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 30 mins followed by goat F(ab')2 anti-human IgM-stimulation and measured after 20 hrs by flow cytometry	B	Cn1nc(-c2cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL4117175	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	18913090	CHEMBL4321361	Inhibition of Kinase Tracer 178 binding to biotinylated-BTK (unknown origin) measured after 18 to 24 hrs by Europium-labeled Streptavidin conjugate based TR-FRET assay	B	Cn1c2c(cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c1=O)-c1cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c1C[C@@H](O)C2		CHEMBL4466633	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	18913091	CHEMBL4321361	Inhibition of Kinase Tracer 178 binding to biotinylated-BTK (unknown origin) measured after 18 to 24 hrs by Europium-labeled Streptavidin conjugate based TR-FRET assay	B	Cn1c2c(cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c1=O)-c1cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c1C[C@H](O)C2		CHEMBL4468226	<	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	18913092	CHEMBL4321361	Inhibition of Kinase Tracer 178 binding to biotinylated-BTK (unknown origin) measured after 18 to 24 hrs by Europium-labeled Streptavidin conjugate based TR-FRET assay	B	Cn1c2c(cc(Nc3ccc(C(=O)N4CCOCC4)cn3)c1=O)-c1cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c1CC(O)C2		CHEMBL4469132	<	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	18913093	CHEMBL4321361	Inhibition of Kinase Tracer 178 binding to biotinylated-BTK (unknown origin) measured after 18 to 24 hrs by Europium-labeled Streptavidin conjugate based TR-FRET assay	B	Cn1nc(-c2cccc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL4117175	<	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	18913150	CHEMBL4321373	Inhibition of human BTK expressed in Sf9 cells using FAM-Srctide peptide substrate incubated for 60 mins by TR-FRET Lantha-screen assay	B	C=CC(=O)N1CCC[C@@H](n2cc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)C1		CHEMBL4456912	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
	18913250	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Activity	%	-1.0	CHEMBL5251	Homo sapiens	Activity	%	-1.0
	18913251	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)C1		CHEMBL4528314	=	Activity	%	97.0	CHEMBL5251	Homo sapiens	Activity	%	97.0
	18913252	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)C1		CHEMBL4443274	=	Activity	%	104.0	CHEMBL5251	Homo sapiens	Activity	%	104.0
	18913253	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	O=C(CCl)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)C1		CHEMBL4562922	=	Activity	%	91.0	CHEMBL5251	Homo sapiens	Activity	%	91.0
	18913254	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)OCC)C1		CHEMBL4465635	=	Activity	%	101.0	CHEMBL5251	Homo sapiens	Activity	%	101.0
	18913255	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)OCC)C1		CHEMBL4467334	=	Activity	%	110.0	CHEMBL5251	Homo sapiens	Activity	%	110.0
	18913256	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	CCOC(=O)c1cc(-c2ccc(Oc3ccccc3)cc2)nn1C1CCCN(C(=O)CCl)C1		CHEMBL4570642	=	Activity	%	111.0	CHEMBL5251	Homo sapiens	Activity	%	111.0
	18913257	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)C1		CHEMBL4462888	=	Activity	%	102.0	CHEMBL5251	Homo sapiens	Activity	%	102.0
	18913258	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)C1		CHEMBL4439058	=	Activity	%	98.0	CHEMBL5251	Homo sapiens	Activity	%	98.0
	18913259	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	O=C(O)c1cc(-c2ccc(Oc3ccccc3)cc2)nn1C1CCCN(C(=O)CCl)C1		CHEMBL4460627	=	Activity	%	85.0	CHEMBL5251	Homo sapiens	Activity	%	85.0
	18913260	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)c1		CHEMBL4453935	=	Activity	%	109.0	CHEMBL5251	Homo sapiens	Activity	%	109.0
	18913261	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)cc1		CHEMBL4555343	=	Activity	%	110.0	CHEMBL5251	Homo sapiens	Activity	%	110.0
	18913262	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)c1		CHEMBL4467280	=	Activity	%	120.0	CHEMBL5251	Homo sapiens	Activity	%	120.0
	18913263	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)cc1		CHEMBL4517485	=	Activity	%	99.0	CHEMBL5251	Homo sapiens	Activity	%	99.0
	18913264	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	O=C(CCl)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)c1		CHEMBL4449173	=	Activity	%	115.0	CHEMBL5251	Homo sapiens	Activity	%	115.0
	18913265	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	O=C(CCl)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2CO)cc1		CHEMBL4444877	=	Activity	%	106.0	CHEMBL5251	Homo sapiens	Activity	%	106.0
	18913266	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)OCC)c1		CHEMBL4530141	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18913267	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)OCC)cc1		CHEMBL4454782	=	Activity	%	120.0	CHEMBL5251	Homo sapiens	Activity	%	120.0
	18913268	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)OCC)c1		CHEMBL4459034	=	Activity	%	98.0	CHEMBL5251	Homo sapiens	Activity	%	98.0
	18913269	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)OCC)cc1		CHEMBL4530707	=	Activity	%	119.0	CHEMBL5251	Homo sapiens	Activity	%	119.0
	18913270	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	CCOC(=O)c1cc(-c2ccc(Oc3ccccc3)cc2)nn1Cc1cccc(NC(=O)CCl)c1		CHEMBL4535255	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18913271	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	CCOC(=O)c1cc(-c2ccc(Oc3ccccc3)cc2)nn1Cc1ccc(NC(=O)CCl)cc1		CHEMBL4516216	=	Activity	%	106.0	CHEMBL5251	Homo sapiens	Activity	%	106.0
	18913272	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)c1		CHEMBL4437778	=	Activity	%	112.0	CHEMBL5251	Homo sapiens	Activity	%	112.0
	18913273	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C=CC(=O)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)cc1		CHEMBL4460820	=	Activity	%	110.0	CHEMBL5251	Homo sapiens	Activity	%	110.0
	18913274	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)c1		CHEMBL4471450	=	Activity	%	110.0	CHEMBL5251	Homo sapiens	Activity	%	110.0
	18913275	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	C/C=C/C(=O)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)cc1		CHEMBL4460329	=	Activity	%	116.0	CHEMBL5251	Homo sapiens	Activity	%	116.0
	18913276	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	O=C(CCl)Nc1cccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)c1		CHEMBL4472679	=	Activity	%	103.0	CHEMBL5251	Homo sapiens	Activity	%	103.0
	18913277	CHEMBL4321379	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	B	O=C(CCl)Nc1ccc(Cn2nc(-c3ccc(Oc4ccccc4)cc3)cc2C(=O)O)cc1		CHEMBL4544825	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	18919459	CHEMBL4322724	Binding affinity to recombinant human full-length N-terminal GST-tagged BTK expressed in baculovirus expression system using srctide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	374.0	CHEMBL5251	Homo sapiens	Kd	nM	374.0
	18919647	CHEMBL4322724	Binding affinity to recombinant human full-length N-terminal GST-tagged BTK expressed in baculovirus expression system using srctide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	437.0	CHEMBL5251	Homo sapiens	Kd	nM	437.0
	18930950	CHEMBL4325608	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells at 1000 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	Inhibition	%	8.0	CHEMBL5251	Homo sapiens	INH	%	8.0
	18930974	CHEMBL4325632	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells at 100 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	18934899	CHEMBL4326800	Inhibition of BTK (unknown origin)	B	O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CCC2)[nH]n1		CHEMBL4439395	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	18934900	CHEMBL4326800	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
	18937739	CHEMBL4327599	Inhibition of human BTK assessed as residual activity at 1 uM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	103.69	CHEMBL5251	Homo sapiens	Activity	%	103.69
	18937740	CHEMBL4327599	Inhibition of human BTK assessed as residual activity at 1 uM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	101.32	CHEMBL5251	Homo sapiens	Activity	%	101.32
	18938440	CHEMBL4327960	Inhibition of human BTK assessed as residual activity at 100 uM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL5251	Homo sapiens	Activity	%	65.0
	18938813	CHEMBL4328324	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	23.3	CHEMBL5251	Homo sapiens	IC50	10'-8M	2.33
	18950211	CHEMBL4331063	Inhibition of human BTK assessed as residual activity at 10 uM using KVEKIGEGTYGVVYK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	Activity	%	12.95	CHEMBL5251	Homo sapiens	Activity	%	12.95
	18950277	CHEMBL4331124	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	IC50	nM	1644.0	CHEMBL5251	Homo sapiens	IC50	nM	1644.0
	18950348	CHEMBL4331124	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	IC50	nM	1584.89	CHEMBL5251	Homo sapiens	pIC50		5.8
	18953709	CHEMBL4331908	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(NC3CCCCC3)c12		CHEMBL4440433	=	Inhibition	%	70.0	CHEMBL5251	Homo sapiens	INH	%	70.0
	18953775	CHEMBL4331908	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccccc3F)c12		CHEMBL4449552	=	Inhibition	%	26.0	CHEMBL5251	Homo sapiens	INH	%	26.0
	18953822	CHEMBL4331908	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(OC3CCCCC3)c12		CHEMBL4524629	=	Inhibition	%	40.0	CHEMBL5251	Homo sapiens	INH	%	40.0
	18953914	CHEMBL4331967	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1		CHEMBL4589022	=	Inhibition	%	39.0	CHEMBL5251	Homo sapiens	INH	%	39.0
	18953978	CHEMBL4331967	Inhibition of BTK (unknown origin) at 1 uM relative to control	B	c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1		CHEMBL4460272	=	Inhibition	%	51.0	CHEMBL5251	Homo sapiens	INH	%	51.0
	18954045	CHEMBL4331908	Inhibition of BTK (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccc4ncsc4c3)c12		CHEMBL4588446	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
Active	18957397	CHEMBL4332976	Inhibition of BTK (unknown origin) at 1 uM after 60 mins by Z-LYTE assay	B	C=CC(=O)N1CCN(c2ccc([N+](=O)[O-])c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1		CHEMBL4450627		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18958781	CHEMBL4333300	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	74.0	CHEMBL5251	Homo sapiens	Activity	%	74.0
	18964095	CHEMBL4334982	Inhibition of recombinant full length human BTK assessed as residual activity at 1 uM using KVEKIGEGTYGVV substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	93.0	CHEMBL5251	Homo sapiens	Activity	%	93.0
	18964096	CHEMBL4334982	Inhibition of recombinant full length human BTK assessed as residual activity at 1 uM using KVEKIGEGTYGVV substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	101.0	CHEMBL5251	Homo sapiens	Activity	%	101.0
	18964097	CHEMBL4334983	Inhibition of recombinant full length human BTK R28H mutant assessed as residual activity at 1 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	94.0	CHEMBL5251	Homo sapiens	Activity	%	94.0
	18964098	CHEMBL4334983	Inhibition of recombinant full length human BTK R28H mutant assessed as residual activity at 1 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	101.0	CHEMBL5251	Homo sapiens	Activity	%	101.0
	18965811	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	Inhibition	%	92.1	CHEMBL5251	Homo sapiens	INH	%	92.1
	18965812	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)cnc12		CHEMBL4443849	=	Inhibition	%	54.2	CHEMBL5251	Homo sapiens	INH	%	54.2
	18965813	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(O)c(C(N)=O)cnc12		CHEMBL4539345	=	Inhibition	%	15.5	CHEMBL5251	Homo sapiens	INH	%	15.5
	18965814	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3ccc4cn[nH]c4c3)cccc2c1N		CHEMBL4443723	=	Inhibition	%	41.6	CHEMBL5251	Homo sapiens	INH	%	41.6
	18965815	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3cc(Oc4ccccc4)c4cn[nH]c4c3)cccc2c1N		CHEMBL4535482	=	Inhibition	%	3.9	CHEMBL5251	Homo sapiens	INH	%	3.9
	18965816	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3cc(Nc4ccccc4)c4cn[nH]c4c3)cccc2c1N		CHEMBL4578341	=	Inhibition	%	10.4	CHEMBL5251	Homo sapiens	INH	%	10.4
	18965817	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3cc(OCc4ccccc4)c4cn[nH]c4c3)cccc2c1N		CHEMBL4457143	=	Inhibition	%	9.5	CHEMBL5251	Homo sapiens	INH	%	9.5
	18965818	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	CN(Cc1ccccc1)c1cc(-c2cccc3c(N)c(C(N)=O)cnc23)cc2[nH]ncc12		CHEMBL4468934	=	Inhibition	%	24.7	CHEMBL5251	Homo sapiens	INH	%	24.7
	18965819	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3cc(Oc4ccc(-c5ccccc5)cc4)c4cn[nH]c4c3)cccc2c1N		CHEMBL4471211	=	Inhibition	%	10.7	CHEMBL5251	Homo sapiens	INH	%	10.7
Not Active	18965820	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3cc(Oc4cccc(-c5ccccc5)c4)c4cn[nH]c4c3)cccc2c1N		CHEMBL4449003		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18965821	CHEMBL4335767	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3cc(Oc4ccc(Oc5ccccc5)cc4)c4cn[nH]c4c3)cccc2c1N		CHEMBL4463024	=	Inhibition	%	11.8	CHEMBL5251	Homo sapiens	INH	%	11.8
	18965827	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	Inhibition	%	44.6	CHEMBL5251	Homo sapiens	INH	%	44.6
	18965828	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4524580	=	Inhibition	%	45.9	CHEMBL5251	Homo sapiens	INH	%	45.9
	18965829	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cc(F)cc2c(N)c(C(N)=O)cnc12		CHEMBL4517376	=	Inhibition	%	25.3	CHEMBL5251	Homo sapiens	INH	%	25.3
	18965830	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cc([N+](=O)[O-])cc2c(N)c(C(N)=O)cnc12		CHEMBL4457952	=	Inhibition	%	12.8	CHEMBL5251	Homo sapiens	INH	%	12.8
	18965831	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2cn[nH]c2cc1-c1cc(N)cc2c(N)c(C(N)=O)cnc12		CHEMBL4581407	=	Inhibition	%	36.5	CHEMBL5251	Homo sapiens	INH	%	36.5
	18965832	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3ccc4[nH]c(=O)[nH]c4c3)ccc(F)c2c1N		CHEMBL4459699	=	Inhibition	%	9.3	CHEMBL5251	Homo sapiens	INH	%	9.3
	18965833	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	NC(=O)c1cnc2c(-c3ccc4[nH]c(=O)[nH]c4c3)cc(F)cc2c1N		CHEMBL4445558	=	Inhibition	%	5.1	CHEMBL5251	Homo sapiens	INH	%	5.1
Not Active	18965834	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2[nH]c(=O)[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4560566		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18965835	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	Cc1cc2[nH]c(=O)[nH]c2cc1-c1cc(F)cc2c(N)c(C(N)=O)cnc12		CHEMBL4457395	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	18965836	CHEMBL4335769	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at 20 nM preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay relative to control	B	COc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4475004	=	Inhibition	%	68.7	CHEMBL5251	Homo sapiens	INH	%	68.7
	18965837	CHEMBL4335770	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	IC50	nM	5.6	CHEMBL5251	Homo sapiens	IC50	nM	5.6
	18965838	CHEMBL4335770	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)cnc12		CHEMBL4443849	=	IC50	nM	72.8	CHEMBL5251	Homo sapiens	IC50	nM	72.8
	18965839	CHEMBL4335770	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay	B	Cc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4524580	=	IC50	nM	11.6	CHEMBL5251	Homo sapiens	IC50	nM	11.6
	18965840	CHEMBL4335770	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells at preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay	B	COc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4475004	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
Dose-dependent effect	18965841	CHEMBL4335766	Reversible inhibition of sodium orthovanadate-stimulated BTK autophosphorylation at Tyr223 residues in human Ramos cells preincubated for 2 hrs followed by sodium orthovanadate addition and measured after 15 mins by Western blot analysis	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18965842	CHEMBL4335766	Reversible inhibition of sodium orthovanadate-stimulated BTK autophosphorylation at Tyr223 residues in human Ramos cells preincubated for 2 hrs followed by sodium orthovanadate addition and measured after 15 mins by Western blot analysis	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	EC50	nM	100.9	CHEMBL5251	Homo sapiens	EC50	nM	100.9
Dose-dependent effect	18965843	CHEMBL4335766	Reversible inhibition of sodium orthovanadate-stimulated BTK autophosphorylation at Tyr223 residues in human Ramos cells preincubated for 2 hrs followed by sodium orthovanadate addition and measured after 15 mins by Western blot analysis	B	Cc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4524580		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	18965844	CHEMBL4335766	Reversible inhibition of sodium orthovanadate-stimulated BTK autophosphorylation at Tyr223 residues in human Ramos cells preincubated for 2 hrs followed by sodium orthovanadate addition and measured after 15 mins by Western blot analysis	B	COc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4475004		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18965845	CHEMBL4335766	Reversible inhibition of sodium orthovanadate-stimulated BTK autophosphorylation at Tyr223 residues in human Ramos cells preincubated for 2 hrs followed by sodium orthovanadate addition and measured after 15 mins by Western blot analysis	B	COc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4475004	=	EC50	nM	42.7	CHEMBL5251	Homo sapiens	EC50	nM	42.7
	18965846	CHEMBL4335771	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK C481S mutant (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay	B	COc1cc2cn[nH]c2cc1-c1ccc(F)c2c(N)c(C(N)=O)cnc12		CHEMBL4475004	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
Not Active	18965847	CHEMBL4335771	Reversible inhibition of FAM-labeled peptide binding to full-length human N-terminal GST-tagged BTK C481S mutant (2 to 659 residues) expressed in baculovirus infected Sf21 insect cells preincubated for 10 mins followed by FAM-labeled peptide addition and measured by off-chip mobility shift assay	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	18971800	CHEMBL4336810	Inhibition of recombinant full length human BTK assessed as residual activity at 10 uM using KVEKIGEGTYGVVYK substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	17.0	CHEMBL5251	Homo sapiens	Activity	%	17.0
	18971801	CHEMBL4336811	Inhibition of recombinant full length human BTK R28H mutant assessed as residual activity at 10 uM using LSNLYHQGKFLQTFCGSPLYRRR substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	116.0	CHEMBL5251	Homo sapiens	Activity	%	116.0
	19018663	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)C2CC2)C1		CHEMBL4582791	=	Inhibition	%	34.01	CHEMBL5251	Homo sapiens	INH	%	34.01
	19018664	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(S(=O)(=O)C2CC2)C1		CHEMBL4436818	=	Inhibition	%	37.16	CHEMBL5251	Homo sapiens	INH	%	37.16
	19018665	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CN(C)C(=O)N1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4440252	=	Inhibition	%	42.61	CHEMBL5251	Homo sapiens	INH	%	42.61
	19018666	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC1(C(=O)N2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)COC1		CHEMBL4460746	=	Inhibition	%	22.41	CHEMBL5251	Homo sapiens	INH	%	22.41
	19018667	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)c2ccccc2)C1		CHEMBL4472538	=	Inhibition	%	29.39	CHEMBL5251	Homo sapiens	INH	%	29.39
	19018668	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CN(C)CC(=O)N1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4460747	=	Inhibition	%	23.67	CHEMBL5251	Homo sapiens	INH	%	23.67
	19018669	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)c2ccccn2)C1		CHEMBL4470198	=	Inhibition	%	28.09	CHEMBL5251	Homo sapiens	INH	%	28.09
	19018670	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	NC(=O)CN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4514557	=	Inhibition	%	48.61	CHEMBL5251	Homo sapiens	INH	%	48.61
	19018671	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C2COC2)C1		CHEMBL4535899	=	Inhibition	%	52.03	CHEMBL5251	Homo sapiens	INH	%	52.03
	19018672	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CO2)C1		CHEMBL4455094	=	Inhibition	%	96.58	CHEMBL5251	Homo sapiens	INH	%	96.58
	19018673	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4443198	=	Inhibition	%	93.51	CHEMBL5251	Homo sapiens	INH	%	93.51
	19018674	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4571839	=	Inhibition	%	86.54	CHEMBL5251	Homo sapiens	INH	%	86.54
	19018675	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CC2)C1		CHEMBL4445701	=	Inhibition	%	15.17	CHEMBL5251	Homo sapiens	INH	%	15.17
	19018676	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CCCO2)C1		CHEMBL4459145	=	Inhibition	%	18.88	CHEMBL5251	Homo sapiens	INH	%	18.88
	19018677	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	COCCN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4463866	=	Inhibition	%	8.09	CHEMBL5251	Homo sapiens	INH	%	8.09
	19018678	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC1(CN2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)COC1		CHEMBL4588815	=	Inhibition	%	36.06	CHEMBL5251	Homo sapiens	INH	%	36.06
	19018679	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CCCO)C1		CHEMBL4561834	=	Inhibition	%	22.35	CHEMBL5251	Homo sapiens	INH	%	22.35
	19018680	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	N#CCCN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4437557	=	Inhibition	%	67.81	CHEMBL5251	Homo sapiens	INH	%	67.81
	19018681	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	COC(CN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1)OC		CHEMBL4466333	=	Inhibition	%	37.1	CHEMBL5251	Homo sapiens	INH	%	37.1
	19018682	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(Cc2cc(F)cc(F)c2)C1		CHEMBL4442243	=	Inhibition	%	30.2	CHEMBL5251	Homo sapiens	INH	%	30.2
	19018683	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CCOC(=O)C(C)N1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4439111	=	Inhibition	%	44.13	CHEMBL5251	Homo sapiens	INH	%	44.13
	19018684	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(CN2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)cc1		CHEMBL4445296	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	19018685	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4438110	=	Inhibition	%	46.61	CHEMBL5251	Homo sapiens	INH	%	46.61
	19018686	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cc3ccccc3o1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4467009	=	Inhibition	%	59.08	CHEMBL5251	Homo sapiens	INH	%	59.08
	19018687	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cc3ccccc3o1)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4585671	=	Inhibition	%	62.94	CHEMBL5251	Homo sapiens	INH	%	62.94
	19018688	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4544821	=	Inhibition	%	98.12	CHEMBL5251	Homo sapiens	INH	%	98.12
	19018689	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4561220	=	Inhibition	%	90.06	CHEMBL5251	Homo sapiens	INH	%	90.06
	19018690	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(Oc2ccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)cc2)cc1		CHEMBL4469582	=	Inhibition	%	19.11	CHEMBL5251	Homo sapiens	INH	%	19.11
	19018691	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(COc2ccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)cc2)cc1		CHEMBL4462841	=	Inhibition	%	7.63	CHEMBL5251	Homo sapiens	INH	%	7.63
	19018692	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)c2)cc1		CHEMBL4561761	=	Inhibition	%	22.25	CHEMBL5251	Homo sapiens	INH	%	22.25
	19018693	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2ccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)cc2)cc1		CHEMBL4525026	=	Inhibition	%	53.79	CHEMBL5251	Homo sapiens	INH	%	53.79
	19018694	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3ccc(Oc4ccccc4)cc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4535872	=	Inhibition	%	36.94	CHEMBL5251	Homo sapiens	INH	%	36.94
	19018695	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cccc(-n3ncc4ccccc4c3=O)c1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4475519	=	Inhibition	%	17.49	CHEMBL5251	Homo sapiens	INH	%	17.49
	19018696	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(NC(=O)c3ccccc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4459860	=	Inhibition	%	22.9	CHEMBL5251	Homo sapiens	INH	%	22.9
	19018697	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@@H]1CCN(C[C@H]2CO2)C1		CHEMBL4472161	=	Inhibition	%	42.03	CHEMBL5251	Homo sapiens	INH	%	42.03
	19018698	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	C[C@@H]1C[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CN1C[C@@H]1CO1		CHEMBL4537798	=	Inhibition	%	47.07	CHEMBL5251	Homo sapiens	INH	%	47.07
	19018699	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4440181	=	Inhibition	%	94.53	CHEMBL5251	Homo sapiens	INH	%	94.53
	19018700	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCCN1C[C@@H]1CO1		CHEMBL4436793	=	Inhibition	%	47.63	CHEMBL5251	Homo sapiens	INH	%	47.63
	19018701	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4457802	=	Inhibition	%	86.32	CHEMBL5251	Homo sapiens	INH	%	86.32
	19018702	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4557548	=	Inhibition	%	63.69	CHEMBL5251	Homo sapiens	INH	%	63.69
	19018703	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2CC1CCN(C[C@@H]2CO2)CC1		CHEMBL4467155	=	Inhibition	%	59.91	CHEMBL5251	Homo sapiens	INH	%	59.91
	19018704	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCCN(C[C@@H]2CO2)C1		CHEMBL4436551	=	Inhibition	%	49.21	CHEMBL5251	Homo sapiens	INH	%	49.21
	19018705	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCCN(C[C@@H]2CO2)C1		CHEMBL4476337	=	Inhibition	%	70.27	CHEMBL5251	Homo sapiens	INH	%	70.27
	19018706	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C1CCN(C[C@@H]2CO2)CC1		CHEMBL4584094	=	Inhibition	%	89.43	CHEMBL5251	Homo sapiens	INH	%	89.43
	19018707	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C1CCN(C2COC2)CC1		CHEMBL4593586	=	Inhibition	%	45.67	CHEMBL5251	Homo sapiens	INH	%	45.67
	19018708	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C1=CCN(C[C@@H]2CO2)CC1		CHEMBL4461495	=	Inhibition	%	42.6	CHEMBL5251	Homo sapiens	INH	%	42.6
	19018709	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2CC1CCCO1		CHEMBL4515826	=	Inhibition	%	21.83	CHEMBL5251	Homo sapiens	INH	%	21.83
	19018710	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187	=	Inhibition	%	99.81	CHEMBL5251	Homo sapiens	INH	%	99.81
	19018711	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)nn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4434832	=	Inhibition	%	56.69	CHEMBL5251	Homo sapiens	INH	%	56.69
	19018712	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4443173	=	Inhibition	%	26.9	CHEMBL5251	Homo sapiens	INH	%	26.9
	19018713	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C(CO)CO		CHEMBL4467235	=	Inhibition	%	54.67	CHEMBL5251	Homo sapiens	INH	%	54.67
	19018714	CHEMBL4347050	Inhibition of BTK (unknown origin) at 1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H](O)CO		CHEMBL4473759	=	Inhibition	%	62.5	CHEMBL5251	Homo sapiens	INH	%	62.5
	19018715	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)C2CC2)C1		CHEMBL4582791	=	Inhibition	%	-3.67	CHEMBL5251	Homo sapiens	INH	%	-3.67
	19018716	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(S(=O)(=O)C2CC2)C1		CHEMBL4436818	=	Inhibition	%	1.64	CHEMBL5251	Homo sapiens	INH	%	1.64
	19018717	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CN(C)C(=O)N1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4440252	=	Inhibition	%	1.87	CHEMBL5251	Homo sapiens	INH	%	1.87
	19018718	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC1(C(=O)N2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)COC1		CHEMBL4460746	=	Inhibition	%	-0.35	CHEMBL5251	Homo sapiens	INH	%	-0.35
	19018719	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)c2ccccc2)C1		CHEMBL4472538	=	Inhibition	%	37.12	CHEMBL5251	Homo sapiens	INH	%	37.12
	19018720	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CN(C)CC(=O)N1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4460747	=	Inhibition	%	-0.41	CHEMBL5251	Homo sapiens	INH	%	-0.41
	19018721	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)c2ccccn2)C1		CHEMBL4470198	=	Inhibition	%	1.45	CHEMBL5251	Homo sapiens	INH	%	1.45
	19018722	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	NC(=O)CN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4514557	=	Inhibition	%	12.59	CHEMBL5251	Homo sapiens	INH	%	12.59
	19018723	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C2COC2)C1		CHEMBL4535899	=	Inhibition	%	19.69	CHEMBL5251	Homo sapiens	INH	%	19.69
	19018724	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CO2)C1		CHEMBL4455094	=	Inhibition	%	70.12	CHEMBL5251	Homo sapiens	INH	%	70.12
	19018725	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4443198	=	Inhibition	%	87.58	CHEMBL5251	Homo sapiens	INH	%	87.58
	19018726	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4571839	=	Inhibition	%	62.16	CHEMBL5251	Homo sapiens	INH	%	62.16
	19018727	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CC2)C1		CHEMBL4445701	=	Inhibition	%	0.04	CHEMBL5251	Homo sapiens	INH	%	0.04
	19018728	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CCCO2)C1		CHEMBL4459145	=	Inhibition	%	3.01	CHEMBL5251	Homo sapiens	INH	%	3.01
	19018729	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	COCCN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4463866	=	Inhibition	%	14.34	CHEMBL5251	Homo sapiens	INH	%	14.34
	19018730	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC1(CN2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)COC1		CHEMBL4588815	=	Inhibition	%	13.92	CHEMBL5251	Homo sapiens	INH	%	13.92
	19018731	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CCCO)C1		CHEMBL4561834	=	Inhibition	%	8.43	CHEMBL5251	Homo sapiens	INH	%	8.43
	19018732	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	N#CCCN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4437557	=	Inhibition	%	21.58	CHEMBL5251	Homo sapiens	INH	%	21.58
	19018733	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	COC(CN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1)OC		CHEMBL4466333	=	Inhibition	%	4.71	CHEMBL5251	Homo sapiens	INH	%	4.71
	19018734	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(Cc2cc(F)cc(F)c2)C1		CHEMBL4442243	=	Inhibition	%	6.07	CHEMBL5251	Homo sapiens	INH	%	6.07
	19018735	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CCOC(=O)C(C)N1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4439111	=	Inhibition	%	5.71	CHEMBL5251	Homo sapiens	INH	%	5.71
	19018736	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(CN2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)cc1		CHEMBL4445296	=	Inhibition	%	0.01	CHEMBL5251	Homo sapiens	INH	%	0.01
	19018737	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4438110	=	Inhibition	%	12.82	CHEMBL5251	Homo sapiens	INH	%	12.82
	19018738	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cc3ccccc3o1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4467009	=	Inhibition	%	20.23	CHEMBL5251	Homo sapiens	INH	%	20.23
	19018739	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cc3ccccc3o1)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4585671	=	Inhibition	%	17.38	CHEMBL5251	Homo sapiens	INH	%	17.38
	19018740	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4544821	=	Inhibition	%	79.06	CHEMBL5251	Homo sapiens	INH	%	79.06
	19018741	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4561220	=	Inhibition	%	52.01	CHEMBL5251	Homo sapiens	INH	%	52.01
	19018742	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(Oc2ccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)cc2)cc1		CHEMBL4469582	=	Inhibition	%	5.96	CHEMBL5251	Homo sapiens	INH	%	5.96
	19018743	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(COc2ccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)cc2)cc1		CHEMBL4462841	=	Inhibition	%	3.73	CHEMBL5251	Homo sapiens	INH	%	3.73
	19018744	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)c2)cc1		CHEMBL4561761	=	Inhibition	%	2.29	CHEMBL5251	Homo sapiens	INH	%	2.29
	19018745	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2ccc(-c3cn([C@H]4CCN(C[C@@H]5CO5)C4)c4ncnc(N)c34)cc2)cc1		CHEMBL4525026	=	Inhibition	%	15.73	CHEMBL5251	Homo sapiens	INH	%	15.73
	19018746	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(C(=O)Nc3ccc(Oc4ccccc4)cc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4535872	=	Inhibition	%	7.58	CHEMBL5251	Homo sapiens	INH	%	7.58
	19018747	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cccc(-n3ncc4ccccc4c3=O)c1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4475519	=	Inhibition	%	3.41	CHEMBL5251	Homo sapiens	INH	%	3.41
	19018748	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(NC(=O)c3ccccc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4459860	=	Inhibition	%	2.53	CHEMBL5251	Homo sapiens	INH	%	2.53
	19018749	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@@H]1CCN(C[C@H]2CO2)C1		CHEMBL4472161	=	Inhibition	%	15.18	CHEMBL5251	Homo sapiens	INH	%	15.18
	19018750	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	C[C@@H]1C[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CN1C[C@@H]1CO1		CHEMBL4537798	=	Inhibition	%	12.74	CHEMBL5251	Homo sapiens	INH	%	12.74
	19018751	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4440181	=	Inhibition	%	81.56	CHEMBL5251	Homo sapiens	INH	%	81.56
	19018752	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCCN1C[C@@H]1CO1		CHEMBL4436793	=	Inhibition	%	13.52	CHEMBL5251	Homo sapiens	INH	%	13.52
	19018753	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4457802	=	Inhibition	%	48.31	CHEMBL5251	Homo sapiens	INH	%	48.31
	19018754	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4557548	=	Inhibition	%	23.86	CHEMBL5251	Homo sapiens	INH	%	23.86
	19018755	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2CC1CCN(C[C@@H]2CO2)CC1		CHEMBL4467155	=	Inhibition	%	14.23	CHEMBL5251	Homo sapiens	INH	%	14.23
	19018756	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCCN(C[C@@H]2CO2)C1		CHEMBL4436551	=	Inhibition	%	16.19	CHEMBL5251	Homo sapiens	INH	%	16.19
	19018757	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCCN(C[C@@H]2CO2)C1		CHEMBL4476337	=	Inhibition	%	34.73	CHEMBL5251	Homo sapiens	INH	%	34.73
	19018758	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C1CCN(C[C@@H]2CO2)CC1		CHEMBL4584094	=	Inhibition	%	60.2	CHEMBL5251	Homo sapiens	INH	%	60.2
	19018759	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C1CCN(C2COC2)CC1		CHEMBL4593586	=	Inhibition	%	9.5	CHEMBL5251	Homo sapiens	INH	%	9.5
	19018760	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C1=CCN(C[C@@H]2CO2)CC1		CHEMBL4461495	=	Inhibition	%	1.81	CHEMBL5251	Homo sapiens	INH	%	1.81
	19018761	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2CC1CCCO1		CHEMBL4515826	=	Inhibition	%	-6.11	CHEMBL5251	Homo sapiens	INH	%	-6.11
	19018762	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187	=	Inhibition	%	96.63	CHEMBL5251	Homo sapiens	INH	%	96.63
	19018763	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)nn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4434832	=	Inhibition	%	13.94	CHEMBL5251	Homo sapiens	INH	%	13.94
	19018764	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4443173	=	Inhibition	%	13.71	CHEMBL5251	Homo sapiens	INH	%	13.71
	19018765	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C(CO)CO		CHEMBL4467235	=	Inhibition	%	18.29	CHEMBL5251	Homo sapiens	INH	%	18.29
	19018766	CHEMBL4347051	Inhibition of BTK (unknown origin) at 0.1 uM in the presence of ATP by caliper mobility shift assay relative to control	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H](O)CO		CHEMBL4473759	=	Inhibition	%	23.86	CHEMBL5251	Homo sapiens	INH	%	23.86
	19018929	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C(=O)C2CC2)C1		CHEMBL4582791	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
	19018930	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	NC(=O)CN1CC[C@H](n2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4514557	>	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
	19018931	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C2COC2)C1		CHEMBL4535899	>	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
	19018932	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(CC2CO2)C1		CHEMBL4455094	=	IC50	nM	45.5	CHEMBL5251	Homo sapiens	IC50	nM	45.5
	19018933	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4443198	=	IC50	nM	36.6	CHEMBL5251	Homo sapiens	IC50	nM	36.6
	19018934	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4571839	=	IC50	nM	41.9	CHEMBL5251	Homo sapiens	IC50	nM	41.9
	19018935	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	CC1(CN2CC[C@H](n3cc(-c4ccc5c(c4)OCO5)c4c(N)ncnc43)C2)COC1		CHEMBL4588815	>	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
	19018936	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	19018937	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4544821	=	IC50	nM	31.1	CHEMBL5251	Homo sapiens	IC50	nM	31.1
	19018938	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CCN(C[C@H]2CO2)C1		CHEMBL4561220	=	IC50	nM	89.4	CHEMBL5251	Homo sapiens	IC50	nM	89.4
	19018939	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2[C@@H]1CCN(C[C@H]2CO2)C1		CHEMBL4472161	>	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
	19018940	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4440181	=	IC50	nM	8.9	CHEMBL5251	Homo sapiens	IC50	nM	8.9
	19018941	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc3c(c1)OCO3)cn2C[C@@H]1CCN(C[C@@H]2CO2)C1		CHEMBL4457802	=	IC50	nM	122.6	CHEMBL5251	Homo sapiens	IC50	nM	122.6
	19018942	CHEMBL4347057	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
Active	19018975	CHEMBL4347088	Inhibition of BTK auto phosphorylation at Tyr223 residue in human Ramos cells at 100 nM measured after 1 hr by Western blot analysis	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19018976	CHEMBL4347089	Inhibition of BTK auto phosphorylation at Tyr223 residue in human JeKo1 cells at 100 nM measured after 1 hr by Western blot analysis	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19018977	CHEMBL4347090	Inhibition of BTK auto phosphorylation at Tyr223 residue in human Daudi cells at 100 nM measured after 1 hr by Western blot analysis	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19018978	CHEMBL4347091	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Try1217 residue at 1000 nM after1 hr by Western blot analysis	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19018979	CHEMBL4347092	Inhibition of BTK in human JeKo1 cells assessed as reduction in PLCgamma-2 phosphorylation at Try1217 residue at 1000 nM after1 hr by Western blot analysis	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19018980	CHEMBL4347093	Inhibition of BTK in human Daudi cells assessed as reduction in PLCgamma-2 phosphorylation at Try1217 residue at 1000 nM after1 hr by Western blot analysis	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C[C@H]1CCCN1C[C@@H]1CO1		CHEMBL4525187		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19026305	CHEMBL4348500	Inhibition of N-terminal GST-tagged full length human BTK (2 to 659 residues) expressed in Baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay	B	COc1cc(N2CCN(CCN(C)C)C2=O)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL4470529	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	19029965	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4ccncc4)c23)c1		CHEMBL4464404	=	IC50	nM	3.9	CHEMBL5251	Homo sapiens	IC50	nM	3.9
	19029966	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(Oc4ccccc4)c23)n1		CHEMBL4465231	=	IC50	nM	1456.0	CHEMBL5251	Homo sapiens	IC50	nM	1456.0
	19029967	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)c1		CHEMBL4438914	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	19029968	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(OC4CCCCC4)c23)n1		CHEMBL4520286	=	IC50	nM	1469.0	CHEMBL5251	Homo sapiens	IC50	nM	1469.0
	19029969	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(OC4CCOCC4)c23)n1		CHEMBL4562744	=	IC50	nM	1607.0	CHEMBL5251	Homo sapiens	IC50	nM	1607.0
	19029970	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC[C@H]1COc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2)nc2[nH]cc(-c3cncc(NC)n3)c12		CHEMBL4543893	=	IC50	nM	434.0	CHEMBL5251	Homo sapiens	IC50	nM	434.0
	19029971	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC[C@@H]1COc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2)nc2[nH]cc(-c3cncc(NC)n3)c12		CHEMBL4593230	=	IC50	nM	286.0	CHEMBL5251	Homo sapiens	IC50	nM	286.0
	19029972	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC[C@H](Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1		CHEMBL4563157	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19029973	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1		CHEMBL4469900	=	IC50	nM	270.0	CHEMBL5251	Homo sapiens	IC50	nM	270.0
	19029974	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCN(CC)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1		CHEMBL4457018	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	19029975	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1		CHEMBL4458344	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	nM	35.0
	19029976	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4463563	=	IC50	nM	1481.0	CHEMBL5251	Homo sapiens	IC50	nM	1481.0
	19029977	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)c4)c23)CC1		CHEMBL4440621	=	IC50	nM	942.0	CHEMBL5251	Homo sapiens	IC50	nM	942.0
	19029978	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cccc(NC)n4)c23)CC1		CHEMBL4574694	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19029979	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4ccnc(NC)c4)c23)CC1		CHEMBL4549626	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	19029980	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C#CCCN1CCN(c2ccc(Nc3nc(OC4CCN(C(=O)C=C)CC4)c4c(-c5cncc(NC)n5)c[nH]c4n3)cc2)CC1		CHEMBL4562542	>	IC50	nM	3000.0	CHEMBL5251	Homo sapiens	IC50	nM	3000.0
	19030031	CHEMBL4349170	Inhibition of recombinant full length human His-tagged BTK cytoplasmic domain expressed in baculovirus expression system assessed as enzyme residual activity at 0.4 uM using fluorophore-labeled tyrosine-1 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4443805	=	Activity	%	41.3	CHEMBL5251	Homo sapiens	Activity	%	41.3
Not Active	19030059	CHEMBL4349186	Inhibition of BTK in human Ramos cells assessed as reduction in anti-CD3/CD28-stimulated PLCgamma2 phosphorylation at 10 to 3000 nM preincubated for 2 hrs followed by anti-CD3/CD28 beads addition and measured after 30 min by Western blot analysis	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4443805		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19030085	CHEMBL4349140	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using STK substrate by HTRF assay	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4443805	=	IC50	nM	996.0	CHEMBL5251	Homo sapiens	IC50	nM	996.0
	19031442	CHEMBL4349461	Inhibition of BTK (unknown origin)	B	CC(C)N1Cc2cc(c(F)cc2F)OCCCNC(=O)c2cnn3ccc1nc23		CHEMBL4449648	=	IC50	nM	9.67	CHEMBL5251	Homo sapiens	IC50	nM	9.67
	19031443	CHEMBL4349461	Inhibition of BTK (unknown origin)	B	CC(C)N1Cc2cc(cc(F)c2Cl)O[C@@H](C)CNC(=O)c2cnn3cc1cnc23		CHEMBL4554856	=	IC50	nM	0.536	CHEMBL5251	Homo sapiens	IC50	nM	0.536
	19032178	CHEMBL4349771	Inhibition of recombinant human full length N-terminal GST/His6-tagged BTK (M1 to S659) expressed in Sf9 insect cells at 20 nM using phosphatidylserine as substrate incubated for 60 mins in presence of [33P]-ATP by scintillation counting method	B	Cn1cc(-c2n[nH]c3ccc(NCc4cc(F)ccc4S(C)(=O)=O)cc23)cn1		CHEMBL4555442	=	Inhibition	%	-6.0	CHEMBL5251	Homo sapiens	INH	%	-6.0
Not Active	19036513	CHEMBL4350940	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Erk phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19036514	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NC)cc3)ncc2F)c1		CHEMBL4473373	=	IC50	nM	8.21	CHEMBL5251	Homo sapiens	IC50	nM	8.21
	19036515	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCC)cc3)ncc2F)c1		CHEMBL4455814	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	19036516	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NC(C)C)cc3)ncc2F)c1		CHEMBL4473486	=	IC50	nM	98.2	CHEMBL5251	Homo sapiens	IC50	nM	98.2
	19036517	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CCNC(=S)SCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1		CHEMBL4540071	=	IC50	nM	91.7	CHEMBL5251	Homo sapiens	IC50	nM	91.7
	19036518	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N(C)C)cc3)ncc2F)c1		CHEMBL4476232	=	IC50	nM	1.44	CHEMBL5251	Homo sapiens	IC50	nM	1.44
	19036519	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N(CC)CC)cc3)ncc2F)c1		CHEMBL4548939	=	IC50	nM	23.3	CHEMBL5251	Homo sapiens	IC50	nM	23.3
	19036520	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N(CCC)CCC)cc3)ncc2F)c1		CHEMBL4476311	=	IC50	nM	240.8	CHEMBL5251	Homo sapiens	IC50	nM	240.8
	19036521	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N(CCCC)CCCC)cc3)ncc2F)c1		CHEMBL4454876	=	IC50	nM	125.2	CHEMBL5251	Homo sapiens	IC50	nM	125.2
	19036522	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NC4CC4)cc3)ncc2F)c1		CHEMBL4470534	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	19036523	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NC4CCCCC4)cc3)ncc2F)c1		CHEMBL4460184	=	IC50	nM	115.2	CHEMBL5251	Homo sapiens	IC50	nM	115.2
	19036524	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCCC4)cc3)ncc2F)c1		CHEMBL4443744	=	IC50	nM	154.5	CHEMBL5251	Homo sapiens	IC50	nM	154.5
	19036525	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCCCC4)cc3)ncc2F)c1		CHEMBL4537525	=	IC50	nM	83.6	CHEMBL5251	Homo sapiens	IC50	nM	83.6
	19036526	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCOCC4)cc3)ncc2F)c1		CHEMBL4462242	=	IC50	nM	29.9	CHEMBL5251	Homo sapiens	IC50	nM	29.9
	19036527	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CC(C)OC(C)C4)cc3)ncc2F)c1		CHEMBL4468913	=	IC50	nM	27.1	CHEMBL5251	Homo sapiens	IC50	nM	27.1
	19036528	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(C)CC4)cc3)ncc2F)c1		CHEMBL4439745	=	IC50	nM	35.6	CHEMBL5251	Homo sapiens	IC50	nM	35.6
	19036529	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(C(C)C)CC4)cc3)ncc2F)c1		CHEMBL4438747	=	IC50	nM	56.9	CHEMBL5251	Homo sapiens	IC50	nM	56.9
	19036530	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(CCO)CC4)cc3)ncc2F)c1		CHEMBL4445733	=	IC50	nM	68.3	CHEMBL5251	Homo sapiens	IC50	nM	68.3
	19036531	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(C(C)=O)CC4)cc3)ncc2F)c1		CHEMBL4453432	=	IC50	nM	80.3	CHEMBL5251	Homo sapiens	IC50	nM	80.3
	19036532	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(C(=O)OC(C)(C)C)CC4)cc3)ncc2F)c1		CHEMBL4434679	=	IC50	nM	263.7	CHEMBL5251	Homo sapiens	IC50	nM	263.7
	19036533	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(c5ccccc5)CC4)cc3)ncc2F)c1		CHEMBL4575729	=	IC50	nM	385.9	CHEMBL5251	Homo sapiens	IC50	nM	385.9
	19036534	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCN(Cc5ccccc5)CC4)cc3)ncc2F)c1		CHEMBL4576295	=	IC50	nM	283.5	CHEMBL5251	Homo sapiens	IC50	nM	283.5
	19036535	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4ccccc4)cc3)ncc2F)c1		CHEMBL4521840	=	IC50	nM	10.8	CHEMBL5251	Homo sapiens	IC50	nM	10.8
	19036536	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4ccc(OC)cc4)cc3)ncc2F)c1		CHEMBL4434879	=	IC50	nM	5.68	CHEMBL5251	Homo sapiens	IC50	nM	5.68
	19036537	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccc(F)c4)cc3)ncc2F)c1		CHEMBL4583844	=	IC50	nM	6.9	CHEMBL5251	Homo sapiens	IC50	nM	6.9
	19036538	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4ccc(C#N)cc4)cc3)ncc2F)c1		CHEMBL4590126	=	IC50	nM	8.58	CHEMBL5251	Homo sapiens	IC50	nM	8.58
	19036539	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cc(OC)c(OC)c(OC)c4)cc3)ncc2F)c1		CHEMBL4551071	=	IC50	nM	48.6	CHEMBL5251	Homo sapiens	IC50	nM	48.6
	19036540	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N4CCc5ccccc5C4)cc3)ncc2F)c1		CHEMBL4449314	>	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
	19036541	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4461112	=	IC50	nM	1.15	CHEMBL5251	Homo sapiens	IC50	nM	1.15
	19036542	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4ccccn4)cc3)ncc2F)c1		CHEMBL4435537	=	IC50	nM	18.5	CHEMBL5251	Homo sapiens	IC50	nM	18.5
	19036543	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4ccncc4)cc3)ncc2F)c1		CHEMBL4464989	=	IC50	nM	7.36	CHEMBL5251	Homo sapiens	IC50	nM	7.36
	19036544	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)N(C)Cc4cccnc4)cc3)ncc2F)c1		CHEMBL4435060	=	IC50	nM	30.7	CHEMBL5251	Homo sapiens	IC50	nM	30.7
	19036545	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cnccn4)cc3)ncc2F)c1		CHEMBL4466032	=	IC50	nM	8.49	CHEMBL5251	Homo sapiens	IC50	nM	8.49
	19036546	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	2.12	CHEMBL5251	Homo sapiens	IC50	nM	2.12
	19036547	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	3.89	CHEMBL5251	Homo sapiens	IC50	nM	3.89
	19036548	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCSC(=S)N(C)C)cc3)ncc2F)c1		CHEMBL4517522	=	IC50	nM	13.9	CHEMBL5251	Homo sapiens	IC50	nM	13.9
	19036549	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCSC(=S)N4CCN(C(C)C)CC4)cc3)ncc2F)c1		CHEMBL4437246	=	IC50	nM	63.2	CHEMBL5251	Homo sapiens	IC50	nM	63.2
	19036550	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4437107	=	IC50	nM	2.39	CHEMBL5251	Homo sapiens	IC50	nM	2.39
	19036551	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCCSC(=S)N(C)C)cc3)ncc2F)c1		CHEMBL4443136	=	IC50	nM	35.4	CHEMBL5251	Homo sapiens	IC50	nM	35.4
	19036552	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCCSC(=S)N4CCN(C(C)C)CC4)cc3)ncc2F)c1		CHEMBL4447148	=	IC50	nM	130.6	CHEMBL5251	Homo sapiens	IC50	nM	130.6
	19036553	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4449266	=	IC50	nM	16.5	CHEMBL5251	Homo sapiens	IC50	nM	16.5
	19036554	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4459604	=	IC50	nM	18.4	CHEMBL5251	Homo sapiens	IC50	nM	18.4
	19036555	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4435828	=	IC50	nM	23.7	CHEMBL5251	Homo sapiens	IC50	nM	23.7
	19036556	CHEMBL4350910	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	B	CCC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4591477	>	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	nM	500.0
Active	19036677	CHEMBL4350930	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in autophosphorylation at Y223 residues at 0.01 to 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4461112		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19036679	CHEMBL4350940	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Erk phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	CCC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4591477		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	19036680	CHEMBL4350931	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Y1217 residues at 0.01 to 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4461112		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19036681	CHEMBL4350932	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Erk phosphorylation at 0.01 to 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4461112		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036682	CHEMBL4350933	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Akt phosphorylation at 0.01 to 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4461112		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036695	CHEMBL4350939	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in autophosphorylation at Y223 residue at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036696	CHEMBL4350939	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in autophosphorylation at Y223 residue at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036697	CHEMBL4350939	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in autophosphorylation at Y223 residue at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	CCC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4591477		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036698	CHEMBL4350941	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Akt phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036699	CHEMBL4350941	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Akt phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19036700	CHEMBL4350941	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Akt phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	CCC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4591477		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19036701	CHEMBL4350942	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Y1217 residues at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	CCC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCSC(=S)NCc4cccnc4)cc3)ncc2F)c1		CHEMBL4591477		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19036705	CHEMBL4350940	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Erk phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19036724	CHEMBL4351046	Inhibition of BTK (unknown origin)	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
Not Active	19039880	CHEMBL4351763	Inhibition of full-length recombinant human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19039881	CHEMBL4351762	Inhibition of full-length recombinant human BTK R28H mutant at 10 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19041025	CHEMBL4352286	Inhibition of human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19043647	CHEMBL4353141	Inhibition of human BTK using poly(Glu,Tyr) 4:1 as substrate in presence of 33P-gamma ATP by hotspot kinase assay	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4ccc5c(c4)OCO5)n[nH]3)cc2)CC1		CHEMBL4456471	=	IC50	nM	161.0	CHEMBL5251	Homo sapiens	IC50	nM	161.0
	19043740	CHEMBL4353135	Inhibition of human BTK using poly (Glu,Tyr)4:1 as substrate at 0.1 uM in presence of 33P-gamma ATP by hotspot kinase assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4ccc5c(c4)OCO5)n[nH]3)cc2)CC1		CHEMBL4456471	=	Inhibition	%	17.96	CHEMBL5251	Homo sapiens	INH	%	17.96
	19048766	CHEMBL4354251	Inhibition of BTK (unknown origin) at 1 uM	B	COc1cc(N2CCNCC2)ccc1Nc1cc(N2CCC[C@H](C(=O)NCc3ccc(OC(F)(F)F)cc3)C2)ccn1		CHEMBL4523063	=	Inhibition	%	-5.0	CHEMBL5251	Homo sapiens	INH	%	-5.0
	19052356	CHEMBL4355290	Inhibition of BTK (unknown origin)	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	19054052	CHEMBL4356095	Inhibition of BTK (unknown origin) after 60 mins by FRET assay	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	uM	0.0014
	19054053	CHEMBL4356095	Inhibition of BTK (unknown origin) after 60 mins by FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	uM	0.0005
	19059479	CHEMBL4357780	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	0.1	CHEMBL5251	Homo sapiens	Activity	%	0.1
	19061001	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N(C)C/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2)c1C		CHEMBL4559123	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
	19061002	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N(C)CC/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2)c1C		CHEMBL4450082	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
	19061003	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CCC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3)c2C)C1		CHEMBL4589396	=	IC50	nM	3651.0	CHEMBL5251	Homo sapiens	IC50	nM	3651.0
	19061004	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3)c2C)C1		CHEMBL4463650	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
	19061005	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3F)c2C)C1		CHEMBL4567040	=	IC50	nM	4.5	CHEMBL5251	Homo sapiens	IC50	nM	4.5
	19061006	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C(C)(C)O)cc3F)c2C)C1		CHEMBL4513614	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	19061007	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C(C)(C)O)c(F)c3F)c2C)C1		CHEMBL4463185	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	19061008	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N(C)C/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4546324	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	19061009	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)NCCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4557061	=	IC50	nM	8.7	CHEMBL5251	Homo sapiens	IC50	nM	8.7
	19061010	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)NCCNc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4461398	=	IC50	nM	51.0	CHEMBL5251	Homo sapiens	IC50	nM	51.0
	19061011	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CCC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3F)c2C)CC1		CHEMBL4445790	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
	19061012	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CCC[C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468095	=	IC50	nM	1290.0	CHEMBL5251	Homo sapiens	IC50	nM	1290.0
	19061013	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CCC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4537231	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	19061014	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4576902	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
	19061015	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC[C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4591291	=	IC50	nM	7.5	CHEMBL5251	Homo sapiens	IC50	nM	7.5
	19061016	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	19061017	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N(C)CCCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4550284	=	IC50	nM	3.6	CHEMBL5251	Homo sapiens	IC50	nM	3.6
	19061018	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N(CC)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4439622	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	19061019	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C/C=C/C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4576801	=	IC50	nM	104.0	CHEMBL5251	Homo sapiens	IC50	nM	104.0
	19061020	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2F)cc(F)cc1-c1ncnc(N)c1OCCN(C)C(=O)/C=C/CN(C)C		CHEMBL4441128	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	19061021	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C#CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4471613	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
	19061022	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	CC#CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4437701	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
	19061023	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	CCC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468719	=	IC50	nM	1300.0	CHEMBL5251	Homo sapiens	IC50	nM	1300.0
	19061024	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	19061025	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	19061026	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	5.2	CHEMBL5251	Homo sapiens	IC50	nM	5.2
	19061027	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	62.0	CHEMBL5251	Homo sapiens	IC50	nM	62.0
	19061028	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(-c3ccc(C(=O)N4CCN(C)CC4)cc3)cc12		CHEMBL4566818	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	uM	0.013
	19061029	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	C=CC(=O)N1CC=C(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4593663	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	uM	0.0009
	19061030	CHEMBL4358487	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1cc(N)ncn1		CHEMBL4446119	=	IC50	nM	7300.0	CHEMBL5251	Homo sapiens	IC50	uM	7.3
	19061031	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N(C)C/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2)c1C		CHEMBL4559123	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	19061032	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N(C)CC/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2)c1C		CHEMBL4450082	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	19061033	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CCC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3)c2C)C1		CHEMBL4589396	=	IC50	nM	1437.0	CHEMBL5251	Homo sapiens	IC50	nM	1437.0
	19061034	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3)c2C)C1		CHEMBL4463650	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	19061035	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3F)c2C)C1		CHEMBL4567040	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	19061036	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C(C)(C)O)cc3F)c2C)C1		CHEMBL4513614	=	IC50	nM	108.0	CHEMBL5251	Homo sapiens	IC50	nM	108.0
	19061037	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C(C)(C)O)c(F)c3F)c2C)C1		CHEMBL4463185	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	19061038	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N(C)C/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4546324	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	19061039	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)NCCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4557061	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	19061040	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)NCCNc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4461398	=	IC50	nM	671.0	CHEMBL5251	Homo sapiens	IC50	nM	671.0
	19061041	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CCC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3F)c2C)CC1		CHEMBL4445790	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	19061042	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CCC[C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468095	=	IC50	nM	1869.0	CHEMBL5251	Homo sapiens	IC50	nM	1869.0
	19061043	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CCC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4537231	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	19061044	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4576902	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19061045	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CC[C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4591291	=	IC50	nM	60.0	CHEMBL5251	Homo sapiens	IC50	nM	60.0
	19061046	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	19061047	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N(C)CCCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4550284	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	19061048	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N(CC)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4439622	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19061049	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C/C=C/C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4576801	=	IC50	nM	263.0	CHEMBL5251	Homo sapiens	IC50	nM	263.0
	19061050	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2F)cc(F)cc1-c1ncnc(N)c1OCCN(C)C(=O)/C=C/CN(C)C		CHEMBL4441128	=	IC50	nM	76.0	CHEMBL5251	Homo sapiens	IC50	nM	76.0
	19061051	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C#CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4471613	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	19061052	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	CC#CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4437701	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	19061053	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	CCC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468719	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19061054	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	19061055	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	19061056	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	19061057	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	nM	61.0
	19061058	CHEMBL4358488	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	19061059	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N(C)C/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2)c1C		CHEMBL4559123	=	IC50	nM	106.0	CHEMBL5251	Homo sapiens	IC50	nM	106.0
	19061060	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N(C)CC/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2)c1C		CHEMBL4450082	=	IC50	nM	223.0	CHEMBL5251	Homo sapiens	IC50	nM	223.0
Not Determined	19061061	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CCC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3)c2C)C1		CHEMBL4589396		IC50			CHEMBL5251	Homo sapiens	IC50		
	19061062	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3)c2C)C1		CHEMBL4463650	=	IC50	nM	95.0	CHEMBL5251	Homo sapiens	IC50	nM	95.0
	19061063	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3F)c2C)C1		CHEMBL4567040	=	IC50	nM	86.0	CHEMBL5251	Homo sapiens	IC50	nM	86.0
	19061064	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C(C)(C)O)cc3F)c2C)C1		CHEMBL4513614	=	IC50	nM	250.0	CHEMBL5251	Homo sapiens	IC50	nM	250.0
	19061065	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C(C)(C)O)c(F)c3F)c2C)C1		CHEMBL4463185	=	IC50	nM	55.0	CHEMBL5251	Homo sapiens	IC50	nM	55.0
	19061066	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N(C)C/C=C/c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4546324	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	19061067	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)NCCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4557061	=	IC50	nM	105.0	CHEMBL5251	Homo sapiens	IC50	nM	105.0
	19061068	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)NCCNc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4461398	=	IC50	nM	1245.0	CHEMBL5251	Homo sapiens	IC50	nM	1245.0
	19061069	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CCC(Oc2c(N)ncnc2-c2cc(F)cc(NC(=O)c3ccc(C4CC4)cc3F)c2C)CC1		CHEMBL4445790	=	IC50	nM	201.0	CHEMBL5251	Homo sapiens	IC50	nM	201.0
Not Determined	19061070	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CCC[C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468095		IC50			CHEMBL5251	Homo sapiens	IC50		
	19061071	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CCC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4537231	=	IC50	nM	57.0	CHEMBL5251	Homo sapiens	IC50	nM	57.0
	19061072	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CC[C@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4576902	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	nM	50.0
	19061073	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CC[C@@H]1COc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4591291	=	IC50	nM	354.0	CHEMBL5251	Homo sapiens	IC50	nM	354.0
	19061074	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	19061075	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N(C)CCCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4550284	=	IC50	nM	91.0	CHEMBL5251	Homo sapiens	IC50	nM	91.0
	19061076	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N(CC)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4439622	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	19061077	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C/C=C/C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4576801	=	IC50	nM	983.0	CHEMBL5251	Homo sapiens	IC50	nM	983.0
	19061078	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2F)cc(F)cc1-c1ncnc(N)c1OCCN(C)C(=O)/C=C/CN(C)C		CHEMBL4441128	=	IC50	nM	151.0	CHEMBL5251	Homo sapiens	IC50	nM	151.0
	19061079	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C#CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4471613	=	IC50	nM	49.0	CHEMBL5251	Homo sapiens	IC50	nM	49.0
	19061080	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	CC#CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4437701	=	IC50	nM	161.0	CHEMBL5251	Homo sapiens	IC50	nM	161.0
	19061081	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	CCC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468719	>	IC50	nM	20000.0	CHEMBL5251	Homo sapiens	IC50	nM	20000.0
	19061082	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	66.0	CHEMBL5251	Homo sapiens	IC50	nM	66.0
	19061083	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	203.0	CHEMBL5251	Homo sapiens	IC50	nM	203.0
	19061084	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	132.0	CHEMBL5251	Homo sapiens	IC50	nM	132.0
	19061085	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	320.0	CHEMBL5251	Homo sapiens	IC50	nM	320.0
	19061086	CHEMBL4358489	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
Active	19061173	CHEMBL4358510	Covalent inhibition of full-length human recombinant BTK assessed as reduction in enzyme recovery at 10-fold molar excess concentration using FITC-Ahx-TSELKKVVALYDYMPMNAND-biotin-NH2 as substrate preincubated for 1 hr followed by enzyme-compound mixture dilution in presence of substrate by HTRF assay	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19061174	CHEMBL4358510	Covalent inhibition of full-length human recombinant BTK assessed as reduction in enzyme recovery at 10-fold molar excess concentration using FITC-Ahx-TSELKKVVALYDYMPMNAND-biotin-NH2 as substrate preincubated for 1 hr followed by enzyme-compound mixture dilution in presence of substrate by HTRF assay	B	CCC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4468719		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19061175	CHEMBL4358510	Covalent inhibition of full-length human recombinant BTK assessed as reduction in enzyme recovery at 10-fold molar excess concentration using FITC-Ahx-TSELKKVVALYDYMPMNAND-biotin-NH2 as substrate preincubated for 1 hr followed by enzyme-compound mixture dilution in presence of substrate by HTRF assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19061176	CHEMBL4358511	Binding affinity to BTK kinase domain (unknown origin) (386 to 659 residues) assessed as 1:1 compound-protein adduct formation by measuring molecular weight at 1.2 molar excess concentration measured after 10 mins by LC-MS analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	Activity	Da	32222.3	CHEMBL5251	Homo sapiens	Activity	Da	32222.3
	19061177	CHEMBL4358512	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	Activity	%	0.25	CHEMBL5251	Homo sapiens	Activity	%	0.25
	19061180	CHEMBL4358514	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	Kd	nM	0.63	CHEMBL5251	Homo sapiens	Kd	nM	0.63
	19061181	CHEMBL4358514	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Kd	nM	1.9	CHEMBL5251	Homo sapiens	Kd	nM	1.9
	19061182	CHEMBL4358514	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	Kd	nM	21.0	CHEMBL5251	Homo sapiens	Kd	nM	21.0
	19061183	CHEMBL4358514	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	Kd	nM	14.0	CHEMBL5251	Homo sapiens	Kd	nM	14.0
	19061184	CHEMBL4358514	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	Kd	nM	16.0	CHEMBL5251	Homo sapiens	Kd	nM	16.0
	19061185	CHEMBL4358514	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	Kd	nM	0.56	CHEMBL5251	Homo sapiens	Kd	nM	0.56
Active	19061270	CHEMBL4358529	Inhibition of BTK in human B cells assessed as reduction in B cell receptor-induced TNFalpha production at 270 to 10000 nM by BioMAP analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19061271	CHEMBL4358530	Inhibition of BTK in human B cells assessed as reduction in B cell receptor-induced IL17A production at 270 to 10000 nM by BioMAP analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19061272	CHEMBL4358531	Inhibition of BTK in human B cells assessed as reduction in B cell receptor-induced IL6 production at 270 to 10000 nM by BioMAP analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19061273	CHEMBL4358532	Inhibition of BTK in human B cells assessed as reduction in B cell receptor-induced IL2 production at 270 to 10000 nM by BioMAP analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19061274	CHEMBL4358533	Inhibition of BTK in human B cells assessed as reduction in B cell proliferation at 270 to 10000 nM by BioMAP analysis	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19061313	CHEMBL4358572	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at <= 300 nM measured up to 100 mins by immunoassay	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		Activity			CHEMBL5251	Homo sapiens	Activity		
	19061314	CHEMBL4358573	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
Active	19061315	CHEMBL4358573	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	19061316	CHEMBL4358573	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	19061317	CHEMBL4358573	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	19061318	CHEMBL4358573	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833		Activity			CHEMBL5251	Homo sapiens	Activity		
	19061319	CHEMBL4358573	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	19061320	CHEMBL4358574	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575	=	IC50	nM	67.0	CHEMBL5251	Homo sapiens	IC50	nM	67.0
	19061321	CHEMBL4358574	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	230.0	CHEMBL5251	Homo sapiens	IC50	nM	230.0
	19061322	CHEMBL4358574	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	747.0	CHEMBL5251	Homo sapiens	IC50	nM	747.0
	19061323	CHEMBL4358574	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry	B	CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4071161	=	IC50	nM	363.0	CHEMBL5251	Homo sapiens	IC50	nM	363.0
	19061324	CHEMBL4358574	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	1182.0	CHEMBL5251	Homo sapiens	IC50	nM	1182.0
	19061325	CHEMBL4358574	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
Not Active	19061514	CHEMBL4358571	Time-dependent inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-biotin-NH2 as substrate by caliper assay	B	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C		CHEMBL4483575		TDI			CHEMBL5251	Homo sapiens	TDI		
Dose-dependent effect	19068056	CHEMBL4360897	Inhibition of BTK in anti-IgM-stimulated human Raji cells assessed as decrease in auto-phosphorylation at Y223 residue after 48 hrs by Western blot analysis	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068057	CHEMBL4360896	Inhibition of BTK in anti-IgM-stimulated human Raji cells assessed as decrease in auto-phosphorylation at Y223 residue at 5 uM after 48 hrs by Western blot analysis	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068058	CHEMBL4360895	Inhibition of BTK in human Raji cells assessed as reduction in PLCgamma-2 phosphorylation at Y1217 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068059	CHEMBL4360894	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Y1217 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19068139	CHEMBL4360844	Inhibition of human recombinant full length N-terminal His tagged BTK C481S mutant expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	uM	0.061
	19068140	CHEMBL4360844	Inhibition of human recombinant full length N-terminal His tagged BTK C481S mutant expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1c[nH]c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4447710	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	uM	0.016
	19068141	CHEMBL4360844	Inhibition of human recombinant full length N-terminal His tagged BTK C481S mutant expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	uM	0.017
Not Determined	19068334	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cn3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4592938		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068335	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(C(F)(F)F)cn5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4460690	=	IC50	nM	637.0	CHEMBL5251	Homo sapiens	IC50	uM	0.637
	19068336	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccco3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4584007	=	IC50	nM	161.0	CHEMBL5251	Homo sapiens	IC50	uM	0.161
	19068337	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccco5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4536906	=	IC50	nM	73.0	CHEMBL5251	Homo sapiens	IC50	uM	0.073
Not Determined	19068338	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3csnn3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4475234		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068339	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5csnn5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4472236	=	IC50	nM	213.0	CHEMBL5251	Homo sapiens	IC50	uM	0.213
Not Determined	19068340	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)[C@H]3CC[C@H](C)CC3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4517927		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068341	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)[C@H]5CC[C@H](C)CC5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4552410	=	IC50	nM	105.0	CHEMBL5251	Homo sapiens	IC50	uM	0.105
Not Determined	19068351	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cccc(F)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4570521		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068352	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5F)c4)sc3C(N)=O)cc2)CC1		CHEMBL4547271	=	IC50	nM	2671.0	CHEMBL5251	Homo sapiens	IC50	uM	2.671
	19068353	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(Cl)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4564665	=	IC50	nM	614.0	CHEMBL5251	Homo sapiens	IC50	uM	0.614
	19068354	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	uM	0.09
	19068355	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(Cl)cc5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4543872	=	IC50	nM	134.0	CHEMBL5251	Homo sapiens	IC50	uM	0.134
Not Determined	19068356	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4590761		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068357	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4455183	=	IC50	nM	159.0	CHEMBL5251	Homo sapiens	IC50	uM	0.159
	19068358	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5F)c4)sc3C(=O)O)cc2)CC1		CHEMBL4585613	=	IC50	nM	21888.0	CHEMBL5251	Homo sapiens	IC50	uM	21.888
	19068359	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cccc(F)c5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4575423	=	IC50	nM	27822.0	CHEMBL5251	Homo sapiens	IC50	uM	27.822
	19068360	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4460489	=	IC50	nM	862.0	CHEMBL5251	Homo sapiens	IC50	uM	0.862
	19068361	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(C(C)(C)C)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4525695	=	IC50	nM	5254.0	CHEMBL5251	Homo sapiens	IC50	uM	5.254
	19068362	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CNC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4470618	=	IC50	nM	8529.0	CHEMBL5251	Homo sapiens	IC50	uM	8.529
	19068363	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CC(C)NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4476146	=	IC50	nM	62845.0	CHEMBL5251	Homo sapiens	IC50	uM	62.845
	19068364	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	uM	0.0018
	19068365	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1c[nH]c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4447710	=	IC50	nM	8.9	CHEMBL5251	Homo sapiens	IC50	uM	0.0089
	19068366	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccccc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4566033	=	IC50	nM	37114.0	CHEMBL5251	Homo sapiens	IC50	uM	37.114
	19068367	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3cccc(F)c3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4556566	=	IC50	nM	19155.0	CHEMBL5251	Homo sapiens	IC50	uM	19.155
	19068368	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccccc3F)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4562578	=	IC50	nM	2096.0	CHEMBL5251	Homo sapiens	IC50	uM	2.096
Not Determined	19068369	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(Cl)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4453518		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068370	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C#N)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4548153	=	IC50	nM	5169.0	CHEMBL5251	Homo sapiens	IC50	uM	5.169
Not Determined	19068371	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)c(Cl)c3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4534997		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19068372	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4473445		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068373	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(C(F)(F)F)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4454852	=	IC50	nM	206.0	CHEMBL5251	Homo sapiens	IC50	uM	0.206
	19068374	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4457726	=	IC50	nM	6754.0	CHEMBL5251	Homo sapiens	IC50	uM	6.754
	19068375	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4450999	=	IC50	nM	258.0	CHEMBL5251	Homo sapiens	IC50	uM	0.258
	19068376	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(N5CCOCC5)cc4)c(C(N)=O)s3)c2)cc1		CHEMBL4441551	=	IC50	nM	2229.0	CHEMBL5251	Homo sapiens	IC50	uM	2.229
	19068377	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4579565	=	IC50	nM	617.0	CHEMBL5251	Homo sapiens	IC50	uM	0.617
	19068378	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4548804	=	IC50	nM	733.0	CHEMBL5251	Homo sapiens	IC50	uM	0.733
	19068379	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(C(=O)N5CCOCC5)cc4)c(C(N)=O)s3)c2)cc1		CHEMBL4587485	=	IC50	nM	333.0	CHEMBL5251	Homo sapiens	IC50	uM	0.333
Not Determined	19068380	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4459694		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068381	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)c(C(=O)O)s2)c1)c1ccc(C(F)(F)F)cc1		CHEMBL4446069	=	IC50	nM	38109.0	CHEMBL5251	Homo sapiens	IC50	uM	38.109
	19068382	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	O=C(Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)c(C(=O)O)s2)c1)c1ccc(F)cc1		CHEMBL4528322	=	IC50	nM	1120.0	CHEMBL5251	Homo sapiens	IC50	uM	1.12
	19068383	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(N5CCOCC5)cc4)c(C(=O)O)s3)c2)cc1		CHEMBL4593580	=	IC50	nM	5323.0	CHEMBL5251	Homo sapiens	IC50	uM	5.323
	19068384	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CN(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(N5CCOCC5)cc4)c(C(=O)O)s3)c2)cc1		CHEMBL4537375	=	IC50	nM	21045.0	CHEMBL5251	Homo sapiens	IC50	uM	21.045
	19068385	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5csnn5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4472236	=	Inhibition	%	94.87	CHEMBL5251	Homo sapiens	INH	%	94.87
	19068386	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)[C@H]3CC[C@H](C)CC3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4517927	=	Inhibition	%	38.02	CHEMBL5251	Homo sapiens	INH	%	38.02
	19068387	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)[C@H]5CC[C@H](C)CC5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4552410	=	Inhibition	%	93.57	CHEMBL5251	Homo sapiens	INH	%	93.57
	19068388	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4450409	=	IC50	nM	2422.0	CHEMBL5251	Homo sapiens	IC50	uM	2.422
Not Determined	19068389	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4568697		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19068390	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4439494		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068391	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4528929	=	IC50	nM	4195.0	CHEMBL5251	Homo sapiens	IC50	uM	4.195
Not Determined	19068392	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4469375		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19068393	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4530794		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19068394	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4574567		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19068395	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4540717		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19068396	CHEMBL4360839	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4528463		IC50			CHEMBL5251	Homo sapiens	IC50		
	19068397	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3csnn3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4475234	=	Inhibition	%	6.05	CHEMBL5251	Homo sapiens	INH	%	6.05
	19068398	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccco5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4536906	=	Inhibition	%	90.33	CHEMBL5251	Homo sapiens	INH	%	90.33
	19068399	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccco3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4584007	=	Inhibition	%	93.57	CHEMBL5251	Homo sapiens	INH	%	93.57
	19068400	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(C(F)(F)F)cn5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4460690	=	Inhibition	%	85.8	CHEMBL5251	Homo sapiens	INH	%	85.8
	19068401	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cn3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4592938	=	Inhibition	%	28.01	CHEMBL5251	Homo sapiens	INH	%	28.01
	19068402	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650	=	Inhibition	%	97.56	CHEMBL5251	Homo sapiens	INH	%	97.56
	19068403	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(Cl)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4564665	=	Inhibition	%	92.12	CHEMBL5251	Homo sapiens	INH	%	92.12
	19068404	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5F)c4)sc3C(N)=O)cc2)CC1		CHEMBL4547271	=	Inhibition	%	94.21	CHEMBL5251	Homo sapiens	INH	%	94.21
	19068405	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cccc(F)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4570521	=	Inhibition	%	75.19	CHEMBL5251	Homo sapiens	INH	%	75.19
	19068406	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4455183	=	Inhibition	%	93.54	CHEMBL5251	Homo sapiens	INH	%	93.54
	19068407	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4590761	=	Inhibition	%	42.85	CHEMBL5251	Homo sapiens	INH	%	42.85
	19068408	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(Cl)cc5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4543872	=	Inhibition	%	94.31	CHEMBL5251	Homo sapiens	INH	%	94.31
	19068409	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3cccc(F)c3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4556566	=	Inhibition	%	47.7	CHEMBL5251	Homo sapiens	INH	%	47.7
	19068410	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccccc3F)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4562578	=	Inhibition	%	85.25	CHEMBL5251	Homo sapiens	INH	%	85.25
	19068411	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(Cl)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4453518	=	Inhibition	%	74.71	CHEMBL5251	Homo sapiens	INH	%	74.71
	19068412	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C#N)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4548153	=	Inhibition	%	73.05	CHEMBL5251	Homo sapiens	INH	%	73.05
	19068413	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)c(Cl)c3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4534997	=	Inhibition	%	22.08	CHEMBL5251	Homo sapiens	INH	%	22.08
	19068414	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4473445	=	Inhibition	%	60.97	CHEMBL5251	Homo sapiens	INH	%	60.97
	19068415	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5cccc(F)c5)c4)sc3C(=O)O)cc2)CC1		CHEMBL4575423	=	Inhibition	%	43.39	CHEMBL5251	Homo sapiens	INH	%	43.39
	19068416	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccccc5F)c4)sc3C(=O)O)cc2)CC1		CHEMBL4585613	=	Inhibition	%	46.35	CHEMBL5251	Homo sapiens	INH	%	46.35
	19068417	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1c[nH]c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4447710	=	Inhibition	%	95.21	CHEMBL5251	Homo sapiens	INH	%	95.21
	19068418	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccccc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4566033	=	Inhibition	%	46.35	CHEMBL5251	Homo sapiens	INH	%	46.35
	19068419	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	99.76	CHEMBL5251	Homo sapiens	INH	%	99.76
	19068420	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)c(C(=O)O)s2)c1)c1ccc(F)cc1		CHEMBL4528322	=	Inhibition	%	80.3	CHEMBL5251	Homo sapiens	INH	%	80.3
	19068421	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(N5CCOCC5)cc4)c(C(=O)O)s3)c2)cc1		CHEMBL4593580	=	Inhibition	%	82.47	CHEMBL5251	Homo sapiens	INH	%	82.47
	19068422	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(N5CCOCC5)cc4)c(C(=O)O)s3)c2)cc1		CHEMBL4537375	=	Inhibition	%	54.46	CHEMBL5251	Homo sapiens	INH	%	54.46
	19068423	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4457726	=	Inhibition	%	75.74	CHEMBL5251	Homo sapiens	INH	%	75.74
	19068424	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4450999	=	Inhibition	%	94.8	CHEMBL5251	Homo sapiens	INH	%	94.8
	19068425	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(N5CCOCC5)cc4)c(C(N)=O)s3)c2)cc1		CHEMBL4441551	=	Inhibition	%	85.04	CHEMBL5251	Homo sapiens	INH	%	85.04
	19068426	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4579565	=	Inhibition	%	82.18	CHEMBL5251	Homo sapiens	INH	%	82.18
	19068427	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4548804	=	Inhibition	%	87.28	CHEMBL5251	Homo sapiens	INH	%	87.28
	19068428	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3nc(Nc4ccc(C(=O)N5CCOCC5)cc4)c(C(N)=O)s3)c2)cc1		CHEMBL4587485	=	Inhibition	%	88.37	CHEMBL5251	Homo sapiens	INH	%	88.37
	19068429	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(C(F)(F)F)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4454852	=	Inhibition	%	93.87	CHEMBL5251	Homo sapiens	INH	%	93.87
	19068430	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4460489	=	Inhibition	%	99.78	CHEMBL5251	Homo sapiens	INH	%	99.78
	19068431	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(C(C)(C)C)cc5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4525695	=	Inhibition	%	76.66	CHEMBL5251	Homo sapiens	INH	%	76.66
	19068432	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CNC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4470618	=	Inhibition	%	79.35	CHEMBL5251	Homo sapiens	INH	%	79.35
	19068433	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CC(C)NC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4476146	=	Inhibition	%	28.24	CHEMBL5251	Homo sapiens	INH	%	28.24
	19068438	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	O=C(Nc1cccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)c(C(=O)O)s2)c1)c1ccc(C(F)(F)F)cc1		CHEMBL4446069	=	Inhibition	%	47.92	CHEMBL5251	Homo sapiens	INH	%	47.92
	19068439	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4459694	=	Inhibition	%	38.18	CHEMBL5251	Homo sapiens	INH	%	38.18
	19068440	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4528463	=	Inhibition	%	69.02	CHEMBL5251	Homo sapiens	INH	%	69.02
	19068441	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(N2CCN(C)CC2)cc1		CHEMBL4540717	=	Inhibition	%	22.04	CHEMBL5251	Homo sapiens	INH	%	22.04
	19068442	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4574567	=	Inhibition	%	21.9	CHEMBL5251	Homo sapiens	INH	%	21.9
	19068443	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4530794	=	Inhibition	%	47.72	CHEMBL5251	Homo sapiens	INH	%	47.72
	19068444	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(C(=O)N2CCOCC2)cc1		CHEMBL4469375	=	Inhibition	%	17.53	CHEMBL5251	Homo sapiens	INH	%	17.53
	19068445	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(N(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4528929	=	Inhibition	%	71.74	CHEMBL5251	Homo sapiens	INH	%	71.74
	19068446	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4439494	=	Inhibition	%	16.6	CHEMBL5251	Homo sapiens	INH	%	16.6
	19068447	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4568697	=	Inhibition	%	29.05	CHEMBL5251	Homo sapiens	INH	%	29.05
	19068448	CHEMBL4360838	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	B	CCOC(=O)c1sc(-c2cccc(NC(=O)c3ccc(C(F)(F)F)cc3)c2)nc1Nc1ccc(N2CCOCC2)cc1		CHEMBL4450409	=	Inhibition	%	84.03	CHEMBL5251	Homo sapiens	INH	%	84.03
Active	19068449	CHEMBL4360898	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068450	CHEMBL4360899	Inhibition of BTK in anti-IgM-stimulated human Raji cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068451	CHEMBL4360900	Inhibition of BTK in anti-IgM-stimulated human Raji cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 1 uM after 48 hrs by Western blot analysis	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1c[nH]c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4447710		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068452	CHEMBL4360901	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 1 uM after 48 hrs by Western blot analysis	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1c[nH]c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4447710		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068453	CHEMBL4360894	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Y1217 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068454	CHEMBL4360895	Inhibition of BTK in human Raji cells assessed as reduction in PLCgamma-2 phosphorylation at Y1217 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19068457	CHEMBL4360898	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	B	CN1CCN(c2ccc(Nc3nc(-c4cccc(NC(=O)c5ccc(F)c(Cl)c5)c4)sc3C(N)=O)cc2)CC1		CHEMBL4541650		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19090052	CHEMBL4365626	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	19091828	CHEMBL4366302	Inhibition of human BTK at 100 nM using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	14.84	CHEMBL5251	Homo sapiens	INH	%	14.84
	19104355	CHEMBL4369293	Inhibition of C-terminal V5-His6 tagged human full-length Btk expressed in Sf9 cells by Lanthascreen assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cn4ccnc4c(Nc4ccccc4)n3)c2)cc1		CHEMBL2057914	=	IC50	nM	400.0	CHEMBL5251	Homo sapiens	IC50	nM	400.0
Active	19104356	CHEMBL4369292	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Try1217 residue at 100 to 3000 nM after 24 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19104357	CHEMBL4369291	Inhibition of BTK phosphorylation at Tyr223 residue in human Ramos cells at 100 to 3000 nM after 24 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19104358	CHEMBL4369290	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Try1217 residue at 100 to 9000 nM after 24 hrs by Western blot analysis	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4cccc(C)c4)cc3)n2)cc1		CHEMBL4548413		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19104359	CHEMBL4369289	Inhibition of BTK phosphorylation at Tyr223 residue in human Ramos cells at 100 to 9000 nM after 24 hrs by Western blot analysis	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4cccc(C)c4)cc3)n2)cc1		CHEMBL4548413		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19104381	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	99.4	CHEMBL5251	Homo sapiens	INH	%	99.4
Not Determined	19104382	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4cc(C)ccc4C)cc3)n2)cc1		CHEMBL4443358		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19104383	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4ccc(OC)cc4)cc3)n2)cc1		CHEMBL4445641	=	Inhibition	%	83.9	CHEMBL5251	Homo sapiens	INH	%	83.9
	19104384	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4cccc(C)c4)cc3)n2)cc1		CHEMBL4548413	=	Inhibition	%	82.7	CHEMBL5251	Homo sapiens	INH	%	82.7
	19104385	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)n2)cc1		CHEMBL4450344	=	Inhibition	%	56.5	CHEMBL5251	Homo sapiens	INH	%	56.5
	19104386	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)Nc4ccc(F)cc4)cc3)n2)cc1		CHEMBL4469959	=	Inhibition	%	83.9	CHEMBL5251	Homo sapiens	INH	%	83.9
	19104387	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)cc1		CHEMBL4464979	=	Inhibition	%	60.7	CHEMBL5251	Homo sapiens	INH	%	60.7
	19104388	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)N4CCCC4)cc3)n2)cc1		CHEMBL4435852	=	Inhibition	%	59.8	CHEMBL5251	Homo sapiens	INH	%	59.8
	19104389	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)N(CC)CC)cc3)n2)cc1		CHEMBL4559021	=	Inhibition	%	40.3	CHEMBL5251	Homo sapiens	INH	%	40.3
Not Determined	19104390	CHEMBL4369277	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control	B	C=CC(=O)Nc1ccc(-c2nc(Cl)cc(Nc3ccc(C(=O)N(C)C)cc3)n2)cc1		CHEMBL4528155		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19118239	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)CC1		CHEMBL4514143	=	Inhibition	%	100.9	CHEMBL5251	Homo sapiens	INH	%	100.9
	19118240	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=CC(=O)N1CC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4545868	=	Inhibition	%	96.1	CHEMBL5251	Homo sapiens	INH	%	96.1
	19118241	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=CC(=O)N1CCC[C@H]1Cn1nc(C#CCOc2ccccc2)c2c(N)ncnc21		CHEMBL4459238	=	Inhibition	%	42.9	CHEMBL5251	Homo sapiens	INH	%	42.9
	19118242	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=CC(=O)N(C)CCn1nc(C#CCOc2ccccc2)c2c(N)ncnc21		CHEMBL4463105	=	Inhibition	%	48.5	CHEMBL5251	Homo sapiens	INH	%	48.5
	19118243	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=CC(=O)NCCn1nc(C#CCOc2ccccc2)c2c(N)ncnc21		CHEMBL4553675	=	Inhibition	%	27.1	CHEMBL5251	Homo sapiens	INH	%	27.1
	19118244	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C#CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4541798	=	Inhibition	%	102.3	CHEMBL5251	Homo sapiens	INH	%	102.3
	19118245	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	CC#CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4531607	=	Inhibition	%	99.7	CHEMBL5251	Homo sapiens	INH	%	99.7
	19118246	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=CS(=O)(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4519813	=	Inhibition	%	103.8	CHEMBL5251	Homo sapiens	INH	%	103.8
	19118247	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C=C(F)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4582141	=	Inhibition	%	73.8	CHEMBL5251	Homo sapiens	INH	%	73.8
	19118248	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	C/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4582434	=	Inhibition	%	98.5	CHEMBL5251	Homo sapiens	INH	%	98.5
	19118249	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4444564	=	Inhibition	%	99.6	CHEMBL5251	Homo sapiens	INH	%	99.6
	19118250	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4439998	=	Inhibition	%	97.1	CHEMBL5251	Homo sapiens	INH	%	97.1
	19118251	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	Nc1ncnc2c1c(C#CCOc1ccccc1)nn2[C@@H]1CCCN(C(=O)/C=C/CBr)C1		CHEMBL4446870	=	Inhibition	%	92.2	CHEMBL5251	Homo sapiens	INH	%	92.2
	19118252	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	Nc1ncnc2c1c(C#CCOc1ccccc1)nn2[C@@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL4436728	=	Inhibition	%	86.1	CHEMBL5251	Homo sapiens	INH	%	86.1
	19118253	CHEMBL4372281	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system at 1 uM using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay relative to control	B	Nc1ncnc2c1c(C#CCOc1ccccc1)nn2[C@@H]1CCCN(C(=O)/C=C/Cn2cncn2)C1		CHEMBL4565960	=	Inhibition	%	76.3	CHEMBL5251	Homo sapiens	INH	%	76.3
	19118254	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4226237	=	IC50	nM	7.95	CHEMBL5251	Homo sapiens	IC50	nM	7.95
	19118255	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)CC1		CHEMBL4514143	=	IC50	nM	14.8	CHEMBL5251	Homo sapiens	IC50	nM	14.8
	19118256	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)N1CC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4545868	=	IC50	nM	18.8	CHEMBL5251	Homo sapiens	IC50	nM	18.8
Not Determined	19118257	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)N1CCC[C@H]1Cn1nc(C#CCOc2ccccc2)c2c(N)ncnc21		CHEMBL4459238		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19118258	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)N(C)CCn1nc(C#CCOc2ccccc2)c2c(N)ncnc21		CHEMBL4463105		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19118259	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)NCCn1nc(C#CCOc2ccccc2)c2c(N)ncnc21		CHEMBL4553675		IC50			CHEMBL5251	Homo sapiens	IC50		
	19118260	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C#CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4541798	=	IC50	nM	11.1	CHEMBL5251	Homo sapiens	IC50	nM	11.1
	19118261	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	CC#CC(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4531607	=	IC50	nM	28.3	CHEMBL5251	Homo sapiens	IC50	nM	28.3
	19118262	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CS(=O)(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4519813	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
Not Determined	19118263	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=C(F)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4582141		IC50			CHEMBL5251	Homo sapiens	IC50		
	19118264	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4582434	=	IC50	nM	7.8	CHEMBL5251	Homo sapiens	IC50	nM	7.8
	19118265	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	CC(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4444564	=	IC50	nM	9.7	CHEMBL5251	Homo sapiens	IC50	nM	9.7
	19118266	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(C#CCOc3ccccc3)c3c(N)ncnc32)C1		CHEMBL4439998	=	IC50	nM	11.1	CHEMBL5251	Homo sapiens	IC50	nM	11.1
	19118267	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	Nc1ncnc2c1c(C#CCOc1ccccc1)nn2[C@@H]1CCCN(C(=O)/C=C/CBr)C1		CHEMBL4446870	=	IC50	nM	13.2	CHEMBL5251	Homo sapiens	IC50	nM	13.2
Not Determined	19118268	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	Nc1ncnc2c1c(C#CCOc1ccccc1)nn2[C@@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL4436728		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19118269	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	Nc1ncnc2c1c(C#CCOc1ccccc1)nn2[C@@H]1CCCN(C(=O)/C=C/Cn2cncn2)C1		CHEMBL4565960		IC50			CHEMBL5251	Homo sapiens	IC50		
	19118270	CHEMBL4372282	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	5.49	CHEMBL5251	Homo sapiens	IC50	nM	5.49
	19132954	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	IC50	nM	310.0	CHEMBL5251	Homo sapiens	IC50	nM	310.0
	19132955	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)Nc1cccc(Oc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4528630	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
	19132956	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)Nc1cccc(Oc2ncncc2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4550271	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	19132957	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)Nc1cccc(Oc2ccnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4461455	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19132958	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)Nc1cccc(Oc2ccncc2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4588680	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	19132959	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)Nc1cccc(-c2c(N)ncnc2Nc2ccc(Oc3ccccc3)cc2)c1		CHEMBL4436563	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	19132960	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)Nc1cccc(Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4554990	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	19132961	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N[C@@H]1CCC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4469908	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	19132962	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N[C@H]1CC[C@@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4475457	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
	19132963	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N[C@@H]1CC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4542934	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	19132964	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)NC12CCC(Nc3ncnc(N)c3-c3ccc(Oc4ccccc4)cc3)(C1)C2		CHEMBL4441219	=	IC50	nM	9.9	CHEMBL5251	Homo sapiens	IC50	nM	9.9
	19132965	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)NC1CCCN(c2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4558157	=	IC50	nM	1500.0	CHEMBL5251	Homo sapiens	IC50	nM	1500.0
	19132966	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4468148	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	19132967	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4469004	=	IC50	nM	5.5	CHEMBL5251	Homo sapiens	IC50	nM	5.5
	19132968	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CC2(CC(Nc3ncnc(N)c3-c3ccc(Oc4ccccc4)cc3)C2)C1		CHEMBL4515024	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
	19132969	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4586433	=	IC50	nM	1510.0	CHEMBL5251	Homo sapiens	IC50	nM	1510.0
	19132970	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	8.9	CHEMBL5251	Homo sapiens	IC50	nM	8.9
	19132971	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(O)(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4476695	=	IC50	nM	5.9	CHEMBL5251	Homo sapiens	IC50	nM	5.9
	19132972	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2C(F)(F)F)CC1		CHEMBL4547696	>	IC50	nM	100000.0	CHEMBL5251	Homo sapiens	IC50	nM	100000.0
	19132973	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2cc(F)c(Oc3ccccc3)cc2F)CC1		CHEMBL4453568	=	IC50	nM	160.0	CHEMBL5251	Homo sapiens	IC50	nM	160.0
	19132974	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccc(F)cc3)cc2)CC1		CHEMBL4539748	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	nM	150.0
	19132975	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccc(C)cc3)cc2)CC1		CHEMBL4537274	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	19132976	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3cccc(F)c3)cc2)CC1		CHEMBL4548457	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	19132977	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccncc3)cc2)CC1		CHEMBL4572535	=	IC50	nM	730.0	CHEMBL5251	Homo sapiens	IC50	nM	730.0
	19132978	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(C(=O)Nc3ccccc3)cc2)CC1		CHEMBL4472627	=	IC50	nM	1200.0	CHEMBL5251	Homo sapiens	IC50	nM	1200.0
	19132979	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4553343	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19132980	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CS(=O)(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4459438	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	19132981	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	Nc1ncnc(NCC2CCN(C(=O)CCl)CC2)c1-c1ccc(Oc2ccccc2)cc1		CHEMBL4532368	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	19132982	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C#CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4543998	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	19132983	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	Nc1ncnc(NCC2CCN(C(=O)C3=CCC3)CC2)c1-c1ccc(Oc2ccccc2)cc1		CHEMBL4587672	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
	19132984	CHEMBL4375192	Covalent inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate incubated for 90 mins by microfluidic off-Chip Mobility Shift Assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3ccccc32)C1		CHEMBL4466205	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	19133000	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)Nc1cccc(Oc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4528630	=	IC50	nM	9.9	CHEMBL5251	Homo sapiens	IC50	nM	9.9
	19133001	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)Nc1cccc(Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1		CHEMBL4554990	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	19133002	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)N[C@H]1CC[C@@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4475457	=	IC50	nM	660.0	CHEMBL5251	Homo sapiens	IC50	nM	660.0
	19133003	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)NC12CCC(Nc3ncnc(N)c3-c3ccc(Oc4ccccc4)cc3)(C1)C2		CHEMBL4441219	=	IC50	nM	70.0	CHEMBL5251	Homo sapiens	IC50	nM	70.0
	19133004	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CCC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4468148	=	IC50	nM	143.0	CHEMBL5251	Homo sapiens	IC50	nM	143.0
	19133005	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1		CHEMBL4469004	=	IC50	nM	217.0	CHEMBL5251	Homo sapiens	IC50	nM	217.0
	19133006	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CC2(CC(Nc3ncnc(N)c3-c3ccc(Oc4ccccc4)cc3)C2)C1		CHEMBL4515024	=	IC50	nM	66.0	CHEMBL5251	Homo sapiens	IC50	nM	66.0
	19133007	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	nM	61.0
	19133008	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CC(=O)N1CCC(O)(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4476695	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
Active	19133063	CHEMBL4375205	Covalent binding affinity to BTK (unknown origin) incubated for 90 mins by Reversed-phase LC-MS analysis	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	19133064	CHEMBL4375206	Covalent binding affinity to human BTK (382 to 659 residues) expressed in baculovirus infected BTI-TN-5B1-4 insect cells by isothermal calorimetry	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833		Activity			CHEMBL5251	Homo sapiens	Activity		
Active	19133065	CHEMBL4375207	Irreversible inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system assessed as reduction in enzyme recovery preincubated for 90 mins followed by FITC-AHA-EEEPLYWSFPAKKK-NH2 substrate addition and measured for 112 mins by jump-dilution experiment based assay	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19133066	CHEMBL4375208	Irreversible inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system assessed as Kinact to Ki ratio measured up to 150 mins	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	Ratio	1/Ms	63000.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	63000.0
	19133067	CHEMBL4375208	Irreversible inhibition of N-terminal GST-fused human BTK (2-659(end) amino acids) expressed in baculovirus expression system assessed as Kinact to Ki ratio measured up to 150 mins	B	C=CS(=O)(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4459438	=	Ratio	1/Ms	113000.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	113000.0
	19133077	CHEMBL4375216	Inhibition of BTK Cys481S mutant (unknown origin)	B	C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4072833	=	IC50	nM	8600.0	CHEMBL5251	Homo sapiens	IC50	uM	8.6
	19133078	CHEMBL4375216	Inhibition of BTK Cys481S mutant (unknown origin)	B	CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4553343	=	IC50	nM	8600.0	CHEMBL5251	Homo sapiens	IC50	uM	8.6
	19133100	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	C=CS(=O)(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1		CHEMBL4459438	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
	19133101	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	Nc1ncnc(NCC2CCN(C(=O)CCl)CC2)c1-c1ccc(Oc2ccccc2)cc1		CHEMBL4532368	=	IC50	nM	160.0	CHEMBL5251	Homo sapiens	IC50	nM	160.0
	19133102	CHEMBL4375195	Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry	B	Nc1ncnc(NCC2CCN(C(=O)C3=CCC3)CC2)c1-c1ccc(Oc2ccccc2)cc1		CHEMBL4587672	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
	19140807	CHEMBL4376571	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay relative to control	B	Cn1cc(-c2ccc(F)cc2)c(=O)c2c(Nc3ccc(Oc4ccnc(NC(=O)C5CC5)c4)c(F)c3)nccc21		CHEMBL4584949	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	19144628	CHEMBL4377644	Inhibition of full-length recombinant human BTK at 1 uM using KVEKIGEGTYGVVYK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	96.0	CHEMBL5251	Homo sapiens	INH	%	96.0
	19144629	CHEMBL4377645	Inhibition of full-length recombinant human BTK R28H mutant at 1 uM using LSNLYHQGKFLQTFCGSPLYRRR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	1.0	CHEMBL5251	Homo sapiens	INH	%	1.0
	19146832	CHEMBL4378960	Inhibition of full-length recombinant human BTK at 10 uM using KVEKIGEGTYGVVYK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	5.0	CHEMBL5251	Homo sapiens	INH	%	5.0
	19147756	CHEMBL4379152	Inhibition of recombinant full length human BTK using KVEKIGEGTYGVV substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	19147757	CHEMBL4379153	Inhibition of recombinant full length human BTK R28H mutant using KVEKIGEGTYGVV substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	19159307	CHEMBL4382411	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	19159727	CHEMBL4382831	Inhibition of recombinant full length His-tagged human BTK cytoplasmic domain expressed in baculovirus expression system by Z-LYTE assay	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	19159849	CHEMBL4382861	Inhibition of recombinant BTK (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA	B	C=CC(=O)N1CC[C@H](n2cc(-c3cc4cc(C)cc(OC)c4s3)c3c(N)ncnc32)C1		CHEMBL4475243	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	19168577	CHEMBL4384438	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM Z'-Lyte assay relative to control	B	CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CCl		CHEMBL4440618	=	Inhibition	%	53.0	CHEMBL5251	Homo sapiens	INH	%	53.0
	19168578	CHEMBL4384438	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM Z'-Lyte assay relative to control	B	C=CC(=O)Oc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC		CHEMBL4435699	=	Inhibition	%	87.0	CHEMBL5251	Homo sapiens	INH	%	87.0
	19168579	CHEMBL4384438	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM Z'-Lyte assay relative to control	B	CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1ncc[nH]1		CHEMBL4526992	=	Inhibition	%	54.0	CHEMBL5251	Homo sapiens	INH	%	54.0
	19172308	CHEMBL4385132	Inhibition of BTK (unknown origin)	B	CS(=O)(=O)Nc1cc(-c2ccncc2)cnc1Cl		CHEMBL4474208	<	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	pIC50		5.0
	19173491	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4436118	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	19173492	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
	19173493	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4572913	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
	19173494	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/C(F)F)C2)c1N		CHEMBL4559065	=	IC50	nM	115.0	CHEMBL5251	Homo sapiens	IC50	nM	115.0
	19173495	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CF)C2)c1N		CHEMBL4556666	=	IC50	nM	90.0	CHEMBL5251	Homo sapiens	IC50	nM	90.0
	19173496	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CO)C2)c1N		CHEMBL4440096	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
	19173497	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=C(F)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4591391	=	IC50	nM	170.0	CHEMBL5251	Homo sapiens	IC50	nM	170.0
	19173498	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4548556	=	IC50	nM	66.0	CHEMBL5251	Homo sapiens	IC50	nM	66.0
	19173499	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=C(C)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4518667	=	IC50	nM	176.0	CHEMBL5251	Homo sapiens	IC50	nM	176.0
	19173500	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4442732	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	19173501	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
	19173502	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	3.4	CHEMBL5251	Homo sapiens	IC50	nM	3.4
	19173503	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4520801	=	IC50	nM	0.18	CHEMBL5251	Homo sapiens	IC50	nM	0.18
	19173504	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	IC50	nM	7.6	CHEMBL5251	Homo sapiens	IC50	nM	7.6
	19173505	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	19173506	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	IC50	nM	6.2	CHEMBL5251	Homo sapiens	IC50	nM	6.2
	19173507	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4436118	=	IC50	nM	0.37	CHEMBL5251	Homo sapiens	IC50	nM	0.37
	19173508	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
	19173509	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4572913	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
	19173510	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/C(F)F)C2)c1N		CHEMBL4559065	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
	19173511	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CF)C2)c1N		CHEMBL4556666	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	19173512	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CO)C2)c1N		CHEMBL4440096	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	19173513	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=C(F)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4591391	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
	19173514	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4548556	=	IC50	nM	61.0	CHEMBL5251	Homo sapiens	IC50	nM	61.0
	19173515	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=C(C)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4518667	=	IC50	nM	247.0	CHEMBL5251	Homo sapiens	IC50	nM	247.0
	19173516	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4442732	=	IC50	nM	0.25	CHEMBL5251	Homo sapiens	IC50	nM	0.25
	19173517	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	19173518	CHEMBL4385484	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	19173532	CHEMBL4385492	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human B cells assessed as reduction in cell proliferation pretreated for 30 mins followed by goat anti-human IgM F(ab')2-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	19173533	CHEMBL4385492	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human B cells assessed as reduction in cell proliferation pretreated for 30 mins followed by goat anti-human IgM F(ab')2-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	IC50	nM	14.9	CHEMBL5251	Homo sapiens	IC50	nM	14.9
	19173534	CHEMBL4385492	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human B cells assessed as reduction in cell proliferation pretreated for 30 mins followed by goat anti-human IgM F(ab')2-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	IC50	nM	19.1	CHEMBL5251	Homo sapiens	IC50	nM	19.1
	19173535	CHEMBL4385493	Inhibition of BTK in anti-CD3/CD28-stimulated human CD4-positive T cells assessed as reduction in cell proliferation pretreated for 30 mins followed by anti-CD3/CD28-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19173536	CHEMBL4385493	Inhibition of BTK in anti-CD3/CD28-stimulated human CD4-positive T cells assessed as reduction in cell proliferation pretreated for 30 mins followed by anti-CD3/CD28-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	8150.0	CHEMBL5251	Homo sapiens	IC50	nM	8150.0
	19173537	CHEMBL4385493	Inhibition of BTK in anti-CD3/CD28-stimulated human CD4-positive T cells assessed as reduction in cell proliferation pretreated for 30 mins followed by anti-CD3/CD28-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19173538	CHEMBL4385493	Inhibition of BTK in anti-CD3/CD28-stimulated human CD4-positive T cells assessed as reduction in cell proliferation pretreated for 30 mins followed by anti-CD3/CD28-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	IC50	nM	10100.0	CHEMBL5251	Homo sapiens	IC50	nM	10100.0
	19173539	CHEMBL4385493	Inhibition of BTK in anti-CD3/CD28-stimulated human CD4-positive T cells assessed as reduction in cell proliferation pretreated for 30 mins followed by anti-CD3/CD28-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	19173540	CHEMBL4385494	Inhibition of BTK in human whole blood assessed as reduction in anti-human IgE antibody-stimulated histamine release pretreated for 2 hrs followed by anti-human IgE antibody-stimulation and measured after 30 mins by ELISA	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	IC50	nM	64.0	CHEMBL5251	Homo sapiens	IC50	nM	64.0
	19173541	CHEMBL4385494	Inhibition of BTK in human whole blood assessed as reduction in anti-human IgE antibody-stimulated histamine release pretreated for 2 hrs followed by anti-human IgE antibody-stimulation and measured after 30 mins by ELISA	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	19173542	CHEMBL4385494	Inhibition of BTK in human whole blood assessed as reduction in anti-human IgE antibody-stimulated histamine release pretreated for 2 hrs followed by anti-human IgE antibody-stimulation and measured after 30 mins by ELISA	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	IC50	nM	95.0	CHEMBL5251	Homo sapiens	IC50	nM	95.0
	19173543	CHEMBL4385494	Inhibition of BTK in human whole blood assessed as reduction in anti-human IgE antibody-stimulated histamine release pretreated for 2 hrs followed by anti-human IgE antibody-stimulation and measured after 30 mins by ELISA	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	IC50	nM	42.0	CHEMBL5251	Homo sapiens	IC50	nM	42.0
	19173544	CHEMBL4385494	Inhibition of BTK in human whole blood assessed as reduction in anti-human IgE antibody-stimulated histamine release pretreated for 2 hrs followed by anti-human IgE antibody-stimulation and measured after 30 mins by ELISA	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	nM	50.0
	19173545	CHEMBL4385495	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 1 hr followed by goat anti-human IgM F(ab')2-stimualtion and measured after 3 hrs by Fix/Lyse reagent based flow cytometry	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	IC50	nM	53.0	CHEMBL5251	Homo sapiens	IC50	nM	53.0
	19173546	CHEMBL4385495	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 1 hr followed by goat anti-human IgM F(ab')2-stimualtion and measured after 3 hrs by Fix/Lyse reagent based flow cytometry	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	46.0	CHEMBL5251	Homo sapiens	IC50	nM	46.0
	19173547	CHEMBL4385495	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 1 hr followed by goat anti-human IgM F(ab')2-stimualtion and measured after 3 hrs by Fix/Lyse reagent based flow cytometry	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
	19173548	CHEMBL4385495	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 1 hr followed by goat anti-human IgM F(ab')2-stimualtion and measured after 3 hrs by Fix/Lyse reagent based flow cytometry	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
	19173549	CHEMBL4385495	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human whole blood assessed as suppression of CD69 expression on B cells pretreated for 1 hr followed by goat anti-human IgM F(ab')2-stimualtion and measured after 3 hrs by Fix/Lyse reagent based flow cytometry	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	IC50	nM	89.0	CHEMBL5251	Homo sapiens	IC50	nM	89.0
	19173552	CHEMBL4385492	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human B cells assessed as reduction in cell proliferation pretreated for 30 mins followed by goat anti-human IgM F(ab')2-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	19173553	CHEMBL4385492	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human B cells assessed as reduction in cell proliferation pretreated for 30 mins followed by goat anti-human IgM F(ab')2-stimulation and measured after 3 days by [3H]-thymidine incorporation assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	19173554	CHEMBL4385491	Binding affinity to BTK (unknown origin) assessed as isothiourea adduct formation at 100 uM measured after 10 hrs by 13C-NMR spectrometric method (Rvb = 119.3 ppm)	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	Activity	ppm	167.2	CHEMBL5251	Homo sapiens	Activity	ppm	167.2
Not Determined	19173555	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	C=C(C)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4518667		t1/2			CHEMBL5251	Homo sapiens	t1/2		
	19173556	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4548556	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173557	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	C=C(F)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4591391	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173558	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CO)C2)c1N		CHEMBL4440096	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173559	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CF)C2)c1N		CHEMBL4556666	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173560	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/C(F)F)C2)c1N		CHEMBL4559065	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173561	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4572913	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173562	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	T1/2	hr	6.0	CHEMBL5251	Homo sapiens	t1/2	hr	6.0
	19173563	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4436118	=	T1/2	hr	7.0	CHEMBL5251	Homo sapiens	t1/2	hr	7.0
	19173564	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	T1/2	hr	7.0	CHEMBL5251	Homo sapiens	t1/2	hr	7.0
	19173565	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	T1/2	hr	3.0	CHEMBL5251	Homo sapiens	t1/2	hr	3.0
	19173566	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	T1/2	hr	5.0	CHEMBL5251	Homo sapiens	t1/2	hr	5.0
Active	19173577	CHEMBL4385490	Binding affinity to BTK (unknown origin) assessed as adduct formation at 35 uM measured after 20 mins by LC-MS analysis	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385		Activity			CHEMBL5251	Homo sapiens	Activity		
	19173578	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4442732	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173579	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	T1/2	hr	6.0	CHEMBL5251	Homo sapiens	t1/2	hr	6.0
	19173580	CHEMBL4385488	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	T1/2	hr	24.0	CHEMBL5251	Homo sapiens	t1/2	hr	24.0
	19173596	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	Ratio	1/Ms	60970.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	60970.0
	19173597	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	Ratio	1/Ms	55870.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	55870.0
	19173598	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	Ratio	1/Ms	24370.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	24370.0
	19173599	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4436118	=	Ratio	1/Ms	135400.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	135400.0
	19173600	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456283	=	Ratio	1/Ms	118300.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	118300.0
	19173601	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4572913	=	Ratio	1/Ms	19180.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	19180.0
	19173602	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/C(F)F)C2)c1N		CHEMBL4559065	=	Ratio	1/Ms	80500.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	80500.0
	19173603	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CF)C2)c1N		CHEMBL4556666	=	Ratio	1/Ms	85770.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	85770.0
	19173604	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CO)C2)c1N		CHEMBL4440096	=	Ratio	1/Ms	26650.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	26650.0
	19173605	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	C=C(F)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4591391	=	Ratio	1/Ms	35300.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	35300.0
	19173606	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4548556	=	Ratio	1/Ms	4910.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	4910.0
	19173607	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	C=C(C)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4518667	<	Ratio	1/Ms	1.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	1.0
	19173608	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4442732	=	Ratio	1/Ms	206500.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	206500.0
	19173609	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	Ratio	1/Ms	123900.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	123900.0
	19173610	CHEMBL4385486	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Ratio	1/Ms	226000.0	CHEMBL5251	Homo sapiens	Ratio	1/Ms	226000.0
	19173635	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1		CHEMBL4469663	=	IC50	nM	92.0	CHEMBL5251	Homo sapiens	IC50	nM	92.0
	19173636	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(C(F)(F)F)n4)cc3)c(C(N)=O)c2N)C1		CHEMBL4456974	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	19173637	CHEMBL4385483	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ncc(Cl)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4462332	=	IC50	nM	230.0	CHEMBL5251	Homo sapiens	IC50	nM	230.0
	19180967	CHEMBL4387177	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 0.1 uM using tyrosine-1 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	19181193	CHEMBL4387177	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 0.1 uM using tyrosine-1 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	4.0	CHEMBL5251	Homo sapiens	INH	%	4.0
	19187549	CHEMBL4388556	Inhibition of probe binding to BTK (unknown origin) using rabbit reticulate lysate system at 250 nM after 1 hr by luminescence assay relative to control	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CC1CCSS1		CHEMBL4457447	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19191270	CHEMBL4389556	Inhibition of BTK in human PBMC assessed as reduction in CD69 expression	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	IC50	nM	240.0	CHEMBL5251	Homo sapiens	IC50	uM	0.24
	19191700	CHEMBL4389130	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	0.6	CHEMBL5251	Homo sapiens	INH	%	0.6
	19191752	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	uM	0.001
	19191753	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	uM	0.009
	19191754	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCCC1		CHEMBL4445919	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	uM	0.55
	19191755	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4448363	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	uM	0.02
	19191756	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1C1CCCC1		CHEMBL4473261	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	uM	0.1
	19191757	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1C1CC1		CHEMBL4551429	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	uM	0.2
	19191758	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	CC(C)(C#N)c1ccccc1NC(=O)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4454413	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	19191759	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	CC(C)(C)c1ccccc1NC(=O)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4435444	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	uM	0.14
	19191760	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1C(F)(F)F		CHEMBL4578569	=	IC50	nM	460.0	CHEMBL5251	Homo sapiens	IC50	uM	0.46
	19191761	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccc(Cl)cc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4448630	=	IC50	nM	2300.0	CHEMBL5251	Homo sapiens	IC50	uM	2.3
	19191762	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(Cl)c1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4445344	=	IC50	nM	1800.0	CHEMBL5251	Homo sapiens	IC50	uM	1.8
	19191763	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1Cl		CHEMBL4461065	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	uM	0.12
	19191764	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccc(F)cc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4558071	=	IC50	nM	1300.0	CHEMBL5251	Homo sapiens	IC50	uM	1.3
	19191765	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(F)c1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4517013	=	IC50	nM	1200.0	CHEMBL5251	Homo sapiens	IC50	uM	1.2
	19191766	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1F		CHEMBL4542554	=	IC50	nM	500.0	CHEMBL5251	Homo sapiens	IC50	uM	0.5
	19191767	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccncc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4581153	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	19191768	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccnc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4468002	=	IC50	nM	3200.0	CHEMBL5251	Homo sapiens	IC50	uM	3.2
	19191769	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccn1		CHEMBL4460419	=	IC50	nM	2700.0	CHEMBL5251	Homo sapiens	IC50	uM	2.7
	19191770	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	N#C/N=C(\Nc1ccccc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4461799	=	IC50	nM	68000.0	CHEMBL5251	Homo sapiens	IC50	uM	68.0
	19191771	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=c1c(Nc2ccccc2)c(Nc2cccc(C3CCCN(c4ncnc5[nH]ccc45)C3)c2)c1=O		CHEMBL4583265	=	IC50	nM	44000.0	CHEMBL5251	Homo sapiens	IC50	uM	44.0
	19191772	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	c1cc(Nc2nc3ccccc3[nH]2)cc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4546811	=	IC50	nM	4100.0	CHEMBL5251	Homo sapiens	IC50	uM	4.1
	19191773	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Cc1ccccc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4558216	=	IC50	nM	45000.0	CHEMBL5251	Homo sapiens	IC50	uM	45.0
	19191774	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=S(=O)(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)c1ccccc1		CHEMBL4589916	=	IC50	nM	19000.0	CHEMBL5251	Homo sapiens	IC50	uM	19.0
	19191775	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1)c1ccccc1		CHEMBL4448573	=	IC50	nM	4900.0	CHEMBL5251	Homo sapiens	IC50	uM	4.9
	19191776	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccccc1)Nc1cccc([C@@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4552458	=	IC50	nM	400.0	CHEMBL5251	Homo sapiens	IC50	uM	0.4
	19191777	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccccc1)Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4465904	>	IC50	nM	20000.0	CHEMBL5251	Homo sapiens	IC50	uM	20.0
	19191778	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccccc1)Nc1cccc(C2CCCN(c3ncnc4[nH]ccc34)C2)c1		CHEMBL4577152	=	IC50	nM	800.0	CHEMBL5251	Homo sapiens	IC50	uM	0.8
	19191779	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(NCCCC1CCCN(c2ncnc3[nH]ccc23)C1)Nc1ccccc1		CHEMBL4461313	=	IC50	nM	2000.0	CHEMBL5251	Homo sapiens	IC50	uM	2.0
	19191780	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(Nc1ccccc1)Nc1cccc(CCNc2ncnc3[nH]ccc23)c1		CHEMBL4444491	=	IC50	nM	8300.0	CHEMBL5251	Homo sapiens	IC50	uM	8.3
	19191781	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(NCCc1cccc(Nc2ncnc3[nH]ccc23)c1)Nc1ccccc1		CHEMBL4581632	=	IC50	nM	12000.0	CHEMBL5251	Homo sapiens	IC50	uM	12.0
	19191782	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(NCCC#CCCNc1ncnc2[nH]ccc12)Nc1ccccc1		CHEMBL4517563	=	IC50	nM	19000.0	CHEMBL5251	Homo sapiens	IC50	uM	19.0
	19191783	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(NCCCCCNc1ncnc2[nH]ccc12)Nc1ccccc1		CHEMBL4576203	=	IC50	nM	16000.0	CHEMBL5251	Homo sapiens	IC50	uM	16.0
	19191784	CHEMBL4389078	Reversible inhibition of recombinant full-length N-terminal 6-His-tagged human BTK expressed in baculovirus infected Sf21 insect cells using fluorescent-labeled polyGAT peptide as substrate incubated for 30 mins by TR-FRET assay	B	O=C(NCCCCCCNc1ncnc2[nH]ccc12)Nc1ccccc1		CHEMBL4474166	=	IC50	nM	11000.0	CHEMBL5251	Homo sapiens	IC50	uM	11.0
	19191793	CHEMBL4389607	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	0.3	CHEMBL5251	Homo sapiens	INH	%	0.3
	19193826	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccccc4)nc32)c1		CHEMBL4128726	=	IC50	nM	6.2	CHEMBL5251	Homo sapiens	IC50	nM	6.2
	19193827	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccccc4OC)nc32)c1		CHEMBL4455486	=	IC50	nM	996.0	CHEMBL5251	Homo sapiens	IC50	nM	996.0
	19193828	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCOCC5)cc4OC)nc32)c1		CHEMBL4126654	=	IC50	nM	852.0	CHEMBL5251	Homo sapiens	IC50	nM	852.0
	19193829	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCSCC5)cc4OC)nc32)c1		CHEMBL4125772	=	IC50	nM	806.0	CHEMBL5251	Homo sapiens	IC50	nM	806.0
	19193830	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4OC)nc32)c1		CHEMBL4126797	=	IC50	nM	718.0	CHEMBL5251	Homo sapiens	IC50	nM	718.0
	19193831	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4129387	=	IC50	nM	364.0	CHEMBL5251	Homo sapiens	IC50	nM	364.0
	19193832	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CC)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4126358	=	IC50	nM	396.0	CHEMBL5251	Homo sapiens	IC50	nM	396.0
	19193833	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CCC)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4129646	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	19193834	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4129781	=	IC50	nM	359.0	CHEMBL5251	Homo sapiens	IC50	nM	359.0
	19193835	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(Cc3ccccc3)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4128415	=	IC50	nM	248.0	CHEMBL5251	Homo sapiens	IC50	nM	248.0
	19193836	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CCc3ccccc3)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4128567	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	19193837	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(CCCc3ccccc3)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1		CHEMBL4130016	=	IC50	nM	76.0	CHEMBL5251	Homo sapiens	IC50	nM	76.0
	19193838	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL4127317	=	IC50	nM	518.0	CHEMBL5251	Homo sapiens	IC50	nM	518.0
	19193839	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N(C)CCN(C)C)cc4OC)nc32)c1		CHEMBL4129902	=	IC50	nM	982.0	CHEMBL5251	Homo sapiens	IC50	nM	982.0
	19193840	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1		CHEMBL4126986	=	IC50	nM	349.0	CHEMBL5251	Homo sapiens	IC50	nM	349.0
	19193841	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCC(N6CCN(C)CC6)CC5)cc4OC)nc32)c1		CHEMBL4129607	=	IC50	nM	145.0	CHEMBL5251	Homo sapiens	IC50	nM	145.0
	19193842	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1		CHEMBL4125940	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	19193843	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1		CHEMBL4126630	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	19193844	CHEMBL4390265	Inhibition of BTK (unknown origin) by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
Dose-dependent effect	19193850	CHEMBL4390268	Inhibition of BTK phosphorylation at Tyr223 residue in human TMD8 cells at 0.1 to 1000 nM by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1		CHEMBL4125940		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	19193851	CHEMBL4390268	Inhibition of BTK phosphorylation at Tyr223 residue in human TMD8 cells at 0.1 to 1000 nM by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1		CHEMBL4126630		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19199989	CHEMBL4391233	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	19236734	CHEMBL4398807	Inhibition of BTK (unknown origin) at 100 nM relative to control	B	COc1cc2c(Nc3ccc(NC(=O)C(c4cc(F)ccc4F)N4Cc5ccccc5C4=O)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL4443483	=	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	19266325	CHEMBL4405275	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	19274868	CHEMBL4407571	Inhibition of full-length recombinant human His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 uM using FRET-labeled tyr 01 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Br)cccc3Br)c(N)nc2n1		CHEMBL57531	=	Inhibition	%	92.0	CHEMBL5251	Homo sapiens	INH	%	92.0
	19274869	CHEMBL4407571	Inhibition of full-length recombinant human His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 uM using FRET-labeled tyr 01 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Cl)cccc3-c3cccnc3)c(N3C[C@H]4[C@H](N)[C@H]4C3)nc2n1		CHEMBL4453148	=	Inhibition	%	16.0	CHEMBL5251	Homo sapiens	INH	%	16.0
	19274870	CHEMBL4407571	Inhibition of full-length recombinant human His-tagged BTK cytoplasmic domain expressed in baculovirus expression system at 25 uM using FRET-labeled tyr 01 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	CC(C)COc1cccc(Cl)c1-c1cc2cnc(N)nc2nc1N1C[C@H]2[C@H](N)[C@H]2C1		CHEMBL4546703	=	Inhibition	%	32.0	CHEMBL5251	Homo sapiens	INH	%	32.0
	19275943	CHEMBL4407946	Inhibition of recombinant full length human BTK at 1 uM using LSNLYHQGKFLQT as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19275944	CHEMBL4407947	Inhibition of recombinant full length human BTK R28H mutant at 1 uM using LSNLYHQGKFLQT as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294845	CHEMBL4412216	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2cc(OC)c(OC)cc2Cl)nc2cc(Cl)ccc12		CHEMBL579353	=	IC50	nM	5150.0	CHEMBL5251	Homo sapiens	IC50	uM	5.15
	19294916	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CC(=O)Oc1ccccc1/C=C/c1nc2ccccc2c(=O)[nH]1		CHEMBL4442304	=	Inhibition	%	51.0	CHEMBL5251	Homo sapiens	INH	%	51.0
	19294917	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CC(=O)Oc1cccc(/C=C/c2nc3ccccc3c(=O)[nH]2)c1		CHEMBL4453032	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294918	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CC(=O)Oc1ccc(/C=C/c2nc3ccccc3c(=O)[nH]2)c(OC(C)=O)c1		CHEMBL4517514	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294919	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccccc1/C=C/c1nc2ccccc2c(=O)[nH]1		CHEMBL1090672	=	Inhibition	%	52.0	CHEMBL5251	Homo sapiens	INH	%	52.0
	19294920	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1cccc(/C=C/c2nc3ccccc3c(=O)[nH]2)c1		CHEMBL1092204	=	Inhibition	%	7.0	CHEMBL5251	Homo sapiens	INH	%	7.0
	19294921	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccc(/C=C/c2nc3ccccc3c(=O)[nH]2)cc1		CHEMBL1092207	=	Inhibition	%	69.0	CHEMBL5251	Homo sapiens	INH	%	69.0
	19294922	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CCOc1ccccc1/C=C/c1nc2ccccc2c(=O)[nH]1		CHEMBL4459848	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294923	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CCOc1ccc(/C=C/c2nc3ccccc3c(=O)[nH]2)cc1		CHEMBL4583163	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294924	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CCCCOc1ccc(/C=C/c2nc3ccccc3c(=O)[nH]2)cc1		CHEMBL4559299	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294925	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=c1[nH]c(/C=C/c2cccc3c2OCO3)nc2ccccc12		CHEMBL4468697	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294926	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=c1[nH]c(/C=C/c2ccc3c(c2)OCO3)nc2ccccc12		CHEMBL4470620	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294927	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=c1[nH]c(/C=C/c2c(Br)ccc3c2OCO3)nc2ccccc12		CHEMBL4518551	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294928	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=c1[nH]c(/C=C/c2cc3c(cc2Br)OCO3)nc2ccccc12		CHEMBL4576121	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294929	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=c1[nH]c(/C=C/c2cccc([N+](=O)[O-])c2)nc2ccccc12		CHEMBL4445408	=	Inhibition	%	45.0	CHEMBL5251	Homo sapiens	INH	%	45.0
	19294930	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=c1[nH]c(/C=C/c2ccc([N+](=O)[O-])cc2)nc2ccccc12		CHEMBL4539405	=	Inhibition	%	54.0	CHEMBL5251	Homo sapiens	INH	%	54.0
	19294931	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CC(=O)Oc1ccccc1/C=C/c1nc(Nc2ccccc2I)c2ccccc2n1		CHEMBL4455338	=	Inhibition	%	43.0	CHEMBL5251	Homo sapiens	INH	%	43.0
	19294932	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccc(OC)c(Nc2nc(/C=C/c3ccccc3OC(C)=O)nc3ccccc23)c1		CHEMBL4458986	=	Inhibition	%	76.0	CHEMBL5251	Homo sapiens	INH	%	76.0
	19294933	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccccc1/C=C/c1nc(Nc2ccccc2Cl)c2ccccc2n1		CHEMBL4550950	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294934	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccccc1/C=C/c1nc(Nc2ccc(O)cc2)c2ccccc2n1		CHEMBL4472770	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294935	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccccc1/C=C/c1nc(Nc2cccc(O)c2)c2ccccc2n1		CHEMBL4459984	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294936	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccccc1/C=C/c1nc(Nc2ccc3c(c2)OCO3)c2ccccc2n1		CHEMBL4476482	=	Inhibition	%	87.0	CHEMBL5251	Homo sapiens	INH	%	87.0
	19294937	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccccc1/C=C/c1nc(NCc2ccc3c(c2)OCO3)c2ccccc2n1		CHEMBL4470772	=	Inhibition	%	18.0	CHEMBL5251	Homo sapiens	INH	%	18.0
	19294938	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccc(/C=C/c2nc(Nc3cccc(O)c3)c3ccccc3n2)cc1		CHEMBL4571210	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294939	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	Oc1cccc(Nc2nc(/C=C/c3cc4c(cc3Br)OCO4)nc3ccccc23)c1		CHEMBL4436086	=	Inhibition	%	74.0	CHEMBL5251	Homo sapiens	INH	%	74.0
	19294940	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	O=[N+]([O-])c1cccc(/C=C/c2nc(Nc3cccc(O)c3)c3ccccc3n2)c1		CHEMBL4437669	=	Inhibition	%	38.0	CHEMBL5251	Homo sapiens	INH	%	38.0
	19294941	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	Oc1ccc(Nc2nc(/C=C/c3cccc(Cl)c3)nc3ccccc23)cc1		CHEMBL4553117	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294942	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	Oc1cccc(Nc2nc(/C=C/c3cccc(Cl)c3)nc3ccccc23)c1		CHEMBL4535076	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294943	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccc(/C=C/c2nc(NCCCN(C)C)c3ccccc3n2)cc1		CHEMBL186928	=	Inhibition	%	37.0	CHEMBL5251	Homo sapiens	INH	%	37.0
	19294944	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294945	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Inhibition	%	97.0	CHEMBL5251	Homo sapiens	INH	%	97.0
	19294946	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19294947	CHEMBL4412225	Inhibition of BTK (unknown origin) at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay relative to control	B	COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1		CHEMBL426161	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19295118	CHEMBL4412233	Inhibition of BTK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay	B	COc1ccccc1/C=C/c1nc2ccccc2c(=O)[nH]1		CHEMBL1090672	=	IC50	nM	456.0	CHEMBL5251	Homo sapiens	IC50	nM	456.0
	19295119	CHEMBL4412233	Inhibition of BTK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay	B	COc1ccccc1/C=C/c1nc(Nc2ccc3c(c2)OCO3)c2ccccc2n1		CHEMBL4476482	=	IC50	nM	237.0	CHEMBL5251	Homo sapiens	IC50	nM	237.0
	19295120	CHEMBL4412233	Inhibition of BTK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay	B	Oc1cccc(Nc2nc(/C=C/c3cc4c(cc3Br)OCO4)nc3ccccc23)c1		CHEMBL4436086	=	IC50	nM	287.0	CHEMBL5251	Homo sapiens	IC50	nM	287.0
	19295121	CHEMBL4412233	Inhibition of BTK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay	B	O=[N+]([O-])c1cccc(/C=C/c2nc(Nc3cccc(O)c3)c3ccccc3n2)c1		CHEMBL4437669	=	IC50	nM	880.0	CHEMBL5251	Homo sapiens	IC50	nM	880.0
	19295122	CHEMBL4412233	Inhibition of BTK (unknown origin) preincubated for 10 mins followed by substrate addition and measured after 1 hr by ADP-Glo luminescence assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	19295858	CHEMBL4412335	Inhibition of BTK (unknown origin) at 1000 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	80.9	CHEMBL5251	Homo sapiens	INH	%	80.9
	19295888	CHEMBL4412365	Inhibition of BTK (unknown origin) at 100 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	47.1	CHEMBL5251	Homo sapiens	INH	%	47.1
	19295918	CHEMBL4412395	Inhibition of BTK (unknown origin) at 10 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	32.0	CHEMBL5251	Homo sapiens	INH	%	32.0
	19296344	CHEMBL4412520	Inhibition of BTK (unknown origin) at 1 uM by LanthaScreen Eu kinase binding assay relative to control	B	Cc1cc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)ccc1-c1cnc(NC2CC2)c2nccn12		CHEMBL4586372	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	19305817	CHEMBL4414892	Inhibition of recombinant BTK (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4447328	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
	19305818	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1ccc(N)cc12		CHEMBL3977187	=	IC50	nM	322.2	CHEMBL5251	Homo sapiens	IC50	nM	322.2
	19305819	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2c1		CHEMBL3948065	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
Not Determined	19305820	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccc2c(c1)[nH]c1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn12		CHEMBL3935234		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305821	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3968222	<	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	19305822	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	CN(C)C/C=C/C(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3973566	=	IC50	nM	6.4	CHEMBL5251	Homo sapiens	IC50	nM	6.4
	19305823	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCc2c([nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)C1		CHEMBL3962133	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	19305824	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2CC1		CHEMBL3913116	=	IC50	nM	8.2	CHEMBL5251	Homo sapiens	IC50	nM	8.2
	19305825	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3922120	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	19305826	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1cccc(-c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3924160	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
Not Determined	19305827	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1cccc(-c2cn3nc(-c4ccc(Oc5ccccc5)cc4)c(C(N)=O)c3[nH]2)c1		CHEMBL3906908		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19305828	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC(c2cn3nc(-c4ccc(Oc5ccccc5)cc4)c(C(N)=O)c3[nH]2)C1		CHEMBL3926815		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305829	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC(c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)CC1		CHEMBL3925102	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
Not Determined	19305830	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1cccc(-c2ccnc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3921373		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19305831	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305832	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	19305833	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167	=	IC50	nM	8.7	CHEMBL5251	Homo sapiens	IC50	nM	8.7
	19305834	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)cc1		CHEMBL3979176	=	IC50	nM	43.4	CHEMBL5251	Homo sapiens	IC50	nM	43.4
Not Determined	19305835	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305836	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
Not Determined	19305837	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305838	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N(C)c1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3897911	=	IC50	nM	232.6	CHEMBL5251	Homo sapiens	IC50	nM	232.6
	19305839	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC4CCCC4)cc3)nn21		CHEMBL3904488	=	IC50	nM	26.3	CHEMBL5251	Homo sapiens	IC50	nM	26.3
Not Determined	19305840	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305841	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
Not Determined	19305842	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305843	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCCOC)cc3)nn21		CHEMBL3890068	=	IC50	nM	16.7	CHEMBL5251	Homo sapiens	IC50	nM	16.7
Not Determined	19305844	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305845	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
Not Determined	19305846	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19305847	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC(F)(F)F)cc3)nn21		CHEMBL3906546		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305848	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C)cc3)nn21		CHEMBL3965262	=	IC50	nM	3.9	CHEMBL5251	Homo sapiens	IC50	nM	3.9
Not Determined	19305849	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C(F)(F)F)cc3)nn21		CHEMBL3954175		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19305850	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305851	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
Not Determined	19305852	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305853	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)cc3)nn21		CHEMBL3908905	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
Not Determined	19305854	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3973435		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305855	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
Not Determined	19305856	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC([C@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL4107402		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	19305857	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305858	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	19305859	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
Not Determined	19305860	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305861	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729	=	IC50	nM	5.3	CHEMBL5251	Homo sapiens	IC50	nM	5.3
	19305862	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729	=	IC50	nM	63.3	CHEMBL5251	Homo sapiens	IC50	nM	63.3
	19305863	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)NC1(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3944698	=	IC50	nM	18.9	CHEMBL5251	Homo sapiens	IC50	nM	18.9
Not Determined	19305864	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)NC(C)(C)C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3916800		IC50			CHEMBL5251	Homo sapiens	IC50		
	19305865	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	19305866	CHEMBL4414893	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1		CHEMBL4447328	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	19305867	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1ccc(N)cc12		CHEMBL3977187	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	19305868	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2c1		CHEMBL3948065	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
	19305869	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccc2c(c1)[nH]c1c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn12		CHEMBL3935234	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	19305870	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3968222	=	IC50	nM	0.14	CHEMBL5251	Homo sapiens	IC50	nM	0.14
	19305871	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	CN(C)C/C=C/C(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3973566	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
	19305872	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCc2c([nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)C1		CHEMBL3962133	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
	19305873	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2CC1		CHEMBL3913116	=	IC50	nM	0.36	CHEMBL5251	Homo sapiens	IC50	nM	0.36
	19305874	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCCc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2C1		CHEMBL3922120	=	IC50	nM	0.15	CHEMBL5251	Homo sapiens	IC50	nM	0.15
	19305875	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1cccc(-c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3924160	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	19305876	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1cccc(-c2cn3nc(-c4ccc(Oc5ccccc5)cc4)c(C(N)=O)c3[nH]2)c1		CHEMBL3906908	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	nM	150.0
	19305877	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC(c2cn3nc(-c4ccc(Oc5ccccc5)cc4)c(C(N)=O)c3[nH]2)C1		CHEMBL3926815	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
	19305878	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC(c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)CC1		CHEMBL3925102	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
	19305879	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1cccc(-c2ccnc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3921373	=	IC50	nM	860.0	CHEMBL5251	Homo sapiens	IC50	nM	860.0
	19305880	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	19305881	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	19305882	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1		CHEMBL3921167	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	19305883	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)cc1		CHEMBL3979176	=	IC50	nM	9.5	CHEMBL5251	Homo sapiens	IC50	nM	9.5
	19305884	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732	=	IC50	nM	0.62	CHEMBL5251	Homo sapiens	IC50	nM	0.62
	19305885	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732	=	IC50	nM	0.38	CHEMBL5251	Homo sapiens	IC50	nM	0.38
	19305886	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3917732	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	nM	130.0
	19305887	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N(C)c1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3897911	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
	19305888	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC4CCCC4)cc3)nn21		CHEMBL3904488	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	19305889	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	19305890	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	19305891	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21		CHEMBL3917026	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	19305892	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCCOC)cc3)nn21		CHEMBL3890068	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	19305893	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	19305894	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	19305895	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21		CHEMBL3926191	=	IC50	nM	130.0	CHEMBL5251	Homo sapiens	IC50	nM	130.0
	19305896	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC(F)(F)F)cc3)nn21		CHEMBL3906546	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
	19305897	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C)cc3)nn21		CHEMBL3965262	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	19305898	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C(F)(F)F)cc3)nn21		CHEMBL3954175	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
	19305899	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697	=	IC50	nM	0.78	CHEMBL5251	Homo sapiens	IC50	nM	0.78
	19305900	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697	=	IC50	nM	0.64	CHEMBL5251	Homo sapiens	IC50	nM	0.64
	19305901	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21		CHEMBL3910697	=	IC50	nM	1500.0	CHEMBL5251	Homo sapiens	IC50	nM	1500.0
	19305902	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)cc3)nn21		CHEMBL3908905	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	19305903	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3973435	=	IC50	nM	0.63	CHEMBL5251	Homo sapiens	IC50	nM	0.63
	19305904	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	19305905	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC([C@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL4107402	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	19305906	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	0.53	CHEMBL5251	Homo sapiens	IC50	nM	0.53
	19305907	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
	19305908	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1		CHEMBL3965549	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	19305909	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	19305910	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729	=	IC50	nM	0.24	CHEMBL5251	Homo sapiens	IC50	nM	0.24
	19305911	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3977729	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	19305912	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)NC1(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3944698	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	19305913	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	C=CC(=O)NC(C)(C)C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3916800	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
	19305914	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1NCCC2c1ccccc1N		CHEMBL3949083	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	nM	200.0
	19305915	CHEMBL4414894	Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	B	CNc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21		CHEMBL3969103	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
Active	19305976	CHEMBL4414898	Irreversible inhibition of human BTK assessed as covalent bond formation at 10 folds of IC50 preincubated for 1 hr followed by 100 fold compound dilution by TR-FRET assay	B	C=CC(=O)Nc1cccc(-c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3924160		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19305977	CHEMBL4414898	Irreversible inhibition of human BTK assessed as covalent bond formation at 10 folds of IC50 preincubated for 1 hr followed by 100 fold compound dilution by TR-FRET assay	B	C=CC(=O)N1CCC(c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)CC1		CHEMBL3925102		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	19305978	CHEMBL4414898	Irreversible inhibition of human BTK assessed as covalent bond formation at 10 folds of IC50 preincubated for 1 hr followed by 100 fold compound dilution by TR-FRET assay	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19305979	CHEMBL4414899	Inhibition of BTK C481S mutant (unknown origin)	B	C=CC(=O)Nc1cccc(-c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1		CHEMBL3924160		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	19305980	CHEMBL4414899	Inhibition of BTK C481S mutant (unknown origin)	B	C=CC(=O)N1CCC(c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)CC1		CHEMBL3925102		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19306050	CHEMBL4414913	Inhibition of human BTK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761	=	IC50	nM	0.92	CHEMBL5251	Homo sapiens	IC50	nM	0.92
	19306051	CHEMBL4414913	Inhibition of human BTK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.46	CHEMBL5251	Homo sapiens	IC50	nM	0.46
Active	19306112	CHEMBL4414943	Irreversible inhibition of human BTK assessed as covalent bond formation preincubated for 5 to 60 mins by protein precipitation based LC-MS/MS or HPLC analysis	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19310340	CHEMBL4416116	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual binding level at 10000 nM by Kinomescan method relative to control	B	CN(C)C/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1		CHEMBL4521381	=	Activity	%	3.0	CHEMBL5251	Homo sapiens	Activity	%	3.0
Dose-dependent effect	19363830	CHEMBL4423393	Inhibition of BTK in anti-human IgM-stimulated human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Tyr1217 residues after 4 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	19363831	CHEMBL4423392	Inhibition of BTK in anti-human IgM-stimulated human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residues after 4 hrs by Western blot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19363850	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccc6[nH]ccc56)cc4c32)cc1		CHEMBL4554208	=	Inhibition	%	47.2	CHEMBL5251	Homo sapiens	INH	%	47.2
	19363853	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1		CHEMBL4546543	=	Inhibition	%	63.4	CHEMBL5251	Homo sapiens	INH	%	63.4
	19363854	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1		CHEMBL4546543	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	uM	0.05
	19363858	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(O)cc5)cc4c32)cc1		CHEMBL4455455	=	Inhibition	%	51.7	CHEMBL5251	Homo sapiens	INH	%	51.7
	19363859	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(O)cc5)cc4c32)cc1		CHEMBL4455455	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	uM	0.15
	19363862	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4c32)cc1		CHEMBL4576325	=	Inhibition	%	49.2	CHEMBL5251	Homo sapiens	INH	%	49.2
	19363865	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	CN(C)CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(C5CCNCC5)cc4c32)cc1		CHEMBL4587769	=	Inhibition	%	33.1	CHEMBL5251	Homo sapiens	INH	%	33.1
	19363868	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5ccc(F)nc5)cc4c32)cc1		CHEMBL4535121	=	Inhibition	%	32.1	CHEMBL5251	Homo sapiens	INH	%	32.1
	19363873	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCN(C)CC6)cc5)c4c3c2)cn1		CHEMBL4247514	=	Inhibition	%	51.4	CHEMBL5251	Homo sapiens	INH	%	51.4
	19363874	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCN(C)CC6)cc5)c4c3c2)cn1		CHEMBL4247514	=	IC50	nM	153.0	CHEMBL5251	Homo sapiens	IC50	uM	0.153
	19363877	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN(C)C)cc5)c4c3c2)cn1		CHEMBL4248320	=	Inhibition	%	55.0	CHEMBL5251	Homo sapiens	INH	%	55.0
	19363878	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN(C)C)cc5)c4c3c2)cn1		CHEMBL4248320	=	IC50	nM	119.0	CHEMBL5251	Homo sapiens	IC50	uM	0.119
	19363881	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCOCC6)cc5)c4c3c2)cn1		CHEMBL4241577	=	Inhibition	%	37.6	CHEMBL5251	Homo sapiens	INH	%	37.6
	19363884	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2ccc3oc4ccc(=O)n(-c5ccc(NC(=O)CN)cc5)c4c3c2)cn1		CHEMBL4580021	=	Inhibition	%	19.0	CHEMBL5251	Homo sapiens	INH	%	19.0
	19363887	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5ccc(OC)nc5)cc4c32)c1		CHEMBL4557720	=	Inhibition	%	67.3	CHEMBL5251	Homo sapiens	INH	%	67.3
	19363888	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5ccc(OC)nc5)cc4c32)c1		CHEMBL4557720	=	IC50	nM	80.0	CHEMBL5251	Homo sapiens	IC50	uM	0.08
	19363892	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)c1		CHEMBL4559706	=	Inhibition	%	86.8	CHEMBL5251	Homo sapiens	INH	%	86.8
	19363893	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)c1		CHEMBL4559706	=	IC50	nM	74.0	CHEMBL5251	Homo sapiens	IC50	uM	0.074
Dose-dependent effect	19363911	CHEMBL4423392	Inhibition of BTK in anti-human IgM-stimulated human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residues after 4 hrs by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)c1		CHEMBL4559706		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	19363912	CHEMBL4423393	Inhibition of BTK in anti-human IgM-stimulated human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Tyr1217 residues after 4 hrs by Western blot analysis	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)c1		CHEMBL4559706		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	19363914	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5ccc(F)nc5)cc4c32)c1		CHEMBL4564014	=	Inhibition	%	40.2	CHEMBL5251	Homo sapiens	INH	%	40.2
	19363915	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	C=CC(=O)Nc1cccc(-n2c(=O)ccc3oc4ccc(-c5ccc(F)nc5)cc4c32)c1		CHEMBL4564014	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	uM	0.55
	19363920	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2cnc3oc4ccc(=O)n(-c5ccc(NC(=O)CN(C)C)cc5)c4c3c2)cn1		CHEMBL4553092	=	Inhibition	%	58.8	CHEMBL5251	Homo sapiens	INH	%	58.8
	19363921	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	COc1ccc(-c2cnc3oc4ccc(=O)n(-c5ccc(NC(=O)CN(C)C)cc5)c4c3c2)cn1		CHEMBL4553092	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	uM	0.15
	19363924	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2cnc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCNCC6)cc5)c4c3c2)cn1		CHEMBL4587749	=	Inhibition	%	32.0	CHEMBL5251	Homo sapiens	INH	%	32.0
	19363927	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	COc1ccc(-c2cnc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCCCC6)cc5)c4c3c2)cn1		CHEMBL4549348	=	Inhibition	%	55.0	CHEMBL5251	Homo sapiens	INH	%	55.0
	19363928	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	COc1ccc(-c2cnc3oc4ccc(=O)n(-c5ccc(NC(=O)CN6CCCCC6)cc5)c4c3c2)cn1		CHEMBL4549348	=	IC50	nM	125.0	CHEMBL5251	Homo sapiens	IC50	uM	0.125
	19363931	CHEMBL4423371	Inhibition of BTK (unknown origin) at 200 nM by ADP-gloassay relative to control	B	C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ncc(-c5cccnc5)cc4c32)cc1		CHEMBL4528988	=	Inhibition	%	38.7	CHEMBL5251	Homo sapiens	INH	%	38.7
	19363936	CHEMBL4423372	Inhibition of BTK (unknown origin) by ADP-gloassay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	uM	0.0007
	19432491	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(NC(=O)c2ccc(F)cc2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL3622189	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19432492	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(NC(=O)c2ccc(F)cn2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(C(=O)N4CCN(C)CC4)ccc3c12		CHEMBL4466870	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	19432493	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(NC(=O)c2ccc(F)cc2)cccc1-c1ccc(C(N)=O)c2[nH]c3cc(NC(C)C)ccc3c12		CHEMBL4466400	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	19432494	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)cccc1N1Cc2ccccc2C1=O		CHEMBL4567605	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19432495	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1N1Cc2ccccc2C1=O		CHEMBL4439761	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19432496	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1N1Cc2ccc(F)cc2C1=O		CHEMBL4543505	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	19432497	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1N1CCc2ccccc2C1=O		CHEMBL4465380	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	19432498	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1ccc2ccccc2c1=O		CHEMBL4554269	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19432499	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	19432500	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2cccc(F)c2c1=O		CHEMBL4473176	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	19432501	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccc(F)cc2c1=O		CHEMBL4513599	=	IC50	nM	7.0	CHEMBL5251	Homo sapiens	IC50	nM	7.0
	19432502	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2cc(F)ccc2c1=O		CHEMBL4467132	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	19432503	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2c(F)cccc2c1=O		CHEMBL4460221	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	19432504	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(CO)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4550390	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	19432505	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3)c12		CHEMBL3939772	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	19432506	CHEMBL4429365	Inhibition of His-tagged full length human recombinant BTK expressed in baculovirus using fluoresceinated peptide substrate after 60 mins by fluorescent electrophoretic separation	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3F)c12		CHEMBL3977725	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	19432565	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(=O)N5CCN(C)CC5)ccc4c23)cccc1N1Cc2ccccc2C1=O		CHEMBL4567605	=	IC50	nM	238.0	CHEMBL5251	Homo sapiens	IC50	nM	238.0
	19432566	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1N1Cc2ccccc2C1=O		CHEMBL4439761	=	IC50	nM	154.0	CHEMBL5251	Homo sapiens	IC50	nM	154.0
	19432567	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1N1Cc2ccc(F)cc2C1=O		CHEMBL4543505	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
	19432568	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1N1CCc2ccccc2C1=O		CHEMBL4465380	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	19432569	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1ccc2ccccc2c1=O		CHEMBL4554269	=	IC50	nM	144.0	CHEMBL5251	Homo sapiens	IC50	nM	144.0
	19432570	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	19432571	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2cccc(F)c2c1=O		CHEMBL4473176	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	19432572	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccc(F)cc2c1=O		CHEMBL4513599	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	19432573	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2cc(F)ccc2c1=O		CHEMBL4467132	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	19432574	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2c(F)cccc2c1=O		CHEMBL4460221	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
	19432575	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(CO)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL4550390	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
	19432576	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3)c12		CHEMBL3939772	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	nM	410.0
	19432577	CHEMBL4429374	Inhibition of BTK in human RamosB cells assessed as suppression of BCR/anti-IgM stimulated calcium flux pre-incubated for 1 hr followed by BCR/anti-IgM stimulation	B	CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)ccc(-c3cccc(-n4cnc5ccccc5c4=O)c3F)c12		CHEMBL3977725	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	19432605	CHEMBL4429402	Inhibition of BTK in human tonsillar B cells assessed as suppression of BCR/anti-IgM/IgG stimulated cell proliferation	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	19432606	CHEMBL4429403	Inhibition of BTK in human peripheral B cells assessed as suppression of BCR/anti-IgM/IgG stimulated CD69 surface expression after 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	uM	0.008
	19432607	CHEMBL4429404	Inhibition of BTK in human peripheral B cells assessed as suppression of CD40/CD40L stimulated CD69 surface expression	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	19432608	CHEMBL4429405	Inhibition of BTK in human PBMC assessed as suppression of FCgamma2aR/FCgamma3R stimulated TNFalpha production after 7 hrs by ELISA	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	uM	0.014
	19432609	CHEMBL4429406	Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM stimulated CD69 surface expression on B cells after 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	uM	0.55
	19432885	CHEMBL4429537	Inhibition of BTK (unknown origin) at 1 uM	B	Cc1nccc(Nc2cc(NC3CCN(c4ccc(C#N)cc4)CC3)c(C(N)=O)cn2)n1		CHEMBL4463436	=	Inhibition	%	49.0	CHEMBL5251	Homo sapiens	INH	%	49.0
	19448506	CHEMBL4433070	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2cc3nccnc3c(NC[C@@H]3CNCCO3)n2)cn1		CHEMBL4466696	=	IC50	nM	251.19	CHEMBL5251	Homo sapiens	pIC50		6.6
	19474677	CHEMBL4479366	Inhibition of BTK (unknown origin)	B	COc1ncc(-c2cc3c(c(NC(=O)CN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O		CHEMBL4561692	<	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	pIC50		5.0
	19476552	CHEMBL4479700	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	290.0	CHEMBL5251	Homo sapiens	IC50	nM	290.0
	19476652	CHEMBL4479700	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	=	IC50	nM	360.0	CHEMBL5251	Homo sapiens	IC50	nM	360.0
	19476752	CHEMBL4479700	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	<	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	19476852	CHEMBL4479700	Inhibition of full-length recombinant human His-tagged BTK expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	13000.0	CHEMBL5251	Homo sapiens	IC50	nM	13000.0
	19485873	CHEMBL4481541	Inhibition of BTK (unknown origin) at 1 uM by proQinase-based assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(-c4ccc(C(C)=O)cc4)nn3)c3c(N)ncnc32)C1		CHEMBL4581088	>	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	20600449	CHEMBL4603300	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system using tyrosine-2 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	=	IC50	nM	39550.0	CHEMBL5251	Homo sapiens	IC50	uM	39.55
	20601589	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cccc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4640099	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	20601590	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NC1(COc2cccc3[nH]c(-c4n[nH]c5cc(C(F)F)ccc45)cc23)CC1		CHEMBL4644905	=	IC50	nM	45.0	CHEMBL5251	Homo sapiens	IC50	nM	45.0
	20601591	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)N1CC(Oc2cccc3[nH]c(-c4n[nH]c5cc(C(F)F)ccc45)cc23)C1		CHEMBL4643808	=	IC50	nM	71.0	CHEMBL5251	Homo sapiens	IC50	nM	71.0
	20601592	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)N1CCC(Oc2cccc3[nH]c(-c4n[nH]c5cc(C(F)F)ccc45)cc23)C1		CHEMBL4644099	=	IC50	nM	1339.0	CHEMBL5251	Homo sapiens	IC50	nM	1339.0
	20601593	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	O=C(CCl)NCCOc1cccc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4638552	=	IC50	nM	8.9	CHEMBL5251	Homo sapiens	IC50	nM	8.9
	20601594	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C/C=C/C(=O)NCCOc1cccc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4637765	=	IC50	nM	907.0	CHEMBL5251	Homo sapiens	IC50	nM	907.0
	20601595	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	O=C(/C=C/C(F)(F)F)NCCOc1cccc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4638862	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	20601596	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	CN(C)C/C=C/C(=O)NCCOc1cccc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4648013	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	20601597	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	CC#CC(=O)NCCOc1cccc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4632698	=	IC50	nM	340.0	CHEMBL5251	Homo sapiens	IC50	nM	340.0
	20601598	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(C(O)(c2ccccc2)c2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4639930	=	IC50	nM	676.0	CHEMBL5251	Homo sapiens	IC50	nM	676.0
	20601599	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(C(O)c2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4637414	=	IC50	nM	34.0	CHEMBL5251	Homo sapiens	IC50	nM	34.0
	20601600	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646281	=	IC50	nM	133.0	CHEMBL5251	Homo sapiens	IC50	nM	133.0
	20601601	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(C(OC2CCOCC2)c2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4633295	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	20601602	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C#CCCOC(c1ccccc1)c1cc(OCCNC(=O)C=C)c2cc(-c3n[nH]c4cc(C(F)F)ccc34)[nH]c2c1		CHEMBL4638717	=	IC50	nM	91.0	CHEMBL5251	Homo sapiens	IC50	nM	91.0
	20601603	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(C(OCCS(C)(=O)=O)c2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4645223	=	IC50	nM	70.0	CHEMBL5251	Homo sapiens	IC50	nM	70.0
	20601604	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2cccc(Cl)c2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4640218	=	IC50	nM	287.0	CHEMBL5251	Homo sapiens	IC50	nM	287.0
	20601605	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2cccc(C(F)(F)F)c2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646367	=	IC50	nM	256.0	CHEMBL5251	Homo sapiens	IC50	nM	256.0
	20601606	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2cccc(C)c2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4642453	=	IC50	nM	235.0	CHEMBL5251	Homo sapiens	IC50	nM	235.0
	20601607	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2ccccc2OC)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4644593	=	IC50	nM	187.0	CHEMBL5251	Homo sapiens	IC50	nM	187.0
	20601608	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2cccc(OC)c2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4635070	=	IC50	nM	138.0	CHEMBL5251	Homo sapiens	IC50	nM	138.0
	20601609	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2ccc(OC)cc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4645126	=	IC50	nM	79.0	CHEMBL5251	Homo sapiens	IC50	nM	79.0
	20601610	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2c(OC)cccc2OC)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4634889	=	IC50	nM	331.0	CHEMBL5251	Homo sapiens	IC50	nM	331.0
	20601611	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2c(C)cc(C)cc2C)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4640845	=	IC50	nM	445.0	CHEMBL5251	Homo sapiens	IC50	nM	445.0
	20601612	CHEMBL4603779	Inhibition of BTK (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(-c5cn[nH]c5)ccc34)cc12		CHEMBL4639739	=	IC50	nM	186.0	CHEMBL5251	Homo sapiens	IC50	nM	186.0
	20601655	CHEMBL4603787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate at 0.6 uM incubated for 1 hr by Z'lyte assay relative to control	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646281	=	Inhibition	%	57.0	CHEMBL5251	Homo sapiens	INH	%	57.0
Not Active	20601708	CHEMBL4603826	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Plcgamma2 phosphorylation at 0.03 to 3 uM by Western blot analysis	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646281		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	20601709	CHEMBL4603826	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Plcgamma2 phosphorylation at 0.03 to 3 uM by Western blot analysis	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(-c5cn[nH]c5)ccc34)cc12		CHEMBL4639739		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	20631234	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(NNc3ccccc3)ncc2C(F)(F)F)c1		CHEMBL4637760	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	20631239	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(B(O)O)cc3)ncc2C(F)(F)F)c1		CHEMBL4640647	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	20631245	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc(B(O)O)c3)ncc2C(F)(F)F)c1		CHEMBL4647100	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	20631320	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20631321	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1		CHEMBL3301625	=	IC50	nM	9.8	CHEMBL5251	Homo sapiens	IC50	nM	9.8
	20631322	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	20631323	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)N1CCCC(Nc2nc(Nc3ccc4c(c3)COB4O)ncc2C(F)(F)F)C1		CHEMBL4633949	=	IC50	nM	36.8	CHEMBL5251	Homo sapiens	IC50	nM	36.8
	20631324	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	CN(C)C/C=C/C(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)COB4O)ncc2C(F)(F)F)c1		CHEMBL4640054	=	IC50	nM	11.8	CHEMBL5251	Homo sapiens	IC50	nM	11.8
	20631325	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc4c(c3)COB4O)ncc2C(F)(F)F)c1		CHEMBL4640192	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	20631326	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc4c(c3)COB4O)ncc2OC)c1		CHEMBL4649397	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	20631327	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)COB4O)ncc2OC)c1		CHEMBL4648257	=	IC50	nM	8.2	CHEMBL5251	Homo sapiens	IC50	nM	8.2
	20631328	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3cc4c(cc3F)COB4O)ncc2C(F)(F)F)c1		CHEMBL4639063	=	IC50	nM	156.2	CHEMBL5251	Homo sapiens	IC50	nM	156.2
	20631329	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)B(O)OC4(C)C)ncc2C(F)(F)F)c1		CHEMBL4645290	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	20631330	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)B(O)OCC4)ncc2C(F)(F)F)c1		CHEMBL4648104	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	20631331	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)COB4O)ncc2C(F)(F)F)c1		CHEMBL4642642	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	20631332	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc4c3COB4O)ncc2C(F)(F)F)c1		CHEMBL4635803	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	20631333	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc4c3B(O)OC4)ncc2C(F)(F)F)c1		CHEMBL4639665	=	IC50	nM	267.8	CHEMBL5251	Homo sapiens	IC50	nM	267.8
	20631334	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Oc3ccc4c(c3)B(O)OC4)ncc2C(F)(F)F)c1		CHEMBL4647525	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	20631335	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1ccc(OC)c(Nc2nc(Nc3ccc4c(c3)B(O)OC4)ncc2C(F)(F)F)c1		CHEMBL4649339	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	20631336	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)B(O)OC4)ncc2C)c1		CHEMBL4647822	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
	20631337	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)B(O)OC4)ncc2Cl)c1		CHEMBL4647555	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
	20631338	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)B(O)OC4)ncc2F)c1		CHEMBL4647623	=	IC50	nM	8.5	CHEMBL5251	Homo sapiens	IC50	nM	8.5
	20631339	CHEMBL4610787	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc4c(c3)B(O)OC4)ncc2C(F)(F)F)c1		CHEMBL4648837	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
	20632947	CHEMBL4611176	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	20632948	CHEMBL4611177	Inhibition of BTK C481S mutant (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	uM	1.0
	20646806	CHEMBL4614397	Inhibition of BTK (unknown origin) by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CN4CCOCC4)cc3)nc3ccsc23)c1		CHEMBL4639986	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20646807	CHEMBL4614397	Inhibition of BTK (unknown origin) by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(CN4CCOCC4)cc3)nc3ccsc23)c1		CHEMBL4637985	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20646808	CHEMBL4614397	Inhibition of BTK (unknown origin) by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OCCN4CCOCC4)cc3)nc3ccsc23)c1		CHEMBL4649751	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20646809	CHEMBL4614397	Inhibition of BTK (unknown origin) by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OCCCN4CCOCC4)cc3)nc3ccsc23)c1		CHEMBL4645703	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20646810	CHEMBL4614397	Inhibition of BTK (unknown origin) by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OCCCN4CCOCC4)c(Cl)c3)nc3ccsc23)c1		CHEMBL4634992	>=	IC50	nM	62.4	CHEMBL5251	Homo sapiens	IC50	nM	62.4
	20646811	CHEMBL4614397	Inhibition of BTK (unknown origin) by ADP-Glo kinase assay	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(SCCCN4CCOCC4)cc3)nc3ccsc23)c1		CHEMBL4645014	>	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20646838	CHEMBL4614414	Inhibition of BTK (unknown origin)	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(=O)CN4CCOCC4)cc3)ncc2Cl)c1		CHEMBL4635399	<	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	20654540	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.08	CHEMBL5251	Homo sapiens	IC50	nM	0.08
	20654541	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)NC1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4644786	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
	20654542	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CS(=O)(=O)NC1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4638741	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	20654543	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CS(=O)(=O)N[C@@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4641586	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	20654544	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CS(=O)(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4645440	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	20654545	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N[C@@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4649352	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	20654546	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4634162	=	IC50	nM	0.14	CHEMBL5251	Homo sapiens	IC50	nM	0.14
	20654547	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	CC#CC(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4642827	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
	20654548	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)NC1CCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4646406	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
	20654549	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CS(=O)(=O)NC1CCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4642103	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	20654550	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N[C@@H]1CCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4634526	=	IC50	nM	6.5	CHEMBL5251	Homo sapiens	IC50	nM	6.5
	20654551	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)N1CC[C@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4640555	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	20654552	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)N1CC[C@@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4643248	=	IC50	nM	8.4	CHEMBL5251	Homo sapiens	IC50	nM	8.4
	20654553	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N1CC[C@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4649284	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
	20654554	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)N1CCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)CC1		CHEMBL4639092	=	IC50	nM	3.3	CHEMBL5251	Homo sapiens	IC50	nM	3.3
	20654555	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N1CCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)CC1		CHEMBL4646648	=	IC50	nM	0.85	CHEMBL5251	Homo sapiens	IC50	nM	0.85
	20654556	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C=CC(=O)N1CCCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4640731	=	IC50	nM	59.0	CHEMBL5251	Homo sapiens	IC50	nM	59.0
	20654557	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N1CCCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4633931	=	IC50	nM	29.0	CHEMBL5251	Homo sapiens	IC50	nM	29.0
	20654558	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	20654559	CHEMBL4616764	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	B	C#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4648442	=	IC50	nM	0.07	CHEMBL5251	Homo sapiens	IC50	nM	0.07
	20654560	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	20654561	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)NC1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4644786	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	20654562	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CS(=O)(=O)NC1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4638741	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	20654563	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CS(=O)(=O)N[C@@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4641586	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	20654564	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CS(=O)(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4645440	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	20654565	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N[C@@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4649352	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	20654566	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4634162	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	20654567	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	CC#CC(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4642827	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	20654568	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)NC1CCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4646406	=	IC50	nM	270.0	CHEMBL5251	Homo sapiens	IC50	nM	270.0
	20654569	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CS(=O)(=O)NC1CCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4642103	=	IC50	nM	170.0	CHEMBL5251	Homo sapiens	IC50	nM	170.0
	20654570	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N[C@@H]1CCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4634526	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	20654571	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)N1CC[C@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4640555	=	IC50	nM	6.9	CHEMBL5251	Homo sapiens	IC50	nM	6.9
	20654572	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)N1CC[C@@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4643248	>	IC50	nM	300.0	CHEMBL5251	Homo sapiens	IC50	nM	300.0
	20654573	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N1CC[C@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4649284	=	IC50	nM	9.4	CHEMBL5251	Homo sapiens	IC50	nM	9.4
	20654574	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)N1CCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)CC1		CHEMBL4639092	=	IC50	nM	43.0	CHEMBL5251	Homo sapiens	IC50	nM	43.0
	20654575	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N1CCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)CC1		CHEMBL4646648	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	20654576	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C=CC(=O)N1CCCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4640731	>	IC50	nM	300.0	CHEMBL5251	Homo sapiens	IC50	nM	300.0
	20654577	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N1CCCC(Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4633931	>	IC50	nM	300.0	CHEMBL5251	Homo sapiens	IC50	nM	300.0
	20654578	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	20654579	CHEMBL4616765	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	B	C#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4648442	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	20654580	CHEMBL4616762	Inhibition of BTK in human whole blood cells after 1 hr by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	105.0	CHEMBL5251	Homo sapiens	IC50	nM	105.0
	20654581	CHEMBL4616762	Inhibition of BTK in human whole blood cells after 1 hr by ELISA	B	C=CS(=O)(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4645440	=	IC50	nM	46.6	CHEMBL5251	Homo sapiens	IC50	nM	46.6
	20654592	CHEMBL4616769	Inhibition of BTK in human whole blood cells assessed as apparent second order rate after 1 hr by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Non standard unit for type	CHEMBL1873475	=	K	10'-4/nM/min	1.2	CHEMBL5251	Homo sapiens	K	10'-4/nM/min	1.2
	20654593	CHEMBL4616769	Inhibition of BTK in human whole blood cells assessed as apparent second order rate after 1 hr by ELISA	B	C#CC(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1	Non standard unit for type	CHEMBL4634162	>	K	10'-4/nM/min	10.0	CHEMBL5251	Homo sapiens	K	10'-4/nM/min	10.0
	20654594	CHEMBL4616769	Inhibition of BTK in human whole blood cells assessed as apparent second order rate after 1 hr by ELISA	B	C=CC(=O)N1CC[C@H](Nc2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1	Non standard unit for type	CHEMBL4640555	=	K	10'-4/nM/min	1.0	CHEMBL5251	Homo sapiens	K	10'-4/nM/min	1.0
	20654595	CHEMBL4616769	Inhibition of BTK in human whole blood cells assessed as apparent second order rate after 1 hr by ELISA	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1	Non standard unit for type	CHEMBL4297674	=	K	10'-4/nM/min	3.5	CHEMBL5251	Homo sapiens	K	10'-4/nM/min	3.5
	20654596	CHEMBL4616770	Inhibition of His-tagged BTK (unknown origin) after 1.5 hrs by HTRF analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Ki	nM	425.0	CHEMBL5251	Homo sapiens	Ki(app)	nM	425.0
	20654597	CHEMBL4616770	Inhibition of His-tagged BTK (unknown origin) after 1.5 hrs by HTRF analysis	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	Ki	nM	116.0	CHEMBL5251	Homo sapiens	Ki(app)	nM	116.0
	20654598	CHEMBL4616770	Inhibition of His-tagged BTK (unknown origin) after 1.5 hrs by HTRF analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Kinact	/s	0.09	CHEMBL5251	Homo sapiens	Kinact	/s	0.09
	20654599	CHEMBL4616770	Inhibition of His-tagged BTK (unknown origin) after 1.5 hrs by HTRF analysis	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	Kinact	/s	0.11	CHEMBL5251	Homo sapiens	Kinact	/s	0.11
	20654600	CHEMBL4616771	Inhibition of His-tagged BTK (unknown origin) assessed as ratio of Kinact to Ki(app) after 1.5 hrs by HTRF analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Ratio	/mM.s	0.23	CHEMBL5251	Homo sapiens	Ratio	/mM.s	0.23
	20654601	CHEMBL4616771	Inhibition of His-tagged BTK (unknown origin) assessed as ratio of Kinact to Ki(app) after 1.5 hrs by HTRF analysis	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	Ratio	/mM.s	0.97	CHEMBL5251	Homo sapiens	Ratio	/mM.s	0.97
	20654603	CHEMBL4616775	Inhibition of BTK in human peripheral B cells assessed as reduction in CD86 surface expression	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	20654604	CHEMBL4616776	Inhibition of BTK in human memory B cells assessed as reduction in CD86 surface expression	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	20654605	CHEMBL4616774	Inhibition of BTK in human peripheral B cells assessed as reduction in CD69 surface expression	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	>	IC50	nM	300.0	CHEMBL5251	Homo sapiens	IC50	nM	300.0
	20654606	CHEMBL4616773	Inhibition of BTK in human PBMC assessed as reduction in TNFalpha expression	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	20654607	CHEMBL4616777	Inhibition of BTK in human peripheral B cells assessed as reduction in CD69 surface expression by whole blood assay	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
Dose-dependent effect	20654608	CHEMBL4616777	Inhibition of BTK in human peripheral B cells assessed as reduction in CD69 surface expression by whole blood assay	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Tde	20654609	CHEMBL4616777	Inhibition of BTK in human peripheral B cells assessed as reduction in CD69 surface expression by whole blood assay	B	CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4297674		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	20654704	CHEMBL4616871	Inhibition of BTK in human assessed as cysteine residues formation up to 10 uM	B	CC#C[14C](=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4639484		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	20654717	CHEMBL4616856	Inhibition of BTK in human whole blood cells after 30 mins by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	nM	200.0
	20654718	CHEMBL4616856	Inhibition of BTK in human whole blood cells after 30 mins by ELISA	B	C=CS(=O)(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4645440	=	IC50	nM	89.8	CHEMBL5251	Homo sapiens	IC50	nM	89.8
	20654719	CHEMBL4616857	Inhibition of BTK in human whole blood cells after 120 mins by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	57.5	CHEMBL5251	Homo sapiens	IC50	nM	57.5
	20654720	CHEMBL4616857	Inhibition of BTK in human whole blood cells after 120 mins by ELISA	B	C=CS(=O)(=O)N[C@H]1CCCN(c2ccc(C(N)=O)c3[nH]c(C)c(C)c23)C1		CHEMBL4645440	=	IC50	nM	21.5	CHEMBL5251	Homo sapiens	IC50	nM	21.5
	20679876	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(N)c1=O		CHEMBL4638802	=	IC50	nM	360.0	CHEMBL5251	Homo sapiens	IC50	nM	360.0
	20679877	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4644856	=	IC50	nM	7.1	CHEMBL5251	Homo sapiens	IC50	nM	7.1
	20679878	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	CC(=O)Nc1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cn(C)c1=O		CHEMBL4646782	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	20679879	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	CCC(=O)Nc1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cn(C)c1=O		CHEMBL4648782	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	20679880	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	CCCC(=O)Nc1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cn(C)c1=O		CHEMBL4649614	=	IC50	nM	44.0	CHEMBL5251	Homo sapiens	IC50	nM	44.0
	20679881	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	CC(C)C(=O)Nc1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cn(C)c1=O		CHEMBL4639728	=	IC50	nM	200.0	CHEMBL5251	Homo sapiens	IC50	nM	200.0
	20679882	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)C2CCC2)c1=O		CHEMBL4638562	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	20679883	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)CC2CC2)c1=O		CHEMBL4647342	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
	20679884	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)C2COC2)c1=O		CHEMBL4640083	=	IC50	nM	74.0	CHEMBL5251	Homo sapiens	IC50	nM	74.0
	20679885	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	COCC(=O)Nc1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cn(C)c1=O		CHEMBL4638921	=	IC50	nM	74.0	CHEMBL5251	Homo sapiens	IC50	nM	74.0
	20679886	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)[C@@H]2CCCO2)c1=O		CHEMBL4646580	=	IC50	nM	320.0	CHEMBL5251	Homo sapiens	IC50	nM	320.0
	20679887	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)C2(F)CC2)c1=O		CHEMBL4636316	=	IC50	nM	60.0	CHEMBL5251	Homo sapiens	IC50	nM	60.0
	20679888	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4644207	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	20679889	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)[C@H]2C[C@H]2F)c1=O		CHEMBL4644448	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
	20679890	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCc4c(cc5n4CCCC5)C3=O)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4638609	=	IC50	nM	98.0	CHEMBL5251	Homo sapiens	IC50	nM	98.0
	20679891	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4c5c(sc4c3=O)CCCC5)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4649410	=	IC50	nM	7.7	CHEMBL5251	Homo sapiens	IC50	nM	7.7
	20679892	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4641507	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
	20679893	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@H]2C[C@H]2F)c1=O		CHEMBL4648439	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
	20679894	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4634904	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
	20679895	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@H]2C[C@@H]2F)c1=O		CHEMBL4633058	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	20679896	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@H]2F)c1=O		CHEMBL4638307	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	20679897	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)nc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4647569	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	20679898	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1nc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4646964	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	20679899	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)C2(O)CC2)c1=O		CHEMBL4643297	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	nM	410.0
	20679900	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)c2cccnc2)c1=O		CHEMBL4643339	=	IC50	nM	280.0	CHEMBL5251	Homo sapiens	IC50	nM	280.0
	20679901	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2cc(F)cc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4643319	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	20679902	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	Cn1cc(-c2cc(F)cc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@H]2C[C@H]2F)c1=O		CHEMBL4638277	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	20679903	CHEMBL4622573	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue incubated for 1 hr by mesoscale assay	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	2.3	CHEMBL5251	Homo sapiens	IC50	nM	2.3
	20679955	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4644856	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
	20679956	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(N3CCc4c(cc5n4CCCC5)C3=O)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4638609	>	IC50	nM	4300.0	CHEMBL5251	Homo sapiens	IC50	nM	4300.0
	20679957	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(-n3ncc4c5c(sc4c3=O)CCCC5)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4649410	=	IC50	nM	1100.0	CHEMBL5251	Homo sapiens	IC50	nM	1100.0
	20679958	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)C2CC2)c1=O		CHEMBL4641507	=	IC50	nM	78.0	CHEMBL5251	Homo sapiens	IC50	nM	78.0
	20679959	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@H]2C[C@H]2F)c1=O		CHEMBL4648439	=	IC50	nM	180.0	CHEMBL5251	Homo sapiens	IC50	nM	180.0
	20679960	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4634904	=	IC50	nM	78.0	CHEMBL5251	Homo sapiens	IC50	nM	78.0
	20679961	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@H]2C[C@@H]2F)c1=O		CHEMBL4633058	=	IC50	nM	326.0	CHEMBL5251	Homo sapiens	IC50	nM	326.0
	20679962	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@H]2F)c1=O		CHEMBL4638307	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	nM	110.0
	20679963	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1nc(-c2ccnc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4646964	=	IC50	nM	214.0	CHEMBL5251	Homo sapiens	IC50	nM	214.0
	20679964	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2cc(F)cc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@@H]2C[C@@H]2F)c1=O		CHEMBL4643319	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
	20679965	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	Cn1cc(-c2cc(F)cc(-n3ncc4cc(C(C)(C)C)cc(F)c4c3=O)c2CO)cc(NC(=O)[C@H]2C[C@H]2F)c1=O		CHEMBL4638277	=	IC50	nM	125.0	CHEMBL5251	Homo sapiens	IC50	nM	125.0
	20679966	CHEMBL4622576	Inhibition of BTK in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression preincubated for 1 hr followed by goat F(ab')2 anti-human IgM stimulation and measured after 18 hrs by FACS analysis	B	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1		CHEMBL4065122	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	20680039	CHEMBL4622603	Inhibition of BTK in human whole blood assessed as reduction in autophosphorylation at Y223 residue at 111 nM incubated for 1 hr by mesoscale assay relative to control	B	Cn1cc(-c2ccnc(N3CCn4c(cc5c4CC(C)(C)C5)C3=O)c2CO)cc(NC(=O)CN2CCOCC2)c1=O		CHEMBL4648111	=	Inhibition	%	38.0	CHEMBL5251	Homo sapiens	INH	%	38.0
	22388097	CHEMBL4666409	Inhibition of BTK (unknown origin) at 500 nM relative to control	B	Cc1cc(Nc2cc(N3CCN(CCCN(C)C)CC3)ncn2)c(=O)n2c1C(=O)NC21CCCCC1		CHEMBL4757546	=	Inhibition	%	3.0	CHEMBL5251	Homo sapiens	INH	%	3.0
	22391924	CHEMBL4667075	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr 01 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	-2.0	CHEMBL5251	Homo sapiens	INH	%	-2.0
	22395635	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	66.0	CHEMBL5251	Homo sapiens	IC50	uM	0.066
	22395636	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4762397	=	IC50	nM	934.0	CHEMBL5251	Homo sapiens	IC50	uM	0.934
	22395637	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C5CC5)cc4)c3C)c12		CHEMBL4788086	=	IC50	nM	7470.0	CHEMBL5251	Homo sapiens	IC50	uM	7.47
	22395638	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cc(F)cc(NC(=O)c4ccc(C5CC5)cc4)c3C)c12		CHEMBL4793026	=	IC50	nM	1260.0	CHEMBL5251	Homo sapiens	IC50	uM	1.26
	22395639	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N(C)C(=O)Cc1c[nH]c2ncnc(-c3cc(F)cc(NC(=O)c4ccc(C5CC5)cc4)c3C)c12		CHEMBL4795673	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	uM	0.016
	22395640	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N1CC(O)(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)C1		CHEMBL4746262	=	IC50	nM	303.0	CHEMBL5251	Homo sapiens	IC50	uM	0.303
	22395641	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N1CCC(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)C1		CHEMBL4740933	=	IC50	nM	225.0	CHEMBL5251	Homo sapiens	IC50	uM	0.225
	22395642	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N1CCCC(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)C1		CHEMBL4744271	=	IC50	nM	8000.0	CHEMBL5251	Homo sapiens	IC50	uM	8.0
	22395643	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N1CCC(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4739958	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	uM	0.019
	22395644	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C=CC(=O)N1CC=C(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4593663	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	uM	0.032
	22395645	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1ncnc2[nH]cc(C3=CCN(C(=O)/C=C/CN4CCCC4)CC3)c12		CHEMBL4749522	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	uM	0.026000000000000002
	22395646	CHEMBL4668242	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	B	C/C=C/C(=O)N1CC=C(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4789435	=	IC50	nM	66.0	CHEMBL5251	Homo sapiens	IC50	uM	0.066
	22395649	CHEMBL4668244	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by immunoblot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	<	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	uM	0.005
	22395650	CHEMBL4668244	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by immunoblot analysis	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4762397	=	IC50	nM	80.0	CHEMBL5251	Homo sapiens	IC50	uM	0.08
Not Active	22395662	CHEMBL4668251	Irreversible inhibition of full length human unphosphorylated BTK at 5.7 uM using peptide substrate preincubated for 2 hrs followed by compound dilution and measured after substrate addition for 1 hr in presence of ATP at Km concentration	B	CCC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4752522		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22395663	CHEMBL4668251	Irreversible inhibition of full length human unphosphorylated BTK at 5.7 uM using peptide substrate preincubated for 2 hrs followed by compound dilution and measured after substrate addition for 1 hr in presence of ATP at Km concentration	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4762397		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22395664	CHEMBL4668251	Irreversible inhibition of full length human unphosphorylated BTK at 5.7 uM using peptide substrate preincubated for 2 hrs followed by compound dilution and measured after substrate addition for 1 hr in presence of ATP at Km concentration	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22395665	CHEMBL4668252	Irreversible inhibition of human BTK kinase domain by LC/MS analysis	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4762397		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22395666	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	CCC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4752522	=	IC50	nM	3900.0	CHEMBL5251	Homo sapiens	IC50	uM	3.9
	22395667	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ncnc2[nH]c(-c3ccc(C(=O)N4CCN(C)CC4)cc3)cc12		CHEMBL4566818	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	22395668	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C/C=C/C(=O)N1CC=C(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4789435	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	uM	0.006
	22395669	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	Cc1c(NC(=O)c2ccc(C3CC3)cc2)cc(F)cc1-c1ncnc2[nH]cc(C3=CCN(C(=O)/C=C/CN4CCCC4)CC3)c12		CHEMBL4749522	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	uM	0.0006
	22395670	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N1CC=C(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4593663	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	uM	0.0009
	22395671	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N1CCC(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)CC1		CHEMBL4739958	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	uM	0.001
	22395672	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N1CCCC(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)C1		CHEMBL4744271	=	IC50	nM	390.0	CHEMBL5251	Homo sapiens	IC50	uM	0.39
	22395673	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N1CCC(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)C1		CHEMBL4740933	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	uM	0.005
	22395674	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N1CC(O)(c2c[nH]c3ncnc(-c4cc(F)cc(NC(=O)c5ccc(C6CC6)cc5)c4C)c23)C1		CHEMBL4746262	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	uM	0.0014
	22395675	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cc(F)cc(NC(=O)c4ccc(C5CC5)cc4)c3C)c12		CHEMBL4793026	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	uM	0.026000000000000002
	22395676	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N(C)C(=O)Cc1c[nH]c2ncnc(-c3cc(F)cc(NC(=O)c4ccc(C5CC5)cc4)c3C)c12		CHEMBL4795673	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	uM	0.0012
	22395677	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C5CC5)cc4)c3C)c12		CHEMBL4788086	=	IC50	nM	190.0	CHEMBL5251	Homo sapiens	IC50	uM	0.19
	22395678	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	uM	0.005
	22395679	CHEMBL4668253	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4762397	=	IC50	nM	0.014	CHEMBL5251	Homo sapiens	IC50	nM	0.013999999999999999
Active	22395681	CHEMBL4668255	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Tyr223 residue at 5 uM by immunoblot analysis	B	C=CC(=O)N(C)Cc1c[nH]c2ncnc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)c12		CHEMBL4762397		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	22395682	CHEMBL4668255	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Tyr223 residue at 5 uM by immunoblot analysis	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22395784	CHEMBL4668322	Induction of wild-type BTK (unknown origin) degradation in HEK293T cells at 1 uM incubated for 4 hrs by immunoblotting method relative to control	B	C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21		CHEMBL4077064	=	Activity	%	50.0	CHEMBL5251	Homo sapiens	Activity	%	50.0
	22395808	CHEMBL4668339	Inhibition of BTK C481S (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	1002.0	CHEMBL5251	Homo sapiens	IC50	nM	1002.0
	22395809	CHEMBL4668339	Inhibition of BTK C481S (unknown origin)	B	NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O		CHEMBL4297640	=	IC50	nM	4.5	CHEMBL5251	Homo sapiens	IC50	nM	4.5
	22395810	CHEMBL4668340	Inhibition of wild type BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	22395811	CHEMBL4668340	Inhibition of wild type BTK (unknown origin)	B	NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O		CHEMBL4297640	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
	22395818	CHEMBL4668347	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCN(CCCCCCNC(=O)CNc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2)n1		CHEMBL4754443	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	22395822	CHEMBL4668351	Inhibition of wild type human BTK C481S mutant using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric assay	B	O=C(c1ccc(Oc2ccccc2)cc1Cl)c1c[nH]c2ncnc(N[C@@H]3CC[C@@H](CO)OC3)c12		CHEMBL4756476	=	IC50	nM	0.39	CHEMBL5251	Homo sapiens	IC50	nM	0.39
	22395823	CHEMBL4668352	Inhibition of wild type human BTK using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric assay	B	O=C(c1ccc(Oc2ccccc2)cc1Cl)c1c[nH]c2ncnc(N[C@@H]3CC[C@@H](CO)OC3)c12		CHEMBL4756476	=	IC50	nM	0.85	CHEMBL5251	Homo sapiens	IC50	nM	0.85
	22418407	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	22418408	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2ccccn2c1=O		CHEMBL4741884	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	22418409	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2ccccn2c1=O		CHEMBL4741884	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
	22418410	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	COc1ccn2c(=O)n(-c3cccc(-c4ccc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc2c1		CHEMBL4789404	=	IC50	nM	0.63	CHEMBL5251	Homo sapiens	IC50	nM	0.63
	22418411	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	COc1cccn2c(=O)n(-c3cccc(-c4ccc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc12		CHEMBL4754459	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
	22418412	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2cc(Cl)ccn2c1=O		CHEMBL4741099	=	IC50	nM	0.49	CHEMBL5251	Homo sapiens	IC50	nM	0.49
	22418413	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	0.94	CHEMBL5251	Homo sapiens	IC50	nM	0.94
	22418414	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	22418415	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
	22418416	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	0.86	CHEMBL5251	Homo sapiens	IC50	nM	0.86
	22418417	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	22418418	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	22418419	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	180.0	CHEMBL5251	Homo sapiens	IC50	nM	180.0
	22418420	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	0.55	CHEMBL5251	Homo sapiens	IC50	nM	0.55
	22418421	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	22418422	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
	22418423	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
	22418424	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
	22418425	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	22418426	CHEMBL4672802	Inhibition of recombinant full-length His-tagged human BTK expressed in baculovirus expression system using fluoresceinated peptide as substrate incubated for 60 mins by fluorescence assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
	22418447	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	22418448	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2ccccn2c1=O		CHEMBL4741884	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	22418449	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2ccccn2c1=O		CHEMBL4741884	=	IC50	nM	8.5	CHEMBL5251	Homo sapiens	IC50	nM	8.5
	22418450	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	COc1ccn2c(=O)n(-c3cccc(-c4ccc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc2c1		CHEMBL4789404	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	22418451	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	COc1cccn2c(=O)n(-c3cccc(-c4ccc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc12		CHEMBL4754459	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	22418452	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2cc(Cl)ccn2c1=O		CHEMBL4741099	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
	22418453	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	22418454	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	22418455	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	22418456	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	22418457	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	22418458	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	22418459	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	>	IC50	nM	300.0	CHEMBL5251	Homo sapiens	IC50	nM	300.0
	22418460	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	22418461	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	87.0	CHEMBL5251	Homo sapiens	IC50	nM	87.0
	22418462	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	6.9	CHEMBL5251	Homo sapiens	IC50	nM	6.9
	22418463	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	600.0	CHEMBL5251	Homo sapiens	IC50	nM	600.0
	22418464	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	6.6	CHEMBL5251	Homo sapiens	IC50	nM	6.6
	22418465	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	170.0	CHEMBL5251	Homo sapiens	IC50	nM	170.0
	22418466	CHEMBL4672804	Inhibition of BTK in human Ramos B cells assessed as reduction in goat anti human IgM-stimulated calcium flux preincubated for 1 hr followed by goat anti human IgM addition and measured for 180 secs by FLIPR assay	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	7.6	CHEMBL5251	Homo sapiens	IC50	nM	7.6
	22418467	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	nM	550.0
Not Determined	22418468	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2ccccn2c1=O		CHEMBL4741884		IC50			CHEMBL5251	Homo sapiens	IC50		
	22418469	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2ccccn2c1=O		CHEMBL4741884	=	IC50	nM	410.0	CHEMBL5251	Homo sapiens	IC50	nM	410.0
	22418470	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	COc1ccn2c(=O)n(-c3cccc(-c4ccc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc2c1		CHEMBL4789404	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
	22418471	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	COc1cccn2c(=O)n(-c3cccc(-c4ccc(C(N)=O)c5[nH]c6cc(C(C)(C)O)ccc6c45)c3C)c(=O)cc12		CHEMBL4754459	=	IC50	nM	140.0	CHEMBL5251	Homo sapiens	IC50	nM	140.0
	22418472	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2cc(Cl)ccn2c1=O		CHEMBL4741099	=	IC50	nM	3000.0	CHEMBL5251	Homo sapiens	IC50	nM	3000.0
	22418473	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	22418474	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	78.0	CHEMBL5251	Homo sapiens	IC50	nM	78.0
	22418475	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL4751952	=	IC50	nM	69.0	CHEMBL5251	Homo sapiens	IC50	nM	69.0
	22418476	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	75.0	CHEMBL5251	Homo sapiens	IC50	nM	75.0
	22418477	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	91.0	CHEMBL5251	Homo sapiens	IC50	nM	91.0
	22418478	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(F)cccn2c1=O		CHEMBL4743497	=	IC50	nM	79.0	CHEMBL5251	Homo sapiens	IC50	nM	79.0
Not Determined	22418479	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976		IC50			CHEMBL5251	Homo sapiens	IC50		
	22418480	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	162.0	CHEMBL5251	Homo sapiens	IC50	nM	162.0
Not Determined	22418481	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976		IC50			CHEMBL5251	Homo sapiens	IC50		
	22418482	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
Not Determined	22418483	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545		IC50			CHEMBL5251	Homo sapiens	IC50		
	22418484	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	64.0	CHEMBL5251	Homo sapiens	IC50	nM	64.0
Not Determined	22418485	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545		IC50			CHEMBL5251	Homo sapiens	IC50		
	22418486	CHEMBL4672805	Inhibition of BTK in human whole blood assessed as reduction in goat anti human IgM/human IL4-stimulated CD69 cell surface expression on peripheral B cells incubated for 18 hrs by FACS analysis	B	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3891545	=	IC50	nM	37.0	CHEMBL5251	Homo sapiens	IC50	nM	37.0
	22418563	CHEMBL4672871	Inhibition of BTK in human peripheral B cells assessed as reduction in anti-IgM/IgG-induced CD86 surface expression	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	22418564	CHEMBL4672871	Inhibition of BTK in human peripheral B cells assessed as reduction in anti-IgM/IgG-induced CD86 surface expression	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	22418565	CHEMBL4672872	Inhibition of BTK in human peripheral B cells assessed as reduction in CD40/CD40L-induced CD86 surface expression	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	22418566	CHEMBL4672872	Inhibition of BTK in human peripheral B cells assessed as reduction in CD40/CD40L-induced CD86 surface expression	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	22418567	CHEMBL4672873	Inhibition of BTK in human PBMC cells assessed as inhibition of FCepsilonR1/immune complex-induced TNFalpha production	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	22418568	CHEMBL4672873	Inhibition of BTK in human PBMC cells assessed as inhibition of FCepsilonR1/immune complex-induced TNFalpha production	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
Not Determined	22418571	CHEMBL4672875	Inhibition of BTK in human whole blood assessed as reduction in FCepsilonR1/anti-IgE-induced CD63 surface expression on basophils	B	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O		CHEMBL3918580		IC50			CHEMBL5251	Homo sapiens	IC50		
	22418572	CHEMBL4672875	Inhibition of BTK in human whole blood assessed as reduction in FCepsilonR1/anti-IgE-induced CD63 surface expression on basophils	B	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O		CHEMBL3928976	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
	22423801	CHEMBL4674476	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	81.28	CHEMBL5251	Homo sapiens	Activity	%	81.28
	22423802	CHEMBL4674476	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	88.21	CHEMBL5251	Homo sapiens	Activity	%	88.21
	22471786	CHEMBL4685326	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system at 100 nM using Tyr01 peptide as substrate incubated for 1 hr by Z'lyte assay relative to control	A	C=CC(=O)Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL4746272	=	Inhibition	%	6.3	CHEMBL5251	Homo sapiens	INH	%	6.3
	22482644	CHEMBL4687850	Inhibition of human BTK assessed as residual activity at 10 uM relative to control	A	CN1CCC(CNC2=NC(=O)/C(=C/c3csc(-c4ccc(OC(F)(F)F)cc4)n3)S2)CC1		CHEMBL4757567	=	Activity	%	94.0	CHEMBL5251	Homo sapiens	Activity	%	94.0
	22751941	CHEMBL4700048	Binding affinity to BTK in human K562 cells at 1 mM incubated for 2 hrs by LC-MS/MS analysis based pull down assay relative to control	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3c(N)c(C(N)=O)c4nc5ccc(NCCCN)cc5nc43)cc2)cc1		CHEMBL4776609	=	FC		1216.0	CHEMBL5251	Homo sapiens	FC		1216.0
	22751957	CHEMBL4700062	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3c(N)c(C(N)=O)c4nc5ccccc5nc43)cc2)cc1		CHEMBL4792853	=	Inhibition	%	3.3	CHEMBL5251	Homo sapiens	INH	%	3.3
	22751958	CHEMBL4700062	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3c(N)c(C(N)=O)c4nc5ccc(NCCCN)cc5nc43)cc2)cc1		CHEMBL4776609	=	Inhibition	%	0.95	CHEMBL5251	Homo sapiens	INH	%	0.95
	22757100	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	CC(C)(C)c1ccc(C(=O)NCc2ccc(-c3ncnc4[nH]ccc34)cc2)cc1		CHEMBL4755663	=	IC50	nM	142.0	CHEMBL5251	Homo sapiens	IC50	nM	142.0
	22757101	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ncnc3[nH]ccc23)ccc1CNC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL4756023	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	22757102	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	CCc1cc(-c2ncnc3[nH]ccc23)ccc1CNC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL4763987	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	22757103	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	CC(C)(C)c1ccc(C(=O)NCc2ccc(-c3ncnc4[nH]ccc34)cc2C(F)(F)F)cc1		CHEMBL4778259	=	IC50	nM	94.0	CHEMBL5251	Homo sapiens	IC50	nM	94.0
	22757104	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	CC(C)(C)c1ccc(C(=O)NCc2ccc(-c3ncnc4[nH]ccc34)cc2C(N)=O)cc1		CHEMBL4757354	=	IC50	nM	3200.0	CHEMBL5251	Homo sapiens	IC50	nM	3200.0
	22757105	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ncnc3[nH]ccc23)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4740150	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	22757106	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2cc(N)ncn2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4764045	=	IC50	nM	9.0	CHEMBL5251	Homo sapiens	IC50	nM	9.0
	22757107	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(N)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4783488	=	IC50	nM	6.0	CHEMBL5251	Homo sapiens	IC50	nM	6.0
	22757108	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3ccccc3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4788285	=	IC50	nM	1.8	CHEMBL5251	Homo sapiens	IC50	nM	1.8
	22757109	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3ccccn3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4791140	=	IC50	nM	32.0	CHEMBL5251	Homo sapiens	IC50	nM	32.0
	22757110	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3ccncc3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4746275	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	22757111	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1nnc(Nc2nccc(-c3ccc(CNC(=O)c4cnc(C(C)(C)C)s4)c(C)c3)n2)s1		CHEMBL4741954	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	22757112	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3conc3C)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4797536	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	22757113	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cn(C)nn3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4753530	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	22757114	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3ccn(C)n3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4792826	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
	22757115	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4754065	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	22757116	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)c1nnc(C(C)(C)C)s1		CHEMBL4749757	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	22757117	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)C1CCC(C(C)(C)C)C1		CHEMBL4760128	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	22757118	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CCC(C(C)(C)C)C1		CHEMBL4782313	=	IC50	nM	0.2	CHEMBL5251	Homo sapiens	IC50	nM	0.2
	22757119	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(CC(C)C)C1		CHEMBL4796367	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	22757120	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	22757121	CHEMBL4701067	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21 insect cells using fluorescein-labeled polyGAT peptide substrate measured after 30 mins by TR-FRET assay	B	O=C(NCc1ccc(-c2ncnc3[nH]ccc23)cc1)c1ccccc1		CHEMBL4789778	=	IC50	nM	3700.0	CHEMBL5251	Homo sapiens	IC50	nM	3700.0
	22757152	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ncnc3[nH]ccc23)ccc1CNC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL4756023	=	IC50	nM	7800.0	CHEMBL5251	Homo sapiens	IC50	uM	7.8
	22757153	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3ccncc3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4746275	=	IC50	nM	5300.0	CHEMBL5251	Homo sapiens	IC50	uM	5.3
	22757154	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4754065	=	IC50	nM	430.0	CHEMBL5251	Homo sapiens	IC50	uM	0.43
	22757155	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)c1nnc(C(C)(C)C)s1		CHEMBL4749757	=	IC50	nM	1400.0	CHEMBL5251	Homo sapiens	IC50	uM	1.4
	22757156	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)C1CCC(C(C)(C)C)C1		CHEMBL4760128	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	22757157	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CCC(C(C)(C)C)C1		CHEMBL4782313	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	uM	0.35
	22757158	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(CC(C)C)C1		CHEMBL4796367	=	IC50	nM	650.0	CHEMBL5251	Homo sapiens	IC50	uM	0.65
	22757159	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	uM	0.12
	22757160	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)c1cnc(C(C)(C)C)s1		CHEMBL4754065	=	fIC50	nM	1.3	CHEMBL5251	Homo sapiens	fIC50	nM	1.3
	22757161	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)c1nnc(C(C)(C)C)s1		CHEMBL4749757	=	fIC50	nM	9.8	CHEMBL5251	Homo sapiens	fIC50	nM	9.8
	22757162	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)C1CCC(C(C)(C)C)C1		CHEMBL4760128	=	fIC50	nM	7.0	CHEMBL5251	Homo sapiens	fIC50	nM	7.0
	22757163	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CCC(C(C)(C)C)C1		CHEMBL4782313	=	fIC50	nM	0.7	CHEMBL5251	Homo sapiens	fIC50	nM	0.7
	22757164	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(CC(C)C)C1		CHEMBL4796367	=	fIC50	nM	5.9	CHEMBL5251	Homo sapiens	fIC50	nM	5.9
	22757165	CHEMBL4701077	Inhibition of BTK in human whole blood assessed as reduction in BTK phosphorylation measured after 30 mins by phosphotyrosine detection method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	fIC50	nM	7.1	CHEMBL5251	Homo sapiens	fIC50	nM	7.1
	22757244	CHEMBL4701101	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system by Kinomescan method	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	Kd	nM	0.3	CHEMBL5251	Homo sapiens	Kd	nM	0.3
	22757245	CHEMBL4701102	Binding affinity to wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	>	Activity	%	70.0	CHEMBL5251	Homo sapiens	Activity	%	70.0
	22757258	CHEMBL4701115	Inhibition of BTK in human Ramos cells assessed as reduction in BCR mediated PLCgamma2 phosphorylation	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	400.0	CHEMBL5251	Homo sapiens	IC50	uM	0.4
	22757259	CHEMBL4701116	Inhibition of BTK in human PBMC assessed as reduction in anti-IgD-induced B cell activation preincubated for 30 mins followed by rabbit F(ab')2 anti-human IgD stimulation and measured after 18 to 22 hrs by CD19-APC and CD69-PE staining based flow cytometry	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	110.0	CHEMBL5251	Homo sapiens	IC50	uM	0.11
	22757260	CHEMBL4701117	Inhibition of BTK in human PBMC assessed as reduction in goat F(ab')2 anti-human IgM antibody-induced B cell activation measured after 3 days by celltiter-glo assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	210.0	CHEMBL5251	Homo sapiens	IC50	uM	0.21
	22757315	CHEMBL4701172	Inhibition of BTK in human whole blood derived neutrophils assessed as reduction in SLE IC/FcgammaR-induced ROS generation preincubated for 30 mins followed by SLE IC/FcgammaR stimulation and measured after 1 hr by DHR123 dye based fluorescence assay	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	uM	0.054000000000000006
	22757316	CHEMBL4701173	Inhibition of BTK in human PBMC assessed as suppression of TNFalpha/FcgammaR-induced monocyte activation by measuring reduction in cytokine production	B	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1		CHEMBL4744041	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	uM	0.063
	22782809	CHEMBL4707750	Inhibition of recombinant full length human His-tagged BTK expressed in baculovirus expression system at 1 uM by Z-lyte assay relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-n3c(SC)nnc3-c3ccc(F)cc3)ccn2)c(OC)cc1N(C)CCN(C)C		CHEMBL4798177	=	Inhibition	%	4.0	CHEMBL5251	Homo sapiens	INH	%	4.0
	22783369	CHEMBL4707899	Inhibition of BTK (unknown origin) at 20 uM relative to control	B	CCCSc1nc2c(nnn2CCNC(=S)Nc2cccc3ccccc23)c(=O)[nH]1		CHEMBL4742820	<	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	22790973	CHEMBL4709478	Inhibition of BTK (unknown origin) assessed as residual activity at 0.1 uM preincubated for 20 min followed by [gamma33P]ATP addition and measured after 120 mins by Hotspot assay relative to control	B	Cc1cccn(-c2ccc(-c3ccc4c(C(=O)NCc5ccncc5)n[nH]c4c3)c(Cl)c2)c1=O		CHEMBL4758500	=	Activity	%	99.13	CHEMBL5251	Homo sapiens	Activity	%	99.13
	22809734	CHEMBL4713269	Inhibition of recombinant full length human BTK assessed as residual activity at 1 uM using KVEKIGEGTYGVV as substrate incubated for 40 mins in presence of Km ATP by radiometric scintillation counting analysis relative to control	B	CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@H](C)C1		CHEMBL4761365	=	Activity	%	114.0	CHEMBL5251	Homo sapiens	Activity	%	114.0
	22813275	CHEMBL4714263	Inhibition of BTK (unknown origin) One-hour enzymatic assay without pre-incubation	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	22813276	CHEMBL4714263	Inhibition of BTK (unknown origin) One-hour enzymatic assay without pre-incubation	B	C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1		CHEMBL4594348	=	IC50	nM	33.0	CHEMBL5251	Homo sapiens	IC50	nM	33.0
	22813277	CHEMBL4714263	Inhibition of BTK (unknown origin) One-hour enzymatic assay without pre-incubation	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1		CHEMBL4163691	=	IC50	nM	1.95	CHEMBL5251	Homo sapiens	IC50	nM	1.95
	22813278	CHEMBL4714263	Inhibition of BTK (unknown origin) One-hour enzymatic assay without pre-incubation	B	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1		CHEMBL3702854	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	22813279	CHEMBL4714263	Inhibition of BTK (unknown origin) One-hour enzymatic assay without pre-incubation	B	N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1		CHEMBL4560385	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	22813280	CHEMBL4714264	Inhibition of BTK (unknown origin) One-hour enzymatic assay with pre-incubation	B	CC#CC(=O)N1CCC[C@@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL4747506	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	22813281	CHEMBL4714265	Inhibition of human BTK in human microglia cells	B	C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1		CHEMBL4650323	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	22818095	CHEMBL4715318	Inhibition of recombinant N-terminal His6-tagged human full-length BTK expressed in Sf21 insect cells at 2 uM using Src peptide as substrate relative to control	B	C[C@@H](c1ccc2ncccc2c1)c1nnc2sc(-c3cnn(C)c3)nn12		CHEMBL4791034	<	Inhibition	%	50.0	CHEMBL5251	Homo sapiens	INH	%	50.0
	22820440	CHEMBL4716222	Inhibition of recombinant full length N-terminal His6-tagged human BTK expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	81.0	CHEMBL5251	Homo sapiens	Activity	%	81.0
	22820441	CHEMBL4716222	Inhibition of recombinant full length N-terminal His6-tagged human BTK expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	48.0	CHEMBL5251	Homo sapiens	Activity	%	48.0
	22822926	CHEMBL4716835	Inhibition of BTK (unknown origin)	B	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1		CHEMBL3651854	=	IC50	nM	9400.0	CHEMBL5251	Homo sapiens	IC50	uM	9.4
	22823644	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CCCO1		CHEMBL4751655	=	IC50	nM	0.22	CHEMBL5251	Homo sapiens	IC50	nM	0.22
	22823645	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1(O)CCC1		CHEMBL4788780	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
	22823646	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C(C)(C)O		CHEMBL4756290	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
	22823647	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C(C)(C)CO		CHEMBL4781173	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
	22823648	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H](O)C(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4784814	=	IC50	nM	0.15	CHEMBL5251	Homo sapiens	IC50	nM	0.15
	22823649	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)[C@@H](C)O		CHEMBL4798236	=	IC50	nM	0.19	CHEMBL5251	Homo sapiens	IC50	nM	0.19
	22823650	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	Cc1oncc1C(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4764139	=	IC50	nM	0.45	CHEMBL5251	Homo sapiens	IC50	nM	0.45
	22823651	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	COCCC(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4761778	=	IC50	nM	0.36	CHEMBL5251	Homo sapiens	IC50	nM	0.36
	22823652	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CCC(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4798188	=	IC50	nM	0.28	CHEMBL5251	Homo sapiens	IC50	nM	0.28
	22823653	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4752314	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
	22823654	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@@H]2C(F)(F)F)COC1		CHEMBL4753001	=	IC50	nM	3.7	CHEMBL5251	Homo sapiens	IC50	nM	3.7
	22823655	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	COC[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)CN1C(=O)C1(C)COC1		CHEMBL4746292	=	IC50	nM	0.31	CHEMBL5251	Homo sapiens	IC50	nM	0.31
	22823656	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]2C(F)F)COC1		CHEMBL4778161	=	IC50	nM	0.86	CHEMBL5251	Homo sapiens	IC50	nM	0.86
	22823657	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1(C)COC1		CHEMBL4744759	=	IC50	nM	0.17	CHEMBL5251	Homo sapiens	IC50	nM	0.17
	22823658	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)c(F)c4F)c4c(N)nccn34)C2)COC1		CHEMBL4787427	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
	22823659	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	COc1cc(-c2nc([C@@H]3CCCN(C(=O)C4(C)COC4)C3)n3ccnc(N)c23)ccc1C(=O)Nc1cc(C(F)(F)F)ccn1		CHEMBL4751902	=	IC50	nM	0.98	CHEMBL5251	Homo sapiens	IC50	nM	0.98
	22823660	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4OC(F)(F)F)c4c(N)nccn34)C2)COC1		CHEMBL4794146	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	22823661	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CCCN(C(=O)C3(C)COC3)C2)n2ccnc(N)c12		CHEMBL4747860	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	22823662	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)c(Cl)c4)c4c(N)nccn34)C2)COC1		CHEMBL4758341	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
	22823663	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)c(F)c4)c4c(N)nccn34)C2)COC1		CHEMBL4779908	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	22823664	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5ncc(C#N)s5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4750989	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	22823665	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5nccs5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4784093	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
	22823666	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)cn1		CHEMBL4757012	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	22823667	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	Cc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)n1		CHEMBL4741355	=	IC50	nM	104.0	CHEMBL5251	Homo sapiens	IC50	nM	104.0
	22823668	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CCc1cc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)ncn1		CHEMBL4756638	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	22823669	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cccnn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4743945	=	IC50	nM	65.0	CHEMBL5251	Homo sapiens	IC50	nM	65.0
	22823670	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	Cc1cccnc1NC(=O)c1ccc(-c2nc([C@@H]3CCCN(C(=O)C4(C)COC4)C3)n3ccnc(N)c23)c(F)c1		CHEMBL4755174	=	IC50	nM	106.0	CHEMBL5251	Homo sapiens	IC50	nM	106.0
	22823671	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(OC(F)(F)Cl)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4743911	=	IC50	nM	0.42	CHEMBL5251	Homo sapiens	IC50	nM	0.42
	22823672	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(-n6cccn6)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4783242	=	IC50	nM	0.53	CHEMBL5251	Homo sapiens	IC50	nM	0.53
	22823673	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(OC6CC6)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4757180	=	IC50	nM	0.52	CHEMBL5251	Homo sapiens	IC50	nM	0.52
	22823674	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CCOc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL4764215	=	IC50	nM	0.41	CHEMBL5251	Homo sapiens	IC50	nM	0.41
	22823675	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C#N)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4744308	=	IC50	nM	0.37	CHEMBL5251	Homo sapiens	IC50	nM	0.37
	22823676	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C6CC6)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4794031	=	IC50	nM	0.74	CHEMBL5251	Homo sapiens	IC50	nM	0.74
	22823677	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)F)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4800034	=	IC50	nM	0.71	CHEMBL5251	Homo sapiens	IC50	nM	0.71
	22823678	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	Cc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL4796764	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	22823679	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	0.31	CHEMBL5251	Homo sapiens	IC50	nM	0.31
	22823680	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4799627	=	IC50	nM	0.32	CHEMBL5251	Homo sapiens	IC50	nM	0.32
	22823681	CHEMBL4717034	Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide as substrate preincubated for 60 mins followed by substrate addition and measured after 120 mins in presence of ATP by TR-FRET assay	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4094125	=	IC50	nM	0.27	CHEMBL5251	Homo sapiens	IC50	nM	0.27
	22823682	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CCCO1		CHEMBL4751655	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	22823683	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1(O)CCC1		CHEMBL4788780	=	IC50	nM	9.8	CHEMBL5251	Homo sapiens	IC50	nM	9.8
	22823684	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C(C)(C)O		CHEMBL4756290	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	22823685	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C(C)(C)CO		CHEMBL4781173	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	22823686	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H](O)C(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4784814	=	IC50	nM	2.4	CHEMBL5251	Homo sapiens	IC50	nM	2.4
	22823687	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)[C@@H](C)O		CHEMBL4798236	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
	22823688	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Cc1oncc1C(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4764139	=	IC50	nM	4.3	CHEMBL5251	Homo sapiens	IC50	nM	4.3
	22823689	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	COCCC(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4761778	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	22823690	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CCC(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4798188	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	22823691	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC(=O)N1C[C@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CC[C@@H]1C		CHEMBL4752314	=	IC50	nM	3.9	CHEMBL5251	Homo sapiens	IC50	nM	3.9
Not Determined	22823692	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@@H]2C(F)(F)F)COC1		CHEMBL4753001		IC50			CHEMBL5251	Homo sapiens	IC50		
	22823693	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	COC[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c3c(N)nccn23)CN1C(=O)C1(C)COC1		CHEMBL4746292	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	22823694	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]2C(F)F)COC1		CHEMBL4778161	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	22823695	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1(C)COC1		CHEMBL4744759	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	22823696	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)c(F)c4F)c4c(N)nccn34)C2)COC1		CHEMBL4787427	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	22823697	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	COc1cc(-c2nc([C@@H]3CCCN(C(=O)C4(C)COC4)C3)n3ccnc(N)c23)ccc1C(=O)Nc1cc(C(F)(F)F)ccn1		CHEMBL4751902	=	IC50	nM	48.0	CHEMBL5251	Homo sapiens	IC50	nM	48.0
Not Determined	22823698	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4OC(F)(F)F)c4c(N)nccn34)C2)COC1		CHEMBL4794146		IC50			CHEMBL5251	Homo sapiens	IC50		
	22823699	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CCCN(C(=O)C3(C)COC3)C2)n2ccnc(N)c12		CHEMBL4747860	=	IC50	nM	40.0	CHEMBL5251	Homo sapiens	IC50	nM	40.0
	22823700	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)c(Cl)c4)c4c(N)nccn34)C2)COC1		CHEMBL4758341	=	IC50	nM	181.0	CHEMBL5251	Homo sapiens	IC50	nM	181.0
	22823701	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)c(F)c4)c4c(N)nccn34)C2)COC1		CHEMBL4779908	=	IC50	nM	81.0	CHEMBL5251	Homo sapiens	IC50	nM	81.0
Not Determined	22823702	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5ncc(C#N)s5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4750989		IC50			CHEMBL5251	Homo sapiens	IC50		
	22823703	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5nccs5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4784093	=	IC50	nM	126.0	CHEMBL5251	Homo sapiens	IC50	nM	126.0
	22823704	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Cc1cnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)cn1		CHEMBL4757012	=	IC50	nM	350.0	CHEMBL5251	Homo sapiens	IC50	nM	350.0
	22823705	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Cc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)n1		CHEMBL4741355	=	IC50	nM	9967.0	CHEMBL5251	Homo sapiens	IC50	nM	9967.0
Not Determined	22823706	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CCc1cc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)ncn1		CHEMBL4756638		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22823707	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cccnn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4743945		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22823708	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Cc1cccnc1NC(=O)c1ccc(-c2nc([C@@H]3CCCN(C(=O)C4(C)COC4)C3)n3ccnc(N)c23)c(F)c1		CHEMBL4755174		IC50			CHEMBL5251	Homo sapiens	IC50		
	22823709	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(OC(F)(F)Cl)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4743911	=	IC50	nM	4.9	CHEMBL5251	Homo sapiens	IC50	nM	4.9
	22823710	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(-n6cccn6)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4783242	=	IC50	nM	47.0	CHEMBL5251	Homo sapiens	IC50	nM	47.0
	22823711	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(OC6CC6)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4757180	=	IC50	nM	18.0	CHEMBL5251	Homo sapiens	IC50	nM	18.0
	22823712	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CCOc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL4764215	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	nM	19.0
	22823713	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C#N)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4744308	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	22823714	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C6CC6)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4794031	=	IC50	nM	38.0	CHEMBL5251	Homo sapiens	IC50	nM	38.0
	22823715	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)F)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4800034	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
	22823716	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Cc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCN(C(=O)C5(C)COC5)C4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL4796764	=	IC50	nM	50.0	CHEMBL5251	Homo sapiens	IC50	nM	50.0
	22823717	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	22823718	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4799627	=	IC50	nM	7.5	CHEMBL5251	Homo sapiens	IC50	nM	7.5
	22823719	CHEMBL4717035	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4094125	=	IC50	nM	8.0	CHEMBL5251	Homo sapiens	IC50	nM	8.0
	22823720	CHEMBL4717036	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	94.0	CHEMBL5251	Homo sapiens	IC50	nM	94.0
	22823721	CHEMBL4717036	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)C2)COC1		CHEMBL4799627	=	IC50	nM	113.0	CHEMBL5251	Homo sapiens	IC50	nM	113.0
	22823722	CHEMBL4717036	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CC1(C(=O)N2CCC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)C2)COC1		CHEMBL4094125	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	22826315	CHEMBL4717500	Inhibition of recombinant full length N-terminal His6-tagged human BTK expressed in baculovirus infected Sf21 cells assessed as residual activity at 10 uM relative to control	B	CN1CCN(CCCOc2cccc3nc(Nc4ccc(Cl)c(C(F)(F)F)c4)ccc23)CC1		CHEMBL4797203	<	Activity	%	60.0	CHEMBL5251	Homo sapiens	Activity	%	60.0
Active	22843001	CHEMBL4720155	Inhibition of BTK in human Raji cells assessed as reduction in PLCgamma2 Y1217 phosphorylation at 0.03 to 10 uM incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22843002	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCc4ccc(F)c(F)c4)cc3)c3c(N)ncnc32)CC1		CHEMBL4793881	=	Inhibition	%	52.7	CHEMBL5251	Homo sapiens	INH	%	52.7
	22843003	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3c(C)noc3C)c3c(N)ncnc32)CC1		CHEMBL4747772	=	Inhibition	%	16.6	CHEMBL5251	Homo sapiens	INH	%	16.6
	22843004	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3cc4ccccc4o3)c3c(N)ncnc32)CC1		CHEMBL4783025	=	Inhibition	%	78.2	CHEMBL5251	Homo sapiens	INH	%	78.2
	22843005	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4cccnc4c3)c3c(N)ncnc32)CC1		CHEMBL4790297	=	Inhibition	%	62.4	CHEMBL5251	Homo sapiens	INH	%	62.4
	22843006	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(C3=CCCCC3)c3c(N)ncnc32)CC1		CHEMBL4786758	=	Inhibition	%	73.3	CHEMBL5251	Homo sapiens	INH	%	73.3
	22843007	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(C(=O)OC)cc3)c3c(N)ncnc32)CC1		CHEMBL4742839	=	Inhibition	%	34.9	CHEMBL5251	Homo sapiens	INH	%	34.9
	22843008	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCCO4)c3c(N)ncnc32)CC1		CHEMBL4763107	=	Inhibition	%	88.6	CHEMBL5251	Homo sapiens	INH	%	88.6
	22843009	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(CO)cc3)c3c(N)ncnc32)CC1		CHEMBL4758845	=	Inhibition	%	73.5	CHEMBL5251	Homo sapiens	INH	%	73.5
	22843010	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698	=	Inhibition	%	98.3	CHEMBL5251	Homo sapiens	INH	%	98.3
	22843011	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCCOC)cc3)c3c(N)ncnc32)CC1		CHEMBL4757262	=	Inhibition	%	84.3	CHEMBL5251	Homo sapiens	INH	%	84.3
	22843012	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCC)cc3)c3c(N)ncnc32)CC1		CHEMBL4799134	=	Inhibition	%	87.4	CHEMBL5251	Homo sapiens	INH	%	87.4
	22843013	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OC)cc3)c3c(N)ncnc32)CC1		CHEMBL4792644	=	Inhibition	%	89.7	CHEMBL5251	Homo sapiens	INH	%	89.7
	22843014	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(O)cc3)c3c(N)ncnc32)CC1		CHEMBL4784114	=	Inhibition	%	94.9	CHEMBL5251	Homo sapiens	INH	%	94.9
	22843015	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(S(C)(=O)=O)cc3)c3c(N)ncnc32)CC1		CHEMBL4749615	=	Inhibition	%	34.0	CHEMBL5251	Homo sapiens	INH	%	34.0
	22843016	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(F)cn3)c3c(N)ncnc32)CC1		CHEMBL4763190	=	Inhibition	%	94.2	CHEMBL5251	Homo sapiens	INH	%	94.2
	22843017	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(C(F)(F)F)cc3)c3c(N)ncnc32)CC1		CHEMBL4760219	=	Inhibition	%	73.6	CHEMBL5251	Homo sapiens	INH	%	73.6
	22843018	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OC(F)(F)F)cc3)c3c(N)ncnc32)CC1		CHEMBL4797298	=	Inhibition	%	52.8	CHEMBL5251	Homo sapiens	INH	%	52.8
	22843019	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(F)cc3)c3c(N)ncnc32)CC1		CHEMBL4777708	=	Inhibition	%	92.8	CHEMBL5251	Homo sapiens	INH	%	92.8
	22843020	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3cccc(Cl)c3)c3c(N)ncnc32)CC1		CHEMBL4740753	=	Inhibition	%	73.3	CHEMBL5251	Homo sapiens	INH	%	73.3
	22843021	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(-c4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4753798	=	Inhibition	%	43.1	CHEMBL5251	Homo sapiens	INH	%	43.1
	22843022	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(C(=O)N4CCOCC4)cc3)c3c(N)ncnc32)CC1		CHEMBL4779185	=	Inhibition	%	8.3	CHEMBL5251	Homo sapiens	INH	%	8.3
	22843023	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccn4)cc3)c3c(N)ncnc32)CC1		CHEMBL4764643	=	Inhibition	%	90.0	CHEMBL5251	Homo sapiens	INH	%	90.0
	22843024	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4759514	=	Inhibition	%	91.0	CHEMBL5251	Homo sapiens	INH	%	91.0
	22843025	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4749370	=	Inhibition	%	97.6	CHEMBL5251	Homo sapiens	INH	%	97.6
	22843026	CHEMBL4720156	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	99.6	CHEMBL5251	Homo sapiens	INH	%	99.6
	22843027	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCc4ccc(F)c(F)c4)cc3)c3c(N)ncnc32)CC1		CHEMBL4793881	=	Inhibition	%	10.6	CHEMBL5251	Homo sapiens	INH	%	10.6
	22843028	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3c(C)noc3C)c3c(N)ncnc32)CC1		CHEMBL4747772	=	Inhibition	%	4.7	CHEMBL5251	Homo sapiens	INH	%	4.7
	22843029	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3cc4ccccc4o3)c3c(N)ncnc32)CC1		CHEMBL4783025	=	Inhibition	%	17.0	CHEMBL5251	Homo sapiens	INH	%	17.0
	22843030	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4cccnc4c3)c3c(N)ncnc32)CC1		CHEMBL4790297	=	Inhibition	%	14.9	CHEMBL5251	Homo sapiens	INH	%	14.9
	22843031	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(C3=CCCCC3)c3c(N)ncnc32)CC1		CHEMBL4786758	=	Inhibition	%	18.4	CHEMBL5251	Homo sapiens	INH	%	18.4
	22843032	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(C(=O)OC)cc3)c3c(N)ncnc32)CC1		CHEMBL4742839	=	Inhibition	%	12.4	CHEMBL5251	Homo sapiens	INH	%	12.4
	22843033	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCCO4)c3c(N)ncnc32)CC1		CHEMBL4763107	=	Inhibition	%	31.7	CHEMBL5251	Homo sapiens	INH	%	31.7
	22843034	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(CO)cc3)c3c(N)ncnc32)CC1		CHEMBL4758845	=	Inhibition	%	0.6	CHEMBL5251	Homo sapiens	INH	%	0.6
	22843035	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698	=	Inhibition	%	82.4	CHEMBL5251	Homo sapiens	INH	%	82.4
	22843036	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCCOC)cc3)c3c(N)ncnc32)CC1		CHEMBL4757262	=	Inhibition	%	32.6	CHEMBL5251	Homo sapiens	INH	%	32.6
	22843037	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCC)cc3)c3c(N)ncnc32)CC1		CHEMBL4799134	=	Inhibition	%	35.8	CHEMBL5251	Homo sapiens	INH	%	35.8
	22843038	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OC)cc3)c3c(N)ncnc32)CC1		CHEMBL4792644	=	Inhibition	%	39.5	CHEMBL5251	Homo sapiens	INH	%	39.5
	22843039	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(O)cc3)c3c(N)ncnc32)CC1		CHEMBL4784114	=	Inhibition	%	48.5	CHEMBL5251	Homo sapiens	INH	%	48.5
	22843040	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(S(C)(=O)=O)cc3)c3c(N)ncnc32)CC1		CHEMBL4749615	=	Inhibition	%	14.7	CHEMBL5251	Homo sapiens	INH	%	14.7
	22843041	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(F)cn3)c3c(N)ncnc32)CC1		CHEMBL4763190	=	Inhibition	%	47.4	CHEMBL5251	Homo sapiens	INH	%	47.4
	22843042	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(C(F)(F)F)cc3)c3c(N)ncnc32)CC1		CHEMBL4760219	=	Inhibition	%	16.0	CHEMBL5251	Homo sapiens	INH	%	16.0
	22843043	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OC(F)(F)F)cc3)c3c(N)ncnc32)CC1		CHEMBL4797298	=	Inhibition	%	9.2	CHEMBL5251	Homo sapiens	INH	%	9.2
	22843044	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(F)cc3)c3c(N)ncnc32)CC1		CHEMBL4777708	=	Inhibition	%	50.3	CHEMBL5251	Homo sapiens	INH	%	50.3
	22843045	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3cccc(Cl)c3)c3c(N)ncnc32)CC1		CHEMBL4740753	=	Inhibition	%	6.5	CHEMBL5251	Homo sapiens	INH	%	6.5
	22843046	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(-c4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4753798	=	Inhibition	%	12.5	CHEMBL5251	Homo sapiens	INH	%	12.5
	22843047	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(C(=O)N4CCOCC4)cc3)c3c(N)ncnc32)CC1		CHEMBL4779185	=	Inhibition	%	6.5	CHEMBL5251	Homo sapiens	INH	%	6.5
	22843048	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccn4)cc3)c3c(N)ncnc32)CC1		CHEMBL4764643	=	Inhibition	%	45.3	CHEMBL5251	Homo sapiens	INH	%	45.3
	22843049	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4759514	=	Inhibition	%	54.0	CHEMBL5251	Homo sapiens	INH	%	54.0
	22843050	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4749370	=	Inhibition	%	94.1	CHEMBL5251	Homo sapiens	INH	%	94.1
	22843051	CHEMBL4720157	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	99.3	CHEMBL5251	Homo sapiens	INH	%	99.3
	22843052	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CS(=O)(=O)N1CCC(Cn2nc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4791520	=	IC50	nM	3220.0	CHEMBL5251	Homo sapiens	IC50	uM	3.22
	22843053	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2nc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4760364	=	IC50	nM	70700.0	CHEMBL5251	Homo sapiens	IC50	uM	70.7
	22843054	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CS(=O)(=O)N1CCC(Cn2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4752349	=	IC50	nM	1790.0	CHEMBL5251	Homo sapiens	IC50	uM	1.79
	22843055	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4798274	=	IC50	nM	2460.0	CHEMBL5251	Homo sapiens	IC50	uM	2.46
	22843056	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	CN(C)C/C=C/C(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4756276	=	IC50	nM	1710.0	CHEMBL5251	Homo sapiens	IC50	uM	1.71
	22843057	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CS(=O)(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4793094	=	IC50	nM	83550.0	CHEMBL5251	Homo sapiens	IC50	uM	83.55
	22843058	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	CN(C)C/C=C/C(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4796406	=	IC50	nM	7340.0	CHEMBL5251	Homo sapiens	IC50	uM	7.34
	22843059	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CS(=O)(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4762013	=	IC50	nM	21700.0	CHEMBL5251	Homo sapiens	IC50	uM	21.7
	22843060	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(CCn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4779219	=	IC50	nM	77040.0	CHEMBL5251	Homo sapiens	IC50	uM	77.04
	22843061	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(CCn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4784737	=	IC50	nM	6090.0	CHEMBL5251	Homo sapiens	IC50	uM	6.09
	22843062	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC[C@H](Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4762469	=	IC50	nM	810.0	CHEMBL5251	Homo sapiens	IC50	uM	0.81
	22843063	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC[C@H](Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4798432	=	IC50	nM	1710.0	CHEMBL5251	Homo sapiens	IC50	uM	1.71
	22843064	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC[C@@H](Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)C1		CHEMBL4798332	=	IC50	nM	83550.0	CHEMBL5251	Homo sapiens	IC50	uM	83.55
	22843065	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC[C@@H](Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL4790832	=	IC50	nM	7340.0	CHEMBL5251	Homo sapiens	IC50	uM	7.34
	22843066	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698	=	IC50	nM	21700.0	CHEMBL5251	Homo sapiens	IC50	uM	21.7
	22843067	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(OCc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4759514	=	IC50	nM	77040.0	CHEMBL5251	Homo sapiens	IC50	uM	77.04
	22843068	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1		CHEMBL4749370	=	IC50	nM	6090.0	CHEMBL5251	Homo sapiens	IC50	uM	6.09
	22843069	CHEMBL4720158	Inhibition of BTK (unknown origin) by caliper mobility shift assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	810.0	CHEMBL5251	Homo sapiens	IC50	uM	0.81
	22843124	CHEMBL4720163	Reversible inhibition of BTK (unknown origin) assessed as association rate constant by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698	=	Ka	/nM/min	0.000578	CHEMBL5251	Homo sapiens	Ka	/nM/min	0.0005780000000000001
	22843125	CHEMBL4720164	Reversible inhibition of BTK (unknown origin) assessed as dissociation rate constant by caliper mobility shift assay	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1	Non standard unit for type	CHEMBL4755698	=	Kd	/nM/min	0.03116	CHEMBL5251	Homo sapiens	Kd	/nM/min	0.031160000000000004
Dose-dependent effect	22843128	CHEMBL4720166	Inhibition of BTK in human Daudi cells assessed as reduction in BTK Y223 phosphorylation incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	22843129	CHEMBL4720167	Inhibition of BTK in human U2932 cells assessed as reduction in BTK Y223 phosphorylation incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-dependent effect	22843130	CHEMBL4720168	Inhibition of BTK in human Raji cells assessed as reduction in BTK Y223 phosphorylation incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	22843131	CHEMBL4720169	Inhibition of BTK in human Daudi cells assessed as reduction in BTK Y551 phosphorylation at 0.03 to 10 uM incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	22843132	CHEMBL4720170	Inhibition of BTK in human U2932 cells assessed as reduction in BTK Y551 phosphorylation at 0.03 to 10 uM incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	22843133	CHEMBL4720171	Inhibition of BTK in human Raji cells assessed as reduction in BTK Y551 phosphorylation at 0.03 to 10 uM incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22843134	CHEMBL4720172	Inhibition of BTK in human Daudi cells assessed as reduction in PLCgamma2 Y1217 phosphorylation at 0.03 to 10 uM incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22843135	CHEMBL4720173	Inhibition of BTK in human U2932 cells assessed as reduction in PLCgamma2 Y1217 phosphorylation at 0.03 to 10 uM incubated for 1 hr by Western blot analysis	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22843485	CHEMBL4720482	Inhibition of human BTK assessed as residual activity using KVEKIGEGTYGVVYK as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	78.7	CHEMBL5251	Homo sapiens	Activity	%	78.7
	22843836	CHEMBL4720822	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	17.2	CHEMBL5251	Homo sapiens	IC50	10^-8M	1.72
	22844633	CHEMBL4721308	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	101.12	CHEMBL5251	Homo sapiens	Activity	%	101.12
	22853931	CHEMBL4724374	Inhibition of BTK (unknown origin)	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.72	CHEMBL5251	Homo sapiens	IC50	nM	0.72
	22877336	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	C=CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4745935	=	IC50	nM	3.5	CHEMBL5251	Homo sapiens	IC50	nM	3.5
	22877337	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	C=CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4cc(CC)ccn4)cc3)c2c1		CHEMBL4752700	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	22877338	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CN(C)C/C=C/C(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4787517	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	22877339	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CC#CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4800082	=	IC50	nM	4.7	CHEMBL5251	Homo sapiens	IC50	nM	4.7
	22877340	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	COCC#CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4744536	=	IC50	nM	0.15	CHEMBL5251	Homo sapiens	IC50	nM	0.15
	22877341	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	O=C(C#CCO)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4791702	=	IC50	nM	0.33	CHEMBL5251	Homo sapiens	IC50	nM	0.33
	22877342	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	O=C(C#CCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4763873	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
	22877343	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	O=C(C#CCCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4792062	=	IC50	nM	0.8	CHEMBL5251	Homo sapiens	IC50	nM	0.8
	22877344	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CCN1CCN(CC#CC(=O)Nc2ccc3nccc(Oc4ccc(C(=O)Nc5ccccn5)cc4)c3c2)CC1		CHEMBL4796130	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	22877345	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OC		CHEMBL4743222	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	22877346	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OC1CCOCC1		CHEMBL4791135	=	IC50	nM	3.8	CHEMBL5251	Homo sapiens	IC50	nM	3.8
	22877347	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4756092	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	22877348	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	CC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OCCN1CCOCC1		CHEMBL4782725	=	IC50	nM	0.54	CHEMBL5251	Homo sapiens	IC50	nM	0.54
	22877349	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	COCC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OC		CHEMBL4794213	=	IC50	nM	0.96	CHEMBL5251	Homo sapiens	IC50	nM	0.96
	22877350	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	COc1cc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2cc1NC(=O)C#CCCN1CCOCC1		CHEMBL4755977	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	22877351	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	COc1cc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2cc1NC(=O)C#CCN1CCOCC1		CHEMBL4759528	=	IC50	nM	0.47	CHEMBL5251	Homo sapiens	IC50	nM	0.47
	22877352	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	C=CC(=O)Nc1ccc2ncnc(Nc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4779297	=	EC50	nM	18.0	CHEMBL5251	Homo sapiens	EC50	nM	18.0
	22877353	CHEMBL4726179	Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lyntide substrate preincubated with enzyme for 60 mins followed by further incubation with substrate and ATP for 120 mins by IMAP assay	B	C=CC(=O)Nc1ccc2ncnc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4798086	=	EC50	nM	7.2	CHEMBL5251	Homo sapiens	EC50	nM	7.2
	22877417	CHEMBL4726192	Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay	B	C=CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4cc(CC)ccn4)cc3)c2c1		CHEMBL4752700	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	22877418	CHEMBL4726192	Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay	B	CC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OCCN1CCOCC1		CHEMBL4782725	=	IC50	nM	8.3	CHEMBL5251	Homo sapiens	IC50	nM	8.3
	22877419	CHEMBL4726192	Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay	B	COc1cc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2cc1NC(=O)C#CCCN1CCOCC1		CHEMBL4755977	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	22877420	CHEMBL4726192	Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.43	CHEMBL5251	Homo sapiens	IC50	nM	0.43
	22877421	CHEMBL4726192	Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	3.1	CHEMBL5251	Homo sapiens	IC50	nM	3.1
Tde	22877482	CHEMBL4726210	Covalent inhibition of His-tagged human full length recombinant BTK expressed in baculovirus expression system incubated for 5 to 120 mins by Lanthascreen TR-FRET assay	B	C=CC(=O)Nc1ccc2ncnc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1		CHEMBL4798086		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22882737	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	0.31	CHEMBL5251	Homo sapiens	IC50	nM	0.31
	22882738	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4749037	=	IC50	nM	0.083	CHEMBL5251	Homo sapiens	IC50	nM	0.083
	22882739	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106978	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	22882740	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3942777	=	IC50	nM	0.13	CHEMBL5251	Homo sapiens	IC50	nM	0.13
	22882741	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4110644	=	IC50	nM	0.11	CHEMBL5251	Homo sapiens	IC50	nM	0.11
	22882742	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	CC1(C)OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]21		CHEMBL4108687	=	IC50	nM	0.12	CHEMBL5251	Homo sapiens	IC50	nM	0.12
	22882743	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@H]3CN4C(=O)CC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4114094	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
	22882744	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@H]3CN4C(=O)OC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4759341	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	22882745	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	CN1C[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4110412	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	22882746	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCN4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106651	=	IC50	nM	0.67	CHEMBL5251	Homo sapiens	IC50	nM	0.67
	22882747	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4111979	=	IC50	nM	1.7	CHEMBL5251	Homo sapiens	IC50	nM	1.7
	22882748	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4COCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108825	=	IC50	nM	0.1	CHEMBL5251	Homo sapiens	IC50	nM	0.1
	22882749	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	CN1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4757041	=	IC50	nM	0.26	CHEMBL5251	Homo sapiens	IC50	nM	0.26
	22882750	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114929	=	IC50	nM	0.21	CHEMBL5251	Homo sapiens	IC50	nM	0.21
	22882751	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108563	=	IC50	nM	0.11	CHEMBL5251	Homo sapiens	IC50	nM	0.11
	22882752	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110388	=	IC50	nM	0.16	CHEMBL5251	Homo sapiens	IC50	nM	0.16
	22882753	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)F)c12		CHEMBL4111338	=	IC50	nM	0.48	CHEMBL5251	Homo sapiens	IC50	nM	0.48
	22882754	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3O)c12		CHEMBL4110993	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
	22882755	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CC3)c12		CHEMBL4107779	=	IC50	nM	0.58	CHEMBL5251	Homo sapiens	IC50	nM	0.58
	22882756	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	CC(C)Oc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4113636	=	IC50	nM	5.7	CHEMBL5251	Homo sapiens	IC50	nM	5.7
	22882757	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Oc3ccccc3)c12		CHEMBL4797320	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	22882758	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	NC(=O)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110727	=	IC50	nM	348.0	CHEMBL5251	Homo sapiens	IC50	nM	348.0
	22882759	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(=O)O)c12		CHEMBL4111886	=	IC50	nM	83.0	CHEMBL5251	Homo sapiens	IC50	nM	83.0
	22882760	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	N#Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4107939	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
	22882761	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	CC(F)(F)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110264	=	IC50	nM	831.0	CHEMBL5251	Homo sapiens	IC50	nM	831.0
	22882762	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(F)(F)F)c12		CHEMBL4762298	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	22882763	CHEMBL4727415	Inhibition of recombinant full length BTK (unknown origin) expressed in baculovirus infected Sf9 cells using Biotin-EQEDEPEGDYFEWLE-NH2 peptide as substrate incubated for 60 mins followed by further incubation with substrate and ATP for 120 mins by TR-FRET assay	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)(F)F)c12		CHEMBL4782472	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	22882764	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	22882765	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4749037	=	IC50	nM	5.8	CHEMBL5251	Homo sapiens	IC50	nM	5.8
	22882766	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106978	=	IC50	nM	2.5	CHEMBL5251	Homo sapiens	IC50	nM	2.5
	22882767	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3942777	=	IC50	nM	4.9	CHEMBL5251	Homo sapiens	IC50	nM	4.9
	22882768	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4110644	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
	22882769	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC1(C)OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]21		CHEMBL4108687	=	IC50	nM	2.8	CHEMBL5251	Homo sapiens	IC50	nM	2.8
	22882770	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@H]3CN4C(=O)CC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4114094	=	IC50	nM	7.2	CHEMBL5251	Homo sapiens	IC50	nM	7.2
	22882771	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@H]3CN4C(=O)OC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4759341	=	IC50	nM	582.0	CHEMBL5251	Homo sapiens	IC50	nM	582.0
	22882772	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CN1C[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4110412	=	IC50	nM	403.0	CHEMBL5251	Homo sapiens	IC50	nM	403.0
	22882773	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCN4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106651	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	22882774	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4111979	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	22882775	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4COCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108825	=	IC50	nM	5.8	CHEMBL5251	Homo sapiens	IC50	nM	5.8
	22882776	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CN1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4757041	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	22882777	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114929	=	IC50	nM	17.0	CHEMBL5251	Homo sapiens	IC50	nM	17.0
	22882778	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108563	=	IC50	nM	4.0	CHEMBL5251	Homo sapiens	IC50	nM	4.0
	22882779	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110388	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	22882780	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)F)c12		CHEMBL4111338	=	IC50	nM	20.0	CHEMBL5251	Homo sapiens	IC50	nM	20.0
	22882781	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3O)c12		CHEMBL4110993	=	IC50	nM	11.0	CHEMBL5251	Homo sapiens	IC50	nM	11.0
	22882782	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CC3)c12		CHEMBL4107779	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	22882783	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC(C)Oc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4113636	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
	22882784	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Oc3ccccc3)c12		CHEMBL4797320	=	IC50	nM	310.0	CHEMBL5251	Homo sapiens	IC50	nM	310.0
	22882785	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	NC(=O)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110727	>	IC50	nM	3000.0	CHEMBL5251	Homo sapiens	IC50	nM	3000.0
	22882786	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(=O)O)c12		CHEMBL4111886	=	IC50	nM	1410.0	CHEMBL5251	Homo sapiens	IC50	nM	1410.0
	22882787	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	N#Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4107939	=	IC50	nM	267.0	CHEMBL5251	Homo sapiens	IC50	nM	267.0
	22882788	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	CC(F)(F)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110264	=	IC50	nM	822.0	CHEMBL5251	Homo sapiens	IC50	nM	822.0
	22882789	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(F)(F)F)c12		CHEMBL4762298	>	IC50	nM	3000.0	CHEMBL5251	Homo sapiens	IC50	nM	3000.0
	22882790	CHEMBL4727416	Inhibition of BTK in human PBMC assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with goat anti-human IgM F(ab')2 for 18 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)(F)F)c12		CHEMBL4782472	=	IC50	nM	74.0	CHEMBL5251	Homo sapiens	IC50	nM	74.0
	22882791	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	C[C@H]1CC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c3c(N)nccn23)CN1C(=O)C1CC1		CHEMBL4103954	=	IC50	nM	94.0	CHEMBL5251	Homo sapiens	IC50	nM	94.0
	22882792	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4COC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4749037	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	22882793	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106978	=	IC50	nM	24.0	CHEMBL5251	Homo sapiens	IC50	nM	24.0
	22882794	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	C[C@@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL3942777	=	IC50	nM	86.0	CHEMBL5251	Homo sapiens	IC50	nM	86.0
	22882795	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	C[C@H]1OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@@H]12		CHEMBL4110644	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	22882796	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CC1(C)OC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CC[C@H]21		CHEMBL4108687	=	IC50	nM	58.0	CHEMBL5251	Homo sapiens	IC50	nM	58.0
	22882797	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@H]3CN4C(=O)CC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4114094	=	IC50	nM	263.0	CHEMBL5251	Homo sapiens	IC50	nM	263.0
Not Determined	22882798	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@H]3CN4C(=O)OC[C@@H]4CO3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4759341		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882799	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CN1C[C@@H]2CC[C@@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4)c4c(N)nccn34)CN2C1=O		CHEMBL4110412		IC50			CHEMBL5251	Homo sapiens	IC50		
	22882800	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCN4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3)c12		CHEMBL4106651	=	IC50	nM	204.0	CHEMBL5251	Homo sapiens	IC50	nM	204.0
Not Determined	22882801	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4111979		IC50			CHEMBL5251	Homo sapiens	IC50		
	22882802	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4COCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108825	=	IC50	nM	78.0	CHEMBL5251	Homo sapiens	IC50	nM	78.0
	22882803	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CN1CC(=O)N2C[C@H](c3nc(-c4ccc(C(=O)Nc5cc(C(F)(F)F)ccn5)cc4F)c4c(N)nccn34)CC[C@H]2C1		CHEMBL4757041	=	IC50	nM	104.0	CHEMBL5251	Homo sapiens	IC50	nM	104.0
	22882804	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	COc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4114929	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	22882805	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3F)c12		CHEMBL4108563	=	IC50	nM	101.0	CHEMBL5251	Homo sapiens	IC50	nM	101.0
	22882806	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CCOc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110388	=	IC50	nM	92.0	CHEMBL5251	Homo sapiens	IC50	nM	92.0
	22882807	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)F)c12		CHEMBL4111338	=	IC50	nM	415.0	CHEMBL5251	Homo sapiens	IC50	nM	415.0
Not Determined	22882808	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3O)c12		CHEMBL4110993		IC50			CHEMBL5251	Homo sapiens	IC50		
	22882809	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC3CC3)c12		CHEMBL4107779	=	IC50	nM	494.0	CHEMBL5251	Homo sapiens	IC50	nM	494.0
Not Determined	22882810	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CC(C)Oc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4113636		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882811	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3Oc3ccccc3)c12		CHEMBL4797320		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882812	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	NC(=O)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110727		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882813	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(=O)O)c12		CHEMBL4111886		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882814	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	N#Cc1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4107939		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882815	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	CC(F)(F)c1cc(C(=O)Nc2cc(C(F)(F)F)ccn2)ccc1-c1nc([C@@H]2CC[C@H]3CCC(=O)N3C2)n2ccnc(N)c12		CHEMBL4110264		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882816	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3C(F)(F)F)c12		CHEMBL4762298		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Determined	22882817	CHEMBL4727417	Inhibition of BTK in human whole blood assessed as reduction in cell surface CD69 expression preincubated for 1 hr followed by stimulation with anti-CD79b for 3 hrs by immunostaining analysis	B	Nc1nccn2c([C@@H]3CC[C@H]4CCC(=O)N4C3)nc(-c3ccc(C(=O)Nc4cc(C(F)(F)F)ccn4)cc3OC(F)(F)F)c12		CHEMBL4782472		IC50			CHEMBL5251	Homo sapiens	IC50		
Not Active	22889491	CHEMBL4729010	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22897053	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2C(=O)c2ccc(Oc3ccccc3)cc2)C1		CHEMBL3810269	=	IC50	nM	921.0	CHEMBL5251	Homo sapiens	IC50	nM	921.0
	22897054	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc3[nH]c4ccc(Oc5ccccc5)cc4c(=O)c23)C1		CHEMBL4745345	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	22897055	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc(N)c2-n2ncc3cc(Oc4ccccc4)ccc32)C1		CHEMBL4794424	=	IC50	nM	1675.0	CHEMBL5251	Homo sapiens	IC50	nM	1675.0
	22897056	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](Nc2ncnc3[nH]c(=O)c(-c4ccc(Oc5ccccc5)cc4)cc23)C1		CHEMBL4750309	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	22897057	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3cc4c(N)ncnc4cc32)C1		CHEMBL4763135	=	IC50	nM	1244.0	CHEMBL5251	Homo sapiens	IC50	nM	1244.0
	22897058	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3cc4c(N)noc4cc32)C1		CHEMBL4762560	=	IC50	nM	4664.0	CHEMBL5251	Homo sapiens	IC50	nM	4664.0
	22897059	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)noc(=O)c32)C1		CHEMBL4751469	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	22897060	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4754834	=	IC50	nM	2.1	CHEMBL5251	Homo sapiens	IC50	nM	2.1
	22897061	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nn(C)c(=O)c32)C1		CHEMBL4763637	=	IC50	nM	160.0	CHEMBL5251	Homo sapiens	IC50	nM	160.0
	22897062	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nn(CC)c(=O)c32)C1		CHEMBL4743952	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	22897063	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nn(CC(F)(F)F)c(=O)c32)C1		CHEMBL4791758	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	22897064	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4761068	=	IC50	nM	1.4	CHEMBL5251	Homo sapiens	IC50	nM	1.4
	22897065	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4748568	=	IC50	nM	9.8	CHEMBL5251	Homo sapiens	IC50	nM	9.8
	22897066	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4785747	=	IC50	nM	6.7	CHEMBL5251	Homo sapiens	IC50	nM	6.7
	22897067	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CC2(CC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)n[nH]c(=O)c43)C2)C1		CHEMBL4764132	=	IC50	nM	46.0	CHEMBL5251	Homo sapiens	IC50	nM	46.0
	22897068	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)CC1		CHEMBL4746704	=	IC50	nM	1.6	CHEMBL5251	Homo sapiens	IC50	nM	1.6
	22897069	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)NC1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4784750	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	22897070	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)n[nH]c(=O)c21		CHEMBL4748236	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	22897071	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	CN(C)C/C=C/C(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)n[nH]c(=O)c21		CHEMBL4794025	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	nM	35.0
	22897072	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CS(=O)(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4752442	=	IC50	nM	4.2	CHEMBL5251	Homo sapiens	IC50	nM	4.2
	22897073	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4758840	=	IC50	nM	2.6	CHEMBL5251	Homo sapiens	IC50	nM	2.6
	22897074	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	Nc1n[nH]c(=O)c2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1		CHEMBL4756629	=	IC50	nM	13.0	CHEMBL5251	Homo sapiens	IC50	nM	13.0
	22897075	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	N#C/C(=C\C1CC1)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4776688	=	IC50	nM	22.0	CHEMBL5251	Homo sapiens	IC50	nM	22.0
	22897076	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	CC#CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1		CHEMBL4759591	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	22897077	CHEMBL4730742	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	2.0	CHEMBL5251	Homo sapiens	IC50	nM	2.0
	22949024	CHEMBL4765731	Inhibition of human BTK assessed as residual activity at 0.1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	97.0	CHEMBL5251	Homo sapiens	Activity	%	97.0
	22949025	CHEMBL4765731	Inhibition of human BTK assessed as residual activity at 0.1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	95.0	CHEMBL5251	Homo sapiens	Activity	%	95.0
	22949026	CHEMBL4765731	Inhibition of human BTK assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	89.0	CHEMBL5251	Homo sapiens	Activity	%	89.0
	22949027	CHEMBL4765731	Inhibition of human BTK assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	100.0	CHEMBL5251	Homo sapiens	Activity	%	100.0
	22949028	CHEMBL4765731	Inhibition of human BTK assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	117.0	CHEMBL5251	Homo sapiens	Activity	%	117.0
	22949029	CHEMBL4765731	Inhibition of human BTK assessed as residual activity at 0.1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	111.0	CHEMBL5251	Homo sapiens	Activity	%	111.0
	22949030	CHEMBL4765732	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	73.0	CHEMBL5251	Homo sapiens	Activity	%	73.0
	22949031	CHEMBL4765732	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	107.0	CHEMBL5251	Homo sapiens	Activity	%	107.0
	22949032	CHEMBL4765732	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	89.0	CHEMBL5251	Homo sapiens	Activity	%	89.0
	22949033	CHEMBL4765732	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	91.0	CHEMBL5251	Homo sapiens	Activity	%	91.0
	22949034	CHEMBL4765732	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	107.0	CHEMBL5251	Homo sapiens	Activity	%	107.0
	22949035	CHEMBL4765732	Inhibition of human BTK assessed as residual activity at 1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	119.0	CHEMBL5251	Homo sapiens	Activity	%	119.0
	22952766	CHEMBL4766703	Inhibition of recombinant full length human BTK assessed as residual activity at 10 uM using KVEKIGEGTYGVVYK substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	88.0	CHEMBL5251	Homo sapiens	Activity	%	88.0
	22955540	CHEMBL4767597	Inhibition of His-tagged full length, recombinant human BTK expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12		CHEMBL4785582	=	Inhibition	%	88.0	CHEMBL5251	Homo sapiens	INH	%	88.0
	22964389	CHEMBL4769122	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Inhibition	%	91.3	CHEMBL5251	Homo sapiens	INH	%	91.3
	22964390	CHEMBL4769122	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCO)cc32)c1C		CHEMBL4800500	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	22964391	CHEMBL4769122	Inhibition of wild-type human full length BTK (M1 to S659 residues) expressed in mammalian expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCC(N)=O)cc32)c1C		CHEMBL4781578	=	Inhibition	%	0.0	CHEMBL5251	Homo sapiens	INH	%	0.0
	22967629	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249	=	Inhibition	%	91.1	CHEMBL5251	Homo sapiens	INH	%	91.1
	22967630	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)ccc1C		CHEMBL4795828	=	Inhibition	%	39.1	CHEMBL5251	Homo sapiens	INH	%	39.1
	22967631	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C/C=C/C(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4785421	=	Inhibition	%	4.8	CHEMBL5251	Homo sapiens	INH	%	4.8
	22967632	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)N1CCc2ccc(Nc3ncnc(Nc4ccc(C(=O)N5CCCCC5)cc4)n3)cc21		CHEMBL4786447	=	Inhibition	%	75.8	CHEMBL5251	Homo sapiens	INH	%	75.8
	22967633	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	CC#CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4781024	=	Inhibition	%	8.9	CHEMBL5251	Homo sapiens	INH	%	8.9
	22967634	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	Inhibition	%	101.0	CHEMBL5251	Homo sapiens	INH	%	101.0
	22967635	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2nc(N)nc(Nc3ccc(Oc4ccccc4)cc3)n2)c1		CHEMBL4788736	=	Inhibition	%	17.1	CHEMBL5251	Homo sapiens	INH	%	17.1
	22967636	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2nc(N)nc(Nc3ccc(OCCOC)cc3)n2)c1		CHEMBL4784056	=	Inhibition	%	27.7	CHEMBL5251	Homo sapiens	INH	%	27.7
	22967637	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2nc(Cl)nc(Nc3ccc(Oc4ccccc4)cc3)n2)c1		CHEMBL4783070	=	Inhibition	%	7.3	CHEMBL5251	Homo sapiens	INH	%	7.3
	22967638	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2nc(Cl)nc(Nc3ccc(OCCOC)cc3)n2)c1		CHEMBL4786829	=	Inhibition	%	10.0	CHEMBL5251	Homo sapiens	INH	%	10.0
	22967639	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(OC)cc3)n2)c1		CHEMBL4782141	=	Inhibition	%	31.9	CHEMBL5251	Homo sapiens	INH	%	31.9
	22967640	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(OCCOC)cc3)n2)c1		CHEMBL4790860	=	Inhibition	%	57.1	CHEMBL5251	Homo sapiens	INH	%	57.1
	22967641	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(Oc4ccc(OC)cc4)cc3)n2)c1		CHEMBL4788249	=	Inhibition	%	23.4	CHEMBL5251	Homo sapiens	INH	%	23.4
	22967642	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(-c4cccnc4)cc3)n2)c1		CHEMBL4790659	=	Inhibition	%	66.6	CHEMBL5251	Homo sapiens	INH	%	66.6
	22967643	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(-c4ccc(C)nc4)cc3)n2)c1		CHEMBL4792545	=	Inhibition	%	55.7	CHEMBL5251	Homo sapiens	INH	%	55.7
	22967644	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(-c4ccc(OC)nc4)cc3)n2)c1		CHEMBL4784690	=	Inhibition	%	32.7	CHEMBL5251	Homo sapiens	INH	%	32.7
	22967645	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(-c4ccc(F)nc4)cc3)n2)c1		CHEMBL4799130	=	Inhibition	%	46.8	CHEMBL5251	Homo sapiens	INH	%	46.8
	22967646	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(-c4ccc(Cl)nc4)cc3)n2)c1		CHEMBL4787126	=	Inhibition	%	36.7	CHEMBL5251	Homo sapiens	INH	%	36.7
	22967647	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)c1		CHEMBL4776731	=	Inhibition	%	77.5	CHEMBL5251	Homo sapiens	INH	%	77.5
	22967648	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)Nc4ccccn4)cc3)n2)c1		CHEMBL4791905	=	Inhibition	%	56.3	CHEMBL5251	Homo sapiens	INH	%	56.3
	22967649	CHEMBL4769952	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)Nc4ccc(C)cn4)cc3)n2)c1		CHEMBL4798036	=	Inhibition	%	41.6	CHEMBL5251	Homo sapiens	INH	%	41.6
	22967692	CHEMBL4769955	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249	=	IC50	nM	21.0	CHEMBL5251	Homo sapiens	IC50	nM	21.0
	22967693	CHEMBL4769955	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	C=CC(=O)Nc1cc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)ccc1C		CHEMBL4795828	=	IC50	nM	146.0	CHEMBL5251	Homo sapiens	IC50	nM	146.0
	22967694	CHEMBL4769955	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	C/C=C/C(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4785421	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	22967695	CHEMBL4769955	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	C=CC(=O)N1CCc2ccc(Nc3ncnc(Nc4ccc(C(=O)N5CCCCC5)cc4)n3)cc21		CHEMBL4786447	=	IC50	nM	54.3	CHEMBL5251	Homo sapiens	IC50	nM	54.3
	22967696	CHEMBL4769955	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	CC#CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4781024	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	22967697	CHEMBL4769955	Inhibition of BTK (unknown origin) by ADP-Glo assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.89	CHEMBL5251	Homo sapiens	IC50	nM	0.89
Active	22967714	CHEMBL4769964	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue at 10 uM incubated for 24 hrs by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22967715	CHEMBL4769965	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Tyr557 residue at 3 uM incubated for 24 hrs by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22967716	CHEMBL4769966	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue at 10 uM incubated for 4 hrs by Western blot analysis relative to control	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249	=	Inhibition	%	100.0	CHEMBL5251	Homo sapiens	INH	%	100.0
Active	22967717	CHEMBL4769967	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue at 10 uM incubated for 4 hrs followed by compound wash-out and measured upto 24 hrs by Western blot analysis	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22967726	CHEMBL4769972	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation incubated for 24 hrs by CCK-8 assay	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249	=	IC50	nM	4360.0	CHEMBL5251	Homo sapiens	IC50	uM	4.36
	22967727	CHEMBL4769972	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation incubated for 24 hrs by CCK-8 assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	10350.0	CHEMBL5251	Homo sapiens	IC50	uM	10.35
Dose-dependent effect	22967728	CHEMBL4769972	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation incubated for 24 hrs by CCK-8 assay	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Tde	22967729	CHEMBL4769973	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation at 10 uM measured upto 60 hrs by CCK-8 assay	B	C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1		CHEMBL4791249		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22967730	CHEMBL4769973	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation at 10 uM measured upto 60 hrs by CCK-8 assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	22982177	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	c1cc(N2CCOCC2)ccc1Nc1nc(-c2ccc3cn[nH]c3c2)nc2[nH]ncc12		CHEMBL4784149	=	IC50	nM	167.0	CHEMBL5251	Homo sapiens	IC50	uM	0.16699999999999998
	22982178	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	c1cc2nc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2[nH]1		CHEMBL4781161	>	IC50	nM	20000.0	CHEMBL5251	Homo sapiens	IC50	uM	20.0
	22982179	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	c1nc2c(Nc3ccc(N4CCOCC4)cc3)nc(-c3ccc4cn[nH]c4c3)nc2[nH]1		CHEMBL4785181	=	IC50	nM	73.0	CHEMBL5251	Homo sapiens	IC50	uM	0.073
	22982180	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	c1nc2c(Nc3ccc(N4CCOCC4)cc3)cc(-c3ccc4cn[nH]c4c3)nc2[nH]1		CHEMBL4783559	=	IC50	nM	1450.0	CHEMBL5251	Homo sapiens	IC50	uM	1.45
	22982181	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	c1nc2c(Nc3ccc(N4CCOCC4)cc3)nc(-c3ccc4cn[nH]c4c3)cc2[nH]1		CHEMBL4785298	=	IC50	nM	369.0	CHEMBL5251	Homo sapiens	IC50	uM	0.369
	22982182	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1		CHEMBL3265032	=	IC50	nM	801.0	CHEMBL5251	Homo sapiens	IC50	uM	0.8009999999999999
	22982183	CHEMBL4773121	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Potential transcription error	CHEMBL1873475	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	uM	0.001
Active	22982187	CHEMBL4773123	Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced BCR mediated PLCgamma2 phosphorylation preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis	B	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1		CHEMBL3265032		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22982188	CHEMBL4773124	Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced BTK phosphorylation at Tyr223 residue preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis	B	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1		CHEMBL3265032		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22982189	CHEMBL4773125	Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced BTK phosphorylation at Tyr551 residue preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis	B	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1		CHEMBL3265032		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Not Active	22982190	CHEMBL4773126	Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced ERK phosphorylation preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis	B	c1nc2c(Nc3ccc(N4CCOCC4)cc3)nc(-c3ccc4cn[nH]c4c3)cc2[nH]1		CHEMBL4785298		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	22982191	CHEMBL4773126	Inhibition of BTK in human Ramos cells assessed as reduction in anti-human IgM F(ab)2-induced ERK phosphorylation preincubated for 10 mins followed by stimulated with antihuman IgM F(ab)2 incubated for 60 mins by Western blot analysis	B	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1		CHEMBL3265032		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	23122465	CHEMBL4804816	Inhibition of human BTK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	78.0	CHEMBL5251	Homo sapiens	Activity	%	78.0
	23123160	CHEMBL4805404	Inhibition of human BTK assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	89.0	CHEMBL5251	Homo sapiens	Activity	%	89.0
	23123727	CHEMBL4805971	Inhibition of DNA-tagged human BTK assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	82.0	CHEMBL5251	Homo sapiens	Activity	%	82.0
	23124410	CHEMBL4806421	Inhibition of human BTK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	81.0	CHEMBL5251	Homo sapiens	Activity	%	81.0
	23124411	CHEMBL4806421	Inhibition of human BTK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	77.0	CHEMBL5251	Homo sapiens	Activity	%	77.0
	23127852	CHEMBL4807759	Inhibition of BTK (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	<	Activity	%	25.0	CHEMBL5251	Homo sapiens	Activity	%	25.0
	23127853	CHEMBL4807759	Inhibition of BTK (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	<	Activity	%	25.0	CHEMBL5251	Homo sapiens	Activity	%	25.0
	23127854	CHEMBL4807759	Inhibition of BTK (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Activity	%	25.0	CHEMBL5251	Homo sapiens	Activity	%	25.0
	23166601	CHEMBL4813333	Inhibition of recombinant wild type human N-terminal His6-tagged BTK expressed in baculovirus incubated for 20 mins by TR-FRET based competitive binding assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	IC50	nM	0.55	CHEMBL5251	Homo sapiens	IC50	nM	0.55
	23166602	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	IC50	nM	3.78	CHEMBL5251	Homo sapiens	IC50	uM	0.0037799999999999995
	23166603	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)[C@@H](Cc1ccccc1)NC(=O)c1c[nH]c(C(N)=O)c1		CHEMBL4866645	=	IC50	nM	22.7	CHEMBL5251	Homo sapiens	IC50	uM	0.0227
	23166604	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	=	IC50	nM	4760.0	CHEMBL5251	Homo sapiens	IC50	uM	4.76
	23166605	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	C=CC(=O)N1[C@H](C(=O)N[C@@H](Cc2ccc(C#N)cc2)C(=O)NC)C[C@@H]2CCCC[C@@H]21		CHEMBL4861473	=	IC50	nM	36400.0	CHEMBL5251	Homo sapiens	IC50	uM	36.4
	23166606	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)C[C@@H](Cc1cccc(F)c1)NC(=O)C1CO1		CHEMBL4873655	=	IC50	nM	232.0	CHEMBL5251	Homo sapiens	IC50	uM	0.23199999999999998
	23166607	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	IC50	nM	58.1	CHEMBL5251	Homo sapiens	IC50	uM	0.0581
	23166608	CHEMBL4813334	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	IC50	nM	84.2	CHEMBL5251	Homo sapiens	IC50	uM	0.0842
	23166609	CHEMBL4813335	Inhibition of recombinant wild type human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as residence time incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	TIME	hr	0.15	CHEMBL5251	Homo sapiens	Time	min	9.0
	23166610	CHEMBL4813335	Inhibition of recombinant wild type human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as residence time incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)[C@@H](Cc1ccccc1)NC(=O)c1c[nH]c(C(N)=O)c1		CHEMBL4866645	=	TIME	hr	0.5667	CHEMBL5251	Homo sapiens	Time	min	34.0
	23166611	CHEMBL4813336	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as inactivation constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)C[C@@H](Cc1cccc(F)c1)NC(=O)C1CO1		CHEMBL4873655	=	Kinact	10^-2/s	1.54	CHEMBL5251	Homo sapiens	Kinact	10^-2/s	1.54
	23166612	CHEMBL4813336	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as inactivation constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Kinact	10^-3/s	8.22	CHEMBL5251	Homo sapiens	Kinact	10^-3/s	8.22
	23166613	CHEMBL4813336	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as inactivation constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Kinact	10^-3/s	9.41	CHEMBL5251	Homo sapiens	Kinact	10^-3/s	9.41
	23166614	CHEMBL4813337	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as inhibitory constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)C[C@@H](Cc1cccc(F)c1)NC(=O)C1CO1		CHEMBL4873655	=	Ki	nM	9270.0	CHEMBL5251	Homo sapiens	Ki	uM	9.27
	23166615	CHEMBL4813337	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as inhibitory constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Ki	nM	1250.0	CHEMBL5251	Homo sapiens	Ki	uM	1.25
	23166616	CHEMBL4813337	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as inhibitory constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Ki	nM	1930.0	CHEMBL5251	Homo sapiens	Ki	uM	1.93
	23166617	CHEMBL4813338	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as ratio of inactivation constant to inhibitory constant incubated for 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	=	Ratio	/s/M	59.2	CHEMBL5251	Homo sapiens	Ratio	/s/M	59.2
	23166618	CHEMBL4813338	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as ratio of inactivation constant to inhibitory constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)C[C@@H](Cc1cccc(F)c1)NC(=O)C1CO1		CHEMBL4873655	=	Ratio	/s/M	1660.0	CHEMBL5251	Homo sapiens	Ratio	/s/M	1660.0
	23166619	CHEMBL4813338	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as ratio of inactivation constant to inhibitory constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Ratio	/s/M	6580.0	CHEMBL5251	Homo sapiens	Ratio	/s/M	6580.0
	23166620	CHEMBL4813338	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected in Sf9 cells assessed as ratio of inactivation constant to inhibitory constant incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Ratio	/s/M	4880.0	CHEMBL5251	Homo sapiens	Ratio	/s/M	4880.0
	23166621	CHEMBL4813339	Binding affinity to recombinant human BTK (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	Delta Tm	degrees C	13.2	CHEMBL5251	Homo sapiens	deltaTm	degrees C	13.2
	23166622	CHEMBL4813339	Binding affinity to recombinant human BTK (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	=	Delta Tm	degrees C	6.55	CHEMBL5251	Homo sapiens	deltaTm	degrees C	6.55
	23166623	CHEMBL4813339	Binding affinity to recombinant human BTK (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Delta Tm	degrees C	4.51	CHEMBL5251	Homo sapiens	deltaTm	degrees C	4.51
	23166624	CHEMBL4813339	Binding affinity to recombinant human BTK (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Delta Tm	degrees C	6.36	CHEMBL5251	Homo sapiens	deltaTm	degrees C	6.36
	23166625	CHEMBL4813340	Binding affinity to BTK (unknown origin) by mass spectrometry analysis relative to control	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	23166626	CHEMBL4813340	Binding affinity to BTK (unknown origin) by mass spectrometry analysis relative to control	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	=	Activity	%	97.9	CHEMBL5251	Homo sapiens	Activity	%	97.9
	23166627	CHEMBL4813340	Binding affinity to BTK (unknown origin) by mass spectrometry analysis relative to control	B	C=CC(=O)N1[C@H](C(=O)N[C@@H](Cc2ccc(C#N)cc2)C(=O)NC)C[C@@H]2CCCC[C@@H]21		CHEMBL4861473	=	Activity	%	94.4	CHEMBL5251	Homo sapiens	Activity	%	94.4
	23166628	CHEMBL4813340	Binding affinity to BTK (unknown origin) by mass spectrometry analysis relative to control	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Activity	%	92.3	CHEMBL5251	Homo sapiens	Activity	%	92.3
	23166629	CHEMBL4813340	Binding affinity to BTK (unknown origin) by mass spectrometry analysis relative to control	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Activity	%	95.2	CHEMBL5251	Homo sapiens	Activity	%	95.2
	23166630	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	IC50	nM	3.04	CHEMBL5251	Homo sapiens	IC50	uM	0.0030399999999999997
	23166631	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)[C@@H](Cc1ccccc1)NC(=O)c1c[nH]c(C(N)=O)c1		CHEMBL4866645	=	IC50	nM	56.2	CHEMBL5251	Homo sapiens	IC50	uM	0.0562
	23166632	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	>	IC50	nM	5920.0	CHEMBL5251	Homo sapiens	IC50	uM	5.92
	23166633	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	C=CC(=O)N1[C@H](C(=O)N[C@@H](Cc2ccc(C#N)cc2)C(=O)NC)C[C@@H]2CCCC[C@@H]21		CHEMBL4861473	>	IC50	nM	5920.0	CHEMBL5251	Homo sapiens	IC50	uM	5.92
	23166634	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)C[C@@H](Cc1cccc(F)c1)NC(=O)C1CO1		CHEMBL4873655	>	IC50	nM	5920.0	CHEMBL5251	Homo sapiens	IC50	uM	5.92
	23166635	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	>	IC50	nM	5920.0	CHEMBL5251	Homo sapiens	IC50	uM	5.92
	23166636	CHEMBL4813341	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	>	IC50	nM	5920.0	CHEMBL5251	Homo sapiens	IC50	uM	5.92
	23166637	CHEMBL4813342	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells assessed as residence time incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	TIME	hr	0.3667	CHEMBL5251	Homo sapiens	Time	min	22.0
	23166638	CHEMBL4813342	Inhibition of recombinant human N-terminal His-tagged BTK C481S mutant expressed in baculovirus infected in Sf9 cells assessed as residence time incubated for 1 hr by TR-FRET assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)[C@@H](Cc1ccccc1)NC(=O)c1c[nH]c(C(N)=O)c1		CHEMBL4866645	=	TIME	hr	0.2333	CHEMBL5251	Homo sapiens	Time	min	14.0
	23166639	CHEMBL4813343	Binding affinity to recombinant human BTK C481S mutant (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	Delta Tm	degrees C	13.4	CHEMBL5251	Homo sapiens	deltaTm	degrees C	13.4
	23166640	CHEMBL4813343	Binding affinity to recombinant human BTK C481S mutant (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	=	Delta Tm	degrees C	0.1	CHEMBL5251	Homo sapiens	deltaTm	degrees C	0.1
	23166641	CHEMBL4813343	Binding affinity to recombinant human BTK C481S mutant (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Delta Tm	degrees C	0.23	CHEMBL5251	Homo sapiens	deltaTm	degrees C	0.23
	23166642	CHEMBL4813343	Binding affinity to recombinant human BTK C481S mutant (389 to 659 residues) expressed in insect cells assessed as change in melting temperature at 50 uM incubated for 120 mins by thermal shift assay	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Delta Tm	degrees C	-0.15	CHEMBL5251	Homo sapiens	deltaTm	degrees C	-0.15
	23166643	CHEMBL4813344	Binding affinity to BTK C481S mutant (unknown origin) by mass spectrometry analysis relative to control	B	CNC(=O)[C@H]1Cc2c([nH]c3ccccc23)CN1C(=O)c1occc1CNc1ccc2nccnc2c1		CHEMBL4850816	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	23166644	CHEMBL4813344	Binding affinity to BTK C481S mutant (unknown origin) by mass spectrometry analysis relative to control	B	C=CC(=O)N1CCC[C@H](CC(=O)N2Cc3[nH]c4ccccc4c3C[C@@H]2C(=O)NC)C1		CHEMBL4859382	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	23166645	CHEMBL4813344	Binding affinity to BTK C481S mutant (unknown origin) by mass spectrometry analysis relative to control	B	C=CC(=O)N1[C@H](C(=O)N[C@@H](Cc2ccc(C#N)cc2)C(=O)NC)C[C@@H]2CCCC[C@@H]21		CHEMBL4861473	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	23166646	CHEMBL4813344	Binding affinity to BTK C481S mutant (unknown origin) by mass spectrometry analysis relative to control	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@]1(C)CO1)[C@@H](C)OC(C)(C)C		CHEMBL4854947	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	23166647	CHEMBL4813344	Binding affinity to BTK C481S mutant (unknown origin) by mass spectrometry analysis relative to control	B	CNC(=O)[C@@H](Cc1ccc(C#N)cc1)NC(=O)[C@@H](NC(=O)[C@@H]1CO1)c1ccccc1		CHEMBL4867490	=	Activity	%	0.0	CHEMBL5251	Homo sapiens	Activity	%	0.0
	23192869	CHEMBL4818905	Binding affinity to recombinant unphosphorylated human GST-tagged BTK kinase domain (389 to 659 residues) expressed in insect cells incubated for 1 hr by Lanthascreen assay	B	CC(C)Oc1ccc(N2C(=O)Nc3c(C(=O)N[C@@H]4CCCNC4)sc4nccc2c34)cc1		CHEMBL4863853	=	IC50	nM	3500.0	CHEMBL5251	Homo sapiens	IC50	uM	3.5
	23192870	CHEMBL4818905	Binding affinity to recombinant unphosphorylated human GST-tagged BTK kinase domain (389 to 659 residues) expressed in insect cells incubated for 1 hr by Lanthascreen assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2)C1		CHEMBL4853953	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	uM	0.12
	23192871	CHEMBL4818905	Binding affinity to recombinant unphosphorylated human GST-tagged BTK kinase domain (389 to 659 residues) expressed in insect cells incubated for 1 hr by Lanthascreen assay	B	CCC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2)C1		CHEMBL4862552	=	IC50	nM	6600.0	CHEMBL5251	Homo sapiens	IC50	uM	6.6
	23192872	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccccc2)C1		CHEMBL4873622	=	Kinact	/s	0.000807	CHEMBL5251	Homo sapiens	Kinact	/s	0.000807
	23192873	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccccc2C)C1		CHEMBL4877611	=	Kinact	/s	0.000573	CHEMBL5251	Homo sapiens	Kinact	/s	0.000573
	23192874	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2C)C1		CHEMBL4871385	=	Kinact	/s	0.000304	CHEMBL5251	Homo sapiens	Kinact	/s	0.000304
	23192875	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2cc(OC(C)C)ccc2C)C1		CHEMBL4877368	=	Kinact	/s	0.000222	CHEMBL5251	Homo sapiens	Kinact	/s	0.00022200000000000003
	23192876	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4853403	=	Kinact	/s	0.000404	CHEMBL5251	Homo sapiens	Kinact	/s	0.000404
	23192877	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4853403	=	Kinact	/s	0.00045	CHEMBL5251	Homo sapiens	Kinact	/s	0.00045
	23192878	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2F)C1		CHEMBL4854911	=	Kinact	/s	0.000348	CHEMBL5251	Homo sapiens	Kinact	/s	0.000348
	23192879	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2Cl)C1		CHEMBL4875401	=	Kinact	/s	0.000376	CHEMBL5251	Homo sapiens	Kinact	/s	0.000376
	23192880	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C(F)(F)F)C1		CHEMBL4863521	=	Kinact	/s	0.000177	CHEMBL5251	Homo sapiens	Kinact	/s	0.000177
	23192881	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)NCCNC(=O)c1sc2nccc3c2c1NC(=O)N3c1ccc(Oc2ccccc2)cc1C		CHEMBL4852459	=	Kinact	/s	0.000407	CHEMBL5251	Homo sapiens	Kinact	/s	0.000407
	23192882	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC(NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4861899	=	Kinact	/s	0.000128	CHEMBL5251	Homo sapiens	Kinact	/s	0.000128
	23192883	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021	=	Kinact	/s	0.000346	CHEMBL5251	Homo sapiens	Kinact	/s	0.000346
	23192884	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC[C@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4871745	=	Kinact	/s	0.000302	CHEMBL5251	Homo sapiens	Kinact	/s	0.000302
	23192885	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3c2c1NC(=O)N3c1ccc(Oc2ccccc2)cc1C		CHEMBL4849068	=	Kinact	/s	0.000257	CHEMBL5251	Homo sapiens	Kinact	/s	0.00025699999999999996
	23192886	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)C[C@@H]1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4846828	=	Kinact	/s	0.000337	CHEMBL5251	Homo sapiens	Kinact	/s	0.000337
	23192887	CHEMBL4818906	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inactivation constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2)C1		CHEMBL4853953	=	Kinact	/s	0.000256	CHEMBL5251	Homo sapiens	Kinact	/s	0.000256
	23192888	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccccc2)C1		CHEMBL4873622	=	Ki	nM	6420.0	CHEMBL5251	Homo sapiens	Ki	uM	6.42
	23192889	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccccc2C)C1		CHEMBL4877611	=	Ki	nM	1580.0	CHEMBL5251	Homo sapiens	Ki	uM	1.58
	23192890	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2C)C1		CHEMBL4871385	=	Ki	nM	337.0	CHEMBL5251	Homo sapiens	Ki	uM	0.337
	23192891	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2cc(OC(C)C)ccc2C)C1		CHEMBL4877368	=	Ki	nM	3290.0	CHEMBL5251	Homo sapiens	Ki	uM	3.29
	23192892	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4853403	=	Ki	nM	150.0	CHEMBL5251	Homo sapiens	Ki	uM	0.15
	23192893	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4853403	=	Ki	nM	4.81	CHEMBL5251	Homo sapiens	Ki	uM	0.00481
	23192894	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2F)C1		CHEMBL4854911	=	Ki	nM	9.2	CHEMBL5251	Homo sapiens	Ki	uM	0.0092
	23192895	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2Cl)C1		CHEMBL4875401	=	Ki	nM	12.3	CHEMBL5251	Homo sapiens	Ki	uM	0.0123
	23192896	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C(F)(F)F)C1		CHEMBL4863521	=	Ki	nM	1850.0	CHEMBL5251	Homo sapiens	Ki	uM	1.85
	23192897	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)NCCNC(=O)c1sc2nccc3c2c1NC(=O)N3c1ccc(Oc2ccccc2)cc1C		CHEMBL4852459	=	Ki	nM	51.9	CHEMBL5251	Homo sapiens	Ki	uM	0.0519
	23192898	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC(NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4861899	=	Ki	nM	141.0	CHEMBL5251	Homo sapiens	Ki	uM	0.141
	23192899	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021	=	Ki	nM	28.8	CHEMBL5251	Homo sapiens	Ki	uM	0.0288
	23192900	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC[C@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4871745	=	Ki	nM	217.0	CHEMBL5251	Homo sapiens	Ki	uM	0.217
	23192901	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3c2c1NC(=O)N3c1ccc(Oc2ccccc2)cc1C		CHEMBL4849068	=	Ki	nM	14.8	CHEMBL5251	Homo sapiens	Ki	uM	0.0148
	23192902	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)C[C@@H]1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4846828	=	Ki	nM	11.7	CHEMBL5251	Homo sapiens	Ki	uM	0.0117
	23192903	CHEMBL4818907	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as inhibition constant using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2)C1		CHEMBL4853953	=	Ki	nM	4220.0	CHEMBL5251	Homo sapiens	Ki	uM	4.22
	23192904	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccccc2)C1		CHEMBL4873622	=	Ratio	/M/s	126.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	126.0
	23192905	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccccc2C)C1		CHEMBL4877611	=	Ratio	/M/s	363.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	363.0
	23192906	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2C)C1		CHEMBL4871385	=	Ratio	/M/s	902.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	902.0
	23192907	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2cc(OC(C)C)ccc2C)C1		CHEMBL4877368	=	Ratio	/M/s	67.5	CHEMBL5251	Homo sapiens	Ratio	/M/s	67.5
	23192908	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4853403	=	Ratio	/M/s	2690.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	2690.0
	23192909	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4853403	=	Ratio	/M/s	93600.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	93600.0
	23192910	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2F)C1		CHEMBL4854911	=	Ratio	/M/s	37800.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	37800.0
	23192911	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2Cl)C1		CHEMBL4875401	=	Ratio	/M/s	30600.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	30600.0
	23192912	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C(F)(F)F)C1		CHEMBL4863521	=	Ratio	/M/s	95.7	CHEMBL5251	Homo sapiens	Ratio	/M/s	95.7
	23192913	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)NCCNC(=O)c1sc2nccc3c2c1NC(=O)N3c1ccc(Oc2ccccc2)cc1C		CHEMBL4852459	=	Ratio	/M/s	7840.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	7840.0
	23192914	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC(NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4861899	=	Ratio	/M/s	908.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	908.0
	23192915	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021	=	Ratio	/M/s	12000.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	12000.0
	23192916	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CC[C@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4871745	=	Ratio	/M/s	1390.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	1390.0
	23192917	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3c2c1NC(=O)N3c1ccc(Oc2ccccc2)cc1C		CHEMBL4849068	=	Ratio	/M/s	17400.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	17400.0
	23192918	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)C[C@@H]1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4846828	=	Ratio	/M/s	28800.0	CHEMBL5251	Homo sapiens	Ratio	/M/s	28800.0
	23192919	CHEMBL4818908	Covalent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system assessed as Kinact/Ki ratio using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2)C1		CHEMBL4853953	=	Ratio	/M/s	60.7	CHEMBL5251	Homo sapiens	Ratio	/M/s	60.7
	23192950	CHEMBL4818911	Inhibition of recombinant human BTK using KVEKIGEGTYGVVYK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021	=	IC50	nM	142.0	CHEMBL5251	Homo sapiens	IC50	uM	0.142
Active	23192979	CHEMBL4818939	Irreversible covalent inhibition of recombinant unphosphorylated human GST-tagged BTK kinase domain (389 to 659 residues) expressed in insect cells assessed as protein-compound adduct formation under native conditions by HPLC analysis	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23192980	CHEMBL4818940	Irreversible covalent inhibition of recombinant unphosphorylated human GST-tagged BTK kinase domain (389 to 659 residues) expressed in insect cells assessed as protein-compound adduct formation under denaturing conditions by HPLC analysis	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	23192981	CHEMBL4818941	Inhibition of BTK in human whole blood assessed as inhibition of IgM-induced B-cell activation	B	C=CC(=O)N1CC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(Oc3ccccc3)cc2C)C1		CHEMBL4851021	=	IC50	nM	84.0	CHEMBL5251	Homo sapiens	IC50	uM	0.084
Active	23192982	CHEMBL4818942	Time dependent inhibition of recombinant human GST-tagged BTK (2 to 659 end residues) expressed in baculovirus expression system using NH2-KKKAPFSWYLPEEG as substrate measured every 2 mins for 2 hrs in presence of ATP by microplate reader assay	B	C=CC(=O)N1CCC[C@@H](NC(=O)c2sc3nccc4c3c2NC(=O)N4c2ccc(OC(C)C)cc2)C1		CHEMBL4853953		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	23196872	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4858294	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	uM	0.025
	23196873	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	uM	0.027000000000000003
	23196874	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2ccccc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4867619	=	IC50	nM	155.0	CHEMBL5251	Homo sapiens	IC50	uM	0.155
	23196875	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2cccc(C(C)(C)C)c2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4868893	=	IC50	nM	709.0	CHEMBL5251	Homo sapiens	IC50	uM	0.7090000000000001
	23196876	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2cccnc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4879055	=	IC50	nM	264.0	CHEMBL5251	Homo sapiens	IC50	uM	0.264
	23196877	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2ccccn2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4852053	=	IC50	nM	166.0	CHEMBL5251	Homo sapiens	IC50	uM	0.166
	23196878	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)C2CCCCC2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4869977	=	IC50	nM	932.0	CHEMBL5251	Homo sapiens	IC50	uM	0.932
	23196879	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	CC(=O)Nc1cccc(-c2cc3[nH]cnc3c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)c1C		CHEMBL4859682	=	IC50	nM	545.0	CHEMBL5251	Homo sapiens	IC50	uM	0.545
	23196880	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2ncc[nH]2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4852342	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	uM	0.040999999999999995
	23196881	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2c[nH]cn2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4873565	=	IC50	nM	79.0	CHEMBL5251	Homo sapiens	IC50	uM	0.079
	23196882	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2nc3ccccc3[nH]2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4875035	=	IC50	nM	35.0	CHEMBL5251	Homo sapiens	IC50	uM	0.035
	23196883	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	=	IC50	nM	19.0	CHEMBL5251	Homo sapiens	IC50	uM	0.019
	23196884	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	COc1ccc(Cn2cnc3c(Nc4ccc(C(=O)N5CCOCC5)cc4)nc(-c4cccc(NC(=O)c5ccc(C(C)(C)C)cc5)c4C)cc32)cc1		CHEMBL4854403	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	uM	10.0
	23196885	CHEMBL4819975	Inhibition of human BTK using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP measured by microplate reader assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc2c(ncn2C)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4855825	=	IC50	nM	527.0	CHEMBL5251	Homo sapiens	IC50	uM	0.527
	23196886	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4858294	=	Activity	%	18.4	CHEMBL5251	Homo sapiens	Activity	%	18.4
	23196887	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664	=	Activity	%	14.7	CHEMBL5251	Homo sapiens	Activity	%	14.7
	23196888	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2ccccc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4867619	=	Activity	%	20.1	CHEMBL5251	Homo sapiens	Activity	%	20.1
	23196889	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2cccc(C(C)(C)C)c2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4868893	=	Activity	%	43.3	CHEMBL5251	Homo sapiens	Activity	%	43.3
	23196890	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2cccnc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4879055	=	Activity	%	25.3	CHEMBL5251	Homo sapiens	Activity	%	25.3
	23196891	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2ccccn2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4852053	=	Activity	%	27.4	CHEMBL5251	Homo sapiens	Activity	%	27.4
	23196892	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)C2CCCCC2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4869977	=	Activity	%	61.5	CHEMBL5251	Homo sapiens	Activity	%	61.5
	23196893	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	CC(=O)Nc1cccc(-c2cc3[nH]cnc3c(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)c1C		CHEMBL4859682	=	Activity	%	38.8	CHEMBL5251	Homo sapiens	Activity	%	38.8
	23196894	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2ncc[nH]2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4852342	=	Activity	%	24.2	CHEMBL5251	Homo sapiens	Activity	%	24.2
	23196895	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2c[nH]cn2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4873565	=	Activity	%	27.2	CHEMBL5251	Homo sapiens	Activity	%	27.2
	23196896	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2nc3ccccc3[nH]2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4875035	=	Activity	%	20.9	CHEMBL5251	Homo sapiens	Activity	%	20.9
	23196897	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	COc1ccc(Cn2cnc3c(Nc4ccc(C(=O)N5CCOCC5)cc4)nc(-c4cccc(NC(=O)c5ccc(C(C)(C)C)cc5)c4C)cc32)cc1		CHEMBL4854403	=	Activity	%	71.2	CHEMBL5251	Homo sapiens	Activity	%	71.2
	23196898	CHEMBL4819976	Inhibition of human BTK assessed as residual activity using poly (Glu,Tyr) as substrate in presence of ATP and Ci(gamma33-P) ATP at 1 uM measured by microplate reader assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc2c(ncn2C)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4855825	=	Activity	%	39.7	CHEMBL5251	Homo sapiens	Activity	%	39.7
Active	23197050	CHEMBL4819989	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated BTK (Y323) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4858294		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197051	CHEMBL4819989	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated BTK (Y323) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)c2cccnc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4879055		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197052	CHEMBL4819989	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated BTK (Y323) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)C2CCCCC2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4869977		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197053	CHEMBL4819989	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated BTK (Y323) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)c2nc3ccccc3[nH]2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4875035		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197054	CHEMBL4819990	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4858294		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197055	CHEMBL4819990	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)c2cccnc2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4879055		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197056	CHEMBL4819990	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)C2CCCCC2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4869977		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197057	CHEMBL4819990	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation at 1 to 5 uM measured after 24 hrs by western blot assay	B	Cc1c(NC(=O)c2nc3ccccc3[nH]2)cccc1-c1cc2[nH]cnc2c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1		CHEMBL4875035		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-Dependent Effect	23197058	CHEMBL4819991	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated BTK phosphorylation measured after 24 hrs by western blot assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-Dependent Effect	23197059	CHEMBL4819992	Inhibition of BTK in human UPF7U cells assessed as reduction of IgM stimulated BTK phosphorylation measured after 24 hrs by western blot assay	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197060	CHEMBL4819993	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma1 (Y783) phosphorylation at 0.125 to 1 uM measured after 24 hrs by western blot assay relative to Ibrutinib	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197061	CHEMBL4819994	Inhibition of BTK in human UPF7U cells assessed as reduction of IgM stimulated PLCgamma1 (Y783) phosphorylation at 0.125 to 1 uM measured after 24 hrs by western blot assay relative to Ibrutinib	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197062	CHEMBL4819995	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation at 0.125 to 1 uM measured after 24 hrs by western blot assay relative to Ibrutinib	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23197063	CHEMBL4819996	Inhibition of BTK in human UPF7U cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation at 0.125 to 1 uM measured after 24 hrs by western blot assay relative to Ibrutinib	B	CC(C)(C)c1ccc(C(=O)Nc2cccc(-c3cc4[nH]cnc4c(Nc4ccc(C(=O)N5CCOCC5)cc4)n3)c2)cc1		CHEMBL4865664		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	23205679	CHEMBL4821566	Inhibition of BTK (unknown origin)	B	COc1cc(Nc2nc(NCc3cccc(NC(=O)CCl)c3)n3ccnc3c2C(N)=O)cc(OC)c1		CHEMBL4870513	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	uM	1.0
	23209696	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc2[nH]c(-c3ccc(C(=O)N4CCOCC4)cc3)nc12		CHEMBL4872106	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	23209697	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc2[nH]c(-c3cnn(C)c3)nc12		CHEMBL4849850	=	IC50	nM	16.0	CHEMBL5251	Homo sapiens	IC50	nM	16.0
	23209698	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1cc(-c2ccnc3[nH]c(-c4cnn(C)c4)nc23)ccc1CNC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL4849446	=	IC50	nM	1.3	CHEMBL5251	Homo sapiens	IC50	nM	1.3
	23209699	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5ccc(C(C)(C)C)cc5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4857217	=	IC50	nM	6.2	CHEMBL5251	Homo sapiens	IC50	nM	6.2
	23209700	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4850235	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	23209701	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C6(C)CC6)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4865369	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	23209702	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5noc(C(C)(C)C)n5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4849220	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	23209703	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5cc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4857263	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	23209704	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5cc6c(s5)CCCC6)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4871425	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	23209705	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5ccc(OC(F)(F)F)cc5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4859528	=	IC50	nM	27.0	CHEMBL5251	Homo sapiens	IC50	nM	27.0
	23209706	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5ccc(C(C)(C)C)cn5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4865481	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	23209707	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	COc1ccc(C(=O)NCc2ccc(-c3ccnc4[nH]c(-c5cnn(C)c5)nc34)cc2F)nc1		CHEMBL4861412	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	23209708	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CN5CCc6cc(C(C)(C)C)ccc6C5=O)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4855455	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	23209709	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)C5CCC(C(C)(C)C)CC5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4876918	=	IC50	nM	15.0	CHEMBL5251	Homo sapiens	IC50	nM	15.0
	23209710	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CC1CC2(C1)CN(C(=O)NCc1ccc(-c3ccnc4[nH]c(-c5cnn(C)c5)nc34)cc1F)C2		CHEMBL4869628	=	IC50	nM	28.0	CHEMBL5251	Homo sapiens	IC50	nM	28.0
	23209711	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)N5CC(OC(C)(C)C)C5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4846816	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	23209712	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CC(C)(C)c1noc(C(=O)NCc2ccc(-c3ccnc4[nH]c(-c5cnn(C6CCOCC6)c5)nc34)cc2F)n1		CHEMBL4861612	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	23209713	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CC(C)(C)c1noc(C(=O)NCc2ccc(-c3ccnc4[nH]c(-c5cnn(CCN6CCOCC6)c5)nc34)cc2F)n1		CHEMBL4878102	=	IC50	nM	0.3	CHEMBL5251	Homo sapiens	IC50	nM	0.3
	23209714	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	COc1ccnc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)c1		CHEMBL4852395	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	23209715	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CC(C)(C)c1noc(C(=O)NCc2ccc(-c3ccnc4[nH]c(C5CC5)nc34)cc2F)n1		CHEMBL4863505	=	IC50	nM	12.0	CHEMBL5251	Homo sapiens	IC50	nM	12.0
	23209716	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc(C5(NC(=O)c6nc(C(C)(C)C)no6)CC5)cc4)ccnc3[nH]2)cn1		CHEMBL4855916	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	23209717	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc5c(c4)CCCC5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4855860	=	IC50	nM	0.7	CHEMBL5251	Homo sapiens	IC50	nM	0.7
	23209718	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4869875	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	23209719	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cn1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4859888	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	23209720	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CC(C)(C)c1noc(C(=O)NC2CCCc3cc(-c4ccnc5[nH]c(-c6cnn(C7CCOCC7)c6)nc45)ccc32)n1		CHEMBL4848010	=	IC50	nM	1.2	CHEMBL5251	Homo sapiens	IC50	nM	1.2
	23209721	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1c(-c2nc3c(-c4ccc5c(c4)CCC[C@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cnn1C1CCOCC1		CHEMBL4876326	=	IC50	nM	0.5	CHEMBL5251	Homo sapiens	IC50	nM	0.5
	23209722	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1nn(C2CCOCC2)cc1-c1nc2c(-c3ccc4c(c3)CCC[C@@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4872092	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	23209723	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1c(-c2nc3c(-c4ccc5c(c4)CCC[C@@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cnn1C(C)C		CHEMBL4857459	=	IC50	nM	1.0	CHEMBL5251	Homo sapiens	IC50	nM	1.0
	23209724	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1nn(C(C)C)cc1-c1nc2c(-c3ccc4c(c3)CCC[C@@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4851951	=	IC50	nM	1.1	CHEMBL5251	Homo sapiens	IC50	nM	1.1
	23209725	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4862532	=	IC50	nM	0.6	CHEMBL5251	Homo sapiens	IC50	nM	0.6
	23209726	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CC(C)n1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4868813	=	IC50	nM	0.23	CHEMBL5251	Homo sapiens	IC50	nM	0.23
	23209727	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4877846	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	23209728	CHEMBL4822448	Inhibition of BTK (unknown origin)	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	23209729	CHEMBL4822449	Inhibition of BTK in human whole blood	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4850235	=	IC50	nM	41.0	CHEMBL5251	Homo sapiens	IC50	nM	41.0
	23209730	CHEMBL4822449	Inhibition of BTK in human whole blood	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4862532	=	IC50	nM	92.0	CHEMBL5251	Homo sapiens	IC50	nM	92.0
	23209731	CHEMBL4822449	Inhibition of BTK in human whole blood	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4877846	=	IC50	nM	58.0	CHEMBL5251	Homo sapiens	IC50	nM	58.0
	23209732	CHEMBL4822449	Inhibition of BTK in human whole blood	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	23209733	CHEMBL4822450	Inhibition of BTK in human PBMC	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	23209734	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1ccnc2[nH]c(-c3ccc(C(=O)N4CCOCC4)cc3)nc12		CHEMBL4872106	=	IC50	nM	1680.0	CHEMBL5251	Homo sapiens	IC50	nM	1680.0
	23209735	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1cc(-c2ccnc3[nH]c(-c4cnn(C)c4)nc23)ccc1CNC(=O)c1ccc(C(C)(C)C)cc1		CHEMBL4849446	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
	23209736	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5ccc(C(C)(C)C)cc5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4857217	=	IC50	nM	151.0	CHEMBL5251	Homo sapiens	IC50	nM	151.0
	23209737	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C6(C)CC6)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4865369	=	IC50	nM	118.0	CHEMBL5251	Homo sapiens	IC50	nM	118.0
	23209738	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5noc(C(C)(C)C)n5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4849220	=	IC50	nM	14.0	CHEMBL5251	Homo sapiens	IC50	nM	14.0
	23209739	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5cc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4857263	=	IC50	nM	77.0	CHEMBL5251	Homo sapiens	IC50	nM	77.0
	23209740	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5cc6c(s5)CCCC6)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4871425	=	IC50	nM	211.0	CHEMBL5251	Homo sapiens	IC50	nM	211.0
	23209741	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5ccc(C(C)(C)C)cn5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4865481	=	IC50	nM	820.0	CHEMBL5251	Homo sapiens	IC50	nM	820.0
	23209742	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CN5CCc6cc(C(C)(C)C)ccc6C5=O)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4855455	=	IC50	nM	64.0	CHEMBL5251	Homo sapiens	IC50	nM	64.0
	23209743	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)N5CC(OC(C)(C)C)C5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4846816	=	IC50	nM	256.0	CHEMBL5251	Homo sapiens	IC50	nM	256.0
	23209744	CHEMBL4822450	Inhibition of BTK in human PBMC	B	CC(C)(C)c1noc(C(=O)NCc2ccc(-c3ccnc4[nH]c(-c5cnn(C6CCOCC6)c5)nc34)cc2F)n1		CHEMBL4861612	=	IC50	nM	23.0	CHEMBL5251	Homo sapiens	IC50	nM	23.0
	23209745	CHEMBL4822450	Inhibition of BTK in human PBMC	B	CC(C)(C)c1noc(C(=O)NCc2ccc(-c3ccnc4[nH]c(-c5cnn(CCN6CCOCC6)c5)nc34)cc2F)n1		CHEMBL4878102	=	IC50	nM	63.0	CHEMBL5251	Homo sapiens	IC50	nM	63.0
	23209746	CHEMBL4822450	Inhibition of BTK in human PBMC	B	COc1ccnc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)c1		CHEMBL4852395	=	IC50	nM	251.0	CHEMBL5251	Homo sapiens	IC50	nM	251.0
	23209747	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(C5(NC(=O)c6nc(C(C)(C)C)no6)CC5)cc4)ccnc3[nH]2)cn1		CHEMBL4855916	=	IC50	nM	36.0	CHEMBL5251	Homo sapiens	IC50	nM	36.0
	23209748	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc5c(c4)CCCC5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4855860	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
	23209749	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4869875	=	IC50	nM	98.0	CHEMBL5251	Homo sapiens	IC50	nM	98.0
	23209750	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4859888	=	IC50	nM	39.0	CHEMBL5251	Homo sapiens	IC50	nM	39.0
	23209751	CHEMBL4822450	Inhibition of BTK in human PBMC	B	CC(C)(C)c1noc(C(=O)NC2CCCc3cc(-c4ccnc5[nH]c(-c6cnn(C7CCOCC7)c6)nc45)ccc32)n1		CHEMBL4848010	=	IC50	nM	51.0	CHEMBL5251	Homo sapiens	IC50	nM	51.0
	23209752	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1c(-c2nc3c(-c4ccc5c(c4)CCC[C@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cnn1C1CCOCC1		CHEMBL4876326	=	IC50	nM	30.0	CHEMBL5251	Homo sapiens	IC50	nM	30.0
	23209753	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1nn(C2CCOCC2)cc1-c1nc2c(-c3ccc4c(c3)CCC[C@@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4872092	=	IC50	nM	87.0	CHEMBL5251	Homo sapiens	IC50	nM	87.0
	23209754	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1c(-c2nc3c(-c4ccc5c(c4)CCC[C@@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cnn1C(C)C		CHEMBL4857459	=	IC50	nM	137.0	CHEMBL5251	Homo sapiens	IC50	nM	137.0
	23209755	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1nn(C(C)C)cc1-c1nc2c(-c3ccc4c(c3)CCC[C@@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4851951	=	IC50	nM	62.0	CHEMBL5251	Homo sapiens	IC50	nM	62.0
	23209756	CHEMBL4822450	Inhibition of BTK in human PBMC	B	CC(C)n1cc(-c2nc3c(-c4ccc5c(c4)CCC[C@@H]5NC(=O)c4nc(C(C)(C)C)no4)ccnc3[nH]2)cn1		CHEMBL4868813	=	IC50	nM	54.0	CHEMBL5251	Homo sapiens	IC50	nM	54.0
	23209757	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4877846	=	IC50	nM	3.0	CHEMBL5251	Homo sapiens	IC50	nM	3.0
	23209758	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4862532	=	IC50	nM	25.0	CHEMBL5251	Homo sapiens	IC50	nM	25.0
	23209759	CHEMBL4822450	Inhibition of BTK in human PBMC	B	Cn1cc(-c2nc3c(-c4ccc(CNC(=O)c5nc(C(C)(C)C)no5)c(F)c4)ccnc3[nH]2)cn1		CHEMBL4850235	=	IC50	nM	26.0	CHEMBL5251	Homo sapiens	IC50	nM	26.0
	23209857	CHEMBL4822466	Inhibition of human BTK at 1 uM	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4877846	>	Inhibition	%	90.0	CHEMBL5251	Homo sapiens	INH	%	90.0
	23209890	CHEMBL4822489	Inhibition of human BTK	B	CN1CCN(c2ccc(Nc3cc(-c4cccc(-n5ccc6cc(C7CC7)cc(F)c6c5=O)c4CO)cn(C)c3=O)nc2)CC1		CHEMBL2057918	=	IC50	nM	2.25	CHEMBL5251	Homo sapiens	IC50	nM	2.25
	23209891	CHEMBL4822489	Inhibition of human BTK	B	Cc1nn(C(C)C)c(C)c1-c1nc2c(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)ccnc2[nH]1		CHEMBL4877846	=	IC50	nM	4.15	CHEMBL5251	Homo sapiens	IC50	nM	4.15
	23212962	CHEMBL4822882	Inhibition of BTK (unknown origin) at 500 nM	B	N[C@H]1CCCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc6cnccc6c5)n4n3)cc2)C1		CHEMBL4878199	=	Inhibition	%	4.1	CHEMBL5251	Homo sapiens	INH	%	4.1
	23216045	CHEMBL4823578	Inhibition of full length recombinant human BTK using KVEKIGEGTYGVVYK as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting based radiometry assay	B	CC(C)n1cc(C(=O)Nc2ccc(Oc3ccnc(NC(=O)C4CC4)c3)c(F)c2)c(=O)n(-c2ccc(F)cc2)c1=O		CHEMBL4873571	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	23258728	CHEMBL4832758	Inhibition of N-terminal GST-fused human full length recombinant BTK expressed in baculovirus-infected Sf21 cells at 5 uM using 5-FAM-EAIYAAPFAKKK as a substrate incubated for 60 mins in the presence of ATP by caliper analysis relative to control	B	COCCOc1cc2ncnc(Sc3nc[nH]n3)c2cc1OCCOC		CHEMBL4868123	<	Inhibition	%	2.0	CHEMBL5251	Homo sapiens	INH	%	2.0
	23289603	CHEMBL4839134	Inhibition of human BTK assessed as residual kinase activity at 1 uM relative to control	B	CN1CCN(c2ccc(-c3cc4c(N5CCN(C(=O)Nc6ccc(Cl)c(C(F)(F)F)c6)CC5)ncnc4s3)cc2)CC1		CHEMBL4874448	=	Activity	%	19.0	CHEMBL5251	Homo sapiens	Activity	%	19.0
	23289609	CHEMBL4839140	Inhibition of human BTK	B	CN1CCN(c2ccc(-c3cc4c(N5CCN(C(=O)Nc6ccc(Cl)c(C(F)(F)F)c6)CC5)ncnc4s3)cc2)CC1		CHEMBL4874448	=	IC50	nM	718.2	CHEMBL5251	Homo sapiens	IC50	nM	718.2
	23291240	CHEMBL4839529	Inhibition of human full length recombinant BTK at 5 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	8.0	CHEMBL5251	Homo sapiens	INH	%	8.0
	23291241	CHEMBL4839529	Inhibition of human full length recombinant BTK at 5 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	-4.0	CHEMBL5251	Homo sapiens	INH	%	-4.0
	23291242	CHEMBL4839529	Inhibition of human full length recombinant BTK at 5 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	16.0	CHEMBL5251	Homo sapiens	INH	%	16.0
	23291312	CHEMBL4839553	Inhibition of human full length recombinant BTK at 50 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	8.0	CHEMBL5251	Homo sapiens	INH	%	8.0
	23291313	CHEMBL4839553	Inhibition of human full length recombinant BTK at 50 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N	Outside typical range	CHEMBL4850154	=	Inhibition	%	-16.0	CHEMBL5251	Homo sapiens	INH	%	-16.0
	23291314	CHEMBL4839553	Inhibition of human full length recombinant BTK at 50 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	27.0	CHEMBL5251	Homo sapiens	INH	%	27.0
	23291384	CHEMBL4839577	Inhibition of human full length recombinant BTK at 500 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	11.0	CHEMBL5251	Homo sapiens	INH	%	11.0
	23291385	CHEMBL4839577	Inhibition of human full length recombinant BTK at 500 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	-2.0	CHEMBL5251	Homo sapiens	INH	%	-2.0
	23291386	CHEMBL4839577	Inhibition of human full length recombinant BTK at 500 nM by radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	49.0	CHEMBL5251	Homo sapiens	INH	%	49.0
	23295376	CHEMBL4840459	Inhibition of recombinant His-tagged full length human BTK expressed in baculovirus expression system at 1 uM measured by select screen assay relative to control	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(Cc3cc(F)cc(F)c3)C4(C)C)cc2)CC1		CHEMBL4849505	=	Inhibition	%	35.0	CHEMBL5251	Homo sapiens	INH	%	35.0
	23297804	CHEMBL4841284	Inhibition of BTK (unknown origin)	B	Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3Cl)cc12		CHEMBL4876497	>	IC50	nM	1000.0	CHEMBL5251	Homo sapiens	IC50	nM	1000.0
	23298999	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c(C(N)=O)n1N		CHEMBL4856467	=	IC50	nM	176.0	CHEMBL5251	Homo sapiens	IC50	nM	176.0
	23299000	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4853848	=	IC50	nM	39.3	CHEMBL5251	Homo sapiens	IC50	nM	39.3
	23299001	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c(C(N)=O)n1N		CHEMBL4871950	=	IC50	nM	13.1	CHEMBL5251	Homo sapiens	IC50	nM	13.1
	23299002	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4856243	=	IC50	nM	11.3	CHEMBL5251	Homo sapiens	IC50	nM	11.3
	23299003	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4875984	=	IC50	nM	226.0	CHEMBL5251	Homo sapiens	IC50	nM	226.0
	23299004	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CC2(CC(c3nc(-c4ccc(C(=O)Nc5cc(CC)ccn5)cc4)c(C(N)=O)n3N)C2)C1		CHEMBL4868212	=	IC50	nM	85.7	CHEMBL5251	Homo sapiens	IC50	nM	85.7
	23299005	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC[C@@H](c2nc(-c3ccc(C(=O)Nc4cc(CC)ccn4)cc3)c(C(N)=O)n2N)C1		CHEMBL4867982	=	IC50	nM	18.9	CHEMBL5251	Homo sapiens	IC50	nM	18.9
	23299006	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(Cc2nc(-c3ccc(C(=O)Nc4ccccn4)cc3)c(C(N)=O)n2N)CC1		CHEMBL4855796	=	IC50	nM	176.0	CHEMBL5251	Homo sapiens	IC50	nM	176.0
	23299007	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=C(C)C(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4875877	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299008	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C/C=C/C(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4847285	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299009	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CCc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCCN4C(=O)C=C(C)C)n(N)c3C(N)=O)cc2)c1		CHEMBL4859685	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299010	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC/C=C/C(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4862011	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299011	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CCc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCCN4C(=O)/C(C#N)=C/C4CC4)n(N)c3C(N)=O)cc2)c1		CHEMBL4876316	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299012	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CCc1ccnc(NC(=O)c2ccc(-c3nc([C@@H]4CCCCN4C(=O)/C(C#N)=C/C(C)C)n(N)c3C(N)=O)cc2)c1		CHEMBL4876231	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299013	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4868899	=	IC50	nM	17.9	CHEMBL5251	Homo sapiens	IC50	nM	17.9
	23299014	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(CC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4875714	=	IC50	nM	10.0	CHEMBL5251	Homo sapiens	IC50	nM	10.0
	23299015	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4850186	=	IC50	nM	18.1	CHEMBL5251	Homo sapiens	IC50	nM	18.1
	23299016	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccc(C)cn3)cc2)c(C(N)=O)n1N		CHEMBL4846437	=	IC50	nM	18.4	CHEMBL5251	Homo sapiens	IC50	nM	18.4
	23299017	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(C)C)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4878506	=	IC50	nM	22.6	CHEMBL5251	Homo sapiens	IC50	nM	22.6
	23299018	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(OC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4874550	=	IC50	nM	9.1	CHEMBL5251	Homo sapiens	IC50	nM	9.1
	23299019	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Cl)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4860527	=	IC50	nM	11.2	CHEMBL5251	Homo sapiens	IC50	nM	11.2
	23299020	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccc(Cl)cn3)cc2)c(C(N)=O)n1N		CHEMBL4868393	=	IC50	nM	29.2	CHEMBL5251	Homo sapiens	IC50	nM	29.2
	23299021	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Br)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4878421	=	IC50	nM	4.4	CHEMBL5251	Homo sapiens	IC50	nM	4.4
	23299022	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(I)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4873581	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
	23299023	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C#N)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4854001	=	IC50	nM	17.1	CHEMBL5251	Homo sapiens	IC50	nM	17.1
	23299024	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4864983	=	IC50	nM	2.7	CHEMBL5251	Homo sapiens	IC50	nM	2.7
	23299025	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C)c(F)cn3)cc2)c(C(N)=O)n1N		CHEMBL4873198	=	IC50	nM	44.5	CHEMBL5251	Homo sapiens	IC50	nM	44.5
	23299026	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccccc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4863836	=	IC50	nM	5.1	CHEMBL5251	Homo sapiens	IC50	nM	5.1
	23299027	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(F)cc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4863913	=	IC50	nM	5.0	CHEMBL5251	Homo sapiens	IC50	nM	5.0
	23299028	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(Cl)cc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4878626	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	23299029	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(C#N)cc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4852838	=	IC50	nM	10.6	CHEMBL5251	Homo sapiens	IC50	nM	10.6
	23299030	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccc3)cc2)c(C(N)=O)n1N		CHEMBL4875477	=	IC50	nM	571.0	CHEMBL5251	Homo sapiens	IC50	nM	571.0
	23299031	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cccnc3)cc2)c(C(N)=O)n1N		CHEMBL4845817	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
	23299032	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cccnn3)cc2)c(C(N)=O)n1N		CHEMBL4862197	=	IC50	nM	211.0	CHEMBL5251	Homo sapiens	IC50	nM	211.0
	23299033	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3nccs3)cc2)c(C(N)=O)n1N		CHEMBL4855655	=	IC50	nM	18.7	CHEMBL5251	Homo sapiens	IC50	nM	18.7
	23299034	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c(C(N)=O)n1N		CHEMBL4873239	=	IC50	nM	100.0	CHEMBL5251	Homo sapiens	IC50	nM	100.0
	23299035	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4874339	=	IC50	nM	58.1	CHEMBL5251	Homo sapiens	IC50	nM	58.1
	23299036	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccc(C)cn3)cc2)c(C(N)=O)n1N		CHEMBL4868737	=	IC50	nM	129.0	CHEMBL5251	Homo sapiens	IC50	nM	129.0
	23299037	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(OC)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4855894	=	IC50	nM	79.6	CHEMBL5251	Homo sapiens	IC50	nM	79.6
	23299038	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Cl)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4852748	=	IC50	nM	19.4	CHEMBL5251	Homo sapiens	IC50	nM	19.4
	23299039	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Br)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4854853	=	IC50	nM	22.6	CHEMBL5251	Homo sapiens	IC50	nM	22.6
	23299040	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(I)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4855886	=	IC50	nM	10.7	CHEMBL5251	Homo sapiens	IC50	nM	10.7
	23299041	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C#N)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4871608	=	IC50	nM	45.6	CHEMBL5251	Homo sapiens	IC50	nM	45.6
	23299042	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4847730	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
	23299043	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C)c(F)cn3)cc2)c(C(N)=O)n1N		CHEMBL4877159	=	IC50	nM	120.0	CHEMBL5251	Homo sapiens	IC50	nM	120.0
	23299044	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccccc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4849268	=	IC50	nM	16.4	CHEMBL5251	Homo sapiens	IC50	nM	16.4
	23299045	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(F)cc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4865483	=	IC50	nM	14.7	CHEMBL5251	Homo sapiens	IC50	nM	14.7
	23299046	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(Cl)cc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4847824	=	IC50	nM	14.8	CHEMBL5251	Homo sapiens	IC50	nM	14.8
	23299047	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(C#N)cc4)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4861285	=	IC50	nM	22.8	CHEMBL5251	Homo sapiens	IC50	nM	22.8
	23299048	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cccnn3)cc2)c(C(N)=O)n1N		CHEMBL4875092	=	IC50	nM	2283.0	CHEMBL5251	Homo sapiens	IC50	nM	2283.0
	23299049	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	0.9	CHEMBL5251	Homo sapiens	IC50	nM	0.9
	23299050	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12		CHEMBL3707348	=	IC50	nM	23.5	CHEMBL5251	Homo sapiens	IC50	nM	23.5
	23299051	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	23299052	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CCC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4847802	=	IC50	nM	4755.0	CHEMBL5251	Homo sapiens	IC50	nM	4755.0
	23299053	CHEMBL4841669	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(=O)OCC)n1N		CHEMBL4875125	=	IC50	nM	5157.0	CHEMBL5251	Homo sapiens	IC50	nM	5157.0
	23299132	CHEMBL4841676	Inhibition of BTK C481S mutant (unknown origin)	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4864983	>	IC50	nM	10000.0	CHEMBL5251	Homo sapiens	IC50	nM	10000.0
Active	23299184	CHEMBL4841705	Inhibition of BTK in human TMD8 cells assessed as reduction in PLCgamma2 phosphorylation at Tyr 1217 residue at 0 to 1000 nM after 4 hrs by Western blot analysis	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4864983		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
	23299185	CHEMBL4841706	Inhibition of BTK in human TMD8 cells assessed as reduction in BTK autophosphorylation at Tyr 223 residue after 4 hrs by Western blot analysis	B	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N		CHEMBL4864983	=	IC50	nM	8.965	CHEMBL5251	Homo sapiens	IC50	nM	8.965
	23309948	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3647964	=	IC50	nM	0.4	CHEMBL5251	Homo sapiens	IC50	nM	0.4
	23309949	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1		CHEMBL3936761	=	IC50	nM	2.2	CHEMBL5251	Homo sapiens	IC50	nM	2.2
	23309950	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4863078	=	IC50	nM	52.0	CHEMBL5251	Homo sapiens	IC50	nM	52.0
	23309951	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=C(C)C(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4865983	=	IC50	nM	11736.0	CHEMBL5251	Homo sapiens	IC50	nM	11736.0
	23309952	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C/C=C/C(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4857664	=	IC50	nM	1510.0	CHEMBL5251	Homo sapiens	IC50	nM	1510.0
	23309953	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC(C)=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4850665	=	IC50	nM	41442.0	CHEMBL5251	Homo sapiens	IC50	nM	41442.0
	23309954	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC/C=C/C(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4846509	=	IC50	nM	119.0	CHEMBL5251	Homo sapiens	IC50	nM	119.0
	23309955	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CN(C)C/C=C/C(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4874730	=	IC50	nM	41.8	CHEMBL5251	Homo sapiens	IC50	nM	41.8
	23309956	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4878090	=	IC50	nM	4.9	CHEMBL5251	Homo sapiens	IC50	nM	4.9
	23309957	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4871192	=	IC50	nM	7.6	CHEMBL5251	Homo sapiens	IC50	nM	7.6
	23309958	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	N#CN1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4870107	=	IC50	nM	13238.0	CHEMBL5251	Homo sapiens	IC50	nM	13238.0
	23309959	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)n(C)c23)CC1		CHEMBL4871949	=	IC50	nM	709.0	CHEMBL5251	Homo sapiens	IC50	nM	709.0
	23309960	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)n(C)c23)CC1		CHEMBL4860487	=	IC50	nM	1622.0	CHEMBL5251	Homo sapiens	IC50	nM	1622.0
	23309961	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)n(N)c23)CC1		CHEMBL4877720	=	IC50	nM	218.0	CHEMBL5251	Homo sapiens	IC50	nM	218.0
	23309962	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)n(N)c23)CC1		CHEMBL4872521	=	IC50	nM	676.0	CHEMBL5251	Homo sapiens	IC50	nM	676.0
	23309963	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)CC1		CHEMBL4873676	=	IC50	nM	494.0	CHEMBL5251	Homo sapiens	IC50	nM	494.0
	23309964	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)CC1		CHEMBL4859613	=	IC50	nM	433.0	CHEMBL5251	Homo sapiens	IC50	nM	433.0
	23309965	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)CC1		CHEMBL4856652	=	IC50	nM	632.0	CHEMBL5251	Homo sapiens	IC50	nM	632.0
	23309966	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)CC1		CHEMBL4857245	=	IC50	nM	14.7	CHEMBL5251	Homo sapiens	IC50	nM	14.7
	23309967	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)CC1		CHEMBL4868355	=	IC50	nM	27.9	CHEMBL5251	Homo sapiens	IC50	nM	27.9
	23309968	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)CC1		CHEMBL4869409	=	IC50	nM	1.5	CHEMBL5251	Homo sapiens	IC50	nM	1.5
	23309969	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5cccc(F)c5)cc4)[nH]c23)CC1		CHEMBL4871465	=	IC50	nM	60.2	CHEMBL5251	Homo sapiens	IC50	nM	60.2
	23309970	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5cccc(F)c5)cc4)[nH]c23)CC1		CHEMBL4876450	=	IC50	nM	14.6	CHEMBL5251	Homo sapiens	IC50	nM	14.6
	23309971	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)[nH]c23)CC1		CHEMBL4870576	=	IC50	nM	54.8	CHEMBL5251	Homo sapiens	IC50	nM	54.8
	23309972	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)[nH]c23)CC1		CHEMBL4874306	=	IC50	nM	78.7	CHEMBL5251	Homo sapiens	IC50	nM	78.7
	23309973	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)[nH]c23)CC1		CHEMBL4857353	=	IC50	nM	6.3	CHEMBL5251	Homo sapiens	IC50	nM	6.3
	23309974	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)CC1		CHEMBL4861061	=	IC50	nM	150.0	CHEMBL5251	Homo sapiens	IC50	nM	150.0
	23309975	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)CC1		CHEMBL4873420	=	IC50	nM	155.0	CHEMBL5251	Homo sapiens	IC50	nM	155.0
	23309976	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)CC1		CHEMBL4856592	=	IC50	nM	6.4	CHEMBL5251	Homo sapiens	IC50	nM	6.4
	23309977	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)CC1		CHEMBL4846339	=	IC50	nM	61.9	CHEMBL5251	Homo sapiens	IC50	nM	61.9
	23309978	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)CC1		CHEMBL4866284	=	IC50	nM	62.5	CHEMBL5251	Homo sapiens	IC50	nM	62.5
	23309979	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)CC1		CHEMBL4863138	=	IC50	nM	13.6	CHEMBL5251	Homo sapiens	IC50	nM	13.6
	23309980	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(Br)cc5)cc4)[nH]c23)CC1		CHEMBL4868372	=	IC50	nM	84.8	CHEMBL5251	Homo sapiens	IC50	nM	84.8
	23309981	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(Br)cc5)cc4)[nH]c23)CC1		CHEMBL4866177	=	IC50	nM	155.0	CHEMBL5251	Homo sapiens	IC50	nM	155.0
	23309982	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(Br)cc5)cc4)[nH]c23)CC1		CHEMBL4867850	=	IC50	nM	7.3	CHEMBL5251	Homo sapiens	IC50	nM	7.3
	23309983	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(C)cc5)cc4)[nH]c23)CC1		CHEMBL4870651	=	IC50	nM	121.0	CHEMBL5251	Homo sapiens	IC50	nM	121.0
	23309984	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(C)cc5)cc4)[nH]c23)CC1		CHEMBL4856336	=	IC50	nM	99.9	CHEMBL5251	Homo sapiens	IC50	nM	99.9
	23309985	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(C)cc5)cc4)[nH]c23)CC1		CHEMBL4870320	=	IC50	nM	6.1	CHEMBL5251	Homo sapiens	IC50	nM	6.1
	23309986	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1		CHEMBL4870437	=	IC50	nM	129.0	CHEMBL5251	Homo sapiens	IC50	nM	129.0
	23309987	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1		CHEMBL4871737	=	IC50	nM	349.0	CHEMBL5251	Homo sapiens	IC50	nM	349.0
	23309988	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1		CHEMBL4875332	=	IC50	nM	2.9	CHEMBL5251	Homo sapiens	IC50	nM	2.9
	23309989	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1		CHEMBL4871869	=	IC50	nM	931.0	CHEMBL5251	Homo sapiens	IC50	nM	931.0
	23309990	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1		CHEMBL4874095	=	IC50	nM	1109.0	CHEMBL5251	Homo sapiens	IC50	nM	1109.0
	23309991	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1		CHEMBL4852264	=	IC50	nM	103.0	CHEMBL5251	Homo sapiens	IC50	nM	103.0
	23309992	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)C1		CHEMBL4865458	=	IC50	nM	149.0	CHEMBL5251	Homo sapiens	IC50	nM	149.0
	23309993	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)C1		CHEMBL4871140	=	IC50	nM	623.0	CHEMBL5251	Homo sapiens	IC50	nM	623.0
	23309994	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)C1		CHEMBL4849585	=	IC50	nM	1.9	CHEMBL5251	Homo sapiens	IC50	nM	1.9
	23309995	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1		CHEMBL4877739	=	IC50	nM	683.0	CHEMBL5251	Homo sapiens	IC50	nM	683.0
	23309996	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1		CHEMBL4850428	=	IC50	nM	550.0	CHEMBL5251	Homo sapiens	IC50	nM	550.0
	23309997	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1		CHEMBL4857322	=	IC50	nM	11.9	CHEMBL5251	Homo sapiens	IC50	nM	11.9
	23309998	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)C1		CHEMBL4859054	=	IC50	nM	926.0	CHEMBL5251	Homo sapiens	IC50	nM	926.0
	23309999	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)C1		CHEMBL4870818	=	IC50	nM	6331.0	CHEMBL5251	Homo sapiens	IC50	nM	6331.0
	23310000	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)C1		CHEMBL4873984	=	IC50	nM	7.4	CHEMBL5251	Homo sapiens	IC50	nM	7.4
	23310001	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1		CHEMBL4861647	=	IC50	nM	19.1	CHEMBL5251	Homo sapiens	IC50	nM	19.1
	23310002	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1		CHEMBL4848746	=	IC50	nM	178.0	CHEMBL5251	Homo sapiens	IC50	nM	178.0
	23310003	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1		CHEMBL4863088	=	IC50	nM	3.2	CHEMBL5251	Homo sapiens	IC50	nM	3.2
	23310004	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1		CHEMBL4856664	=	IC50	nM	772.0	CHEMBL5251	Homo sapiens	IC50	nM	772.0
	23310005	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1		CHEMBL4869123	=	IC50	nM	505.0	CHEMBL5251	Homo sapiens	IC50	nM	505.0
	23310006	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1		CHEMBL4853615	=	IC50	nM	4.8	CHEMBL5251	Homo sapiens	IC50	nM	4.8
	23310007	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1		CHEMBL4856208	=	IC50	nM	34.7	CHEMBL5251	Homo sapiens	IC50	nM	34.7
	23310008	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CC#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1		CHEMBL4871640	=	IC50	nM	153.0	CHEMBL5251	Homo sapiens	IC50	nM	153.0
	23310009	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1		CHEMBL4867893	=	IC50	nM	5.4	CHEMBL5251	Homo sapiens	IC50	nM	5.4
	23310010	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)Nc1ccc(-c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)cc1		CHEMBL4846287	=	IC50	nM	1722.0	CHEMBL5251	Homo sapiens	IC50	nM	1722.0
	23310011	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C#CC(=O)Nc1ccc(-c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)cc1		CHEMBL4878064	=	IC50	nM	82.6	CHEMBL5251	Homo sapiens	IC50	nM	82.6
	23310012	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)Nc1cccc(-c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)c1		CHEMBL4878459	=	IC50	nM	223.0	CHEMBL5251	Homo sapiens	IC50	nM	223.0
	23310013	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCc2nn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c3c2C1		CHEMBL4849212	=	IC50	nM	99.6	CHEMBL5251	Homo sapiens	IC50	nM	99.6
	23310014	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	CN(C)C/C=C/C(=O)N1CCc2nn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c3c2C1		CHEMBL4876114	=	IC50	nM	408.0	CHEMBL5251	Homo sapiens	IC50	nM	408.0
	23310015	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCCc2nn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c3c2C1		CHEMBL4863193	=	IC50	nM	1931.0	CHEMBL5251	Homo sapiens	IC50	nM	1931.0
	23310016	CHEMBL4843875	Inhibition of full-length N-terminal GST tagged BTK (1 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	B	C=CC(=O)N1CCc2nn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c3c2CC1		CHEMBL4868610	=	IC50	nM	1181.0	CHEMBL5251	Homo sapiens	IC50	nM	1181.0
Active	23310187	CHEMBL4843910	Inhibition of BTK in human Ramos cells assessed as reduction in BTK auto-phosphorylation at 10 nM after 4 hrs by Western blot analysis	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4863078		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Active	23310188	CHEMBL4843910	Inhibition of BTK in human Ramos cells assessed as reduction in BTK auto-phosphorylation at 10 nM after 4 hrs by Western blot analysis	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4878090		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-Dependent Effect	23310189	CHEMBL4843911	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 after 4 hrs by Western blot analysis	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4863078		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-Dependent Effect	23310190	CHEMBL4843911	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 after 4 hrs by Western blot analysis	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4878090		Inhibition	%		CHEMBL5251	Homo sapiens	INH		
Dose-Dependent Effect	23310221	CHEMBL4843927	Binding affinity to BTK in human TMD8 cells assessed as protein occupancy incubated for 1 hr by ELISA	B	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4863078		Activity			CHEMBL5251	Homo sapiens	Activity		
Dose-Dependent Effect	23310222	CHEMBL4843927	Binding affinity to BTK in human TMD8 cells assessed as protein occupancy incubated for 1 hr by ELISA	B	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1		CHEMBL4878090		Activity			CHEMBL5251	Homo sapiens	Activity		
Not Active	23317300	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	78.0	CHEMBL5251	Homo sapiens	% Control	%	78.0
Not Active	23317768	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23318440	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	92.0	CHEMBL5251	Homo sapiens	% Control	%	92.0
Not Active	23318918	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	82.0	CHEMBL5251	Homo sapiens	% Control	%	82.0
Not Active	23319558	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	61.3	CHEMBL5251	Homo sapiens	% Control	%	61.3
Not Active	23320030	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23320708	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	96.0	CHEMBL5251	Homo sapiens	% Control	%	96.0
Not Active	23321176	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	79.0	CHEMBL5251	Homo sapiens	% Control	%	79.0
Not Active	23321806	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	55.0	CHEMBL5251	Homo sapiens	% Control	%	55.0
Not Active	23322274	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	72.0	CHEMBL5251	Homo sapiens	% Control	%	72.0
Not Active	23322963	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	81.0	CHEMBL5251	Homo sapiens	% Control	%	81.0
Not Active	23323431	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	92.0	CHEMBL5251	Homo sapiens	% Control	%	92.0
Not Active	23323959	CHEMBL4880578	BTK (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-8.0	CHEMBL5251	Homo sapiens	% inhibition	%	-8.0
Not Active	23324285	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	99.9	CHEMBL5251	Homo sapiens	% Control	%	99.9
Not Active	23324920	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23325388	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23326035	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	76.0	CHEMBL5251	Homo sapiens	% Control	%	76.0
Not Active	23326503	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	88.0	CHEMBL5251	Homo sapiens	% Control	%	88.0
Not Active	23327203	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	64.0	CHEMBL5251	Homo sapiens	% Control	%	64.0
Not Active	23327671	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	73.0	CHEMBL5251	Homo sapiens	% Control	%	73.0
Not Active	23328258	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	70.0	CHEMBL5251	Homo sapiens	% Control	%	70.0
Not Active	23328726	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23329261	CHEMBL4880968	BTK(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	98.0	CHEMBL5251	Homo sapiens	% residual kinase activity	%	98.0
Not Active	23329672	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23330140	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	87.0	CHEMBL5251	Homo sapiens	% Control	%	87.0
Not Active	23330896	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23331364	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	96.0	CHEMBL5251	Homo sapiens	% Control	%	96.0
Not Active	23331951	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23332419	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	83.8	CHEMBL5251	Homo sapiens	% Control	%	83.8
Not Active	23333135	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23333774	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	90.0	CHEMBL5251	Homo sapiens	% Control	%	90.0
Not Active	23334242	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	89.0	CHEMBL5251	Homo sapiens	% Control	%	89.0
Not Active	23334870	CHEMBL4881494	BTK (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	1.0	CHEMBL5251	Homo sapiens	% inhibition	%	1.0
Not Active	23335221	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	96.0	CHEMBL5251	Homo sapiens	% Control	%	96.0
Not Active	23335689	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	84.0	CHEMBL5251	Homo sapiens	% Control	%	84.0
Not Active	23336316	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23336784	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	99.0	CHEMBL5251	Homo sapiens	% Control	%	99.0
Not Active	23337526	CHEMBL4881897	BTK Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	89.5	CHEMBL5251	Homo sapiens	% Ctrl	%	89.5
Not Active	23337865	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	73.0	CHEMBL5251	Homo sapiens	% Control	%	73.0
Not Active	23338333	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	82.0	CHEMBL5251	Homo sapiens	% Control	%	82.0
Not Active	23338945	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23339413	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23340050	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	97.0	CHEMBL5251	Homo sapiens	% Control	%	97.0
Not Active	23340518	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23341175	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23341643	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	97.0	CHEMBL5251	Homo sapiens	% Control	%	97.0
Not Active	23342259	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	77.0	CHEMBL5251	Homo sapiens	% Control	%	77.0
Not Active	23342727	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	87.0	CHEMBL5251	Homo sapiens	% Control	%	87.0
Not Active	23343242	CHEMBL4882427	BTK Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	68.0	CHEMBL5251	Homo sapiens	% Ctrl	%	68.0
Not Active	23343357	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	77.0	CHEMBL5251	Homo sapiens	% Control	%	77.0
Not Active	23343825	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	77.0	CHEMBL5251	Homo sapiens	% Control	%	77.0
Not Active	23344463	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	79.0	CHEMBL5251	Homo sapiens	% Control	%	79.0
Not Active	23345036	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	85.0	CHEMBL5251	Homo sapiens	% Control	%	85.0
Not Active	23345504	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23346081	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	81.5	CHEMBL5251	Homo sapiens	% Control	%	81.5
Not Active	23346550	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	86.1	CHEMBL5251	Homo sapiens	% Control	%	86.1
Not Active	23347160	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23347641	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	92.0	CHEMBL5251	Homo sapiens	% Control	%	92.0
Not Active	23348220	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	88.0	CHEMBL5251	Homo sapiens	% Control	%	88.0
Not Active	23348688	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	84.0	CHEMBL5251	Homo sapiens	% Control	%	84.0
Not Active	23349275	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23349893	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23350361	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	82.0	CHEMBL5251	Homo sapiens	% Control	%	82.0
Not Active	23350966	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	86.0	CHEMBL5251	Homo sapiens	% Control	%	86.0
Not Active	23351434	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	90.0	CHEMBL5251	Homo sapiens	% Control	%	90.0
Not Active	23351975	CHEMBL4882668	BTK Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	4.499	CHEMBL5251	Homo sapiens	% Inhibition	%	4.4991
Not Active	23352458	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	73.0	CHEMBL5251	Homo sapiens	% Control	%	73.0
Not Active	23352926	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	80.0	CHEMBL5251	Homo sapiens	% Control	%	80.0
Not Active	23353808	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	96.0	CHEMBL5251	Homo sapiens	% Control	%	96.0
Not Active	23354276	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	94.0	CHEMBL5251	Homo sapiens	% Control	%	94.0
Not Active	23355008	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23355476	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23356112	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	83.0	CHEMBL5251	Homo sapiens	% Control	%	83.0
Not Active	23356580	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	93.0	CHEMBL5251	Homo sapiens	% Control	%	93.0
Not Active	23357189	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	95.0	CHEMBL5251	Homo sapiens	% Control	%	95.0
Not Active	23357836	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23358304	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	59.0	CHEMBL5251	Homo sapiens	% Control	%	59.0
Not Active	23358890	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	63.0	CHEMBL5251	Homo sapiens	% Control	%	63.0
Not Active	23359488	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	91.0	CHEMBL5251	Homo sapiens	% Control	%	91.0
Not Active	23359956	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	98.0	CHEMBL5251	Homo sapiens	% Control	%	98.0
Not Active	23360541	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	85.0	CHEMBL5251	Homo sapiens	% Control	%	85.0
Not Active	23361009	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23361582	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	63.0	CHEMBL5251	Homo sapiens	% Control	%	63.0
Not Active	23362118	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23362586	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23364228	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23364696	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23365435	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	96.0	CHEMBL5251	Homo sapiens	% Control	%	96.0
Not Active	23365978	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23366568	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23367036	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23367485	CHEMBL4883838	BTK ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	100.0	CHEMBL5251	Homo sapiens	% Residual activity with Skepinone-L	%	100.0
Not Active	23367914	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	92.0	CHEMBL5251	Homo sapiens	% Control	%	92.0
Not Active	23368382	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	93.0	CHEMBL5251	Homo sapiens	% Control	%	93.0
Not Active	23368981	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23369449	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	80.0	CHEMBL5251	Homo sapiens	% Control	%	80.0
Not Active	23369989	CHEMBL4884233	BTK(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	96.0	CHEMBL5251	Homo sapiens	% residual kinase activity	%	96.0
Not Active	23370417	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	99.0	CHEMBL5251	Homo sapiens	% Control	%	99.0
Not Active	23370885	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	85.0	CHEMBL5251	Homo sapiens	% Control	%	85.0
Not Active	23371694	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23372162	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
	23372672	CHEMBL4884637	BTK(BTK1CGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL5251	Homo sapiens	pIC50		6.0
	23373081	CHEMBL4884928	BTK(BTK1CGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL5251	Homo sapiens	pIC50		6.0
	23373442	CHEMBL4885219	BTK(BTK1CGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL5251	Homo sapiens	pIC50		6.0
Not Active	23374923	CHEMBL4885917	BTK Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	42.0	CHEMBL5251	Homo sapiens	% Inhibition	%	42.0
Not Active	23375589	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23376057	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23376635	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	96.0	CHEMBL5251	Homo sapiens	% Control	%	96.0
Not Active	23377104	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	74.0	CHEMBL5251	Homo sapiens	% Control	%	74.0
Not Active	23377962	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	87.0	CHEMBL5251	Homo sapiens	% Control	%	87.0
Not Active	23378430	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	97.0	CHEMBL5251	Homo sapiens	% Control	%	97.0
Not Active	23379597	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23380065	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23380759	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	84.0	CHEMBL5251	Homo sapiens	% Control	%	84.0
Not Active	23381407	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23381875	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23382389	CHEMBL4887110	BTK Invitrogen kinase activity assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		Inhibition	%	14.0	CHEMBL5251	Homo sapiens	% inhibition	%	14.0
Not Active	23382499	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	83.0	CHEMBL5251	Homo sapiens	% Control	%	83.0
Not Active	23382967	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	63.0	CHEMBL5251	Homo sapiens	% Control	%	63.0
Not Active	23383713	CHEMBL4887363	BTK Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	85.0	CHEMBL5251	Homo sapiens	% Ctrl	%	85.0
Not Active	23383714	CHEMBL4887363	BTK Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	96.0	CHEMBL5251	Homo sapiens	% Ctrl	%	96.0
Not Active	23384197	CHEMBL4887792	BTK(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	12.82	CHEMBL5251	Homo sapiens	% inhibition	%	12.82
Not Active	23384637	CHEMBL4888163	BTK SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	6.0	CHEMBL5251	Homo sapiens	% Inhibition	%	6.0
Not Active	23384882	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
Not Active	23385349	CHEMBL4879606	KinomeScan assay: inhibition of BTK	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL5251	Homo sapiens	% Control	%	100.0
